"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT01095666","A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Metformin|Drug: Dapagliflozin Placebo|Drug: Pioglitazone","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in 2-hour Post Meal Glucose (PMG) (mg/dL) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])|Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])","AstraZeneca|AstraZeneca, Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","1484","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MB102-055","June 2010","March 2013","March 2013","March 30, 2010","September 11, 2017","September 11, 2017","Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Changsha, Hunan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Wuxi, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Chongqing, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Xi'An, China|Local Institution, Bangalore, Karnataka, India|Local Institution, Indore, Madhya Pradesh, India|Local Institution, Bangalore, India|Local Institution, Jaipur, India|Local Institution, Vellore, Tamilnadu, India|Local Institution, Seoul, Nowon-Gu, Korea, Republic of|Local Institution, Busan, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01095666"
2,"NCT01095653","A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Metformin|Drug: Dapagliflozin Placebo","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in 2-hour Post Liquid Meal Glucose (PLMG) (mg/dL) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])|Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])","AstraZeneca|AstraZeneca, Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","1179","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MB102-054","June 2010","March 2012","March 2012","March 30, 2010","February 6, 2017","February 6, 2017","Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Wuhan, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Wuxi, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Wuhan, China|Local Institution, Xian, China|Local Institution, Bangalore, Karnataka, India|Local Institution, Indore, Madhya Pradesh, India|Local Institution, Bangalore, India|Local Institution, Jaipur, India|Local Institution, Seoul, Nowon-GU, Korea, Republic of|Local Institution, Busanjin-gu, Korea, Republic of|Local Institution, Guri-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Yung Kang city, Taiwan",,"https://ClinicalTrials.gov/show/NCT01095653"
3,"NCT00683878","Add-on to Thiazolidinedione (TZD) Failures",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin|Drug: Thiazolidinedione (Pioglitazone)","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in 120-minute Post-challenge Plasma Glucose (PPG) (mg/dL) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])|Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Waist Circumference (cm) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Total Body Weight (kg) Among Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])","AstraZeneca|Astra Zeneca, Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","972","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MB102-030","July 2008","January 2010","June 2010","May 26, 2008","February 23, 2017","February 23, 2017","Pinnacle Research Group, Llc, Anniston, Alabama, United States|Iicr, Ozark, Alabama, United States|43rd Medical Associates, P.C., Phoenix, Arizona, United States|Clinical Research Advantage Inc / Desert Clinical Res, Llc, Tempe, Arizona, United States|Clinical Research Advantage, Inc, Tempe, Arizona, United States|Little Rock Family Practice Clinic, Little Rock, Arkansas, United States|Searcy Medical Center, Searcy, Arkansas, United States|Clinical Innovations, Inc., Costa Mesa, California, United States|Marin Endocrine Care And Research, Inc., Greenbrae, California, United States|Torrance Clinical Research, Lomita, California, United States|Randall Shue, D.O., Los Angeles, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Desert Medical Advances, Palm Desert, California, United States|Avastra Clinical Trials, Redlands, California, United States|Sierra Clinical Research, Roseville, California, United States|Ritchken & First M.D.'S, San Diego, California, United States|Advantage Clinical Research, Santa Ana, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Diabetes Research Center, Tustin, California, United States|Aurora Family Medicine Center, P.C., Aurora, Colorado, United States|Denver Internal Medicine, Denver, Colorado, United States|Central Florida Clinical Trials, Altamonte Springs, Florida, United States|Health First Clinical Research Group, Inc., Chipley, Florida, United States|Clinical Therapeutics Corporation, Coral Gables, Florida, United States|Westside Center For Clinical Research, Jacksonville, Florida, United States|Panhandle Family Care Associates, Marianna, Florida, United States|Baptist Diabetes Associates, Pa, Miami, Florida, United States|Suncoast Clinical Res Inc., New Port Richey, Florida, United States|Stone Mountain Clinical Research, Stone Mountain, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Northwest Indiana Center For Clinical Research, Valparaiso, Indiana, United States|Professional Research Network Of Kansas, Wichita, Kansas, United States|St. Mary'S Center For Diabetes And Endocrinology, Grand Rapids, Michigan, United States|Endocrine Research Associates, Jackson, Mississippi, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Danny W. Jackson P.A., Rolling Fork, Mississippi, United States|Association Of International Professionals, Las Vegas, Nevada, United States|Physicians Research Center, Toms River, New Jersey, United States|Finger Lakes Clinical Research, Rochester, New York, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|The Center For Nutrition & Preventive Medicine, Pllc, Charlotte, North Carolina, United States|Northstate Clinical Research, Lenoir, North Carolina, United States|New Hanover Medical Research, Wilmington, North Carolina, United States|Providence Health Partners - Center For Clinical Research, Dayton, Ohio, United States|Physician Research, Inc., Zanesville, Ohio, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Banksville Medical, Pc, Pittsburgh, Pennsylvania, United States|Brookside Family Practice & Pediatrics, Pottstown, Pennsylvania, United States|Columbia Clinical Research, Inc., Columbia, South Carolina, United States|Southeastern Research Associates, Inc., Taylors, South Carolina, United States|Holston Medical Group, Kingsport, Tennessee, United States|Dallas Diabetes & Endocrine Center, Dallas, Texas, United States|Village Family Practice, Houston, Texas, United States|Office Of Dr. Michelle Zaniewski Singh, Houston, Texas, United States|Diabetes & Glandular Disease Research Assoc,, Inc., San Antonio, Texas, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|William L. Gray, Md, Spokane, Washington, United States|Local Institution, Ciudad Auton, Buenos Aires, Argentina|Local Institution, Zarate, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Mount Pearl, Newfoundland and Labrador, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Sarnia, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Mirabel, Quebec, Canada|Local Institution, Hariyana, India|Local Institution, Mumbai, India|Local Institution, Vellore, India|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nl, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Cebu City, Philippines|Local Institution, Manila, Philippines|Local Institution, Pasig City, Philippines|Local Institution, Ponce, Puerto Rico|Local Institution, Changhua, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00683878"
4,"NCT00643851","An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Metformin XR","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])|Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) in Subjects With Baseline HbA1c ≥ 9% at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Total Body Weight (kg) in Subjects With Baseline Body Mass Index (BMI) ≥ 27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])","AstraZeneca|Astra Zeneca, Bristol-Myers Squibb","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","994","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MB102-021","June 2008","August 2009","August 2009","March 26, 2008","February 23, 2017","February 23, 2017","Greystone Medical Research, Llc, Birmingham, Alabama, United States|Winston Technology Research, Llc, Haleyville, Alabama, United States|Clinical Research Advantage, Inc., Tempe, Arizona, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Southland Clinical Research Center, Inc., Fountain Valley, California, United States|Valley Research, Fresno, California, United States|Central Florida Clinical Trials, Inc., Altamonte Springs, Florida, United States|Clinical Therapeutics Corporation, Coral Gables, Florida, United States|Florida Research Network, Llc, Gainesville, Florida, United States|Fpa Clinical Research, Kissimmee, Florida, United States|Nextphase Clinical Trials, Inc., Miami, Florida, United States|Middle Georgia Drug Study Center, Llc, Perry, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Deerbrook Medical Associates, Vernon Hills, Illinois, United States|Jackson Clinic, Rolling Fork, Mississippi, United States|Mercy Medical Group/Dba Woodlake Research, Chesterfield, Missouri, United States|Hudson Valley Clinical Research Center, Kingston, New York, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Crescent Medical Research, Salisbury, North Carolina, United States|Community Health Care, Inc., Canal Fulton, Ohio, United States|Wells Institute For Health Awareness, Kettering, Ohio, United States|Newark Physician Associates, Newark, Ohio, United States|Physician Research, Inc., Zanesville, Ohio, United States|Gilbert Medical Research, Llc, Bethany, Oklahoma, United States|Integris Family Care South Penn, Oklahoma City, Oklahoma, United States|Integris Family Care Yukon, Yukon, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Commonwealth Primary Care, Pc / Fleetwood Clinical Research, Fleetwood, Pennsylvania, United States|Biomedical Research Associates, Llc, Shippensburg, Pennsylvania, United States|Safe Harbor Clinical Research, East Providence, Rhode Island, United States|Southeastern Research Associates, Inc., Greenville, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Middle Tennessee Clinical Research, Fayetteville, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Endocrine Associates, Houston, Texas, United States|Village Family Practice, Houston, Texas, United States|Non-Invasive Cardiovascular, Pa, Houston, Texas, United States|Excel Clinical Research, Llc, Houston, Texas, United States|Texas Center For Drug Development, Houston, Texas, United States|Inst. Of Clin. Research At The Diabetes Cntr. Of The Sw, Midland, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|Southwest Clinical Research Center, Llc, Pearland, Texas, United States|S.A.M. Clinical Research Center, San Antoinio, Texas, United States|Covenant Clinical Research, Pa, San Antonio, Texas, United States|Local Institution, Guri-Si, Gyeonggi-Do, Korea, Republic of|Local Institution, Seoul, Nowon-Gu, Korea, Republic of|Local Institution, Bucheon, Korea, Republic of|Local Institution, Incheon, Korea, Republic of|Local Institution, Incheon, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Sungnam-Si, Gyeonggi-Do, Korea, Republic of|Local Institution, Ciudad De Mexico, Distrito Federal, Mexico|Local Institution, Pachuca, Hidelgo, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michioacan, Mexico|Local Institution, Monterrey, Nl, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Tampico, Tamaulipas, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Durango, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Cebu City, Philippines|Local Institution, Jaro Iloilo City, Philippines|Local Institution, Las Pinas City, Philippines|Local Institution, Marikina City, Philippines|Local Institution, Pasig City, Philippines|Local Institution, Quezon City, Philippines|Local Institution, Ponce, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Villa Fontana, Puerto Rico|Local Institution, Moscow, Russia, Russian Federation|Local Institution, Arkhangelsk, Russian Federation|Local Institution, Dzerzhinskiy, Russian Federation|Local Institution, Kemerovo, Russian Federation|Local Institution, Moscov, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Volgograd, Russian Federation|Local Institution, Voronezh, Russian Federation|Local Institution, Yaroslav, Russian Federation|Local Institution, Dnepropetrovsk, Ukraine|Local Institution, Donetsk, Ukraine|Local Institution, Kiev, Ukraine|Local Institution, Kiev, Ukraine|Local Institution, Lviv, Ukraine|Local Institution, Odessa, Ukraine|Local Institution, Odessa, Ukraine|Local Institution, Odessa, Ukraine|Local Institution, Vinnytsya, Ukraine|Local Institution, Zhytomyr, Ukraine",,"https://ClinicalTrials.gov/show/NCT00643851"
5,"NCT03836677","A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Combination Product: BGF|Combination Product: GFF","Specific Image-based Airway Volume (siVaw)|Specific Image-based Airway Resistance (siRaw)|Image-based Airway Volume (iVaw)|Image-based Airway Resistance (iRaw)|Forced Expiratory Volume in One Second (Post-dose FEV1).|Functional Residual Capacity (FRC)","AstraZeneca","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 3","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D5980C00019","February 26, 2019","November 11, 2019","November 11, 2019","February 11, 2019","February 11, 2021","February 11, 2021","Research Site, Erpent, Belgium|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Zutphen, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03836677/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT03836677/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT03836677"
6,"NCT03354429","THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death","THALES","Completed","Has Results","Acute Ischaemic Stroke|Transient Ischaemic Attack","Drug: Ticagrelor|Drug: Placebo","Composite of Subsequent Stroke or Death|Ischaemic Stroke|Number of Participants With Modified Rankin Scale (mRS) Score >1 at Visit 3","AstraZeneca","All","40 Years to 130 Years   (Adult, Older Adult)","Phase 3","11016","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5134C00003|2016-004232-37","January 22, 2018","December 13, 2019","December 13, 2019","November 28, 2017","December 22, 2020","December 22, 2020","Research Site, Adrogué, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Cordoba, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mendoza, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, Salta, Argentina|Research Site, Adelaide, Australia|Research Site, Heidelberg, Australia|Research Site, Herston, Australia|Research Site, Parkville, Australia|Research Site, Southport, Australia|Research Site, St Albans, Australia|Research Site, Antwerpen, Belgium|Research Site, Assebroek (Brugge), Belgium|Research Site, Bruges, Belgium|Research Site, Brussels, Belgium|Research Site, Dendermonde, Belgium|Research Site, Edegem, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Oostende, Belgium|Research Site, Roeselare, Belgium|Research Site, Sint-Truiden, Belgium|Research Site, Yvoir, Belgium|Research Site, Botucatu, Brazil|Research Site, Curitiba, Brazil|Research Site, Goiania, Brazil|Research Site, Joinville, Brazil|Research Site, Maringa, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirao Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Dupnitsa, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Lukovit, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Teteven, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Lethbridge, Alberta, Canada|Research Site, Chicoutimi, Canada|Research Site, Baoji, China|Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chifeng, China|Research Site, Daqing, China|Research Site, Foshan, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guiyang, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Hohhot, China|Research Site, Hohhot, China|Research Site, Jinan, China|Research Site, Jinzhou, China|Research Site, Liuzhou, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Ningbo, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Tangshan, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Wenzhou, China|Research Site, Wu Han, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuxi, China|Research Site, Xi'an, China|Research Site, Xiamen, China|Research Site, Xining, China|Research Site, Xuzhou, China|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Ostrava, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 4, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Bayonne, France|Research Site, Besancon Cedex, France|Research Site, Bordeaux Cedex, France|Research Site, Bourg en Bresse, France|Research Site, Brest Cedex 2, France|Research Site, Caen, France|Research Site, Corbeil Essonnes Cedex, France|Research Site, Dijon, France|Research Site, Le Chesnay Cedex, France|Research Site, Lille, France|Research Site, Metz, France|Research Site, Montpellier Cedex 5, France|Research Site, Nancy, France|Research Site, NICE Cedex 01, France|Research Site, PARIS Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Paris Cedex 18, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Rennes, France|Research Site, Rouen Cedex, France|Research Site, Saint Herblain, France|Research Site, Saint-Priez En Jarez, France|Research Site, Strasbourg Cedex, France|Research Site, Suresnes Cedex, France|Research Site, Toulouse Cedex 9, France|Research Site, Altenburg, Germany|Research Site, Bad Neustadt, Germany|Research Site, Berlin, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Minden, Germany|Research Site, Münster, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, Baja, Hungary|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Győr, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Sopron-Balf, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Tatabánya, Hungary|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bengaluru, India|Research Site, Dehradun, India|Research Site, Guntur, India|Research Site, Gurgaon, India|Research Site, Gurgaon, India|Research Site, Hyderabad, India|Research Site, Kanpur, India|Research Site, Kolkata, India|Research Site, Mangalore, India|Research Site, Nagpur, India|Research Site, Nagpur, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Srikakulam, India|Research Site, Varanasi, India|Research Site, Cona, Italy|Research Site, Genova, Italy|Research Site, Genova, Italy|Research Site, Massa, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Negrar, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Pietra Ligure, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Varese, Italy|Research Site, Verona, Italy|Research Site, Vicenza, Italy|Research Site, Vizzolo Predabissi, Italy|Research Site, Anyang-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon-si, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeju-do, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Culiacan, Mexico|Research Site, D.F, Mexico|Research Site, Durango, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico City, Mexico|Research Site, Mexico City, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Tijuana, Mexico|Research Site, Bellavista, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Trujillo, Peru|Research Site, Urb. El Chipe, Peru|Research Site, Białystok, Poland|Research Site, Chełm, Poland|Research Site, Działdowo, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Gryfice, Poland|Research Site, Katowice, Poland|Research Site, Końskie, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Olsztyn, Poland|Research Site, Ostrołęka, Poland|Research Site, Rybnik, Poland|Research Site, Sandomierz, Poland|Research Site, Skarżysko-Kamienna, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Zielona Góra, Poland|Research Site, Łódź, Poland|Research Site, Łódź, Poland|Research Site, Świebodzin, Poland|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Tirgu-Mures, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Ar Riyāḑ, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Dolny Kubin, Slovakia|Research Site, Levoca, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Skalica, Slovakia|Research Site, Spisska Nova Ves, Slovakia|Research Site, Trencin, Slovakia|Research Site, Trnava, Slovakia|Research Site, Ziar nad Hronom, Slovakia|Research Site, Albacete, Spain|Research Site, Alicante, Spain|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valladolid, Spain|Research Site, Zaragoza, Spain|Research Site, Göteborg, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Malmö, Sweden|Research Site, Ostersund, Sweden|Research Site, Skövde, Sweden|Research Site, Solna, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Changhua, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Keelung, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan Hsien, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chonburi, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khlong Luang, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Lampang, Thailand|Research Site, Muang, Thailand|Research Site, Nakhonpathom, Thailand|Research Site, Prachinburi, Thailand|Research Site, Rajthevi, Thailand|Research Site, Ratchaburi, Thailand|Research Site, Ubonratchathani, Thailand|Research Site, Chernivtsі, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kherson, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Dong Nai, Vietnam|Research Site, Ha Noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh, Vietnam","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03354429/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/29/NCT03354429/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03354429"
7,"NCT03303521","A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.","DIALIZE","Completed","Has Results","Hyperkalemia","Drug: Placebo|Drug: Sodium Zirconium Cyclosilicate (ZS)","Percentage of Responders|Percentage of Responders When Accounting for Missing Central Laboratory Serum Potassium Data|Percentage of Patients Needing Rescue Therapy","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","196","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D9480C00006|2017-003029-14","December 14, 2017","November 7, 2018","November 7, 2018","October 6, 2017","February 20, 2020","February 20, 2020","Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Ontario, California, United States|Research Site, San Dimas, California, United States|Research Site, Whittier, California, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Paterson, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Fresh Meadows, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Ridgewood, New York, United States|Research Site, East Providence, Rhode Island, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Hamamatsu-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Miyagi-gun, Japan|Research Site, Nagano-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Ora-gun, Japan|Research Site, Osaka-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sashima-gun, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Toride-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yachiyo-shi, Japan|Research Site, Yokosuka-shi, Japan|Research Site, Kemerovo, Russian Federation|Research Site, Kolomna, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Podolsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Yekaterinburg, Russian Federation|Research Site, Cardiff, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, York, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03303521/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03303521/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03303521"
8,"NCT03172702","Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia",,"Completed","Has Results","Hyperkalemia","Drug: Zirconium Cyclosilicate","Number of Patients Who Experienced Adverse Events (AEs) in the MP|Percentage of Patients Who Were Normokalemic in the MP|Percentage of Patients With Average S-K Levels of ≤5.1 mmol/L and ≤5.5 mmol/L in the MP|Percentage of Patients Who Were Hypokalemic in the MP|Percentage of Patients Who Were Hyperkalemic in the MP|Mean Change From CP Baseline in the Mean S-K Level Over Specified Time Periods in the MP|Mean Change From MP Baseline in the Mean S-K Level Over Specified Time Periods in the MP|Mean Number of Normokalemic Days During the MP|Mean Change in S-K Level From Last On-treatment MP Visit to the End of Study|Change From CP Baseline in S-Aldosterone Levels Over the MP|Percentage of Patients With Normal S-Aldosterone Levels Over the MP|Change From CP Baseline in S-Bicarbonate Levels Over the MP|Percentage of Patients With Normal S-Bicarbonate Levels Over the MP|Baseline and Post-baseline 36-Item Short Form Health Survey Version 2 (SF-36 v2) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores|Mean Change From CP Baseline in the Mean S-K Levels in the CP|Percentage of Patients Who Were Normokalemic in the CP|Number of Patients Who Experienced AEs in the CP","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","D9482C00001","September 4, 2017","July 6, 2019","July 6, 2019","June 1, 2017","May 1, 2020","May 1, 2020","Research Site, Akashi-shi, Japan|Research Site, Amagasaki-shi, Japan|Research Site, Chiba-shi, Japan|Research Site, Chiba-shi, Japan|Research Site, Chiyoda-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Funabashi-shi, Japan|Research Site, Hanyu-shi, Japan|Research Site, Higashiibaraki-gun, Japan|Research Site, Hitachinaka-shi, Japan|Research Site, Ina-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kahoku-gun, Japan|Research Site, Kamakura-shi, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kasugai-shi, Japan|Research Site, Kasugai-shi, Japan|Research Site, Kawachinagano-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Kochi-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Minokamo-shi, Japan|Research Site, Mito-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Naka-shi, Japan|Research Site, Omura-shi, Japan|Research Site, Onomichi-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Shimajiri-gun, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Toride-shi, Japan|Research Site, Toshima-ku, Japan|Research Site, Toyohashi-shi, Japan|Research Site, Yao-shi, Japan|Research Site, Yotsukaido-shi, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03172702/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03172702/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03172702"
9,"NCT03170271","A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.","ANDHI","Completed","Has Results","Asthma","Drug: Benralizumab (Medi-563)|Drug: Placebo","Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24)|Change From Baseline in Saint George Respiratory Questionnaire (SGRQ) Total Score to the EOT (Week 24)|Change From Baseline in Pre-Bronchodilator (BD) Forced Expiratory Volume in First Second (FEV1) to the EOT (Week 24)|Change From Baseline in Asthma Control Questionnaire 6 (ACQ-6) Score to the EOT (Week 24)|Time to First Asthma Exacerbation (up to Week 24)|Change From Run-in Baseline Home Peak Expiratory Flow (PEF) (Morning and Evening) to the EOT (Week 24)|Change From Baseline in Social Functioning Short Form 36-item Health Survey, Version 2 (SF-36v2) to the EOT (Week 24)|Patient Global Impression of Severity (PGI-S): Responder Status at the EOT (Week 24)|Clinician Global Impression of Change (CGI-C) and Patient Global Impression of Change (PGI-C): Responder Status at the EOT (Week 24)|Change From Baseline in Predominant Symptom and Impairment Assessment (PSIA) Severity Score for Average of Top 3 Ranked Symptoms/Impairments and for Top Ranked Symptom/Impairment at the EOT (Week 24)|Change From Baseline in the Sino-Nasal Outcome Test Item 22 (SNOT-22) Total Score to the EOT (Week 24)","AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","660","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D3250C00045|2017-001040-35","July 7, 2017","September 25, 2019","October 21, 2020","May 31, 2017","December 16, 2020","December 16, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Bakersfield, California, United States|Research Site, Encinitas, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Newport Beach, California, United States|Research Site, Riverside, California, United States|Research Site, San Diego, California, United States|Research Site, Stockton, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Aurora, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Albany, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Peoria, Illinois, United States|Research Site, South Bend, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, White Marsh, Maryland, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Highland Park, New Jersey, United States|Research Site, Marlton, New Jersey, United States|Research Site, Northfield, New Jersey, United States|Research Site, Piscataway, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Verona, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Elizabeth City, North Carolina, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Grove City, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Clackamas, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, North Charleston, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Franklin, Tennessee, United States|Research Site, Cypress, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Galveston, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Provo, Utah, United States|Research Site, South Burlington, Vermont, United States|Research Site, Abingdon, Virginia, United States|Research Site, Fairfax, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Williamsburg, Virginia, United States|Research Site, Everett, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Greenfield, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, West Allis, Wisconsin, United States|Research Site, Feldbach, Austria|Research Site, Wien, Austria|Research Site, Liège, Belgium|Research Site, Montigny-le-Tilleul, Belgium|Research Site, Namur, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Kelowna, Columbia Británica, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Aarhus N, Denmark|Research Site, Odense C, Denmark|Research Site, Vejle, Denmark|Research Site, Helsinki, Finland|Research Site, Turku, Finland|Research Site, Bayonne, France|Research Site, Besancon Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Dijon, France|Research Site, GRENOBLE Cedex 9, France|Research Site, La Roche sur Yon, France|Research Site, Le Kremlin-Bicêtre, France|Research Site, Lille cedex, France|Research Site, Lyon Cedex 4, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nantes Cedex 1, France|Research Site, Nice cedex 1, France|Research Site, Paris Cedex 18, France|Research Site, Pessac, France|Research Site, Reims, France|Research Site, Rouen Cedex, France|Research Site, Saint-Quentin cedex, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse, France|Research Site, Vandoeuvre-Les-Nancy, France|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bonn, Germany|Research Site, Cottbus, Germany|Research Site, Essen, Germany|Research Site, Hamburg, Germany|Research Site, Jena, Germany|Research Site, Marburg, Germany|Research Site, Oldenburg, Germany|Research Site, Rheine, Germany|Research Site, Rüdersdorf, Germany|Research Site, Brescia, Italy|Research Site, Catania, Italy|Research Site, Cona, Italy|Research Site, Foggia, Italy|Research Site, Garbagnate Milanese, Italy|Research Site, Milaan, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Piacenza, Italy|Research Site, Pietra Ligure, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Verona, Italy|Research Site, Amersfoort, Netherlands|Research Site, Deventer, Netherlands|Research Site, Enschede, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Helmond, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Bergen, Norway|Research Site, Lørenskog, Norway|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Jerez de la Frontera, Spain|Research Site, Laredo, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Pozuelo de Alarcon, Spain|Research Site, Sabadell, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Valdemoro, Spain|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Östersund, Sweden|Research Site, Birmingham, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Chertsey, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03170271/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT03170271/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03170271"
10,"NCT03162055","Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease","AERISTO","Completed","Has Results","Chronic Obstructive Pulmonary Disease COPD","Drug: Glycopyrronium/Formoterol Fumarate|Drug: umeclidinium/vilanterol","Mean Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) Over 24 Weeks|Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in PP Analysis Set Population|Mean Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks in FAS Population|Percentage of Participants With Increase of FEV1 of >=100 mL From Baseline at 5 Minutes Post-dosing on Day 1|Mean Peak Change From Baseline in Inspiratory Capacity (IC) Within 2 Hours Post-dosing Over 24 Weeks|Mean Transition Dyspnea Index (TDI) Focal Score Over 24 Weeks|Mean Change From Baseline in Early Morning Symptoms of COPD Instrument (EMSCI) Over 24 Weeks","AstraZeneca|Parexel International Ltd|Cognizant Technology Solution|Center for Information & Study on Clinical Research Participation (CISCRP)|eResearchTechnology|QuintilesIMS Limited|Corporate Translations Inc","All","40 Years to 95 Years   (Adult, Older Adult)","Phase 3","1119","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5970C00002","May 25, 2017","May 4, 2018","May 4, 2018","May 22, 2017","May 22, 2019","May 22, 2019","Research Site, Tempe, Arizona, United States|Research Site, Escondido, California, United States|Research Site, Sacramento, California, United States|Research Site, Hollywood, Florida, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Rincon, Georgia, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Bronx, New York, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Dublin, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Sherman, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Dupnitsa, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Petrich, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Razlog, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vidin, Bulgaria|Research Site, Sherwood Park, Alberta, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Truro, Nova Scotia, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Besancon Cedex, France|Research Site, Brest Cedex, France|Research Site, Lyon Cedex 04, France|Research Site, Montpellier, France|Research Site, Nantes Cedex 2, France|Research Site, Pessac, France|Research Site, Poitiers, France|Research Site, Reims, France|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Farkasgyepü, Hungary|Research Site, Hajdúnánás, Hungary|Research Site, Komló, Hungary|Research Site, Komárom, Hungary|Research Site, Miskolc, Hungary|Research Site, Püspökladány, Hungary|Research Site, Siófok, Hungary|Research Site, Szeged, Hungary|Research Site, Szombathely, Hungary|Research Site, Vásárosnamény, Hungary|Research Site, Barnaul, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Ulyanovsk, Russian Federation|Research Site, Chernivtsi, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03162055/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT03162055/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03162055"
11,"NCT03036124","Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure","DAPA-HF","Completed","Has Results","Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)","Drug: Dapagliflozin|Drug: Placebo","Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.|Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.|Events Included in the Composite Endpoint of Recurrent Hospitalizations Due to Heart Failure and CV Death.|Change From Baseline in the KCCQ Total Symptom Score|Subjects Included in the Composite Endpoint of ≥50% Sustained Decline in eGFR, ESRD or Renal Death.|Subjects Included in the Endpoint of All-cause Mortality.","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","4744","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1699C00001|2016-003897-41","February 8, 2017","July 17, 2019","July 17, 2019","January 30, 2017","September 1, 2020","September 1, 2020","Research Site, Fairhope, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Bakersfield, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Palm Springs, California, United States|Research Site, Stockton, California, United States|Research Site, Torrance, California, United States|Research Site, Vista, California, United States|Research Site, Wilmington, Delaware, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Smyrna Beach, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Augustine, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Tucker, Georgia, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Jerseyville, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Chalmette, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Flint, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, New York, New York, United States|Research Site, Orchard Park, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Burlington, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Beaumont, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Farmington, Utah, United States|Research Site, Falls Church, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aire, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Esperanza, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Quilmes, Argentina|Research Site, Quilmes, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Luis, Argentina|Research Site, San Martin, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Vicente Lopez, Argentina|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Brasilia, Brazil|Research Site, Brasillia, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Goiânia, Brazil|Research Site, Marilia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Uberlandia, Brazil|Research Site, Votuporanga, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Dimitrovgrad, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Lom, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Abbotsford, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, North Vancouver, British Columbia, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Peterborough, Ontario, Canada|Research Site, Port Perry, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Rimouski, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chifeng, China|Research Site, Dalian, China|Research Site, Guangzhou, China|Research Site, Haerbin, China|Research Site, Lanzhou, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Ningbo, China|Research Site, Pingxiang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenzhen, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xuzhou, China|Research Site, Xuzhou, China|Research Site, Yinchuan, China|Research Site, Zhuhai, China|Research Site, Benesov, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Kolin, Czechia|Research Site, Louny, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha, Czechia|Research Site, Trebic, Czechia|Research Site, Hellerup, Denmark|Research Site, Herlev, Denmark|Research Site, Hvidovre, Denmark|Research Site, København Ø, Denmark|Research Site, Odense C, Denmark|Research Site, Svendborg, Denmark|Research Site, Bad Oeynhausen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Homburg, Germany|Research Site, Kassel, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Papenburg, Germany|Research Site, Stuttgart, Germany|Research Site, Wermsdorf, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Kecskemét, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Szentes, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ahmedabad, India|Research Site, Aurangabad, India|Research Site, Bangalore, India|Research Site, Belagavi, India|Research Site, Ernakulam, India|Research Site, Gurgaon, India|Research Site, Kanpur, India|Research Site, Karamsad, India|Research Site, Kolkata, India|Research Site, Maharashtra, India|Research Site, Nadiad, India|Research Site, Nagpur, India|Research Site, Nagpur, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Adachi-ku, Japan|Research Site, Aki-gun,, Japan|Research Site, Azumino-shi, Japan|Research Site, Beppu-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Chikushino-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Hiratsuka-shi, Japan|Research Site, Hitachinaka-shi, Japan|Research Site, Iizuka-shi, Japan|Research Site, Itabashi-ku, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kakamigahara-shi, Japan|Research Site, Kasama-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kitakyusyu-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kusatsu-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Mito-shi, Japan|Research Site, Miura-gun, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sakai-shi,Kita-ku, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sanyoonoda-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shimonoseki-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Suwa-shi, Japan|Research Site, Tachikawa-shi, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Toride-shi, Japan|Research Site, Tsuchiura-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Wako-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Apeldoorn, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sneek, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Bochnia, Poland|Research Site, Gdynia, Poland|Research Site, Jasło, Poland|Research Site, Katowice, Poland|Research Site, Kraków, Poland|Research Site, Kędzierzyn Koźle, Poland|Research Site, Legnica, Poland|Research Site, Lublin, Poland|Research Site, Oława, Poland|Research Site, Płock, Poland|Research Site, Sokółka, Poland|Research Site, Torun, Poland|Research Site, Wierzchosławice, Poland|Research Site, Łódź, Poland|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Yekaterinburg, Russian Federation|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Martin, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Presov, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trebisov, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Ostersund, Sweden|Research Site, Stockholm, Sweden|Research Site, Umeå, Sweden|Research Site, Changhua City, Taiwan|Research Site, Hsinchu, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kweishan Shiang, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Airdrie, United Kingdom|Research Site, Clydebank, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Inverness, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Paisley, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Hcmc, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03036124/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT03036124/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03036124"
12,"NCT02918071","Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home","GRECO","Completed","Has Results","Asthma","Biological: Benralizumab","Number of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an AI Device at Home|Number of Returned AI Devices Used to Administer Benralizumab at Home That Have Been Evaluated as Functional|Number of AI Devices Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints)|Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score|The Pharmacokinetics (PK) of Benralizumab in the Terms of PK Parameters: Serum Concentration of Benralizumab|The Pharmacodynamics of Benralizumab in the Terms of Peripheral Blood Eosinophil Levels|The Immunogenicity of Benralizumab in the Terms of Anti-drug Antibodies (ADA)","AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","121","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D3250C00031","November 10, 2016","August 21, 2017","August 21, 2017","September 28, 2016","November 2, 2018","November 2, 2018","Research Site, Northridge, California, United States|Research Site, Riverside, California, United States|Research Site, Westminster, California, United States|Research Site, Miami, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Albany, Georgia, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Canton, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Boerne, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sherwood Park, Alberta, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Kanata, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Trois-Rivières, Quebec, Canada|Research Site, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02918071/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02918071/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02918071"
13,"NCT02875834","A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia","HARMONIZE GL","Completed","Has Results","Hyperkalemia","Drug: Sodium Zirconium Cyclosilicate (ZS) 10g|Drug: Sodium Zirconium Cyclosilicate (ZS) 5g|Drug: Placebo","Least Square Mean S-K Level on Days 8-29|Proportion of Patients Achieving Normokalemia|Exponential Rate of Change in S-K Levels|Absolute Change From Baseline in S-K Levels|Percentage Change From Baseline in S-K Levels|Proportion of Patients Remaining Normokalemic|Proportion of Normokalemic Patients at Day 1 Through Day 29/Exit|Days Patients Remain Normokalemic|Mean Change in S-K Levels|Mean Percentage Change in S-K Levels|Number of Hyperkalemic Patients|Mean Changes in S-Aldosterone and P Renin Levels|Patient Reported Health State (EQ-5D) Questionnaire","AstraZeneca","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","267","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D9480C00002","March 3, 2017","February 14, 2018","February 14, 2018","August 23, 2016","August 19, 2020","August 19, 2020","Research Site, Chiba-shi, Japan|Research Site, Hanyu-shi, Japan|Research Site, Hitachinaka-shi, Japan|Research Site, Ina-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Shimajiri-gun, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Toride-shi, Japan|Research Site, Toyohashi-shi, Japan|Research Site, Yao-shi, Japan|Research Site, Anyang-si, Korea, Republic of|Research Site, Bucheon-si, Korea, Republic of|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Hwaseong-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Uijeongbu-si, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Ekaterinburg, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Hualien City, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02875834/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02875834/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02875834"
14,"NCT02869438","A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation","SOLANA","Completed","Has Results","Asthma","Drug: Benralizumab|Other: Placebo","Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1|Change From Baseline (Visit 4) to End of Treatment Day 84 (Visit 10) in Residual Volume (RV)|Percent Change From Baseline to End of Treatment in Eosinophils Counts|Change From Baseline (Visit 4) to Post Baseline Visits in Pre-BD FEV1|Change From Baseline to Post Baseline for Pre-BD FVC|Percentage of Pre-BD FEV1 Responder|Change From Baseline in ACQ-6|Change From Baseline in St. George's Respiratory Questionnaire (SGRQ)|Change From Baseline to End of Treatment in FeNO|Change From Baseline to End of Treatment in Total Lung Capacity (TLC) for Sub-study Patients|Change From Baseline to End of Treatment in Ratio of Residual Volume (RV) and Total Lung Capacity (TLC) for Sub-study Patients|Change From Baseline to End of Treatment in Inspiratory Capacity (IC) for Sub-study Patients|Change From Baseline to End of Treatment in Functional Residual Capacity (FRC) for Sub-study Patients|Change From Baseline to End of Treatment in Vital Capacity (VC) for Sub-study Patients|Duration of IP Administration","AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","233","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","D3250C00038|2016-002094-36|U1111-1185-6625","November 9, 2016","August 1, 2018","August 1, 2018","August 17, 2016","October 7, 2019","October 29, 2019","Research Site, Scottsboro, Alabama, United States|Research Site, Gilbert, Arizona, United States|Research Site, Denver, Colorado, United States|Research Site, Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Rochester, Minnesota, United States|Research Site, New Bern, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Lampasas, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Curico, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Bamberg, Germany|Research Site, Darmstadt, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Hannover, Germany|Research Site, Hannover, Germany|Research Site, Mainz, Germany|Research Site, München, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Edelény, Hungary|Research Site, Farkasgyepü, Hungary|Research Site, Gödöllő, Hungary|Research Site, Hajdúnánás, Hungary|Research Site, Komárom, Hungary|Research Site, Miskolc, Hungary|Research Site, Pécs, Hungary|Research Site, Pécs, Hungary|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02869438/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02869438/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02869438"
15,"NCT02821416","Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics","ARIA","Completed","Has Results","Asthma","Biological: Benralizumab|Other: Placebo","Change in Percent of Eosinophils in Sputum 7 Hours Post Allergen Challenge|Maximal Percentage Decrease in Forced Expiratory Volume in 1 Second 3-7 Hours Post Allergen Challenge","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D3250C00040","October 11, 2016","October 22, 2019","October 22, 2019","July 1, 2016","January 7, 2021","January 7, 2021","Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02821416/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02821416/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02821416"
16,"NCT02814643","Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma","ALIZE","Completed","Has Results","Asthma","Drug: Benralizumab|Drug: Benralizumab Placebo|Drug: Seasonal influenza virus vaccine","Postdose Strain-specific Hemagglutination-inhibition (HAI) Antibody Geometric Mean Fold Rise From Week 8 to Week 12|Postdose Strain-specific Hemagglutination-inhibition Antibody Geometric Mean Titers Obtained at Week 12|Proportion of Patients Who Experienced a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Hemagglutination-inhibition Antibody Titer From Week 8 to Week 12|Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination-inhibition Antibody Titer ≥40 at Week 12|Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination Inhibition Antibody Titre ≥320 at Week 12|Postdose Strain-specific Microneutralization Antibody Geometric Mean Fold Rise From Week 8 to Week 12|Postdose Strain-specific Serum Microneutralization Antibody Geometric Mean Titers Obtained at Week 12|Proportion of Patients Who Experience a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a ≥4-fold Rise in Microneutralization Antibody Titer From Week 8 to Week 12|Change From Baseline in Mean Asthma Control Questionnaire 6 (ACQ-6) Score at Week 12","AstraZeneca","All","12 Years to 21 Years   (Child, Adult)","Phase 3","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","D3250C00033","July 1, 2016","January 24, 2017","January 24, 2017","June 28, 2016","March 1, 2018","October 24, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Huntington Beach, California, United States|Research Site, Newport Beach, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Aventura, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Northfield, New Jersey, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, North Charleston, South Carolina, United States|Research Site, Arlington, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, New Braunfels, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Clinton, Utah, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02814643/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02814643/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02814643"
17,"NCT02796677","AMPLIFY - D6571C00001 Duaklir USA Phase III Study",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)|Drug: Aclidinium bromide 400 μg (AB 400 μg)|Drug: Formoterol fumarate 12 μg (FF 12 μg)|Other: Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg|Drug: Tiotropium 18 μg (TIO 18 μg)|Other: Placebo to TIO 18 μg","Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24|Change From Baseline in Morning Predose (Trough) FEV1 of AB/FF 400/12 μg Compared to FF 12 μg at Week 24|Change From Baseline in Morning Predose (Trough) FEV1 at Week 24 Comparing AB 400 μg Versus TIO 18 μg to Demonstrate Non-inferiority|Change From Baseline in Normalized Area Under Curve 3hours Post-dose (nAUC0-3/3h) FEV1 of AB/FF 400/12 μg Compared to AB 400 μg and and FF 12 μg at Week 24|Responder (Number of Participants) Analysis of St. George's Respiratory Questionnaire (SGRQ) Total Score With AB/FF 400/12 μg Versus AB 400 μg and FF 12 μg.","AstraZeneca","All","40 Years to 130 Years   (Adult, Older Adult)","Phase 3","1595","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D6571C00001","July 5, 2016","June 8, 2017","June 8, 2017","June 13, 2016","November 9, 2018","November 9, 2018","Research Site, Gulf Shores, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Corona, California, United States|Research Site, Fresno, California, United States|Research Site, Fullerton, California, United States|Research Site, Lincoln, California, United States|Research Site, San Diego, California, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Blue Ridge, Georgia, United States|Research Site, Woodstock, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Portage, Indiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Chelsea, Michigan, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Fridley, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Woodbury, Minnesota, United States|Research Site, Saint Charles, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Fremont, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dublin, Ohio, United States|Research Site, Grove City, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Midwest City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Columbia, South Carolina, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Union, South Carolina, United States|Research Site, Arlington, Texas, United States|Research Site, Baytown, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lewisville, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Midvale, Utah, United States|Research Site, Abingdon, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Dimitrovgrad, Bulgaria|Research Site, Gabrovo, Bulgaria|Research Site, Roman, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Vidin, Bulgaria|Research Site, Jaromer, Czechia|Research Site, Jindrichuv Hradec, Czechia|Research Site, Praha 8, Czechia|Research Site, Rokycany, Czechia|Research Site, Strakonice, Czechia|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Frankfurt, Germany|Research Site, Grosshansdorf, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Luebeck, Germany|Research Site, Marburg, Germany|Research Site, München, Germany|Research Site, Schwerin, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gödöllő, Hungary|Research Site, Komló, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Szigetszentmiklós, Hungary|Research Site, Szombathely, Hungary|Research Site, Jerusalem, Israel|Research Site, Petach Tikva, Israel|Research Site, Rehovot, Israel|Research Site, Bialystok, Poland|Research Site, Częstochowa, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Inowrocław, Poland|Research Site, Katowice, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Pabianice, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Zabrze, Poland|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Lleida, Spain|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zhytomyr, Ukraine|Research Site, Birmingham, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Chorley, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hexham, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02796677/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/77/NCT02796677/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02796677"
18,"NCT02725593","Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Dapagliflozin placebo","Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24|Adjusted Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Percentage of Participants Who Required Glycemic Rescue Medication or Permanently Discontinued Treatment Due to Lack of Glycemic Control|Percentage of Participants With Baseline Glycated Haemoglobin (HbA1c) >= 7% Who Achieved HbA1c Level < 7% at Week 24","AstraZeneca|Parexel|Q2 Solutions|PRA Health Sciences|Covance Laboratories, Inc","All","10 Years to 24 Years   (Child, Adult)","Phase 3","72","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D1690C00017|2015-005041-31","June 22, 2016","April 6, 2020","April 6, 2020","April 1, 2016","December 2, 2020","December 2, 2020","Research Site, New Haven, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainesville, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Boston, Massachusetts, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Lampasas, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Budapest, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Ramat Gan, Israel|Research Site, Zerifin, Israel|Research Site, Culiacan, Mexico|Research Site, Guadalajara, Mexico|Research Site, Merida, Mexico|Research Site, Monterrey, Mexico|Research Site, México, D.F., Mexico|Research Site, Zapopan, Mexico|Research Site, Oradea, Romania|Research Site, Timisoara, Romania|Research Site, Izhevsk, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Kent, United Kingdom|Research Site, Leicester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02725593/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02725593/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02725593"
19,"NCT02681094","A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus|Inadequate Glycaemic Control","Drug: Dapagliflozin|Drug: Placebo for Dapagliflozin|Drug: Saxagliptin|Drug: Placebo for Saxagliptin","Change From Baseline in HbA1c at Week 24|Proportion of Participants Achieving HbA1c <7.0% at 24 Weeks|Change in Fasting Plasma Glucose at 24 Weeks|Change in Total Body Weight at 24 Weeks","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","905","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D1683C00005","February 26, 2016","July 15, 2017","July 15, 2017","February 12, 2016","October 10, 2018","October 10, 2018","Research Site, Saraland, Alabama, United States|Research Site, Fresno, California, United States|Research Site, Harbor City, California, United States|Research Site, Hawaiian Gardens, California, United States|Research Site, Lancaster, California, United States|Research Site, Los Angeles, California, United States|Research Site, Montclair, California, United States|Research Site, Pomona, California, United States|Research Site, Spring Valley, California, United States|Research Site, Vallejo, California, United States|Research Site, Denver, Colorado, United States|Research Site, Northglenn, Colorado, United States|Research Site, Wheat Ridge, Colorado, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Cooper City, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Buford, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Zachary, Louisiana, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Florissant, Missouri, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Columbus, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, East Providence, Rhode Island, United States|Research Site, West Columbia, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Norfolk, Virginia, United States|Research Site, Moncton, New Brunswick, Canada|Research Site, Bridgewater, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Mirabel, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Saint-Marc-des-Carrieres, Quebec, Canada|Research Site, Ceske Budejovice, Czechia|Research Site, Chrudim III, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Praha - Klanovice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 8, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Berlin, Germany|Research Site, Bünde, Germany|Research Site, Essen, Germany|Research Site, Giengen, Germany|Research Site, Grossheirath, Germany|Research Site, Hof, Germany|Research Site, Hohenmölsen, Germany|Research Site, Karlsruhe, Germany|Research Site, Lichtenfels, Germany|Research Site, Meine, Germany|Research Site, Münster, Germany|Research Site, Rehburg Loccum, Germany|Research Site, Stolberg, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Zapopan, Mexico|Research Site, Arkhangelsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladikavkaz, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02681094/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02681094/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02681094"
20,"NCT02582814","The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM",,"Completed","Has Results","Type 1 Diabetes Mellitus","Drug: Dapagliflozin 5 mg|Drug: Dapagliflozin 10mg","Overall Adverse Event Summary|Hypoglycemia|Diabetic Ketoacidosis (DKA)|Vital Signs (Heart Rate)|ECGs|Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)|Vital Signs (Blood Pressure)|Adjusted Change From Baseline in HbA1c|Adjusted Percent Change From Baseline in Total Daily Insulin Dose|Adjusted Percent Change From Baseline in Body Weight|Adjusted Change From Baseline in Glycoalbumin|Adjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG|Adjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG|Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia|Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent|Proportion of Subjects Achieving HbA1c < 7.0 Percent|Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg","AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1695C00001","October 26, 2015","June 15, 2017","June 15, 2017","October 21, 2015","April 12, 2019","April 12, 2019","Research Site, Aizu Wakamatsu-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Ise-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kunitachi-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Otsu-shi, Japan|Research Site, Oyama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjyuku-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Tama-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Yokohama-shi, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02582814/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02582814/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02582814"
21,"NCT02551874","A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Saxagliptin, Onglyza|Drug: Dapagliflozin, Farxiga|Drug: Glargine insulin|Drug: Metformin","Mean Change From Baseline in HbA1c at Week 24|Mean Change From Baseline in Total Body Weight at Week 24|Percentage of Subjects With Confirmed Hypoglycaemia at Week 24|Percentage of Subjects Achieving a Therapeutic Glycemic Response, Without Hypoglycaemia, at Week 24|Percentage of Subjects Achieving a Therapeutic Glycemic Response at Week 24|Change From Baseline in the Mean Value of 24-hour Glucose at Week 2","AstraZeneca","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","650","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CV181-369|2015-001702-33","October 20, 2015","May 8, 2017","November 10, 2017","September 16, 2015","September 18, 2018","December 11, 2018","Research Site, Anaheim, California, United States|Research Site, Los Angeles, California, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Norcross, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Lexington, Kentucky, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Beavercreek, Ohio, United States|Research Site, Norman, Oklahoma, United States|Research Site, Barto, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Bountiful, Utah, United States|Research Site, Karlovy Vary, Czechia|Research Site, Olomouc, Czechia|Research Site, Koebenhavn, Denmark|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Lodz, Poland|Research Site, Nowy Duninow, Poland|Research Site, Sochaczew, Poland|Research Site, Craiova, Romania|Research Site, Ploiesti, Romania|Research Site, Timisoara, Romania|Research Site, Timișoara, Romania|Research Site, Lenasia, South Africa|Research Site, La Coruña, Spain|Research Site, Uddevalla, Sweden","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02551874/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02551874/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02551874"
22,"NCT02546323","A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis",,"Completed","Has Results","Atherosclerosis","Drug: Rosuvastatin|Drug: Placebo","Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period|Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA|Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb|Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA|Annualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA|Percent Change From Baseline in Lipid, Lipoprotein and Apolipoprotein Values at Final Visit: Last Observation Carried Forward (LOCF)|Percent Change From Baseline in Lipid and Lipoprotein Values at Final Visit: Time Weighted Average","AstraZeneca","All","45 Years to 69 Years   (Adult, Older Adult)","Phase 3","543","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D3565C00003","September 17, 2015","January 29, 2019","January 29, 2019","September 10, 2015","December 11, 2019","December 11, 2019","Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Changsha, China|Research Site, Chongqin, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haerbin, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Ningbo, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Xian, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02546323/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02546323/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02546323"
23,"NCT02463071","AZD0585 Phase III Long-term Study in Japan",,"Completed","Has Results","Hypertriglyceridemia","Drug: AZD0585|Drug: AZD0585 placebo","Efficacy of AZD0585 by Assessment of Percent Change in Serum Triglycerides|Safety of AZD0585 by Assessment of Adverse Events in Patients|Efficacy of AZD0585 by Assessment of Percent Change in Serum Lipid Profile|Efficacy of AZD0585 by Assessment of Percent Changes in Plasma Fatty Acids Profile.|Efficacy of AZD0585 by Assessment of Percent Changes in Apolipoproteins Profile|Efficacy of AZD0585 by Assessment of Percent Changes in Small Dense LDL and LDL-C/Apo B Ratio|Efficacy of AZD0585 by Assessment of Percent Changes in Lp(a), RLP-C, PCSK9, and Hs-CRP","AstraZeneca","All","20 Years to 130 Years   (Adult, Older Adult)","Phase 3","383","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5884C00002","June 10, 2015","March 11, 2017","March 11, 2017","June 4, 2015","October 1, 2018","October 1, 2018","Research Site, Aki-gun, Japan|Research Site, Chiba-shi, Japan|Research Site, Chofu-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Itami-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Komatsu-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Naha-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Ota-ku, Japan|Research Site, Sendai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Toyonaka-shi, Japan|Research Site, Urasoe-shi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02463071/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02463071/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02463071"
24,"NCT02460978","Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes","DEPICT 2","Completed","Has Results","Type 1 Diabetes Mellitus","Drug: Dapagliflozin|Other: Placebo for dapagliflozin","Adjusted Mean Change From Baseline in HbA1c at Week 24|Adjusted Mean Percentage Change From Baseline in Total Daily Insulin Dose at Week 24|Adjusted Mean Percentage Change From Baseline in Body Weight at Week 24|Adjusted Mean Change From Baseline in 24-hour Continuous Glucose Monitoring (CGM) Mean Value at Week 24|Adjusted Mean Change From Baseline in 24-hour CGM Mean Amplitude of Glycemic Excursion (MAGE) Value at Week 24|Change From Baseline in the Percent of 24-hour Glucose Readings Obtained From CGM That Falls Within the Target Range of > 70 mg/dL and <= 180 mg/dL (%) at Week 24|Percentage of Subjects With HbA1c Reduction From Baseline to Week 24 Last Observation Carried Forward (LOCF) >= 0.5% and Without Severe Hypoglycemia Events at Week 24","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","815","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MB102-230|2014-004599-49|D1695C00007","July 8, 2015","September 2, 2017","April 18, 2018","June 3, 2015","November 6, 2018","March 5, 2019","Research Site, Concord, California, United States|Research Site, Fresno, California, United States|Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, San Mateo, California, United States|Research Site, San Ramon, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Golden, Colorado, United States|Research Site, Newark, Delaware, United States|Research Site, Bradenton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Des Moines, Iowa, United States|Research Site, Overland Park, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Reno, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Flushing, New York, United States|Research Site, Mineola, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Edinburg, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Bennington, Vermont, United States|Research Site, Federal Way, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Brussels (Uccle), Belgium|Research Site, Leuven, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Falkensee, Germany|Research Site, Freiburg im Breisgau, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Oldenburg, Germany|Research Site, Pohlheim, Germany|Research Site, Saarlouis, Germany|Research Site, Sulzbach-Rosenberg, Germany|Research Site, Wangen, Germany|Research Site, Aki-gun, Japan|Research Site, Amagasaki-shi, Japan|Research Site, Chitose-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Higashiosaka-shi, Japan|Research Site, Ibusuki-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kamakura-shi, Japan|Research Site, Kashiwara-shi, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Miura-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Obihiro-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Oyama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shibuya-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Ushiku-shi, Japan|Research Site, Uwajima-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Hoogeveen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Gdańsk, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Warsaw, Poland|Research Site, Wroclaw, Poland|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Linkoping, Sweden|Research Site, Uddevalla, Sweden|Research Site, Olten, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zollikerberg, Switzerland|Research Site, Manchester, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Oldham, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Wakefield, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02460978/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02460978/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02460978"
25,"NCT02446912","Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus",,"Completed","Has Results","Active Systemic Lupus Erythematosus","Biological: Anifrolumab|Drug: Placebo","Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index ≥4 (SRI[4]) at Week 52 (Original Analysis With Restricted Medication Rules)|Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 at Week 52 in the Interferon (IFN) Test-High Sub-Group (Original Analysis With Restricted Medication Rules)|Number of Participants Who Achieved and Maintained an Oral Corticosteroid (OCS) Dose of ≤7.5 mg/Day in the Sub-group of Participants With Baseline OCS ≥10 mg/Day (Original Analysis With Restricted Medication Rules)|Number of Participants With a ≥50% Reduction in CLASI Activity Score at Week 12 in the Sub-group of Participants With Baseline CLASI Activity Score ≥10 (Original Analysis With Restricted Medication Rules)|Number of Participants Who Achieved a Systemic Lupus Erythematosus (SLE) Responder Index of ≥4 (SRI[4]) at Week 24 (Original Analysis With Restricted Medication Rules)|Annualized Flare Rate|Number of Participants Who Met the Criteria for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response (Original Analysis With Restricted Medication Rules)|Number of Participants Reporting One or More Adverse Events (AE)|Number of Participants Reporting One or More Adverse Events of Special Interest (AESI)|Number of Participants With Markedly Abnormal Vital Signs|Number of Participants With Markedly Abnormal Physical Examinations|Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Scores|Number of Participants With Mild To Moderate Lupus Flare Evaluated by Modified Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare Index|Number of Participants With Markedly Abnormal Laboratory Tests|Number of Participants With Suicidal Ideation or Behaviour Assessed Via the Columbia Suicide Severity Rating Scale (C-SSRS)|Change From Baseline in Personal Health Questionnaire Depression Scale-8 (PHQ-8) Score","AstraZeneca|PRA Health Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","460","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D3461C00005","June 9, 2015","July 17, 2018","July 17, 2018","May 18, 2015","December 5, 2019","December 5, 2019","Research Site, Birmingham, Alabama, United States|Research Site, El Cajon, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Aventura, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Nashua, New Hampshire, United States|Research Site, Freehold, New Jersey, United States|Research Site, Great Neck, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Jackson, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Glendale, Wisconsin, United States|Research Site, Cordoba, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Fitzroy, Australia|Research Site, Kogarah, Australia|Research Site, St Leonards, Australia|Research Site, Belo Horizonte, Brazil|Research Site, Juiz de Fora, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Salvador, Brazil|Research Site, Osorno, Chile|Research Site, Santiago, Chile|Research Site, Vina del Mar, Chile|Research Site, Armenia, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bogota, Colombia|Research Site, Bucaramanga, Colombia|Research Site, Medellin, Colombia|Research Site, Berlin, Germany|Research Site, Dessau-RoBlau, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Göttingen, Germany|Research Site, Kirchheim, Germany|Research Site, Köln, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Szeged, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Petach-Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Hamilton, New Zealand|Research Site, Wellington, New Zealand|Research Site, Arequipa, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Białystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Elblag, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Nadarzyn, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Sosnowiec, Poland|Research Site, Starachowice, Poland|Research Site, Szczecin, Poland|Research Site, Ustron, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj Napoca, Romania|Research Site, Galati, Romania|Research Site, Tg Mures, Romania|Research Site, Kaohsiung Hsien, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Brighton, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Staffordshire, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02446912/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02446912/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02446912"
26,"NCT02446899","Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus",,"Completed","Has Results","Active Systemic Lupus Erythematosus","Biological: Anifrolumab|Drug: Placebo","Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52|Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group|Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of ≤7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS ≥10 mg/Day|Number of Participants With a ≥50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of ≥10|Number of Participants With ≥50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With ≥6 Swollen and ≥6 Tender Joints at Baseline|Annualised Flare Rate Through 52 Weeks|Number of Participants With One or More Adverse Events (AEs)|Number of Participants With One or More Adverse Events of Special Interest (AESIs)|Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements|Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests","AstraZeneca|PRA Health Sciences","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","373","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D3461C00004","July 9, 2015","September 27, 2018","September 27, 2018","May 18, 2015","March 18, 2020","April 21, 2020","Research Site, Covina, California, United States|Research Site, Hemet, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Leandro, California, United States|Research Site, Torrance, California, United States|Research Site, Upland, California, United States|Research Site, Denver, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Brandon, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Cruces, New Mexico, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Greenville, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Stafford, Texas, United States|Research Site, Arlington, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Mendoza, Argentina|Research Site, Quilmes, Argentina|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Merksem, Belgium|Research Site, Goiania, Brazil|Research Site, Juiz de Fora, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Hamilton, Ontario, Canada|Research Site, Rimouski, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Lille, France|Research Site, Montpellier CEDEX 5, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Toulouse, France|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Jena, Germany|Research Site, Mainz, Germany|Research Site, München, Germany|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Kurashiki-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Meguro-ku, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Omura-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sasebo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Tsukuba, Japan|Research Site, Jeju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Chihuahua, Mexico|Research Site, Leon, Mexico|Research Site, Mexico D.F., Mexico|Research Site, Mexico, Mexico|Research Site, Morelia, Mexico|Research Site, Mérida, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Kemerovo, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Tolyatti, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Cape Town, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Stellenbosch, South Africa|Research Site, Barcelona, Spain|Research Site, Getafe, Spain|Research Site, Las Palmas de Gran Canaria, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Mérida, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Servilla, Spain|Research Site, Vigo, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02446899/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02446899/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02446899"
27,"NCT02434497","A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia",,"Completed","Has Results","Homozygous Familial Hypercholesterolemia (HoFH)","Drug: Rosuvastatin 20mg","The Number of Participants Who Experianced Adverse Events and Serious Adverse Events|Safety and Tolerability in Terms of Number of Participants Who Had Adverse Events, Discontinuations Due to Adverse Events|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Basophils/Leukocytes (%) >Upper Limite of Normal (ULN)|Safety and Tolerability in Terms of Growth, Height|Safety and Tolerability in Terms of Abnormalitites in Sexual Maturation|Safety and Tolerability in Terms of Growth, Height SD-score (or Z-score)|Safety and Tolerability in Terms of Growth, Weight|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Alanine Aminotransferase (U/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Albumin (g/dL) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Aspartate Aminotransferase (U/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Bicarbonate (Mol/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB Concentration (g/dL) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular HGB (pg) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Ery. Mean Corpuscular Volume (fL) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Erythrocytes (10^12/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hematocrit (%) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Hemoglobin (g/dL) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Leukocytes >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lymphocytes/Leukocytes (%) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Monocytes/Leukocytes (%) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Platelets (10^9/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Blood Urea Nitrogen (mg/dL) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Chloride (mmol/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Creatine Kinase (U/L) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Glucose (mg/dL) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Lactate Dehydrogenase (U/L) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Phosphate (mg/dL) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Protein (g/dL) >ULN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Sodium (mmol/L) <LLN|Safety and Tolerability in Terms of Abnormal Serum Laboratory Values, Urate (mg/dL) >ULN|Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Ketones|Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Occult Blood|Safety and Tolerability in Terms of Abnormal Urine Laboratory Values, Urine Protein|Safety and Tolerability in Terms of Abnormal ECG, Abnormalities|Safety and Tolerability in Terms of Abnormal Physical Exams, Cardiovascular|Safety and Tolerability in Terms of Abnormal Physical Exams, General Appearance|Safety and Tolerability in Terms of Abnormal Physical Exams, Head and Neck|Safety and Tolerability in Terms of Abnormal Physical Exams, Musculoskeletal/Extremities|Safety and Tolerability in Terms of Abnormal Physical Exams, Skin|Safety and Tolerability in Terms of Abnormal Vital Signs|Percent Change in LDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in Total Cholesterol (TC) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in Triglycerides (TG) From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in Non-HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in LDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in TC/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in Non-HDL-C/HDL-C From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in ApoB From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Percent Change in ApoB/ApoA-1 From End of Placebo of D3561C00004 to the End of D356NC00001, Repeated Measures Analysis|Pharmacokinetic Profile in Terms of Trough Concentrations in Pediatric HoFH Taking a Daily Dose of Rosuvastatin 40mg","AstraZeneca","All","6 Years to 18 Years   (Child, Adult)","Phase 3","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D356NC00001","June 6, 2015","November 17, 2016","November 17, 2016","May 5, 2015","February 27, 2018","February 27, 2018","Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Chicoutimi, Quebec, Canada|Research Site, Copenhagen, Denmark|Research Site, Halfa, Israel|Research Site, Kubang Kerian, Malaysia|Research Site, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT02434497"
28,"NCT02419612","A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",,"Completed","Has Results","Diabetes","Drug: Saxagliptin|Drug: Dapagliflozin|Drug: Glimepiride|Other: Placebo","Change From Baseline in Hemoglobin A1c (HbA1c) at Week 52|Change From Baseline in Total Body Weight at Week 52|Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 52|Change From Baseline in Systolic Blood Pressure (SBP) at Week 52|Percentage of Subjects With Treatment Intensification During the 52-week Short-term Treatment Period|Percentage of Subjects With Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.|Percentage of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%, at Week 156|Time to Treatment Intensification During the 156-Week Short-term Plus Long-Term Treatment Period.","AstraZeneca","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","444","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CV181-365","August 14, 2015","August 29, 2017","September 18, 2019","April 17, 2015","October 19, 2018","June 23, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Tempe, Arizona, United States|Research Site, Huntington Park, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, Tarzana, California, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Edina, Minnesota, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Greer, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Cheb, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Krnov, Czechia|Research Site, Kromeriz, Czechia|Research Site, Nachod, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Dresden, Germany|Research Site, Leipzig, Germany|Research Site, Ajka, Hungary|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Cuautla, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guanajuato, Mexico|Research Site, Monterrey, Mexico|Research Site, Veracruz, Mexico|Research Site, Białystok, Poland|Research Site, Katowice, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Opole, Poland|Research Site, Oswiecim, Poland|Research Site, Poznań, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Łódź, Poland|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Buzau, Romania|Research Site, Galati, Romania|Research Site, Oradea, Romania|Research Site, Oradea, Romania|Research Site, Ploiesti, Romania|Research Site, Ploiesti, Romania|Research Site, Satu-Mare, Romania|Research Site, Targu, Romania|Research Site, Timisoara, Romania|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.-Petersburg, Russian Federation|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Rättvik, Sweden|Research Site, Dundee, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02419612/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02419612/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02419612"
29,"NCT02417961","Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home",,"Completed","Has Results","Asthma","Biological: Benralizumab","Number and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home|Number and Percentage of Returned APFS Used to Administer Benralizumab at Home That Have Been Evaluated as Functional|Number and Percentage of APFS Used to Administer Benralizumab at Home or in the Clinic and Have Been Reported as Malfunctioning (Product Complaints)|The Effect of Benralizumab on Asthma Control Metrics in Terms of Change From Baseline in Mean Asthma Control Questionnaire-6 (ACQ-6) Score|The Pharmacokinetics (PK) of Benralizumab in the Terms of PK Parameters: Serum Concentration of Benralizumab|The Pharmacodynamics of Benralizumab in the Terms of Peripheral Blood Eosinophil Levels|The Immunogenicity of Benralizumab in the Terms of Anti-drug Antibodies (ADA)","AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","162","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D3250C00029","April 27, 2015","March 14, 2016","March 14, 2016","April 16, 2015","June 12, 2017","May 23, 2018","Research Site, Fountain Valley, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Celebration, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Albany, Georgia, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, San Antonio, Texas, United States|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Trois-Rivières, Quebec, Canada|Research Site, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02417961"
30,"NCT02413398","A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes","DERIVE","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Dapagliflozin 10 mg|Drug: Matching Placebo for Dapagliflozin","Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24|Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24.|Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24.|Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24.","AstraZeneca","All","18 Years to 74 Years   (Adult, Older Adult)","Phase 3","321","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D1690C00024","June 15, 2015","November 7, 2017","November 7, 2017","April 9, 2015","October 31, 2018","October 31, 2018","Research Site, Huntsville, Alabama, United States|Research Site, Burbank, California, United States|Research Site, Chula Vista, California, United States|Research Site, Concord, California, United States|Research Site, Fullerton, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Gatos, California, United States|Research Site, Newport Beach, California, United States|Research Site, Salinas, California, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Brownsburg, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Monroe, Louisiana, United States|Research Site, Flint, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Manassas, Virginia, United States|Research Site, Blagoevgrad, Bulgaria|Research Site, Botevgrad, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Red Deer, Alberta, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Concord, Ontario, Canada|Research Site, Courtice, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Cheb, Czechia|Research Site, Horovice, Czechia|Research Site, Krnov, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha - Klanovice, Czechia|Research Site, Praha 10, Czechia|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Chieti Scalo, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Pisa, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Bielsko-Biała, Poland|Research Site, Bydgoszcz, Poland|Research Site, Mrągowo, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Tczew, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, A Coruña, Spain|Research Site, Alicante, Spain|Research Site, Ferrol, Spain|Research Site, La Laguna (Tenerife), Spain|Research Site, Lérida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Pozuelo de Alarcon, Spain|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02413398/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02413398/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02413398"
31,"NCT02369874","Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer","EAGLE","Completed","Has Results","Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN","Drug: MEDI4736|Drug: MEDI4736 + Tremelimumab|Drug: Standard of Care","Overall Survival (OS)|Overall Survival (OS) in PD-L1 Negative Participants|Overall Survival (OS) in PD-L1 Positive Participants|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Percentage of Participants Alive and Progression Free (APF)|Percentage of Participants Alive|Progression Free Survival (PFS) in PD-L1 Negative Participants|Objective Response Rate (ORR) in PD-L1 Negative Participants|Time to Deterioration in European Organisation for Research and Treatment of Cancer 30-item Core Quality of Life Questionnaire, Version 3 (EORTC QLQ-C30)|Time to Deterioration for European Organisation for Research and Treatment of Cancer 35-item Head and Neck Quality of Life Questionnaire (EORTC QLQ-H&N35)|Number of Participants Reporting One or More Adverse Events (AE)","AstraZeneca","All","18 Years to 96 Years   (Adult, Older Adult)","Phase 3","736","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4193C00002","September 9, 2015","September 10, 2018","November 13, 2020","February 24, 2015","October 3, 2019","February 10, 2021","Research Site, Tucson, Arizona, United States|Research Site, Fullerton, California, United States|Research Site, Los Angeles, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Stanford, California, United States|Research Site, Denver, Colorado, United States|Research Site, Newark, Delaware, United States|Research Site, Miami Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Evanston, Illinois, United States|Research Site, Lexington, Kentucky, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, New York, United States|Research Site, Rochester, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Germantown, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Caba, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Adelaide, Australia|Research Site, Heidelberg, Australia|Research Site, Melbourne, Australia|Research Site, St Leonards, Australia|Research Site, Woolloongabba, Australia|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Namur, Belgium|Research Site, Barretos, Brazil|Research Site, Curitiba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Shumen, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Temuco, Chile|Research Site, Osijek, Croatia|Research Site, Zagreb, Croatia|Research Site, Olomouc, Czechia|Research Site, Zlin, Czechia|Research Site, Angers, France|Research Site, Bordeaux, France|Research Site, Dijon, France|Research Site, Le Mans, France|Research Site, Lyon Cedex 08, France|Research Site, Montpellier Cedex 5, France|Research Site, Paris Cedex 5, France|Research Site, Plerin SUR MER, France|Research Site, Rouen, France|Research Site, St Grégoire, France|Research Site, Strasbourg Cedex, France|Research Site, Villejuif Cedex, France|Research Site, Lorient Cedex, Georgia|Research Site, Berlin, Germany|Research Site, Essen, Germany|Research Site, Halle, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Potsdam, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Kecskemét, Hungary|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Petach-Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Hashomer, Israel|Research Site, Aosta, Italy|Research Site, Bologna, Italy|Research Site, Gallarate, Italy|Research Site, Legnago, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya, Japan|Research Site, Natori-shi, Japan|Research Site, Okayama, Japan|Research Site, Osakasayama, Japan|Research Site, Osaka, Japan|Research Site, Sapporo, Japan|Research Site, Sapporo, Japan|Research Site, Shimotsuke-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama, Japan|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Kraków, Poland|Research Site, Poznań, Poland|Research Site, Łódź, Poland|Research Site, Baia Mare, Romania|Research Site, Brasov, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Cluj, Romania|Research Site, Craiova, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sankt-Peterburg, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Belgrad, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Marbella, Spain|Research Site, Pamplona, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoynan, Taiwan|Research Site, Dnipro, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Zaporizhzhia, Ukraine","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02369874/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02369874/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02369874"
32,"NCT02322788","Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3",,"Completed","Has Results","Asthma","Drug: Terbutaline sulphate|Drug: Placebo for terbutaline sulphate","Provocative Concentration of Methacholine Which Produces a 20% Fall in FEV1 (PC20)","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","95","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science","D4711C00001","March 2015","November 2015","November 2015","December 23, 2014","November 6, 2016","January 13, 2017","Research Site, Hamilton, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Groningen, Netherlands|Research Site, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT02322788"
33,"NCT02322775","Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma",,"Completed","Has Results","Asthma","Biological: Benralizumab|Biological: Placebo","Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12|Change From Baseline in Morning Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12|Change From Baseline in Evening Peak Expiratory Flow (PEF) (L/Min) at Home at Week 12|Change From Baseline in Total Asthma Symptom Score at Week 12|Change From Baseline in Total Asthma Rescue Medication Use (Puffs) at Week 12|Change From Baseline in Proportion of Nights With Nocturnal Awakenings at Week 12|Change From Baseline in Mean ACQ-6 Score at Week 12|Asthma Exacerbations|Change From Baseline in AQLQ(S)+12 Total and Domain Scores at Week 12|Serum Concentrations (ng/mL)|Peripheral Blood Eosinophil Levels","AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","211","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D3250C00032|2014-004427-40","February 2, 2015","October 7, 2015","October 7, 2015","December 23, 2014","February 14, 2017","August 15, 2017","Research Site, Los Angeles, California, United States|Research Site, Rolling Hills Estates, California, United States|Research Site, Clearwater, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Blue Island, Illinois, United States|Research Site, Skillman, New Jersey, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Monroe, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Grove City, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, El Paso, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Vancouver, British Columbia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Trois Rivieres, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Frankfurt/Main, Germany|Research Site, Frankfurt, Germany|Research Site, Hannover, Germany|Research Site, Neu-Isenburg, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Komárom, Hungary|Research Site, Miskolc, Hungary|Research Site, Pécs, Hungary|Research Site, Pécs, Hungary|Research Site, Százhalombatta, Hungary|Research Site, Katowice, Poland|Research Site, Mrągowo, Poland|Research Site, Ostrów Wielkopolski, Poland|Research Site, Pabianice, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Tarnów, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Humenne, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Poprad, Slovakia|Research Site, Presov, Slovakia|Research Site, Vrable, Slovakia|Research Site, Zilina, Slovakia",,"https://ClinicalTrials.gov/show/NCT02322775"
34,"NCT02284893","Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Dapagliflozin|Drug: Sitagliptin|Drug: Placebo matching with Saxagliptin|Drug: Placebo matching with Dapagliflozin|Drug: Placebo matching with Sitagliptin","Mean Change in HbA1c|Percent of Subjects Achieving a Therapeutic Glycemic Response, Defined as HbA1c < 7.0%|Mean Change in Total Body Weight|Mean Change in Fasting Plasma Glucose (FPG)","AstraZeneca","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","461","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CV181-363|2014-001102-17","September 9, 2014","September 20, 2016","September 20, 2016","November 6, 2014","June 1, 2018","June 1, 2018","Research Site, Mesa, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Huntington Beach, California, United States|Research Site, Huntington Park, California, United States|Research Site, Lomita, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Norwalk, California, United States|Research Site, Paramount, California, United States|Research Site, Sacramento, California, United States|Research Site, Tarzana, California, United States|Research Site, Tustin, California, United States|Research Site, Golden, Colorado, United States|Research Site, Coral Gables, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Norman, Oklahoma, United States|Research Site, Columbia, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Pasadena, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Manassas, Virginia, United States|Research Site, Suffolk, Virginia, United States|Research Site, Kenosha, Wisconsin, United States|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyula, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szekszárd, Hungary|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Cuautla, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research Site, Białystok, Poland|Research Site, Gdańsk, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Opole, Poland|Research Site, Poznań, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Buzau, Romania|Research Site, Craiova, Romania|Research Site, Galati, Romania|Research Site, Oradea, Romania|Research Site, Satu-Mare, Romania|Research Site, Timisoara, Romania|Research Site, Boksburg North, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Lenasia, South Africa|Research Site, Moloto, South Africa|Research Site, Soweto, South Africa",,"https://ClinicalTrials.gov/show/NCT02284893"
35,"NCT02281357","Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma","TROPOS","Completed","Has Results","Asthma","Biological: Tralokinumab|Other: Placebo","Percent Change From Baseline in the Final Daily, Average, OCS Dose at Week 40 While Not Losing Asthma Control.|The Number of Patients With Final Daily Average OCS Dose ≤5 mg at Week 40.|The Number of Patients With ≥50% Reduction in Final Average Daily OCS Dose at Week 40.|Annual Asthma Exacerbation Rate (AAER) up to Week 40.","AstraZeneca","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D2210C00013","February 19, 2015","September 7, 2017","September 7, 2017","November 2, 2014","May 16, 2018","March 15, 2019","Research Site, New Haven, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Bronx, New York, United States|Research Site, Rochester, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Monroeville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Boerne, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Brussels (Anderlecht), Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Leuven, Belgium|Research Site, Woluwé-St-Lambert, Belgium|Research Site, GRENOBLE Cedex 9, France|Research Site, Lille Cedex, France|Research Site, Lyon Cedex 04, France|Research Site, Nantes Cedex 1, France|Research Site, Pessac, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Mainz, Germany|Research Site, München-Pasing, Germany|Research Site, München, Germany|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Bystra Śląska, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Lubin, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Rzeszów, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Dnipro, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Vinnytsia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02281357/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02281357/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02281357"
36,"NCT02273050","Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Saxagliptin 5 mg|Drug: Placebo 5 mg for Saxagliptin|Drug: Placebo 500 mg for metformin (with titration)|Drug: Metformin 500 mg with titration","Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue|Glycemic Response Defined as HbA1c < 7.0% at Week 24|Change From Baseline to Week 24 (Prior to Rescue) in Fasting Plasma Glucose|Change From Baseline to Week 24 (Prior to Rescue) in Area Under the Curve From 0-180 Minutes for Postprandial Glucose Response to a Meal Tolerance Test|Glycemic Response Defined as HbA1c ≤ 6.5% at Week 24|Change From Baseline to Week 24 in 120-minute Postprandial Glucose Response to a Meal Tolerance Test|Patients Rescued for Failing to Achieve Pre-specified Glycemic Targets or Discontinuation for Lack of Efficacy During the 24-week Double-blind Treatment Phase","AstraZeneca","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","1136","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680C00009","December 2014","August 2016","August 2016","October 23, 2014","February 5, 2018","February 5, 2018","Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chuangchun, China|Research Site, Fuzhou, China|Research Site, Guiyang, China|Research Site, Ha'er bin, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shijiazhuang, China|Research Site, Siping, China|Research Site, Tianjin, China|Research Site, Wuxi, China|Research Site, Yueyang, China",,"https://ClinicalTrials.gov/show/NCT02273050"
37,"NCT02269488","A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years",,"Completed","Has Results","Healthy Japanese Children Age 2 Years Through 6 Years","Drug: MEDI3250","Number of Participants With Solicited Symptoms Experienced From Administration of MEDI3250","AstraZeneca","All","2 Years to 6 Years   (Child)","Phase 3","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","D2560C00007","November 2014","February 2015","February 2015","October 21, 2014","September 28, 2015","September 28, 2015","Research Site, Kameyama-shi, Japan|Research Site, Suzuka-shi, Japan|Research Site, Tsu-shi, Japan",,"https://ClinicalTrials.gov/show/NCT02269488"
38,"NCT02269475","A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years",,"Completed","Has Results","Healthy Japanese Children Age 7 Years Through 18 Years","Drug: MEDI3250|Drug: Placebo","the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain)|the Incidence of Laboratory-confirmed Influenza Infection (Any Strain)|the Incidence of Laboratory-confirmed Influenza Infection (Matched Strain, by Strain)","AstraZeneca","All","7 Years to 18 Years   (Child, Adult)","Phase 3","1369","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","D2560C00006","October 2014","April 2015","April 2015","October 21, 2014","December 3, 2015","April 4, 2017","Research Site, Akashi-shi, Japan|Research Site, Chofu-shi, Japan|Research Site, Fuchu-shi, Japan|Research Site, Fujimi-shi, Japan|Research Site, Fukui-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuroi-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hatsukaichi-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Ichikawa-shi, Japan|Research Site, Isumi-shi, Japan|Research Site, Iwate-gun, Japan|Research Site, Katsushika-ku, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kisarazu-shi, Japan|Research Site, Kiyose-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kunitachi-shi, Japan|Research Site, Kuwana-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Morioka-shi, Japan|Research Site, Nakano-ku, Japan|Research Site, Okayama-shi, Japan|Research Site, Ota-ku, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Setagaya-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Taito-ku, Japan|Research Site, Toshima-ku, Japan|Research Site, Tsu-shi, Japan|Research Site, Yokkaichi-shi, Japan",,"https://ClinicalTrials.gov/show/NCT02269475"
39,"NCT02268214","Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes","DEPICT 1","Completed","Has Results","Type 1 Diabetes Mellitus","Drug: Dapagliflozin|Drug: Placebo for dapagliflozin","Adjusted Mean Change in HbA1c From Baseline at Week 24|Adjusted Mean Percent Change in Total Daily Insulin Dose From Baseline at Week 24|Adjusted Mean Percent Change in Body Weight From Baseline at Week 24|Adjusted Mean Change in 24-hour Mean Continuous Glucose Monitoring Glucose From Baseline at Week 24|Adjusted Mean Change in 24-hour Continuous Glucose Monitoring MAGE From Baseline at Week 24|Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose > 70 and <= 180 (mg/dL) From Baseline at Week 24|Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) >= 0.5% and Without Severe Hypoglycemia Events","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","833","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MB102-229|2013-004674-97|D1695C00006","November 11, 2014","January 4, 2017","August 25, 2017","October 20, 2014","March 29, 2018","September 13, 2018","Research Site, Little Rock, Arkansas, United States|Research Site, Encino, California, United States|Research Site, La Mesa, California, United States|Research Site, San Diego, California, United States|Research Site, Tarzana, California, United States|Research Site, Torrance, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Cooper City, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Des Moines, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Portland, Maine, United States|Research Site, Hyattsville, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albany, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Olympia, Washington, United States|Research Site, Concord, Australia|Research Site, Daw Park, Australia|Research Site, Fitzroy, Australia|Research Site, Heidelberg West, Australia|Research Site, Newcastle, Australia|Research Site, Southport, Australia|Research Site, Wollongong, Australia|Research Site, Innsbruck, Austria|Research Site, Saint Stefan/Stainz, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Bonheiden, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, London, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Arhus C, Denmark|Research Site, Esbjerg, Denmark|Research Site, Odense, Denmark|Research Site, Randers NØ, Denmark|Research Site, Helsinki, Finland|Research Site, Jyvaskyla, Finland|Research Site, Kuopio, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Besançon Cedex, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon, France|Research Site, SAINT HERBLAIN Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Aschaffenburg, Germany|Research Site, Aßlar, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Falkensee, Germany|Research Site, Munich, Germany|Research Site, Munster, Germany|Research Site, Neuwied, Germany|Research Site, Oldenburg, Germany|Research Site, Pohlheim, Germany|Research Site, Schweinfurt, Germany|Research Site, Sulzbach, Germany|Research Site, Witten, Germany|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Létavértes, Hungary|Research Site, Szeged, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Safed, Israel|Research Site, Tel-Aviv, Israel|Research Site, Tikva, Israel|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Padowa, Italy|Research Site, Palermo, Italy|Research Site, Ravenna, Italy|Research Site, Sesto San Giovanni, Italy|Research Site, Siena, Italy|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Cuernavaca, Mexico|Research Site, Guadalajara, Mexico|Research Site, Merida, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Torreon, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Mexico|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Dolj, Romania|Research Site, Galati, Romania|Research Site, Iasi, Romania|Research Site, Timisoara, Romania|Research Site, A Coruña, Spain|Research Site, Almeria, Spain|Research Site, Barcelona, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Göteborg, Sweden|Research Site, Karlstad, Sweden|Research Site, Lund, Sweden|Research Site, Uppsala, Sweden|Research Site, Belfast, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Welwyn Garden City, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02268214"
40,"NCT02258542","A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA","BORA","Completed","Has Results","Asthma","Biological: Benralizumab","Change From Baseline in Basophils, Full Analysis Set, Excluding MELTEMI Patients|Change From Baseline in Basophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Leukocytes, Full Analysis Set, Excluding MELTEMI Patients|Change From Baseline in Leukocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Lymphocytes, Full Analysis Set, Excluding MELTEMI Patients|Change From Baseline in Lymphocytes, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Neutrophils, Full Analysis Set, Excluding MELTEMI Patients|Change From Baseline in Neutrophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Eosinophils, Full Analysis Set, Excluding MELTEMI Patients|Change From Baseline in Eosinophils, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set, Excluding MELTEMI Patients|Change From Baseline in ALT, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set, Excluding MELTEMI Patients|Change From Baseline in AST, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Bilirubin, Full Analysis Set, Excluding MELTEMI Patients|Change From Baseline in Bilirubin, Full Analysis Set, Adolescents Only (SIROCCO/CALIMA)|Number of Overall Patients With Asthma Exacerbations During Study Period|Number of Overall Patients With Asthma Exacerbations During Study Period, Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Pre-bronchodilator FEV1 (L)|Change From Baseline in Pre-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Post-bronchodilator FEV1 (L)|Change From Baseline in Post-bronchodilator FEV1 (L), Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients|Change From Baseline in Asthma Control Questionnaire (ACQ) as a Measure of Asthma Control in Overall Patients, Adolescents Only (SIROCCO/CALIMA)|Change From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12)|Change From Baseline in Total Score of Asthma Related and General Health-related Quality of Life Questionnaire (AQLQ(S)+12), Adolescents Only (SIROCCO/CALIMA)|Change of Blood Eosinophil Levels' Measurement in Overall Patients|Change of Blood Eosinophil Levels' Measurement in Adolescents Patients (SIROCCO/CALIMA).|Change From Baseline in EQ-5D-5L Visual Analog Scale|Change From Baseline in EQ-5D-5L Visual Analog Scale, Adolescents Only (SIROCCO/CALIMA)|Work Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI)|Work Productivity Loss in Adults, Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)|Classroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ)|Classroom Productivity Loss Using Classroom Impairment Questionnaire (CIQ), Adolescents Only (SIROCCO/CALIMA)|Activity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI)|Activity Impairment (%), Using Work Productivity and Activity Impairment Questionnaire (WPAI), Adolescents Only (SIROCCO/CALIMA)|Number of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period|Number of Patients Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period, Adolescents Only (SIROCCO/CALIMA)|Pre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study|Pre-dose Benralizumab Concentration in Serum During the Treatment Phase of the Safety Study, Adolescents Only (SIROCCO/CALIMA)|Number of Patients With Anti-drug Antibodies (ADA) Responses During the Study|Number of Patients With Anti-drug Antibodies (ADA) Responses During the Study, Adolescents Only (SIROCCO/CALIMA)","AstraZeneca","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","2133","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","D3250C00021|U1111-1162-2422","November 19, 2014","October 18, 2017","July 2, 2018","October 7, 2014","February 6, 2019","August 21, 2019","Research Site, Andalusia, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Scottsboro, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Bakersfield, California, United States|Research Site, Newport Beach, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, San Jose, California, United States|Research Site, Stockton, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Westminster, California, United States|Research Site, Woodland, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Wheat Ridge, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Brandon, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Cutler Bay, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Albany, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Gurnee, Illinois, United States|Research Site, Normal, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Traverse City, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Northfield, New Jersey, United States|Research Site, Union, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Jefferson Hills, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Hodges, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Arlington, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Splendora, Texas, United States|Research Site, Provo, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Abingdon, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Greenfield, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Concepción del Uruguay, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Florida, Argentina|Research Site, Godoy Cruz, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mendoza, Argentina|Research Site, Mendoza, Argentina|Research Site, Nueve de julio, Argentina|Research Site, Ranelagh, Argentina|Research Site, Rosario, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Bedford Park, Australia|Research Site, Box Hill, Australia|Research Site, Clayton, Australia|Research Site, Concord, Australia|Research Site, Frankston, Australia|Research Site, Nedlands, Australia|Research Site, New Lambton Heights, Australia|Research Site, Parkville, Australia|Research Site, Prahran, Australia|Research Site, Randwick, Australia|Research Site, Woolloongabba, Australia|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sorocaba, Brazil|Research Site, São Paulo, Brazil|Research Site, Dupnitsa, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Petrich, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Samokov, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Velingrad, Bulgaria|Research Site, Vratsa, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Sherwood Park, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quillota, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Valparaiso, Chile|Research Site, Viña del Mar, Chile|Research Site, Jindrichuv Hradec, Czechia|Research Site, Karlovy Vary, Czechia|Research Site, Ostrava, Czechia|Research Site, Plzen, Czechia|Research Site, Praha, Czechia|Research Site, Rokycany, Czechia|Research Site, Strakonice, Czechia|Research Site, Teplice, Czechia|Research Site, Brest Cedex, France|Research Site, Dijon Cedex, France|Research Site, Le Kremlin Bicêtre, France|Research Site, Le Mans Cedex, France|Research Site, Lyon Cedex 4, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Paris, France|Research Site, Pau Cedex, France|Research Site, Pringy Cedex, France|Research Site, Saint Pierre, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse CEDEX 09, France|Research Site, Aschaffenburg, Germany|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt/Main, Germany|Research Site, Frankfurt, Germany|Research Site, Geesthacht, Germany|Research Site, Grosshansdorf, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Hannover, Germany|Research Site, Hannover, Germany|Research Site, Herford, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Mainz Am Rhein, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Neu-Isenburg, Germany|Research Site, Rostock, Germany|Research Site, Rüdersdorf, Germany|Research Site, Witten, Germany|Research Site, Asahi-shi, Japan|Research Site, Chiyoda-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Itabashi-ku, Japan|Research Site, Itabashi-ku, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kokubunji-shi, Japan|Research Site, Matsue-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Mizunami-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Obihiro-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Setagaya-ku, Japan|Research Site, Shibuya-ku, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Sumida-ku, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Toshima-ku, Japan|Research Site, Tsukubo-gun, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Anyang-si, Korea, Republic of|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Quezon City, Philippines|Research Site, Aleksandrów Łódzki, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Bielsko Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bystra Śląska, Poland|Research Site, Dobre Miasto, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Giżycko, Poland|Research Site, Gorzów Wlkp, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Karczew, Poland|Research Site, Katowice, Poland|Research Site, Koszalin, Poland|Research Site, Kościan, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Lubin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Ostrów Wielkopolski, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Proszowice, Poland|Research Site, Ruda Slaska, Poland|Research Site, Rzeszów, Poland|Research Site, Rzeszów, Poland|Research Site, Skierniewice, Poland|Research Site, Sosnowiec, Poland|Research Site, Szczecin, Poland|Research Site, Tarnów, Poland|Research Site, Trzebnica, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wieluń, Poland|Research Site, Wołomin, Poland|Research Site, Wroclaw, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Łódź, Poland|Research Site, Łódź, Poland|Research Site, Żnin, Poland|Research Site, Bragadiru, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Constanta, Romania|Research Site, Deva, Romania|Research Site, Iasi, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint - Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, StPetersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yekaterinburg, Russian Federation|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Mowbray, South Africa|Research Site, Stanger, South Africa|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Lugo, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Oviedo, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Sagunto(Valencia), Spain|Research Site, Salamanca, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Bursa, Turkey|Research Site, Istanbul, Turkey|Research Site, İstanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Mersin, Turkey|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Birmingham, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Chertsey, United Kingdom|Research Site, Chester, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Darlington, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Portsmouth, United Kingdom|Research Site, Soham, United Kingdom|Research Site, Somerset, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Stockton, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02258542/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02258542/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02258542"
41,"NCT02229396","Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo",,"Completed","Has Results","Diabetes Mellitus","Drug: Exantide with Dapagliflozin|Drug: Exentide|Drug: Dapagliflozin","Change in HbA1c From Baseline to Week 28|Change in Body Weight From Baseline to Week 28|Change in Fasting Plasma Glucose From Baseline to Week 28|Change From Baseline to Week 28 in 2-hour Postprandial Glucose After a Standard Meal Tolerance Test|Percentage of Patients Achieving Weight Loss ≥5.0% at Week 28|Change in Fasting Plasma Glucose From Baseline to Week 2|Percentage of Patients Achieving HbA1c <7% at Week 28|Change in Systolic Blood Pressure From Baseline to Week 28","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","695","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5553C00003|2014-003503-29","September 4, 2014","April 26, 2016","December 28, 2017","September 1, 2014","September 8, 2017","December 31, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Tuscumbia, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Tempe, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Chula Vista, California, United States|Research Site, El Cajon, California, United States|Research Site, Fresno, California, United States|Research Site, La Mesa, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Hills, California, United States|Research Site, Montclair, California, United States|Research Site, Oceanside, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, Tustin, California, United States|Research Site, Van Nuys, California, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, North Miami Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Williston, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Franklin, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Newton, Kansas, United States|Research Site, Monroe, Louisiana, United States|Research Site, Hazelwood, Missouri, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Haddon Heights, New Jersey, United States|Research Site, Burlington, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Vandalia, Ohio, United States|Research Site, Medford, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Dakota Dunes, South Dakota, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Pearland, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Baja, Hungary|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budaörs, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Godollo, Hungary|Research Site, Gyula, Hungary|Research Site, Gödöllő, Hungary|Research Site, Kecskemét, Hungary|Research Site, Komárom, Hungary|Research Site, Létavértes, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszárd, Hungary|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Oświęcim, Poland|Research Site, Parczew, Poland|Research Site, Poznań, Poland|Research Site, Torun, Poland|Research Site, Zgierz, Poland|Research Site, Łódź, Poland|Research Site, Baia Mare, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Galati, Romania|Research Site, Oradea, Romania|Research Site, Oradea, Romania|Research Site, Oradea, Romania|Research Site, Ploiesti, Romania|Research Site, Timișoara, Romania|Research Site, Banska Bystrica, Slovakia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Dolny Kubin, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Nitra, Slovakia|Research Site, Pezinok, Slovakia|Research Site, Sturovo, Slovakia|Research Site, Trebišov, Slovakia|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kempton Park, South Africa|Research Site, Middelburg, South Africa|Research Site, Parow, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT02229396"
42,"NCT02229383","Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus","Drug: Exenatide|Drug: Exenatide matching placebo","Change in HbA1c From Baseline to Week 28|Change in Body Weight From Baseline to Week 28|Change From Baseline to Week 28 in 2-hour Postprandial Glucose After a Standard Meal Tolerance Test (MTT)|Percentage of Participants Achieving HbA1c <7.0% at Week 28|Change From Baseline to Week 28 in Daily Insulin Dose|Percentage of Participants Achieving HbA1c <7.0% at Week 28, No Weight Gain at Week 28, and No Major Hypoglycemia Over 28 Weeks|Change in Seated Systolic Blood Pressure From Baseline to Week 28","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","464","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5553C00002|2014-003502-33","September 6, 2014","August 29, 2016","August 29, 2016","September 1, 2014","September 18, 2017","January 8, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Muscle Shoals, Alabama, United States|Research Site, Tempe, Arizona, United States|Research Site, Chino, California, United States|Research Site, Chula Vista, California, United States|Research Site, El Cajon, California, United States|Research Site, Fresno, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Hills, California, United States|Research Site, Tustin, California, United States|Research Site, West Hills, California, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Chiefland, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, North Miami Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Franklin, Indiana, United States|Research Site, Newton, Kansas, United States|Research Site, Monroe, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Hazelwood, Missouri, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Haddon Heights, New Jersey, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Medford, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greer, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Dakota Dunes, South Dakota, United States|Research Site, Johnson City, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Ogden, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Manassas, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Port Orchard, Washington, United States|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Gödöllő, Hungary|Research Site, Komárom, Hungary|Research Site, Létavértes, Hungary|Research Site, Pécs, Hungary|Research Site, Satoraljaujhely, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszárd, Hungary|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Oświęcim, Poland|Research Site, Poznań, Poland|Research Site, Torun, Poland|Research Site, Zamość, Poland|Research Site, Zgierz, Poland|Research Site, Łódź, Poland|Research Site, Baia Mare, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Galati, Romania|Research Site, Oradea, Romania|Research Site, Oradea, Romania|Research Site, Ploiesti, Romania|Research Site, Tg Mures, Romania|Research Site, Timișoara, Romania|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Dolny Kubin, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Sturovo, Slovakia|Research Site, Bloemfontein, South Africa|Research Site, Kempton Park, South Africa|Research Site, Krugersdorp, South Africa|Research Site, Paarl, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Somerset West, South Africa|Research Site, Worcester, South Africa",,"https://ClinicalTrials.gov/show/NCT02229383"
43,"NCT02226198","A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia","HYDRA","Completed","Has Results","Homozygous Familial Hypercholesterolemia (HoFH)","Drug: Rosuvastatin 20mg|Drug: Placebo","LDL-Cholesterol (mg/dL)|LDL-Cholesterol (mmol/L)|TC (mg/dL)|TC (mmol/L)|Non-HDL C (mg/dL)|Non-HDL C (mmol/L)|ApoB (mg/dL)|ApoB (g/L)|HDL-C (mg/dL)|HDL-C (mmol/L)|LDL-C, Not on Apheresis (mg/dL)|LDL-C, Not on Apheresis (mmol/L)|LDL-C From End of Placebo (mg/dL)|LDL-C From End of Placebo (mmol/L)|Trough Concentrations|Adverse Events|AE's Leading to Discontinuation|Abnormal Serum Levels|Height|Height Z-score|Weight|Tanner Stage|TG (mg/dL)|TG (mmol/L)|LDL C/HDL C|TC/HDL C|Non-HDL C/HDL C|ApoB/ApoA|Urinalysis Abnormalitites|ECG Abnormalities|Physical Exam Abnormalitites|Abnormal Vital Signs","AstraZeneca","All","6 Years to 17 Years   (Child)","Phase 3","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D3561C00004","November 2014","July 2015","July 2015","August 27, 2014","July 4, 2016","July 4, 2016","Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Chicoutimi, Quebec, Canada|Research Site, København Ø, Denmark|Research Site, Haifa, Israel|Research Site, Kuala Lumpur, Malaysia|Research Site, Kubang Kerian, Malaysia|Research Site, Amsterdam, Netherlands|Research Site, Goteborg, Netherlands|Research Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02226198"
44,"NCT02224157","A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma","SYGMA2","Completed","Has Results","Asthma","Drug: budesonide/formoterol 'as needed' + budesonide placebo bid|Drug: budesonode bid + terbutaline 'as needed'","Annual Severe Asthma Exacerbation Rate - Non-inferiority Analysis|Annual Severe Asthma Exacerbation Rate - Superiority Analysis|Number of Participants Experiencing at Least One Severe Asthma Exacerbation|Average Change From Baseline in Pre-bronchodilator FEV1|Number of Participants With Study Specific Asthma Related Discontinuation|Average Change From Baseline in 'as Needed' Use|Change From Baseline in Percent of 'as Needed' Free Days|Percentage of Controller Use Days|Average Change From Baseline in Asthma Control Questionnaire (5-item Version) - ACQ-5 Score|Average Change From Baseline in Asthma Quality of Life Questionnaire Standardised Version - AQLQ(S) Score","AstraZeneca","All","12 Years to 130 Years   (Child, Adult, Older Adult)","Phase 3","4215","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D589SC00003|2013-004473-28","November 28, 2014","August 16, 2017","August 16, 2017","August 25, 2014","November 25, 2019","November 25, 2019","Research Site, Sydney, Australia|Research Site, Botucatu, Brazil|Research Site, Florianopolis, Brazil|Research Site, Goiania, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Salvador, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sorocaba, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Petrich, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Razlog, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Vidin, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Curico, Chile|Research Site, Quillota, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talca, Chile|Research Site, Viña del Mar, Chile|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bogotá, Colombia|Research Site, Bogotá, Colombia|Research Site, Medellin, Colombia|Research Site, Ceska Lipa, Czechia|Research Site, Kladno, Czechia|Research Site, Kralupy nad Vltavou, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Liberec 1, Czechia|Research Site, Neratovice, Czechia|Research Site, Ostrava, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Plzen, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha, Czechia|Research Site, Rokycany, Czechia|Research Site, Rudna U Prahy, Czechia|Research Site, Tabor, Czechia|Research Site, Teplice, Czechia|Research Site, Zatec, Czechia|Research Site, Brii-sous-forges, France|Research Site, Colmar, France|Research Site, Joue-les-Tours, France|Research Site, Nantes Cedex 2, France|Research Site, Nimes, France|Research Site, Reze, France|Research Site, Bad Lippspringe, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Cottbus, Germany|Research Site, Frankfurt/Main, Germany|Research Site, Geesthacht, Germany|Research Site, Großhansdorf, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Lübeck, Germany|Research Site, Neu-Isenburg, Germany|Research Site, Oldenburg, Germany|Research Site, Reinfeld, Germany|Research Site, Rüdersdorf, Germany|Research Site, Schleswig, Germany|Research Site, Warendorf, Germany|Research Site, Aszód, Hungary|Research Site, Balassagyarmat, Hungary|Research Site, Berettyóújfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Cegléd, Hungary|Research Site, Gyula, Hungary|Research Site, Gyula, Hungary|Research Site, Gödöllő, Hungary|Research Site, Hajdúnánás, Hungary|Research Site, Létavértes, Hungary|Research Site, Makó, Hungary|Research Site, Miskolc, Hungary|Research Site, Mórahalom, Hungary|Research Site, Pécs, Hungary|Research Site, Siófok, Hungary|Research Site, Szeged, Hungary|Research Site, Szombathely, Hungary|Research Site, Vásárosnamény, Hungary|Research Site, Érd, Hungary|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Uijeongbu-si, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Chihuahua, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico City, Mexico|Research Site, Mérida, Mexico|Research Site, México, Mexico|Research Site, San Juan del Rio, Mexico|Research Site, Tlanepantla, Mexico|Research Site, Villahermosa, Mexico|Research Site, Zapopan, Mexico|Research Site, Auckland, New Zealand|Research Site, Christchurch Central, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Grafton, New Zealand|Research Site, Hamilton West, New Zealand|Research Site, Maroubra, New Zealand|Research Site, New Lambton, New Zealand|Research Site, Newtown, New Zealand|Research Site, Rotorua, New Zealand|Research Site, South Brisbane, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Wellington, New Zealand|Research Site, Cercado De Lima, Peru|Research Site, Chancay, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Miraflores, Peru|Research Site, Santa Beatriz, Peru|Research Site, Lipa City, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Giżycko, Poland|Research Site, Kościan, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Mrągowo, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Ostrów Wielkopolski, Poland|Research Site, Pabianice, Poland|Research Site, Pila, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Proszowice, Poland|Research Site, Rzeszów, Poland|Research Site, Warszawa, Poland|Research Site, Zabrze, Poland|Research Site, Bragadiru, Romania|Research Site, Brasov, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Constanta, Romania|Research Site, Constanta, Romania|Research Site, Deva, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Pskov, Russian Federation|Research Site, Saint - Petersburg, Russian Federation|Research Site, Saint - Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Ulyanovsk, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Vsevolozhsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Dhahran, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Kezmarok, Slovakia|Research Site, Komarno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Poprad, Slovakia|Research Site, Poprad, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Skalica, Slovakia|Research Site, Surany, Slovakia|Research Site, Topolcany, Slovakia|Research Site, Trebisov, Slovakia|Research Site, Zilina, Slovakia|Research Site, Zvolen, Slovakia|Research Site, Bellville, South Africa|Research Site, Boksburg North, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Lenasia, South Africa|Research Site, Mowbray, South Africa|Research Site, Panorama, South Africa|Research Site, Phoenix, South Africa|Research Site, Verulam, South Africa|Research Site, Alicante, Spain|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Bilbao (Vizcaya), Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Marbella (Málaga), Spain|Research Site, Oviedo, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Terrassa (Barcelona), Spain|Research Site, Valencia, Spain|Research Site, Borås, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Stockholm, Sweden|Research Site, Värnamo, Sweden|Research Site, Västra Frölunda, Sweden|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chonburi, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang,, Thailand|Research Site, Nonthaburi, Thailand|Research Site, Pathumthani, Thailand|Research Site, Cherkasy, Ukraine|Research Site, Chernihiv, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kherson, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odessa, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Can Tho, Vietnam|Research Site, Ha Noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam|Research Site, Hue, Vietnam","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02224157/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02224157/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02224157"
45,"NCT02194699","A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma","STRATOS2","Completed","Has Results","Uncontrolled Asthma","Biological: Experimental: Tralokinumab|Other: Placebo","Annualised Asthma Exacerbation Rate (AAER) up to Week 52|Percent Change From Baseline to Week 52 in Pre-dose/Pre-bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV1)|Change From Baseline to Week 52 in Total Asthma Symptom Score (Bi-weekly Means)|Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score|Change From Baseline to Week 52 in Asthma Control Questionnaire-6 (ACQ-6) Score|AAER Associated With an ER/UC Visit, or a Hospitalisation up to Week 52|Change From Baseline in European Quality of Life - 5 Dimension 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Scores at Week 52|Change From Baseline in Total Asthma Rescue Medication Use at Week 52 (Bi-weekly Means)|Change From Baseline in Home Peak Expiratory Flow (PEF) (Morning and Evening) at Week 52|Change From Baseline in Night-time Awakenings Due to Asthma Requiring Rescue Medication Use at Week 52 (Bi-weekly Means [Percentage])|Number of Patients With ≥1 Asthma Exacerbation up to Week 52|Work Productivity and Activity Impairment Questionnaire and Classroom Impairment Questions (WPAI+CIQ): Productivity Loss at Week 52|WPAI+CIQ: Activity Impairment at Week 52|Asthma-related Healthcare Encounters by Type up to Week 52|Asthma-related Healthcare Encounters by Type up to Week 52: Hospitalisations|Asthma-related Healthcare Encounters by Type up to Week 52: Spirometry|Serum Trough Concentration (Ctrough) of Tralokinumab During the Treatment Period up to Week 72|Incidence Rate of Positive Anti-drug Antibodies (ADAs) Including the Characterization of Their Neutralizing Potential","AstraZeneca","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","856","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D2210C00008","October 30, 2014","May 10, 2017","September 21, 2017","July 18, 2014","March 21, 2018","May 15, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Hoover, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Bakersfield, California, United States|Research Site, Buena Park, California, United States|Research Site, Encinitas, California, United States|Research Site, Lakewood, California, United States|Research Site, Lomita, California, United States|Research Site, Northridge, California, United States|Research Site, Palmdale, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, San Francisco, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Ventura, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Centennial, Colorado, United States|Research Site, Celebration, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palmetto Bay, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Eagle, Idaho, United States|Research Site, Evergreen Park, Illinois, United States|Research Site, Kenilworth, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, White Marsh, Maryland, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Reno, Nevada, United States|Research Site, Northfield, New Jersey, United States|Research Site, Ocean City, New Jersey, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Verona, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Larchmont, New York, United States|Research Site, Wappingers Falls, New York, United States|Research Site, Burlington, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Arlington, Texas, United States|Research Site, Baytown, Texas, United States|Research Site, Frisco, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Orem, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Fairfax, Virginia, United States|Research Site, Greenfield, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Sherwood Park, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Brandys nad Labem, Czechia|Research Site, Jindrichuv Hradec, Czechia|Research Site, Praha 10 - Strasnice, Czechia|Research Site, Praha, Czechia|Research Site, Rokycany, Czechia|Research Site, Teplice, Czechia|Research Site, Catania, Italy|Research Site, Genova, Italy|Research Site, Legnago, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Salerno, Italy|Research Site, Verona, Italy|Research Site, Asahi-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukui-shi, Japan|Research Site, Fukushima-shi, Japan|Research Site, Habikino-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Itabashi-ku, Japan|Research Site, Izumo-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kanazawa, Japan|Research Site, Kanuma-shi, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kochi-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Matsue-shi, Japan|Research Site, Matsusaka-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Minato-ku, Japan|Research Site, Morioka-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sasebo-shi, Japan|Research Site, Seto-shi, Japan|Research Site, Shibuya-ku, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sumida-ku, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Toshima-ku, Japan|Research Site, Touon-shi, Japan|Research Site, Toyama-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Tsukubo-gun, Japan|Research Site, Uozu-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Villahermosa, Mexico|Research Site, Caloocan City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, San Fernando, Philippines|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Saint - Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Ulyanovsk, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Boksburg North, South Africa|Research Site, Durban, South Africa|Research Site, Mount Edgecombe, South Africa|Research Site, Mowbray, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Stanger, South Africa|Research Site, Kaohsiung Hsien, Taiwan|Research Site, Keelung, Taiwan|Research Site, New-Taipei, Taiwan|Research Site, Cherkasy, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kremenchuk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Sumy, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Bradford, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Chertsey, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Sidcup, United Kingdom|Research Site, Wishaw, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02194699/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02194699/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02194699"
46,"NCT02174731","Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis.",,"Completed","Has Results","Anemia","Drug: Roxadustat|Drug: Epoetin alfa","Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52|Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8-Week Evaluation Period|Proportion of Total Time of Hb Within the Interval of >=10 g/dL From Week 28 to Week 52|Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52|Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24|Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)|Mean Monthly IV Iron Use From Week 36 to End of Study (EOS)|Time-To-First Administration of RBC Transfusion as Rescue Therapy","AstraZeneca|FibroGen","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","2133","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5740C00002","July 1, 2014","September 26, 2018","September 26, 2018","June 25, 2014","December 16, 2019","December 16, 2019","Research Site, Huntsville, Alabama, United States|Research Site, El Centro, California, United States|Research Site, Fairfield, California, United States|Research Site, Glendale, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site, Northridge, California, United States|Research Site, Ontario, California, United States|Research Site, Orange, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, Sun Valley, California, United States|Research Site, Whittier, California, United States|Research Site, Whittier, California, United States|Research Site, Denver, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Miami Gardens, Florida, United States|Research Site, River Forest, Illinois, United States|Research Site, Wichita, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Lanham, Maryland, United States|Research Site, Plymouth, Massachusetts, United States|Research Site, Roseville, Michigan, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Reno, Nevada, United States|Research Site, Paterson, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Orchard Park, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Shawnee, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Newport News, Virginia, United States|Research Site, Sterling, Virginia, United States|Research Site, Bluefield, West Virginia, United States|Research Site, Camperdown, Australia|Research Site, Clayton, Australia|Research Site, Concord, Australia|Research Site, Launceston, Australia|Research Site, Prahan, Australia|Research Site, St Leonards, Australia|Research Site, Wahroonga, Australia|Research Site, Botevgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Razlog, Bulgaria|Research Site, Samokov, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Shumen, Bulgaria|Research Site, Silistra, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Kamloops, British Columbia, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha, Czechia|Research Site, Rychnov nad Kneznou, Czechia|Research Site, Slany, Czechia|Research Site, Tabor, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Ajka, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Tatabánya, Hungary|Research Site, Chennai, India|Research Site, Ghaziabad NCR, India|Research Site, Hyderabad, India|Research Site, Kolkatta, India|Research Site, Lucknow, India|Research Site, Maharashtra, India|Research Site, Mumbai, India|Research Site, Mysore, India|Research Site, Nadiad, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Vellore, India|Research Site, Vijayawada, India|Research Site, Aguascalientes, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Veracruz, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Cebu City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Iloilo, Philippines|Research Site, Ciechanów, Poland|Research Site, Katowice, Poland|Research Site, Końskie, Poland|Research Site, Pszczyna, Poland|Research Site, Suwałki, Poland|Research Site, Tarnów, Poland|Research Site, Warszawa, Poland|Research Site, Łódź, Poland|Research Site, Łódź, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Irkutsk, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kralovsky Chlmec, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Zvolen, Slovakia|Research Site, Almería, Spain|Research Site, Barcelona, Spain|Research Site, Granollers (Barcelona), Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Tarragona, Spain|Research Site, Valencia, Spain|Research Site, Karlstad, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chernivtsi, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odesa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Can Tho, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Hochiminh, Vietnam|Research Site, Hue, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02174731/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02174731/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02174731"
47,"NCT02174627","Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis",,"Completed","Has Results","Anemia","Drug: Roxadustat|Drug: Placebo","Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52|Percentage of Participants With Hb Response During the First 24 Weeks of Treatment|Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)|Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52|Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52|Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24|Time-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy|Time-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy|Mean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 28|Annual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant|Mean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 28","AstraZeneca|FibroGen","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","2781","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5740C00001","June 26, 2014","October 4, 2018","October 4, 2018","June 25, 2014","December 16, 2019","December 16, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Bakersfield, California, United States|Research Site, El Centro, California, United States|Research Site, Escondido, California, United States|Research Site, Glendale, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Lynwood, California, United States|Research Site, National City, California, United States|Research Site, Northridge, California, United States|Research Site, Orange, California, United States|Research Site, Sacramento, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Dimas, California, United States|Research Site, San Francisco, California, United States|Research Site, San Luis Obispo, California, United States|Research Site, Upland, California, United States|Research Site, Arvada, Colorado, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Aventura, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Joliet, Illinois, United States|Research Site, La Grange, Illinois, United States|Research Site, Metairie, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Rockport, Maine, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Port Huron, Michigan, United States|Research Site, Gulfport, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Rochester, New Hampshire, United States|Research Site, Flushing, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Jacksonville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Columbia, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lufkin, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Saint George, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Norfolk, Virginia, United States|Research Site, Salem, Virginia, United States|Research Site, Woodbridge, Virginia, United States|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Ciudadela, Argentina|Research Site, La Plata, Argentina|Research Site, La Plata, Argentina|Research Site, Lanus, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Munro, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Isidro, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Santa Rosa, Argentina|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Feira de Santana, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiânia, Brazil|Research Site, Joinville, Brazil|Research Site, Juiz de Fora, Brazil|Research Site, Maringa, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Bernardo do Campo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Botevgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Samokov, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Silistra, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Kamloops, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Whitby, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Cali, Colombia|Research Site, Chia, Colombia|Research Site, Medellin, Colombia|Research Site, Zipaquira, Colombia|Research Site, Brno, Czechia|Research Site, Havlickuv Brod, Czechia|Research Site, Ivancice, Czechia|Research Site, Praha, Czechia|Research Site, Rychnov nad Kneznou, Czechia|Research Site, Slany, Czechia|Research Site, Slavkov u Brna, Czechia|Research Site, Sumperk, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Berlin, Germany|Research Site, Cloppenburg, Germany|Research Site, Köln, Germany|Research Site, Ajka, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyula, Hungary|Research Site, Hatvan, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Polgár, Hungary|Research Site, Pécs, Hungary|Research Site, Salgótarján, Hungary|Research Site, Siófok, Hungary|Research Site, Tatabánya, Hungary|Research Site, Velence, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Ghaziabad NCR, India|Research Site, Hyderabad, India|Research Site, Hyderabad, India|Research Site, Kolkatta, India|Research Site, Lucknow, India|Research Site, Maharashtra, India|Research Site, Mumbai, India|Research Site, Mysore, India|Research Site, Nagpur, India|Research Site, Nagpur, India|Research Site, Nagpur, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Vijayawada, India|Research Site, Vijayawada, India|Research Site, Vishakhapatnam, India|Research Site, Ansan-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Uijeongbu-si, Korea, Republic of|Research Site, George Town, Malaysia|Research Site, Kubang Kerian, Malaysia|Research Site, Putrajaya, Malaysia|Research Site, Taiping, Malaysia|Research Site, Aguascalientes, Mexico|Research Site, Culiacán, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Minatitlán, Mexico|Research Site, México, Mexico|Research Site, Veracruz, Mexico|Research Site, Xalapa, Mexico|Research Site, Bellavista, Peru|Research Site, Ica, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Trujillo, Peru|Research Site, Cebu City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Iloilo, Philippines|Research Site, Quezon City, Philippines|Research Site, Ciechanów, Poland|Research Site, Końskie, Poland|Research Site, Poznań, Poland|Research Site, Sochaczew, Poland|Research Site, Tczew, Poland|Research Site, Łódź, Poland|Research Site, Cidra, Puerto Rico|Research Site, Rio Grande, Puerto Rico|Research Site, Rio Piedras, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, Toa Baja, Puerto Rico|Research Site, Arad, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Targu Mures, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Irkutsk, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kralovsky Chlmec, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Zvolen, Slovakia|Research Site, Almería, Spain|Research Site, Málaga, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Kaohsiung City, Taiwan|Research Site, Keelung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, New Taipei, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, TaoYuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Chernivtsi, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Khmelnytsky, Ukraine|Research Site, Kirovograd, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Rivne, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Can Tho, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Hochiminh, Vietnam|Research Site, Hochiminh, Vietnam|Research Site, Hue, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02174627/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02174627/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02174627"
48,"NCT02165826","Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","OPTIMIZE","Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Roflumilast|Drug: Roflumilast Placebo|Drug: Standard of Care COPD Treatment","Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason|Percentage of Participants With Adverse Events of Interest|Change From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period|Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason During Down-Titration Period|Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Down-Titration Period|Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Main Period|Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Main Period|Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Down-Titration Period|Change From Baseline in Treatment Satisfaction Scores During the Main Period|Change From Baseline in Treatment Satisfaction Scores During the Down-Titration Period|Population PK Model Point Estimate for Absorption Rate Constant (Ka) of Roflumilast and Roflumilast N-oxide|Population PK Model Point Estimate for Apparent Oral Clearance (CL/F) of Roflumilast and Roflumilast N-oxide|Population PK Model Point Estimate for Apparent Central Volume (Vc/F) of Roflumilast and Roflumilast N-oxide|Population PK Model Point Estimate for Apparent Peripheral Volume (Vp/F) of Roflumilast and Roflumilast N-oxide|Total PDE4 Inhibitory Activity (tPDE4i)|Summary Statistics of Predicted Total PDE4 Inhibitory Activity (tPDE4i)|Median Simulated Percentage of Participants With Adverse Events of Interest|Median Simulated Absolute Change From Baseline in FEV1 at Weeks 4 and 12","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","1323","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RO-2455-302-RD|U1111-1150-2477|2013-001788-21","May 1, 2014","September 1, 2015","September 1, 2015","June 18, 2014","March 14, 2017","April 20, 2017","Bardejov, Slovakia|Spisska Nova Ves, Slovakia",,"https://ClinicalTrials.gov/show/NCT02165826"
49,"NCT02161757","A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma","STRATOS1","Completed","Has Results","Uncontrolled Asthma","Biological: Tralokinumab|Other: Placebo","Annualised Asthma Exacerbation Rate (AAER) up to Week 52|Percent Change From Baseline to Week 52 in Pre-dose/Pre-bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV1)|Change From Baseline to Week 52 in Total Asthma Symptom Score (Bi-weekly Means)|Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) Total Score|Change From Baseline to Week 52 in Asthma Control Questionnaire-6 (ACQ-6) Score|AAER Associated With an ER/UC Visit, or a Hospitalisation up to Week 52|Change From Baseline in European Quality of Life - 5 Dimension 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) Scores at Week 52|Change From Baseline in Total Asthma Rescue Medication Use at Week 52 (Bi-weekly Means)|Change From Baseline in Home Peak Expiratory Flow (PEF) (Morning and Evening) at Week 52|Change From Baseline in Night-time Awakenings Due to Asthma Requiring Rescue Medication Use at Week 52 (Bi-weekly Means [Percentage])|Number of Patients With ≥1 Asthma Exacerbation up to Week 52|Work Productivity and Activity Impairment Questionnaire and Classroom Impairment Questions (WPAI+CIQ): Productivity Loss at Week 52|WPAI+CIQ: Activity Impairment at Week 52|Asthma-related Healthcare Encounters by Type up to Week 52|Asthma-related Healthcare Encounters by Type up to Week 52: Hospitalisations|Asthma-related Healthcare Encounters by Type up to Week 52: Spirometry|Serum Trough Concentration (Ctrough) of Tralokinumab During the Study Period up to Week 72|Number of Patients Positive for Anti-drug Antibodies (ADAs)","AstraZeneca","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","1207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D2210C00007","June 13, 2014","February 28, 2017","July 18, 2017","June 12, 2014","April 17, 2018","August 28, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Arcadia, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Poway, California, United States|Research Site, San Jose, California, United States|Research Site, Tustin, California, United States|Research Site, Wildomar, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Cutler Bay, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Albany, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Twin Falls, Idaho, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, South Bend, Indiana, United States|Research Site, Bowling Green, Kentucky, United States|Research Site, Bangor, Maine, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Union, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Cornelius, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Shelby, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Monroeville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Scottdale, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, Johnston, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Boerne, Texas, United States|Research Site, Corsicana, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lampasas, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Provo, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, South Burlington, Vermont, United States|Research Site, Arlington, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richland, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Cap. Fed, Argentina|Research Site, Ciudad Autonomade Buenos Aires, Argentina|Research Site, Concepción del Uruguay, Argentina|Research Site, Córdoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Mendoza, Argentina|Research Site, Quilmes, Argentina|Research Site, Rosario, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Brussels (Anderlecht), Belgium|Research Site, Erpent, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Dupnitsa, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Vratsa, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Armenia, Colombia|Research Site, Bogotá, Colombia|Research Site, Bogotá, Colombia|Research Site, Cali, Colombia|Research Site, Aschaffenburg, Germany|Research Site, Augsburg, Germany|Research Site, Bad Lippspringe, Germany|Research Site, Geesthacht, Germany|Research Site, Herford, Germany|Research Site, Landsberg, Germany|Research Site, Leipzig, Germany|Research Site, München-Pasing, Germany|Research Site, Reinfeld, Germany|Research Site, Rodgau-Dudenhofen, Germany|Research Site, Warendorf, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Edelény, Hungary|Research Site, Farkasgyepü, Hungary|Research Site, Komárom, Hungary|Research Site, Létavértes, Hungary|Research Site, Miskolc, Hungary|Research Site, Pécs, Hungary|Research Site, Pécs, Hungary|Research Site, Százhalombatta, Hungary|Research Site, Bucheon-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Bydgoszcz, Poland|Research Site, Będzin, Poland|Research Site, Chorzów, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Grudziądz, Poland|Research Site, Kielce, Poland|Research Site, Kraków, Poland|Research Site, Lubin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Mrozy, Poland|Research Site, Olsztyn, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Ostrów Wielkopolski, Poland|Research Site, Oświęcim, Poland|Research Site, Puławy, Poland|Research Site, Racibórz, Poland|Research Site, Skierniewice, Poland|Research Site, Staszów, Poland|Research Site, Warszawa, Poland|Research Site, Wieluń, Poland|Research Site, Wołomin, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Zamość, Poland|Research Site, Zgierz, Poland|Research Site, Łódź, Poland|Research Site, Humenne, Slovakia|Research Site, Kezmarok, Slovakia|Research Site, Presov, Slovakia|Research Site, Sabinov, Slovakia|Research Site, Topolcany, Slovakia|Research Site, Alicante, Spain|Research Site, Badalona, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Santander, Spain|Research Site, Valencia, Spain|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, New-Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Yilan, Taiwan|Research Site, Chernivtsi, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Can Tho, Vietnam|Research Site, Ha Noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02161757/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/57/NCT02161757/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT02161757"
50,"NCT02157935","Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","RISE","Completed","Has Results","COPD Patients","Drug: Symbicort|Drug: Formoterol turbohaler|Other: Placebo for Symbicort pMDI|Other: Placebo for Formoterol Turbohaler","The Rate of Moderate and Severe COPD Exacerbations Defined as: Worsening of ≥2 Major Symptoms or Worsening of 1 Major Symptom Together With ≥1 Minor Symptom for ≥2 Consecutive Days|Number of Patients With Moderate or Severe COPD Exacerbation.|St. George's Respiratory Questionnaire (SGRQ)|Pre-dose/Pre-bronchodilator FEV1 at the Study Site|Total Rescue Medication Use (Average Puffs/Day)|Nights With Awakening Due to COPD","AstraZeneca","All","40 Years to 95 Years   (Adult, Older Adult)","Phase 3","2026","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D589UC00001","June 27, 2014","February 8, 2016","February 8, 2016","June 6, 2014","June 12, 2017","November 7, 2017","Research Site, Andalusia, Alabama, United States|Research Site, Andalusia, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Foley, Alabama, United States|Research Site, Foley, Alabama, United States|Research Site, Jasper, Alabama, United States|Research Site, Jasper, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Chandler, Arizona, United States|Research Site, Chandler, Arizona, United States|Research Site, Flagstaff, Arizona, United States|Research Site, Flagstaff, Arizona, United States|Research Site, Peoria, Arizona, United States|Research Site, Peoria, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Fresno, California, United States|Research Site, Fresno, California, United States|Research Site, Fullerton, California, United States|Research Site, Fullerton, California, United States|Research Site, Gold River, California, United States|Research Site, Gold River, California, United States|Research Site, Lakewood, California, United States|Research Site, Lakewood, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Newport Beach, California, United States|Research Site, Orange, California, United States|Research Site, Orange, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, San Jose, California, United States|Research Site, San Jose, California, United States|Research Site, Westminster, California, United States|Research Site, Westminster, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Clearwater, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Sebring, Florida, United States|Research Site, Sebring, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Rincon, Georgia, United States|Research Site, Rincon, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Eagle, Idaho, United States|Research Site, Eagle, Idaho, United States|Research Site, Nampa, Idaho, United States|Research Site, Nampa, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Avon, Indiana, United States|Research Site, Brownsburg, Indiana, United States|Research Site, Brownsburg, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Hazard, Kentucky, United States|Research Site, Hazard, Kentucky, United States|Research Site, Opelousas, Louisiana, United States|Research Site, Opelousas, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Sunset, Louisiana, United States|Research Site, Sunset, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Port Huron, Michigan, United States|Research Site, Port Huron, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Billings, Montana, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Marlton, New Jersey, United States|Research Site, Marlton, New Jersey, United States|Research Site, Summit, New Jersey, United States|Research Site, Summit, New Jersey, United States|Research Site, Jackson Heights, New York, United States|Research Site, Jackson Heights, New York, United States|Research Site, Rochester, New York, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Cornelius, North Carolina, United States|Research Site, Cornelius, North Carolina, United States|Research Site, Flat Rock, North Carolina, United States|Research Site, Flat Rock, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Cadiz, Ohio, United States|Research Site, Cadiz, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Genoa, Ohio, United States|Research Site, Genoa, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Jefferson Hills, Pennsylvania, United States|Research Site, Jefferson Hills, Pennsylvania, United States|Research Site, Scottdale, Pennsylvania, United States|Research Site, Scottdale, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Anderson, South Carolina, United States|Research Site, Easley, South Carolina, United States|Research Site, Easley, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Boerne, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Sealy, Texas, United States|Research Site, Sealy, Texas, United States|Research Site, Midvale, Utah, United States|Research Site, Midvale, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Herndon, Virginia, United States|Research Site, Herndon, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Kingwood, West Virginia, United States|Research Site, Kingwood, West Virginia, United States|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Corrientes, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Mendoza, Argentina|Research Site, Nueve de julio, Argentina|Research Site, Nueve de julio, Argentina|Research Site, Ranelagh, Argentina|Research Site, Ranelagh, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Dupnitsa, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Velingrad, Bulgaria|Research Site, Velingrad, Bulgaria|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Beroun, Czechia|Research Site, Beroun, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Brandys nad Labem, Czechia|Research Site, Krnov, Czechia|Research Site, Krnov, Czechia|Research Site, Liberec, Czechia|Research Site, Liberec, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Ostrava-Poruba, Czechia|Research Site, Ostrava, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 6, Czechia|Research Site, Praha 6, Czechia|Research Site, Strakonice, Czechia|Research Site, Strakonice, Czechia|Research Site, Zatec, Czechia|Research Site, Zatec, Czechia|Research Site, Aschaffenburg, Germany|Research Site, Aschaffenburg, Germany|Research Site, Bad Lippspringe, Germany|Research Site, Bad Lippspringe, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Hannover, Germany|Research Site, Hannover, Germany|Research Site, Koblenz, Germany|Research Site, Koblenz, Germany|Research Site, Köln, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Magdeburg, Germany|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, San Juan del Rio, Mexico|Research Site, San Juan del Rio, Mexico|Research Site, Sonora, Mexico|Research Site, Sonora, Mexico|Research Site, Aleksandrów Łódzki, Poland|Research Site, Aleksandrów Łódzki, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Bielsk Podlaski, Poland|Research Site, Bielsk Podlaski, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bydgoszcz, Poland|Research Site, Kościan, Poland|Research Site, Kościan, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Pila, Poland|Research Site, Pila, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Rzeszów, Poland|Research Site, Rzeszów, Poland|Research Site, Skarżysko-Kamienna, Poland|Research Site, Skarżysko-Kamienna, Poland|Research Site, Turek, Poland|Research Site, Turek, Poland|Research Site, Zabrze, Poland|Research Site, Zabrze, Poland|Research Site, Żnin, Poland|Research Site, Żnin, Poland|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, Amanzimtoti, South Africa|Research Site, Amanzimtoti, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Gauteng, South Africa|Research Site, Gauteng, South Africa|Research Site, Badalona(Barcelona), Spain|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Loja (Granada), Spain|Research Site, Loja (Granada), Spain|Research Site, Zaragoza, Spain|Research Site, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02157935"
51,"NCT02157376","Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients","SUP","Completed","Has Results","Stress Ulcer Prophylaxis","Drug: Esomeprazole|Drug: Cimetidine","The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase|Proportion of Patients With Any Overt Upper-GI Bleeding (Significant and Non-significant) During the Treatment Evaluation Phase","AstraZeneca","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","D961OC00002","July 2014","February 2016","February 2016","June 6, 2014","January 23, 2017","March 10, 2017","Research Site, Baotou, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guilin, China|Research Site, Haikou, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shenzhen, China|Research Site, Tianjin, China|Research Site, Wulumuqi, China|Research Site, Xi'an, China|Research Site, Xian, China|Research Site, Zhanjiang, China",,"https://ClinicalTrials.gov/show/NCT02157376"
52,"NCT02155881","Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia",,"Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Ciclesonide|Drug: Ciclesonide Placebo","Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Reflective Total Nasal Symptom Scores (TNSS)|Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Instantaneous Total Nasal Symptom Scores|Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Reflective Total Ocular Symptom Scores (TOSS)|Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Instantaneous Total Ocular Symptom Scores|Change From Baseline Over 2 Weeks in Participant-Reported Individual Morning and Evening Reflective Total Nasal Symptom Score|Change From Baseline Over 2 Weeks in Participant-Reported Individual Morning and Evening Reflective Total Ocular Symptom Score|Change From Baseline Over 2 Weeks in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Total Score|Change From Baseline Over 2 Weeks in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Individual Domain Score","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIC-RR-001|U1111-1152-9472","August 2014","October 2014","November 2014","June 4, 2014","October 6, 2016","February 2, 2017","Kazan, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Saratov, Russian Federation|Stavropol, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02155881"
53,"NCT02155660","Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","TERRANOVA","Completed","Has Results","Moderate to Very Severe Chronic Obstructive Pulmonary Disease","Drug: Benralizumab Arm A|Drug: Benralizumab Arm B|Drug: Benralizumab Arm C|Drug: Placebo","Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL|Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL|Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL|Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL|Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL|Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL|Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL|Mean Change From Baseline in Proportion of Nights With Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL|Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS>=220/uL|Severity of EXACT-PRO for Patients With Baseline EOS>=220/uL|Duration of COPD Exacerbation Based on EXACT-PRO Score for Patients With Baseline EOS>=220/uL|Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL|Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL|Time to First COPD Exacerbation|Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL|Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS>=220/uL|Duration of Study Treatment Administration|Serum Concentration of Benralizumab|Immunogenicity of Benralizumab","AstraZeneca|MedImmune LLC","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","2255","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D3251C00004","June 25, 2014","April 9, 2018","April 9, 2018","June 4, 2014","June 26, 2019","June 26, 2019","Research Site, Birmingham, Alabama, United States|Research Site, Gulf Shores, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Flagstaff, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Arcadia, California, United States|Research Site, Bakersfield, California, United States|Research Site, Fresno, California, United States|Research Site, Fullerton, California, United States|Research Site, Hawaiian Gardens, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Palmdale, California, United States|Research Site, Peninsula, California, United States|Research Site, Placentia, California, United States|Research Site, Rolling Hills Estates, California, United States|Research Site, Westminster, California, United States|Research Site, Centennial, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Chiefland, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coconut Creek, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeBary, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Blue Ridge, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Woodstock, Georgia, United States|Research Site, Nampa, Idaho, United States|Research Site, Evergreen Park, Illinois, United States|Research Site, O'Fallon, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, River Forest, Illinois, United States|Research Site, Topeka, Kansas, United States|Research Site, Henderson, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Opelousas, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Sunset, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Lutherville, Maryland, United States|Research Site, White Marsh, Maryland, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Marlborough, Massachusetts, United States|Research Site, Buckley, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Fridley, Minnesota, United States|Research Site, Woodbury, Minnesota, United States|Research Site, Picayune, Mississippi, United States|Research Site, Port Gibson, Mississippi, United States|Research Site, Belton, Missouri, United States|Research Site, Florissant, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Fremont, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Marlton, New Jersey, United States|Research Site, Union, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Mineola, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, Potsdam, New York, United States|Research Site, Burlington, North Carolina, United States|Research Site, Calabash, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Shelby, North Carolina, United States|Research Site, Chardon, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Clackamas, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Monroeville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Uniontown, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Hodges, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Corsicana, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Duncanville, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Huntsville, Texas, United States|Research Site, Killeen, Texas, United States|Research Site, Lampasas, Texas, United States|Research Site, Longview, Texas, United States|Research Site, Lufkin, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Sealy, Texas, United States|Research Site, Bountiful, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Abingdon, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Everett, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Kingwood, West Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autónoma de Buenos Aire, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Concepción del Uruguay, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Florencio Varela, Argentina|Research Site, Florida, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mendoza, Argentina|Research Site, Mendoza, Argentina|Research Site, Nueve de julio, Argentina|Research Site, Quilmes, Argentina|Research Site, Rosario, Argentina|Research Site, San Fernando, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Clayton, Australia|Research Site, Gosford, Australia|Research Site, Murdoch, Australia|Research Site, Nedlands, Australia|Research Site, New Lambton, Australia|Research Site, Woolloongabba, Australia|Research Site, Brussels, Belgium|Research Site, Genk, Belgium|Research Site, Jambes, Belgium|Research Site, Leuven, Belgium|Research Site, Malmedy, Belgium|Research Site, Turnhout, Belgium|Research Site, Veurne, Belgium|Research Site, Fortaleza, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sorocaba, Brazil|Research Site, Vitória, Brazil|Research Site, Dupnitsa, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Petrich, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Silistra, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Vidin, Bulgaria|Research Site, Vratsa, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Curico, Chile|Research Site, Quillota, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talca, Chile|Research Site, Armenia, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bogotá, Colombia|Research Site, Bogotá, Colombia|Research Site, Cali, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Medillin, Colombia|Research Site, Petrinja, Croatia|Research Site, Aarhus N, Denmark|Research Site, København NV, Denmark|Research Site, Næstved, Denmark|Research Site, Odense C, Denmark|Research Site, Roskilde, Denmark|Research Site, Silkeborg, Denmark|Research Site, Bois Guillaume, France|Research Site, Brest Cedex, France|Research Site, La Tronche, France|Research Site, Lille cedex, France|Research Site, Lyon Cedex 04, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, NIMES Cedex 9, France|Research Site, Orléans Cedex 2, France|Research Site, Pessac, France|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Petach Tikva, Israel|Research Site, Rehovot, Israel|Research Site, Tel Aviv, Israel|Research Site, Durango, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Auckland, New Zealand|Research Site, Auckland, New Zealand|Research Site, Dunedin, New Zealand|Research Site, Greenlane, New Zealand|Research Site, Hamilton West, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Bodø, Norway|Research Site, Kolbjørnsvik, Norway|Research Site, Svelvik, Norway|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Piura, Peru|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdańsk, Poland|Research Site, Gorzów Wlkp, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Karczew, Poland|Research Site, Katowice, Poland|Research Site, Kraków, Poland|Research Site, Ostrowiec Świętokrzyski, Poland|Research Site, Ostrów Wielkopolski, Poland|Research Site, Ruda Śląska, Poland|Research Site, Skierniewice, Poland|Research Site, Sosnowiec, Poland|Research Site, Starachowice, Poland|Research Site, Szczecin, Poland|Research Site, Słupca, Poland|Research Site, Trzebnica, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Żnin, Poland|Research Site, Belgrade, Serbia|Research Site, Celje, Slovenia|Research Site, Golnik, Slovenia|Research Site, Kamnik, Slovenia|Research Site, Ljubljana, Slovenia|Research Site, Maribor, Slovenia|Research Site, Goteborg, Sweden|Research Site, Göteborg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, New-Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang,, Thailand|Research Site, Nonthaburi, Thailand|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Bursa, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, İstanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Mersin, Turkey|Research Site, Cherkasy, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Can Tho, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02155660/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/60/NCT02155660/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02155660"
54,"NCT02153398","A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases",,"Completed","Has Results","Gastric Ulcer (GU)|Duodenal Ulcer (DU)|Anastomotic Ulcer (AU)|Non-erosive Reflux Esophagitis Disease (NERD)|Reflux Esophagitis (RE)|Zollinger-Ellison Syndrome","Drug: D961H sachet 10 mg|Drug: D961H capsule 10mg|Drug: D961H capsule 20 mg","Disappearance of Heartburn at Week 8 by Patient Diaries|Disappearance of Epigastric Pain at Week 8 by Patient Diaries|Disappearance of Upper Abdominal Discomfort at Week 8 by Patient Diaries|Disappearance of Regurgitation at Week 8 by Patient Diaries|Aggravation of Heartburn at Week 8 by Patient Diaries|Aggravation of Epigastric Pain at Week 8 by Patient Diaries|Aggravation of Upper Abdominal Discomfort at Week 8 by Patient Diaries|Aggravation of Regurgitation at Week 8 by Patient Diaries|Disappearance of Heartburn at Week 8 by Investigators|Disappearance of Epigastric Pain at Week 8 by Investigators|Disappearance of Upper Abdominal Discomfort at Week 8 by Investigators|Disappearance of Regurgitation at Week 8 by Investigators|Aggravation of Heartburn at Week 8 by Investigators|Aggravation of Epigastric Pain at Week 8 by Investigators|Aggravation of Upper Abdominal Discomfort at Week 8 by Investigators|Aggravation of Regurgitation at Week 8 by Investigators|Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCtau) of Esomeprazole After at Least 5 Days of Repeated Dose|AUC From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of Esomeprazole After at Least 5 Days of Repeated Dose|Maximum Plasma Concentration (Cmax) of Esomeprazole After at Least 5 Days of Repeated Dose|Time to Reach Maximum Plasma Concentration (Tmax) of Esomeprazole After at Least 5 Days of Repeated Dose|Elimination Half-life (t1/2) of Esomeprazole After at Least 5 Days of Repeated Dose|Apparent Total Clearance (CL/F) of Esomeprazole After at Least 5 Days of Repeated Dose|Apparent Volume of Distribution (Vz/F) of Esomeprazole After at Least 5 Days of Repeated Dose","AstraZeneca","All","1 Year to 14 Years   (Child)","Phase 3","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D961TC00002|26-022","June 2014","April 2016","April 2016","June 3, 2014","January 19, 2017","January 19, 2017","Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Izumi-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saitama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Setagaya-ku, Japan|Research Site, Shimotsuke-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Suzaka-shi, Japan|Research Site, Ureshino-shi, Japan|Research Site, Yokohama-shi, Japan",,"https://ClinicalTrials.gov/show/NCT02153398"
55,"NCT02149199","A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.","SYGMA1","Completed","Has Results","Asthma","Drug: budesonide/formoterol 'as needed' + budesonide placebo bid|Drug: terbutaline 'as needed' + placebo budesonide bid|Drug: budesonide bid + terbutaline 'as needed'","'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)|Number of Participants Experiencing at Least One Severe Asthma Exacerbation|Number of Participants Experiencing at Least One Moderate or Severe Asthma Exacerbation|Average Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1)|Average Change From Baseline in Morning Peak Expiratory Flow (PEF)|Average Change From Baseline in Evening PEF|Average Change From Baseline in Number of Inhalations of 'as Needed' Medication.|Average Change From Baseline in Asthma Symptom Score|Change From Baseline in the Percentage of Nighttime Awakenings Due to Asthma|Change From Baseline in Percentage of Symptom-free Days|Change From Baseline in Percentage of 'As Needed' Free Days|Change From Baseline in Percentage of Asthma Control Days|Number of Patients With Study Specific Asthma Related Discontinuation|Poorly Controlled Asthma Weeks|Number of Participants Experiencing at Least One Occasion With Additional Steroids for Asthma|Average Change From Baseline in Asthma Control Questionnaire (ACQ-5)|Average Change From Baseline in Asthma Quality of Life Questionnaire; Standard Version (AQLQ(S))|Percentage of Controller Use Days|Annual Severe Asthma Exacerbation Rate|Annual Moderate or Severe Asthma Exacerbation Rate","AstraZeneca","All","12 Years to 130 Years   (Child, Adult, Older Adult)","Phase 3","3850","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D589SC00001|2013-004474-96","July 7, 2014","August 2, 2017","August 2, 2017","May 29, 2014","September 13, 2019","November 15, 2019","Research Site, Bedford Park, Australia|Research Site, Concord, Australia|Research Site, Maroubra, Australia|Research Site, Murdoch, Australia|Research Site, Wollongong, Australia|Research Site, Alphaville, Brazil|Research Site, Botucatu, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Salvador, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sorocaba, Brazil|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Razgrad, Bulgaria|Research Site, Roman, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Velingrad, Bulgaria|Research Site, Vratsa, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Sherwood Park, Alberta, Canada|Research Site, Maple Ridge, British Columbia, Canada|Research Site, North Vancouver, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kanata, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe Claire, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Trois Rivieres, Quebec, Canada|Research Site, Victoriaville, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quillota, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chengdu, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haikou, China|Research Site, Hohhot, China|Research Site, Nanchang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Xi'an, China|Research Site, Xiamen, China|Research Site, Xuzhou, China|Research Site, Balassagyarmat, Hungary|Research Site, Berettyóújfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Edelény, Hungary|Research Site, Hajdúnánás, Hungary|Research Site, Miskolc, Hungary|Research Site, Monor, Hungary|Research Site, Mátészalka, Hungary|Research Site, Nyírbátor, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Pécs, Hungary|Research Site, Szeged, Hungary|Research Site, Bucheon-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, D.f., Mexico|Research Site, Durango, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Morelia, Mexico|Research Site, México, Mexico|Research Site, México, Mexico|Research Site, Villahermosa, Mexico|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Piura, Peru|Research Site, Surco, Peru|Research Site, Lipa City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Elbląg, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Grudziądz, Poland|Research Site, Kielce, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Rzeszów, Poland|Research Site, Rzeszów, Poland|Research Site, Skierniewice, Poland|Research Site, Strzelce Opolskie, Poland|Research Site, Szczecin, Poland|Research Site, Szczecin, Poland|Research Site, Słupca, Poland|Research Site, Tarnów, Poland|Research Site, Trzebnica, Poland|Research Site, Turek, Poland|Research Site, Zabrze, Poland|Research Site, Łódź, Poland|Research Site, Łódź, Poland|Research Site, Łódź, Poland|Research Site, Bragadiru, Romania|Research Site, Brasov, Romania|Research Site, Brasov, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Constanta, Romania|Research Site, Pitesti, Romania|Research Site, Timisoara, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint - Petersburg, Russian Federation|Research Site, Saint - Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Ulyanovsk, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Boksburg North, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Middelburg, South Africa|Research Site, Queenswood, South Africa|Research Site, Stanger, South Africa|Research Site, Verulam, South Africa|Research Site, Cherkasy, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Bath, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Leamington Spa, United Kingdom|Research Site, Mortimer Reading, United Kingdom|Research Site, Trowbridge, United Kingdom|Research Site, Dong Nai, Vietnam|Research Site, Hai Phong, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02149199/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02149199/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT02149199"
56,"NCT02138916","Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","GALATHEA","Completed","Has Results","Moderate to Very Severe Chronic Obstructive Pulmonary Disease","Drug: Benralizumab Arm A|Drug: Benralizumab Arm B|Drug: Placebo","Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL|Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL|Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL|Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL|Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL|Mean Change From Baseline in E-RS: COPD Total Score for Patients With Baseline EOS>=220/uL|Mean Change From Baseline in Total Rescue Medication Use (Number of Puffs Per Day) for Patients With Baseline EOS>=220/uL|Mean Change From Baseline in Proportion of Nights Awakenings Due to Respiratory Symptoms for Patients With Baseline EOS>=220/uL|Number of Participants by Number of COPD Exacerbations Based on EXACT-PRO for Patients With Baseline EOS>=220/uL|Severity of EXACT-PRO for Patients With Baseline EOS>=220/uL|Duration of EXACT-PRO for Patients With Baseline EOS>=220/uL|Annual EXACT-PRO Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL|Number of Participants Having at Least 1 COPD Exacerbation for Patients With Baseline EOS>=220/uL|Time to First COPD Exacerbation|Annual COPD Exacerbation Rate Associated With ER or Hospitalization Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL|Number of Participants Had COPD-related Healthcare Encounter for Patient With Baseline EOS>=220/uL|Duration of Study Treatment Administration|Serum Concentration of Benralizumab|Immunogenicity of Benralizumab","AstraZeneca|MedImmune LLC","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","1656","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D3251C00003","June 13, 2014","April 10, 2018","April 10, 2018","May 15, 2014","June 13, 2019","June 13, 2019","Research Site, Andalusia, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Dothan, Alabama, United States|Research Site, Jasper, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Gold River, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Huntington Park, California, United States|Research Site, Lakewood, California, United States|Research Site, Lomita, California, United States|Research Site, Newport Beach, California, United States|Research Site, Palm Desert, California, United States|Research Site, Palo Alto, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Loxahatchee Groves, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sebring, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Calhoun, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Duluth, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Eagle, Idaho, United States|Research Site, Aurora, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Michigan City, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Hazard, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Rochester, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Charles, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Summit, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronxville, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Fayetteville, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Elizabeth City, North Carolina, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Mount Airy, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Jefferson Hills, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Franklin, Tennessee, United States|Research Site, Hendersonville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, Frisco, Texas, United States|Research Site, Galveston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Midvale, Utah, United States|Research Site, Provo, Utah, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richland, Washington, United States|Research Site, Feldkirch, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Calgary, Alberta, Canada|Research Site, Calgary, Alberta, Canada|Research Site, Sherwood Park, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Grimsby, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Trois Rivieres, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Jindrichuv Hradec, Czechia|Research Site, Karlovy Vary, Czechia|Research Site, Kralupy nad Vltavou, Czechia|Research Site, Mlada Boleslav, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 8, Czechia|Research Site, Rokycany, Czechia|Research Site, Strakonice, Czechia|Research Site, Teplice, Czechia|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt/Main, Germany|Research Site, Frankfurt, Germany|Research Site, Geesthacht, Germany|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Marburg, Germany|Research Site, Neu-Isenburg, Germany|Research Site, Rodgau-Dudenhofen, Germany|Research Site, Teuchern, Germany|Research Site, Witten, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Edelény, Hungary|Research Site, Farkasgyepü, Hungary|Research Site, Gödöllő, Hungary|Research Site, Hajdúnánás, Hungary|Research Site, Hatvan, Hungary|Research Site, Miskolc, Hungary|Research Site, Mátraháza, Hungary|Research Site, Pécs, Hungary|Research Site, Pécs, Hungary|Research Site, Szeged, Hungary|Research Site, Százhalombatta, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Bolzano, Italy|Research Site, Catania, Italy|Research Site, Ferrara, Italy|Research Site, Genova, Italy|Research Site, Orbassano, Italy|Research Site, Palermo, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Pisa, Italy|Research Site, Tradate, Italy|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Higashiibaraki-gun, Japan|Research Site, Himeji-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Iwata-shi, Japan|Research Site, Izumo-shi, Japan|Research Site, Joyo-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kasugai-shi, Japan|Research Site, Kawaguchi-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kiryu-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kitakami-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kochi-shi, Japan|Research Site, Kodaira-shi, Japan|Research Site, Kokubunji-shi, Japan|Research Site, Koshi-shi, Japan|Research Site, Kuki-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kurashiki-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsue-shi, Japan|Research Site, Matsue-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Matsusaka-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Mizunami-shi, Japan|Research Site, Morioka-shi, Japan|Research Site, Nagaoka-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Obihiro-shi, Japan|Research Site, Ohota-ku, Japan|Research Site, Ota-shi, Japan|Research Site, Saiki-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Seto-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Toon-shi, Japan|Research Site, Toshima-ku, Japan|Research Site, Ube-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Urasoe-shi, Japan|Research Site, Uruma-shi, Japan|Research Site, Yachiyo-shi, Japan|Research Site, Yanagawa-shi, Japan|Research Site, Yao-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Bucheon-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Breda, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Horn, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Bydgoszcz, Poland|Research Site, Dobre Miasto, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Katowice, Poland|Research Site, Kościan, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Mrozy, Poland|Research Site, Mrągowo, Poland|Research Site, Olsztyn, Poland|Research Site, Proszowice, Poland|Research Site, Radom, Poland|Research Site, Ruda Slaska, Poland|Research Site, Rzeszów, Poland|Research Site, Tarnów, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wrocław, Poland|Research Site, Zakopane, Poland|Research Site, Łódź, Poland|Research Site, Bragadiru, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Constanta, Romania|Research Site, Deva, Romania|Research Site, Iasi, Romania|Research Site, Timisoara, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Pskov, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Ulyanovsk, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Amanzimtoti, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Gauteng, South Africa|Research Site, Middelburg, South Africa|Research Site, Alicante, Spain|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Sabadell (Barcelona), Spain|Research Site, Santander, Spain|Research Site, Valencia, Spain|Research Site, Basel, Switzerland|Research Site, Biel, Switzerland|Research Site, Gossau, Switzerland|Research Site, Liestal, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Aberdeen, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Chertsey, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Le3 9qp, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle-Under-Lyme, United Kingdom|Research Site, Newcastle-Upon-Tyne, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Wishaw, United Kingdom|Research Site, Wolverhampton, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02138916/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT02138916/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02138916"
57,"NCT02104804","Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Saxagliptin 5mg|Drug: Placebo for Saxagliptin","Change in HbA1c From Baseline to Week 24|Change in Postprandial Glucose AUC From Baseline to Week 24 During a Meal Tolerance Test|Analysis of Change in 120-minute PPG From Baseline to Week 24 During a Meal Tolerance Test|Percentage of Patients Achieving a Therapeutic Glycaemic Response of HbA1c <7%|The Analysis of Change in Fasting Plasma Glucose From Baseline to Week 24 (This Was the Average of Weeks 20 and 24)|Analysis of Change in Mean Total Daily Dose of Insulin From Baseline to Week 24","AstraZeneca","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","953","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680C00010|2014L00001","May 7, 2014","February 26, 2016","February 26, 2016","April 4, 2014","October 2, 2017","October 2, 2017","Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Ha'er bing, China|Research Site, Hefei, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, ShiJiazhuang, China|Research Site, Shiyan, China",,"https://ClinicalTrials.gov/show/NCT02104804"
58,"NCT02096705","Phase III Insulin Add-On Asia Regional Program - ST",,"Completed","Has Results","Diabetes","Drug: Dapagliflozin|Drug: Dapagliflozin Placebo","Adjusted Mean Change in HbA1c From Baseline to Week 24|Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24|Adjusted Mean Change in Body Weight From Baseline to Week 24|Adjusted Mean Change in Absolute Calculated Mean Total Daily Dose of Insulin (TDDI) From Baseline to Week 24","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","477","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MB102-137","March 31, 2014","January 28, 2016","January 28, 2016","March 26, 2014","March 6, 2017","August 9, 2017","Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Changsha, Hunan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Suzhou, Jiangsu, China|Local Institution, Wuxi, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Xi An, Shanxi, China|Local Institution, Xi'an, Shanxi, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Chongqing, Sichuan, China|Local Institution, Beijing, China|Local Institution, Tianjin, China|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daejeon, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT02096705"
59,"NCT02091986","A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg","CHASE 3","Completed","Has Results","Asthma","Drug: Symbicort pMDI|Other: Budesonide pMDI","Change From Baseline to Week 12 in 1h Post-dose FEV1|Change From Baseline to Week 12 in 1h Post-dose PEF|Change From Baseline to Week 12 in 1h Post-dose FEF25-75|Change From Baseline to Week 12 in 1h Post-dose FVC|Change From Baseline to Week 12 in Pre-dose FEV1|Change From Baseline to Week 12 in Pre-dose PEF|Change From Baseline to Week 12 in Pre-dose FEF25-75|Change From Baseline to Week 12 in Pre-dose FVC|Change From Baseline to Week 12 in 15 Min Post-dose FEV1|Change From Baseline to End of Study Average in Total Asthma Symptoms|Change From Baseline to End of Study Average in % of Night Time Awakenings Due to Asthma Symptoms|Change From Baseline to End of Study Average in Total Daily Reliever Medication|Change From Baseline to Study Period Average in Overall PAQLQ Score|Number of Patients With an Asthma Exacerbation During Study","AstraZeneca","All","6 Years to 11 Years   (Child)","Phase 3","882","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D589GC00003","April 2014","April 2016","April 2016","March 19, 2014","April 10, 2017","April 10, 2017","Research Site, Hoover, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Gilbert, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Huntington Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Newport Beach, California, United States|Research Site, Ontario, California, United States|Research Site, Stockton, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Aventura, Florida, United States|Research Site, Coral Gables, Florida, United States|Research Site, Fort Walton Beach, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Williston, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Lenexa, Kansas, United States|Research Site, Waldorf, Maryland, United States|Research Site, Plymouth, Minnesota, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Verona, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Rockville Centre, New York, United States|Research Site, Watertown, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Edmond, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Gresham, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Upland, Pennsylvania, United States|Research Site, North Charleston, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, West Columbia, South Carolina, United States|Research Site, Allen, Texas, United States|Research Site, Baytown, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kerville, Texas, United States|Research Site, Richmond, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Fairfax, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Washington, Washington, United States|Research Site, Cuautitlan Izcalli, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Ciudad de Panama, Panama|Research Site, David Chiriqui, Panama|Research Site, Panama, Panama|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Poprad, Slovakia|Research Site, Presov, Slovakia",,"https://ClinicalTrials.gov/show/NCT02091986"
60,"NCT02075255","Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy",,"Completed","Has Results","Asthma","Biological: Benralizumab|Biological: Placebo","Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control|Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control|Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL|The Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control|The Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control|The Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.|The Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control|Number and Percentage of Patients With ≥1 Asthma Exacerbation|Time to the First Asthma Exacerbation|Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit|The Annualized Rate of Asthma Exacerbation|The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization|Number of Days in Hospital Due to Asthma|Change From Baseline to Week 28 in Pre-bronchodilator FEV1|Change From Baseline to Week 28 in Asthma Symptom Scores (Total)|Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime)|Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)|Change From Baseline to Week 28 in Rescue Medication Use|Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)|Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)|Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication|Change From Baseline to Week 28 in ACQ-6|ACQ-6 Responders (Improvement) at Week 28|Change From Baseline at Week 28 in AQLQ(S)+12 (Overall)|AQLQ(s)+12 Responders (Improvement) at Week 28|Extent of Exposure|Serum Concentration of Benralizumab|Anti-drug Antibody Response|Percent Change From Baseline in Blood Eosinophil Counts|Total Lung Capacity|Residual Volume|Vital Capacity|Functional Residual Capacity|Inspiratory Capacity","AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D3250C00020","April 28, 2014","August 8, 2016","August 8, 2016","March 3, 2014","October 17, 2017","June 8, 2018","Research Site, Los Angeles, California, United States|Research Site, Centennial, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Iowa City, Iowa, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Rochester, Minnesota, United States|Research Site, Bronx, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Madison, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Florida, Argentina|Research Site, Mendoza, Argentina|Research Site, Kozloduy, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Petrich, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Samokov, Bulgaria|Research Site, Vratsa, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quillota, Chile|Research Site, Rancagua, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Talca, Chile|Research Site, Valparaiso, Chile|Research Site, Brest Cedex 2, France|Research Site, Lyon Cedex 04, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse, France|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Freiburg, Germany|Research Site, Grosshansdorf, Germany|Research Site, Hannover, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Bydgoszcz, Poland|Research Site, Karczew, Poland|Research Site, Koszalin, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Lubin, Poland|Research Site, Szczecin, Poland|Research Site, Tarnów, Poland|Research Site, Trzebnica, Poland|Research Site, Wroclaw, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Málaga, Spain|Research Site, Valencia, Spain|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Bursa, Turkey|Research Site, Istanbul, Turkey|Research Site, İstanbul, Turkey|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT02075255"
61,"NCT02009865","Epanova® for Lowering Very High Triglycerides II (EVOLVE II)","EVOLVEII","Completed","Has Results","Hypertriglyceridemia","Drug: Epanova|Drug: Olive Oil","Percent Change in Triglyceride for All Subjects|Percent Change in Triglycerides for Subjects With at Least 1 Qualifying Triglyceride >885 mg/dL|Percent Change in Non-High-Density Lipoprotein Cholesterol (mg/dL)|Percent Change in High-Density Lipoprotein Cholesterol (mg/dL)|Percent Change in Triglyceride(mg/dL) in Subjects With Biochemically Defined Fredrickson Type V (Triglyceride/Very-Low-Density Lipoprotein Cholesterol ≥6)","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","379","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5880C00001|OM-EPA-011","December 16, 2013","December 23, 2014","December 23, 2014","December 12, 2013","January 15, 2016","September 10, 2019","Research Site, Los Angeles, California, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Addison, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Lyndhurst, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Chicoutimi, Quebec, Canada|Research Site, Hradec Kralova, Czechia|Research Site, Trutnov, Czechia|Research Site, Zlín, Czechia|Research Site, Esbjerg, Denmark|Research Site, Gentofte, Denmark|Research Site, Herlev, Denmark|Research Site, Viborg, Denmark|Research Site, Baja, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Szikszó, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Sátoraljaújhely, Hungary|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02009865"
62,"NCT01994720","[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]","SOCRATES","Completed","Has Results","Acute Ischaemic Stroke|Transient Ischaemic Attack","Drug: ticagrelor|Drug: Acetylsalicylic acid (ASA)","Number of Participants With Composite of Stroke/MI/Death|Number of Participants With Ischaemic Stroke|Net Clinical Outcome|Number of Participants With Composite of Ischaemic Stroke, MI and CV Death|Number of Participants With All-Cause Death|Number of Participants With CV Death|Number of Participants With MI|Number of Participants by Severity of Stroke and Overall Disability|Number of Participants With Stroke|Number of Participants With Fatal Stroke|Number of Participants With Disabling Stroke|Change in NIHSS|EQ-5D at Visit 1 (Enrolment)|EQ-5D at Visit 2 (Day 7+-2d)|EQ-5D (EuroQol Five Dimensions Questionnaire) at End of Treatment Visit|EQ-5D (EuroQol Five Dimensions Questionnaire) at Premature Treatment Discontinuation Visit|Number of Participants With PLATO Major Bleeding Event|Number of Participants With Premature Discontinuation of Study Drug Due to Any Bleeding Adverse Event","AstraZeneca","All","40 Years to 130 Years   (Adult, Older Adult)","Phase 3","13307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","D5134C00001|2012-003895-38","January 7, 2014","March 2, 2016","March 2, 2016","November 26, 2013","June 12, 2017","June 12, 2017","Research Site, Montgomery, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Fayetteville, Arkansas, United States|Research Site, Fort Smith, Arkansas, United States|Research Site, Fullerton, California, United States|Research Site, Glendale, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport, California, United States|Research Site, Oakland, California, United States|Research Site, San Diego, California, United States|Research Site, Stanford, California, United States|Research Site, Torrance, California, United States|Research Site, Englewood, Colorado, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Weston, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Glenview, Illinois, United States|Research Site, Harvey, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Urbana, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Alexandria, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Annapolis, Maryland, United States|Research Site, Frederick, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, West Bloomfield Township, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Robbinsdale, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Helena, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Bayonne, New Jersey, United States|Research Site, Edison, New Jersey, United States|Research Site, Englewood, New Jersey, United States|Research Site, Flemington, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, West Orange, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Syracuse, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Maumee, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Clackamas, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Baytown, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Harlingen, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, Southlake, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Huntington, West Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, San Martin, Argentina|Research Site, Adelaide, Australia|Research Site, Bedford Park, Australia|Research Site, Camperdown, Australia|Research Site, Clayton, Australia|Research Site, Darlinghurst, Australia|Research Site, Footscray, Australia|Research Site, Herston, Australia|Research Site, New Lambton Heights, Australia|Research Site, Parkville, Australia|Research Site, Southport, Australia|Research Site, Sydney, Australia|Research Site, Woodville, Australia|Research Site, Aalst, Belgium|Research Site, Assebroek, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Gent, Belgium|Research Site, Godinne, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Tielt, Belgium|Research Site, Wilrijk, Belgium|Research Site, Botucatu, Brazil|Research Site, Curitiba, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirao Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Botevgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Lukovit, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Teteven, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Los Angeles, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Temuco, Chile|Research Site, Valdivia, Chile|Research Site, Viña del Mar, Chile|Research Site, Baotou, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chongqin, China|Research Site, Guang Zhou, China|Research Site, Guangzhou, China|Research Site, Guilin, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Huai'an, China|Research Site, Jinan, China|Research Site, Lanzhou, China|Research Site, Linhai, China|Research Site, Nanjing, China|Research Site, Ningbo, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Wenzhou, China|Research Site, Wu Han, China|Research Site, Xi'an, China|Research Site, Xiamen, China|Research Site, Yangzhou, China|Research Site, Zhanjiang, China|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jihlava, Czechia|Research Site, Liberec, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 2, Czechia|Research Site, Trutnov, Czechia|Research Site, Antony, France|Research Site, Bayonne, France|Research Site, Bordeaux Cedex, France|Research Site, Bourg en Bresse, France|Research Site, Brest Cedex 2, France|Research Site, Bron, France|Research Site, Caen, France|Research Site, Corbeil Essonnes Cedex, France|Research Site, Creteil, France|Research Site, Dijon, France|Research Site, La Roche sur Yon, France|Research Site, Le Chesnay Cedex, France|Research Site, Le Coudray Cedex, France|Research Site, Lille, France|Research Site, NICE Cedex 01, France|Research Site, PARIS Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Paris Cedex 18, France|Research Site, Paris, France|Research Site, Pringy Cedex, France|Research Site, Rennes, France|Research Site, Rouen Cedex, France|Research Site, Saint Herblain, France|Research Site, Saint-priest En Jarez, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse, France|Research Site, Tours, France|Research Site, Altenburg, Germany|Research Site, Bad Neustadt, Germany|Research Site, Berlin, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Minden, Germany|Research Site, Münster, Germany|Research Site, Osnabrück, Germany|Research Site, Wiesbaden, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Hongkong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Győr, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Miskolc, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Sopron-Balf, Hungary|Research Site, Szekszárd, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Petach Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Tel Aviv, Israel|Research Site, Carrara, Italy|Research Site, Citta' di Castello, Italy|Research Site, Foligno, Italy|Research Site, Genova, Italy|Research Site, Gubbio, Italy|Research Site, Lecco, Italy|Research Site, Milano, Italy|Research Site, Modena, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Piacenza, Italy|Research Site, Pisa, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Siena, Italy|Research Site, Varese, Italy|Research Site, Verona, Italy|Research Site, Vibo Valentia, Italy|Research Site, Aki-gun, Japan|Research Site, Asahikawa-shi, Japan|Research Site, Chiba-shi, Japan|Research Site, Chikushi-gun, Japan|Research Site, Chikushino-shi, Japan|Research Site, Chitose-shi, Japan|Research Site, Daito-shi, Japan|Research Site, Date-gun, Japan|Research Site, Eniwa-shi, Japan|Research Site, Fujinomiya-shi, Japan|Research Site, Fukui-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukushima-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hakodate-shi, Japan|Research Site, Hamada-shi, Japan|Research Site, Hanamaki-shi, Japan|Research Site, Hatsukaichi-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Higashiibaraki-gun, Japan|Research Site, Higashiosaka-shi, Japan|Research Site, Hitachi-shi, Japan|Research Site, Ina-shi, Japan|Research Site, Itami-shi, Japan|Research Site, Izumisano-shi, Japan|Research Site, Izumo-shi, Japan|Research Site, Kaga-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kakegawa-shi, Japan|Research Site, Kamakura-shi, Japan|Research Site, Kashiwazaki-shi, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kochi-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Komatsu-shi, Japan|Research Site, Komoro-shi, Japan|Research Site, Koshigaya-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maizuru-shi, Japan|Research Site, Marugame-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagano-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nakano-ku, Japan|Research Site, Nakano-shi, Japan|Research Site, Narita-shi, Japan|Research Site, Nihonmatsu-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Okinawa-shi, Japan|Research Site, Onga-gun, Japan|Research Site, Ookawa-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Saijo-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sanuki-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shiroishi-shi, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Suita-shi, Japan|Research Site, Suwa-shi, Japan|Research Site, Tachikawa-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takayama-shi, Japan|Research Site, Tokushima-shi, Japan|Research Site, Toyama-shi, Japan|Research Site, Toyohashi-shi, Japan|Research Site, Toyota-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Ureshino-shi, Japan|Research Site, Utsunomiya-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Zentsuji-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Culiacan, Mexico|Research Site, D.F, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Monterrey, Mexico|Research Site, Bellavista, Peru|Research Site, Callao, Peru|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Baguio City, Philippines|Research Site, Cagayan de Oro City, Philippines|Research Site, Cebu, Philippines|Research Site, Iloilo City, Philippines|Research Site, Manila, Philippines|Research Site, Pasay City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Białystok, Poland|Research Site, Chełm, Poland|Research Site, Działdowo, Poland|Research Site, Gdańsk, Poland|Research Site, Gryfice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Końskie, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Ostrołęka, Poland|Research Site, Sandomierz, Poland|Research Site, Warszawa, Poland|Research Site, Włocławek, Poland|Research Site, Łódź, Poland|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Tirgu-Mures, Romania|Research Site, Belgorod, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Irkutsk, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Levoca, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Spisska Nova Ves, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Albacete, Spain|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valladolid, Spain|Research Site, Falun, Sweden|Research Site, Göteborg, Sweden|Research Site, Halmstad, Sweden|Research Site, Karlstad, Sweden|Research Site, Lidköping, Sweden|Research Site, Linköping, Sweden|Research Site, Malmö, Sweden|Research Site, Mora, Sweden|Research Site, Norrköping, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Östersund, Sweden|Research Site, Aarau, Switzerland|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Chur, Switzerland|Research Site, Genève 14, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Lugano, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Villars-sur-Glâne, Switzerland|Research Site, Zürich, Switzerland|Research Site, Changhua City, Taiwan|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan Hsien, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chonburi, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang, Thailand|Research Site, Patumthani, Thailand|Research Site, Rajthevi, Thailand|Research Site, Ratchathewi, Thailand|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Eskisehir, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Konya, Turkey|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Hochiminh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01994720"
63,"NCT01991795","A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus","THEMIS","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Ticagrelor 60 mg|Drug: Ticagrelor placebo","Composite of Cardiovascular (CV) Death, MI or Stroke|CV Death|MI|Ischaemic Stroke|All-cause Death","AstraZeneca","All","50 Years to 130 Years   (Adult, Older Adult)","Phase 3","19271","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D513BC00001","February 10, 2014","January 25, 2019","January 25, 2019","November 25, 2013","March 18, 2020","March 18, 2020","Research Site, Alexander City, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Fairhope, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Tuscumbia, Alabama, United States|Research Site, Cottonwood, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Bakersfield, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Fremont, California, United States|Research Site, Fresno, California, United States|Research Site, Irvine, California, United States|Research Site, La Mesa, California, United States|Research Site, Long Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Hills, California, United States|Research Site, Newport Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, Stanford, California, United States|Research Site, Stockton, California, United States|Research Site, Tarzana, California, United States|Research Site, Torrance, California, United States|Research Site, Denver, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Greenwich, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Cooper City, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Cutler Bay, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Merritt Island, Florida, United States|Research Site, Miami Gardens, Florida, United States|Research Site, Miami Shores, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Smyrna Beach, Florida, United States|Research Site, North Miami Beach, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Saint Cloud, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Tucker, Georgia, United States|Research Site, Nampa, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Crystal Lake, Illinois, United States|Research Site, Elmhurst, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Hinsdale, Illinois, United States|Research Site, Moline, Illinois, United States|Research Site, North Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Elkhart, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Davenport, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Bossier City, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Crowley, Louisiana, United States|Research Site, Minden, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bowie, Maryland, United States|Research Site, Glen Burnie, Maryland, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Oxon Hill, Maryland, United States|Research Site, Prince Frederick, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, North Attleboro, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Mount Clemens, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Rochester Hills, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, Olive Branch, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Joplin, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Lee's Summit, Missouri, United States|Research Site, North Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Helena, Montana, United States|Research Site, Hastings, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, East Brunswick, New Jersey, United States|Research Site, Flemington, New Jersey, United States|Research Site, Morristown, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Binghamton, New York, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Hawthorne, New York, United States|Research Site, Manhasset, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Orchard Park, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Utica, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Calabash, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Clayton, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Sanford, North Carolina, United States|Research Site, Smithfield, North Carolina, United States|Research Site, Tabor City, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Lyndhurst, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Willoughby, Ohio, United States|Research Site, Youngstown, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Butler, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Danville, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Harleysville, Pennsylvania, United States|Research Site, Indiana, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Port Matilda, Pennsylvania, United States|Research Site, Scranton, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Columbia, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Greenwood, South Carolina, United States|Research Site, North Myrtle Beach, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Simpsonville, South Carolina, United States|Research Site, Varnville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Beaumont, Texas, United States|Research Site, Channelview, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Sam Houston, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Huntsville, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Pharr, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Shavano Park, Texas, United States|Research Site, Bountiful, Utah, United States|Research Site, Draper, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Alexandria, Virginia, United States|Research Site, Arlington, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Port Orchard, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Huntington, West Virginia, United States|Research Site, Kenosha, Wisconsin, United States|Research Site, Waukesha, Wisconsin, United States|Research Site, Buenos aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad Autonomade Buenos Aires, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Ciudadela, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ranelagh, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Luis, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Venado Tuerto, Argentina|Research Site, Villa Maria, Argentina|Research Site, Adelaide, Australia|Research Site, Ashford, Australia|Research Site, Coffs Harbour, Australia|Research Site, Fitzroy, Australia|Research Site, Fullarton, Australia|Research Site, Geelong, Australia|Research Site, Heidelberg West, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Maroubra, Australia|Research Site, Melbourne, Australia|Research Site, Merewether, Australia|Research Site, Milton, Australia|Research Site, Murdoch, Australia|Research Site, Braunau, Austria|Research Site, Eisenstadt, Austria|Research Site, Feldkirch, Austria|Research Site, Innsbruck, Austria|Research Site, Saint Stefan/Stainz, Austria|Research Site, Salzburg, Austria|Research Site, Vienna, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Bouge, Belgium|Research Site, Bruges, Belgium|Research Site, De Pinte, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Huy, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Mechelen, Belgium|Research Site, Mol, Belgium|Research Site, Overpelt, Belgium|Research Site, Roeselare, Belgium|Research Site, Yvoir, Belgium|Research Site, Zottegem, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Blumenau, Brazil|Research Site, Brasilia, Brazil|Research Site, Brasillia, Brazil|Research Site, Brasillia, Brazil|Research Site, Brasília, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Campo Grande, Brazil|Research Site, Cariacica, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiânia, Brazil|Research Site, Goiânia, Brazil|Research Site, Marilia, Brazil|Research Site, Maringa, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, S.J.Rio Preto, Brazil|Research Site, Sao Jose dos Campos, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Tatui, Brazil|Research Site, Uberlândia, Brazil|Research Site, Vitoria, Brazil|Research Site, Vitória, Brazil|Research Site, Votuporanga, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Botevgrad, Bulgaria|Research Site, Burgas, Bulgaria|Research Site, Dimitrovgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gabrovo, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Lom, Bulgaria|Research Site, Pazardzhik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Red Deer, Alberta, Canada|Research Site, Spruce Grove, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Jarvis, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Thornhill, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Waterloo, Ontario, Canada|Research Site, Brossard, Quebec, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Saint-Georges, Quebec, Canada|Research Site, St Jean sur Richelieu, Quebec, Canada|Research Site, St-Lambert, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Chicoutimi, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Los Angeles, Chile|Research Site, Osorno, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Temuco, Chile|Research Site, Viña del Mar, Chile|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Cangzhou, China|Research Site, Chengdu, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Pingxiang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Yinchuan, China|Research Site, Armenia, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogotá, Colombia|Research Site, Bucaramanga, Colombia|Research Site, Cali, Colombia|Research Site, Cali, Colombia|Research Site, Cartagena, Colombia|Research Site, Floridablanca, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Medellin, Colombia|Research Site, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Benesov, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Ceska Lipa, Czechia|Research Site, Chomutov, Czechia|Research Site, Frydek-Mistek, Czechia|Research Site, Jablonec nad Nisou, Czechia|Research Site, Karlovy Vary, Czechia|Research Site, Kolin, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Louny, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava - Zabreh, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Ostrava, Czechia|Research Site, Pelhrimov, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 9, Czechia|Research Site, Praha, Czechia|Research Site, Praha, Czechia|Research Site, Pribram VIII, Czechia|Research Site, Slany, Czechia|Research Site, Trebic, Czechia|Research Site, Turnov, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Usti nad Orlici, Czechia|Research Site, Aarhus N, Denmark|Research Site, Esbjerg, Denmark|Research Site, Hjørring, Denmark|Research Site, Hvidovre, Denmark|Research Site, Kolding, Denmark|Research Site, Købehhavn Ø, Denmark|Research Site, København NV, Denmark|Research Site, Næstved, Denmark|Research Site, Odense C, Denmark|Research Site, Roslev, Denmark|Research Site, Svendborg, Denmark|Research Site, Viborg, Denmark|Research Site, Værløse, Denmark|Research Site, Helsinki, Finland|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Jyväskylä, Finland|Research Site, Kokkola, Finland|Research Site, Kuopio, Finland|Research Site, Lahti, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Avignon Cedex, France|Research Site, Bayonne, France|Research Site, Bobigny, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon, France|Research Site, La Rochelle Cedex, France|Research Site, Le Coudray Cedex, France|Research Site, Lyon, France|Research Site, Montauban, France|Research Site, NICE Cedex 01, France|Research Site, Nimes, France|Research Site, PARIS Cedex 15, France|Research Site, Paris, France|Research Site, Paris, France|Research Site, Toulouse Cedex, France|Research Site, TOURCOING cedex, France|Research Site, TOURS Cedex 9, France|Research Site, Altdorf, Germany|Research Site, Aschaffenburg, Germany|Research Site, Bad Krozingen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Leipzig, Germany|Research Site, Markkleeberg, Germany|Research Site, Meißen, Germany|Research Site, Mühldorf Am Inn, Germany|Research Site, München, Germany|Research Site, Neuwied, Germany|Research Site, Nürnberg, Germany|Research Site, Papenburg, Germany|Research Site, Schwerin, Germany|Research Site, Wangen, Germany|Research Site, Wermsdorf, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Hongkong, Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Berettyóújfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Hajdúszoboszló, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Kisvárda, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pásztó, Hungary|Research Site, Pécs, Hungary|Research Site, Sopron, Hungary|Research Site, Szentes, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Naharia, Israel|Research Site, Petach Tikva, Israel|Research Site, Petah Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Pavia, Italy|Research Site, Rivoli, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Udine, Italy|Research Site, Viterbo, Italy|Research Site, Adachi-ku, Japan|Research Site, Beppu-shi, Japan|Research Site, Chikushino-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Daito-shi, Japan|Research Site, Edogawa-ku, Japan|Research Site, Fujisawa-shi, Japan|Research Site, Fukui-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Fussa-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Hitachi-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kawanishi-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Miura-gun, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Otaru-shi, Japan|Research Site, Sanyoonoda-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Shimajiri-gun, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takayama-shi, Japan|Research Site, Toyohashi-shi, Japan|Research Site, Toyota-shi, Japan|Research Site, Tsuchiura-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Urasoe-shi, Japan|Research Site, Ureshino-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Wako-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Anyang-si, Korea, Republic of|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Changwon-si, Korea, Republic of|Research Site, Cheonan-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Iksan-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Jinju-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Culiacan, Mexico|Research Site, Culiacán, Mexico|Research Site, D.F, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Morelia, Mexico|Research Site, México, Mexico|Research Site, Nuevo Leon, Mexico|Research Site, Pachuca, Mexico|Research Site, Querétaro, Mexico|Research Site, Tijuana, Mexico|Research Site, Xalapa, Mexico|Research Site, Zapopan, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Blaricum, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Emmen, Netherlands|Research Site, Enschede, Netherlands|Research Site, Goes, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Roosendaal, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Stadskanaal, Netherlands|Research Site, Tiel, Netherlands|Research Site, Uden, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Bergen, Norway|Research Site, Bodø, Norway|Research Site, Bodø, Norway|Research Site, Kongsvinger, Norway|Research Site, Lillehammer, Norway|Research Site, Oslo, Norway|Research Site, Oslo, Norway|Research Site, Oslo, Norway|Research Site, Sandefjord, Norway|Research Site, Skedsmokorset, Norway|Research Site, Skien, Norway|Research Site, Stavanger, Norway|Research Site, Svelvik, Norway|Research Site, Tromsø, Norway|Research Site, Trondheim, Norway|Research Site, Ålesund, Norway|Research Site, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Callao, Peru|Research Site, Chiclayo, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Miraflores, Peru|Research Site, Cebu City, Philippines|Research Site, Cebu, Philippines|Research Site, Davao City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Taguig City, Philippines|Research Site, Biała Rawska, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Białystok, Poland|Research Site, Bielsko-Biała, Poland|Research Site, Bochnia, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chojnice, Poland|Research Site, Chorzów, Poland|Research Site, Chrzanow, Poland|Research Site, Chrzanów, Poland|Research Site, Elbląg, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Giżycko, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Jasło, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Kielce, Poland|Research Site, Koszalin, Poland|Research Site, Kościan, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Kędzierzyn Koźle, Poland|Research Site, Legnica, Poland|Research Site, Lubin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Lublin, Poland|Research Site, Mikołów, Poland|Research Site, Myszków, Poland|Research Site, Nakło nad Notecią, Poland|Research Site, Nowogard, Poland|Research Site, Nysa, Poland|Research Site, Opole, Poland|Research Site, Ostrów Mazowiecka, Poland|Research Site, Oświęcim, Poland|Research Site, Poznań, Poland|Research Site, Poznań, Poland|Research Site, Puławy, Poland|Research Site, Płock, Poland|Research Site, Ruda Slaska, Poland|Research Site, Rzeszów, Poland|Research Site, Rzeszów, Poland|Research Site, Siedlce, Poland|Research Site, Sobótka, Poland|Research Site, Sokółka, Poland|Research Site, Staszów, Poland|Research Site, Szczecin, Poland|Research Site, Szczecin, Poland|Research Site, Tarnów, Poland|Research Site, Torun, Poland|Research Site, Toruń, Poland|Research Site, Tychy, Poland|Research Site, Ustroń, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Włocławek, Poland|Research Site, Zabrze, Poland|Research Site, Zamość, Poland|Research Site, Zgierz, Poland|Research Site, Zielona Góra, Poland|Research Site, Łódź, Poland|Research Site, Żnin, Poland|Research Site, Canovanas, Puerto Rico|Research Site, Cidra, Puerto Rico|Research Site, Bacau, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Craiova, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Suceava, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Khanty-Mansiysk, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-na-Donu, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint- Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, StPetersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Dammam, Saudi Arabia|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Khobar, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Brezno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kralovsky Chlmec, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Alberton, South Africa|Research Site, Benoni, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Greenbury, Phoenix, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Paarl, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Soweto, South Africa|Research Site, Stanger, South Africa|Research Site, Verulam, South Africa|Research Site, Worcester, South Africa|Research Site, A Coruña, Spain|Research Site, Alcalá de Henares, Spain|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Cáceres, Spain|Research Site, El Palmar, Spain|Research Site, Ferrol (A Coruña), Spain|Research Site, Girona, Spain|Research Site, Granada, Spain|Research Site, Hospitalet de Llobregat, Spain|Research Site, Huelva, Spain|Research Site, La Laguna (Tenerife), Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Móstoles, Spain|Research Site, Pontevedra, Spain|Research Site, Sabadell, Spain|Research Site, San Juan de Alicante, Spain|Research Site, San Sebastian de los Reyes, Spain|Research Site, Santander, Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Sevilla, Spain|Research Site, Son Ferriol, Spain|Research Site, Valdemoro, Spain|Research Site, Valencia, Spain|Research Site, Göteborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Lessebo, Sweden|Research Site, Lund, Sweden|Research Site, Lund, Sweden|Research Site, Malmö, Sweden|Research Site, Rättvik, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Örebro, Sweden|Research Site, Changhua City, Taiwan|Research Site, Hsinchu, Taiwan|Research Site, Hualien City, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kweishan Shiang, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, Pingtung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Muang, Thailand|Research Site, Naimuang, Thailand|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Antalya, Turkey|Research Site, Aydin, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, İstanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Mersin, Turkey|Research Site, Belo Horizonte, Ukraine|Research Site, Cherkasy, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mykolaiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odesa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Rivne, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Airdrie, United Kingdom|Research Site, Antrim, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Doncaster, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Durham, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Faringdon, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrogate, United Kingdom|Research Site, High Wycombe, United Kingdom|Research Site, London, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Newcastle-Upon-Tyne, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Paisley, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Rotherham, United Kingdom|Research Site, Rothwell, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, York, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Hcmc, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01991795/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT01991795/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01991795"
64,"NCT01974752","Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)","SUMIT","Completed","Has Results","Metastatic|Uveal Melanoma","Drug: 75mg selumetinib|Drug: placebo|Drug: Dacarbazine","Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival (PFS) Using BICR According to RECIST 1.1.|Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine in Terms of Objective Response Rate (ORR) by BICR|Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine in Terms of Change in Tumour Size at Week 6 by BICR|Assessment of the Overall Survival (OS) in Patients Taking Selumetinib in Combination With Dacarbazine Compared With Those Taking Placebo in Combination With Dacarbazine","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","152","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1344C00001","April 2014","May 2015","October 2016","November 3, 2013","September 28, 2016","January 5, 2017","Research Site, Los Angeles, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Atlanta, Georgia, United States|Research Site, Lutherville, Maryland, United States|Research Site, St. Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Olomouc, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Hus, Finland|Research Site, Nice Cedex 2, France|Research Site, Paris Cedex 5, France|Research Site, Heidelberg, Germany|Research Site, München, Germany|Research Site, Jerusalem, Israel|Research Site, Ramat Gan, Israel|Research Site, Leiden, Netherlands|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Glasgow, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01974752"
65,"NCT01961349","Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy","Kagami_SDS","Completed","Has Results","Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy","Drug: Intralipid|Drug: ICI35,868 (Diprivan)|Drug: ICI35,868 (Diprivan) + EES0000645/A (SDS)","Achivement of Target Sedation|PSSI Total Score","AstraZeneca|Johnson & Johnson","All","20 Years and older   (Adult, Older Adult)","Phase 3","279","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D0092C00002","October 2013","March 2014","March 2014","October 11, 2013","November 27, 2015","November 27, 2015","Research Site, Moriya-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Yokohama-shi, Japan",,"https://ClinicalTrials.gov/show/NCT01961349"
66,"NCT01928771","Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma",,"Completed","Has Results","Asthma","Biological: Benralizumab|Biological: Placebo","Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL|Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL|Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations|Number of Patients With >=1 Asthma Exacerbations|Time to First Asthma Exacerbation|Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL|Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL|Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils >=300/uL|Mean Change From Baseline to Week 48 in Asthma Symptom Score for Baseline Eosinophils <300/uL|Change in Asthma Rescue Medication|Home Lung Function Assessment Based on Morning PEF|Home Lung Function Assessment Based on Evening PEF|Proportion of Night Awakening Due to Asthma|Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils >=300/uL|Mean Change From Baseline to Week 48 in ACQ-6 for Baseline Eosinophils <300/uL|Pharmacokinetics of Benralizumab|Immunogenicity of Benralizumab|Extend of Exposure|Mean Change From Baseline to Week 48 in AQLQ(S)+12|Mean Change From Baseline to Week 48 in EQ-5D-5L VAS|Mean Work Productivity Loss Due to Asthma|Mean Productivity Loss Due to Asthma in Classroom|Number of Participants That Utilized Health Care Resources|Patient and Clinician's Responder Assessment to Treatment","AstraZeneca","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","2681","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D3250C00017","September 19, 2013","April 5, 2016","April 5, 2016","August 27, 2013","May 3, 2017","May 3, 2017","Research Site, Foley, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Scottsboro, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Bakersfield, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Costa Mesa, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Huntington Park, California, United States|Research Site, Los Angles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Orange, California, United States|Research Site, Riverside, California, United States|Research Site, San Jose, California, United States|Research Site, Santa Ana, California, United States|Research Site, Hartford, Connecticut, United States|Research Site, New Haven, Connecticut, United States|Research Site, Brandon, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Cutler Bay, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Jackonsville, Florida, United States|Research Site, Lynn Haven, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Sebring, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Albany, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Gurnee, Illinois, United States|Research Site, Normal, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Hazard, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Opelousas, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Gardner, Massachusetts, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Quincy, Massachusetts, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, St. Paul, Minnesota, United States|Research Site, Picayune, Mississippi, United States|Research Site, Billings, Montana, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Sparks, Nevada, United States|Research Site, Marlton, New Jersey, United States|Research Site, Northfield, New Jersey, United States|Research Site, Union, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Hopewell Jct, New York, United States|Research Site, New York City, New York, United States|Research Site, New York, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Shelby, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Oregon, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Wooster, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Phoenixville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Easley, South Carolina, United States|Research Site, Hodges, South Carolina, United States|Research Site, Mt Pleasant, South Carolina, United States|Research Site, Rock Hill, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Germantown, Tennessee, United States|Research Site, Allen, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dickinson, Texas, United States|Research Site, Duncanville, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Pharr, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Sealy, Texas, United States|Research Site, Splendora, Texas, United States|Research Site, Orem, Utah, United States|Research Site, Provo, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Abingdon, Virginia, United States|Research Site, Hopewell, Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Greenfield, Wisconsin, United States|Research Site, Bedford Park, Australia|Research Site, Box Hill, Australia|Research Site, Clayton, Australia|Research Site, Concord, Australia|Research Site, Frankston, Australia|Research Site, Nedlands, Australia|Research Site, New Lambton Heights, Australia|Research Site, Parkville, Australia|Research Site, Prahran, Australia|Research Site, Randwick, Australia|Research Site, Woolloongabba, Australia|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo André, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sorocaba, Brazil|Research Site, São Paulo, Brazil|Research Site, Dupnitsa, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Samokov, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Velingrad, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Brno, Czech Republic|Research Site, Jindrichuv Hradec, Czech Republic|Research Site, Karlovy Vary, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Rokycany, Czech Republic|Research Site, Strakonice, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Brest Cedex, France|Research Site, Clermont Ferrand, France|Research Site, Dijon Cedex, France|Research Site, Le Kremlin Bicêtre, France|Research Site, Le Mans Cedex, France|Research Site, Lyon Cedex 4, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Paris, France|Research Site, Pau Cedex, France|Research Site, Pringy Cedex, France|Research Site, Saint Pierre, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse, France|Research Site, Bari, Italy|Research Site, Bologna, Italy|Research Site, Catania, Italy|Research Site, Cona, Italy|Research Site, Firenze, Italy|Research Site, Foggia, Italy|Research Site, Legnago, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, San Pietro Vernotico, Italy|Research Site, Torino, Italy|Research Site, Verona, Italy|Research Site, Anyang-si, Korea, Republic of|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Jeju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research Site, Morelia, Mexico|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Surco, Peru|Research Site, Białystok, Poland|Research Site, Dobre Miasto, Poland|Research Site, Gdańsk, Poland|Research Site, Giżycko, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Kościan, Poland|Research Site, Legnica, Poland|Research Site, Lublin, Poland|Research Site, Poznań, Poland|Research Site, Proszowice, Poland|Research Site, Rzeszów, Poland|Research Site, Sosnowiec, Poland|Research Site, Wołomin, Poland|Research Site, Wrocław, Poland|Research Site, Zgierz, Poland|Research Site, Łódź, Poland|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint - Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, StPetersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Vladimir, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Yekaterinburg, Russian Federation|Research Site, Benoni, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Mowbray, South Africa|Research Site, Stanger, South Africa|Research Site, Barcelona, Spain|Research Site, Lugo, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Oviedo, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Sagunto(Valencia), Spain|Research Site, Salamanca, Spain|Research Site, Valencia, Spain|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Bursa, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Mersin, Turkey|Research Site, Birmingham, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Chertsey, United Kingdom|Research Site, Chester, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Cottingham, United Kingdom|Research Site, Darlington, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, High Heaton/Newcastle upon Tyn, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Portsmouth, United Kingdom|Research Site, Soham, United Kingdom|Research Site, Somerset, United Kingdom|Research Site, Stevenage, United Kingdom|Research Site, Stockton, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01928771"
67,"NCT01914757","Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist",,"Completed","Has Results","Asthma","Biological: Benralizumab|Biological: Placebo","Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL|Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils <300/uL|Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils >=300/uL|Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline Eosinophils <300/uL|Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils >=300/uL|Mean Change From Baseline to Week 56 Asthma Symptoms Score for Patients With Baseline Eosinophils <300/uL|Change in Asthma Rescue Medication Use|Home Lung Function Assessments Based on PEF|Proportion of Nights With Awakening Due to Asthma|Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils >=300/uL|Mean Change From Baseline to Week 56 in ACQ-6 for Patients With Baseline Eosinophils <300/uL|Number of Patients With >=1 Asthma Exacerbation|Time to First Asthma Exacerbation|Annual Rate of Asthma Exacerbation Resulting Emergency Room Visits and Hospitalizations|Pharmacokinetics of Benralizumab|Immunogenicity of Benralizumab|Extent of Exposure|Mean Change From Baseline to Week 56 in AQLQ(S)+12|Change From Baseline to Week 56 in EQ-5D-5L VAS|Mean Work Productivity Loss Due to Asthma|Mean Productivity Loss Due to Asthma in Classroom|Number of Participants That Utilized Health Care Resources|Patient and Clinician Assessment of Response to Treatment","AstraZeneca","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","2508","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D3250C00018","August 2013","March 2016","March 2016","August 2, 2013","January 25, 2017","January 25, 2017","Research Site, Andalusia, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Flagstaff, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Garden Grove, California, United States|Research Site, Lakewood, California, United States|Research Site, North Hollywood, California, United States|Research Site, Northridge, California, United States|Research Site, Palmdale, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Rolling Hills Estate, California, United States|Research Site, Sacramento, California, United States|Research Site, Stockton, California, United States|Research Site, Thousand Oaks, California, United States|Research Site, Upland, California, United States|Research Site, Ventura, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Westminister, California, United States|Research Site, Woodland, California, United States|Research Site, Centennial, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Wheat Ridge, Colorado, United States|Research Site, Celebration, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Homestead, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lehigh Acres, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Virginia Gardens, Florida, United States|Research Site, Gainesville, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Eagle, Idaho, United States|Research Site, Shiloh, Illinois, United States|Research Site, Lenexa, Kansas, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Traverse City, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, St Louis, Missouri, United States|Research Site, Las Vagas, Nevada, United States|Research Site, Union, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Corvallis, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Jefferson Hills, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Boerne, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Midvale, Utah, United States|Research Site, Murray, Utah, United States|Research Site, Fairfax, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Concepción del Uruguay, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Florida, Argentina|Research Site, Godoy Cruz, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mendoza, Argentina|Research Site, Ranelagh, Argentina|Research Site, Rosario, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Calgary, Alberta, Canada|Research Site, Sherwood Park, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, St Charles Borromee, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Quillota, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Valparaiso, Chile|Research Site, Viña del Mar, Chile|Research Site, Aschaffenburg, Germany|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Frankfurt/Main, Germany|Research Site, Frankfurt, Germany|Research Site, Geesthacht, Germany|Research Site, Gelsenkirchen, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Herford, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, München, Germany|Research Site, Neu-Isenburg, Germany|Research Site, Rostock, Germany|Research Site, Rüdersdorf, Germany|Research Site, Witten, Germany|Research Site, Asahi-shi, Japan|Research Site, Chiyoda-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Itabashi-ku, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kokubunji-shi, Japan|Research Site, Matsue-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Mizunami-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Obihiro-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Setagaya-ku, Japan|Research Site, Shibuya-ku, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Sumida-ku, Japan|Research Site, Takamatsu-shi, Japan|Research Site, Toshima-ku, Japan|Research Site, Tsukubo-gun, Japan|Research Site, Yokohama-shi, Japan|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Quezon City, Philippines|Research Site, Aleksandrów Łódzki, Poland|Research Site, Białystok, Poland|Research Site, Bielsko Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bystra Śląska, Poland|Research Site, Gdańsk, Poland|Research Site, Gorzów Wlkp, Poland|Research Site, Karczew, Poland|Research Site, Katowice, Poland|Research Site, Koszalin, Poland|Research Site, Kraków, Poland|Research Site, Lubin, Poland|Research Site, Lublin, Poland|Research Site, Ostrów Wielkopolski, Poland|Research Site, Poznań, Poland|Research Site, Ruda Slaska, Poland|Research Site, Rzeszów, Poland|Research Site, Skierniewice, Poland|Research Site, Szczecin, Poland|Research Site, Tarnów, Poland|Research Site, Toruń, Poland|Research Site, Trzebnica, Poland|Research Site, Warszawa, Poland|Research Site, Wieluń, Poland|Research Site, Wroclaw, Poland|Research Site, Wrocław, Poland|Research Site, Zabrze, Poland|Research Site, Łódź, Poland|Research Site, Łęczna, Poland|Research Site, Żnin, Poland|Research Site, Bragadiru, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Constanta, Romania|Research Site, Deva, Romania|Research Site, Iasi, Romania|Research Site, Timisoara, Romania|Research Site, Goteborg, Sweden|Research Site, Luleå, Sweden|Research Site, Lund, Sweden|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Mykolayiv, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vinnytsya, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporozhye, Ukraine",,"https://ClinicalTrials.gov/show/NCT01914757"
68,"NCT01908140","Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Aclidinium Bromide / Formoterol Fumarate|Drug: Salmeterol / Fluticasone","Peak Forced Expiratory Volume in One Second (FEV1) at Week 24|Transition Dyspnoea Index (TDI) Focal Score at Week 24","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","933","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M/40464/39|2013-000116-14","September 2013","August 2014","August 2014","July 25, 2013","March 7, 2016","March 7, 2016","Almirall Investigational Site, Feldbach, Austria|Almirall Investigational Site, Feldkirch, Austria|Almirall Investigational Site, Grieskirchen, Austria|Almirall Investigational Site, Linz, Austria|Almirall Investigational Site, Salzburg, Austria|Almirall Investigational Site, Dimitrovgrad, Bulgaria|Almirall Investigational Site, Gabrovo, Bulgaria|Almirall Investigational Site, Kozlodui, Bulgaria|Almirall Investigational Site, Petrich, Bulgaria|Almirall Investigational Site, Plovdiv, Bulgaria|Almirall Investigational Site, Razgrad, Bulgaria|Almirall Investigational Site, Stara Zagora, Bulgaria|Almirall Investigational Site, Vidin, Bulgaria|Almirall Investigational Site, Edmonton, Alberta, Canada|Almirall Investigational Site, Vancouver, British Columbia, Canada|Almirall Investigational Site, Vancouver, British Columbia, Canada|Almirall Investigational Site, Moncton, New Brunswick, Canada|Almirall Investigational Site, Toronto, Ontario, Canada|Almirall Investigational Site, Saint Romuald, Quebec, Canada|Almirall Investigational Site, Trois-Rivières, Quebec, Canada|Almirall Investigational Site, Karlovy Vary, Czech Republic|Almirall Investigational Site, Kralupy nad Vltavou, Czech Republic|Almirall Investigational Site, Liberec, Czech Republic|Almirall Investigational Site, Ostrava - Hrabuvka, Czech Republic|Almirall Investigational Site, Rokycany, Czech Republic|Almirall Investigational Site, Strakonice, Czech Republic|Almirall Investigational Site, Nîmes, France|Almirall Investigational Site, Perpignan, France|Almirall Investigational Site, Vieux Conde, France|Almirall Investigational Site, Berlin, Germany|Almirall Investigational Site, Berlin, Germany|Almirall Investigational Site, Berlin, Germany|Almirall Investigational Site, Berlin, Germany|Almirall Investigational Site, Berlin, Germany|Almirall Investigational Site, Berlin, Germany|Almirall Investigational Site, Berlin, Germany|Almirall Investigational Site, Berlin, Germany|Almirall Investigational Site, Bochum, Germany|Almirall Investigational Site, Bonn, Germany|Almirall Investigational Site, Cologne, Germany|Almirall Investigational Site, Cottbus, Germany|Almirall Investigational Site, Dortmund, Germany|Almirall Investigational Site, Dresden, Germany|Almirall Investigational Site, Frankfurt, Germany|Almirall Investigational Site, Frankfurt, Germany|Almirall Investigational Site, Gauting, Germany|Almirall Investigational Site, Großhansdorf, Germany|Almirall Investigational Site, Hamburg, Germany|Almirall Investigational Site, Hamburg, Germany|Almirall Investigational Site, Hamburg, Germany|Almirall Investigational Site, Hannover, Germany|Almirall Investigational Site, Jena, Germany|Almirall Investigational Site, Leipzig, Germany|Almirall Investigational Site, Marburg, Germany|Almirall Investigational Site, Munich, Germany|Almirall Investigational Site, Rüdersdorf, Germany|Almirall Investigational Site, Schwabach, Germany|Almirall Investigational Site, Wiesbaden, Germany|Almirall Investigational Site, Wiesloch, Germany|Almirall Investigational Site, Witten, Germany|Almirall Investigational Site, Balassagyarmat, Hungary|Almirall Investigational Site, Budapest, Hungary|Almirall Investigational Site, Budapest, Hungary|Almirall Investigational Site, Debrecen, Hungary|Almirall Investigational Site, Komárom, Hungary|Almirall Investigational Site, Nyíregyháza, Hungary|Almirall Investigational Site, Pécs, Hungary|Almirall Investigational Site, Szazhalombatta, Hungary|Almirall Investigational Site, Szigetszentmiklós, Hungary|Almirall Investigational Site, Vásárosnamény, Hungary|Almirall Investigational Site, Pisa, Italy|Almirall Investigational Site, Pordenone, Italy|Almirall Investigational Site, Trieste, Italy|Almirall Investigational Site, Kaunas, Lithuania|Almirall Investigational Site, Klaipeda, Lithuania|Almirall Investigational Site, Klaipeda, Lithuania|Almirall Investigational Site, Vilnius, Lithuania|Almirall Investigational Site, Almere, Netherlands|Almirall Investigational Site, Beek, Netherlands|Almirall Investigational Site, Eindhoven, Netherlands|Almirall Investigational Site, Hoofddorp, Netherlands|Almirall Investigational Site, Leeuwarden, Netherlands|Almirall Investigational Site, Rotterdam, Netherlands|Almirall Investigational Site, Bialystok, Poland|Almirall Investigational Site, Bialystok, Poland|Almirall Investigational Site, Bialystok, Poland|Almirall Investigational Site, Gdansk, Poland|Almirall Investigational Site, Katowice, Poland|Almirall Investigational Site, Krakow, Poland|Almirall Investigational Site, Lodz, Poland|Almirall Investigational Site, Ostrowiec Swietokrzyski, Poland|Almirall Investigational Site, Pila, Poland|Almirall Investigational Site, Poznan, Poland|Almirall Investigational Site, Proszowice, Poland|Almirall Investigational Site, Sopot, Poland|Almirall Investigational Site, Szczecin, Poland|Almirall Investigational Site, Tarnow, Poland|Almirall Investigational Site, Tczew, Poland|Almirall Investigational Site, Warsaw, Poland|Almirall Investigational Site, Wilkowice-Bystra, Poland|Almirall Investigational Site, Belville, South Africa|Almirall Investigational Site, Cape Town, South Africa|Almirall Investigational Site, Gauteng, South Africa|Almirall Investigational Site, Gauteng, South Africa|Almirall Investigational Site, Middelburg, South Africa|Almirall Investigational Site, Pretoria, South Africa|Almirall Investigational Site, Somerset West, South Africa|Almirall Investigational Site, Alicante, Spain|Almirall Investigational Site, Barcelona, Spain|Almirall Investigational Site, Barcelona, Spain|Almirall Investigational Site, Barcelona, Spain|Almirall Investigational Site, Elda, Spain|Almirall Investigational Site, Laredo, Spain|Almirall Investigational Site, Madrid, Spain|Almirall Investigational Site, Palma de Mallorca, Spain|Almirall Investigational Site, Sant Boi de Llobregat, Spain|Almirall Investigational Site, Santander, Spain|Almirall Investigational Site, Seville, Spain|Almirall Investigational Site, Birmingham, United Kingdom|Almirall Investigational Site, Chorley, United Kingdom|Almirall Investigational Site, Glasgow, United Kingdom|Almirall Investigational Site, Liverpool, United Kingdom|Almirall Investigational Site, Manchester, United Kingdom|Almirall Investigational Site, Middlesex, United Kingdom|Almirall Investigational Site, Reading, United Kingdom|Almirall Investigational Site, Sidcup, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01908140"
69,"NCT01880424","A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","D5630C00001","Completed","Has Results","Irritable Bowel Syndrome With Constipation (IBS-C)","Drug: Placebo|Drug: Linaclotide","12-week Abdominal Pain/Abdominal Discomfort Weekly Responder|12-week Irritable Bowel Syndrome (IBS) Degree of Relief Responder|Change From Baseline in 12-week Complete Spontaneous Bowel Movement Frequency Rate|Change From Baseline in 12-week Spontaneous Bowel Movement Frequency Rate|Change From Baseline in 12-week Stool Consistency|Change From Baseline in 12-week Severity of Straining|Change From Baseline in 12-week Abdominal Bloating|Change From Baseline in 12-week Abdominal Pain|Change From Baseline in 12-week Abdominal Discomfort","AstraZeneca|Ironwood Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1722","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ICP-103-307","July 2013","May 2015","May 2015","June 19, 2013","September 27, 2016","September 27, 2016","Research Site, Huntsville, Alabama, United States|Research Site, North Little Rock, Arkansas, United States|Research Site, Phoenix, Arkansas, United States|Research Site, Artesia, California, United States|Research Site, Chula Vista, California, United States|Research Site, Encino, California, United States|Research Site, North Hollywood, California, United States|Research Site, Orange, California, United States|Research Site, Riverside, California, United States|Research Site, San Diego, California, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Doral, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Addison, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Crowley, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Chesterfield, Michigan, United States|Research Site, Wyoming, Michigan, United States|Research Site, St. Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Brooklyn, New York, United States|Research Site, Great Neck, New York, United States|Research Site, New York, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Franklin, Ohio, United States|Research Site, Mentor, Ohio, United States|Research Site, Greer, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Smyrna, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Adelaide, Australia|Research Site, Brisbane, Australia|Research Site, Five Dock, Australia|Research Site, Malvern, Australia|Research Site, Maroubra, Australia|Research Site, Melbourne, Australia|Research Site, Parkville, Australia|Research Site, Vaughan, Ontario, Canada|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Harerbin, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shijiazhuang, China|Research Site, Wuhan, China|Research Site, Xi An, China|Research Site, Xiamen, China|Research Site, Auckland, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Dunedin, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Wellington, New Zealand",,"https://ClinicalTrials.gov/show/NCT01880424"
70,"NCT01757275","High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer",,"Completed","Has Results","Bleeding Peptic Ulcer","Drug: Esomeprazole Na|Drug: Cimetidine|Drug: Esomeprazole Mg","Rate of Clinically Significant Rebleeding Within 72 Hours|Rate of Clinically Significant Rebleeding During 7 Days|Rate of Clinically Significant Rebleeding During 30 Days|Number of Patients With Endoscopic Re-treatment Within 72 Hours|Number of Patients With Endoscopic Re-treatment Within 30 Days|Number of Patients With Surgery Due to Rebleeding Within 72 Hours|Number of Patients With Surgery Due to Rebleeding Within 30 Days|Number of Blood Units Transfused Within 72 Hours|Number of Blood Units Transfused Within 30 Days","AstraZeneca","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","239","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D961DC00007","February 2013","December 2014","December 2014","December 28, 2012","March 8, 2016","March 8, 2016","Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Ha'er bing, China|Research Site, Hangzhou, China|Research Site, Ji Nan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Wuhan, China|Research Site, Xian, China",,"https://ClinicalTrials.gov/show/NCT01757275"
71,"NCT01732822","A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease","EUCLID","Completed","Has Results","Peripheral Artery Disease","Drug: Ticagrelor|Drug: Clopidogrel","Composite of Cardiovascular (CV) Death/MI/Ischemic Stroke|Composite of CV Death, MI, Ischemic Stroke, and ALI|CV Death|MI|All-cause Mortality|Composite of CV Death, MI, and All-cause Stroke (Ischemic or Hemorrhagic)|ALI|Lower Extremity Revascularization|Any Revascularisation (Coronary, Peripheral [Limb, Mesenteric, Renal, Carotid and Other])","AstraZeneca","All","50 Years to 130 Years   (Adult, Older Adult)","Phase 3","13885","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D5135C00001|2011-004616-36","December 4, 2012","September 26, 2016","September 26, 2016","November 26, 2012","October 30, 2017","October 30, 2017","Research Site, Alexander City, Alabama, United States|Research Site, Auburn, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Cottonwood, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Fort Smith, Arkansas, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Berkeley, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Chula Vista, California, United States|Research Site, El Cajon, California, United States|Research Site, Fresno, California, United States|Research Site, La Jolla, California, United States|Research Site, La Mesa, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Moreno Valley, California, United States|Research Site, Northridge, California, United States|Research Site, Oceanside, California, United States|Research Site, Orange, California, United States|Research Site, Palo Alto, California, United States|Research Site, Sacramento, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Stockton, California, United States|Research Site, Torrance, California, United States|Research Site, Torrance, California, United States|Research Site, Loveland, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Guilford, Connecticut, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Trumbull, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Newark, Delaware, United States|Research Site, Wilmington, Delaware, United States|Research Site, Washington, D.C., District of Columbia, United States|Research Site, Atlantis, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hudson, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange Park, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Stuart, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Trinity, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Lithonia, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Martinez, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Tucker, Georgia, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hinsdale, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Rockford, Illinois, United States|Research Site, Elkhart, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Merrillville, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Edgewood, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Bossier City, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Beltsville, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Flint, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Mount Clemens, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Kalispell, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, North Las Vegas, Nevada, United States|Research Site, Belleville, New Jersey, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, Camden, New Jersey, United States|Research Site, East Orange, New Jersey, United States|Research Site, Eatontown, New Jersey, United States|Research Site, Elmer, New Jersey, United States|Research Site, Flemington, New Jersey, United States|Research Site, Freehold, New Jersey, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Haddon Heights, New Jersey, United States|Research Site, Linden, New Jersey, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Ocean City, New Jersey, United States|Research Site, Sewell, New Jersey, United States|Research Site, Summit, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, West Orange, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Hawthorne, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Liverpool, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, The Bronx, New York, United States|Research Site, The Bronx, New York, United States|Research Site, Troy, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Yonkers, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Concord, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Minot, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Centerville, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Youngstown, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Dunmore, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, Wormleysburg, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Easley, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greenwood, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Hurst, Texas, United States|Research Site, Killeen, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Leesburg, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Midlothian, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Puyallup, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Charleston, West Virginia, United States|Research Site, South Charleston, West Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Manitowoc, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, Buenos aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudadela, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, La Plata, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario Santa Fe, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Brasilia, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Canoas, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Juiz de Fora, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Salvador, Brazil|Research Site, Santo André, Brazil|Research Site, Sao Bernardo do Campo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Tatui, Brazil|Research Site, Uberlândia, Brazil|Research Site, Burgas, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Razlog, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Samokov, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Bridgewater, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Brossard, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Chicoutimi, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talcahuano, Chile|Research Site, Temuco, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Fuzhou, China|Research Site, Haerbin, China|Research Site, Hubei, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuxi, China|Research Site, Xi'an, China|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Hodonin, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jindrichuv Hradec, Czechia|Research Site, Kladno, Czechia|Research Site, Liberec, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava-Dubina, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 1, Czechia|Research Site, Praha 2, Czechia|Research Site, Slany, Czechia|Research Site, Amiens Cedex 1, France|Research Site, Bayonne, France|Research Site, Bordeaux Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Caen, France|Research Site, Castelnau-Le-Lez, France|Research Site, Dijon, France|Research Site, La Tronche, France|Research Site, Le Chesnay Cedex, France|Research Site, Le Coudray Cedex, France|Research Site, Limoges, France|Research Site, MONTPELLIER Cedex 5, France|Research Site, Nantes Cedex 2, France|Research Site, Paris 14, France|Research Site, Paris Cedex 13, France|Research Site, PARIS Cedex 15, France|Research Site, PESSAC Cedex, France|Research Site, Rambouillet, France|Research Site, Saint-priest En Jarez, France|Research Site, Strasbourg Cedex, France|Research Site, Thionville, France|Research Site, Toulouse Cedex 3, France|Research Site, Toulouse Cedex 9, France|Research Site, Tours, France|Research Site, Vandoeuvre-Les-Nancy, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Erlangen, Germany|Research Site, Ettlingen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kaiserslautern, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Merseburg, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Riesa, Germany|Research Site, Tübingen, Germany|Research Site, Wesel, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Gyöngyös, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Szeged, Hungary|Research Site, Szombathely, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Veszprém, Hungary|Research Site, Ancona, Italy|Research Site, Avellino, Italy|Research Site, Castelfranco Veneto, Italy|Research Site, Catania, Italy|Research Site, Catania, Italy|Research Site, Chieti, Italy|Research Site, Genova, Italy|Research Site, Lecce, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Napoli, Italy|Research Site, Oristano, Italy|Research Site, Padova, Italy|Research Site, Palermo, Italy|Research Site, Perugia, Italy|Research Site, Piacenza, Italy|Research Site, Pisa, Italy|Research Site, Ragusa, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Siena, Italy|Research Site, Asahi-shi, Japan|Research Site, Beppu-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hamada-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Imabari-shi, Japan|Research Site, Itabashi-ku, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsubara-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Mito-shi, Japan|Research Site, Miura-gun, Japan|Research Site, Ogori-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Suwa-shi, Japan|Research Site, Toyonaka-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yamagata-shi, Japan|Research Site, Yatsushiro-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokosuka-shi, Japan|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheonan-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Culiacan, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monclova, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Queretaro, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Tijuana, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Capelle Aan Den Ijssel, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Cebu City, Philippines|Research Site, Cebu, Philippines|Research Site, Dasmarinas, Philippines|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Makati, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Taguig City, Philippines|Research Site, Tanauan City, Philippines|Research Site, Vigan, Philippines|Research Site, Białystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Katowice, Poland|Research Site, Kraków, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Ostrów Mazowiecka, Poland|Research Site, Tarnów, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Zamość, Poland|Research Site, Łódź, Poland|Research Site, Łódź, Poland|Research Site, Łęczna, Poland|Research Site, Bacau, Romania|Research Site, Braila, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Buzau, Romania|Research Site, Cluj Napoca, Romania|Research Site, Craiova, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Sibiu, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Tg. Mures, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Dunajska Streda, Slovakia|Research Site, Kosice, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Poprad, Slovakia|Research Site, Presov, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Albacete, Spain|Research Site, Alcorcón, Spain|Research Site, Alicante, Spain|Research Site, Badalona (Barcelona), Spain|Research Site, Badalona(Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Boadilla del Monte, Spain|Research Site, Coruña, Spain|Research Site, Getafe, Spain|Research Site, Granada, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Huelva, Spain|Research Site, Lérida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Mallorca, Spain|Research Site, Manises, Spain|Research Site, Málaga, Spain|Research Site, Oviedo, Spain|Research Site, Sabadell, Spain|Research Site, Tarragona, Spain|Research Site, Toledo, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Eksjö, Sweden|Research Site, Gävle, Sweden|Research Site, Göteborg, Sweden|Research Site, Karlstad, Sweden|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Örebro, Sweden|Research Site, Bangkoknoi, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Muang, Thailand|Research Site, Songkla, Thailand|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Bursa, Turkey|Research Site, Bursa, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Aberdeen, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Cheltenham, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Newcastle upon TYNE, United Kingdom|Research Site, Worcester, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Hcmc, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01732822"
72,"NCT01730534","Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events","DECLARE-TIMI58","Completed","Has Results","Diabetes Mellitus, Non-Insulin-Dependent|High Risk for Cardiovascular Event","Drug: Dapagliflozin 10 mg|Drug: Placebo tablet","Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke|Subjects Included in the Composite Endpoint of CV Death or Hospitalization Due to Heart Failure.|Subjects Included in the Renal Composite Endpoint: Confirmed Sustained ≥40% Decrease in eGFR to eGFR <60 ml/Min/1.73m2 and/or ESRD and/or Renal or CV Death.|Subjects Included in the Endpoint of All-cause Mortality.","AstraZeneca|Bristol-Myers Squibb|The TIMI Study Group|Hadassah Medical Organization","All","40 Years to 130 Years   (Adult, Older Adult)","Phase 3","17190","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1693C00001","April 25, 2013","September 11, 2018","September 11, 2018","November 21, 2012","December 26, 2019","December 26, 2019","Research Site, Alexander City, Alabama, United States|Research Site, Athens, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Bakersfield, California, United States|Research Site, Greenbrae, California, United States|Research Site, Huntington Park, California, United States|Research Site, La Mesa, California, United States|Research Site, Lomita, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, San Diego, California, United States|Research Site, San Marino, California, United States|Research Site, San Ramon, California, United States|Research Site, Torrance, California, United States|Research Site, Ventura, California, United States|Research Site, Vista, California, United States|Research Site, Fort Collins, Colorado, United States|Research Site, Golden, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Bristol, Connecticut, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Trumbull, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Seaford, Delaware, United States|Research Site, Wilmington, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Bradenton, Florida, United States|Research Site, Chiefland, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Green Cove Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville Beach, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Palm Beach Gardens, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Spring Hill, Florida, United States|Research Site, Stuart, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Trinity, Florida, United States|Research Site, Vero Beach, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Calhoun, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Avon, Indiana, United States|Research Site, Bloomington, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Newburgh, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Topeka, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Hammond, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Beltsville, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, Methuen, Massachusetts, United States|Research Site, Natick, Massachusetts, United States|Research Site, Alpena, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Blanc, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Eagan, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Lee's Summit, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Reno, Nevada, United States|Research Site, Edison, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, Northport, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Southampton, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Westfield, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Lenoir, North Carolina, United States|Research Site, Monroe, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Fargo, North Dakota, United States|Research Site, Canal Fulton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Delaware, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Parma Hts., Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Indiana, Pennsylvania, United States|Research Site, Johnstown, Pennsylvania, United States|Research Site, Kittanning, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, Tyrone, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Midland, Texas, United States|Research Site, Odessa, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Bennington, Vermont, United States|Research Site, Burke, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Burien, Washington, United States|Research Site, Puyallup, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Buenos Aire, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, La Plata, Argentina|Research Site, La Plata, Argentina|Research Site, Lanus, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Nicolás, Argentina|Research Site, Santa Fe, Argentina|Research Site, Adelaide - Oaklands Park, Australia|Research Site, Ashford, Australia|Research Site, Box Hill, Australia|Research Site, Camperdown, Australia|Research Site, Darlinghurst, Australia|Research Site, Fullarton, Australia|Research Site, Garran, Australia|Research Site, Geelong, Australia|Research Site, Heidelberg West, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Maroubra, Australia|Research Site, Melbourne, Australia|Research Site, Milton, Australia|Research Site, Murdoch, Australia|Research Site, Wollongong, Australia|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brasschaat, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Mechelen, Belgium|Research Site, Merksem, Belgium|Research Site, Roeselare, Belgium|Research Site, Tienen, Belgium|Research Site, Turnhout, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Brasilia, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Marilia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Jose dos Campos, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Botevgrad, Bulgaria|Research Site, Dimitrovgrad, Bulgaria|Research Site, Dupnitsa, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Kyustendil, Bulgaria|Research Site, Lukovit, Bulgaria|Research Site, Petrich, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Smolyan, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Yambol, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Calgary, Alberta, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Sydney Mines, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Concord, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Pointe-Claire, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Saint-Georges, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Laval, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, ShiJiazhuang, China|Research Site, Tianjin, China|Research Site, Beroun, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Cheb, Czechia|Research Site, Chomutov, Czechia|Research Site, Chrudim III, Czechia|Research Site, Hodonin, Czechia|Research Site, Horovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jilove u Prahy, Czechia|Research Site, Kromeriz, Czechia|Research Site, Ostrava - Belsky les, Czechia|Research Site, Ostrava - Dubina, Czechia|Research Site, Ostrava - Kuncice, Czechia|Research Site, Ostrava-Moravska, Czechia|Research Site, Plzen - Severni Predmesti, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 6, Czechia|Research Site, Praha, Czechia|Research Site, Prelouc, Czechia|Research Site, Rakovnik, Czechia|Research Site, Slany, Czechia|Research Site, Teplice, Czechia|Research Site, Uherske Hradiste, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Zlin, Czechia|Research Site, Angers cedex 9, France|Research Site, Corbeil-Essonnes, France|Research Site, Dijon Cedex, France|Research Site, Dijon, France|Research Site, La Rochelle, France|Research Site, Le Creusot, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes Cedex 2, France|Research Site, Pessac, France|Research Site, Poitiers Cedex, France|Research Site, TOULOUSE Cedex 9, France|Research Site, Aschaffenburg, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Dippoldiswalde, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, Villingen-Schwenningen, Germany|Research Site, Causeway Bay, Hong Kong|Research Site, Hongkong, Hong Kong|Research Site, Tai Po, Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Ballasagyarmat, Hungary|Research Site, Berettyóújfalu, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Cegléd, Hungary|Research Site, Csongrád, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Gyöngyös, Hungary|Research Site, Kecskemét, Hungary|Research Site, Kistarcsa, Hungary|Research Site, Komárom, Hungary|Research Site, Mórahalom, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Polgár, Hungary|Research Site, Sopron, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Tát, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ács, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Pune, India|Research Site, Vellore, India|Research Site, Afula, Israel|Research Site, Ashkelon, Israel|Research Site, Beer Sheva, Israel|Research Site, Bnei Barak, Israel|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Naharia, Israel|Research Site, Petach Tikva, Israel|Research Site, Bergamo, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Negrar - VR, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Rozzano, Italy|Research Site, S Maria Capua Vetere, Italy|Research Site, Sessa Aurunca, Italy|Research Site, Verona, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Daito-shi, Japan|Research Site, Kasuga-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsubara-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Yao-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Gyeonggi-do, Korea, Republic of|Research Site, Jeonju-si, Jeollabuk-do, Korea, Republic of|Research Site, Jung-gu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Uijeongbu-si, Korea, Republic of|Research Site, Acapulco, Mexico|Research Site, Culiacan, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Meridas, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Pachuca de Soto, Mexico|Research Site, Queretaro, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, Tijuana, Mexico|Research Site, Veracruz, Mexico|Research Site, Xalapa, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, EDE, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Gouda, Netherlands|Research Site, Groningen, Netherlands|Research Site, Haarlem, Netherlands|Research Site, Hardenberg, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sliedrecht, Netherlands|Research Site, Sneek, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zutphen, Netherlands|Research Site, Bacolod, Philippines|Research Site, Cebu City, Philippines|Research Site, Dasmarinas City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Makati City, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Marikina City, Philippines|Research Site, Pasay City, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Tanauan City, Philippines|Research Site, Biała Rawska, Poland|Research Site, Bydgoszcz, Poland|Research Site, ChrzanÓw, Poland|Research Site, Gdansk, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Giżycko, Poland|Research Site, Katowice, Poland|Research Site, Koluszki, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Legnica, Poland|Research Site, Lublin, Poland|Research Site, Mrągowo, Poland|Research Site, Nakło nad Notecią, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Płock, Poland|Research Site, Ruda Śląska, Poland|Research Site, Skierniewice, Poland|Research Site, Sobótka, Poland|Research Site, Sokółka, Poland|Research Site, Torun, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wierzchosławice, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Węgrów, Poland|Research Site, Włocławek, Poland|Research Site, Zabrze, Poland|Research Site, Łęczna, Poland|Research Site, Bacau, Romania|Research Site, Bacau, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj Napoca, Romania|Research Site, Constanta, Romania|Research Site, Galati, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Iasi, Romania|Research Site, Ploiesti, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Tirgu Mures, Romania|Research Site, Târgu Mures, Romania|Research Site, Zalau, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint- Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yekaterinburg, Russian Federation|Research Site, Banská Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Dolný Kubín, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Košice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lučenec, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Námestovo, Slovakia|Research Site, Piešťany, Slovakia|Research Site, Poprad, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Rimavská Sobota, Slovakia|Research Site, Sabinov, Slovakia|Research Site, Sala, Slovakia|Research Site, Trebišov, Slovakia|Research Site, Trenčín, Slovakia|Research Site, Vrutky, Slovakia|Research Site, Žilina, Slovakia|Research Site, Alberton, South Africa|Research Site, Benoni, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Diepkloof, Soweto, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Goodwood, South Africa|Research Site, Houghton, South Africa|Research Site, Muckleneuk, South Africa|Research Site, Parktown West, South Africa|Research Site, Parktown, South Africa|Research Site, Phoenix, South Africa|Research Site, Somerset West, South Africa|Research Site, Verulam, South Africa|Research Site, Worcester, South Africa|Research Site, Almeria, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, Sant Joan Despi, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Sevilla, Spain|Research Site, Borås, Sweden|Research Site, Eksjö, Sweden|Research Site, Finspång, Sweden|Research Site, Gothenburg, Sweden|Research Site, Gothenburg, Sweden|Research Site, Järfälla, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Ostersund, Sweden|Research Site, Rättvik, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Umeå, Sweden|Research Site, Vällingby, Sweden|Research Site, Changhua, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Muang, Thailand|Research Site, Nakhon Ratchasima, Thailand|Research Site, Pathumthani, Thailand|Research Site, Phisanulok, Thailand|Research Site, Rajthevi, Thailand|Research Site, Ratchaburi, Thailand|Research Site, Ratchathewi, Thailand|Research Site, Antalya, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, İzmir, Turkey|Research Site, Dnepropetrovsk, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vynnitsa, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, Addlestone, United Kingdom|Research Site, Aylesbury, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Canterbury, United Kingdom|Research Site, Corsham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Irvine, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Mortimer Reading, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Whitstable, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh City, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01730534/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01730534/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01730534"
73,"NCT01669811","Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)",,"Completed","Has Results","Refractory Reflux Esophagitis","Drug: Esomeprazole (D961H) twice daily|Drug: Esomeprazole (D961H) once daily","Percentage of Participants With Healing of RE Who Were Graded ""O"" at Week 8 Out of Participants Who Were Graded ""A"" to ""D"" at Baseline According to Los Angeles Classification|Percentage of Participants With Healing of RE Who Were Graded ""O"" at Week 4 Out of Participants Who Were Graded ""A"" to ""D"" at Baseline According to Los Angeles Classification|Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Heartburn at Week 4|Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Acid Regurgitation at Week 4|Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Abdominal Pain at Week 4|Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Difficulty of Swallowing at Week 4|Cumulative Percentage of Participants Who Had Sustained Resolution of GERD Symptom -Sleep Disturbance at Week 4","AstraZeneca","All","20 Years and older   (Adult, Older Adult)","Phase 3","1398","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D961UC00002","August 2012","May 2014","May 2014","August 21, 2012","August 14, 2015","August 27, 2015","Research Site, Abiko-shi, Japan|Research Site, Adachi-ku, Japan|Research Site, Annaka-shi, Japan|Research Site, Asahikawa-shi, Japan|Research Site, Asakura-shi, Japan|Research Site, Beppu-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fujiidera-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukushima-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Hitachi-shi, Japan|Research Site, Ibara-shi, Japan|Research Site, Ichiki-Kushikino-shi, Japan|Research Site, Ishikari-shi, Japan|Research Site, Iwata-shi, Japan|Research Site, Izumo-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kamakura-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Karatsu-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kirishima-shi, Japan|Research Site, Kita-ku, Japan|Research Site, Kobe-shi, Japan|Research Site, Kochi-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumagaya-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Machida-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Moriguchi-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Ogori-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-ku, Japan|Research Site, Otawara-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Saitama-shi, Japan|Research Site, Sakaide-shi, Japan|Research Site, Saku-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shibuya-ku, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Toshima-ku, Japan|Research Site, Toyama-shi, Japan|Research Site, Uji-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yanagawa-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yufu-shi, Japan",,"https://ClinicalTrials.gov/show/NCT01669811"
74,"NCT01652729","Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","DURATION-NEO-2","Completed","Has Results","Diabetes Type 2","Drug: Exenatide once weekly suspension|Drug: Sitagliptin|Drug: Placebo","Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28|Percentage of Subjects Achieving HbA1c <7% at Week 28|Change in Fasting Plasma Glucose Concentrations From Baseline to Week 28|Change in Body Weight (kg) From Baseline to Week 28|Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16 (Visit 8)","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","365","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCB120|MB001-004","February 2013","April 2014","April 2014","July 30, 2012","April 23, 2015","August 20, 2015","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Beverly Hills, California, United States|Research Site, Buena Park, California, United States|Research Site, Chino, California, United States|Research Site, Chula Vista, California, United States|Research Site, Encinitas, California, United States|Research Site, Greenbrae, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, North Hollywood, California, United States|Research Site, Walnut Creek, California, United States|Research Site, West Hills, California, United States|Research Site, Boca Raton, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Oxon Hill, Maryland, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, Hartsdale, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Clayton, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Franklin, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Yukon, Oklahoma, United States|Research Site, Eugene, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Greer, South Carolina, United States|Research Site, Simpsonville, South Carolina, United States|Reseach Site, Rapid City, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Carrolton, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Katy, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01652729"
75,"NCT01652716","Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes","DURATION-NEO-1","Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Exenatide once weekly suspension|Drug: Exenatide twice daily","Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28|Percentage of Subjects Achieving HbA1c <7% at Week 28|Change in Fasting Plasma Glucose Concentrations From Baseline to Week 28|Change in Body Weight (kg) From Baseline to Week 28|Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","377","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCB118|MB001-003","January 2013","August 2014","August 2014","July 30, 2012","September 16, 2015","July 3, 2018","Research Site, Muscle Shoals, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Escondido, California, United States|Research Site, Garden Grove, California, United States|Research Site, Lomita, California, United States|Research Site, Los Angeles, California, United States|Research Site, Santa Ana, California, United States|Research Site, Spring Valley, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, Coral Gables, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Oviedo, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Ponte Vedra, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Lexington, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Columbia, Maryland, United States|Research Site, Elkridge, Maryland, United States|Research Site, Hyattsville, Maryland, United States|Research Site, New Bedford, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Port Gibson, Mississippi, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Henderson, Nevada, United States|Research Site, Endwell, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Harleysville, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Manassas, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Olympia, Washington, United States|Research Site, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01652716"
76,"NCT01646320","Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Placebo matching with Dapagliflozin|Drug: Saxagliptin|Drug: Metformin immediate release (IR)","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24|Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24|Adjusted Mean Change From Baseline in 120-minute Postprandial Glucose (PPG) at Week 24|Adjusted Mean Change From Baseline in Body Weight at Week 24|Percentage of Subjects Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MB102-129|2011-006324-20","September 2012","August 2014","February 2015","July 20, 2012","April 11, 2016","June 22, 2016","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Clinical Research Advantage Inc/Desert Clinical Research Llc, Mesa, Arizona, United States|Clinical Research Advantage, Inc., Phoenix, Arizona, United States|Elite Clinical Studies, Llc, Phoenix, Arizona, United States|Arkansas Clinical Research, Little Rock, Arkansas, United States|Torrance Clinical Research Institute Inc., Lomita, California, United States|Randall G. Shue, Do, Inc., Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Cassidy Medical Group/Clinical Research Advantage, Vista, California, United States|Palm Springs Research Institute, Hialeah, Florida, United States|Fpa Clinical Research, Kissimmee, Florida, United States|International Research Associates, Llc, Miami, Florida, United States|Omega Research Consultants, Llc, Orlando, Florida, United States|Compass Research East, Llc, Oviedo, Florida, United States|Palm Harbor Medical Associates, Palm Harbor, Florida, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Clinical Research Advantage, Evansville, Indiana, United States|Associated Internal Medicine Specialists, Battle Creek, Michigan, United States|Jackson Clinic, Rolling Fork, Mississippi, United States|Premier Research, Trenton, New Jersey, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|Sterling Research Grp, Ltd., Cincinnati, Ohio, United States|Endocrine Associates, Houston, Texas, United States|Sam Clinical Research Center, San Antonio, Texas, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Local Institution, Broumov, Czech Republic|Local Institution, Pardubice, Czech Republic|Local Institution, Praha 10, Czech Republic|Local Institution, Praha 4, Czech Republic|Local Institution, Pribram V, Czech Republic|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Bialystok, Poland|Local Institution, Krakow, Poland|Local Institution, Ruda Slaska, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Zory, Poland|Clinical Research Puerto Rico, San Juan, Puerto Rico|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Constanta, Romania|Local Institution, Craiova, Romania|Local Institution, Galati, Romania|Local Institution, Ploiesti, Romania|Local Institution, Kursk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Yaroslaval, Russian Federation|Local Institution, Portsmouth, Hants, United Kingdom|Local Institution, Newport, Isle of Wight, United Kingdom|Local Institution, Liverpool, Merseyside, United Kingdom|Local Institution, Chippenham, Wiltshire, United Kingdom|Local Institution, Bedfordshire, United Kingdom|Local Institution, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01646320"
77,"NCT01619059","Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Dapagliflozin|Drug: Metformin IR|Drug: Placebo matching with Saxagliptin","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24|Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24|Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24|Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CV181-168|2011-006323-37","June 2012","June 2014","January 2015","June 14, 2012","March 17, 2016","April 22, 2016","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Terence T. Hart, Md, Muscle Shoals, Alabama, United States|Mesa Family Medical Center, Mesa, Arizona, United States|Clinical Research Advantage Inc/Desert Clinical Research Llc, Mesa, Arizona, United States|Clinical Research Advantage, Inc, Phoenix, Arizona, United States|Clinical Research Advantage, Inc./ Stonecreek Medical Associates, Pc, Phoenix, Arizona, United States|Beach Physicians Clinical Research Corp., Huntington Beach, California, United States|Torrance Clinical Research, Lomita, California, United States|Randall G. Shue, Do, Inc., Los Angeles, California, United States|National Research Institute, Los Angeles, California, United States|Cassidy Medical Group/Clinical Research Advantage, Vista, California, United States|Infosphere Clinical Research, Inc., West Hills, California, United States|New West Physicians, Pc, Golden, Colorado, United States|Southeast Clinical Research, Llc, Chiefland, Florida, United States|Clinical Therapeutics Corporation, Coral Gables, Florida, United States|Medical Research Unlimited, Llc, Hialeah, Florida, United States|University Of Florida Endocrinology & Diabetes, Jacksonville, Florida, United States|Care Partners Clinical Research, Llc, Jacksonville, Florida, United States|Clinical Research Of Miami, Inc., Miami, Florida, United States|Clinical Research Advantage, Inc., Evansville, Indiana, United States|Clinical Research Advantage, Evansville, Indiana, United States|Mercy Health Research, Saint Louis, Missouri, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|Joslin Diabetes Center Affiliate Of Snhmc, Nashua, New Hampshire, United States|N. Shore Diabetes & Endoc Assoc, New Hyde Park, New York, United States|Digiovanna Institute For Medical Education & Research, North Massapequa, New York, United States|Barat Research Group, Inc., Charlotte, North Carolina, United States|Sterling Research Grp, Ltd., Cincinnati, Ohio, United States|Physicians Research, Inc., Zanesville, Ohio, United States|Tlm Medical Services, Columbia, South Carolina, United States|Family Medicine Of Sayebrook, Myrtle Beach, South Carolina, United States|Holston Medical Group, Bristol, Tennessee, United States|Vanderbilt Diabetes Center, Nashville, Tennessee, United States|Padre Coast Clinical Research, Corpus Christi, Texas, United States|Local Institution, Moncton, New Brunswick, Canada|Local Institution, St-john, Newfoundland and Labrador, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Brampton, Ontario, Canada|Local Institution, Sarnia, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Karlovy Vary, Czech Republic|Local Institution, Praha 5, Czech Republic|Local Institution, Balatonfured, Hungary|Local Institution, Budaors, Hungary|Local Institution, Budapest, Hungary|Local Institution, Zalaegerszeg, Hungary|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michioacan, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Del. Benito Juarez, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Bialystok, Poland|Local Institution, Katowice, Poland|Local Institution, Katowice, Poland|Local Institution, Krakow, Poland|Local Institution, Pszczyna, Poland|Local Institution, Pulawy, Poland|Local Institution, Szczecin, Poland|Local Institution, Warszawa, Poland|Local Institution, Wegrow, Poland|Local Institution, Wroclaw, Poland|Research & Cardiovascular Corp, Ponce, Puerto Rico|Local Institution, Brasov, Romania|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Constanta, Romania|Local Institution, Craiova, Romania|Local Institution, Galati, Romania|Local Institution, Ploiesti, Romania|Local Institution, Kursk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Yaroslaval, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01619059"
78,"NCT01606007","Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Metformin XR|Drug: Dapagliflozin|Drug: Placebo matching with Dapagliflozin|Drug: Placebo matching with Saxagliptin","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24|Adjusted Mean Change From Baseline in 2-hour Post Prandial Glucose (PPG) From a Liquid Meal Tolerance Test (MTT) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Body Weight at Week 24","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","1282","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CV181-169|2012-000679-18","July 2012","January 2014","January 2014","May 25, 2012","October 20, 2015","May 15, 2017","Central Alabama Research, Birmingham, Alabama, United States|Central Alabama Research, Homewood, Alabama, United States|Terence T. Hart, Md, Muscle Shoals, Alabama, United States|International Institute Of Clinical Research, Ozark, Alabama, United States|Clinical Research Advantage, Mesa, Arizona, United States|Elite Clinical Studies, Llc, Phoenix, Arizona, United States|Genova Clinical Research, Tucson, Arizona, United States|Medical Investigations, Inc., Little Rock, Arkansas, United States|Aureus Research, Inc., Little Rock, Arkansas, United States|Southland Clinical Research Center, Inc., Fountain Valley, California, United States|Torrance Clinical Research, Lomita, California, United States|National Research Inst, Los Angeles, California, United States|Providence Clinical Research, North Hollywood, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Mehrdad Kevin Ariani Md, Inc., Northridge, California, United States|Lucita M. Cruz,Md.,Inc., Norwalk, California, United States|Center For Clinical Trials, Llc., Paramount, California, United States|Center For Clinical Trials Of Sacramento, Inc., Sacramento, California, United States|Trinitas Research, Inc, San Jose, California, United States|Orange County Research Center, Tustin, California, United States|Clinical Research Advantage, Colorado Springs, Colorado, United States|Infocus Clinical Research, Denver, Colorado, United States|Lynn Institute Of Denver, Denver, Colorado, United States|Southeast Clinical Research, Llc, Chiefland, Florida, United States|Clinical Therapeutics Corporation, Coral Gables, Florida, United States|Southeast Clinical Research, Llc, Jacksonville, Florida, United States|Fpa Clinical Research, Kissimmee, Florida, United States|Newphase Clinical Trials, Inc., Miami Beach, Florida, United States|Clinical Research Of Miami, Inc., Miami, Florida, United States|Advanced Pharma Cr, Llc, Miami, Florida, United States|Omega Research Consultants, Llc, Orlando, Florida, United States|Palm Harbor Medical Associates, Palm Harbor, Florida, United States|Andres Patron, Do Pa, Pembroke Pines, Florida, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Deerbrook Medical Associates, Vernon Hills, Illinois, United States|Clinical Research Advantage, Council Bluffs, Iowa, United States|Horizon Research Group Of Opelousas, Llc, Eunice, Louisiana, United States|Associated Internal Medicine Specialists, Battle Creek, Michigan, United States|Harris And Associates, P.C., Detroit, Michigan, United States|Patterson Medical Clinic, Florissant, Missouri, United States|Bellevue Family Practice, Bellevue, Nebraska, United States|Clinical Research Advantage, Elkhorn, Nebraska, United States|Clinical Research Advantage, Fremont, Nebraska, United States|Clinical Research Advantage, Omaha, Nebraska, United States|South Jersey Medical Associates, P.A., Blackwood, New Jersey, United States|Central Jersey Health And Medical Research, Elizabeth, New Jersey, United States|Southgate Medical Group, West Seneca, New York, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|Triad Clinical Trials, Llc, Greensboro, North Carolina, United States|Diabetes & Endocrinology Consultants, Morehead City, North Carolina, United States|Pmg Research Of Winston-Salem, Llc, Winston-salem, North Carolina, United States|Daystar Clinical Resarch, Inc., Akron, Ohio, United States|Sterling Research Grp, Ltd., Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Primed Clinical Research, Dayton, Ohio, United States|Physicians Research, Inc., Zanesville, Ohio, United States|Lynn Institute Of Norman, Norman, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Oregon Clinical Research, Portland, Oregon, United States|Heritage Valley Medical Group, Beaver, Pennsylvania, United States|Wellmon Family Practice, Shippensburg, Pennsylvania, United States|Tlm Medical Services, Columbia, South Carolina, United States|Palmetto Clinical Trial Services Llc, Fountain Inn, South Carolina, United States|Holston Medical Group, Bristol, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Pmg Research Of Knoxville, Knoxville, Tennessee, United States|Arlington Family Research Center, Inc., Arlington, Texas, United States|Padre Coast Clinical Research, Corpus Christi, Texas, United States|Dallas Diabetes & Endocrine Center, Dallas, Texas, United States|Excel Clinical Research, Llc, Houston, Texas, United States|North Hills Medical Research, Inc., North Richland Hills, Texas, United States|Med-Olam Clinical Research, Pasadena, Texas, United States|Sam Clinical Research Center, San Antoinio, Texas, United States|Covenant Clinical Research, Pa, San Antonio, Texas, United States|Hillcrest Family Health Center, Waco, Texas, United States|Val R. Hansen, M.D., Bountiful, Utah, United States|Highland Clinical Research, Salt Lake City, Utah, United States|Southwestern Vermont Med Cntr, Bennington, Vermont, United States|Hampton Roads Center For Clinical Research, Inc., Suffolk, Virginia, United States|Local Institution, Coquitlam, British Columbia, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Brampton, Ontario, Canada|Local Institution, Smiths Falls, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Granby, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Quebec, Canada|Local Institution, Bucheon, Gyeonggi-do, Korea, Republic of|Local Institution, Sungnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Incheon, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuautla, Morelos, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, Durango, Mexico|Local Institution, Gdansk, Poland|Local Institution, Katowice, Poland|Local Institution, Katowice, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Opole, Poland|Local Institution, Poznan, Poland|Local Institution, Pulawy, Poland|Local Institution, Warszawa, Poland|Local Institution, Cidra, Puerto Rico|Local Institution, Manati, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Villa Fontana, Puerto Rico|Local Institution, Ploiesti, Prahova, Romania|Local Institution, Ploiesti, Prahova, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Cluj Napoca Cluj, Romania|Local Institution, Craiova, Romania|Local Institution, Galati, Romania|Local Institution, Soweto, Gauteng, South Africa|Local Institution, Gauteng, Johannesburg, South Africa|Local Institution, Durban, Kwa-Zulu Natal, South Africa|Local Institution, Cape Town, Western Cape, South Africa|Local Institution, Goodwood, Western Cape, South Africa|Local Institution, Paarl, Western Cape, South Africa|Local Institution, Rondebosch, Western Cape, South Africa|Local Institution, Somerset West, Western Cape, South Africa|Local Institution, Johannesburg, South Africa|Local Institution, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT01606007"
79,"NCT01572792","Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Drug: Aclidinium bromide|Drug: Formoterol Fumarate|Drug: Placebo","Percentage of Patients to Experience Any Treatment-emergent Adverse Event|Percentage of Patients to Experience Potentially Clinically Significant Post-baseline Clinical Laboratory Values for Hematology, Chemistry or Urinalysis|Percentage of Patients to Experience a Potentially Significant Post-baseline 12-lead ECG Value|Percentage of Patients to Experience Potentially Clinically Significant Post-baseline Vital Signs (Pulse Rate, Systolic or Diastolic Blood Pressure or Weight)","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","921","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAC-MD-36","April 2012","June 2013","June 2013","April 6, 2012","April 21, 2017","April 21, 2017","Forest Investigative Site 1827, Anniston, Alabama, United States|Forest Investigative Site 1920, Athens, Alabama, United States|Forest Investigative Site 1162, Birmingham, Alabama, United States|Forest Investigative Site 1493, Birmingham, Alabama, United States|Forest Investigative Site 1937, Birmingham, Alabama, United States|Forest Investigative Site 1824, Gulf Shores, Alabama, United States|Forest Investigative Site 2088, Jasper, Alabama, United States|Forest Investigative Site 1918, Scottsboro, Alabama, United States|Forest Investigative Site 0909, Glendale, Arizona, United States|Forest Investigative Site 1379, Phoenix, Arizona, United States|Forest Investigative Site 1822, Anaheim, California, United States|Forest Investigative Site 1483, Buena Park, California, United States|Forest Investigative Site 1156, Fresno, California, United States|Forest Investigative Site 1871, Lincoln, California, United States|Forest Investigative Site 1873, Los Angeles, California, United States|Forest Investigative Site 2064, Riverside, California, United States|Forest Investigative Site 1427, Sacramento, California, United States|Forest Investigative Site 1866, Sacramento, California, United States|Forest Investigative Site 1125, San Diego, California, United States|Forest Investigative Site 2009, San Diego, California, United States|Forest Investigative Site 1374, Torrance, California, United States|Forest Investigative Site 1813, Tustin, California, United States|Forest Investigative Site 1883, Vista, California, United States|Forest Investigative Site 1380, Golden, Colorado, United States|Forest Investigative Site 1137, Pueblo, Colorado, United States|Forest Investigative Site 1327, Wheat Ridge, Colorado, United States|Forest Investigative Site 1976, Waterbury, Connecticut, United States|Forest Investigative Site 1821, Bay Pines, Florida, United States|Forest Investigative Site 1154, Brandon, Florida, United States|Forest Investigative Site 1944, Brandon, Florida, United States|Forest Investigative Site 1364, Clearwater, Florida, United States|Forest Investigative Site 1152, Clearwater, Florida, United States|Forest Investigative Site 1875, Clearwater, Florida, United States|Forest Investigative Site 1811, Covington, Florida, United States|Forest Investigative Site 0670, DeLand, Florida, United States|Forest Investigative Site 1516, Edgewater, Florida, United States|Forest Investigative Site 0990, Fort Lauderdale, Florida, United States|Forest Investigative Site 1513, Hialeah, Florida, United States|Forest Investigative Site 1854, Hialeah, Florida, United States|Forest Investigative Site 1882, Hollywood, Florida, United States|Forest Investigative Site 1543, Jacksonville, Florida, United States|Forest Investigative Site 1416, Kissimmee, Florida, United States|Forest Investigative Site 1167, Melbourne, Florida, United States|Forest Investigative Site 1432, Miami, Florida, United States|Forest Investigative Site 1808, N. Miami, Florida, United States|Forest Investigative Site 1819, Naples, Florida, United States|Forest Investigative Site 1950, Oldsmar, Florida, United States|Forest Investigative Site 1145, Ormond Beach, Florida, United States|Forest Investigative Site 1094, Panama City, Florida, United States|Forest Investigative Site 1803, Pembroke Pines, Florida, United States|Forest Investigative Site 0974, Pensacola, Florida, United States|Forest Investigative Site 1817, Sarasota, Florida, United States|Forest Investigative Site 1874, St. Petersburg, Florida, United States|Forest Investigative Site 2082, Tamarac, Florida, United States|Forest Investigative Site 2053, Tampa, Florida, United States|Forest Investigative Site 2047, Tampa, Florida, United States|Forest Investigative Site 1185, Winter Park, Florida, United States|Forest Investigative Site 1860, Winter Park, Florida, United States|Forest Investigative Site 1900, Atlanta, Georgia, United States|Forest Investigative Site 0987, Austell, Georgia, United States|Forest Investigative Site 1828, Canton, Georgia, United States|Forest Investigative Site 1830, Marietta, Georgia, United States|Forest Investigative Site 2089, Woodstock, Georgia, United States|Forest Investigative Site 0679, Coeur d Alene, Idaho, United States|Forest Investigative Site 1858, Eagle, Idaho, United States|Forest Investigative Site 1095, Normal, Illinois, United States|Forest Investigative Site 1912, Normal, Illinois, United States|Forest Investigative Site 2051, River Forest, Illinois, United States|Forest Investigative Site 2033, Bowling Green, Kentucky, United States|Forest Investigative Site 2085, Fort Mitchell, Kentucky, United States|Forest Investigative Site 0539, Lexington, Kentucky, United States|Forest Investigative Site 1478, Louisville, Kentucky, United States|Forest Investigative Site 1519, Owensboro, Kentucky, United States|Forest Investigative Site 1430, New Orleans, Louisiana, United States|Forest Investigative Site 1812, Opelousas, Louisiana, United States|Forest Investigative Site 1814, Bangor, Maine, United States|Forest Investigative Site 1924, Baltimore, Maryland, United States|Forest Investigative Site 1872, Wheaton, Maryland, United States|Forest Investigative Site 1570, Fall River, Massachusetts, United States|Forest Investigative Site 1852, Fall River, Massachusetts, United States|Forest Investigative Site 1431, No. Dartmouth, Massachusetts, United States|Forest Investigative Site 1892, Ann Arbor, Michigan, United States|Forest Investigative Site 1342, Stevensville, Michigan, United States|Forest Investigative Site 1487, Troy, Michigan, United States|Forest Investigative Site 1128, Edina, Minnesota, United States|Forest Investigative Site 1527, Fridley, Minnesota, United States|Forest Investigative Site 2041, Minneapolis, Minnesota, United States|Forest Investigative Site 1124, Minneapolis, Minnesota, United States|Forest Investigative Site 1619, Plymouth, Minnesota, United States|Forest Investigative Site 1118, Rochester, Minnesota, United States|Forest Investigative Site 1884, Olive Branch, Mississippi, United States|Forest Investigative Site 1602, Kansas City, Missouri, United States|Forest Investigative Site 1587, N. Chesterfield, Missouri, United States|Forest Investigative Site 1856, Springfield, Missouri, United States|Forest Investigative Site 1867, Springfield, Missouri, United States|Forest Investigative Site 2079, St. Charles, Missouri, United States|Forest Investigative Site 1399, St. Louis, Missouri, United States|Forest Investigative Site 1599, St. Louis, Missouri, United States|Forest Investigative Site 1831, Bozeman, Montana, United States|Forest Investigative Site 1400, Missoula, Montana, United States|Forest Investigative Site 1609, Bellevue, Nebraska, United States|Forest Investigative Site 1948, Fremont, Nebraska, United States|Forest Investigative Site 1815, Lincoln, Nebraska, United States|Forest Investigative Site 1363, Omaha, Nebraska, United States|Forest Investigative Site 1907, Omaha, Nebraska, United States|Forest Investigative Site 1911, Omaha, Nebraska, United States|Forest Investigative Site 1908, Omaha, Nebraska, United States|Forest Investigative Site 1804, Omaha, Nebraska, United States|Forest Investigative Site 1807, Henderson, Nevada, United States|Forest Investigative Site 1834, Las Vegas, Nevada, United States|Forest Investigative Site 1562, Las Vegas, Nevada, United States|Forest Investigative Site 1559, Cherry Hill, New Jersey, United States|Forest Investigative Site 1923, Hackensack, New Jersey, United States|Forest Investigative Site 1949, Albuquerque, New Mexico, United States|Forest Investigative Site 1151, Great Neck, New York, United States|Forest Investigative Site 1489, Larchmont, New York, United States|Forest Investigative Site 550, New York, New York, United States|Forest Investigative Site 1425, New York, New York, United States|Forest Investigative Site 2098, Rochester, New York, United States|Forest Investigative Site 1392, Charlotte, North Carolina, United States|Forest Investigative Site 2035, Elizabeth City, North Carolina, United States|Forest Investigative Site 1366, High Point, North Carolina, United States|Forest Investigative Site 1153, Raleigh, North Carolina, United States|Forest Investigative Site 1823, Salisbury, North Carolina, United States|Forest Investigative Site 1891, Cadiz, Ohio, United States|Forest Investigative Site 1134, Canton, Ohio, United States|Forest Investigative Site 1885, Cincinnati, Ohio, United States|Forest Investigative Site 1806, Cincinnati, Ohio, United States|Forest Investigative Site 2028, Cincinnati, Ohio, United States|Forest Investigative Site 1903, Cincinnati, Ohio, United States|Forest Investigative Site 1361, Columbus, Ohio, United States|Forest Investigative Site 1433, Columbus, Ohio, United States|Forest Investigative Site 2090, Sylvania, Ohio, United States|Forest Investigative Site 1530, Toledo, Ohio, United States|Forest Investigative Site 1393, Zanesville, Ohio, United States|Forest Investigative Site 1915, Oklahoma City, Oklahoma, United States|Forest Investigative Site 1889, Bend, Oregon, United States|Forest Investigative Site 2043, Medford, Oregon, United States|Forest Investigative Site 1833, Altoona, Pennsylvania, United States|Forest Investigative Site 1820, Downington, Pennsylvania, United States|Forest Investigative Site 1423, Erie, Pennsylvania, United States|Forest Investigative Site 1899, Langhorne, Pennsylvania, United States|Forest Investigative Site 1443, Philadelphia, Pennsylvania, United States|Forest Investigative Site 1863, Phoenixville, Pennsylvania, United States|Forest Investigative Site 1146, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 1449, Tipton, Pennsylvania, United States|Forest Investigative Site 1862, Uniontown, Pennsylvania, United States|Forest Investigative Site 1832, Cumberland, Rhode Island, United States|Forest Investigative Site 1089, East Providence, Rhode Island, United States|Forest Investigative Site 2072, Charleston, South Carolina, United States|Forest Investigative Site 1905, Charleston, South Carolina, United States|Forest Investigative Site 1802, Charleston, South Carolina, United States|Forest Investigative Site 1914, Fort Mill, South Carolina, United States|Forest Investigative Site 1913, Gaffney, South Carolina, United States|Forest Investigative Site 1121, Spartanburg, South Carolina, United States|Forest Investigative Site 1957, Brentwood, Tennessee, United States|Forest Investigative Site 1526, Fayetteville, Tennessee, United States|Forest Investigative Site 1440, Arlington, Texas, United States|Forest Investigative Site 1879, Boerne, Texas, United States|Forest Investigative Site 1861, Carrollton, Texas, United States|Forest Investigative Site 1816, Corsicana, Texas, United States|Forest Investigative Site 1890, Dallas, Texas, United States|Forest Investigative Site 1332, El Paso, Texas, United States|Forest Investigative Site 2012, Fort Worth, Texas, United States|Forest Investigative Site 1951, Houston, Texas, United States|Forest Investigative Site 1091, McKinney, Texas, United States|Forest Investigative Site 1826, Plano, Texas, United States|Forest Investigative Site 1895, San Antonio, Texas, United States|Forest Investigative Site 1936, Salt Lake City, Utah, United States|Forest Investigative Site 1330, South Burlington, Vermont, United States|Forest Investigative Site 1945, Newport News, Virginia, United States|Forest Investigative Site 1404, Norfolk, Virginia, United States|Forest Investigative Site 1120, Bellingham, Washington, United States|Forest Investigative Site 1977, Spokane, Washington, United States|Forest Investigative Site 1878, Spokane, Washington, United States|Forest Investigative Site 1573, Spokane, Washington, United States|Forest Investigative Site 0988, Tacoma, Washington, United States|Forest Investigative Site 1870, Tacoma, Washington, United States|Forest Investigative Site 1555, Morgantown, West Virginia, United States|Forest Investigative Site 1991, New Lambton, New South Wales, Australia|Forest Investigative Site 1987, Redcliffe, Queensland, Australia|Forest Investigative Site 1973, Woolloongabba, Queensland, Australia|Forest Investigative Site 2253, Adelaide, South Australia, Australia|Forest Investigative Site 1981, Bedford Park, South Australia, Australia|Forest Investigative Site 1990, Daw Park, South Australia, Australia|Forest Investigative Site 2251, Toorak Gardens, South Australia, Australia|Forest Investigative Site 2250, Clayton, Victoria, Australia|Forest Investigative Site 1972, Fitzroy, Victoria, Australia|Forest Investigative Site 1986, Geelong, Victoria, Australia|Forest Investigative Site 1985, Parkville, Victoria, Australia|Forest Investigative Site 1904, Langley, British Columbia, Canada|Forest Investigative Site 905, Vancouver, British Columbia, Canada|Forest Investigative Site 0976, Winnipeg, Manitoba, Canada|Forest Investigative Site 1877, Sarina, Ontario, Canada|Forest Investigative Site 1896, Sarnia, Ontario, Canada|Forest Investigative Site 1171, Toronto, Ontario, Canada|Forest Investigative Site 2203, Toronto, Ontario, Canada|Forest Investigative Site 1952, Montreal, Quebec, Canada|Forest Investigative Site 0943, Saskatoon, Saskatchewan, Canada|Forest Investigative Site 1859, Quebec, Canada|Forest Investigative Site 1027, Auckland, New Zealand|Forest Investigative Site 1970, Christchurch, New Zealand|Forest Investigative Site 1967, Dunedin, New Zealand|Forest Investigative Site 1964, Dunedin, New Zealand|Forest Investigative Site 1968, Hamilton, New Zealand|Forest Investigative Site 1965, Tauranga, New Zealand|Forest Investigative Site 1980, Tauranga, New Zealand|Forest Investigative Site 1025, Wellington, New Zealand",,"https://ClinicalTrials.gov/show/NCT01572792"
80,"NCT01544179","A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone","IMPRESS","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Gefitinib|Drug: Placebo|Drug: Pemetrexed|Drug: Cisplatin","Progression-Free Survival (Site Read, Investigator Assessment)|Median Progression-Free Survival (Site Read, Investigator Assessment)|Overall Survival (OS)|Median Overall Survival (OS) at Time of PFS Analysis|Objective Response Rate (ORR) (Site Read Data)|Disease Control Rate (DCR)|Improvement in Trial Outcome Index|Time to Worsening in Trial Outcome Index|Improvement in FACT-L Total Score|Time to Worsening in FACT-L Total Score|Improvement in Lung Cancer Subscale|Time to Worsening in Lung Cancer Subscale","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","265","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D791LC00001","March 15, 2012","May 5, 2014","November 20, 2019","March 5, 2012","February 15, 2016","September 25, 2020","Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, Chengdu, China|Research Site, Dalian, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Kunming, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shijiazhuang, China|Research Site, Suzhou, China|Research Site, Taiyuan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Ürümqi, China|Research Site, Clermont Ferrand, France|Research Site, Lille, France|Research Site, Lyon, France|Research Site, Paris, France|Research Site, Villejuif, France|Research Site, Hamburg, Germany|Research Site, Löwenstein, Germany|Research Site, Würzburg, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Genova, Italy|Research Site, Parma, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Fukuoka-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Osakasayama, Japan|Research Site, Sakai-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, St.Petersburg, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Sevilla, Spain|Research Site, Zaragoza, Spain|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01544179"
81,"NCT01514240","Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan",,"Completed","Has Results","Crohn's Disease","Drug: D9421-C capsule 3 mg|Drug: Mesalazine tablets","Remission After 8-week of Treatment|Remission After 2-week of Treatment|Remission After 4-week of Treatment|Change in Observed CDAI Scores From Baseline to Weeks 2|Change in Observed CDAI Scores From Baseline to Weeks 4|Change in Observed CDAI Scores From Baseline to Weeks 8|Cumulative Remission Rate at Week 2|Cumulative Remission Rate at Week 4|Cumulative Remission Rate at Week 8|Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 70 Points) at Weeks 2|Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 70 Points) at Weeks 4|Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 70 Points) at Weeks 8|Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 100 Points) at Weeks 2|Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 100 Points) at Weeks 4|Clinical Improvement Rates (Decrease in CDAI Score From Baseline of at Least 100 Points) at Weeks 8|Change in Total IBDQ Scores From Baseline to Weeks 2|Change in Total IBDQ Scores From Baseline to Weeks 4|Change in Total IBDQ Scores From Baseline to Weeks 8|Change in Total IBDQ Scores From Baseline to Weeks 10|Change in IBDQ Scores From Baseline to Weeks 2 - Bowel Function|Change in IBDQ Scores From Baseline to Weeks 4 - Bowel Function|Change in IBDQ Scores From Baseline to Weeks 8 - Bowel Function|Change in IBDQ Scores From Baseline to Weeks 10 - Bowel Function|Change in IBDQ Scores From Baseline to Weeks 2 - Systemic Symptom|Change in IBDQ Scores From Baseline to Weeks 4 - Systemic Symptom|Change in IBDQ Scores From Baseline to Weeks 8 - Systemic Symptom|Change in IBDQ Scores From Baseline to Weeks 10 - Systemic Symptom|Change in IBDQ Scores From Baseline to Weeks 2 - Emotional Function|Change in IBDQ Scores From Baseline to Weeks 4 - Emotional Function|Change in IBDQ Scores From Baseline to Weeks 8 - Emotional Function|Change in IBDQ Scores From Baseline to Weeks 10 - Emotional Function|Change in IBDQ Scores From Baseline to Weeks 2 - Social Function|Change in IBDQ Scores From Baseline to Weeks 4 - Social Function|Change in IBDQ Scores From Baseline to Weeks 8 - Social Function|Change in IBDQ Scores From Baseline to Weeks 10 - Social Function","AstraZeneca","All","15 Years to 130 Years   (Child, Adult, Older Adult)","Phase 3","123","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D9423C00001","February 2012","September 2014","September 2014","January 23, 2012","October 31, 2016","October 31, 2016","Research Site, Chikushino-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Koshigaya-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Nagakute-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Omura-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka, Japan|Research Site, Sakura, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjyuku-ku, Japan|Research Site, Suginami-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Toyoake-shi, Japan|Research Site, Toyota-shi, Japan",,"https://ClinicalTrials.gov/show/NCT01514240"
82,"NCT01509677","Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease",,"Completed","Has Results","COPD|Chronic Obstructive Pulmonary Disease","Drug: Roflumilast|Drug: Placebo","Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue.|Change in Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue|CD68+ Count in Biopsied Material (Submucosa)|CD68+ Cell Count in Biopsied Material (Submucosa): Poisson Regression (Ratio)|Change From V2 to V6 in CD68+ Cell Count (Cells/mm^2) in Biopsied Material (Submucosa) (ITT)|CD4+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model|CD45+ Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model|Neutrophils Cell Counts in Biopsied Material (Submucosa):Poisson Regression Model|CD8+ Cell Count in Biopsied Material (Bronchial Epithelium): Poisson Regression Model|CD68+ Cell Count in Biopsied Material (Bronchial Epithelium):Poisson Regression Model|Change From V1 to V5 in Absolute Cell Count in Induced Sputum (10^6 Neutrophils/mL): Between-Treatment Difference|Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Macrophages/mL): Between-Treatment Difference|Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Eosinophils/mL): Between-Treatment Difference|Change From V1 to V5 in Absolute Cell Count inInduced Sputum (10^6 Lymphocytes/mL): Between-Treatment Difference|Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Neutrophils/mL)|Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Macrophages/mL)|Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Eosinophils/mL)|Change From V1 to V5 in Differential Cell Count in Induced Sputum(10^6 Lymphocytes)/mL)|Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (Alfa- 2-Macroglobulin (µg/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (MCP-1 (pg/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (TIMP-1 (ng/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Induced Sputum: Primary Parameters of Interest (FAS) (VEGF (pg/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (Alfa-2-Macroglobulin (µg/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (IL-8 (pg/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MMP Type 9 (ng/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (MCP-1(pg/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (TIMP-1(ng/mL))|Change From Baseline of Concentration of Inflammatory Biomarkers in Blood Serum: Primary Parameters of Interest (FAS) (VEGF(pg/mL))|Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FEV1 (L))|Change From Baseline in Lung Function Variables: Between-Treatment Differences (FAS) (FVC (L))|Wicoxon Signed-rank Test for Change From V2 to V6 in Post-bronchodilator FEV1/FVC","AstraZeneca","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 3","158","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RO-2455-402-RD|2011-000582-13|U1111-1155-8767|D7120C00003","February 1, 2012","February 1, 2016","February 1, 2016","January 13, 2012","November 29, 2019","November 29, 2019","Kobenhavn NV, Denmark|København NV, Denmark|Freiburg, Germany|Grosshansdorf, Germany|Hannover, Germany|Heidelberg, Germany|Immenhausen, Germany|Kiel, Germany|Mainz, Germany|Bialystok, Poland|Krakow, Poland|Lodz, Poland|Lodz, Poland|Lund, Sweden|Cottingham, United Kingdom|Dafen, United Kingdom|Leicester, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Norwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01509677"
83,"NCT01471171","Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Aclidinium Bromide|Drug: Placebo","Change From Baseline in Endurance Time (Seconds)|Change From Baseline in Trough Inspiratory Capacity (IC) (Litres)|Change From Baseline in Intensity of Dyspnoea","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M/34273/40","November 2011","June 2012","June 2012","November 15, 2011","July 30, 2013","January 4, 2017","Almirall Investigational Site #10, Berlin, Germany|Almirall Investigational Site #6, Berlin, Germany|Almirall Investigational Site #2, Berlin, Germany|Almirall Investigational Site #4, Frankfurt, Germany|Almirall Investigational Site #5, Grosshansdorf, Germany|Almirall Investigational Site #8, Hamburg, Germany|Almirall Investigational Site #9, Hamburg, Germany|Almirall Investigational Site #3, Hannover, Germany|Almirall Investigational Site #7, Lübeck, Germany|Almirall Investigational Site #1, Wiesbaden, Germany|Almirall Investigational Site #1, Alicante, Spain|Almirall Investigational Site #4, Barcelona, Spain|Almirall Investigational Site #2, Madrid, Spain|Almirall Investigational Site #2, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01471171"
84,"NCT01462942","Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Aclidinium Bromide/Formoterol Fumarate|Drug: Aclidinium Bromide|Drug: Placebo|Drug: Formoterol Fumarate","Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)|Change in Transition Dyspnoea Index (TDI) Focal Score|Change From Baseline in St. George´s Respiratory Questionnaire (SGRQ) Total Score","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","2443","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M/40464/30","October 2011","January 2013","January 2013","November 1, 2011","February 15, 2017","February 15, 2017","Almirall Investigational Site #2, Graz, Austria|Almirall Investigational Site #3, Salzburg, Austria|Almirall Investigational Site #3, Edegem, Belgium|Almirall Investigational Site #2, Genk, Belgium|Almirall Investigational Site #6, Ruse, Bulgaria|Almirall Investigational Site #10, Sevlievo, Bulgaria|Almirall Investigational Site #8, Sofia, Bulgaria|Almirall Investigational Site #2, Sofia, Bulgaria|Almirall Investigational Site #11, Sofia, Bulgaria|Almirall Investigational Site #2, Zagreb, Croatia|Almirall Investigational Site #4, Zagreb, Croatia|Almirall Investigational Site #8, Brno, Czech Republic|Almirall Investigational Site #3, Jindrichuv Hradec, Czech Republic|Almirall Investigational Site #10, Karlovy Vary, Czech Republic|Almirall Investigational Site #9, Liberec, Czech Republic|Almirall Investigational Site #16, Ostrava Hrabuvka, Czech Republic|Almirall Investigational Site #2, Praha 3, Czech Republic|Almirall Investigational Site #6, Praha 5 - Radotin, Czech Republic|Almirall Investigational Site #12, Praha 5, Czech Republic|Almirall Investigational Site #15, Praha 6, Czech Republic|Almirall Investigational Site #14, Praha 8, Czech Republic|Almirall Investigational Site #11, Strakonice, Czech Republic|Almirall Investigational Site #1, Tabor, Czech Republic|Almirall Investigational Site #4, Hillerød, Denmark|Almirall Investigational Site #1, København NV, Denmark|Almirall Investigational Site #5, Odense, Denmark|Almirall Investigational Site #2, Silkeborg, Denmark|Almirall Investigational Site #7, Espoo, Finland|Almirall Investigational Site #8, Jyväskylä, Finland|Almirall Investigational Site #1, Tampere, Finland|Almirall Investigational Site #6, Tampere, Finland|Almirall Investigational Site #3, Turku, Finland|Almirall Investigational Site #6, Lille cedex, France|Almirall Investigational Site #10, Marseille cedex 6, France|Almirall Investigational Site #11, Montpellier cedex 5, France|Almirall Investigational Site #1, Pessac, France|Almirall Investigational Site #3, Rennes, France|Almirall Investigational Site #8, Toulouse, France|Almirall Investigational Site #12, Vieux Conde, France|Almirall Investigational Site #2, Berlin, Germany|Almirall Investigational Site #12, Berlin, Germany|Almirall Investigational Site #19, Berlin, Germany|Almirall Investigational Site #11, Berlin, Germany|Almirall Investigational Site #24, Berlin, Germany|Almirall Investigational Site #16, Bochum, Germany|Almirall Investigational Site #23, Bonn, Germany|Almirall Investigational Site #15, Dresden, Germany|Almirall Investigational Site #10, Dresden, Germany|Almirall Investigational Site #5, Frankfurt, Germany|Almirall Investigational Site #13, Frankfurt, Germany|Almirall Investigational Site #33, Haltern in Westfalen, Germany|Almirall Investigational Site #7, Hamburg, Germany|Almirall Investigational Site #21, Hamburg, Germany|Almirall Investigational Site #36, Hessen, Germany|Almirall Investigational Site #32, Land Niedersachsen, Germany|Almirall Investigational Site #1, Luebeck, Germany|Almirall Investigational Site #6, Mainz, Germany|Almirall Investigational Site #20, Marburg, Germany|Almirall Investigational Site #34, Muenchen, Germany|Almirall Investigational Site #18, Nuernberg, Germany|Almirall Investigational Site #22, Reinfeld, Germany|Almirall Investigational Site #35, Sachsen, Germany|Almirall Investigational Site #27, Sachsen, Germany|Almirall Investigational Site #28, Sachsen, Germany|Almirall Investigational Site #25, Sachsen, Germany|Almirall Investigational Site #8, Schwerin, Germany|Almirall Investigational Site #4, Witten, Germany|Almirall Investigational Site #4, Balassagyarmat, Hungary|Almirall Investigational Site #16, Budapest, Hungary|Almirall Investigational Site #12, Budapest, Hungary|Almirall Investigational Site #17, Budapest, Hungary|Almirall Investigational Site #6, Budapest, Hungary|Almirall Investigational Site #14, Budapest, Hungary|Almirall Investigational Site #5, Budapest, Hungary|Almirall Investigational Site #1, Deszk, Hungary|Almirall Investigational Site #9, Komarom, Hungary|Almirall Investigational Site #2, Miskolc, Hungary|Almirall Investigational Site #15, Mosonmagyarovar, Hungary|Almirall Investigational Site #13, Nagykanizsa, Hungary|Almirall Investigational Site #3, Nyiregyhaza, Hungary|Almirall Investigational Site #7, Torokbalint, Hungary|Almirall Investigational Site #11, Zalaegerszeg, Hungary|Almirall Investigational Site #15, Genova, Italy|Almirall Investigational Site #3, Parma, Italy|Almirall Investigational Site #5, Pisa, Italy|Almirall Investigational Site #1, Siena, Italy|Almirall Investigational Site #7, Buchon-si, Korea, Republic of|Almirall Investigational Site #4, Gyeonggi-do, Korea, Republic of|Almirall Investigational Site #8, Seoul, Korea, Republic of|Almirall Investigational Site #6, Seoul, Korea, Republic of|Almirall Investigational Site #3, Seoul, Korea, Republic of|Almirall Investigational Site #5, Seoul, Korea, Republic of|Almirall Investigational Site #2, Seoul, Korea, Republic of|Almirall Investigational Site #1, Seoul, Korea, Republic of|Almirall Investigational Site #8, Beek, Netherlands|Almirall Investigational Site #7, Breda, Netherlands|Almirall Investigational Site #13, Eindhoven, Netherlands|Almirall Investigational Site #1, Leiderdorp, Netherlands|Almirall Investigational Site #9, Rotterdam, Netherlands|Almirall Investigational Site #11, Velp, Netherlands|Almirall Investigational Site #10, Zoetermeer, Netherlands|Almirall Investigational Site #26, Bialystok, Poland|Almirall Investigational Site #3, Bialystok, Poland|Almirall Investigational Site #19, Bielsko-Biala, Poland|Almirall Investigational Site #23, Bydgoszcz, Poland|Almirall Investigational Site #21, Gdynia, Poland|Almirall Investigational Site #5, Katowice, Poland|Almirall Investigational Site #22, Katowice, Poland|Almirall Investigational Site #7, Krakow, Poland|Almirall Investigational Site #9, Krakow, Poland|Almirall Investigational Site #6, Lodz, Poland|Almirall Investigational Site #1, Lodz, Poland|Almirall Investigational Site #14, Lublin, Poland|Almirall Investigational Site #8, Olawa, Poland|Almirall Investigational Site #2, Poznan, Poland|Almirall Investigational Site #11, Poznan, Poland|Almirall Investigational Site #4, Poznan, Poland|Almirall Investigational Site #13, Torun, Poland|Almirall Investigational Site #18, Torun, Poland|Almirall Investigational Site #10, Warszawa, Poland|Almirall Investigational Site #15, Warszawa, Poland|Almirall Investigational Site #16, Warszawa, Poland|Almirall Investigational Site #1, Brasov, Romania|Almirall Investigational Site #9, Bucuresti, Romania|Almirall Investigational Site #18, Bucuresti, Romania|Almirall Investigational Site #7, Bucuresti, Romania|Almirall Investigational Site #10, Bucuresti, Romania|Almirall Investigational Site #17, Constanta, Romania|Almirall Investigational Site #2, Constanta, Romania|Almirall Investigational Site #3, Craiova, Romania|Almirall Investigational Site #8, Deva, Romania|Almirall Investigational Site #6, Iasi, Romania|Almirall Investigational Site #16, Iasi, Romania|Almirall Investigational Site #5, Targu Mures, Romania|Almirall Investigational Site #2, Moscow, Russian Federation|Almirall Investigational Site #1, Moscow, Russian Federation|Almirall Investigational Site #9, Novosibirsk, Russian Federation|Almirall Investigational Site #7, St. Petersburg, Russian Federation|Almirall Investigational Site #12, St. Petersburg, Russian Federation|Almirall Investigational Site #6, Banska Bystrica, Slovakia|Almirall Investigational Site #5, Bardejov, Slovakia|Almirall Investigational Site #3, Bratislava, Slovakia|Almirall Investigational Site #1, Nove Zamky, Slovakia|Almirall Investigational Site #4, Spisska Nova Ves, Slovakia|Almirall Investigational Site #9, Sturovo, Slovakia|Almirall Investigational Site #10, Vysne Hagy, Slovakia|Almirall Investigational Site #1, Amanzimtoti, South Africa|Almirall Investigational Site #15, Cape Town, Western Cape, South Africa|Almirall Investigational Site #16, Cape Town, South Africa|Almirall Investigational Site #2, Cape Town, South Africa|Almirall Investigational Site #12, Pretoria, South Africa|Almirall Investigational Site #13, Pretoria, South Africa|Almirall Investigational Site #3, Pretoria, South Africa|Almirall Investigational Site #8, Roodepoort, South Africa|Almirall Investigational Site #5, Somerset West, South Africa|Almirall Investigational Site #7, Barcelona, Spain|Almirall Investigational Site #12, Barcelona, Spain|Almirall Investigational Site #10, Caceres, Spain|Almirall Investigational Site #3, Canet de Mar, Spain|Almirall Investigational Site #1, Malaga, Spain|Almirall Investigational Site #9, Oviedo, Spain|Almirall Investigational Site #8, Sevilla, Spain|Almirall Investigational Site #2, Göteborg, Sweden|Almirall Investigational Site #1, Lund, Sweden|Almirall Investigational Site #6, Lund, Sweden|Almirall Investigational Site #3, Malmö, Sweden|Almirall Investigational Site #4, Vällingby, Sweden|Almirall Investigational Site #18, Crimea Oblast, Ukraine|Almirall Investigational Site #12, Dnipropetrovsk, Ukraine|Almirall Investigational Site #9, Donetsk, Ukraine|Almirall Investigational Site #11, Ivano-Frankivsk, Ukraine|Almirall Investigational Site #17, Kharkiv, Ukraine|Almirall Investigational Site #1, Kharkov, Ukraine|Almirall Investigational Site #15, Kyiv, Ukraine|Almirall Investigational Site #2, Kyiv, Ukraine|Almirall Investigational Site #3, Kyiv, Ukraine|Almirall Investigational Site #4, Kyiv, Ukraine|Almirall Investigational Site #5, Kyiv, Ukraine|Almirall Investigational Site #6, Lugansk, Ukraine|Almirall Investigational Site #8, Mykolaiv, Ukraine|Almirall Investigational Site #10, Vinnytsya, Ukraine|Almirall Investigational Site #6, Birmingham, United Kingdom|Almirall Investigational Site #12, Bradford, United Kingdom|Almirall Investigational Site #10, Cambridge, United Kingdom|Almirall Investigational Site #13, Cardiff, United Kingdom|Almirall Investigational Site #5, Chorley, United Kingdom|Almirall Investigational Site #2, Glasgow, United Kingdom|Almirall Investigational Site #11, Hull, United Kingdom|Almirall Investigational Site #14, Liverpool, United Kingdom|Almirall Investigational Site #1, London, United Kingdom|Almirall Investigational Site #4, Manchester, United Kingdom|Almirall Investigational Site #8, Manchester, United Kingdom|Almirall Investigational Site #18, Newcastle upon Tyne, United Kingdom|Almirall Investigational Site #7, Reading, United Kingdom|Almirall Investigational Site #16, Stockton on Tees, United Kingdom|Almirall Investigational Site #15, West midlands, United Kingdom|Almirall Investigational Site #17, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01462942"
85,"NCT01462929","Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Aclidinium bromide|Drug: Tiotropium|Drug: Placebo","Change From Baseline in Normalised Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over the 24-h Period After 6 Weeks of Treatment|Change From Baseline in Normalised FEV1 Area Under the Curve Over the 12-h Night-time Period After 6 Weeks of Treatment","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","414","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M/34273/39","November 2011","March 2012","May 2012","November 1, 2011","May 22, 2013","January 4, 2017","Almirall Investigational Site #9, Humpolec, Czech Republic|Almirall Investigational Site #1, Jaromer, Czech Republic|Almirall Investigational Site #3, Melnik, Czech Republic|Almirall Investigational Site #4, Berlin, Germany|Almirall Investigational Site #12, Berlin, Germany|Almirall Investigational Site #10, Berlin, Germany|Almirall Investigational Site #8, Berlin, Germany|Almirall Investigational Site #20, Berlin, Germany|Almirall Investigational Site #21, Berlin, Germany|Almirall Investigational Site #2, Berlin, Germany|Almirall Investigational Site #13, Dresden, Germany|Almirall Investigational Site #9, Frankfurt, Germany|Almirall Investigational Site #3, Grosshansdorf, Germany|Almirall Investigational Site #1, Hamburg, Germany|Almirall Investigational Site #18, Hamburg, Germany|Almirall Investigational Site #5, Hannover, Germany|Almirall Investigational Site #22, Hannover, Germany|Almirall Investigational Site #14, Jena, Germany|Almirall Investigational Site #24, Koln, Germany|Almirall Investigational Site #17, Lubeck, Germany|Almirall Investigational Site #23, Rudersdorf, Germany|Almirall Investigational Site #6, Schwerin, Germany|Almirall Investigational Site #16, Wiesbaden, Germany|Almirall Investigational Site #4, Debrecen, Hungary|Almirall Investigational Site #2, Komarom, Hungary|Almirall Investigational Site #3, Matrahaza, Hungary|Almirall Investigational Site #1, Szarvas, Hungary|Almirall Investigational Site #11, Szigetszentmiklos, Hungary|Almirall Investigational Site #18, Bialystok, Poland|Almirall Investigational Site #8, Bialystok, Poland|Almirall Investigational Site #2, Elblag, Poland|Almirall Investigational Site #17, Krakow, Poland|Almirall Investigational Site #10, Krakow, Poland|Almirall Investigational Site #16, Lodz, Poland|Almirall Investigational Site #20, Lodz, Poland|Almirall Investigational Site #4, Proszowice, Poland|Almirall Investigational Site #6, Sopot, Poland|Almirall Investigational Site #14, Tarnow, Poland|Almirall Investigational Site #19, Warszawa, Poland|Almirall Investigational Site #12, Wilkowice-Bystra, Poland|Almirall Investigational Site #13, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT01462929"
86,"NCT01455194","Effect of High Dose Ciclesonide on Asthma Control","CONTRAST","Completed","Has Results","Bronchial Asthma","Drug: Ciclesonide","Asthma Control Questionnaire (ACQ) Score at Baseline|Change From Baseline in ACQ Score to Tlast|Time Course of ACQ|Number of Weeks With Well-controlled Asthma Over the Course of the Study|Number of Participants With Well-controlled Asthma and ACQ Improvement at the End of the Study|Number of Participants Reporting Time to First Well-Controlled Asthma and ACQ Improvement|Number of Participants Reporting Time to First Well-Controlled Asthma Measurement by ACQ Cut-Off Point|Number of Participants Reporting Time to First Asthma Exacerbation|Number of Participants Reporting Asthma Exacerbations Rates|Number of Participants With Markedly High Benefits|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)|Number of Participants Reporting Clinically Significant Change From Baseline in Vital Signs|Number of Participants Reporting Clinically Significant Change From Baseline in Physical Examination Findings|Number of Participants With Markedly Abnormal Laboratory Values","AstraZeneca","All","12 Years to 70 Years   (Child, Adult, Older Adult)","Phase 3","520","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CL-9709-301-RD|2011-000683-99|U1111-1133-6333|CL-9709-301-RDCTID","November 2011","August 2014","August 2014","October 19, 2011","October 25, 2016","February 10, 2017","Capital Federal, Buenos Aires, Argentina|Ciudad Autonoma de Buenos Aires, Argentina|Rosario-Santa Fe, Argentina|Rosario, Argentina|Salta, Argentina|Tucuman, Argentina|Florianopolis, Brazil|Goiania, Brazil|Porto Alegre, Brazil|Rio de Janiero, Brazil|Santo Andre, Sao Paulo, Brazil|Sao Paulo, Brazil|Sorocaba, Brazil|Berlin, Germany|Bonn, Germany|Landsberg, Germany|Rudersdorf, Germany|Schwetzingen, Germany|Beer-Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Barnaul, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01455194"
87,"NCT01444430","A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents",,"Completed","Has Results","Asthma","Drug: Symbicort pMDI|Drug: budesonide pMDI","Number of Participants Experiencing an Event in the Composite Endpoint (Asthma-related Death, Asthma-related Intubation or Asthma-related Hospitalization)|Number of Participants Experiencing an Event Included in the Definition of Asthma Exacerbation|Percent of Days With no Asthma Symptoms|Percent of Days With Activity Limitation Due to Asthma|Mean Number of Puffs of Rescue Medication Per 24 Hours|Asthma Control Questionnaire (ACQ6)|Percent of Nights With Awakening(s) Due to Asthma|Number of Participants Experiencing Discontinuation of Investigational Product Due to a Protocol Defined Asthma Exacerbation","AstraZeneca","All","12 Years to 130 Years   (Child, Adult, Older Adult)","Phase 3","12460","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5896C00027|2011-002790-28","December 2011","October 2015","October 2015","September 30, 2011","December 15, 2016","December 15, 2016","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Anchorage, Alaska, United States|Research Site, Gilbert, Arizona, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Fort Smith, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Alhambra, California, United States|Research Site, Anaheim, California, United States|Research Site, Arvin, California, United States|Research Site, Bellflower, California, United States|Research Site, Buena Park, California, United States|Research Site, Costa Mesa, California, United States|Research Site, Encinitas, California, United States|Research Site, Escondido, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Glendale, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Palmdale, California, United States|Research Site, Pasadena, California, United States|Research Site, Poway, California, United States|Research Site, Riverside, California, United States|Research Site, Roseville, California, United States|Research Site, San Diego, California, United States|Research Site, San Jose, California, United States|Research Site, Santa Ana, California, United States|Research Site, Stockton, California, United States|Research Site, Tustin, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Denver, Colorado, United States|Research Site, Thornton, Colorado, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, DeLand, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Leesburg, Florida, United States|Research Site, Lehigh Acres, Florida, United States|Research Site, Lynn Haven, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocoee, Florida, United States|Research Site, Opalocka, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Royal Palm Beach, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Calhoun, Georgia, United States|Research Site, Conyers, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Hayden Lake, Idaho, United States|Research Site, Meridan, Idaho, United States|Research Site, Kenilworth, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Anderson, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Fort Mitchell, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Lanham, Maryland, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Madison Hgts, Michigan, United States|Research Site, Port Huron, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Sterling Heights, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Edina, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, Vicksburg, Mississippi, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Verona, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Great Neck, New York, United States|Research Site, Hopewell Jct, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Rockville Centre, New York, United States|Research Site, Watertown, New York, United States|Research Site, Cary, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Miamishburg, Ohio, United States|Research Site, Stow, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Bryn Mawr, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Phoenixville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Warwick, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greeneville, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Indian Land, South Carolina, United States|Research Site, Summerville, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Baytown, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Killeen, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, Pharr, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Spring, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Sugarland, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Layton, Utah, United States|Research Site, South Burlington, Vermont, United States|Research Site, Danville, Virginia, United States|Research Site, Vienna, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, La Crosse, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Monte Grande, Argentina|Research Site, Quilmes, Argentina|Research Site, Ranelagh, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Miguel de Tucumán, Argentina|Research Site, Barueri, Brazil|Research Site, Botucatu, Brazil|Research Site, Goiania, Brazil|Research Site, Juiz de Fora, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Santo André, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Gotse Delchev, Bulgaria|Research Site, Kozloduy, Bulgaria|Research Site, Petrich, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Razgrad, Bulgaria|Research Site, Razlog, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sandanski, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vidin, Bulgaria|Research Site, Quillota, Chile|Research Site, Santiago, Chile|Research Site, Vina del Mar, Chile|Research Site, Bogotá, Colombia|Research Site, Cali, Colombia|Research Site, Manizales, Colombia|Research Site, Beroun, Czech Republic|Research Site, Breclav, Czech Republic|Research Site, Krnov, Czech Republic|Research Site, Kutna Hora, Czech Republic|Research Site, Litomerice, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha 8, Czech Republic|Research Site, Rokycany, Czech Republic|Research Site, Angers, France|Research Site, Perpignan, France|Research Site, Tierce, France|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Marburg, Germany|Research Site, Bangalore, India|Research Site, Calicut, India|Research Site, Coimbatore, India|Research Site, Goa, India|Research Site, Hyderabad, India|Research Site, Mangalore, India|Research Site, Mysore, India|Research Site, Nagpur, India|Research Site, New Delhi, India|Research Site, Trivandrum, India|Research Site, Benevento, Italy|Research Site, Bologna, Italy|Research Site, Catanzaro, Italy|Research Site, Ferrara, Italy|Research Site, Genova, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Palermo, Italy|Research Site, Roma, Italy|Research Site, Ansan-si, Korea, Republic of|Research Site, Cheonan-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Jinju-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Durango, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Morelia, Mexico|Research Site, México, Mexico|Research Site, Santiago de Querétaro, Mexico|Research Site, Villahermosa, Mexico|Research Site, Zapopan, Mexico|Research Site, Ciudad de Panama, Panama|Research Site, Cusco, Peru|Research Site, Lima, Peru|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Białystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chęciny, Poland|Research Site, Gorzów Wlkp, Poland|Research Site, Karpacz, Poland|Research Site, Kraków, Poland|Research Site, Ostrów Wielkopolski, Poland|Research Site, Skarżysko Kamienna, Poland|Research Site, Strzelce Opolskie, Poland|Research Site, Szczecin, Poland|Research Site, Tarnów, Poland|Research Site, Turek, Poland|Research Site, Urszulin, Poland|Research Site, Wrocław, Poland|Research Site, Caguas, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, Toa Baja, Puerto Rico|Research Site, Bragadiru, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj Napoca, Romania|Research Site, Constanta, Romania|Research Site, Craiova, Romania|Research Site, Deva, Romania|Research Site, Iasi, Romania|Research Site, Tg. Mures, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, StPetersburg, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Yekaterinburg, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Dunajska Streda, Slovakia|Research Site, Komarno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Skalica, Slovakia|Research Site, Zilina, Slovakia|Research Site, Zvolen, Slovakia|Research Site, Boksburg North, South Africa|Research Site, Breyton, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Lenasia, South Africa|Research Site, Lyttleton, South Africa|Research Site, Pretoria, South Africa|Research Site, Umkomaas, South Africa|Research Site, Verulam, South Africa|Research Site, Bangkok, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang,, Thailand|Research Site, Naimuang, Thailand|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Odesa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnitsa, Ukraine|Research Site, Zaporozye, Ukraine|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Canterbury, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Crawley, United Kingdom|Research Site, Leamington Spa, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Stockport, United Kingdom|Research Site, Trowbridge, United Kingdom|Research Site, Watford, United Kingdom|Research Site, Westbury, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01444430"
88,"NCT01437540","Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Aclidinium Bromide/Formoterol Fumarate|Drug: Formoterol Fumarate","Percentage of Patients to Experience at Least One Treatment-emergent Adverse Event (TEAE)|Percentage of Patients to Experience Any Potentially Clinically Significant (PCS) Post-baseline Change in Clinical Laboratory Values for Hematology, Chemistry or Urinalysis at the End of the Study|Percentage of Patients to Experience a Potentially Clinically Significant (PCS) Change in Pulse Rate, Systolic and Diastolic Blood Pressure|Percentage of Patients to Experience Potentially Clinically Significant Changes in ECG From Baseline","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","590","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAC-MD-32","September 19, 2011","March 31, 2013","April 30, 2013","September 21, 2011","May 11, 2017","May 11, 2017","Forest Investigative Site 1162, Birmingham, Alabama, United States|Forest Investigative Site 1493, Birmingham, Alabama, United States|Forest Investigative Site 1620, Birmingham, Alabama, United States|Forest Investigative Site 1127, Mobile, Alabama, United States|Forest Investigative Site 1613, Chandler, Arizona, United States|Forest Investigative Site 1623, Peoria, Arizona, United States|Forest Investigative Site 1582, Phoenix, Arizona, United States|Forest Investigative Site 1379, Phoenix, Arizona, United States|Forest Investigative Site 1581, Phoenix, Arizona, United States|Forest Investigative Site 1571, Phoenix, Arizona, United States|Forest Investigative Site 1596, Fort Smith, Arkansas, United States|Forest Investigative Site 1547, Encinitas, California, United States|Forest Investigative Site 1088, Lakewood, California, United States|Forest Investigative Site 1624, Los Angeles, California, United States|Forest Investigative Site 1927, Los Angeles, California, United States|Forest Investigative Site 1388, Paramount, California, United States|Forest Investigative Site 1503, San Diego, California, United States|Forest Investigative Site 1374, Torrance, California, United States|Forest Investigative Site 1331, Vista, California, United States|Forest Investigative Site 2039, Walnut Creek, California, United States|Forest Investigative Site 1597, Boulder, Colorado, United States|Forest Investigative Site 1137, Colorado Springs, Colorado, United States|Forest Investigative Site 0892, Denver, Colorado, United States|Forest Investigative Site 2037, Fort Collins, Colorado, United States|Forest Investigative Site 1327, Wheat Ridge, Colorado, United States|Forest Investigative Site 2045, Wheat Ridge, Colorado, United States|Forest Investigative Site 1589, Norwalk, Connecticut, United States|Forest Investigative Site 1598, Stamford, Connecticut, United States|Forest Investigative Site 1154, Brandon, Florida, United States|Forest Investigative Site 1944, Brandon, Florida, United States|Forest Investigative Site 1152, Clearwater, Florida, United States|Forest Investigative Site 1617, Debary, Florida, United States|Forest Investigative Site 1959, Debary, Florida, United States|Forest Investigative Site 1516, Edgewater, Florida, United States|Forest Investigative Site 1403, Hollywood, Florida, United States|Forest Investigative Site 1556, Orlando, Florida, United States|Forest Investigative Site 1542, Ormond Beach, Florida, United States|Forest Investigative Site 0974, Pensacola, Florida, United States|Forest Investigative Site 2047, Tampa, Florida, United States|Forest Investigative Site 1565, Venice, Florida, United States|Forest Investigative Site 1851, Atlanta, Georgia, United States|Forest Investigative Site 0980, Atlanta, Georgia, United States|Forest Investigative Site 1567, Atlanta, Georgia, United States|Forest Investigative Site 1607, Lawrenceville, Georgia, United States|Forest Investigative Site 1409, O'Fallon, Illinois, United States|Forest Investigative Site 2051, River Forest, Illinois, United States|Forest Investigative Site 1604, Springfield, Illinois, United States|Forest Investigative Site 1576, Evansville, Indiana, United States|Forest Investigative Site 1549, Council Bluffs, Iowa, United States|Forest Investigative Site 2033, Bowling Green, Kentucky, United States|Forest Investigative Site 2085, Crescent Springs, Kentucky, United States|Forest Investigative Site 1336, Louisville, Kentucky, United States|Forest Investigative Site 2024, Lafayette, Louisiana, United States|Forest Investigative Site 1430, New Orleans, Louisiana, United States|Forest Investigative Site 1360, Sunset, Louisiana, United States|Forest Investigative Site 1566, Auburn, Maine, United States|Forest Investigative Site 1333, Baltimore, Maryland, United States|Forest Investigative Site 1622, Columbia, Maryland, United States|Forest Investigative Site 1590, Towson, Maryland, United States|Forest Investigative Site 1570, Fall River, Massachusetts, United States|Forest Investigative Site 1546, Haverhill, Massachusetts, United States|Forest Investigative Site 1029, North Dartmouth, Massachusetts, United States|Forest Investigative Site 1595, Worcestor, Massachusetts, United States|Forest Investigative Site 1605, Traverse City, Michigan, United States|Forest Investigative Site 1527, Fridley, Minnesota, United States|Forest Investigative Site 1124, Minneapolis, Minnesota, United States|Forest Investigative Site 1619, Plymouth, Minnesota, United States|Forest Investigative Site 1587, Chesterfield, Missouri, United States|Forest Investigative Site 1572, Jefferson City, Missouri, United States|Forest Investigative Site 1399, St. Louis, Missouri, United States|Forest Investigative Site 1599, St. Louis, Missouri, United States|Forest Investigative Site 1831, Bozeman, Montana, United States|Forest Investigative Site 1400, Missoula, Montana, United States|Forest Investigative Site 1609, Bellevue, Nebraska, United States|Forest Investigative Site 1616, Lincoln, Nebraska, United States|Forest Investigative Site 1615, Omaha, Nebraska, United States|Forest Investigative Site 1562, Las Vegas, Nevada, United States|Forest Investigative Site 1610, Rochester, New Hampshire, United States|Forest Investigative Site 1558, Brick, New Jersey, United States|Forest Investigative Site 1559, Cherry Hill, New Jersey, United States|Forest Investigative Site 1394, Ocean, New Jersey, United States|Forest Investigative Site 2084, Summit, New Jersey, United States|Forest Investigative Site 0972, Brooklyn, New York, United States|Forest Investigative Site 1163, New York, New York, United States|Forest Investigative Site 1425, New York, New York, United States|Forest Investigative Site 1554, Newburgh, New York, United States|Forest Investigative Site 1563, Syracuse, New York, United States|Forest Investigative Site 1557, Raleigh, North Carolina, United States|Forest Investigative Site 1588, Shelby, North Carolina, United States|Forest Investigative Site 1553, Wilmington, North Carolina, United States|Forest Investigative Site 1550, Winston-Salem, North Carolina, United States|Forest Investigative Site 1134, Canton, Ohio, United States|Forest Investigative Site 1594, Cincinnati, Ohio, United States|Forest Investigative Site 2028, Cincinnati, Ohio, United States|Forest Investigative Site 1541, Marion, Ohio, United States|Forest Investigative Site 1530, Toledo, Ohio, United States|Forest Investigative Site 1393, Zanesville, Ohio, United States|Forest Investigative Site 1612, Ashland, Oregon, United States|Forest Investigative Site 1575, Corvallis, Oregon, United States|Forest Investigative Site 1081, Eugene, Oregon, United States|Forest Investigative Site 1580, Portland, Oregon, United States|Forest Investigative Site 1552, Portland, Oregon, United States|Forest Investigative Site 1574, Beaver, Pennsylvania, United States|Forest Investigative Site 1577, Beaver, Pennsylvania, United States|Forest Investigative Site 1126, Bethlehem, Pennsylvania, United States|Forest Investigative Site 1423, Erie, Pennsylvania, United States|Forest Investigative Site 1504, Hershey, Pennsylvania, United States|Forest Investigative Site 1569, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 1548, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 1146, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 1560, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 1449, Tipton, Pennsylvania, United States|Forest Investigative Site 1564, Uniontown, Pennsylvania, United States|Forest Investigative Site 1144, Johnston, Rhode Island, United States|Forest Investigative Site 2072, Charleston, South Carolina, United States|Forest Investigative Site 1568, Easley, South Carolina, United States|Forest Investigative Site 1506, Greenville, South Carolina, United States|Forest Investigative Site 1601, Greer, South Carolina, United States|Forest Investigative Site 0900, Spartanburg, South Carolina, United States|Forest Investigative Site 1450, Union, South Carolina, United States|Forest Investigative Site 1365, Rapid City, South Dakota, United States|Forest Investigative Site 1440, Arlington, Texas, United States|Forest Investigative Site 1954, Austin, Texas, United States|Forest Investigative Site 1155, Dallas, Texas, United States|Forest Investigative Site 1328, Dallas, Texas, United States|Forest Investigative Site 1332, El Paso, Texas, United States|Forest Investigative Site 2012, Fort Worth, Texas, United States|Forest Investigative Site 1902, Killeen, Texas, United States|Forest Investigative Site 1498, San Antonio, Texas, United States|Forest Investigative Site 1614, San Antonio, Texas, United States|Forest Investigative Site 1906, San Antonio, Texas, United States|Forest Investigative Site 2004, San Antonio, Texas, United States|Forest Investigative Site 1600, Magna, Utah, United States|Forest Investigative Site 1480, Abingdon, Virginia, United States|Forest Investigative Site 1579, Alexandria, Virginia, United States|Forest Investigative Site 1142, Spokane, Washington, United States|Forest Investigative Site 1573, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01437540"
89,"NCT01437397","Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Aclidinium Bromide/Formoterol Fumarate|Drug: Aclidinium Bromide|Drug: Formoterol Fumarate|Drug: Placebo","Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Morning Trough Forced Expiratory Volume in One Second (FEV1)|Change in Transition Dyspnea Index (TDI) Focal Score|Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","1692","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAC-MD-31","September 2011","February 2013","February 2013","September 20, 2011","March 23, 2017","March 23, 2017","Forest Investigative Site 1827, Anniston, Alabama, United States|Forest Investigative Site 1920, Athens, Alabama, United States|Forest Investigative Site 1162, Birmingham, Alabama, United States|Forest Investigative Site 1493, Birmingham, Alabama, United States|Forest Investigative Site 1937, Birmingham, Alabama, United States|Forest Investigative Site 1893, Florence, Alabama, United States|Forest Investigative Site 1824, Gulf Shores, Alabama, United States|Forest Investigative Site 2088, Jasper, Alabama, United States|Forest Investigative Site 1918, Scottsboro, Alabama, United States|Forest Investigative Site 0909, Glendale, Arizona, United States|Forest Investigative Site 1958, Mesa, Arizona, United States|Forest Investigative Site 1379, Phoenix, Arizona, United States|Forest Investigative Site 1822, Anaheim, California, United States|Forest Investigative Site 1483, Buena Park, California, United States|Forest Investigative Site 1809, Fountain Valley, California, United States|Forest Investigative Site 1156, Fresno, California, United States|Forest Investigative Site 1871, Lincoln, California, United States|Forest Investigative Site 1873, Los Angeles, California, United States|Forest Investigative Site 2064, Riverside, California, United States|Forest Investigative Site 1427, Sacramento, California, United States|Forest Investigative Site 1866, Sacramento, California, United States|Forest Investigative Site 1125, San Diego, California, United States|Forest Investigative Site 1898, San Diego, California, United States|Forest Investigative Site 2009, San Diego, California, United States|Forest Investigative Site 1374, Torrance, California, United States|Forest Investigative Site 1813, Tustin, California, United States|Forest Investigative Site 1883, Vista, California, United States|Forest Investigative Site 1380, Golden, Colorado, United States|Forest Investigative Site 1137, Pueblo, Colorado, United States|Forest Investigative Site 1327, Wheat Ridge, Colorado, United States|Forest Investigative Site 1976, Waterbury, Connecticut, United States|Forest Investigative Site 1821, Bay Pines, Florida, United States|Forest Investigative Site 1154, Brandon, Florida, United States|Forest Investigative Site 1944, Brandon, Florida, United States|Forest Investigative Site 1364, Clearwater, Florida, United States|Forest Investigative Site 1152, Clearwater, Florida, United States|Forest Investigative Site 1875, Clearwater, Florida, United States|Forest Investigative Site 0670, DeLand, Florida, United States|Forest Investigative Site 1516, Edgewater, Florida, United States|Forest Investigative Site 0990, Fort Lauderdale, Florida, United States|Forest Investigative Site 1513, Hialeah, Florida, United States|Forest Investigative Site 1854, Hialeah, Florida, United States|Forest Investigative Site 1882, Hollywood, Florida, United States|Forest Investigative Site 1543, Jacksonville, Florida, United States|Forest Investigative Site 1416, Kissimmee, Florida, United States|Forest Investigative Site 1167, Melbourne, Florida, United States|Forest Investigative Site 1868, Miami, Florida, United States|Forest Investigative Site 1432, Miami, Florida, United States|Forest Investigative Site 1979, Miami, Florida, United States|Forest Investigative Site 1819, Naples, Florida, United States|Forest Investigative Site 1808, North Miami Beach, Florida, United States|Forest Investigative Site 1950, Oldsmar, Florida, United States|Forest Investigative Site 1145, Ormond Beach, Florida, United States|Forest Investigative Site 1094, Panama City, Florida, United States|Forest Investigative Site 1803, Pembroke Pines, Florida, United States|Forest Investigative Site 974, Pensacola, Florida, United States|Forest Investigative Site 1876, Saint Petersburg, Florida, United States|Forest Investigative Site 1817, Sarasota, Florida, United States|Forest Investigative Site 1829, St. Cloud, Florida, United States|Forest Investigative Site 1874, St. Petersburg, Florida, United States|Forest Investigative Site 2082, Tamarac, Florida, United States|Forest Investigative Site 2053, Tampa, Florida, United States|Forest Investigative Site 2047, Tampa, Florida, United States|Forest Investigative Site 1185, Winter Park, Florida, United States|Forest Investigative Site 1860, Winter Park, Florida, United States|Forest Investigative Site 1982, Albany, Georgia, United States|Forest Investigative Site 1900, Atlanta, Georgia, United States|Forest Investigative Site 0987, Austell, Georgia, United States|Forest Investigative Site 1828, Canton, Georgia, United States|Forest Investigative Site 1830, Marietta, Georgia, United States|Forest Investigative Site 2089, Woodstock, Georgia, United States|Forest Investigative Site 0679, Coeur d' Alene, Idaho, United States|Forest Investigative Site 1858, Eagle, Idaho, United States|Forest Investigative Site 1095, Normal, Illinois, United States|Forest Investigative Site 1912, Normal, Illinois, United States|Forest Investigative Site 2051, River Forest, Illinois, United States|Forest Investigative Site 2033, Bowling Green, Kentucky, United States|Forest Investigative Site 2085, Fort Mitchell, Kentucky, United States|Forest Investigative Site 0539, Lexington, Kentucky, United States|Forest Investigative Site 1478, Louisville, Kentucky, United States|Forest Investigative Site 1519, Owensboro, Kentucky, United States|Forest Investigative Site 1811, Covington, Louisiana, United States|Forest Investigative Site 1430, New Orleans, Louisiana, United States|Forest Investigative Site 1812, Opelousas, Louisiana, United States|Forest Investigative Site 1814, Bangor, Maine, United States|Forest Investigative Site 1924, Baltimore, Maryland, United States|Forest Investigative Site 1865, Hollywood, Maryland, United States|Forest Investigative Site 1872, Wheaton, Maryland, United States|Forest Investigative Site 1570, Fall River, Massachusetts, United States|Forest Investigative Site 1852, Fall river, Massachusetts, United States|Forest Investigative Site 1029, North Dartmouth, Massachusetts, United States|Forest Investigative Site 1431, North Dartmouth, Massachusetts, United States|Forest Investigative Site 1892, Ann Arbor, Michigan, United States|Forest Investigative Site 1342, Stevensville, Michigan, United States|Forest Investigative Site 1487, Troy, Michigan, United States|Forest Investigative Site 1128, Edina, Minnesota, United States|Forest Investigative Site 1527, Fridley, Minnesota, United States|Forest Investigative Site 2041, Minneapolis, Minnesota, United States|Forest Investigative Site 1124, Minneapolis, Minnesota, United States|Forest Investigative Site 1619, Plymouth, Minnesota, United States|Forest Investigative Site 1118, Rochester, Minnesota, United States|Forest Investigative Site 1884, Olive Branch, Mississippi, United States|Forest Investigative Site 1587, Chesterfield, Missouri, United States|Forest Investigative Site 1602, Kansas City, Missouri, United States|Forest Investigative Site 1856, Springfield, Missouri, United States|Forest Investigative Site 1867, Springfield, Missouri, United States|Forest Investigative Site 2079, St. Charles, Missouri, United States|Forest Investigative Site 1399, St. Louis, Missouri, United States|Forest Investigative Site 1599, St. Louis, Missouri, United States|Forest Investigative Site 1831, Bozeman, Montana, United States|Forest Investigative Site 1400, Missoula, Montana, United States|Forest Investigative Site 1609, Bellevue, Nebraska, United States|Forest Investigative Site 1948, Fremont, Nebraska, United States|Forest Investigative Site 1815, Lincoln, Nebraska, United States|Forest Investigative Site 1363, Omaha, Nebraska, United States|Forest Investigative Site 1907, Omaha, Nebraska, United States|Forest Investigative Site 1911, Omaha, Nebraska, United States|Forest Investigative Site 1908, Omaha, Nebraska, United States|Forest Investigative Site 1804, Omaha, Nebraska, United States|Forest Investigative Site 1807, Henderson, Nevada, United States|Forest Investigative Site 1834, Las Vegas, Nevada, United States|Forest Investigative Site 1562, Las Vegas, Nevada, United States|Forest Investigative Site 1559, Cherry Hill, New Jersey, United States|Forest Investigative Site 1923, Hackensack, New Jersey, United States|Forest Investigative Site 1949, Albuquerque, New Mexico, United States|Forest Investigative Site 1151, Great Neck, New York, United States|Forest Investigative Site 1489, Larchmont, New York, United States|Forest Investigative Site 0550, New York, New York, United States|Forest Investigative Site 1425, New York, New York, United States|Forest Investigative Site 2098, Rochester, New York, United States|Forest Investigative Site 1392, Charlotte, North Carolina, United States|Forest Investigative Site 2035, Elizabeth City, North Carolina, United States|Forest Investigative Site 1366, High Point, North Carolina, United States|Forest Investigative Site 1153, Raleigh, North Carolina, United States|Forest Investigative Site 1823, Salisbury, North Carolina, United States|Forest Investigative Site 1891, Cadiz, Ohio, United States|Forest Investigative Site 1134, Canton, Ohio, United States|Forest Investigative Site 1885, Cincinnati, Ohio, United States|Forest Investigative Site 1806, Cincinnati, Ohio, United States|Forest Investigative Site 2028, Cincinnati, Ohio, United States|Forest Investigative Site 1903, Cincinnati, Ohio, United States|Forest Investigative Site 1361, Columbus, Ohio, United States|Forest Investigative Site 1433, Columbus, Ohio, United States|Forest Investigative Site 2090, Sylvania, Ohio, United States|Forest Investigative Site 1530, Toledo, Ohio, United States|Forest Investigative Site 1393, Zanesville, Ohio, United States|Forest Investigative Site 1915, Oklahoma City, Oklahoma, United States|Forest Investigative Site 1889, Bend, Oregon, United States|Forest Investigative Site 2043, Medford, Oregon, United States|Forest Investigative Site 1833, Altoona, Pennsylvania, United States|Forest Investigative Site 1855, Clairton, Pennsylvania, United States|Forest Investigative Site 1820, Downington, Pennsylvania, United States|Forest Investigative Site 1423, Erie, Pennsylvania, United States|Forest Investigative Site 1899, Langhorne, Pennsylvania, United States|Forest Investigative Site 1443, Philadelphia, Pennsylvania, United States|Forest Investigative Site 1863, Phoenixville, Pennsylvania, United States|Forest Investigative Site 1146, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 1449, Tipton, Pennsylvania, United States|Forest Investigative Site 1862, Uniontown, Pennsylvania, United States|Forest Investigative Site 1832, Cumberland, Rhode Island, United States|Forest Investigative Site 1089, East Providence, Rhode Island, United States|Forest Investigative Site 2072, Charleston, South Carolina, United States|Forest Investigative Site 1905, Charleston, South Carolina, United States|Forest Investigative Site 1802, Charleston, South Carolina, United States|Forest Investigative Site 1914, Fort Mill, South Carolina, United States|Forest Investigative Site 1913, Gaffney, South Carolina, United States|Forest Investigative Site 1121, Spartanburg, South Carolina, United States|Forest Investigative Site 1957, Brentwood, Tennessee, United States|Forest Investigative Site 1526, Fayetteville, Tennessee, United States|Forest Investigative Site 1440, Arlington, Texas, United States|Forest Investigative Site 1879, Boerne, Texas, United States|Forest Investigative Site 1861, Carrollton, Texas, United States|Forest Investigative Site 1816, Corsicana, Texas, United States|Forest Investigative Site 1890, Dallas, Texas, United States|Forest Investigative Site 1332, El Paso, Texas, United States|Forest Investigative Site 2012, Fort Worth, Texas, United States|Forest Investigative Site 1951, Houston, Texas, United States|Forest Investigative Site 1902, Killeen, Texas, United States|Forest Investigative Site 1091, Mckinney, Texas, United States|Forest Investigative Site 1826, Plano, Texas, United States|Forest Investigative Site 0526, San Angelo, Texas, United States|Forest Investigative Site 1895, San Antonio, Texas, United States|Forest Investigative Site 1936, Salt Lake City, Utah, United States|Forest Investigative Site 1330, South Burlington, Vermont, United States|Forest Investigative Site 1945, Newport News, Virginia, United States|Forest Investigative Site 1404, Norfolk, Virginia, United States|Forest Investigative Site 1120, Bellingham, Washington, United States|Forest Investigative Site 1977, Spokane, Washington, United States|Forest Investigative Site 1878, Spokane, Washington, United States|Forest Investigative Site 1573, Spokane, Washington, United States|Forest Investigative Site 0988, Tacoma, Washington, United States|Forest Investigative Site 1870, Tacoma, Washington, United States|Forest Investigative Site 1555, Morgantown, West Virginia, United States|Forest Investigative Site 1991, New Lambton, New South Wales, Australia|Forest Investigative Site 1987, Redcliffe, Queensland, Australia|Forest Investigative Site 1973, Woolloongabba, Queensland, Australia|Forest Investigative Site 1981, Bedford Park, South Australia, Australia|Forest Investigative Site 1990, Daw Park, South Australia, Australia|Forest Investigative Site 2251, Toorak Gardens, South Australia, Australia|Forest Investigative Site 2250, Clayton, Victoria, Australia|Forest Investigative Site 1972, Fitzroy, Victoria, Australia|Forest Investigative Site 1986, Geelong, Victoria, Australia|Forest Investigative Site 1985, Parkville, Victoria, Australia|Forest Investigative Site 2253, Adelaide, Western Australia, Australia|Forest Investigative Site 1904, Langley, British Columbia, Canada|Forest Investigative Site 0905, Vancouver, British Columbia, Canada|Forest Investigative Site 0976, Winnipeg, Manitoba, Canada|Forest Investigative Site 1877, Sarina, Ontario, Canada|Forest Investigative Site 1896, Sarnia, Ontario, Canada|Forest Investigative Site 1171, Toronto, Ontario, Canada|Forest Investigative Site 2203, Toronto, Ontario, Canada|Forest Investigative Site 1952, Montreal, Quebec, Canada|Forest Investigative Site 0943, Saskatoon, Saskatchewan, Canada|Forest Investigative Site 1859, Quebec, Canada|Forest Investigative Site 1027, Auckland, New Zealand|Forest Investigative Site 1970, Christchurch, New Zealand|Forest Investigative Site 1967, Dunedin, New Zealand|Forest Investigative Site 1964, Dunedin, New Zealand|Forest Investigative Site 1968, Hamilton, New Zealand|Forest Investigative Site 1965, Tauranga, New Zealand|Forest Investigative Site 1980, Tauranga, New Zealand|Forest Investigative Site 1025, Wellington, New Zealand",,"https://ClinicalTrials.gov/show/NCT01437397"
90,"NCT01434186","A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Placebo matching with Saxagliptin|Drug: Metformin IR|Drug: Metformin XR|Drug: Saxagliptin","Mean Change in HbA1c From Baseline to Week 16","AstraZeneca|Bristol-Myers Squibb","All","10 Years to 17 Years   (Child)","Phase 3","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV181-147|2010-024568-16","May 2012","April 2016","April 2016","September 14, 2011","April 18, 2017","April 18, 2017","Research Site, Los Angeles, California, United States|Research Site, Tallahassee, Florida, United States|Research Site, Dearborn, Michigan, United States|Research Site, St. Paul, Minnesota, United States|Research Site, Mineola, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Memphis, Tennessee, United States|Research Site, Namur, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Bangalore, India|Research Site, Aguascalientes, Mexico|Research Site, Meridas, Mexico|Research Site, Monterrey, Mexico|Research Site, Veracruz, Mexico|Research Site, Taichung, Taiwan|Research Site, Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01434186"
91,"NCT01408303","[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL","ESPRIT","Completed","Has Results","Hypertriglyceridemia|Cardiovascular Disease","Drug: Olive oil, 4g|Drug: omega-3-carboxylic acids, 2g|Drug: omega-3-carboxylic acids, 4g","Serum Non-HDL Cholesterol","AstraZeneca|Omthera Pharmaceuticals, Inc|Medpace, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","646","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OM-EPA-004","August 2011","June 2012","June 2012","August 3, 2011","December 5, 2014","December 5, 2014","Muscle Shoals, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|Little Rock, Arkansas, United States|Encinitas, California, United States|Lomita, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|Spring Valley, California, United States|Westlake Village, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Brandon, Florida, United States|Clearwater, Florida, United States|Coral Gables, Florida, United States|Hialeah, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Oviedo, Florida, United States|Ponte Vedra, Florida, United States|St. Petersburg, Florida, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Oakbrook Terrace, Illinois, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Wichita, Kansas, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Madisonville, Kentucky, United States|Auburn, Maine, United States|Oxon Hill, Maryland, United States|Troy, Michigan, United States|Edina, Minnesota, United States|Chesterfield, Missouri, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Berlin, New Jersey, United States|Endwell, New York, United States|New Windsor, New York, United States|Rochester, New York, United States|Cary, North Carolina, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|High Point, North Carolina, United States|Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Lyndhurst, Ohio, United States|Marion, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Eugene, Oregon, United States|Harleysville, Pennsylvania, United States|Jersey Shore, Pennsylvania, United States|Lansdale, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Mount Pleasant, South Carolina, United States|Mt Pleasant, South Carolina, United States|Rapid City, South Dakota, United States|Bristol, Tennessee, United States|Gray, Tennessee, United States|Kingsport, Tennessee, United States|Corpus Christi, Texas, United States|Houston, Texas, United States|Katy, Texas, United States|San Antonio, Texas, United States|Murray, Utah, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01408303"
92,"NCT01395524","A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation",,"Completed","Has Results","Opioid-Induced Constipation (OIC)","Drug: NKTR-118|Drug: Placebo","Incidence of Patients Experiencing at Least One Adverse Event (AE)|Incidence of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)|Incidence of Patients Experiencing Severe Adverse Events (SAEs)|Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM)|Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL)","AstraZeneca","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 3","302","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D3820C00007","July 2011","September 2012","September 2012","July 15, 2011","June 17, 2015","February 23, 2017","Research Site, Birmingham, Alabama, United States|Research Site, Calera, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Malvern, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Garden Grove, California, United States|Research Site, Laguana Hills, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Gatos, California, United States|Research Site, Montebello, California, United States|Research Site, National City, California, United States|Research Site, Norwalk, California, United States|Research Site, Paramount, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Denver, Colorado, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Deland, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Venice, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Bloomington, Illinois, United States|Research Site, Rockford, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Evansville, Indiana, United States|Reserach Site, Indianapolis, Indiana, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Pikesville, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Biloxi, Mississippi, United States|Research Site, St Joseph, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Trenton, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Morrisville, North Carolina, United States|Research Site, Beavercreek, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Medord, Oregon, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Huntingdon Valley, Pennsylvania, United States|Research Site, Levittown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, Cumberland, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Clarksville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Doral, Texas, United States|Research Site, Houston, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Spokane, Washington, United States|Research Site, Broadmeadow, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Port Kembla, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Greenslopes, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Fremantle, Western Australia, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Potsdam, BR, Germany|Research Site, Dietzenbach, HE, Germany|Research Site, Huttenberg, HE, Germany|Research Site, Wetzlar, HE, Germany|Research Site, Hamburg, HH, Germany|Research Site, Schwerin, MV, Germany|Research Site, Celle, NI, Germany|Research Site, Hannover, NI, Germany|Research Site, Essen, NW, Germany|Research Site, Mainz, RP, Germany|Research Site, Kiel, SH, Germany|Research Site, Leipzig, SN, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Presov, Slovakia",,"https://ClinicalTrials.gov/show/NCT01395524"
93,"NCT01392677","Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea",,"Completed","Has Results","Type 2 Diabetes Mellitus|High HbA1c Level|Inadequate Glycaemic Control","Drug: dapagliflozin|Drug: placebo","Adjusted Mean Change From Baseline in HbA1c Levels|Adjusted Mean Change From Baseline in FPG|Adjusted Mean Change From Baseline in Total Body Weight|Proportion of Participants With HbA1c Value < 7.0% at Week 24 (LOCF)|Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","311","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1693C00005","October 2011","January 2013","August 2013","July 12, 2011","December 27, 2013","March 12, 2014","Research Site, Edmonton, Alberta, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Sydney Mines, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Kensington, Prince Edward Island, Canada|Research Site, Laval, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beroun, Czech Republic|Research Site, Ceske Budejovice, Czech Republic|Research Site, Jilove U Prahy, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Semily, Czech Republic|Research Site, Vyskov, Czech Republic|Research Site, Asslar, Germany|Research Site, Aßlar, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Falkensee, Germany|Research Site, Neuwied, Germany|Research Site, Pirna, Germany|Research Site, Kielce, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Poznań, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, Łódź, Poland|Research Site, Banska Bystrica, Slovakia|Research Site, Kosice, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Oviedo, Asturias, Spain|Research Site, Sta Coloma de Gramanet (bcn), Catalu?a, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, A Coruna, Galicia, Spain|Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Oviedo, Spain|Research Site, Sta Coloma de Gramenet (BCN), Spain",,"https://ClinicalTrials.gov/show/NCT01392677"
94,"NCT01370538","Efficacy of Esomeprazole in Patients With Frequent Heartburn","NEXT2","Completed","Has Results","Heartburn","Drug: Esomeprazole","Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment|Number of Subjects Reporting Heartburn 2 Days or Less During the 14 Days Randomized Treatment Period|Comparison of Number of Subjects With 0, 1, 2, 3 or 4 Days With no Heartburn Over Days 1 to 4 Between Esomeprazole 20 mg and Placebo|Number of Subjects With Heartburn 1 Day or Less During the Final Week, Second Week, First Week of Treatment","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","341","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D961RC00002","August 2011","October 2011","October 2011","June 10, 2011","April 11, 2013","April 11, 2013","Research site, Mobile, Alabama, United States|Research site, San Francisco, California, United States|Research site, Westlake Village, California, United States|Research site, Lexington, Kentucky, United States|Research site, Rochester, New York, United States|Research site, Dakota Dunes, South Dakota, United States|Research site, Nashville, Tennessee, United States|Research site, Austin, Texas, United States|Research site, San Angelo, Texas, United States|Research site, West Jordan, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01370538"
95,"NCT01370525","Efficacy of Esomeprazole in Patients With Frequent Heartburn","NEXT1","Completed","Has Results","Heartburn","Drug: Esomeprazole","Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment|Number of Subjects Reporting Heartburn 2 Days or Less During the 14 Days Randomized Treatment Period|Comparison of Number of Subjects With 0, 1, 2, 3 or 4 Days With no Heartburn Over Days 1 to 4 Between Esomeprazole 20 mg and Placebo|Number of Subjects With Heartburn 1 Day or Less During the Final Week, Second Week, First Week of Treatment","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","340","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D961RC00001","August 2011","October 2011","October 2011","June 10, 2011","March 14, 2013","March 14, 2013","Research site, Sacramento, California, United States|Research site, Seminole, Florida, United States|Research site, Meridian, Idaho, United States|Research site, Indianapolis, Indiana, United States|Research site, Metairie, Louisiana, United States|Research site, Omaha, Nebraska, United States|Research site, Raleigh, North Carolina, United States|Research site, Cleveland, Ohio, United States|Research site, Mt Pleasant, South Carolina, United States|Research site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01370525"
96,"NCT01360021","New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day","BAI","Completed","Has Results","Asthma","Drug: Symbicort|Drug: Budesonide","Forced Expiratory Volume in 1 Second (FEV1) - Post Dose|Forced Expiratory Volume in 1 Second (FEV1) - Pre Dose|Peak Expiratory Flow|Asthma Symptoms Score (Total)|Night-time Awakenings Due to Asthma Symptoms(% Awakening-free Nights)|Use of Rescue Medication Day and Night (Total Daily Rescue Medication Use)","AstraZeneca","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","214","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D589OC00003","November 2011","August 2012","August 2012","May 25, 2011","March 11, 2014","March 11, 2014","Research Site, Huntington Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Jose, California, United States|Research Site, Tallahassee, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, River Forest, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Metairie, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Wheaton, Maryland, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Columbia, Missouri, United States|Research Site, Rolla, Missouri, United States|Research Site, Skillman, New Jersey, United States|Research Site, North Syracuse, New York, United States|Research Site, Rochester, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Collegeville, Pennsylvania, United States|Research Site, Lincoln, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Tacoma, Washington, United States|Research Site, Greenfield, Wisconsin, United States|Research Site, Madison, Wisconsin, United States|Research Site, Ruse, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Salgotarjan, Hungary|Research Site, Szazhalombatta, Hungary|Research Site, Ekaterinburg, Russia, Russian Federation|Research Site, Moscow, Russia, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01360021"
97,"NCT01336205","Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation",,"Completed","Has Results","Opioid-Induced Constipation (OIC)","Drug: NKTR-118|Drug: Usual care","Incidence of Patients Experiencing at Least One Adverse Event (AE)|Incidence of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)|Incidence of Patients Experiencing Severe Adverse Events (SAEs)","AstraZeneca","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 3","844","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D3820C00008","April 2011","December 2012","December 2012","April 15, 2011","October 20, 2014","October 20, 2014","Research Site, Athens, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Pell City, Alabama, United States|Research Site, Garden Grove, Arizona, United States|Research Site, Goodyear, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tuscon, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, North Little Rock, Arkansas, United States|Research Site, Sherwood, Arkansas, United States|Research Site, Arcadia, California, United States|Research Site, Chino, California, United States|Research Site, Encino, California, United States|Research Site, Fremont, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Park, California, United States|Research Site, La Mesa, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Lakewood, California, United States|Research Site, Long Beach, California, United States|Research Site, Oceanside, California, United States|Research Site, Orange, California, United States|Research Site, Pasadena, California, United States|Research Site, Riverside, California, United States|Research Site, San Bernardino, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Ana, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Whittier, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Chiefland, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Debary, Florida, United States|Research Site, Deerfield Beach, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Edgewater, Florida, United States|Research Site, Eustis, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jackson, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Lauderhill, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Oviedo, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pinellas Park, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Port St. Lucie, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, St. Doral, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, West Palm, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Alpharetta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Suwanee, Georgia, United States|Research Site, Tucker, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Bloomington, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, Schaumburg, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Lansing, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Hollywood, Maryland, United States|Research Site, Pikesville, Maryland, United States|Research Site, Reisterstown, Maryland, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Calamazoo, Michigan, United States|Research Site, Traverse City, Michigan, United States|Research Site, St Louis, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Bellevue, Nebraska, United States|Research Site, Fremont, Nebraska, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Clifton, New Jersey, United States|Research Site, Freehold, New Jersey, United States|Research Site, Lumberton, New Jersey, United States|Research Site, Toms River, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Great Neck, New York, United States|Research Site, Hartsdale, New York, United States|Research Site, New York, New York, United States|Research Site, North Massapequa, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Elkin, North Carolina, United States|Research Site, Flat Rock, North Carolina, United States|Research Site, Harrisburg, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Morrisville, North Carolina, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Akron, Ohio, United States|Research Site, Beavercreek, Ohio, United States|Research Site, Centerville, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Downingtown, Pennsylvania, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pottstown, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Clarksville, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Milan, Tennessee, United States|Research Site, New Tazewell, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Hurst, Texas, United States|Research Site, Lexington, Texas, United States|Research Site, Marshall, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugarland, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Ogden, Utah, United States|Research Site, Saint George, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, Richmond, Virginia, United States|Research Site, Springfield, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01336205"
98,"NCT01323790","Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation",,"Completed","Has Results","Opioid-Induced Constipation (OIC)","Drug: NKTR-118|Drug: Placebo","Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12|Response (Responder/Non-responder) to Study Drug in the LIR Subgroup During Weeks 1 to 12|Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours|Change From Baseline in Mean Number of Days Per Week With at Least 1 SBM During Weeks 1 to 12|Change From Baseline in Degree of Straining|Change From Baseline in Stool Consistency (Bristol Stool Scale)|Change From Baseline in Percent Numbers of Days With a CSBM (Complete Spontaneous Bowel Movement)|Change From Baseline in Mean Spontaneous Bowel Movements/Week|Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours in the Laxative Inadequate Response (LIR) Subgroup|Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM)|Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL) Satisfaction Domain","AstraZeneca","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D3820C00005|2011-001986-41","March 2011","September 2012","September 2012","March 28, 2011","June 2, 2015","June 2, 2015","Research Site, Mobile, Alabama, United States|Research Site, Pell City, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Sun Lakes, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, North Little Rock, Arkansas, United States|Research Site, Sherwood, Arkansas, United States|Research Site, Chino, California, United States|Research Site, La Jolla, California, United States|Research Site, Lincoln, California, United States|Research Site, Modesto, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Stamford, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Sanford, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Conyers, Georgia, United States|Research Site, John's Creek, Georgia, United States|Research Site, Peoria, Illinois, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Chestnut Hill, Massachusetts, United States|Research Site, Watertown, Massachusetts, United States|Research Site, Livonia, Michigan, United States|Research Site, St. Clair Shores, Michigan, United States|Research Site, Florissant, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Freehold, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Great Neck, New York, United States|Research Site, Hartsdale, New York, United States|Research Site, North Massapequa, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Morrisville, North Carolina, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Bellevue, Ohio, United States|Research Site, Downingtown, Pennsylvania, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pottstown, Pennsylvania, United States|Research Site, Anderson, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Milan, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Hurst, Texas, United States|Research Site, Marshall, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugarland, Texas, United States|Research Site, Clinton, Utah, United States|Research Site, Saint George, Utah, United States|Research Site, West Jordan, Utah, United States|Research Site, Antwerpen, Belgium|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Moerkerke, Belgium|Research Site, Mouscron, Belgium|Research Site, Roeselare, Belgium|Research Site, Bjelovar, Croatia|Research Site, Osijek, Croatia|Research Site, Susak, Croatia|Research Site, Zagreb, Croatia|Research Site, Chocen, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Prague, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Pusztaszer, Hungary|Research Site, Satoraljaujhely, Hungary|Research Site, Szeged, Hungary|Research Site, Szikszo, Hungary|Research Site, Urhida, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Malaga, Andalucia, Spain|Research Site, L' Hospitalet de Llobregat, Catalu?a, Spain|Research Site, VIC, Catalu?a, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Centelles (barcelona), Cataluna, Spain|Research Site, Fuenlabrada, Comunidad de Madrid, Spain|Research Site, Almeria, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Valencia, Spain|Research Site, Valladolid, Spain|Research Site, Goteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Vallingby, Sweden|Research Site, Ayrshire, AYR, United Kingdom|Research Site, Chesterfield, Derby, United Kingdom|Research Site, Plymouth, Devon, United Kingdom|Research Site, London, Gt Lon, United Kingdom|Research Site, Royton, Lancashire, United Kingdom|Research Site, Thornton-cleveleys, Lancashire, United Kingdom|Research Site, Norwich, Norflk, United Kingdom|Research Site, Barry, S Glam, United Kingdom|Research Site, Bath, Somer, United Kingdom|Research Site, Glasgow, Strath, United Kingdom|Research Site, Coventry, Warwks, United Kingdom|Research Site, Derby, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01323790"
99,"NCT01313494","A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore:","ACROSS","Completed","Has Results","COPD","Drug: Roflumilast|Drug: Placebo|Drug: Salbutamol","Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)|Change From Baseline in Post-bronchodilator FEV1|Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC)|Change From Baseline in Post-bronchodilator Forced Vital Capacity (FVC)|Change From Baseline in Pre-bronchodilator Forced Expiratory Flow 25-75%|Change From Baseline in Post-bronchodilator Forced Expiratory Flow 25-75%|Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)|Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Three Seconds (FEV3)|Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)|Change From Baseline in Post-bronchodilator Forced Expiratory Volume in First Six Seconds (FEV6)|Change From Baseline in Pre-bronchodilator Peak Expiratory Flow Rate (PEF)|Change From Baseline in Post-bronchodilator Peak Expiratory Flow Rate (PEF)|Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity|Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Vital Capacity|Change From Baseline in Pre-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds|Change From Baseline in Post-bronchodilator Ratio of Forced Expiratory Volume After 1 Second to Forced Expiratory Volume After 6 Seconds|Change From Baseline in COPD Symptom Scores|Change From Baseline in Use of Rescue Medication|Transition Dyspnoea Index (TDI) Total Score at Week 24|Percentage of Participants With Moderate or Severe COPD Exacerbations|Mean Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year|Time to Onset of First Moderate or Severe COPD Exacerbation|Time to Onset of Second Moderate or Severe COPD Exacerbation|Number of Participants With Adverse Events","AstraZeneca","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 3","626","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RO-2455-301-RD|U1111-1133-6304","March 2011","May 2012","May 2012","March 11, 2011","August 2, 2013","February 1, 2017","Beijing, China|Changsha, China|Chengdu, China|Chongqing, China|Fuzhou, China|Guangzhou, China|Hangzhou, China|Nanjing, China|Nanning, China|Qingdao, China|Shanghai, China|Shenyang, China|Shijiazhuang, China|Hong Kong, Hong Kong|Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01313494"
100,"NCT01309841","Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation",,"Completed","Has Results","Opioid-Induced Constipation (OIC)","Drug: NKTR-118|Drug: Placebo","Response (Responder/Non-responder) to Study Drug During Weeks 1 to 12|Response (Responder/Non-responder) to Study Drug in the LIR Subgroup During Weeks 1 to 12|Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours|Change From Baseline in Mean Number of Days Per Week With at Least 1 SBM During Weeks 1 to 12|Change From Baseline in Degree of Straining|Change From Baseline in Stool Consistency (Bristol Stool Scale)|Change From Baseline in Percent Numbers of Days With a CSBM (Complete Spontaneous Bowel Movement)|Change From Baseline in Mean Spontaneous Bowel Movements/Week|Time (in Hours) to First Post-dose Laxation Without the Use of Rescue Laxatives Within the Previous 24 Hours in the Laxative Inadequate Response (LIR) Subgroup|Change From Baseline in Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM)|Change From Baseline in Patient Assessment of Constipation Quality of Life (PAC-QOL) Satisfaction Domain","AstraZeneca","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 3","652","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D3820C00004|2011-001987-24","March 2011","August 2012","August 2012","March 7, 2011","June 1, 2015","June 1, 2015","Research Site, Birmingham, Alabama, United States|Research Site, Calera, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Malvern, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Garden Grove, California, United States|Research Site, Laguana Hills, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Gatos, California, United States|Research Site, Montebello, California, United States|Research Site, National City, California, United States|Research Site, Norwalk, California, United States|Research Site, Paramount, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Denver, Colorado, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Deland, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Inverness, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jackson, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Venice, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Bloomington, Illinois, United States|Research Site, Rockford, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Pikesville, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Biloxi, Mississippi, United States|Research Site, St Joseph, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Trenton, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Morrisville, North Carolina, United States|Research Site, Beavercreek, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Medord, Oregon, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Huntingdon Valley, Pennsylvania, United States|Research Site, Levittown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, Cumberland, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greer, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Clarksville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Doral, Texas, United States|Research Site, Houston, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Spokane, Washington, United States|Research Site, Broadmeadow, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Port Kembla, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Greenslopes, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Fremantle, Western Australia, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Berlin, BE, Germany|Research Site, Potsdam, BR, Germany|Research Site, Dietzenbach, HE, Germany|Research Site, Huttenberg, HE, Germany|Research Site, Wetzlar, HE, Germany|Research Site, Hamburg, HH, Germany|Research Site, Schwerin, MV, Germany|Research Site, Celle, NI, Germany|Research Site, Hannover, NI, Germany|Research Site, Essen, NW, Germany|Research Site, Mainz, RP, Germany|Research Site, Kiel, SH, Germany|Research Site, Dresden, SN, Germany|Research Site, Leipzig, SN, Germany|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Presov, Slovakia",,"https://ClinicalTrials.gov/show/NCT01309841"
101,"NCT01300351","Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women",,"Completed","Has Results","Breast Cancer","Drug: Fulvestrant|Drug: Placebo","Progression-free Survival|Objective Response Rate|Clinical Benefit Rate|Duration of Response|Duration of Clinical Benefit","AstraZeneca","Female","18 Years and older   (Adult, Older Adult)","Phase 3","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D6997L00021","March 2011","March 2014","March 2014","February 21, 2011","April 24, 2015","April 24, 2015","Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Jiangsu, China|Research Site, Kunming, China|Research Site, Nanning, China|Research Site, Shandong, China|Research Site, Shanghai, China|Research Site, Shijiazhuang, China|Research Site, Taiyuan, China|Research Site, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT01300351"
102,"NCT01294462","Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)",,"Completed","Has Results","Acute Coronary Syndrome|Percutaneous Coronary Intervention","Drug: Ticagrelor|Drug: Clopidogrel|Drug: Acetylsalicylic acid ASA","Major Bleeding|Major Adverse Cardiac Events (MACE)|Major and Minor Bleeding|Composite of All-cause Mortality, MI or Stroke","AstraZeneca","All","20 Years and older   (Adult, Older Adult)","Phase 3","801","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5130C00027","February 2011","July 2012","July 2012","February 11, 2011","May 2, 2014","June 27, 2014","Research Site, Ichinomiya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Okazaki-shi, Aichi, Japan|Research Site, Toyohashi-shi, Aichi, Japan|Research Site, Toyota-shi, Aichi, Japan|Research Site, Akita-shi, Akita, Japan|Research Site, Ichihara-shi, Chiba, Japan|Research Site, Kamogawa-shi, Chiba, Japan|Research Site, Kisarazu-shi, Chiba, Japan|Research Site, Matsuyama, Ehime, Japan|Research Site, Fukui-shi, Fukui, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kasuya-gun, Fukuoka, Japan|Research Site, Kurume, Fukuoka, Japan|Research Site, Gifu-shi, Gifu, Japan|Research Site, Isesaki, Gunma, Japan|Research Site, Maebashi, Gunma, Japan|Research Site, Takasaki-shi, Gunma, Japan|Research Site, Kure, Hiroshima, Japan|Research Site, Sapporo-shi, Hokkaido, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Akashi-shi, Hyogo, Japan|Research Site, Amagasaki-shi, Hyogo, Japan|Research Site, Kawanishi-shi, Hyogo, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Kobe, Hyogo, Japan|Research Site, Nishinomiya, Hyogo, Japan|Research Site, Takarazuka-shi, Hyogo, Japan|Research Site, Higashiibaragi-gun, Ibaragi, Japan|Research Site, Sashima-gun, Ibaragi, Japan|Research Site, Hakusan-shi, Ishikawa, Japan|Research Site, Kanazawa-shi, Ishikawa, Japan|Research Site, Kanazawa, Ishikawa, Japan|Research Site, Sakaide-shi, Kagawa, Japan|Research Site, Atsugi-shi, Kanagawa, Japan|Research Site, Isehara, Kanagawa, Japan|Research Site, Kamakura-shi, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Yamato-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Nankoku-shi, Kochi, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Yatsushiro-city, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Azumino-shi, Nagano, Japan|Research Site, Ueda-shi, Nagano, Japan|Research Site, Nagasaki-shi, Nagasaki, Japan|Research Site, Kurashiki, Okayama, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Hirakata, Osaka, Japan|Research Site, Kawachinagano-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Sakai-shi, Osaka, Japan|Research Site, Saga-shi, Saga, Japan|Research Site, Ageo-shi, Saitama, Japan|Research Site, Hidaka, Saitama, Japan|Research Site, Sayama-shi, Saitama, Japan|Research Site, Kusatsu-shi, Shiga, Japan|Research Site, Moriyama, Shiga, Japan|Research Site, Matsue, Shimane, Japan|Research Site, Hamamatsu-shi, Shizuoka, Japan|Research Site, Izunokuni, Shizuoka, Japan|Research Site, Shimada-shi, Shizuoka, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Komatsushima-shi, Tokushima, Japan|Research Site, Tokushima-shi, Tokushima, Japan|Research Site, Adachi-ku, Tokyo, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Bunkyo, Tokyo, Japan|Research Site, Chiyoda-ku, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Meguro, Tokyo, Japan|Research Site, Ome-shi, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Shinjuku, Tokyo, Japan|Research Site, Suginami-ku, Tokyo, Japan|Research Site, Tanabe-shi, Wakayama, Japan|Research Site, Chuo-shi, Yamanashi, Japan|Research Site, Fukuoka, Japan|Research Site, Gifu, Japan|Research Site, Kumamoto, Japan|Research Site, Oita, Japan|Research Site, Saga, Japan|Research Site, Wakayama, Japan|Research Site, Cheonan, Chungcheongnam-do, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Niao-song-shiang, Kaohsiung, Taiwan|Research Site, Kweishan Shiang, Taoyuan Hsien, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01294462"
103,"NCT01294436","Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus",,"Completed","Has Results","Type2 Diabetes|High Blood Sugar","Drug: Dapagliflozin","Proportion of Participants With Adverse Events|Proportion of Participants With Serious Adverse Events|Proportion of Participants With At Least One Episode of Hypoglycemia|Mean Change in Hematocrit|Mean Change in Alanine Aminotransferase (ALT)|Mean Change in Aspartate Aminotransferase (AST)|Mean Change in Blood Urea Nitrogen (BUN)|Mean Change in Magnesium|Mean Change in Serum Uric Acid|Mean Change in Seated Heart Rate|Mean Change in Seated Diastolic Blood Pressure|Mean Change in Seated Systolic Blood Pressure","AstraZeneca|Bristol-Myers Squibb","All","20 Years and older   (Adult, Older Adult)","Phase 3","728","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1692C00012","February 2011","September 2012","September 2012","February 11, 2011","September 16, 2013","December 17, 2013","Research Site, Nagoya, Aichi, Japan|Research Site, Owariasahi, Aichi, Japan|Research Site, Toyohashi, Aichi, Japan|Research Site, Hirosaki, Aomori, Japan|Research Site, Niihama, Ehime, Japan|Research Site, Itoshima, Fukuoka, Japan|Research Site, Yukuhashi, Fukuoka, Japan|Research Site, Annaka, Gunma, Japan|Research Site, OTA, Gunma, Japan|Research Site, Aki-gun, Hiroshima, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Sanuki, Kagawa, Japan|Research Site, Takamatsu, Kagawa, Japan|Research Site, Kamakura, Kanagawa, Japan|Research Site, Kawasaki, Kanagawa, Japan|Research Site, Yokohamashi, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Zushi, Kanagawa, Japan|Research Site, Sendai, Miyagi, Japan|Research Site, Matsumoto, Nagano, Japan|Research Site, Suita, Osaka, Japan|Research Site, Otsu, Shiga, Japan|Research Site, Atami, Shizuoka, Japan|Research Site, Komatsushima, Tokushima, Japan|Research Site, Chiyoda, Tokyo, Japan|Research Site, Chuo, Tokyo, Japan|Research Site, Mitaka, Tokyo, Japan|Research Site, OTA, Tokyo, Japan|Research Site, Shibuya, Tokyo, Japan|Research Site, Shinjuku, Tokyo, Japan|Research Site, Taito, Tokyo, Japan|Research Site, Takaoka, Toyama, Japan|Research Site, UBE, Yamaguchi, Japan|Research Site, Fukuoka, Japan|Research Site, Hiroshima, Japan|Research Site, Kochi, Japan|Research Site, Osaka, Japan|Research Site, Shizuoka, Japan|Research Site, Toyama, Japan",,"https://ClinicalTrials.gov/show/NCT01294436"
104,"NCT01294423","Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus",,"Completed","Has Results","Type 2 Diabetes|High Blood Sugar","Drug: Dapagliflozin|Drug: Placebo","Adjusted Mean Change in HbA1c Levels|Adjusted Mean Change in Fasting Plasma Glucose (FPG)|Adjusted Mean Change in Body Weight","AstraZeneca|Bristol-Myers Squibb","All","20 Years and older   (Adult, Older Adult)","Phase 3","261","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1692C00006","February 2011","March 2012","March 2012","February 11, 2011","August 23, 2013","July 24, 2014","Research Site, Noda, Chiba, Japan|Research Site, Yukuhashi, Fukuoka, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Chitose-shi, Hokkaido, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Takasago-shi, Hyogo, Japan|Research Site, Hakusan-shi, Ishikawa, Japan|Research Site, Sanuki-shi, Kagawa, Japan|Research Site, Takamatsu-shi, Kagawa, Japan|Research Site, Ebina-shi, Kanagawa, Japan|Research Site, Kamakura-shi, Kanagawa, Japan|Research Site, Sendai-shi, Miyagi, Japan|Research Site, Sendai, Miyagi, Japan|Research Site, Matsumoto-shi, Nagano, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Suita, Osaka, Japan|Research Site, Otsu-shi, Shiga, Japan|Research Site, Shizuoka-shi, Shizuoka, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Chuo, Tokyo, Japan|Research Site, Meguro-ku,, Tokyo, Japan|Research Site, Ota-ku, Tokyo, Japan|Research Site, Takaoka-shi, Toyama, Japan|Research Site, Toyama-shi, Toyama, Japan|Research Site, Fukuoka, Japan|Research Site, Okayama, Japan|Research Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01294423"
105,"NCT01256177","Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression",,"Completed","Has Results","Bipolar Depression","Drug: Quetiapine Fumarate (SEROQUEL) Extended Release|Drug: Placebo","Change From Baseline (Visit 2) to End of Study (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score|Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Response (Subjects With ≥50% Reduction From Baseline to Week 8 in MADRS Total Score)|Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Remission (the Proportion of Subjects With a MADRS Total Score ≤ 12 at Week 8 Assessment)|Change From Baseline to Each Assessment in MADRS Total Score|Change From Baseline to Week 8 in HAM-D Total Scores|Change From Baseline to Week 8 Assessment in the Clinical Global Impression Bipolar - Severity (CGI-BP-S)|The Proportion of Patients at Week 8 With a Clinical Global Impression - Bipolar - Change (CGI-BP-C) of ""Much"" or ""Very Much"" Improved|Change From Baseline to Week 8 in Item 10 of Montgomery-Asberg Depression Rating Scale (MADRS) for Suicidal Ideation|Incidence of Treatment-emergent Mania (AE of Mania or Hypomania, Defined as Young Mania Rating Scale [YMRS] Score ≥16 on 2 Consecutive Assessments or Final Assessment)","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","361","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D144CC00005","December 2010","November 2012","November 2012","December 8, 2010","February 3, 2016","April 15, 2016","Research Site, Baoding, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Kunming, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shanxi, China|Research Site, Tianjin, China|Research Site, Wu Han, China|Research Site, Xi An, China|Research Site, Xi'an, China|Research Site, Xian, China",,"https://ClinicalTrials.gov/show/NCT01256177"
106,"NCT01225562","Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin","PEGASUS","Completed","Has Results","Myocardial Infarction|Cardiovascular Death|Atherothrombosis|Stroke","Drug: Ticagrelor 90 mg|Drug: Ticagrelor 60 mg|Drug: Ticagrelor Placebo","Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization|Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients|Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization|Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization","AstraZeneca","All","50 Years to 130 Years   (Adult, Older Adult)","Phase 3","21379","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D5132C00001|2009-017242-30","October 2010","December 2014","December 2014","October 21, 2010","December 9, 2015","January 25, 2016","Research Site, Alexander City, Alabama, United States|Research Site, Athens, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Sheffield, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Alhambra, California, United States|Research Site, Anaheim, California, United States|Research Site, Bakersfield, California, United States|Research Site, Fountain Valley, California, United States|Research Site, La Mesa, California, United States|Research Site, Larkspur, California, United States|Research Site, Lomita, California, United States|Research Site, Los Angeles, California, United States|Research Site, Modesto, California, United States|Research Site, Newport Beach, California, United States|Research Site, Oakland, California, United States|Research Site, Oceanside, California, United States|Research Site, San Diego, California, United States|Research Site, San Marino, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Ventura, California, United States|Research Site, Westlake Village, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Loveland, Colorado, United States|Research Site, Hartford, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boca Raton, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Crystal River, Florida, United States|Research Site, Davie, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Daytona, Florida, United States|Research Site, Ft Lauderdale, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Leesburg, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pannama City, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Safety Harbor, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, The Villages, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Cumming, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Boise, Idaho, United States|Research Site, Aurora, Illinois, United States|Research Site, Bannockburn, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Melrose Park, Illinois, United States|Research Site, Normal, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Elkhart, Indiana, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Franklin, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Munster, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Crestview Hills, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Covington, Louisiana, United States|Research Site, Minden, Louisiana, United States|Research Site, New Iberia, Louisiana, United States|Research Site, Opelousas, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Slidell, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Biddeford, Maine, United States|Research Site, S Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Oxon Hill, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Ayer, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Burlington, Massachusetts, United States|Research Site, Haverhill, Massachusetts, United States|Research Site, North Dartmouth, Massachusetts, United States|Research Site, Alpena, Michigan, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Flint, Michigan, United States|Research Site, Grand Blanc, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Jackson, Michigan, United States|Research Site, Lapeer, Michigan, United States|Research Site, Marquette, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Baxter, Minnesota, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Robbinsdale, Minnesota, United States|Research Site, St Cloud, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Papillion, Nebraska, United States|Research Site, Reno, Nevada, United States|Research Site, Bridgewater, New Jersey, United States|Research Site, Elizabeth, New Jersey, United States|Research Site, Elmer, New Jersey, United States|Research Site, Haddon Heights, New Jersey, United States|Research Site, Linden, New Jersey, United States|Research Site, Mine Hill, New Jersey, United States|Research Site, Newark, New Jersey, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Somerset, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Cortlandt Manor, New York, United States|Research Site, Mineola, New York, United States|Research Site, New Windsor, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Saratoga Springs, New York, United States|Research Site, Southampton, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Cary, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Morganton, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Sanford, North Carolina, United States|Research Site, Smithfield, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Grand Forks, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Fairfield, Ohio, United States|Research Site, Mansfield, Ohio, United States|Research Site, Sandusky, Ohio, United States|Research Site, Springfield, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Youngstown, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Beaver, Pennsylvania, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Chambersburg, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Johnstown, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Scranton, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, West Chester, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Florence, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Watertown, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Tullahoma, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, Grapevine, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Katy, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, MC Allen, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Plano, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Provo, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Alexandria, Virginia, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Danville, Virginia, United States|Research Site, Falls Church, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Everett, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Wausau, Wisconsin, United States|Research Site, Bahia Blanca, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de BA, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Ciudadela, Argentina|Research Site, Cordoba, Argentina|Research Site, Coronel Suarez, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, Haedo, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario Santa Fe, Argentina|Research Site, Rosario, Argentina|Research Site, San Luis, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, San Nicolas, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Santa Fe, Argentina|Research Site, Santa Fé, Argentina|Research Site, Tucuman, Argentina|Research Site, Tucumán, Argentina|Research Site, Zarate, Argentina|Research Site, Adelaide, Australia|Research Site, Ashford, Australia|Research Site, Auchenflower, Australia|Research Site, Ballarat, Australia|Research Site, Bruce, Australia|Research Site, Chermside, Australia|Research Site, Clayton, Australia|Research Site, Concord, Australia|Research Site, East St Kilda, Australia|Research Site, Elizabeth Vale, Australia|Research Site, Epping, Australia|Research Site, Fremantle, Australia|Research Site, Geelong, Australia|Research Site, Gosford, Australia|Research Site, Greenslopes, Australia|Research Site, Herston, Australia|Research Site, Joondalup, Australia|Research Site, Kingswood, Australia|Research Site, Kogorah, Australia|Research Site, Launceston, Australia|Research Site, Melbourne, Australia|Research Site, Nedlands, Australia|Research Site, New Lambton Heights, Australia|Research Site, Richmond, Australia|Research Site, St Leonards, Australia|Research Site, Wollongong, Australia|Research Site, Woodville, Australia|Research Site, Woolloongabba, Australia|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Bouge, Belgium|Research Site, Brasschaat, Belgium|Research Site, Brussels (Anderlecht), Belgium|Research Site, Brussels (Jette), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Brussels, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Huy, Belgium|Research Site, La Louvière, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Liège, Belgium|Research Site, Mechelen, Belgium|Research Site, Mol, Belgium|Research Site, Ottignies, Belgium|Research Site, Roeselare, Belgium|Research Site, Tienen, Belgium|Research Site, Turnhout, Belgium|Research Site, Yvoir, Belgium|Research Site, Zottegem, Belgium|Research Site, Aracaju, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Blumenau, Brazil|Research Site, Brasília, Brazil|Research Site, Campina Grande do Sul, Brazil|Research Site, Campinas, Brazil|Research Site, Campo Grande, Brazil|Research Site, Curitiba, Brazil|Research Site, Goiânia, Brazil|Research Site, Maceio, Brazil|Research Site, Marilia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, S.J.Rio Preto, Brazil|Research Site, Salvador, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Uberlândia, Brazil|Research Site, Votuporanga, Brazil|Research Site, Dimitrovgrad, Bulgaria|Research Site, Gotse Delchev, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Razlog, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sarnia, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Levis, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Saint-Charles-Borromee, Quebec, Canada|Research Site, Saint-Georges, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, St-Lambert, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Thetford Mines, Quebec, Canada|Research Site, Val d'Or, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Concepcion, Chile|Research Site, Osorno, Chile|Research Site, Rancagua, Chile|Research Site, Santiago Centro, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Chongqing, China|Research Site, Guang Zhou, China|Research Site, Guangzhou, China|Research Site, Hang Zhou, China|Research Site, Lanzhou, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shengyang, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Armenia, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bogotá D.C., Colombia|Research Site, Bucaramanga, Colombia|Research Site, Cali, Colombia|Research Site, Cartagena, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Medillin, Colombia|Research Site, Brno, Czech Republic|Research Site, Caslav, Czech Republic|Research Site, Ceska Lipa, Czech Republic|Research Site, Cesky Krumlov, Czech Republic|Research Site, Chomutov, Czech Republic|Research Site, Havirov, Czech Republic|Research Site, Kromeriz, Czech Republic|Research Site, Kyjov, Czech Republic|Research Site, Liberec, Czech Republic|Research Site, Marianske Lazne, Czech Republic|Research Site, Ostrava-Poruba, Czech Republic|Research Site, Ostrava-Zabreh, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Pelhrimov, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Pribram, Czech Republic|Research Site, Slany, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Usti nad Orlici, Czech Republic|Research Site, Znojmo, Czech Republic|Research Site, ABBEVILLE cedex, France|Research Site, Albi, France|Research Site, ANGERS Cedex 9, France|Research Site, Angers, France|Research Site, Avignon Cedex, France|Research Site, Bayonne, France|Research Site, Cannes, France|Research Site, Creteil, France|Research Site, Dijon, France|Research Site, Jossigny, France|Research Site, La Rochelle Cedex, France|Research Site, Le Chesnay, France|Research Site, Le Coudray Cedex, France|Research Site, Limoges Cedex, France|Research Site, MARSEILLE Cedex 5, France|Research Site, Metz Cedex 1, France|Research Site, NICE Cedex 01, France|Research Site, NIMES Cedex 9, France|Research Site, Orléans Cedex 2, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Poitiers, France|Research Site, Toulouse Cedex, France|Research Site, TOURCOING cedex, France|Research Site, Bad Krozingen, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Nauheim, Germany|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Coburg, Germany|Research Site, Deggingen, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Esslingen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kassel, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Limburg, Germany|Research Site, Ludwigshafen, Germany|Research Site, Lübeck, Germany|Research Site, Mainz, Germany|Research Site, Mönchengladbach, Germany|Research Site, Ulm, Germany|Research Site, Warendorf, Germany|Research Site, Witten, Germany|Research Site, Ballasagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Békéscsaba, Hungary|Research Site, Cegléd, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kecskemét, Hungary|Research Site, Mosonmagyaróvár, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pécs, Hungary|Research Site, Sopron, Hungary|Research Site, Szeged, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Albano Laziale, Italy|Research Site, Bari, Italy|Research Site, Benevento, Italy|Research Site, Brescia, Italy|Research Site, Carpi, Italy|Research Site, Catania, Italy|Research Site, Genova, Italy|Research Site, Legnano, Italy|Research Site, Lucca, Italy|Research Site, Massa, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Osio Sotto frazione di Zingoni, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Perugia, Italy|Research Site, Pescara, Italy|Research Site, Pisa, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, S Maria Capua Vetere, Italy|Research Site, San Remo, Italy|Research Site, Sassari, Italy|Research Site, Sessa Aurunca, Italy|Research Site, Siena, Italy|Research Site, Sorrento NA, Italy|Research Site, Vimercate, Italy|Research Site, Akishima-shi, Japan|Research Site, Amagasaki-shi, Japan|Research Site, Beppu-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Daito-shi, Japan|Research Site, Fukui-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Imabari-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Kamogawa-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kawachinagano-shi, Japan|Research Site, Kisarazu-shi, Japan|Research Site, Komatsushima-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kure-shi, Japan|Research Site, Kusatsu-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Matsue-shi, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Meguro-ku, Japan|Research Site, Miyazaki-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Saitama-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sakaide-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sayama-shi, Japan|Research Site, Shimada-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Suwa-shi, Japan|Research Site, Takarazuka-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Tomakomai-shi, Japan|Research Site, Toyonaka-shi, Japan|Research Site, Ueda-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Wako-shi, Japan|Research Site, Yatsushiro-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Bucheon-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Jeonju, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Uijeongbu, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Almere, Netherlands|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Beverwijk, Netherlands|Research Site, Breda, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Deventer, Netherlands|Research Site, Drachten, Netherlands|Research Site, EDE, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Goes, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hardenberg, Netherlands|Research Site, Heerenveen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hilversum, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Leiderdorp, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, OSS, Netherlands|Research Site, Roosendaal, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Shertogenbosch, Netherlands|Research Site, Sittardgeleen, Netherlands|Research Site, Sneek, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Bergen, Norway|Research Site, Bodo, Norway|Research Site, Bodø, Norway|Research Site, Flekkefjord, Norway|Research Site, Hamar, Norway|Research Site, Levanger, Norway|Research Site, Lillehammer, Norway|Research Site, Nesttun, Norway|Research Site, Oslo, Norway|Research Site, Skien, Norway|Research Site, Tromsø, Norway|Research Site, Tynset, Norway|Research Site, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, San Borja, Peru|Research Site, Trujillo, Peru|Research Site, Cebu City, Philippines|Research Site, Fuente Osmena Cebu City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Las Pinas City, Philippines|Research Site, Lipa City, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon, Philippines|Research Site, San Juan, Philippines|Research Site, Białystok, Poland|Research Site, Bielsko Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chorzow, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Giżycko, Poland|Research Site, Kraków, Poland|Research Site, Legnica, Poland|Research Site, Lubin, Poland|Research Site, Nowa Sól, Poland|Research Site, Olsztyn, Poland|Research Site, Opole, Poland|Research Site, Ostrów Mazowiecka, Poland|Research Site, Oława, Poland|Research Site, Piotrkow, Poland|Research Site, Poznań, Poland|Research Site, Płock, Poland|Research Site, Skierniewice, Poland|Research Site, Sobótka, Poland|Research Site, Sokolka, Poland|Research Site, Szczecin, Poland|Research Site, Tarnów, Poland|Research Site, Torun, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Włocławek, Poland|Research Site, Łańcut, Poland|Research Site, Łódź, Poland|Research Site, Łęczna, Poland|Research Site, Bacau, Romania|Research Site, Braila, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Buzau, Romania|Research Site, Cluj Napoca, Romania|Research Site, Craiova, Romania|Research Site, Deva, Romania|Research Site, Focsani, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Tg. Mures, Romania|Research Site, Timisoara, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Gatchina, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St.-Petersburg,, Russian Federation|Research Site, St.-Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, StPetersburg, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Komarno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Liptovsky Hradok, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Partizanske, Slovakia|Research Site, Piestany, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Presov, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Alberton, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Centurion, South Africa|Research Site, Durban, South Africa|Research Site, Gatesville, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kempron Park, South Africa|Research Site, Panorama, South Africa|Research Site, Parow, South Africa|Research Site, Pretoria, South Africa|Research Site, Somerset West, South Africa|Research Site, Soweto, South Africa|Research Site, Worcester, South Africa|Research Site, Almeria, Spain|Research Site, Aviles, Spain|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Don Benito (Badajoz), Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Oviedo, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Sabadell, Spain|Research Site, San Sebastian de los Reyes, Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Eksjö, Sweden|Research Site, Göteborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Linkoping, Sweden|Research Site, Ljungby, Sweden|Research Site, Lund, Sweden|Research Site, Molndal, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, Umea, Sweden|Research Site, Västerås, Sweden|Research Site, Örebro, Sweden|Research Site, Östersund, Sweden|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Mersin, Turkey|Research Site, Dnepropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnitsa, Ukraine|Research Site, Zaporozye, Ukraine|Research Site, Airdrie, United Kingdom|Research Site, Antrim, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Brighton, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, East Kilbride, United Kingdom|Research Site, Ely, United Kingdom|Research Site, Hastings, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Rotherham, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01225562"
107,"NCT01217892","Evaluation of Dapagliflozin Taken Twice-daily",,"Completed","Has Results","Type 2 Diabetes","Drug: dapagliflozin|Drug: metformin|Drug: placebo","Adjusted Mean Change in HbA1c Levels|Adjusted Percent Change in Body Weight|Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 1|Adjusted Mean Change in Fasting Plasma Glucose (FPG) From Baseline to Week 16|Proportion of Participants With HbA1c<7.0% at Week 16, in Participants Who Had HbA1c ≥7.0% at Baseline.","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1691C00003","November 2010","August 2011","August 2011","October 8, 2010","November 1, 2013","October 27, 2014","Research Site, Asslar, Germany|Research Site, Berlin, Germany|Research Site, Biberach A.d. Riss, Germany|Research Site, Bosenheim, Germany|Research Site, Dippoldiswalde, Germany|Research Site, Falkensee, Germany|Research Site, Meissen, Germany|Research Site, Munchen, Germany|Research Site, Neuwied, Germany|Research Site, Pirna, Germany|Research Site, Wahlstedt, Germany|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Csongrad, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyongyos, Hungary|Research Site, Kecskemet, Hungary|Research Site, Mako, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, TAT, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Iasi, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Dolny Kubin, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Namestovo, Slovakia|Research Site, Piestany, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Zilina, Slovakia|Research Site, Verulam, Kwa Zulu Natal, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Umkomaas, South Africa|Research Site, Chur, Graubunden, Switzerland|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Kreuzlingen, Switzerland|Research Site, Lugano, Switzerland|Research Site, Rorschach, Switzerland|Research Site, Dnipropetrov'sk, Ukraine|Research Site, Kiev, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Vynnitsa, Ukraine|Research Site, Zaporozhye, Ukraine",,"https://ClinicalTrials.gov/show/NCT01217892"
108,"NCT01204775","Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo (Saxagliptin)|Drug: Metformin IR|Drug: Placebo (Metformin)|Drug: Metformin (Active Rescue)","Mean Change in HbA1c From Baseline to Week 16","AstraZeneca","All","10 Years to 17 Years   (Child)","Phase 3","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CV181-058|2010-020360-38","June 2011","April 2016","April 2016","September 17, 2010","April 18, 2017","April 18, 2017","Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, Hollywood, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Dearborn, Michigan, United States|Research Site, Buffalo, New York, United States|Research Site, Memphis, Tennessee, United States|Research Site, Richmond, Virginia, United States|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Cape Town, South Africa|Research Site, Pretoria, South Africa|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01204775"
109,"NCT01197755","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist","OSKIRA - 3","Completed","Has Results","Rheumatoid Arthritis","Drug: fostamatinib|Drug: placebo","Proportion of Patients Achieving ACR20 at Week 24, Comparison Between Fostamatinib and Placebo|Proportion of Patients Achieving ACR20 at Week 1, Comparison Between Fostamatinib and Placebo|Proportion of Patients Achieving ACR50 at Week 24, Comparison Between Fostamatinib and Placebo|Proportion of Patients Achieving ACR70 at Week 24, Comparison Between Fostamatinib and Placebo|ACRn - Comparison Between Fostamatinib and Placebo at Week 24|Proportion of Patients Achieving DAS28-CRP <2.6 at Week 24, Comparison Between Fostamatinib and Placebo|Proportion of Patients Achieving DAS28-CRP <=3.2 at Week 12, Comparison Between Fostamatinib and Placebo|Proportion of Patients Achieving DAS28-CRP EULAR Response at Week 24, Comparison Between Fostamatinib and Placebo|Proportion of Patients With a HAQ-DI Response at Week 24 - Comparison Between Fostamatinib and Placebo|Change From Baseline to Week 24 in mTSS Score, Comparison Between Fostamatinib and Placebo|SF-36 - Comparison of the Change in PCS From Baseline Between Fostamatinib and Placebo at Week 24|SF-36 - Comparison of the Change in MCS From Baseline Between Fostamatinib and Placebo at Week 24","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","323","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4300C00003|2010-020745-27","September 2010","February 2013","February 2013","September 9, 2010","April 7, 2014","April 7, 2014","Research Site, Anniston, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Glendale, California, United States|Research Site, La Jolla, California, United States|Research Site, Long Beach, California, United States|Research Site, Palo Alto, California, United States|Research Site, Santa Maria, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Upland, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Trumbull, Connecticut, United States|Research Site, Lewes, Delaware, United States|Research Site, Brandon, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Venice, Florida, United States|Research Site, Zephyr Hills, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Canton, Georgia, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Decatur, Illinois, United States|Research Site, Cedar Rapids, Iowa, United States|Research Site, Bowling Green, Kentucky, United States|Research Site, Elizabethtown, Kentucky, United States|Research Site, Crofton, Maryland, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Lansing, Michigan, United States|Research Site, Flowood, Mississippi, United States|Research Site, Florissant, Missouri, United States|Research Site, Richmond Heights, Missouri, United States|Research Site, Las Cruces, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Olean, New York, United States|Research Site, Rochester, New York, United States|Research Site, Roslyn, New York, United States|Research Site, Smithtown, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Dayton, Ohio, United States|Research Site, Mayfield Village, Ohio, United States|Research Site, Lake Oswego, Oregon, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, West Reading, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Hixson, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tacoma, Washington, United States|Research Site, Buenos Aires, Caba, Argentina|Research Site, Cordoba, CRD, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, TUC, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Quilmes, Argentina|Research Site, Rosario, Argentina|Research Site, San Juan, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Liege, Belgium|Research Site, Yvoir, Belgium|Research Site, Porto Alegre, Brasil, Brazil|Research Site, Goiania, GO, Brazil|Research Site, Curitiba, PR, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, St John's, Newfoundland and Labrador, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Pointe-claire, Quebec, Canada|Research Site, Rimouski, Quebec, Canada|Research Site, Bruntal, Czech Republic|Research Site, Ceske Budejovice, Czech Republic|Research Site, Hlucin, Czech Republic|Research Site, Ostrava-trebovice, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Orleans Cedex 1, France|Research Site, Hamburg, HH, Germany|Research Site, Aachen, Nordrhein Westfalen, Germany|Research Site, Leipzig, SN, Germany|Research Site, Erlangen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Muenchen, Germany|Research Site, Budapest, Hungary|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Ramat Gan, Israel|Research Site, Tel-hashomer, Israel|Research Site, Jesi, AN, Italy|Research Site, Ferrara, FE, Italy|Research Site, Obrergon, SON, Mexico|Research Site, Chihuahua, Mexico|Research Site, DF, Mexico|Research Site, Monterrey, Mexico|Research Site, Saltillo, Mexico|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Cape Town, South Africa|Research Site, Pretoria, South Africa|Research Site, Stellenbosch, South Africa|Research Site, Barcelona, Spain|Research Site, Reading, Berkshire, United Kingdom|Research Site, Warrington, Cheshire, United Kingdom|Research Site, Maidstone, Kent, United Kingdom|Research Site, Eastbourne, Sussex, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Christchurch, United Kingdom|Research Site, Ipswich, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Westcliff-on-the Sea, United Kingdom|Research Site, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01197755"
110,"NCT01197534","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.","OSKIRA - 2","Completed","Has Results","Rheumatoid Arthritis","Drug: fostamatinib|Drug: placebo, fostamatinib","Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo|Proportion of Patients Achieving ACR20, Comparison Between Fostamatinib and Placebo at Week 1|Proportion of Patients Achieving ACR50, Comparison Between Fostamatinib and Placebo at Week 24|Proportion of Patients Achieving ACR70, Comparison Between Fostamatinib and Placebo at Week 24|ACRn - Comparison Between Fostamatinib and Placebo at Week 24|Proportion of Patients Achieving DAS28-CRP <2.6 at Week 12, Comparison Between Fostamatinib and Placebo|Proportion of Patients Achieving DAS28-CRP <2.6 at Week 24, Comparison Between Fostamatinib and Placebo|Proportion of Patients Achieving DAS28 EULAR Response at Week 24|HAQ-DI Response - Comparison of the Change(>=0.22) From Baseline Between Fostamatinib and Placebo at Week 24|Change From Baseline to Week 24 in mTSS, Comparison Between Fostamatinib and Placebo|SF-36 - Comparison of the Change in PCS From Baseline Between Fostamatinib and Placebo at Week 24|SF-36 - Comparison of the Change in MCS From Baseline Between Fostamatinib and Placebo at Week 24","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","913","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4300C00002|2010-020744-35","September 2010","March 2013","March 2013","September 9, 2010","April 17, 2014","April 17, 2014","Research Site, Birmingham, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Mesa, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Huntington Beach, California, United States|Research Site, Torrance, California, United States|Research Site, Trumbull, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boca Raton, Florida, United States|Research Site, Brandon, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Venice, Florida, United States|Research Site, Zephyr Hills, Florida, United States|Research Site, Canton, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, South Bend, Indiana, United States|Research Site, Elizabethtown, Kentucky, United States|Research Site, Crofton, Maryland, United States|Research Site, Cumberland, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Flowood, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Kalispell, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Manalapan, New Jersey, United States|Research Site, Las Cruces, New Mexico, United States|Research Site, Brooklyn, New York, United States|Research Site, Rochester, New York, United States|Research Site, Roslyn, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Dayton, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, West Reading, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Edmonton, Alberta, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Bowmanville, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Trois-rivieres, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Reading, Canada|Research Site, Brno, Czech Republic|Research Site, Bruntal, Czech Republic|Research Site, Ceska Lipa, Czech Republic|Research Site, Ceske Budejovice, Czech Republic|Research Site, Hlucin, Czech Republic|Research Site, Liberec, Czech Republic|Research Site, Ostrava - Trebovice, Czech Republic|Research Site, Praha 11, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Sokolov, Czech Republic|Research Site, Terezin, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Erlangen, Germany|Research Site, Hamburg, Germany|Research Site, Muenchen, Germany|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Gandhinagar, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Mumbai, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Coimbatore, Tamil Nadu, India|Research Site, Madurai, Tamil Nadu, India|Research Site, Lucknow, India|Research Site, Ashkelon, Israel|Research Site, Beer Yaakov, Israel|Research Site, Haifa, Israel|Research Site, Kfar-saba, Israel|Research Site, Petah-tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Ramat-gan, Israel|Research Site, Rehovot, Israel|Research Site, Tel Aviv, Israel|Research Site, Jesi, AN, Italy|Research Site, Legnano, MI, Italy|Research Site, Udine, UD, Italy|Research Site, Varese, VA, Italy|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Valmiera, Latvia|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Siauliai, Lithuania|Research Site, Aveiro, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Baia Mare, Romania|Research Site, Brailari, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Ploiesti, Romania|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Niska Banja, Serbia|Research Site, Novi Sad, Serbia|Research Site, Kempron Park, Gauteng, South Africa|Research Site, Pretoria, Gauteng, South Africa|Research Site, Durban, Kz-natal, South Africa|Research Site, Cape Town, W Cape, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Stellenbosch, South Africa|Research Site, La Laguna (tenerife), Canarias, Spain|Research Site, Merida, Extremadura, Spain|Research Site, Barcelona, Spain|Research Site, Getafe, Spain|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Simferopol, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporyzhzhya, Ukraine|Research Site, Maidstone, Kent, United Kingdom|Research Site, Eastbourne, Sussex, United Kingdom|Research Site, Solihull, West Midlands, United Kingdom|Research Site, Basingstoke, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, London, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Stoke on Trent, United Kingdom|Research Site, Swindon, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01197534"
111,"NCT01197521","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.","OSKIRA - 1","Completed","Has Results","Rheumatoid Arthritis","Drug: fostamatinib|Drug: placebo, fostamatinib","Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo.|Change From Baseline to Week 24 in mTSS, Comparison Between Fostamatinib and Placebo.|ACR20 - Proportion of Patients Achieving ACR20, Comparison Between Fostamatinib and Placebo at Week 1|Proportion of Patients Achieving ACR50 up to Week 24|Proportion of Patients Achieving ACR70 up to Week 24|ACRn - Comparison Between Fostamatinib and Placebo at Week 24|Proportion of Patients Achieving DAS28-CRP <2.6 at Week 12|Proportion of Patients Achieving DAS28-CRP <2.6 at Week 24|Proportion of Patients Achieving DAS28-CRP EULAR Response at Week 24|HAQ-DI Response - Comparison of the Change (>=0.22) From Baseline Between Fostamatinib and Placebo at Week 24|SF-36 - Comparison of the Change in PCS From Baseline Between Fostamatinib and Placebo at Week 24|SF-36 - Comparison of the Change in MCS From Baseline Between Fostamatinib and Placebo at Week 24","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","923","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4300C00001|2010-020743-12","September 2010","November 2012","November 2012","September 9, 2010","April 7, 2014","April 7, 2014","Research Site, Anniston, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Huntington Beach, California, United States|Research Site, Long Beach, California, United States|Research Site, Santa Maria, California, United States|Research Site, Santa Monica, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Lewes, Delaware, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Springfield, Illinois, United States|Research Site, Wichita, Kansas, United States|Research Site, Bowling Green, Kentucky, United States|Research Site, Flowood, Mississippi, United States|Research Site, Florissant, Missouri, United States|Research Site, Richmond Heights, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Kalispell, Montana, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Olean, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Perrysburg, Ohio, United States|Research Site, Lake Oswego, Oregon, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Waxford, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Hixson, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Reading, Berkshire, Argentina|Research Site, Buenos Aires, Caba, Argentina|Research Site, Ciudad Autonoma Bs As, CBA, Argentina|Research Site, Cordoba, CRD, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, TUC, Argentina|Research Site, Caba, Argentina|Research Site, Quilmes, Argentina|Research Site, San Juan, Argentina|Research Site, Camperdown, New South Wales, Australia|Research Site, Cairns, Queensland, Australia|Research Site, Southport, Queensland, Australia|Research Site, Brussels, Belgium|Research Site, Yvoir, Belgium|Research Site, Vitoria, ES, Brazil|Research Site, Recife, PE, Brazil|Research Site, Curitiba, PR, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Osorno, X Region, Chile|Research Site, Santiago, Chile|Research Site, Parnu, Estonia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Orleans Cedex 1, France|Research Site, Paris Cedex 13, France|Research Site, Balatonfured, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Mako, Hungary|Research Site, Sopron, Hungary|Research Site, Szentes, Hungary|Research Site, Zalaegerszeg-pozva, Hungary|Research Site, Secunderabad, Andhra Pradesh, India|Research Site, Vishakhapatnam, Andhra Pradesh, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Udupi, Karnataka, India|Research Site, Nagpur, Maharshtra, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Calcutta, India|Research Site, Hyderabad, India|Research Site, Saltillo, Coahuila, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Guadalajara, JAL, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, Obrergon, SON, Mexico|Research Site, Chihuahua, Mexico|Research Site, Mexicali, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, Pueblo Libre, Lima, Peru|Research Site, Arequipa, Peru|Research Site, Lima, Peru|Research Site, Bytom, Poland|Research Site, Chelm Slaski, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Zyrardow, Poland|Research Site, Bratislava, Slovakia|Research Site, Poprad, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Zilina, Slovakia|Research Site, Donetsk, Ukraine|Research Site, Ivano-frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Vinnytsya, Ukraine|Research Site, Zaporyzhzhya, Ukraine|Research Site, Warrington, Cheshire, United Kingdom|Research Site, Christchurch, United Kingdom|Research Site, Ipswich, United Kingdom|Research Site, London, United Kingdom|Research Site, Westcliff-on-the Sea, United Kingdom|Research Site, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01197521"
112,"NCT01197508","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.",,"Completed","Has Results","Major Depressive Disorder","Drug: TC-5214|Drug: Placebo","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.|Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)|Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)|Early and Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 10, Week 12, Week 14, and End of Treatment (Week 16)|Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)|Sustained Remission, Defined as a MADRS Total Score of ≤8 at Week 12, Week 14, and End of Treatment (Week 16)|Change in Depressive Symptoms From Randomization (Week 8) to End of Treatment (Week 16) as Measured by Hamilton Rating Scale for Depression-17 Items (HAMD-17) Total Score|Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 8) to End of Treatment (Week 16)|Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"" From Randomization (Week 8) to End of Treatment (Week 16)|Change in Hamilton Anxiety Scale (HAM-A) Total Score From Randomization (Week 8) to End of Treatment (Week 16)|Change in MADRS Total Score From Randomization (Week 8) to Week 9|Change in MADRS Total Score From Randomization (Week 8) to Week 10|Change in MADRS Total Score From Randomization (Week 8) to Week 12|Change in MADRS Total Score From Randomization (Week 8) to Week 14|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by the Sheehan Disability Scale (SDS) Total Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Work/School Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Social Life Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Family Life/Home Responsibilities Domain Score|Change in Overall Quality of Life and Satisfaction From Randomization (Week 8) to End of Treatment (Week 16) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 15|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 16|Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 8) to End of Treatment (Week 16)","AstraZeneca|Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","696","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4130C00005","September 2010","January 2012","January 2012","September 9, 2010","October 29, 2012","April 11, 2014","Research Site, Buenos Aires, Caba, Argentina|Research Site, Ciudad Autonoma Bs As, Cba, Argentina|Research Site, Dublin, Argentina|Research Site, Mendoza, Argentina|Research Site, Rio de Janeiro, Brazil|Research Site, Novi Iskar, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Antofagasta, Chile|Research Site, Providencia Santiago, Chile|Research Site, Santiago, Chile|Research Site, Bello, Antioquia, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Pereira, Risaralda, Colombia|Research Site, Cali, Valle, Colombia|Research Site, Rijeka, Croatia|Research Site, Bully Les Mines, France|Research Site, Caen, France|Research Site, Cherbourg, France|Research Site, Colmar Cedex, France|Research Site, Dole Cedex, France|Research Site, Douai, France|Research Site, Elancourt, France|Research Site, Montpellier, France|Research Site, Sartrouville, France|Research Site, Strasbourg, France|Research Site, Toulon, France|Research Site, Toulouse, France|Research Site, Tours Cedex 9, France|Research Site, Huttenberg, HE, Germany|Research Site, Bad Homburg, Germany|Research Site, Bielefeld, Germany|Research Site, Gelsenkirchen, Germany|Research Site, Schwerin, Germany|Research Site, Siegen, Germany|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Leszno, Poland|Research Site, Lublin, Poland|Research Site, Torun, Poland|Research Site, Arad, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Cluj-napoca, Romania|Research Site, Focsani, Romania|Research Site, Oradea, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Chita, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Kragujevac, Serbia and Montenegro, Serbia|Research Site, NIS, Serbia|Research Site, Banska Stiavnica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Levice, Slovakia|Research Site, Presov, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Svidnik, Slovakia|Research Site, Trencin, Slovakia|Research Site, Bloemfontein, Free State, South Africa|Research Site, Vereeniging, Free State, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Centurion, South Africa|Research Site, Durban, South Africa|Research Site, George, South Africa|Research Site, Paarl, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Sama de Langreo, Asturias, Spain|Research Site, Alcala de Henares, Madrid, Spain|Research Site, Coslada, Madrid, Spain|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kherson, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Simferpool, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01197508"
113,"NCT01195662","A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Placebo matching Dapagliflozin","Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants|Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) for 12 Week Double-Blind Treatment Period - Randomized Participants|Adjusted Mean Change From Baseline in 24-hour Ambulatory Systolic Blood Pressure at Week 12 Last Observation Carried Forward (LOCF)|Adjusted Mean Change From Baseline in Seated Diastolic Blood Pressure (DBP) for 12 Week Double-Blind Treatment Period - Randomized Participants|Adjusted Mean Change From Baseline in 24-hr Ambulatory Diastolic Blood Pressure at Week 12 (LOCF)|Adjusted Mean Change From Baseline in Serum Uric Acid at Week 12 in Double-Blind Treatment Period - Randomized Participants|Number of Participants With Deaths,Serious Adverse Events (SAEs), Adverse Events (AEs), Hypoglycemia Events, Discontinuation Due to AEs, SAEs and Hypoglycemia, During the 12 Week Double Blind Period, Including Data After Rescue|Number of Participants With Marked Chemistry Laboratory Abnormalities in 12 Week Double Blind Treatment Period, Including Data After Rescue|Number of Participants With Elevated Liver Laboratory Tests in Participants Treated With Double Blind 10 mg Dapagliflozin or Placebo , Including Data After Rescue|Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 12 (LOCF), Including Data After Rescue|Proportion of Participants With Orthostatic Hypotension at Baseline and Week 12, Including Data After Rescue","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 3","2245","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MB102-077 ST|2010-019798-13","October 2010","February 2013","February 2013","September 6, 2010","May 23, 2014","December 29, 2016","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States|Wilmax Clinical Research, Inc., Mobile, Alabama, United States|43rd Medical Associates, Phoenix, Arizona, United States|Central Phoenix Medical Center, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Mesa Family Med Ctr, Pc, Tempe, Arizona, United States|Clinical Research Advantage/Desert Clinical Research, Tempe, Arizona, United States|Visions Clinical Research - Tucson, Tucson, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Aureus Research, Inc., Little Rock, Arkansas, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Cmp Research, Anaheim, California, United States|Catalina Research Institute, Llc, Chino, California, United States|Southland Clinical Research Center, Inc., Fountain Valley, California, United States|Marin Endocrine Care & Research, Inc., Greenbrae, California, United States|Del Rosario Medical Clinic, Inc., Huntington Park, California, United States|Time Clinical Research Inc., Huntington Park, California, United States|Clinica Medica San Miguel, Los Angeles, California, United States|American Institute Of Research, Los Angeles, California, United States|Randall G. Shue, D.O., Los Angeles, California, United States|Mcs Clinical Trials, Los Angeles, California, United States|National Research Inst, Los Angeles, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Valley Clinical Trials, Northridge, California, United States|Lucita M. Cruz,Md.,Inc., Norwalk, California, United States|Sds Clinical Trials, Orange, California, United States|Bayview Research Group, Llc, Paramount, California, United States|San Diego Managed Care Group, Poway, California, United States|Integrated Research Group, Inc., Riverside, California, United States|Quality Control Research, Inc, Sacramento, California, United States|Wetlin Research Associates, Inc., San Diego, California, United States|Crest Clinical Trials, Inc., Santa Ana, California, United States|Neurological Research Institute, Santa Monica, California, United States|Orrin M. Troum, Md And Medical Associates, Santa Monica, California, United States|Torrance Clinical Research, Torrance, California, United States|Orange County Research Center, Tustin, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Chase Medical Research, Llc, Waterbury, Connecticut, United States|Christiana Care Health Services, Inc, Newark, Delaware, United States|Zasa Clinical Research, Boynton Beach, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Innovative Research Of West Florida, Inc, Clearwater, Florida, United States|Clinical Research Of South Florida, Coral Gables, Florida, United States|Avail Clinical Research, Llc, Deland, Florida, United States|International Research Associates, Llc, Hialeah, Florida, United States|Palm Springs Research Institute, Hialeah, Florida, United States|The Community Research Of South Florida, Hialeah, Florida, United States|Central Florida Internists, Kissimmee, Florida, United States|Newphase Clinical Trials, Inc., Miami Beach, Florida, United States|Ocean Blue Medical Research Center, Inc., Miami Springs, Florida, United States|Flcri Global Research, Llc, Miami, Florida, United States|Clinical Research Of Miami, Inc., Miami, Florida, United States|Pharmax Research Clinic, Inc., Miami, Florida, United States|Apf Research, Llc, Miami, Florida, United States|Community Research Foundation, Inc., Miami, Florida, United States|Baptist Diabetes Associates, Pa, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Florida Institute For Clinical Research, Llc, Orlando, Florida, United States|Michele A. Morrison Internal Medicine, Inc., Pembroke Pines, Florida, United States|Medsol Clinical Research Center, Port Charlotte, Florida, United States|Meridien Research, Tampa, Florida, United States|Perimeter Institute For Clinical Research, Atlanta, Georgia, United States|Bainbridge Medical Associates, Bainbridge, Georgia, United States|River Birch Research Alliance, Llc, Blue Ridge, Georgia, United States|In-Quest Medical Research, Llc, Duluth, Georgia, United States|Middle Georgia Drug Study Center, Llc, Perry, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|So. Illinois Clin Res Ctr @ Div Of Kevin L Pritchett Md, Pc, O?Fallon, Illinois, United States|Springfield Diabetes And Endocrine Center, Springfield, Illinois, United States|American Health Network Of Indiana Llc, Avon, Indiana, United States|Investigators Research Group, Llc, Brownsburg, Indiana, United States|American Health Network Of In Llc, Franklin, Indiana, United States|Laporte County Institute For Clinical Research, Inc., Michigan City, Indiana, United States|American Health Network Of In Llc, Muncie, Indiana, United States|Medical Development Centers, Llc, Baton Rouge, Louisiana, United States|Omega Clinical Research, Llc, Metairie, Louisiana, United States|Acadia Clinical Research, Llc, Bangor, Maine, United States|Alternative Primary Care, Silver Spring, Maryland, United States|Hci-Metromedic Walk-In Medical Office, New Bedford, Massachusetts, United States|Neurocare, Inc., Newton, Massachusetts, United States|Atlantic Clinical Trials, Llc, Watertown, Massachusetts, United States|Providence Park Clinical Research, Novi, Michigan, United States|The Center For Clinical Trials, Biloxi, Mississippi, United States|Phillips Medical Services, Pllc, Jackson, Mississippi, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|Kcumb Dybedal Clinical Research Center, Kansas City, Missouri, United States|Clin Research Advantage, Inc. James Meli, Do Family Pracice, Henderson, Nevada, United States|Office Of Ted Thorp, Md, Las Vegas, Nevada, United States|Independent Clinical Researchers@ Wolfson Medical Center, Las Vegas, Nevada, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|Palm Medical Research Center, Las Vegas, Nevada, United States|Comprehensive Clinical Research, Berlin, New Jersey, United States|Premier Research, Trenton, New Jersey, United States|Medex Healthcare Research, Inc., New York, New York, United States|Digiovanna Institute For Medical Education & Research, North Massapequa, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Diabetes & Endocrinology Consultants, Morehead City, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Lillestol Research, Fargo, North Dakota, United States|Community Health Care, Inc., Canal Fulton, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Parsons Avenue Medical Clinical, Columbus, Ohio, United States|Clinical Research Source, Inc, Perrysburg, Ohio, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Integris Family Care Yukon, Yukon, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Southeastern Pa Medical Institute, Broomall, Pennsylvania, United States|Abington Memorial Hos/Feasterville Family Health Care Center, Feasterville, Pennsylvania, United States|The Clinical Trial Center, Llc, Jenkintown, Pennsylvania, United States|Arcuri Clinical Research Llc, Philadelphia, Pennsylvania, United States|Philadelphia Health Associates - Adult Medicine, Philadelphia, Pennsylvania, United States|Research Across America, Reading, Pennsylvania, United States|Pish Medical Associates, Uniontown, Pennsylvania, United States|Greater Providence Clinical Research, Llc, Warwick, Rhode Island, United States|Medical Research South, Charleston, South Carolina, United States|Southeastern Research Associates, Inc., Greenville, South Carolina, United States|North Myrtle Beach Family Practice, North Myrtle Beach, South Carolina, United States|Pawleys Pediatrics And Adult Medicine, Pawleys Island, South Carolina, United States|Hillcrest Clinical Reseach, Llc, Simpsonville, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Southwind Medical Specialists, Memphis, Tennessee, United States|Tn Medical Research, Spring Hill, Tennessee, United States|Arlington Family Research Center, Inc., Arlington, Texas, United States|3rd Coast Research Associates, Corpus Christi, Texas, United States|Krk Medical Research, Dallas, Texas, United States|Research Institute Of Dallas, Dallas, Texas, United States|Internal Medicine Clinical Reaseach, Dallas, Texas, United States|Renaissance Clinical Research And Hypertension Pllc, Dallas, Texas, United States|Sergio F. Rovner, M.D., El Paso, Texas, United States|Pioneer Research Solutions, Inc., Houston, Texas, United States|Village Family Practice, Houston, Texas, United States|Dependable Clinical Research, Llc, Houston, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Bellaire Medical Care Group, Houston, Texas, United States|Excel Clinical Research, Llc, Houston, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|North Hills Medical Research, Inc., North Richland Hills, Texas, United States|Med-Olam Clinical Research, Pasadena, Texas, United States|Lisa E. Medwedeff, Md, Pa, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Abbott Clinical Research Group, Inc., San Antonio, Texas, United States|Covenant Clinical Research, Pa, San Antonio, Texas, United States|Innovative Clinical Trials, San Antonio, Texas, United States|Breco Research, Ltd, Sugarland, Texas, United States|Exodus Healthcare Network, Magna, Utah, United States|Wasatch Endocrinology And Diabetes Specialists, Salt Lake City, Utah, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Alexandria Health Care Center, Alexandria, Virginia, United States|Millennium Clinical Trials Llc, Arlington, Virginia, United States|Burke Internal Medicine And Research, Burke, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Hampton Roads Center For Clinical Research, Inc., Suffolk, Virginia, United States|Larry D. Stonesifer, Md, Federal Way, Washington, United States|Sound Medical Research, Port Orchard, Washington, United States|Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Kelowona, British Columbia, Canada|Local Institution, Victoria, British Columbia, Canada|Local Institution, Monction, New Brunswick, Canada|Local Institution, Brampton, Ontario, Canada|Local Institution, Granby, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Armenia, Quindio, Colombia|Local Institution, Bucaramanga, Santander, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Bogota, Colombia|Local Institution, Beroun, Czech Republic|Local Institution, Cheb, Czech Republic|Local Institution, Havirov, Czech Republic|Local Institution, Krnov, Czech Republic|Local Institution, Liberec, Czech Republic|Local Institution, Ostrava, Czech Republic|Local Institution, Prague 1, Czech Republic|Local Institution, Praha 4, Czech Republic|Local Institution, Copenhagen, Denmark|Local Institution, Frederiksberg, Denmark|Local Institution, Gentofte, Denmark|Local Institution, Slagelse, Denmark|Local Institution, Helsinki, Finland|Local Institution, Kerava, Finland|Local Institution, Kokkola, Finland|Local Institution, Oulu, Finland|Local Institution, Aschaffenburg, Bavaria, Germany|Local Institution, Augsburg, Bavaria, Germany|Local Institution, Duisburg, Nordrhein-Westfalen, Germany|Local Institution, Bad Kreuznach, Germany|Local Institution, Berlin, Germany|Local Institution, Dortmund, Germany|Local Institution, Dresden, Germany|Local Institution, Karlsruhe, Germany|Local Institution, Kothen, Germany|Local Institution, Kronshagen, Germany|Local Institution, Langenfeld, Germany|Local Institution, Lueneburg, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Saarbruecken, Germany|Local Institution, Wuestensachsen, Germany|Local Institution, Gyongyos, Heves, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Eger, Hungary|Local Institution, Kisvarda, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Nyiregyhaza, Hungary|Local Institution, Satoraljaujhely, Hungary|Local Institution, Sopron, Hungary|Local Institution, Szeged, Hungary|Local Institution, Szekszard, Hungary|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Mangalore, Karnataka, India|Local Institution, Belgaum, Karnatka, India|Local Institution, Indore, Madhya Pradesh, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Delhi, New Delhi, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Chennai, Tamil Nadu, India|Local Institution, Coimbatore, Tamil Nadu, India|Local Institution, Madurai, Tamilnadu, India|Local Institution, Chennai Tamilnadu, India|Local Institution, Hyderabad, India|Local Institution, Nagpur, India|Local Institution, Trivandrum, India|Local Institution, Dublin 15, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Torreon, Coahuila, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuautla, Morelos, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Culiacan, Sinaloa, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, Del. Benito Juarez, Mexico|Local Institution, Delegacion Tlalpan, Mexico|Local Institution, Distrito Federal, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Bialystok, Poland|Local Institution, Bialystok, Poland|Local Institution, Chrzanow, Poland|Local Institution, Elblag, Poland|Local Institution, Gdansk, Poland|Local Institution, Gdynia, Poland|Local Institution, Kamieniec Zabkowicki, Poland|Local Institution, Katowice, Poland|Local Institution, Kielce, Poland|Local Institution, Krakow, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Lodz, Poland|Local Institution, Lublin, Poland|Local Institution, Ostroda, Poland|Local Institution, Poznan, Poland|Local Institution, Warsaw, Poland|Local Institution, Warsaw, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Wroclaw, Poland|Local Institution, Zabrze, Poland|Local Institution, Fajard, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Oradea, Bihor, Romania|Local Institution, Oradea, Jud. Bihor, Romania|Local Institution, Timisoara, Jud. Timis, Romania|Local Institution, Targu Mures, Mures, Romania|Local Institution, Targu Mures, Mures, Romania|Local Institution, Ploiesti, Prahova, Romania|Local Institution, Ploiesti, Prahova, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Satu Mare, Romania|Local Institution, Sibiu, Romania|Local Institution, Sibiu, Romania|Local Institution, Irvine, Ayrshire, United Kingdom|Local Institution, Ely, Cambridgeshire, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom|Local Institution, Bath, Wiltshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01195662"
114,"NCT01180400","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder|Depression","Drug: TC-5214|Drug: Placebo","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.|Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)|Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)|Early and Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 10, Week 12, Week 14, and End of Treatment (Week 16)|Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)|Sustained Remission, Defined as a MADRS Total Score of ≤8 at Week 12, Week 14, and End of Treatment (Week 16)|Change in Depressive Symptoms From Randomization (Week 8) to End of Treatment (Week 16) as Measured by Hamilton Rating Scale for Depression-17 Items (HAMD-17) Total Score|Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 8) to End of Treatment (Week 16)|Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"" From Randomization (Week 8) to End of Treatment (Week 16)|Change in MADRS Total Score From Randomization (Week 8) to Week 9|Change in MADRS Total Score From Randomization (Week 8) to Week 10|Change in MADRS Total Score From Randomization (Week 8) to Week 12|Change in MADRS Total Score From Randomization (Week 8) to Week 14|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by the Sheehan Disability Scale (SDS) Total Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Work/School Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Social Life Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Family Life/Home Responsibilities Domain Score|Change in Overall Quality of Life and Satisfaction From Randomization (Week 8) to End of Treatment (Week 16) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 15|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 16|Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 8) to End of Treatment (Week 16)","AstraZeneca|Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","295","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4130C00003","September 2010","September 2011","September 2011","August 12, 2010","November 20, 2012","April 11, 2014","Research Site, Brno, Czech Republic|Research Site, Kutna Hora, Czech Republic|Research Site, Litomerice, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha 10 - Strasnice, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Praha 8, Czech Republic|Research Site, Praha 9, Czech Republic|Research Site, Dublin, Estonia|Research Site, Tallinn, Estonia|Research Site, Tallin, Estonia|Research Site, Tartu, Estonia|Research Site, Voru, Estonia|Research Site, Dublin, Finland|Research Site, Espoo, Finland|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Mikkeli, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Toulon, La Seyne Sur Mer, France|Research Site, Douai, France|Research Site, Dublin, France|Research Site, Elancourt, France|Research Site, Jarnac, France|Research Site, La Seyne Sur Mer, France|Research Site, Nimes Cedex 9, France|Research Site, Rennes, France|Research Site, Toulon, France|Research Site, Villejuif, France|Research Site, Mainz, Rp, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Dublin, Germany|Research Site, Siegen, Germany|Research Site, Dublin, Hungary|Research Site, Dublin, Latvia|Research Site, Jelgava, Latvia|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Sigulda, Latvia|Research Site, Strenci, Latvia|Research Site, Ziegzdrai, Kaunas, Lithuania|Research Site, Dublin, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Palanga, Lithuania|Research Site, Silute, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Belchatow, Poland|Research Site, Bialystok, Poland|Research Site, Bydgoszczy, Poland|Research Site, Dublin, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Leszno, Poland|Research Site, Lublin, Poland|Research Site, Sosnowiec, Poland|Research Site, Torun, Poland|Research Site, Toru, Poland|Research Site, Zuromin, Poland|Research Site, Dublin, Sweden|Research Site, Goteborg, Sweden|Research Site, Halmstad, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Solna, Sweden|Research Site, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01180400"
115,"NCT01157078","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)",,"Completed","Has Results","Major Depressive Disorder|Depression","Drug: TC-5214|Drug: Placebo","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.|Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)|Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)|Early and Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 10, Week 12, Week 14, and End of Treatment (Week 16)|Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)|Sustained Remission, Defined as a MADRS Total Score of ≤8 at Week 12, Week 14, and End of Treatment (Week 16)|Change in Depressive Symptoms From Randomization (Week 8) to End of Treatment (Week 16) as Measured by Hamilton Rating Scale for Depression-17 Items (HAMD-17) Total Score|Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 8) to End of Treatment (Week 16)|Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"" From Randomization (Week 8) to End of Treatment (Week 16)|Change in MADRS Total Score From Randomization (Week 8) to Week 9|Change in MADRS Total Score From Randomization (Week 8) to Week 10|Change in MADRS Total Score From Randomization (Week 8) to Week 12|Change in MADRS Total Score From Randomization (Week 8) to Week 14|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by the Sheehan Disability Scale (SDS) Total Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Work/School Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Social Life Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Family Life/Home Responsibilities Domain Score|Change in Overall Quality of Life and Satisfaction From Randomization (Week 8) to End of Treatment (Week 16) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 15|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 16|Change in Irritability Symptoms as Measured by the Sheehan Irritability Scale (SIS) Total Score From Randomization (Week 8) to End of Treatment (Week 16)|Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 8) to End of Treatment (Week 16)","AstraZeneca|Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","319","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4130C00002","June 2010","November 2011","November 2011","July 5, 2010","November 20, 2012","April 11, 2014","Research Site, Tuscaloosa, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Chino, California, United States|Research Site, Costa Mesa, California, United States|Research Site, Encino, California, United States|Research Site, Escondido, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Oceanside, California, United States|Research Site, Pico Rivera, California, United States|Research Site, San Diego, California, United States|Research Site, Torrance, California, United States|Research Site, Hamden, Connecticut, United States|Research Site, Coral Springs, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Florence, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, St. Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Salem, Oregon, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Woodstock, Vermont, United States|Research Site, Seattle, Washington, United States|Research Site, Visakhapatnam, Andh Prad, India|Research Site, Guntur, Andhra Pradesh, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Rajkot, Gujrat, India|Research Site, Mangalore, Karnataka, India|Research Site, Aurangabad, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Nashik, Mahara, India|Research Site, Jaipur, Rajasthan, India|Research Site, Khatipura, Rajasthan, India|Research Site, Madurai, Tamilnadu, India|Research Site, Varanasi, Uttar Prad, India|Research Site, Kanpur, India|Research Site, Mysore, India",,"https://ClinicalTrials.gov/show/NCT01157078"
116,"NCT01153347","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder|Depression","Drug: TC-5214|Drug: Placebo","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.|Response in Depressive Symptoms of Major Depressive Disorder (MDD), Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score at End of Treatment (Week 16)|Remission in Depressive Symptoms of MDD, Defined as MADRS Total Score of ≤8 at End of Treatment (Week 16)|Early and Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 10, Week 12, Week 14, and End of Treatment (Week 16)|Sustained Response, Defined as a ≥50% Reduction From Randomization (Week 8) in MADRS Total Score and a MADRS Total Score of ≤12 at Week 12, Week 14, and End of Treatment (Week 16)|Sustained Remission, Defined as a MADRS Total Score of ≤8 at Week 12, Week 14, and End of Treatment (Week 16)|Change in Depressive Symptoms From Randomization (Week 8) to End of Treatment (Week 16) as Measured by Hamilton Rating Scale for Depression-17 Items (HAMD-17) Total Score|Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 8) to End of Treatment (Week 16)|Response in the Clinical Global Impression-Improvement (CGI-I) Defined as CGI-I Rating of ""Very Much Improved"" or ""Much Improved"" From Randomization (Week 8) to End of Treatment (Week 16)|Change in Hamilton Anxiety Scale (HAM-A) Total Score From Randomization (Week 8) to End of Treatment (Week 16)|Change in MADRS Total Score From Randomization (Week 8) to Week 9|Change in MADRS Total Score From Randomization (Week 8) to Week 10|Change in MADRS Total Score From Randomization (Week 8) to Week 12|Change in MADRS Total Score From Randomization (Week 8) to Week 14|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by the Sheehan Disability Scale (SDS) Total Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Work/School Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Social Life Domain Score|Change in Functional Impairment From Randomization (Week 8) to End of Treatment (Week 16) as Measured by SDS Family Life/Home Responsibilities Domain Score|Change in Overall Quality of Life and Satisfaction From Randomization (Week 8) to End of Treatment (Week 16) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form(Q LES-Q-SF)Item 15|Change From Randomization (Week 8) to End of Treatment (Week 16) in Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q LES-Q-SF) Item 16|Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 8) to End of Treatment (Week 16)|Change in Irritability Symptoms as Measured by the Sheehan Irritability Scale (SIS) Total Score From Randomization (Week 8) to End of Treatment (Week 16)","AstraZeneca|Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2409","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4130C00004","June 2010","January 2012","January 2012","June 30, 2010","November 20, 2012","April 11, 2014","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Conway, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Arcadia, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Garden Grove, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Oakland, California, United States|Research Site, Oceanside, California, United States|Research Site, Pico Rivera, California, United States|Research Site, Santa Ana, California, United States|Research Site, Upland, California, United States|Research Site, Denver, Colorado, United States|Research Site, Cromwell, Connecticut, United States|Research Site, New London, Connecticut, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Bradenton, Florida, United States|Research Site, Ft Myers, Florida, United States|Research Site, Ft Walton Beach, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Schaumburg, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Florence, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Gaithersburg, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Weymouth, Massachusetts, United States|Research Site, Flowood, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, North Platte, Nebraska, United States|Research Site, Toms River, New Jersey, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Mount Kisco, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Avon Lake, Ohio, United States|Research Site, Beachwood, Ohio, United States|Research Site, Beechwood, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Mason, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sellersvillle, Pennsylvania, United States|Research Site, Lincoln, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Irving, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Bellevue, Washington, United States|Research Site, Bothell, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, South Kirkland, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Guntur, Andhra Pradesh, India|Research Site, Vijayawada, Andhra Pradesh, India|Research Site, Vishakhapatnam, Andhra Pradesh, India|Research Site, Anand, Gujarat, India|Research Site, Junagadh, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Rajkot, Gujrat, India|Research Site, Bangalore, Karnataka, India|Research Site, Aurangabad, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Nashik, Mahara, India|Research Site, Durham, NC, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Madurai, Tamilnadu, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Varanasi, Uttar Prad, India|Research Site, Kanpur, India|Research Site, Karnataka, India|Research Site, Mysore, India|Research Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01153347"
117,"NCT01152554","A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder|MDD|Depression","Drug: TC-5214|Drug: Placebo","Frequency of Patients Experiencing at Least One Adverse Event (AE)|Frequency of Patients Experiencing AEs That Resulted in Discontinuation of Investigational Product (IP)|Frequency of Patients Experiencing Serious Adverse Events (SAEs)|Sustained Efficacy at 3 Months, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤12 at Week 12 and All Visits up to and Including Week 24|Sustained Efficacy at 9 Months, Defined as a MADRS Total Score of ≤12 at Week 12 and at All Visits up to and Including Week 52|Change in the Clinician-rated Global Outcome of Severity as Measured by the Clinical Global Impression-Severity (CGI-S) Score From Randomization (Week 0) to End of Treatment (Week 52)|Change in Functional Impairment From Randomization (Week 0) to End of Treatment (Week 52) as Measured by the Sheehan Disability Scale (SDS) Total Score|Change in Overall Quality of Life and Satisfaction From Randomization (Week 0) to End of Treatment (Week 52) by Assessing the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) % Maximum Total Score|Change in EuroQol - 5 Dimensions (EQ-5D) From Randomization (Week 0) to End of Treatment (Week 52)","AstraZeneca|Targacept Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","813","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4130C00007","June 2010","February 2012","February 2012","June 29, 2010","October 29, 2012","April 11, 2014","Research Site, Birmingham, Alabama, United States|Research Site, Tuscaloosa, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Arcadia, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Carson, California, United States|Research Site, Cerritos, California, United States|Research Site, Chino, California, United States|Research Site, Costa Mesa, California, United States|Research Site, Encino, California, United States|Research Site, Escondido, California, United States|Research Site, Garden Grove, California, United States|Research Site, Irvine, California, United States|Research Site, Los Alamitos, California, United States|Research Site, Los Angeles, California, United States|Research Site, Newport Beach, California, United States|Research Site, Pico Rivera, California, United States|Research Site, Riverside, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Torrance, California, United States|Research Site, Upland, California, United States|Research Site, Denver, Colorado, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Norwich, Connecticut, United States|Research Site, Bradenton, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Ft Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pinecrest, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Roswell, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Schaumburg, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Lafayette, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Florence, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Gaithersburg, Maryland, United States|Research Site, Glen Burnie, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Weymouth, Massachusetts, United States|Research Site, Flowood, Mississippi, United States|Research Site, Creve Coeur, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Toms River, New Jersey, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Fresh Meadows, New York, United States|Research Site, Mount Kisco, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Beechwood, Ohio, United States|Research Site, Canton, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Dublin, Ohio, United States|Research Site, Mason, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Salem, Oregon, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Norristown, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Lake Jackson, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Woodstock, Vermont, United States|Research Site, Seattle, Washington, United States|Research Site, South Kirkland, Washington, United States|Research Site, Middleton, Wisconsin, United States|Research Site, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01152554"
118,"NCT01144338","Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Exenatide Once Weekly|Drug: Placebo","Primary Efficacy Outcome MACE Events|Primary Safety Outcome MACE Events|Secondary Efficacy Outcome All-Cause Mortality|Secondary Efficacy Outcome CV Death|Secondary Efficacy Outcome MI|Secondary Efficacy Outcome Stroke|Secondary Efficacy Outcome Hospitalization for ACS|Secondary Efficacy Outcome Hospitalization for HF","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","14752","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5551C00003|MB001-002|BCB109","June 18, 2010","April 21, 2017","April 24, 2017","June 15, 2010","August 8, 2018","August 8, 2018","Research Site, Birmingham, Alabama, United States|Research Site, Glendale, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Chula Vista, California, United States|Research Site, Concord, California, United States|Research Site, Escondido, California, United States|Research Site, Fullerton, California, United States|Research Site, Greenbrae, California, United States|Research Site, La Mesa, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Oceanside, California, United States|Research Site, Orange, California, United States|Research Site, Redondo Beach, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, Sylmar, California, United States|Research Site, Torrance, California, United States|Research Site, Tustin, California, United States|Research Site, Victorville, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Littleton, Colorado, United States|Research Site, Thomaston, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Cape Coral, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Roswell, Georgia, United States|Research Site, Pocatello, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Hines, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Gary, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Covington, Kentucky, United States|Research Site, Evansville, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Randallstown, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Alpena, Michigan, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Bloomfield Hills, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Cloud, Minnesota, United States|Research Site, Bridgeton, Missouri, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Butte, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Hamilton, New Jersey, United States|Research Site, Lyons, New Jersey, United States|Research Site, Margate City, New Jersey, United States|Research Site, South Plainfield, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Manhasset, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, North Massapequa, New York, United States|Research Site, Rosedale, New York, United States|Research Site, Smithtown, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Barberton, Ohio, United States|Research Site, Canal Fulton, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Mentor, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Feasterville, Pennsylvania, United States|Research Site, Lansdale, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Newport, Pennsylvania, United States|Research Site, Penndel, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Tipton, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Murrells Inlet, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Bristol, Tennessee, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Jackson, Tennessee, United States|Research Site, Johnson City, Tennessee, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, McKenzie, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Arlington, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Capital Federal, Argentina|Research Site, CiudadAutonoma De Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Cordoba, Argentina|Research Site, Godoy Cruz, Argentina|Research Site, Jujuy, Argentina|Research Site, Mar Del Plata Buenos Aires, Argentina|Research Site, Rosario, Argentina|Research Site, Salta, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Santa Rosa, Argentina|Research Site, Adelaide, Australia|Research Site, Camperdown, Australia|Research Site, Clayton, Australia|Research Site, East Gosford, Australia|Research Site, Elizabeth Vale, Australia|Research Site, Fitzroy, Australia|Research Site, Garran, Australia|Research Site, Geelong, Australia|Research Site, Heidelberg West, Australia|Research Site, Meadobank, Australia|Research Site, Milton, Australia|Research Site, Parkville, Australia|Research Site, Sydney, Australia|Research Site, Feldkirch, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Zams, Austria|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Merksem, Belgium|Research Site, Ronse, Belgium|Research Site, Aparecida de Goiânia, Brazil|Research Site, Belém, Brazil|Research Site, Brasilia, Brazil|Research Site, Campinas, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiânia, Brazil|Research Site, Marília, Brazil|Research Site, Passo Fundo, Brazil|Research Site, Recife, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Blagoevgrad, Bulgaria|Research Site, Gabrovo, Bulgaria|Research Site, Gulyantsi, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sliven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Delta, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Bridgewater, Nova Scotia, Canada|Research Site, Liverpool, Nova Scotia, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sainte Foy, Quebec, Canada|Research Site, Terrebonne, Quebec, Canada|Research Site, Osorno, Chile|Research Site, Puerto Varas, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Chuangchun, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hong Kong, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Shijiazhuang, China|Research Site, Siping, China|Research Site, Suzhou, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Xian, China|Research Site, Yinchuan, China|Research Site, Barranquilla, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogotá D.C., Colombia|Research Site, Bogotá, Colombia|Research Site, Cali, Colombia|Research Site, Manizales, Colombia|Research Site, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Olomouc-Lazce, Czechia|Research Site, Praha 10, Prague, Czechia|Research Site, Praha 4, Czechia|Research Site, Svitavy, Czechia|Research Site, Znojmo, Czechia|Research Site, Aachen, Germany|Research Site, Aschaffenburg, Germany|Research Site, Bad Nauheim, Germany|Research Site, Bad Oeynhausen, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Burghausen, Germany|Research Site, Burg, Germany|Research Site, Chemnitz, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Eschweiler, Germany|Research Site, Essen, Germany|Research Site, Gießen, Germany|Research Site, Herne, Germany|Research Site, Hohenmölsen, Germany|Research Site, Kassel, Germany|Research Site, Kiel-Kronshagen, Germany|Research Site, Köthen, Germany|Research Site, Lichtenfels, Germany|Research Site, Mainz, Germany|Research Site, Mayen, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Obermichelbach, Germany|Research Site, Osnabrueck, Germany|Research Site, Riesa, Germany|Research Site, Rotenburg, Germany|Research Site, Stuttgart, Germany|Research Site, Würzburg, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Csongrad, Hungary|Research Site, Debrecen, Hungary|Research Site, Eger, Hungary|Research Site, Gyor, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Jászberény, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Komarom, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Pápa, Hungary|Research Site, Pécs, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szentes, Hungary|Research Site, Szentes, Hungary|Research Site, Szigetvár, Hungary|Research Site, Szikszo, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Sátoraljaújhely, Hungary|Research Site, Veszprem, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Givatayim, Israel|Research Site, Hadera, Israel|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Nahariya, Israel|Research Site, Nazareth, Israel|Research Site, Petah Tikva, Israel|Research Site, Safed, Israel|Research Site, Tel-Aviv, Israel|Research Site, Tel-Aviv, Israel|Research Site, Firenze, Italy|Research Site, Foggia, Italy|Research Site, Milano, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Sesto San Giovanni, Italy|Research Site, Terni, Italy|Research Site, Udine, Italy|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangjin-gu, Korea, Republic of|Research Site, Gyeonggi-do, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Jelgava, Latvia|Research Site, Kuldiga, Latvia|Research Site, Kuldiga, Latvia|Research Site, Ogre, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Talsi, Latvia|Research Site, Tukums, Latvia|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kaunas, Lithuania|Research Site, Kedainiai, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Panevezys, Lithuania|Research Site, Ukmerge, Lithuania|Research Site, Utena, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Alor Setar, Malaysia|Research Site, Batu Caves, Malaysia|Research Site, Kota Samarahan, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuching, Malaysia|Research Site, Sungai Buloh, Malaysia|Research Site, Taiping, Malaysia|Research Site, Aguascalientes, Mexico|Research Site, Cuautla, Mexico|Research Site, Durango, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Puebla, Mexico|Research Site, Queretaro, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hardenberg, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Meppel, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sneek, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Christchurch, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Hamilton, New Zealand|Research Site, Nelson, New Zealand|Research Site, Newtown, New Zealand|Research Site, Palmerston North, New Zealand|Research Site, Takapuna, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Wellington, New Zealand|Research Site, Cebu, Philippines|Research Site, Iloilo City, Philippines|Research Site, Manila, Philippines|Research Site, Marikina City, Philippines|Research Site, Marikina, Philippines|Research Site, Pasig, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon, Philippines|Research Site, Quezon, Philippines|Research Site, Quezon, Philippines|Research Site, San Juan, Philippines|Research Site, Elbląg, Poland|Research Site, Gdynia, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Grudziadz, Poland|Research Site, Katowice, Poland|Research Site, Lublin, Poland|Research Site, Ostrołęka, Poland|Research Site, Poznań, Poland|Research Site, Płock, Poland|Research Site, Słupsk, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wrocław, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Łęczna, Poland|Research Site, Bacau, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Bucuresti, Romania|Research Site, Buzau, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj Napoca, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Oradea, Romania|Research Site, Ploiesti, Romania|Research Site, Satu-Mare, Romania|Research Site, Timisoara, Romania|Research Site, Timișoara, Romania|Research Site, Zalau, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St. Peterburg, Russian Federation|Research Site, St.Рetersburg, Russian Federation|Research Site, Thymen, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Presov, Slovakia|Research Site, Roznava, Slovakia|Research Site, Trebisov, Slovakia|Research Site, Zilina, Slovakia|Research Site, Boksburg, South Africa|Research Site, Brits, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Centurion, South Africa|Research Site, Durban, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kempton Park, South Africa|Research Site, Lenasia, South Africa|Research Site, Paarl, South Africa|Research Site, Parktown, South Africa|Research Site, Phoenix, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Potchefstroom, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Somerset West, South Africa|Research Site, Soweto, South Africa|Research Site, Umkomaas, South Africa|Research Site, A Coruña, Spain|Research Site, Alcalá de Henares, Spain|Research Site, Avila, Spain|Research Site, Ferrol, Spain|Research Site, Girona, Spain|Research Site, Granada, Spain|Research Site, Granada, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Manacor, Spain|Research Site, Málaga, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Palma deMallorca, Spain|Research Site, Salamanca, Spain|Research Site, Sevilla, Spain|Research Site, Tarragona, Spain|Research Site, Changhua, Taiwan|Research Site, Kaohsiung Hsien, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kweishan Shiang, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan County, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chernivtsi, Ukraine|Research Site, Dnepropetrovsk, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetck, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Odesa, Ukraine|Research Site, Sumy, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhia, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zhytomyr, Ukraine|Research Site, Aberdeen, United Kingdom|Research Site, Addlestone, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Inverness, United Kingdom|Research Site, Irvine, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northampton, United Kingdom|Research Site, Ormskirk, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Redhill, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Suffolk, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Trowbridge, United Kingdom|Research Site, West Sussex, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT01144338/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT01144338/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01144338"
119,"NCT01137474","A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Placebo-matching dapagliflozin","Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12|Adjusted Mean Change From Baseline in Hemoglobin (HbA1c) at Week 12|Adjusted Mean Change From Baseline in 24-Hour Ambulatory Systolic Blood Pressure at Week 12 (Last Observation Carried Forward)|Adjusted Mean Change From Baseline in Seated Diastolic Blood Pressure at Week 12|Adjusted Mean Change in 24-Hour Ambulatory Diastolic Blood Pressure at Week 12 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Serum Uric Acid Levels at Week 12","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 89 Years   (Adult, Older Adult)","Phase 3","2996","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MB102-073 ST|2010-019797-32","July 2010","February 2013","February 2013","June 4, 2010","May 1, 2014","January 26, 2017","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Horizon Research Group, Inc., Mobile, Alabama, United States|Iicr, Inc. (International Institute Of Clinical Research), Ozark, Alabama, United States|Hope Research Institute, Phoenix, Arizona, United States|43rd Medical Associates, Phoenix, Arizona, United States|Central Phoenix Medical Clinic, Llc, Tempe, Arizona, United States|Clinical Research Advantage/Desert Clinical Research, Tempe, Arizona, United States|Visions Clinical Research - Tucson, Tucson, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Aureus Research, Inc., Little Rock, Arkansas, United States|Preferred Research Partners, Inc., Little Rock, Arkansas, United States|Orange County Research Institute, Anaheim, California, United States|Cmp Research, Anaheim, California, United States|Med Center, Carmichael, California, United States|Catalina Research Institute, Llc, Chino, California, United States|Southland Clinical Research Center, Inc., Fountain Valley, California, United States|Marin Endocrine Care & Research, Inc., Greenbrae, California, United States|Del Rosario Medical Clinic, Inc., Huntington Park, California, United States|Time Clinical Research Inc., Huntington Park, California, United States|Marina Raikhel, M.D., F.A.A.F.P, Lomita, California, United States|Clinica Medica San Miguel, Los Angeles, California, United States|American Institute Of Research, Los Angeles, California, United States|Randall G. Shue, D.O., Los Angeles, California, United States|National Research Inst, Los Angeles, California, United States|Quest Diagnostics West Hills, Los Angeles, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Valley Clinical Trials, Northridge, California, United States|Lucita M. Cruz,Md.,Inc., Norwalk, California, United States|Sds Clinical Trials, Orange, California, United States|Integrated Research Group, Inc., Riverside, California, United States|Quality Control Research, Inc, Sacramento, California, United States|Crest Clinical Trials, Inc., Santa Ana, California, United States|Orrin M. Troum, Md And Medical Associates, Santa Monica, California, United States|Orange County Research Center, Tustin, California, United States|University Clinical Investigators, Inc., Tustin, California, United States|Infosphere Clinical Research, Inc., West Hills, California, United States|Aurora Family Medicine, P.C., Aurora, Colorado, United States|Horizons Clinical Research Center, Llc, Denver, Colorado, United States|Chase Medical Research, Llc, Waterbury, Connecticut, United States|Zasa Clinical Research, Boynton Beach, Florida, United States|Bradenton Research Center, Inc., Bradenton, Florida, United States|Meridien Research, Brooksville, Florida, United States|Family Care Associates Of Nw Fl, Chipley, Florida, United States|Innovative Research Of West Florida, Inc, Clearwater, Florida, United States|Clinical Research Of South Florida, Coral Gables, Florida, United States|Avail Clinical Research, Llc, Deland, Florida, United States|In Vivo Clinical Research, Doral, Florida, United States|Palm Springs Research Institute, Hialeah, Florida, United States|The Community Research Of South Florida, Hialeah, Florida, United States|Newphase Clinical Trials, Inc., Miami Beach, Florida, United States|Ocean Blue Medical Research Center, Inc., Miami Springs, Florida, United States|San Marcus Research Clinic, Inc., Miami, Florida, United States|Flcri Global Research, Llc, Miami, Florida, United States|International Research Associates, Llc, Miami, Florida, United States|Clinical Research Of Miami, Inc., Miami, Florida, United States|Apf Research, Llc, Miami, Florida, United States|Community Research Foundation, Inc., Miami, Florida, United States|Medical Research Marseilles, Miami, Florida, United States|Baptist Diabetes Associates, Pa, Miami, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Compass Research, Llc, Orlando, Florida, United States|Florida Institute For Clinical Research, Llc, Orlando, Florida, United States|South Miami Clinical Research, Llc, South Miami, Florida, United States|Meridien Research, St Petersburg, Florida, United States|Meridien Research, Tampa, Florida, United States|Perimeter Institute For Clinical Research, Atlanta, Georgia, United States|Bainbridge Medical Associates, Bainbridge, Georgia, United States|River Birch Research Alliance, Llc, Blue Ridge, Georgia, United States|In-Quest Medical Research, Llc, Duluth, Georgia, United States|Middle Georgia Clinical Research Center, Llc, Perry, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|James R. Herron, Md, Ltd, Chicago, Illinois, United States|So. Illinois Clin Res Ctr @ Div Of Kevin L Pritchett Md, Pc, O?Fallon, Illinois, United States|Springfield Diabetes And Endocrine Center, Springfield, Illinois, United States|American Health Network Of Indiana Llc, Avon, Indiana, United States|Investigators Research Group, Llc, Brownsburg, Indiana, United States|American Health Network Of In Llc, Franklin, Indiana, United States|Laporte County Institute For Clinical Research, Inc., Michigan City, Indiana, United States|American Health Network Of In Llc, Muncie, Indiana, United States|Medical Development Centers, Llc, Baton Rouge, Louisiana, United States|Crescent City Clinical Research Center, Metairie, Louisiana, United States|Acadia Clinical Research, Llc, Bangor, Maine, United States|Alternative Primary Care, Silver Spring, Maryland, United States|Neurocare, Inc., Brookline, Massachusetts, United States|Genesis Clinical Research, Llc, Fall River, Massachusetts, United States|Hci-Metromedic Walk-In Medical Office, New Bedford, Massachusetts, United States|Atlantic Clinical Trials, Llc, Watertown, Massachusetts, United States|Providence Park Clinical Research, Novi, Michigan, United States|The Center For Clinical Trials, Biloxi, Mississippi, United States|Phillips Medical Services, Pllc, Jackson, Mississippi, United States|Jackson Clinic, Rolling Fork, Mississippi, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|St. Louis Center For Clinical Research, St. Louis, Missouri, United States|Kcumb Dybedal Clinical Research Center, Kansas City, Montana, United States|Clin Research Advantage, Inc. James Meli, Do Family Pracice, Henderson, Nevada, United States|Office Of Ted Thorp, Md, Las Vegas, Nevada, United States|Independent Clinical Researchers@ Wolfson Medical Center, Las Vegas, Nevada, United States|Clinical Research Advantage, Inc., Las Vegas, Nevada, United States|Palm Medical Research Center, Las Vegas, Nevada, United States|Joslin Diabetes Center Affiliate Of Snhmc, Nashua, New Hampshire, United States|Central Jersey Medical Research Center, Elizabeth, New Jersey, United States|Premier Research, Trenton, New Jersey, United States|Medex Healthcare Research, Inc., New York, New York, United States|Digiovanna Institute For Medical Education & Research, North Massapequa, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Barat Research Group, Inc., Charlotte, North Carolina, United States|Pharmquest, Greensboro, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Pmg Research Of Wilmington Llc, Wilmington, North Carolina, United States|Lillestol Research, Fargo, North Dakota, United States|Community Health Care, Inc., Canal Fulton, Ohio, United States|Community Research, Cincinnati, Ohio, United States|Cleveland Sleep Research Center, Middleburg Heights, Ohio, United States|Clinical Research Source, Inc, Perrysburg, Ohio, United States|Integris Family Care Central, Oklahoma City, Oklahoma, United States|Sooner Clinical Research, Oklahoma City, Oklahoma, United States|Integris Family Care Yukon, Yukon, Oklahoma, United States|Willamette Valley Clinical Studies, Eugene, Oregon, United States|Fanno Creek Clinic, Portland, Oregon, United States|Southeastern Pa Medical Institute, Broomall, Pennsylvania, United States|Abington Memorial Hos/Feasterville Family Health Care Center, Feasterville Trevose, Pennsylvania, United States|The Clinical Trial Center, Llc, Jenkintown, Pennsylvania, United States|Arcuri Clinical Research Llc, Philadelphia, Pennsylvania, United States|Philadelphia Health Associates - Adult Medicine, Philadelphia, Pennsylvania, United States|Banksville Medical Pc, Pittsburgh, Pennsylvania, United States|Research Across America, Reading, Pennsylvania, United States|Pish Medical Associates, Uniontown, Pennsylvania, United States|Greater Providence Clinical Research, Llc, Warwick, Rhode Island, United States|Southeastern Research Associates, Inc., Anderson, South Carolina, United States|Southeastern Research Associates, Inc., Greenville, South Carolina, United States|Hillcrest Clinical Reseach, Llc, Simpsonville, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Chattanooga Research & Medicine, Pllc, Chattanooga, Tennessee, United States|Complete Family Care Of Knoxville, Pllc, Knoxville, Tennessee, United States|Premier Internal Medicine, Memphis, Tennessee, United States|Arlington Family Research Center, Inc., Arlington, Texas, United States|Krk Medical Research, Dallas, Texas, United States|Research Institute Of Dallas, Dallas, Texas, United States|Internal Medicine Clinical Research, Dallas, Texas, United States|Renaissance Clinical Research And Hypertension Pllc, Dallas, Texas, United States|Sergio F. Rovner, M.D., El Paso, Texas, United States|Mercury Clinical Research, Houston, Texas, United States|Southwest Clinical Trials, Houston, Texas, United States|Excel Clinical Research, Llc, Houston, Texas, United States|Lone Star Clinical Research, Houston, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|North Hills Medical Research, Inc., North Richland Hills, Texas, United States|Med-Olam Clinical Research, Pasadena, Texas, United States|Lisa E. Medwedeff, Md, Pa, Plano, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Abbott Clinical Research Group, Inc., San Antonio, Texas, United States|Covenant Clinical Research, Pa, San Antonio, Texas, United States|Breco Research, Ltd, Sugarland, Texas, United States|Pioneer Research Solutions, Inc., Sugarland, Texas, United States|Exodus Healthcare Network, Magna, Utah, United States|Wasatch Endocrinology And Diabetes Specialists, Salt Lake City, Utah, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Millennium Clinical Trials Llc, Arlington, Virginia, United States|Burke Internal Medicine And Research, Burke, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Hampton Roads Center For Clinical Research, Inc., Suffolk, Virginia, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Sound Medical Research, Port Orchard, Washington, United States|Local Institution, Kelowona, British Columbia, Canada|Local Institution, Victoria, British Columbia, Canada|Local Institution, Brampton, Ontario, Canada|Local Institution, Granby, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Medellin, Antioquia, Colombia|Local Institution, Bogota, Cundinamarca, Colombia|Local Institution, Armenia, Quindio, Colombia|Local Institution, Cali, Valle, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Barranquilla, Colombia|Local Institution, Bogota, Colombia|Local Institution, Beroun, Czech Republic|Local Institution, Cheb, Czech Republic|Local Institution, Havirov, Czech Republic|Local Institution, Liberec, Czech Republic|Local Institution, Ostrava, Czech Republic|Local Institution, Prague 1, Czech Republic|Local Institution, Praha 4, Czech Republic|Local Institution, Copenhagen, Denmark|Local Institution, Copenhagen, Denmark|Local Institution, Frederiksberg, Denmark|Local Institution, Slagelse, Denmark|Local Institution, Kokkola, Finland|Local Institution, Oulu, Finland|Local Institution, Aschaffenburg, Bavaria, Germany|Local Institution, Vellmar, Hessen, Germany|Local Institution, Duisburg, Nordrhein-Westfalen, Germany|Local Institution, Bad Kreuznach, Germany|Local Institution, Berlin, Germany|Local Institution, Karlsruhe, Germany|Local Institution, Kothen, Germany|Local Institution, Kronshagen, Germany|Local Institution, Langenfeld, Germany|Local Institution, Lueneburg, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Pirna, Germany|Local Institution, Saarbruecken, Germany|Local Institution, Gyongyos, Heves, Hungary|Local Institution, Eger, Hungary|Local Institution, Hatvan, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Nagykanizsa, Hungary|Local Institution, Nyiregyhaza, Hungary|Local Institution, Satoraljaujhely, Hungary|Local Institution, Sopron, Hungary|Local Institution, Szeged, Hungary|Local Institution, Szekszard, Hungary|Local Institution, Szentes, Hungary|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Vijayawada, Andhra Pradesh, India|Local Institution, New Delhi, Delhi, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Belgaum, Karnatka, India|Local Institution, Indore, Madhya Pradesh, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Delhi, New Delhi, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Jaipur, Rajasthan, India|Local Institution, Coimbatore, Tamil Nadu, India|Local Institution, Madurai, Tamilnadu, India|Local Institution, Bangalore, India|Local Institution, Hyderabad, India|Local Institution, Manipal, India|Local Institution, Nagpur, India|Local Institution, Torreon, Coahuila, Mexico|Local Institution, Del. Benito Juarez, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Df, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuautla, Morelos, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Culiacan, Sinaloa, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, Durango, Mexico|Local Institution, Guadalajara, Mexico|Local Institution, Puebla, Mexico|Local Institution, Queretaro, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Chiclayo, Lambayeque, Peru|Local Institution, Lince, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Arequipa, Peru|Local Institution, Cusco, Peru|Local Institution, Ica, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Piura, Peru|Local Institution, Bialystok, Poland|Local Institution, Bydgoszcz, Poland|Local Institution, Chrzanow, Poland|Local Institution, Gdansk, Poland|Local Institution, Gdynia, Poland|Local Institution, Golub-Dobrzyn, Poland|Local Institution, Kamieniec Zabkowicki, Poland|Local Institution, Katowice, Poland|Local Institution, Krakow, Poland|Local Institution, Krakow, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Lodz, Poland|Local Institution, Lodz, Poland|Local Institution, Ostroda, Poland|Local Institution, Poznan, Poland|Local Institution, Szczecin, Poland|Local Institution, Warsaw, Poland|Local Institution, Warsaw, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroc#Aw, Poland|Local Institution, WrocB Aw, Poland|Local Institution, Zamosc, Poland|Local Institution, Cidra, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Oradea, Bihor, Romania|Local Institution, Oradea, Jud. Bihor, Romania|Local Institution, Timisoara, Jud. Timis, Romania|Local Institution, Targu Mures, Mures, Romania|Local Institution, Targu Mures, Mures, Romania|Local Institution, Ploiesti, Prahova, Romania|Local Institution, Ploiesti, Prahova, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Satu Mare, Romania|Local Institution, Sibiu, Romania|Local Institution, Sibiu, Romania|Local Institution, Dzerzhinskiy, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Smolensk, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, Yaroslavl, Russian Federation|Local Institution, Yaroslavl, Russian Federation|Local Institution, Yaroslav, Russian Federation|Local Institution, Santiago De Compostela, A Coruna, Spain|Local Institution, Barcelona, Spain|Local Institution, La Roca Del Valles, Spain|Local Institution, Peralada, Spain",,"https://ClinicalTrials.gov/show/NCT01137474"
120,"NCT01128153","Saxagliptin Triple Oral Therapy",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo","Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF)|Change in 2-hour Postprandial Glucose (PPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mg/dL]|Change in 2-hour Postprandial Glucose (PPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mmol/L]|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mg/dL]|Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mmol/L]|Proportion of Participants Achieving a Therapeutic Response: HbA1c Less Than 7% at Week 24, Last Observation Carried Forward (LOCF)","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","257","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680L00006|CV181-117","June 2010","June 2011","June 2011","May 21, 2010","August 3, 2012","August 10, 2012","Research Site, Broadmeadow, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Daw Park, South Australia, Australia|Research Site, Elizabeth Vale, South Australia, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Camperdown, Australia|Research Site, Herston, Australia|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Sydney Mines, Nova Scotia, Canada|Research Site, Thornhill, Ontario, Canada|Research Site, Kensington, Prince Edward Island, Canada|Research Site, Karnal, Haryana, India|Research Site, Bangalore, Karnataka, India|Research Site, Indore, Madhya Pradesh, India|Research Site, Pune, Maharashtra, India|Research Site, Coimbatore, Tamil Nadu, India|Research Site, Wonju, Kangwon-do, Korea, Republic of|Research Site, Goyang, Kyounggi-do, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Bangkok, Thailand|Research Site, Reading, Berks, United Kingdom|Research Site, ELY, Cambridgeshire, United Kingdom|Research Site, Whitstable, Kent, United Kingdom|Research Site, Westbury, Wiltshire, United Kingdom|Research Site, Ashford, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Chesterfield, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Wellingborough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01128153"
121,"NCT01096017","To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study",,"Completed","Has Results","Asthma","Drug: Terbutaline Turbuhaler®|Drug: Salbutamol pMDI|Other: pMDI placebo pMDI|Other: Placebo Turbuhaler®","FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation|FEV1 (Forced Expiratory Volume in 1 Second) at 5 Minutes After Inhalations of Study Drug as Percentage of Pre-dose|FEV1 (Forced Expiratory Volume in 1 Second) at 15 Minutes After Inhalations of Study Drug as Percentage of Pre-dose|FEV1 (Forced Expiratory Volume in 1 Second) at 30 Minutes After Inhalations of Study Drug as Percentage of Pre-dose|FEV1 (Forced Expiratory Volume in 1 Second) at 60 Minutes After Inhalations of Study Drug as Percentage of Pre-dose|FEV1 (Forced Expiratory Volume in 1 Second) at 120 Minutes After Inhalations of Study Drug as Percentage of Pre-dose|FEV1 (Forced Expiratory Volume in 1 Second) at 180 Minutes After Inhalations of Study Drug as Percentage of Pre-dose|FEV1 (Forced Expiratory Volume in 1 Second) at 240 Minutes After Inhalations of Study Drug as Percentage of Pre-dose|Maximum % Change in FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation|Time to Peak FEV1 (Forced Expiratory Volume in 1 Second) Within 4 Hours After Drug Inhalation|Number of Patients With % Change in FEV1 (Forced Expiratory Volume in 1 Second) >15% Within 4 Hours After Drug Inhalation|Time to Change More Than or Equal to 15% (Time to Onset Response) Within 4 Hours After Drug Inhalation","AstraZeneca","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","D589LC00002","March 2010","April 2010","April 2010","March 30, 2010","August 31, 2012","August 31, 2012","Research Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01096017"
122,"NCT01078675","An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia",,"Completed","Has Results","Familial Hypercholesterolaemia","Drug: rosuvastatin calcium","Percent Change From Baseline in LDL-C|Sexual Maturation by Tanner Staging at Baseline|Single Dose PK - Cmax|Percent Change From Baseline in Height|Sexual Maturation by Tanner Staging at Month 12|Sexual Maturation by Tanner Staging at Month 24|Single Dose PK - Tmax|Single Dose PK - AUC(0-24)|Percent Change From Baseline in HDL-C, TC, TG, Non-HDL-C, LDL-C/HDL-C, TC/HDL-C, Non HDL C/HDL-C, ApoB, ApoA-1, and ApoB/ApoA-1|Change From Baseline in Max and Mean Carotid Intima and Media Wall Thickness (cIMT)|Adverse Events|Total Duration of Exposure|Overal Treatment Adherence","AstraZeneca","All","6 Years to 17 Years   (Child)","Phase 3","315","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D3561C00002","February 2010","February 2013","February 2013","March 2, 2010","February 2, 2015","April 7, 2015","Research Site, Cincinnati, Ohio, United States|Research Site, Leuven, Belgium|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Leiderdorp, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Waalwijk, Netherlands|Research Site, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT01078675"
123,"NCT01073865","Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: ZD9393 (Zoladex) 10.8 mg|Drug: ZD9393 (Zoladex) 3.6 mg","Number of Patients With Progression-free Survival (PFS) at 24 Weeks|Number of Responders at 24 Weeks|Oestradiol (E2) Serum Concentrations at 24 Weeks","AstraZeneca","Female","20 Years to 130 Years   (Adult, Older Adult)","Phase 3","222","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D8666C00001","February 26, 2010","September 19, 2012","November 20, 2017","February 23, 2010","January 10, 2014","December 12, 2018","Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Hubli, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Mumbai, India|Research Site, Nagpur, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Thiruvananthapuram, India|Research Site, Amagasaki-shi, Japan|Research Site, Chiba, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hamamatsu, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kamogawa-shi, Japan|Research Site, Kitaadachi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Mitaka-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka, Japan|Research Site, Sakai-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Pasay City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Maharat Nakorn Ratchasima, Thailand|Research Site, Songkla, Thailand|Research Site, Ubonratchathani, Thailand",,"https://ClinicalTrials.gov/show/NCT01073865"
124,"NCT01070784","A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Symbicort Turbuhaler (Budesonide/formoterol)|Drug: Drug: any available COPD treatment; investigator to decide","Clinical Laboratory Test: Haematology -Erythrocytes|Clinical Laboratory Test: Haematology -Haemoglobin|Clinical Laboratory Test: Haematology -Leucocytes|Clinical Laboratory Test: Haematology -Platelet Count|Clinical Laboratory Test: Haematology -Eosinophils|Clinical Laboratory Test: Haematology -Basophils|Clinical Laboratory Test: Haematology -Lymphocytes|Clinical Laboratory Test: Haematology -Monocytes|Clinical Laboratory Test: Haematology -Neutrophils|Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase|Clinical Laboratory Test: Clinical Chemistry- S-Aspartate Aminotransferase|Clinical Laboratory Test: Clinical Chemistry- S-Alkaline Phosphatase (ALP)|Clinical Laboratory Test: Clinical Chemistry- S-Creatinine|Clinical Laboratory Test: Clinical Chemistry- S-Total Bilirubin|Clinical Laboratory Test: Clinical Chemistry- S-Sodium|Clinical Laboratory Test: Clinical Chemistry- S-Potassium|Clinical Laboratory Test: Clinical Chemistry- S- Calcium|Clinical Laboratory Test: Clinical Chemistry- S-Albumin|Clinical Laboratory Test: Clinical Chemistry- S-Protein, Total|Clinical Laboratory Test: Clinical Chemistry- S-C-Reactive Protein|Clinical Laboratory Test: Clinical Chemistry- S-Urea Nitrogen|Vital Signs- Sitting Systolic Blood Pressure(SBP)|Vital Signs- Sitting Diastolic Blood Pressure(DBP)|Vital Signs- Pulse Rate|ECG Variables - Heart Rate|ECG Variables - QT Interval|ECG Variables - QTcB Interval|ECG Variables - QTcF Interval|ECG Variables - RR Interval|Chronic Obstructive Pulmonary Disease (COPD) symptoms_Night-time Awakening|Chronic Obstructive Pulmonary Disease (COPD) symptoms_Breathlessness|Chronic Obstructive Pulmonary Disease (COPD) symptoms_cough|Forced Expiratory Volume in 1 Second (FEV1) Measured With the Spirometer at the Clinic|Forced Vital Capacity (FVC) Measured With the Spirometer at the Clinic|Time to First COPD Exacerbation|Number of COPD Exacerbations Over the Study Treatment Period|Rescue Medication Use|Health Related Quality of Life (HRQL) Based on the St. George's Respiratory Questionnaire (SGRQ)|Morning Peak Expiratory Flow (PEF) Measured at Home|Evening Peak Expiratory Flow (PEF) Measured at Home|Morning FEV1 Measured by the Subjects at Home|Evening FEV1 Measured by the Subjects at Home","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","328","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D589DC00008","January 2010","October 2011","October 2011","February 18, 2010","December 5, 2013","April 29, 2014","Research Site, Nagoya, Aichi, Japan|Research Site, Toyota, Aichi, Japan|Research Site, Yanagawa, Fukuoka, Japan|Research Site, Asahikawa, Hokkaido, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Itami, Hyogo, Japan|Research Site, Hitachi, Ibaraki, Japan|Research Site, Tsukuba, Ibaraki, Japan|Research Site, Sakaide, Kagawa, Japan|Research Site, Fujisawa, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Koshi, Kumamoto, Japan|Research Site, Shibata, Miyagi, Japan|Research Site, Chuo, Tokyo, Japan|Research Site, Setagaya, Tokyo, Japan|Research Site, Hiroshima, Japan|Research Site, Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT01070784"
125,"NCT01069939","Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin",,"Completed","Has Results","Prevention","Drug: Esomeprazole|Drug: Placebo","Time From Randomization to Occurrence of Gastric and/or Duodenal Ulcers up to Data Cut-off Date for Interim Analysis.|Change in Degree of Gastric Mucosal Lesion by Modified Lanza Scale From Baseline to Last Measurement up to Week 48|Number of Participants With Reflux Esophagitis Evaluated by the LA Classification up to Week 48.|Change in the Severity of Epigastric Pain From Baseline to Last Measurement up to Week 48|Change in the Severity of Heartburn From Baseline to Last Measurement up to Week 48.|Change in the Severity of Anorexia From Baseline to Last Measurement up to Week 48|Change in the Severity of Abdomen Enlarged Feeling From Baseline to Last Measurement up to Week|Change in the Severity of Nausea and/or Vomiting From Baseline to Last Measurement up to Week 48|Change in the Severity of Discomfort in the Stomach From Baseline to Last Measurement up to Week 48|Number of Participants With Adverse Events","AstraZeneca","All","20 Years and older   (Adult, Older Adult)","Phase 3","427","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D961PC00001","February 2010","November 2011","November 2011","February 17, 2010","November 22, 2012","November 22, 2012","Research Site, Yotsukaidou, Chiba, Japan|Research Site, Kitakyushu-Shi, Fukuoka, Japan|Research Site, Onga-Gun, Fukuoka, Japan|Research Site, Yukuhashi, Fukuoka, Japan|Research Site, Koriyama, Fukushima, Japan|Research Site, Nihonmatsu, Fukushima, Japan|Research Site, Fukuyama, Hiroshima, Japan|Research Site, Kure, Hiroshima, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Amagasaki, Hyogo, Japan|Research Site, Itami, Hyogo, Japan|Research Site, Kobe, Hyogo, Japan|Research Site, Nishinomiya, Hyogo, Japan|Research Site, Higashi-ibaraki,, Ibaraki, Japan|Research Site, Komatsu, Ishikawa, Japan|Research Site, Nomi, Ishikawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, UJI, Kyoto, Japan|Research Site, Sendai, Miyagi, Japan|Research Site, Daito, Osaka, Japan|Research Site, Kishiwada, Osaka, Japan|Research Site, Matsubara, Osaka, Japan|Research Site, Minato, Osaka, Japan|Research Site, Yao, Osaka, Japan|Research Site, Hanyu, Saitama, Japan|Research Site, Shimotsuke, Tochigi, Japan|Research Site, Chuo, Tokyo, Japan|Research Site, Minato, Tokyo, Japan|Research Site, Shinagawa, Tokyo, Japan|Research Site, Shinjuku, Tokyo, Japan|Research Site, Shimonoseki, Yamaguchi, Japan|Research Site, Fukui, Japan|Research Site, Fukuoka, Japan|Research Site, Fukushima, Japan|Research Site, Shizuoka, Japan|Research Site, Gangneung, Gangwon-Do, Korea, Republic of|Research Site, Wonju-si, Gangwon-do, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Niao-Song-Shiang, Kaohsiung, Taiwan|Research Site, Kweishan Shiang, Taoyuan Hsien, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01069939"
126,"NCT01069289","Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients","SUMIRE","Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Budesonide/formoterol (Symbicort Turbuhaler)|Drug: Formoterol (Oxis Turbuhaler)","Pre-dose Forced Expiratory Volume in One Second (FEV1)|1 Hour Post Dose Forced Expiratory Volume in One Second (FEV1)|Pre-dose Forced Vital Capacity (FVC)|1 Hour Post-dose Forced Vital Capacity (FVC)|Percentage of Participants With Exacerbations|Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation|Morning Peak Expiratory Flow(PEF)|Evening Peak Expiratory Flow (PEF)|Total Number of Day With Exacerbation|Morning Forced Expiratory Volume in One Second (FEV1)|Evening Forced Expiratory Volume in One Second (FEV1)|Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms|Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms|Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms|Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score|Use of Rescue Medication|St George's Respiratory Questionnaire (SGRQ) Total Score","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","1293","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D589DC00007","January 2010","March 2011","March 2011","February 17, 2010","October 25, 2012","October 25, 2012","Research Site, New Delhi, Delhi, India|Research Site, Bangalore, Karnataka, India|Research Site, Mysore, Karnataka, India|Research Site, Trivandrum, Kerala, India|Research Site, Indore, Madhya Pradesh, India|Research Site, Nagpur, Maharashtra, India|Research Site, Coimbatore, Tamil Nadu, India|Research Site, Nagoya, Aichi, Japan|Research Site, Okazaki, Aichi, Japan|Research Site, Seto, Aichi, Japan|Research Site, Toyota-shi, Aichi, Japan|Research Site, Toyota, Aichi, Japan|Research Site, Akita-shi, Akita, Japan|Research Site, Yanagawa, Fukuoka, Japan|Research Site, Takayama-shi, Gifu, Japan|Research Site, Maebashi, Gunma, Japan|Research Site, OTA, Gunma, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Asahikawa, Hokkaido, Japan|Research Site, Obihiro, Hokkaido, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Tomakomai, Hokkaido, Japan|Research Site, Himeji, Hyogo, Japan|Research Site, Itami, Hyogo, Japan|Research Site, Kobe, Hyogo, Japan|Research Site, Naka-gun, Ibaragi, Japan|Research Site, Hitachi, Ibaraki, Japan|Research Site, Tsukuba, Ibaraki, Japan|Research Site, Kanazawa, Ishikawa, Japan|Research Site, Sakaide, Kagawa, Japan|Research Site, Kagoshima-shi, Kagoshima, Japan|Research Site, Fujisawa, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Yokohama-shi, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Zama-shi, Kanagawa, Japan|Research Site, Matsusaka-shi, MIE, Japan|Research Site, Sendai, Miyagi, Japan|Research Site, Shibata, Miyagi, Japan|Research Site, Chino-shi, Nagano, Japan|Research Site, Matsumoto, Nagano, Japan|Research Site, Isahaya-shi, Nagasaki, Japan|Research Site, Nagaoka, Niigata, Japan|Research Site, Saiki-shi, Oita, Japan|Research Site, Yufu-shi, Oita, Japan|Research Site, Kurashiki-shi, Okayama, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Urasoe-shi, Okinawa, Japan|Research Site, Izumi-shi, Osaka, Japan|Research Site, Kishiwada, Osaka, Japan|Research Site, Moriguchi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Researche Site, Sakai-shi, Osaka, Japan|Research Site, Kitakatsushika-gun, Saitama, Japan|Research Site, Koshigaya-shi, Saitama, Japan|Research Site, Matsue, Shimane, Japan|Research Site, Chuo, Tokyo, Japan|Research Site, Itabashi-ku, Tokyo, Japan|Research Site, Meguro, Tokyo, Japan|Research Site, Minato-ku, Tokyo, Japan|Research Site, Setagaya, Tokyo, Japan|Research Site, Shinagawa-ku, Tokyo, Japan|Research Site, Suginami-ku, Tokyo, Japan|Research Site, Sumida-ku, Tokyo, Japan|Research Site, Fukuoka, Japan|Research Site, Gifu, Japan|Research Site, Kochi, Japan|Research Site, Kyoto, Japan|Research Site, Saga, Japan|Research Site, Wakayama, Japan|Research Site, Ansan, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Researche Site, San Fernando, Pampanga, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Batangas, Philippines|Research Site, Olongapo City, Philippines|Research Site, Quezon City, Philippines|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chodziez, Poland|Research Site, Jaroslaw, Poland|Research Site, Karpacz, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Loma, Poland|Research Site, Lublin, Poland|Research Site, Ostrow Wielkopolski, Poland|Research Site, Pila, Poland|Research Site, Poznan, Poland|Research Site, Ruda Slaska, Poland|Research Site, Slupca, Poland|Research Site, Tczew, Poland|Research Site, Torun, Poland|Research Site, Turek, Poland|Research Site, Wloszczowa, Poland|Research Site, Zabrze, Poland|Research Site, Zawadzkie, Poland|Research Site, Znin, Poland|Research Site, Barnaul, Russia, Russian Federation|Research Site, Ekaterinburg, Russia, Russian Federation|Research Site, Kazan, Russia, Russian Federation|Research Site, Moscow, Russia, Russian Federation|Research Site, St.petersburg, Russia, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Vladikavkaz, Russian Federation|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Keelung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinytsa, Ukraine|Research Site, Zaporozye, Ukraine|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01069289"
127,"NCT01047553","Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Formoterol (OT)","Clinical Laboratory Test: Haematology -Erythrocytes|Clinical Laboratory Test: Haematology -Haemoglobin|Clinical Laboratory Test: Haematology-Leucocytes|Clinical Laboratory Test: Haematology-Platelet Count|Clinical Laboratory Test: Haematology Eosinophils|Clinical Laboratory Test: Haematology Basophil|Clinical Laboratory Test: Haematology-Lymphocytes|Clinical Laboratory Test: Haematology-Monocytes|Clinical Laboratory Test: Haematology -Neutrophils|Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase|Clinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase|Clinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP)|Clinical Laboratory Test: Clinical Chemistry-S-Creatinine|Clinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin|Clinical Laboratory Test: Clinical Chemistry-S-Sodium|Clinical Laboratory Test: Clinical Chemistry-S-Potassium|Clinical Laboratory Test: Clinical Chemistry-S- Calcium|Clinical Laboratory Test: Clinical Chemistry-S-Albumin|Clinical Laboratory Test: Clinical Chemistry-S-Total Protein|Clinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN)|Vital Signs- Sitting SBP|Vital Signs- Sitting DBP|Vital Signs - Pulse Rate|ECG Variables - Heart Rate|ECG Variables - QT Interval|ECG Variables - QTcB Interval|ECG Variables QTcF Interval|ECG Variables RR Interval|Forced Expiratory Volume in One Second (FEV1)|Forced Vital Capacity (FVC)|Morning Peak Expiratory Flow(PEF)|Evening Peak Expiratory Flow (PEF)|Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms|Daytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms|Daytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms|Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score|Number of COPD Exacerbations Over the Treatment Period|Use of SABA (Salbutamol) as Reliever Medication|St George's Respiratory Questionnaire (SGRQ) Total Score","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","251","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5122C00002","December 2009","January 2011","July 2011","January 13, 2010","January 4, 2013","January 4, 2013","Research Site, Nagoya, Aichi, Japan|Research Site, Akita-shi, Akita, Japan|Research Site, Chitose, Hokkaido, Japan|Research Site, Obihiro, Hokkaido, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, AKO, Hyogo, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Hitachi, Ibaraki, Japan|Research Site, Tsukuba, Ibaraki, Japan|Research Site, Kanazawa, Ishikawa, Japan|Research Site, Sakaide, Kagawa, Japan|Research Site, Fujisawa, Kanagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Koshi, Kumamoto, Japan|Research Site, Nagaoka, Niigata, Japan|Research Site, Saiki-shi, Oita, Japan|Research Site, Moriguchi, Osaka, Japan|Research Site, Matsue, Shimane, Japan|Research Site, Bunkyo, Tokyo, Japan|Research Site, Chuo, Tokyo, Japan|Research Site, Katsushika-ku, Tokyo, Japan|Research Site, Kodaira, Tokyo, Japan|Research Site, Setagaya, Tokyo, Japan|Research Site, Tosima-ku, Tokyo, Japan|Research Site, Fukuoka, Japan|Research Site, Kyoto, Japan",,"https://ClinicalTrials.gov/show/NCT01047553"
128,"NCT01045161","Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)","LAS-MD-38","Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Aclidinium bromide|Drug: Placebo","Part A: Morning Predose (Trough) Forced Expiratory Volume in 1 Second (FEV1)|Part B: Morning Predose (Trough) FEV1|Part A: Peak Forced Expiratory Volume in 1 Second (FEV1)|Part B: Peak FEV1","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","544","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAS-MD-38","March 2009","June 2011","June 2011","January 8, 2010","December 9, 2015","January 23, 2017","Forest Investigative Site 1493, Birmingham, Alabama, United States|Forest Investigative Site 1419, Birmingham, Alabama, United States|Forest Investigative Site 1413, Muscle Shoals, Alabama, United States|Forest Investigative Site 1353, Pell City, Alabama, United States|Forest Investigative Site 1379, Phoenix, Arizona, United States|Forest Investigative Site 2065, Fullerton, California, United States|Forest Investigative Site 1451, National City, California, United States|Forest Investigative Site 1388, Paramount, California, United States|Forest Investigative Site 1424, Rolling Hill Estates, California, United States|Forest Investigative Site 1427, Sacramento, California, United States|Forest Investigative Site 1418, San Diego, California, United States|Forest Investigative Site 2009, San Diego, California, United States|Forest Investigative Site 1374, Torrance, California, United States|Forest Investigative Site 1331, Vista, California, United States|Forest Investigative Site 1380, Golden, Colorado, United States|Forest Investigative Site 1447, Pueblo, Colorado, United States|Forest Investigative Site 1364, Clearwater, Florida, United States|Forest Investigative Site 1516, Edgewater, Florida, United States|Forest Investigative Site 1403, Hollywood, Florida, United States|Forest Investigative Site 1485, Homestead, Florida, United States|Forest Investigative Site 1352, Miami, Florida, United States|Forest Investigative Site 1391, Naples, Florida, United States|Forest Investigative Site 1376, Port Orange, Florida, United States|Forest Investigative Site 1372, South Miami, Florida, United States|Forest Investigative Site 1407, Trinity, Florida, United States|Forest Investigative Site 1185, Winter Park, Florida, United States|Forest Investigative Site 1386, Atlanta, Georgia, United States|Forest Investigative Site 1411, Calhoun, Georgia, United States|Forest Investigative Site 1528, Lawrenceville, Georgia, United States|Forest Investigative Site 0679, Coeur d' Alene, Idaho, United States|Forest Investigative Site 1385, Elk Grove Village, Illinois, United States|Forest Investigative Site 1409, O'Fallon, Illinois, United States|Forest Investigative Site 1479, Anderson, Indiana, United States|Forest Investigative Site 2022, Evansville, Indiana, United States|Forest Investigative Site 1441, Indianapolis, Indiana, United States|Forest Investigative Site 1149, South Bend, Indiana, United States|Forest Investigative Site 1406, Iowa City, Iowa, United States|Forest Investigative Site 1080, Topeka, Kansas, United States|Forest Investigative Site 2033, Bowling Green, Kentucky, United States|Forest Investigative Site 1090, Hazard, Kentucky, United States|Forest Investigative Site 1430, New Orleans, Louisiana, United States|Forest Investigative Site 1446, New Orleans, Louisiana, United States|Forest Investigative Site 1360, Sunset, Louisiana, United States|Forest Investigative Site 1412, Baltimore, Maryland, United States|Forest Investigative Site 1518, North East, Maryland, United States|Forest Investigative Site 1442, Brockton, Massachusetts, United States|Forest Investigative Site 1421, Fall River, Massachusetts, United States|Forest Investigative Site 1029, North Dartmouth, Massachusetts, United States|Forest Investigative Site 1405, Chelsea, Michigan, United States|Forest Investigative Site 0889, Livonia, Michigan, United States|Forest Investigative Site 1487, Troy, Michigan, United States|Forest Investigative Site 1128, Edina, Minnesota, United States|Forest Investigative Site 1527, Fridley, Minnesota, United States|Forest Investigative Site 1124, Minneapolis, Minnesota, United States|Forest Investigative Site 1118, Rochester, Minnesota, United States|Forest Investigative Site 1399, St. Louis, Missouri, United States|Forest Investigative Site 1400, Missoula, Montana, United States|Forest Investigative Site 1354, Bellevue, Nebraska, United States|Forest Investigative Site 1367, Bellevue, Nebraska, United States|Forest Investigative Site 1476, Fremont, Nebraska, United States|Forest Investigative Site 1363, Omaha, Nebraska, United States|Forest Investigative Site 1390, Omaha, Nebraska, United States|Forest Investigative Site 1422, Omaha, Nebraska, United States|Forest Investigative Site 1359, Henderson, Nevada, United States|Forest Investigative Site 1355, Las Vegas, Nevada, United States|Forest Investigative Site 1486, Albuquerque, New Mexico, United States|Forest Investigative Site 1489, Larchmont, New York, United States|Forest Investigative Site 1425, New York, New York, United States|Forest Investigative Site 1373, North Syracuse, New York, United States|Forest Investigative Site 1392, Charlotte, North Carolina, United States|Forest Investigative Site 1366, High Point, North Carolina, United States|Forest Investigative Site 1136, Cincinnati, Ohio, United States|Forest Investigative Site 1371, Cincinnati, Ohio, United States|Forest Investigative Site 1361, Columbus, Ohio, United States|Forest Investigative Site 1433, Columbus, Ohio, United States|Forest Investigative Site 1530, Toledo, Ohio, United States|Forest Investigative Site 1393, Zanesville, Ohio, United States|Forest Investigative Site 1362, Oklahoma City, Oklahoma, United States|Forest Investigative Site 2018, Medford, Oregon, United States|Forest Investigative Site 2043, Medford, Oregon, United States|Forest Investigative Site 1377, Collegeville, Pennsylvania, United States|Forest Investigative Site 1423, Erie, Pennsylvania, United States|Forest Investigative Site 1428, Feasterville, Pennsylvania, United States|Forest Investigative Site 1443, Philadelphia, Pennsylvania, United States|Forest Investigative Site 1510, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 1449, Tipton, Pennsylvania, United States|Forest Investigative Site 1445, Johnston, Rhode Island, United States|Forest Investigative Site 1477, Lincoln, Rhode Island, United States|Forest Investigative Site 1144, Columbia, South Carolina, United States|Forest Investigative Site 1517, Easley, South Carolina, United States|Forest Investigative Site 1506, Grenville, South Carolina, United States|Forest Investigative Site 1450, Union, South Carolina, United States|Forest Investigative Site 1526, Fayetteville, Tennessee, United States|Forest Investigative Site 1356, Knoxville, Tennessee, United States|Forest Investigative Site 1417, Knoxville, Tennessee, United States|Forest Investigative Site 1389, Amarillo, Texas, United States|Forest Investigative Site 1440, Arlington, Texas, United States|Forest Investigative Site 1494, Austin, Texas, United States|Forest Investigative Site 1375, Houston, Texas, United States|Forest Investigative Site 1444, Houston, Texas, United States|Forest Investigative Site 1401, Houston, Texas, United States|Forest Investigative Site 1381, Houston, Texas, United States|Forest Investigative Site 1357, Hurst, Texas, United States|Forest Investigative Site 1426, Plano, Texas, United States|Forest Investigative Site 1410, Tomball, Texas, United States|Forest Investigative Site 1480, Abingdon, Virginia, United States|Forest Investigative Site 1402, Lynchburg, Virginia, United States|Forest Investigative Site 1404, Norfolk, Virginia, United States|Forest Investigative Site 1358, Richmond, Virginia, United States|Forest Investigative Site 0988, Tacoma, Washington, United States|Forest Investigative Site 1177, Vancouver, British Columbia, Canada|Forest Investigative Site 0969, Windsor, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01045161"
129,"NCT01044459","Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)","LAS-MD-35","Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Aclidinium Bromide 200 µg|Drug: Aclidinium Bromide 400 µg","Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Peak FEV1","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","605","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAS-MD-35","November 2009","April 2011","April 2011","January 7, 2010","September 13, 2012","April 20, 2017","Forest Investigative Site 1162, Birmingham, Alabama, United States|Forest Investigative Site 1127, Mobile, Alabama, United States|Forest Investigative Site 1475, Scottsdale, Arizona, United States|Forest Investigative Site 1338, Tempe, Arizona, United States|Forest Investigative Site 1349, Tucson, Arizona, United States|Forest Investigative Site 1483, Buena Park, California, United States|Forest Investigative Site 1350, Foothill Ranch, California, United States|Forest Investigative Site 1509, Fresno, California, United States|Forest Investigative Site 2065, Fullerton, California, United States|Forest Investigative Site 1502, Huntington Park, California, United States|Forest Investigative Site 1088, Lakewood, California, United States|Forest Investigative Site 1534, Long Beach, California, United States|Forest Investigative Site 2209, Los Angeles, California, United States|Forest Investigative Site 1122, Orange, California, United States|Forest Investigative Site 1508, Palm Springs, California, United States|Forest Investigative Site 2064, Riverside, California, United States|Forest Investigative Site 1533, Sacramento, California, United States|Forest Investigative Site 2009, San Diego, California, United States|Forest Investigative Site 1439, San Diego, California, United States|Forest Investigative Site 1503, San Diego, California, United States|Forest Investigative Site 1347, San Jose, California, United States|Forest Investigative Site 1344, Spring Valley, California, United States|Forest Investigative Site 2039, Walnut Creek, California, United States|Forest Investigative Site 2037, Fort Collins, Colorado, United States|Forest Investigative Site 1327, Wheat Ridge, Colorado, United States|Forest Investigative Site 1104, Hartford, Connecticut, United States|Forest Investigative Site 1482, Stamford, Connecticut, United States|Forest Investigative Site 1346, Newark, Delaware, United States|Forest Investigative Site 1154, Brandon, Florida, United States|Forest Investigative Site 1152, Clearwater, Florida, United States|Forest Investigative Site 1514, Coral Gables, Florida, United States|Forest Investigative Site 0670, DeLand, Florida, United States|Forest Investigative Site 1516, Edgewater, Florida, United States|Forest Investigative Site 0990, Fort Lauderdale, Florida, United States|Forest Investigative Site 1513, Hialeah, Florida, United States|Forest Investigative Site 1420, Miami, Florida, United States|Forest Investigative Site 1432, Miami, Florida, United States|Forest Investigative Site 1484, Miramar, Florida, United States|Forest Investigative Site 1340, Ocala, Florida, United States|Forest Investigative Site 1488, Pembroke Pines, Florida, United States|Forest Investigative Site 0974, Pensacola, Florida, United States|Forest Investigative Site 1397, Port Charlotte, Florida, United States|Forest Investigative Site 1383, Port Orange, Florida, United States|Forest Investigative Site 2082, Tamarac, Florida, United States|Forest Investigative Site 2047, Tampa, Florida, United States|Forest Investigative Site 1395, Valrico, Florida, United States|Forest Investigative Site 0980, Atlanta, Georgia, United States|Forest Investigative Site 1491, Atlanta, Georgia, United States|Forest Investigative Site 0987, Austell, Georgia, United States|Forest Investigative Site 1532, Columbus, Georgia, United States|Forest Investigative Site 2051, River Forest, Illinois, United States|Forest Investigative Site 0989, Skokie, Illinois, United States|Forest Investigative Site 1436, Avon, Indiana, United States|Forest Investigative Site 2085, Crescent Springs, Kentucky, United States|Forest Investigative Site 1520, Crestview Hills, Kentucky, United States|Forest Investigative Site 0539, Lexington, Kentucky, United States|Forest Investigative Site 1336, Louisville, Kentucky, United States|Forest Investigative Site 1478, Louisville, Kentucky, United States|Forest Investigative Site 2024, Lafayette, Louisiana, United States|Forest Investigative Site 1333, Baltimore, Maryland, United States|Forest Investigative Site 1421, Fall River, Massachusetts, United States|Forest Investigative Site 1342, Stevensville, Michigan, United States|Forest Investigative Site 1438, Ypsilanti, Michigan, United States|Forest Investigative Site 2041, Minneapolis, Minnesota, United States|Forest Investigative Site 1351, Plymouth, Minnesota, United States|Forest Investigative Site 1100, Florissant, Missouri, United States|Forest Investigative Site 2079, St. Charles, Missouri, United States|Forest Investigative Site 1343, St. Louis, Missouri, United States|Forest Investigative Site 1329, St. Louis, Missouri, United States|Forest Investigative Site 1369, St. Louis, Missouri, United States|Forest Investigative Site 1335, St. Louis, Missouri, United States|Forest Investigative Site 1367, Papillion, Nebraska, United States|Forest Investigative Site 1150, Berlin, New Jersey, United States|Forest Investigative Site 1339, Cherry Hill, New Jersey, United States|Forest Investigative Site 1515, Elizabeth, New Jersey, United States|Forest Investigative Site 1394, Ocean, New Jersey, United States|Forest Investigative Site 2062, Bronxville, New York, United States|Forest Investigative Site 1368, Bronx, New York, United States|Forest Investigative Site 1147, Brooklyn, New York, United States|Forest Investigative Site 1151, New Hyde Park, New York, United States|Forest Investigative Site 1114, New York, New York, United States|Forest Investigative Site 1163, New York, New York, United States|Forest Investigative Site 1481, Newburgh, New York, United States|Forest Investigative Site 0479, Rochester, New York, United States|Forest Investigative Site 2081, Charlotte, North Carolina, United States|Forest Investigative Site 1334, Charlotte, North Carolina, United States|Forest Investigative Site 1366, HighPoint, North Carolina, United States|Forest Investigative Site 1382, Statesville, North Carolina, United States|Forest Investigative Site 1134, Canton, Ohio, United States|Forest Investigative Site 2007, Cincinnati, Ohio, United States|Forest Investigative Site 1434, Cleveland, Ohio, United States|Forest Investigative Site 1433, Columbus, Ohio, United States|Forest Investigative Site 0959, Columbus, Ohio, United States|Forest Investigative Site 1505, Columbus, Ohio, United States|Forest Investigative Site 1435, Dayton, Ohio, United States|Forest Investigative Site 1348, Bend, Oregon, United States|Forest Investigative Site 1504, Hershey, Pennsylvania, United States|Forest Investigative Site 2072, Charleston, South Carolina, United States|Forest Investigative Site 0900, Spartanburg, South Carolina, United States|Forest Investigative Site 1365, Rapid City, South Dakota, United States|Forest Investigative Site 0962, Nashville, Tennessee, United States|Forest Investigative Site 1155, Dallas, Texas, United States|Forest Investigative Site 1328, Dallas, Texas, United States|Forest Investigative Site 1332, El Paso, Texas, United States|Forest Investigative Site 1337, Houston, Texas, United States|Forest Investigative Site 1396, San Antonio, Texas, United States|Forest Investigative Site 1384, San Antonio, Texas, United States|Forest Investigative Site 1330, South Burlington, Vermont, United States|Forest Investigative Site 1120, Bellingham, Washington, United States|Forest Investigative Site 1531, Tacoma, Washington, United States|Forest Investigative Site 2201, Kelowna, British Columbia, Canada|Forest Investigative Site 1157, Toronto, Ontario, Canada|Forest Investigative Site 1168, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01044459"
130,"NCT01042977","Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease",,"Completed","Has Results","Type 2 Diabetes Mellitus|Cardiovascular Disease|Inadequate Glycaemic Control","Drug: Dapagliflozin|Drug: Placebo","Adjusted Mean Change in HbA1c Levels|Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit|Adjusted Mean Percent Change in Body Weight|Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²|Adjusted Mean Change in Systolic Blood Pressure at Week 8 (LOCF)|Adjusted Mean Change in Seated Systolic Blood Pressure at Week 24 (LOCF)|Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg","AstraZeneca|Bristol-Myers Squibb","All","45 Years and older   (Adult, Older Adult)","Phase 3","964","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00019","March 2010","May 2011","December 2012","January 6, 2010","August 23, 2013","February 17, 2014","Research Site, Birmingham, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Bell Gardens, California, United States|Research Site, Chino, California, United States|Research Site, Chula Vista, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Mission Hills, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Torrance, California, United States|Research Site, Aventura, Florida, United States|Research Site, Boca Raton, Florida, United States|Research Site, Bradenton, Florida, United States|Research Site, Brooksville, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Dania, Florida, United States|Research Site, Delray Beach, Florida, United States|Research Site, New Smyrna Beach, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Springfield, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Franklin, Indiana, United States|Research Site, Greenfield, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Waterloo, Iowa, United States|Research Site, Topeka, Kansas, United States|Research Site, Paducah, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Rockville, Maryland, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Livonia, Michigan, United States|Research Site, Billings, Montana, United States|Research Site, Berlin, New Jersey, United States|Research Site, Brick, New Jersey, United States|Research Site, Asheboro, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Altoona, Pennsylvania, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Holland, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Media, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Richardson, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugarland, Texas, United States|Research Site, Alexandria, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Buenos Aires, Caba, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Cordoba, Argentina|Research Site, Salta, Argentina|Research Site, Santa Fe, Argentina|Research Site, Blacktown, New South Wales, Australia|Research Site, Broadmeadow, New South Wales, Australia|Research Site, Hornsby, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, Kippa-ring, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Keswick, South Australia, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Herston, Australia|Research Site, Wien, Austria|Research Site, Blagoevgrad, Bulgaria|Research Site, Pernik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Sevlievo, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Thornhill, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Mirabel, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Santiago, Region Metropolitana, Chile|Research Site, Damme, Germany|Research Site, Dortmund, Germany|Research Site, Homburg, Germany|Research Site, Munster, Germany|Research Site, Wangen, Germany|Research Site, Ajka, Hungary|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Komarom, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, TAT, Hungary|Research Site, Veszprem, Hungary|Research Site, Bialystok, Poland|Research Site, Chrzanow, Poland|Research Site, Gdansk, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Ilawa, Poland|Research Site, Kielce, Poland|Research Site, Krakow, Poland|Research Site, Leczna, Poland|Research Site, Leczyca, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Mragowo, Poland|Research Site, Nowy Sacz, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Ruda Slaska, Poland|Research Site, Skierniewice, Poland|Research Site, Sopot, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Zabrze, Poland|Research Site, Zgierz, Poland|Research Site, Zielona Gora, Poland",,"https://ClinicalTrials.gov/show/NCT01042977"
131,"NCT01031680","Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension",,"Completed","Has Results","Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Control","Drug: Dapagliflozin|Drug: Placebo","Adjusted Mean Change in HbA1c Levels|Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit|Adjusted Mean Change in Seated Systolic Blood Pressure (SBP)|Adjusted Mean Percent Change in Body Weight|Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 24 (LOCF)|Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²","AstraZeneca|Bristol-Myers Squibb","All","45 Years and older   (Adult, Older Adult)","Phase 3","922","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00018","February 2010","May 2011","December 2012","December 14, 2009","August 23, 2013","October 29, 2013","Research Site, Gulf Shores, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Burbank, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Park, California, United States|Research Site, Lancaster, California, United States|Research Site, Salinas, California, United States|Research Site, San Marino, California, United States|Research Site, San Ramon, California, United States|Research Site, Tustin, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Waterbury, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Deerfield Beach, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Park, Florida, United States|Research Site, Columbus, Georgia, United States|Research Site, Decatur, Georgia, United States|Research Site, Stone Mountain, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Wichita, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, West Monroe, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Kansas City, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Brick, New Jersey, United States|Research Site, Oradell, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Phoenixville, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Reading, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Kingsport, Tennessee, United States|Research Site, Carrollton, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tomball, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Danville, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Buenos Aires, Caba, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Santa Fe, Argentina|Research Site, Calgary, Alberta, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Carbonear, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Courtice, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Smiths Falls, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Lachine, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-marc-des-carrieres, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Potsdam, BR, Germany|Research Site, Bad Nauheim, Germany|Research Site, Berlin, Germany|Research Site, Erdmannhausen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Heilbronn, Germany|Research Site, Hildesheim, Germany|Research Site, Mainz, Germany|Research Site, Munster, Germany|Research Site, Potsdam, Germany|Research Site, Speyer, Germany|Research Site, Wahlstedt, Germany|Research Site, Braila, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Constanta, Romania|Research Site, Iasi, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Dolny Kubin, Slovakia|Research Site, Komarno, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kysucke Nove Mesto, Slovakia|Research Site, Liptovsky Hradok, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Nitra, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Prievidza, Slovakia|Research Site, Rimavska Sobota, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Zilina, Slovakia|Research Site, Cordoba, Andalucia, Spain|Research Site, Granada, Andalucia, Spain|Research Site, Sevilla, Andalucia, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Lerida, Cataluna, Spain|Research Site, Olot (girona), Cataluna, Spain|Research Site, Majadahonda, Comunidad de Madrid, Spain|Research Site, San Juan (alicante), Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruna, Galicia, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Palma de Mallorca, Islas Baleares, Spain|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan County, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-yuan, Taiwan|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT01031680"
132,"NCT01029886","Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide once weekly|Drug: liraglutide","Change in HbA1c From Baseline to Week 26|Percentage of Patients Achieving HbA1c <7.0% at Week 26|Change in Fasting Serum Glucose From Baseline to Week 26|Change in Body Weight From Baseline to Week 26|Change in Total Cholesterol From Baseline to Week 26|Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26|Ratio of Fasting Triglycerides at Week 26 to Baseline|Change in Systolic Blood Pressure (SBP) From Baseline to Week 26|Change in Diastolic Blood Pressure (DBP) From Baseline to Week 26|Assessment of Event Rate of Treatment-emergent Hypoglycemic Events","AstraZeneca|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","912","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-MC-GWDE","January 2010","January 2011","April 2011","December 10, 2009","March 21, 2012","April 9, 2015","Research Site, Buenos Aires, Argentina|Research site, Mendoza, Argentina|Research Site, Rosario, Argentina|Research Site, Box Hill, Australia|Research Site, Geelong, Australia|Research Site, Keswick, Australia|Research Site, Vienna, Austria|Research site, Bonheiden, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Charlottetown, Canada|Research Site, Gatineau, Canada|Research Site, Ottawa, Canada|Research Site, Sherbrooke, Canada|Research Site, Vancouver, Canada|Research Site, Victoria, Canada|Research Site, Windsor, Canada|Research Site, Winnipeg, Canada|Research Site, Brandys nad Labem, Czech Republic|Research Site, Prague 2, Czech Republic|Research Site, Prerov, Czech Republic|Research Site, Grenoble, France|Research Site, Le Creuzot, France|Research Site, Marseille Cedex 5, France|Research Site, Marseille Cedex 9, France|Research Site, Marseille, France|Research Site, Paris, France|Research Site, Poitiers, France|Research Site, Reims Cedex, France|Research Site, Strasbourg, France|Research Site, Bad Staffelstein, Germany|Research Site, Beckum, Germany|Research Site, Biberach, Germany|Research Site, Datteln, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Ludwigshafen, Germany|Research Site, Mainz, Germany|Research Site, Meissen, Germany|Research Site, Muenster, Germany|Research Site, Regensburg, Germany|Research Site, Riesa, Germany|Research Site, Stuttgart, Germany|Research Site, Athens, Greece|Research Site, Cholargos, Greece|Research Site, Patras, Greece|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Mako, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Nagykanizsa, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Aligarh, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Coimbatore, India|Research Site, Hyderabad, India|Research Site, Indore, India|Research Site, Karnal/Haryana, India|Research site, Karnataka, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Raanana, Israel|Research Site, Bari, Italy|Research Site, Cagliari, Italy|Research Site, Catanzaro, Italy|Research Site, Chieti, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Treviglio, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Bialystok, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Poznan, Poland|Research site, Rzeszow, Poland|Research Site, Warszawa, Poland|Research site, Bucuresti, Romania|Research site, Galati, Romania|Research site, Iasi, Romania|Research site, Oradea, Romania|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Malacky, Slovakia|Research Site, Martin, Slovakia|Research Site, Halfway House, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kempton Park, South Africa|Research Site, Parktown, South Africa|Research Site, Pretoria, South Africa|Research Site, Alcira, Spain|Research Site, Alicante, Spain|Research Site, Bilbao, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Teruel, Spain|Research Site, Changhua, Taiwan|Research Site, Jhonghe, Taiwan|Research Site, Sindian, Taiwan|Research Site, Taichung, Taiwan|Research Site, Yung-Kang, Tainan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01029886"
133,"NCT01003184","Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide once weekly|Drug: insulin detemir","Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26)|Percentage of Patients Who Have Achieved HbA1c ≤7.4% With Weight Loss (≥1.0 kg) at Endpoint (Week 26)|Change in HbA1c From Baseline to Week 26|Change in Body Weight From Baseline to Week 26|Percentage of Patients Achieving HbA1c ≤7.4% at Endpoint|Percentage of Patients Achieving ≤7.0% at Endpoint|Percentage of Patients Achieving ≤6.5% at Endpoint|Change in Fasting Serum Glucose From Baseline to Endpoint (Week 26).|Changes in Systolic Blood Pressure From Baseline to Week 26|Change in Diastolic Blood Pressure From Baseline to Week 26.|Change in Total Cholesterol From Baseline to Endpoint (Week 26).|Change in High-density Lipoprotein (HDL) Cholesterol From Baseline to Endpoint (Week 26).|Change in Triglycerides From Baseline to Endpoint (Week 26).|Hypoglycemia Rate Per Year","AstraZeneca|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","222","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-EW-GWDL","October 2009","July 2011","December 2011","October 28, 2009","December 18, 2012","April 7, 2015","Research Site, Dublin, Ireland|Research Site, Addlestone, England, United Kingdom|Research Site, Bath, England, United Kingdom|Research Site, Birmingham, England, United Kingdom|Research Site, Blackburn, England, United Kingdom|Research Site, Bournemouth, England, United Kingdom|Research Site, Chippenham, England, United Kingdom|Research Site, Derby, England, United Kingdom|Research Site, Exeter, England, United Kingdom|Research Site, High Wycombe, England, United Kingdom|Research Site, Hull, England, United Kingdom|Research Site, Leicester, England, United Kingdom|Research Site, Liverpool, England, United Kingdom|Research Site, London, England, United Kingdom|Research Site, Manchester, England, United Kingdom|Research Site, Merseyside, England, United Kingdom|Research Site, Middlesborough, England, United Kingdom|Research Site, Newcastle, England, United Kingdom|Research Site, Northampton, England, United Kingdom|Research Site, Oldham, England, United Kingdom|Research Site, Plymouth, England, United Kingdom|Research Site, Portsmouth, England, United Kingdom|Research Site, Sheffield, England, United Kingdom|Research Site, Stevenage, England, United Kingdom|Research Site, Suffolk, England, United Kingdom|Research Site, Wakefield, England, United Kingdom|Research Site, Wiltshire, England, United Kingdom|Research Site, Aberdeen, Scotland, United Kingdom|Research Site, Dundee, Scotland, United Kingdom|Research Site, Carmathen, Wales, United Kingdom|Research Site, Swansea, Wales, United Kingdom|Research Site, Wrexham, Wales, United Kingdom|Research Site, Leytonstone, United Kingdom|Research Site, Livingston, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01003184"
134,"NCT01001494","Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Aclidinium bromide 200 μg bid|Drug: Aclidinium bromide 400 μg bid|Drug: Placebo","Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment|Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 12 on Treatment|Change From Baseline in Peak Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment|Percentage of Patients Who Achieved at Least a 1-unit Decrease From Baseline in TDI Focal Score at Week 24 on Treatment|Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at Week 24 on Treatment","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","828","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M/34273/34|ATTAIN","October 2009","November 2010","November 2010","October 26, 2009","September 17, 2012","January 4, 2017","Almirall Investigational Sites#4, Benesov, Czech Republic|Almirall Investigational Sites#9, Jaromer, Czech Republic|Almirall Investigational Sites#3, Liberec, Czech Republic|Almirall Investigational Sites#2, Lovosice, Czech Republic|Almirall Investigational Sites#1, Neratovice, Czech Republic|Almirall Investigational Sites#11, Praha, Czech Republic|Almirall Investigational Sites#6, Praha, Czech Republic|Almirall Investigational Sites#12, Praha, Czech Republic|Almirall Investigational Sites#7, Praha, Czech Republic|Almirall Investigational Sites#10, Strakonice, Czech Republic|Almirall Investigational Sites#3, Clermont-Ferrand Cedex, France|Almirall Investigational Sites#1, Marseille Cedex 20, France|Almirall Investigational Sites#2, Marseille, France|Almirall Investigational Sites#6, Montpellier, France|Almirall Investigational Sites#4, Toulouse Cedex, France|Almirall Investigational Sites#8, Berlin, Germany|Almirall Investigational Sites#9, Berlin, Germany|Almirall Investigational Sites#6, Berlin, Germany|Almirall Investigational Sites#14, Berlin, Germany|Almirall Investigational Site#7, Berlin, Germany|Almirall Investigational Sites#12, Bonn, Germany|Almirall Investigational Sites#3, Dortmund, Germany|Almirall Investigational Sites#13, Frankfurt, Germany|Almirall Investigational Sites#15, Gelsenkirchen, Germany|Almirall Investigational Sites#1, Grosshansdorf, Germany|Almirall Investigational Sites#5, Hamburg, Germany|Almirall Investigational Sites#4, Hamburg, Germany|Almirall Investigational Site#16, Hannover, Germany|Almirall Investigational Sites#18, Jena, Germany|Almirall Investigational Sites#10, Koln, Germany|Almirall Investigational Sites#11, Mainz, Germany|Almirall Investigational Site#2, Rüdersdorf, Germany|Almirall Investigational Sites#13, Budapest, Hungary|Almirall Investigational Sites#4, Budapest, Hungary|Almirall Investigational Sites#1, Budapest, Hungary|Almirall Investigational Sites#2, Budapest, Hungary|Almirall Investigational Sites#6, Debrecen, Hungary|Almirall Investigational Sites#5, Debrecen, Hungary|Almirall Investigational Sites#7, Deszk, Hungary|Almirall Investigational Sites#10, Dunaüjváros, Hungary|Almirall Investigational Sites#9, Mátraháza, Hungary|Almirall Investigational Sites#12, Pécs, Hungary|Almirall Investigational Sites#11, Ráckeve, Hungary|Almirall Investigational Sites#3, Százhalombatta, Hungary|Almirall Investigational Sites#8, Zalaegerszeg, Hungary|Almirall Investigational Sites#3, Cagliari, Italy|Almirall Investigational Sites#1, Genova, Italy|Almirall Investigational Sites#10, Pisa, Italy|Almirall Investigational Sites#8, Cusco, Peru|Almirall Investigational Sites#12, Białystok, Poland|Almirall Investigational Sites#9, Białystok, Poland|Almirall Investigational Sites#19, Elblag, Poland|Almirall Investigational Sites#18, Gdansk, Poland|Almirall Investigational Sites#20, Ilawa, Poland|Almirall Investigational Sites#7, Lodz, Poland|Almirall Investigational Sites#1, Lodz, Poland|Almirall Investigational Sites#8, Lublin, Poland|Almirall Investigational Sites#24, Olsztyn, Poland|Almirall Investigational Sites#5, Olsztyn, Poland|Almirall Investigational Sites#21, Poznan, Poland|Almirall Investigational Sites#16, Poznan, Poland|Almirall Investigational Site#11, Proszowice, Poland|Almirall Investigational Sites#2, Ruda Slaska, Poland|Almirall Investigational Sites#13, Rudka, Poland|Almirall Investigational Sites#4, Sopot, Poland|Almirall Investigational Sites#14, Szczecin, Poland|Almirall Investigational Sites#6, Tarnow, Poland|Almirall Investigational Sites#15, Tarnów, Poland|Almirall Investigational Sites#25, Warszawa, Poland|Almirall Investigational Sites#23, Wilkowice-Bystra, Poland|Almirall Investigational Site#10, Wrocław, Poland|Almirall Investigational Sites#7, Ekaterinburg, Russian Federation|Almirall Investigational Sites#5, Kazan, Russian Federation|Almirall Investigational Sites#2, Moscow, Russian Federation|Almirall Investigational Sites#14, Moscow, Russian Federation|Almirall Investigational Sites#6, Moscow, Russian Federation|Almirall Investigational Sites#13, Novosibirsk, Russian Federation|Almirall Investigational Sites#10, Saint-Petersburg, Russian Federation|Almirall Investigational Sites#3, Saint-Petersburg, Russian Federation|Almirall Investigational Sites#4, Saint-Petersburg, Russian Federation|Almirall Investigational Sites#8, Tomsk, Russian Federation|Almirall Investigational Sites#12, Tomsk, Russian Federation|Almirall Investigational Sites#8, Bloemfontein, South Africa|Almirall Investigational Sites#11, Bloemfontein, South Africa|Almirall Investigational Sites#3, Bloemfontein, South Africa|Almirall Investigational Sites#10, Cape Town, South Africa|Almirall Investigational Sites#1, Cape Town, South Africa|Almirall Investigational Sites#12, Cape Town, South Africa|Almirall Investigational Sites#15, Cape Town, South Africa|Almirall Investigational Sites#2, Durban, South Africa|Almirall Investigational Sites#9, George, South Africa|Almirall Investigational Sites#4, Port Elizabeth, South Africa|Almirall Investigational Sites#5, Pretoria, South Africa|Almirall Investigational Sites#14, Pretoria, South Africa|Almirall Investigational Sites#6, Pretoria, South Africa|Almirall Investigational Sites#6, Badalona, Spain|Almirall Investigational Sites#8, Barcelona, Spain|Almirall Investigational Sites#7, Barcelona, Spain|Almirall Investigational Sites#3, Madrid, Spain|Almirall Investigational Sites#5, Valencia, Spain|Almirall Investigational Sites#4, Donetsk, Ukraine|Almirall Investigational Sites#3, Kharkiv, Ukraine|Almirall Investigational Sites#1, Kyiv, Ukraine|Almirall Investigational Sites#2, Kyiv, Ukraine|Almirall Investigational Sites#7, Kyiv, Ukraine|Almirall Investigational Sites#5, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01001494"
135,"NCT00984867","Dapagliflozin DPPIV Inhibitor add-on Study",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Placebo","Adjusted Mean Change in HbA1c Levels|Adjusted Mean Change in Body Weight|Adjusted Mean Change in HbA1c in Participants With Baseline HbA1c ≥8%|Adjusted Mean Change in Fasting Plasma Glucose (FPG)|Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) in Participants With Baseline SBP>=130 mmHg|Adjusted Mean Change in 2-hour Post Liquid Meal Glucose Rise|Proportion of Participants Achieving a Therapeutic Glycemic Response Defined as a Reduction in HbA1c of ≥0.7% Compared to Baseline","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","833","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00010","October 2009","March 2011","September 2011","September 25, 2009","October 14, 2013","June 13, 2014","Research Site, Huntsville, Alabama, United States|Research Site, Ozark, Alabama, United States|Research Site, Anaheim, California, United States|Research Site, Chula Vista, California, United States|Research Site, Greenbrae, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Riverside, California, United States|Research Site, West Hills, California, United States|Research Site, Boca Raton, Florida, United States|Research Site, Deland, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Longwood, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Port Orange, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Stone Mountain, Georgia, United States|Research Site, Wichita, Kansas, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Edina, Minnesota, United States|Research Site, St Louis, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Pahrump, Nevada, United States|Research Site, Staten Island, New York, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medord, Oregon, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Mount Pleasant, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Simpsonville, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, North Richland Hills, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Lakewood, Washington, United States|Research Site, Berazategui, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Lanus, Buenos Aires, Argentina|Research Site, Mar Del Plata, Buenos Aires, Argentina|Research Site, Moron, Buenos Aires, Argentina|Research Site, Buenos Aires, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Cordoba, Argentina|Research Site, Salta, Argentina|Research Site, Santa Fe, Argentina|Research Site, Bad Nauheim, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Meissen, Germany|Research Site, Munster, Germany|Research Site, Pirna, Germany|Research Site, Wangen, Germany|Research Site, Mexico, DF, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Ciechocinek, Poland|Research Site, Czechowice-dziedzice, Poland|Research Site, Gdansk, Poland|Research Site, Gniewkowo, Poland|Research Site, Krakow, Poland|Research Site, Krotoszyn, Poland|Research Site, Leczyca, Poland|Research Site, Mragowo, Poland|Research Site, Poznan, Poland|Research Site, Sopot, Poland|Research Site, Torun, Poland|Research Site, Zabrze, Poland|Research Site, Bolton, Lancs, United Kingdom|Research Site, Burbage, Leicester, United Kingdom|Research Site, Sunbury on Thames, Middlesex, United Kingdom|Research Site, Wansford, Peterborough, United Kingdom|Research Site, Ecclesfield, Sheffield, United Kingdom|Research Site, Addlestone, Surrey, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00984867"
136,"NCT00970268","Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Aclidinium bromide","Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Peak FEV1","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","291","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAS-MD-36","August 2009","October 2010","October 2010","September 2, 2009","September 14, 2012","January 6, 2017","Forest Investigative Site 1162, Birmingham, Alabama, United States|Forest Investigative Site 1127, Mobile, Alabama, United States|Forest Investigative Site 0909, Glendale, Arizona, United States|Forest Investigative Site 2060, Phoenix, Arizona, United States|Forest Investigative Site 2065, Fullerton, California, United States|Forest Investigative Site 1088, Lakewood, California, United States|Forest Investigative Site 1122, Orange, California, United States|Forest Investigative Site 2029, Rancho Mirage, California, United States|Forets Investigative Site 2064, Riverside, California, United States|Forest Investigative Site 0517, Sacramento, California, United States|Forest Investigative Site 2009, San Diego, California, United States|Forest Investigative Site 1137, Colorado Springs, Colorado, United States|Forest Investigative Site 2100, Waterbury, Connecticut, United States|Forest Investigative Site 1154, Brandon, Florida, United States|Forest Investigative Site 1152, Clearwater, Florida, United States|Forest Investigative Site 0670, DeLand, Florida, United States|Forest Investigative Site 0990, Fort Lauderdale, Florida, United States|Forest Investigative Site 1167, Melbourne, Florida, United States|Forest Investigative Site 1060, Ormond Beach, Florida, United States|Forest Investigative Site 0974, Pensacola, Florida, United States|Forest Investigative Site 2082, Tamarac, Florida, United States|Forest Investigative Site 2053, Tampa, Florida, United States|Forest Investigative Site 2047, Tampa, Florida, United States|Forest Investigative Site 1185, Winter Park, Florida, United States|Forest Investigative Site 1183, Atlanta, Georgia, United States|Forest Investigative Site 0987, Austell, Georgia, United States|Forest Investigative Site 1101, Blue Ridge, Georgia, United States|Forest Investigative Site 1180, Decatur, Georgia, United States|Forest Investigative Site 1161, Duluth, Georgia, United States|Forest Investigative Site 2051, River Forest, Illinois, United States|Forest Investigative Site 0989, Skokie, Illinois, United States|Forest Investigative Site 1149, South Bend, Indiana, United States|Forest Investigative Site 2085, Crescent Springs, Kentucky, United States|Forest Investigative Site 0539, Lexington, Kentucky, United States|Forest Investigative Site 2024, Lafayette, Louisiana, United States|Forest Investigative Site 2040, Biddeford, Maine, United States|Forest Investigative Site 1128, Edina, Minnesota, United States|Forest Investigative Site 2041, Minneapolis, Minnesota, United States|Forest Investigative Site 1124, Minneapolis, Minnesota, United States|Forest Investigative Site 1100, Florissant, Missouri, United States|Forest Investigative Site 2079, St. Charles, Missouri, United States|Forest Investigative Site 2067, Butte, Montana, United States|Forest Investigative Site 1169, Papillion, Nebraska, United States|Forest Investigative Site 1150, Berlin, New Jersey, United States|Forest Investigative Site 2084, Summit, New Jersey, United States|Forest Investigative Site 1147, Brooklyn, New York, United States|Forest Investigative Site 1119, Elmira, New York, United States|Forest Investigative Site 1151, New Hyde Park, New York, United States|Forest Investigative Site 1141, New York, New York, United States|Forest Investigative Site 1163, New York, New York, United States|Forest Investigative Site 1130, Asheville, North Carolina, United States|Forest Investigative Site 1134, Canton, Ohio, United States|Forest Investigative Site 1181, Centerville, Ohio, United States|Forest Investigative Site 1136, Cincinnati, Ohio, United States|Forest Investigative Site 2007, Cincinnati, Ohio, United States|Forest Investigative Site 2028, Cincinnati, Ohio, United States|Forest Investigative Site 0959, Columbus, Ohio, United States|Forest Investigative Site 2006, Columbus, Ohio, United States|Forest Investigative Site 2043, Medford, Oregon, United States|Forest Investigative Site 1106, Portland, Oregon, United States|Forest Investigative Site 1126, Bethlehem, Pennsylvania, United States|Forest Investigative Site 2016, Erie, Pennsylvania, United States|Forest Investigative Site 1146, Pittsburgh, Pennsylvania, United States|Forest Investigative Site 1158, Upland, Pennsylvania, United States|Forest Investigative Site 1089, East Providence, Rhode Island, United States|Forest Investigative Site 1144, Johnston, Rhode Island, United States|Forest Investigative Site 2072, Charleston, South Carolina, United States|Forest Investigative Site 1078, Greenville, South Carolina, United States|Forest Investigative Site 2080, Greer, South Carolina, United States|Forest Investigative Site 1121, Spartanburg, South Carolina, United States|Forest Investigative Site 1155, Dallas, Texas, United States|Forest Investigative Site 2012, Fort Worth, Texas, United States|Forest Investigative Site 1165, San Antonio, Texas, United States|Forest Investigative Site 1129, Waco, Texas, United States|Forest Investigative Site 2099, Richmond, Virginia, United States|Forest Investigative Site 1142, Spokane, Washington, United States|Forest Investigative Site 0988, Tacoma, Washington, United States|Forest Investigative Site 2201, Kelowna, British Columbia, Canada|Forest Investigative Site 1177, Vancouver, British Columbia, Canada|Forest Investigative Site 2200, Niagara Falls, Ontario, Canada|Forest Investigative Site 1168, Toronto, Ontario, Canada|Forest Investigative Site 1171, Toronto, Ontario, Canada|Forest Investigative Site 2203, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00970268"
137,"NCT00960661","A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide|Drug: insulin lispro|Drug: Metformin|Drug: Insulin/ Glargine","Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30|Percentage of Participants Achieving HbA1C < 7.0%|Percent of Participants Achieving HbA1c ≤ 6.5%.|Change in Fasting Blood Glucose (FBG) From Baseline to Week 30.|Change in Total Cholesterol From Baseline to Week 30|Change in High Density Lipoprotein (HDL) From Baseline to Week 30|Change in Low Density Lipoprotein (LDL) From Baseline to Week 30|Change in Body Weight From Baseline to Week 30.|Change in Systolic Blood Pressure (SBP) From Baseline to Week 30|Change in Diastolic Blood Pressure (DBP) From Baseline to Week 30|Daily Insulin Glargine Dose at Baseline and at Week 30|Major Hypoglycemia Rate Per Year|Minor Hypoglycemia Rate Per Year","AstraZeneca|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1036","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-EW-GWDM","September 2009","August 2012","August 2012","August 18, 2009","December 17, 2013","April 7, 2015","Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad Autonoma de Buenos Aire, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Corrientes, Argentina|Research Site, Rosario, Argentina|Research Site, San Rafael, Argentina|Research Site, Arlon, Belgium|Research Site, Bonheiden, Belgium|Research Site, Edegem, Belgium|Research Site, Merksem, Belgium|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Helsinki, Finland|Research Site, Oulu, Finland|Research Site, Vantaa, Finland|Research Site, Angers, France|Research Site, Auxerre, France|Research Site, Bar Le Duc, France|Research Site, Douai Cedex, France|Research Site, La Roche Sur Yon, France|Research Site, La Rochelle Cedex 1, France|Research Site, Le Creuzot, France|Research Site, Lille Cedex, France|Research Site, Marseille Cedex 20, France|Research Site, Montpellier Cedex 5, France|Research Site, Nanterre, France|Research Site, Pessac Cedex, France|Research Site, Rennes Cedex 2, France|Research Site, Strasbourg, France|Research Site, Toulouse Cedex 9, France|Research Site, Venissieux, France|Research Site, Bad Lauterberg, Germany|Research Site, Dippoldiswalde, Germany|Research Site, Friedrichsthal, Germany|Research Site, Goch, Germany|Research Site, Grevenbroich, Germany|Research Site, Hamburg, Germany|Research Site, Mainz, Germany|Research Site, Saarbruecken, Germany|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Firenze, Italy|Research Site, Napoli, Italy|Research Site, Olbia, Italy|Research Site, Perugia, Italy|Research Site, Trieste, Italy|Research Site, Verona, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Ulsan-Si, Korea, Republic of|Research Site, Wonju-Si, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Cuernavaca, Mexico|Research Site, Mexico City, Mexico|Research Site, Monterrey, Mexico|Research Site, Almere, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Beek, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Groningen, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Sittard-Geleen, Netherlands|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisbon, Portugal|Research Site, Portugal, Portugal|Research Site, Hato Rey, Puerto Rico|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Constanta, Romania|Research Site, Craiova, Romania|Research Site, Oradea, Romania|Research Site, Ploiesti, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Dos Hermanas, Spain|Research Site, La Coruna, Spain|Research Site, Santander, Spain|Research Site, Valencia, Spain|Research Site, Halmstad, Sweden|Research Site, Karlstad, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Solna, Sweden|Research Site, Stockholm, Sweden|Research Site, Umea, Sweden|Research Site, Bournemouth, United Kingdom|Research Site, Ipswich, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Penarth, United Kingdom|Research Site, Wakefield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00960661"
138,"NCT00960076","An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes","SCORE","Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Metformin XR","Change in HbA1c Level From Baseline to Week 18 (LOCF)|Change in 2-hour PPG Following Mixed Meal Tolerance Test (MMTT) From Baseline to Week 18 (LOCF)|Change in FPG From Baseline to Week 18 (LOCF)|Percent of Subjects Reaching Goal (HbA1c <7%) at Week 18 (LOCF) - Percent of Subjects (1)","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 78 Years   (Adult, Older Adult)","Phase 3","282","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680L00005","August 2009","October 2010","October 2010","August 17, 2009","September 27, 2011","September 27, 2011","Research Site, Jonesboro, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Los Angeles, California, United States|Research Site, Pasadena, California, United States|Research Site, Sacramento, California, United States|Research Site, Gainesville, Florida, United States|Research Site, Wellington, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, St Louis, Missouri, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Marion, Ohio, United States|Research Site, Simpsonville, South Carolina, United States|Research Site, Bristol, Tennessee, United States|Research Site, Alexandria, Virginia, United States|Research Site, Burke, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Barranquilla, Atlantico, Colombia|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Curridabat, San Jose, Costa Rica|Research Site, Los Yoses, San Jose, Costa Rica|Research Site, Heredia, Costa Rica|Research Site, Mexico, D.f., Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Durango, Mexico|Research Site, Queretaro, Mexico|Research Site, Lima, Peru",,"https://ClinicalTrials.gov/show/NCT00960076"
139,"NCT00935532","Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide once weekly|Drug: insulin glargine","Change in HbA1c From Baseline to Endpoint (Week 26)|Percentage of Subjects Achieving HbA1c<=7%|Percentage of Subjects Achieving HbA1c<=6.5%|Change in Fasting Serum Glucose (FSG) From Baseline to Endpoint (Week 26)|Change in Body Weight From Baseline to Endpoint (Week 26)|Change in Total Cholesterol From Baseline to Endpoint (Week 26)|Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Endpoint (Week 26)|Ratio of Fasting Triglycerides at Endpoint (Week 26) to Baseline|Change in Blood Pressure From Baseline to Endpoint (Week 26)|Assessment on Event Rate of Treatment-emergent Major Hypoglycemic Events|Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events","AstraZeneca|Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 3","427","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-JE-GWBX","July 2009","September 2010","July 2011","July 9, 2009","October 24, 2012","June 15, 2015","Research Site, Aomori, Japan|Research Site, Chiba, Japan|Research Site, Ehime, Japan|Research Site, Fukuoka, Japan|Research Site, Gunma, Japan|Research Site, Hiroshima, Japan|Research Site, Hokkaido, Japan|Research Site, Hyogo, Japan|Research Site, Ibaragi, Japan|Research Site, Kagawa, Japan|Research Site, Kanagawa, Japan|Research Site, Kumamoto, Japan|Research Site, Kyoto, Japan|Research Site, Nagano, Japan|Research Site, Nagasaki, Japan|Research Site, Nara, Japan|Research Site, Oita, Japan|Research Site, Osaka, Japan|Research Site, Saitama, Japan|Research Site, Shizuoka, Japan|Research Site, Tokyo, Japan|Research Site, Toyama, Japan",,"https://ClinicalTrials.gov/show/NCT00935532"
140,"NCT00918879","Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo","Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)|Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG)|Proportion of Patients (Expressed in Percentage of Total Participants) Achieving a Therapeutic Glycemic Response Defined as HbA1c < 7.0% at Week 24","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","213","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680C00008","May 2009","July 2010","July 2010","June 11, 2009","September 26, 2011","September 26, 2011","Research Site, Gujarat, Ahmedabad, India|Research Site, Karnataka, Bangalore, India|Research Site, Tamil Nadu, Chennai, India|Research Site, Tamil Nadu, Coimbatore, India|Research Site, Andhra Pradesh, Hyderabad, India|Research Site, Madhya Pradesh, Indore, India|Research Site, Haryana, Karnal, India|Research Site, Kerala, Kochi, India|Research Site, Maharashtra, Pune, India",,"https://ClinicalTrials.gov/show/NCT00918879"
141,"NCT00918138","Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Metformin XR|Drug: Placebo matching Metformin XR|Drug: Placebo matching Saxagliptin","Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4|Change From Baseline to Week 4 in 2-hour Postprandial Glucose (PPG) (2 Hours After the Evening Meal)|Change From Baseline Fasting Plasma Glucose (FPG) at Week 4, Obtained Immediately Before the Morning Meal","AstraZeneca","All","18 Years to 78 Years   (Adult, Older Adult)","Phase 3","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CV181-085","August 2009","May 2010","May 2010","June 11, 2009","October 6, 2011","May 21, 2015","Dedicated Phase I, Inc., Phoenix, Arizona, United States|Pacific Sleep Medicine Services (Avastra Clinical Trials), Redlands, California, United States|Orange County Research Center, Tustin, California, United States|Clinical Research Of South Florida, Coral Gables, Florida, United States|Palm Springs Research Institute, Hialeah, Florida, United States|Healthcare Clinical Data, Inc., North Miami, Florida, United States|River Birch Research Alliance, Llc, Blue Ridge, Georgia, United States|Jasper Clinic, Inc., Kalamazoo, Michigan, United States|Clinilabs, Inc., New York, New York, United States|Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States|Clinical Trials Of Texas Inc., San Antonio, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Beer-Sheva, Israel|Local Institution, Holon, Israel|Local Institution, Kfar-Saba, Israel|Local Institution, Zefat, Israel|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Durango, Mexico|Local Institution, Durango, Mexico",,"https://ClinicalTrials.gov/show/NCT00918138"
142,"NCT00917267","A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide once weekly|Drug: exenatide twice daily","Change in HbA1c From Baseline to Week 26.|Percentage of Patients Achieving HbA1c Targets <=7% at Week 26|Percentage of Patients Achieving HbA1c Targets <=6.5% at Week 26|Change in Fasting Serum Glucose (FSG) From Baseline to Week 26|Change in Body Weight (BW) From Baseline to Week 26|Change in Total Cholesterol (TC) From Baseline to Week 26|Change in High-Density Lipoprotein (HDL) From Baseline to Week 26|Ratio of Triglycerides (TG) at Week 26 to Baseline|Change in Blood Pressure From Baseline to Week 26|Assessment of Event Rate of Treatment-emergent Hypoglycemic Events","AstraZeneca|Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 3","691","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-MC-GWCK","July 2009","September 2010","April 2011","June 10, 2009","December 31, 2012","April 9, 2015","Research Site, Beijing, China|Research Site, Chengdu, China|Research Site, Chongqin, China|Research Site, Guangzhou, China|Research Site, Shanghai, China|Research Site, Ahmedabad, India|Research Site, Aligarh, India|Research Site, Bangalore, India|Research Site, Ghaziabad, India|Research Site, Hyderabaad, India|Research Site, Indore, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Trivandrum, India|Research Site, Uttar Pradesh, India|Research Site, Varanasi, India|Research Site, Ageo, Japan|Research Site, Chiyoda-ku, Japan|Research Site, Izumisano, Japan|Research Site, Kashiwara, Japan|Research Site, Kitaazumi-gun, Japan|Research Site, Kumamoto, Japan|Research Site, Kurume, Japan|Research Site, Matsumoto, Japan|Research Site, Matsuyama, Japan|Research Site, Miyazaki-shi, Japan|Research Site, Ooita-shi, Japan|Research Site, Osaka, Japan|Research Site, Ota-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Takatsuki, Japan|Research Site, Yokohama, Japan|Research Site, Bucheon, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Changhua, Taiwan|Research Site, Chia-Yi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00917267"
143,"NCT00891462","Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Aclidinium bromide|Drug: Placebo","Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1)|Change From Baseline in Peak Forced Expiratory Volume in 1 Second (FEV1)","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","561","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAS-MD-33|ACCORD COPD I","April 2009","November 2009","November 2009","May 1, 2009","September 13, 2012","January 6, 2017","Forest Investigative Site, Birmingham, Alabama, United States|Forest Investigative Site, Jasper, Alabama, United States|Forest Investigative Site, Mobile, Alabama, United States|Forest Investigative Site, Mesa, Arizona, United States|Forest Investigative Site, Phoenix, Arizona, United States|Forest Investigative Site, Phoenix, Arizona, United States|Forest Investigative Site, Anaheim, California, United States|Forest Investigative Site, Encinitas, California, United States|Forest Investigative Site, Fresno, California, United States|Forest Investigative Site, Fullerton, California, United States|Forest Investigative Site, Lakewood, California, United States|Forest Investigative Site, Orange, California, United States|Forest Investigative Site, Palo Alto, California, United States|Forest Investigative Site, Rancho Mirage, California, United States|Forest Investigative Site, Sacramento, California, United States|Forest Investigative Site, San Diego, California, United States|Forest Investigative Site, San Diego, California, United States|Forest Investigative Site, Colorado Springs, Colorado, United States|Forest Investigative Site, Denver, Colorado, United States|Forest Investigative Site, Wheat Ridge, Colorado, United States|Forest Investigative Site, Waterbury, Connecticut, United States|Forest Investigative Site, Brandon, Florida, United States|Forest Investigative Site, Clearwater, Florida, United States|Forest Investigative Site, DeLand, Florida, United States|Forest Investigative Site, Fort Lauderdale, Florida, United States|Forest Investigative Site, Melbourne, Florida, United States|Forest Investigative Site, Melbourne, Florida, United States|Forest Investigative Site, Ormond Beach, Florida, United States|Forest Investigative Site, Panama City, Florida, United States|Forest Investigative Site, Pensacola, Florida, United States|Forest Investigative Site, Tamarac, Florida, United States|Forest Investigative Site, Tampa, Florida, United States|Forest Investigative Site, Tampa, Florida, United States|Forest Investigative Site, Austell, Georgia, United States|Forest Investigative Site, Blue Ridge, Georgia, United States|Forest Investigative Site, Duluth, Georgia, United States|Forest Investigative Site, Marietta, Georgia, United States|Forest Investigative Site, River Forest, Illinois, United States|Forest Investigative Site, Skokie, Illinois, United States|Forest Investigative Site, South Bend, Indiana, United States|Forest Investigative Site, Crescent Springs, Kentucky, United States|Forest Investigative Site, Lexington, Kentucky, United States|Forest Investigative Site, Lafayette, Louisiana, United States|Forest Investigative Site, Bangor, Maine, United States|Forest Investigative Site, Baltimore, Maryland, United States|Forest Investigative Site, Baltimore, Maryland, United States|Forest Investigative Site, Hagerstown, Maryland, United States|Forest Investigative Site, North Dartmouth, Massachusetts, United States|Forest Investigative Site, Livonia, Michigan, United States|Forest Investigative Site, Edina, Minnesota, United States|Forest Investigative Site, Minneapolis, Minnesota, United States|Forest Investigative Site, Minneapolis, Minnesota, United States|Forest Investigative Site, Florissant, Missouri, United States|Forest Investigative Site, Saint Charles, Missouri, United States|Forest Investigative Site, Billings, Montana, United States|Forest Investigative Site, Butte, Montana, United States|Forest Investigative Site, Papillion, Nebraska, United States|Forest Investigative Site, Berlin, New Jersey, United States|Forest Investigative Site, Summit, New Jersey, United States|Forest Investigative Site, Brooklyn, New York, United States|Forest Investigative Site, Buffalo, New York, United States|Forest Investigative Site, Great Neck, New York, United States|Forest Investigative Site, Ithaca, New York, United States|Forest Investigative Site, New Hyde Park, New York, United States|Forest Investigative Site, New York, New York, United States|Forest Investigative Site, New York, New York, United States|Forest Investigative Site, Asheville, North Carolina, United States|Forest Investigative Site, Charlotte, North Carolina, United States|Forest Investigative Site, Raleigh, North Carolina, United States|Forest Investigative Site, Canton, Ohio, United States|Forest Investigative Site, Cincinnati, Ohio, United States|Forest Investigative Site, Cincinnati, Ohio, United States|Forest Investigative Site, Cincinnati, Ohio, United States|Forest Investigative Site, Columbus, Ohio, United States|Forest Investigative Site, Toledo, Ohio, United States|Forest Investigative Site, Oklahoma City, Oklahoma, United States|Forest Investigative Site, Medford, Oregon, United States|Forest Investigative Site, Portland, Oregon, United States|Forest Investigative Site, Bethlehem, Pennsylvania, United States|Forest Investigative Site, Erie, Pennsylvania, United States|Forest Investigative Site, Hershey, Pennsylvania, United States|Forest Investigative Site, Pittsburgh, Pennsylvania, United States|Forest Investigative Site, Upland, Pennsylvania, United States|Forest Investigative Site, East Providence, Rhode Island, United States|Forest Investigative Site, Johnston, Rhode Island, United States|Forest Investigative Site, Charleston, South Carolina, United States|Forest Investigative Site, Greenville, South Carolina, United States|Forest Investigative Site, Greer, South Carolina, United States|Forest Investigative Site, Spartanburg, South Carolina, United States|Forest Investigative Site, Nashville, Tennessee, United States|Forest Investigative Site, Dallas, Texas, United States|Forest Investigative Site, Dallas, Texas, United States|Forest Investigative Site, Fort Worth, Texas, United States|Forest Investigative Site, Houston, Texas, United States|Forest Investigative Site, San Antonio, Texas, United States|Forest Investigative Site, Tyler, Texas, United States|Forest Investigative Site, Waco, Texas, United States|Forest Investigative Site, Midvale, Utah, United States|Forest Investigative Site, Richmond, Virginia, United States|Forest Investigative Site, Richmond, Virginia, United States|Forest Investigative Site, Bellingham, Washington, United States|Forest Investigative Site, Spokane, Washington, United States|Forest Investigative Site, Tacoma, Washington, United States|Forest Investigative Site, Milwaukee, Wisconsin, United States|Forest Investigative Site, Saskatoon, Saskatchewan, Canada|Forest Investigative Site, Edmonton, Canada|Forest Investigative Site, Hamilton, Canada|Forest Investigative Site, Kelowna, Canada|Forest Investigative Site, Niagara Falls, Canada|Forest Investigative Site, Sainte-Foy, Canada|Forest Investigative Site, Toronto, Canada|Forest Investigative Site, Toronto, Canada",,"https://ClinicalTrials.gov/show/NCT00891462"
144,"NCT00885378","Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Saxagliptin plus metformin IR|Drug: Placebo plus metformin IR","Mean Hemoglobin A1C (A1c) and Change From Baseline to Week 12|Mean Baseline and Change From Baseline in Fasting Plasma Glucose (FPG)|Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C < 7.0%) at Week 12|Percentage of Participants Achieving a Therapeutic Glycemic Response (A1C <= 6.5%) at Week 12","AstraZeneca","All","18 Years to 78 Years   (Adult, Older Adult)","Phase 3","166","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CV181-080|EUDRACT #: 2009-010224-25","May 2009","February 2010","February 2010","April 22, 2009","December 16, 2011","June 1, 2015","John Muir Physician Network Clinical Research Center, Concord, California, United States|Southland Clinical Research Center, Inc., Fountain Valley, California, United States|Torrance Clinical Research, Lomita, California, United States|Ritchken & First M.D.'S, San Diego, California, United States|Central Florida Clinical Trials, Inc., Altamonte Springs, Florida, United States|Family Care Associates Of Nw Florida, Chipley, Florida, United States|Clinical Therapeutics Corporation, Coral Gables, Florida, United States|Nextphase Clinical Trials, Inc., Miami, Florida, United States|Middle Georgia Drug Study Center, Llc, Perry, Georgia, United States|Louisiana Heart Center Research, Slidell, Louisiana, United States|Jackson Clinic, Rolling Fork, Mississippi, United States|Community Health Care Of Manchester, Akron, Ohio, United States|Midwest Regional Research, Inc., Bellbrook, Ohio, United States|Wells Institute For Health Awareness, Kettering, Ohio, United States|Newark Physician Associates, Newark, Ohio, United States|Integris Family Care South, Oklahoma, Oklahoma, United States|Integris Family Care Yukon, Yukon, Oklahoma, United States|Williamette Valley Clinical Studies, Eugene, Oregon, United States|Integrated Medical Group Pc/Fleetwood Clinical Research, Fleetwood, Pennsylvania, United States|Southeastern Research Associates, Inc, Taylors, South Carolina, United States|Holston Medical Group, Kingsport, Tennessee, United States|Village Family Practice, Houston, Texas, United States|Southwest Clinical Research Centers, Llc, Pearland, Texas, United States|Jolene K. Berg, Md., Dgd Research, Inc., San Antonio, Texas, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Local Institution, Ludwigshafen, Germany|Local Institution, Magdeberg, Germany|Local Institution, Pirna, Germany|Local Institution, Saarbrucken, Germany|Local Institution, Saarlouis, Germany|Local Institution, Tann, Germany|Local Institution, Wuestensachsen, Germany|Local Institution, Balatonfured, Hungary|Local Institution, Budapest, Hungary|Local Institution, Eger, Hungary|Local Institution, Szigetvar, Hungary|Local Institution, Zalaegerszeg, Hungary|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00885378"
145,"NCT00883493","Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression","QUALITY","Completed","Has Results","Acute Bipolar Depression","Drug: Quetiapine fumarate XR|Drug: Lithium carbonate","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.|Response Rate for MADRS.|Hamilton Rating Scale for Depression (HAM-D) Total Score.|Change in Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Change in the Clinical Global Impression Severity (CGI-S) Score.|Change in Young Mania Rating Scale (YMRS) Total Score.|Change in the Pittsburgh Sleep Quality Index (PSQI)Total Score.|Change in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Score.|Change in the Sheehan Disability Scale (SDS) Total Score.|Treatment Satisfaction Questionnaire (TSQ) Scores.","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","421","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1443L00055","April 2009","March 2011","March 2011","April 17, 2009","June 29, 2012","July 11, 2012","Research Site, La Plata, Buenos Aires, Argentina|Research Site, Godoy Cruz, Mendoza, Argentina|Research Site, Caba, Argentina|Research Site, Mendoza, Argentina|Research Site, Aparecida de Goiania, GO, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santiago, Chile|Research Site, Medellin, Antioquia, Colombia|Research Site, Bogota D.c, Cundinamarca, Colombia|Research Site, Guatemala, Ciudad de Guatemala, Guatemala|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, Durango, Mexico|Research Site, Monterrey, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, Lima, Peru|Research Site, Ankara, Turkey|Research Site, Elazig, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Malatya, Turkey|Research Site, Manisa, Turkey|Research Site, Caracas, Venezuela",,"https://ClinicalTrials.gov/show/NCT00883493"
146,"NCT00882518","Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients","ESPRIT","Completed","Has Results","Schizophrenia","Drug: Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|Drug: Chlorpromazine","Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment at Day 42|Change From Baseline in PANSS Positive Subscale Score at the End of Treatment at Day 42|Change From Baseline in PANSS Negative Subscale Score at the End of Treatment at Day 42|Change From Baseline in PANSS General Psychopathological Subscale Score at the End of Treatment at Day 42|Change From Baseline in PANSS Aggression, Hostility Clusters Score at the End of Treatment at Day 42|Change From Baseline in PANSS Depression Clusters Score at the End of Treatment at Day 42|Number of Patients Achieving a Reduction of at Least 30% From Baseline PANSS Total Score at the End of Treatment at Day 42|Percentage of Patients With Clinical Global Impression (CGI) Global Improvement Rating Less Than or Equal to 3 at the End of Treatment at Day 42|Change in the CGI Severity of Illness Score From Baseline at the End of Treatment at Day 42","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","388","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D1444C00008","April 2009","July 2010","July 2010","April 16, 2009","May 15, 2012","May 15, 2012","Research Site, Hunan, Changsha, China|Research Site, Guangzhou, Guangdong, China|Research Site, Baoding, Hebei, China|Research Site, Ha Er Bin, Heilongjiang, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Xi'an, Shanxi, China|Research Site, Kunming, Yunnan, China|Research Site, Beijing, China|Research Site, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00882518"
147,"NCT00877890","A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide once weekly|Drug: exenatide twice daily","Change in HbA1c From Baseline to Week 24|Percentage of Subjects Achieving HbA1c Target of <7%|Percentage of Subjects Achieving HbA1c Target of <=6.5%|Change in Fasting Plasma Glucose From Baseline to Week 24|Percentage of Subjects Achieving Fasting Plasma Glucose Target of <=126 mg/dL|Change in Body Weight From Baseline to Week 24|Change in Sitting Systolic Blood Pressure From Baseline to Week 24|Change in Sitting Diastolic Blood Pressure From Baseline to Week 24|Change in Total Cholesterol From Baseline to Week 24|Change in High-density Lipoprotein (HDL) From Baseline to Week 24|Ratio of Triglycerides at Week 24 to Baseline|Assessment on Event Rate of Treatment-emergent Major Hypoglycemic Events|Assessment on Event Rate of Treatment-emergent Minor Hypoglycemic Events","AstraZeneca|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","254","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCB108 (DURATION-5)","March 2009","October 2009","January 2010","April 8, 2009","June 19, 2012","April 7, 2015","Research Site, Birmingham, Alabama, United States|Research Site, Mesa, Arizona, United States|Research Site, Peoria, Arizona, United States|Research Site, Artesia, California, United States|Research Site, Concord, California, United States|Research Site, Encino, California, United States|Research Site, Greenbrae, California, United States|Research Site, La Mesa, California, United States|Research Site, Walnut Creek, California, United States|Research Site, DeLand, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Avon, Indiana, United States|Research Site, Evansville, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Detroit, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, New Hyde Park, New York, United States|Research Site, Rochester, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Delaware, Ohio, United States|Research Site, Mentor, Ohio, United States|Research Site, Eugene, Oregon, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Burke, Virginia, United States|Research Site, Manassas, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Olympia, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00877890"
148,"NCT00859898","Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Dapagliflozin|Drug: Metformin XR|Drug: dapagliflozin matching Placebo|Drug: metformin HCl Modified Release matching Placebo","Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants|Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (LOCF) - Randomized, Treated Participants|Percent Adjusted for Baseline HbA1c of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized, Treated Participants|Adjusted Mean Change From Baseline in HbA1C at Week 24 (LOCF) in Participants Whose Baseline HbA1C Category ≥9.0%|The Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized, Treated Participants|Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Discontinuation Due to AEs, During the 12 Week Double Blind Period, Including Data After Rescue - All Treated Participants|Number of Participants With Adverse Events of Special Interest During the 12 Week Double Blind Period - All Treated Participants|Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure at Week 24 - Treated Participants|Mean Change From Baseline in Seated Heart Rate at Week 24 - Randomized, Treated Participants|Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 24 (LOCF) - Randomized, Treated Participants|Number of Participants With Marked Laboratory Abnormalities (Not Including Liver Function) in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants|Number of Participants With Marked Laboratory Abnormalities in Liver Function in 24 Week Double Blind Treatment Period, Including Data After Rescue - Randomized, Treated Participants","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","1093","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MB102-034|Eudract #: 2008-007548-33","April 2009","May 2010","May 2010","March 11, 2009","March 20, 2014","July 7, 2016","International Institute Of Clinical Research, Ozark, Alabama, United States|Clinical Research Advantage, Inc./Mesa Family Med Ctr, Pc, Tempe, Arizona, United States|Clinical Research Advantage, Inc., Tempe, Arizona, United States|John Muir Physician Network Clinical Research Center, Concord, California, United States|Encompass Clinical Research-North Coast, Encinitas, California, United States|Southland Clinical Research Center, Inc., Fountain Valley, California, United States|Valley Research, Fresno, California, United States|Del Rosario Medical Clinic, Inc., Huntington Park, California, United States|Irvine Center For Clinical Research, Inc., Irvine, California, United States|Pacific Sleep Medicine Services (Avastra Clinical Trials), Redlands, California, United States|Orange County Research Center, Tustin, California, United States|Lynn Institute Of The Rockies, Colorado Springs, Colorado, United States|Radiant Research, Inc., Denver, Colorado, United States|Clinical Therapeutics Corporation, Coral Gables, Florida, United States|Nextphase Clinical Trials, Inc., Miami, Florida, United States|Baptist Diabetes Associates, Miami, Florida, United States|Metabolic Research Institute, Inc., W Palm Beach, Florida, United States|Lake Hartwell Family Medicine, Hartwell, Georgia, United States|Middle Georgia Drug Study Center, Llc, Perry, Georgia, United States|Northwest Clinical Trials, Boise, Idaho, United States|Provident Clinical Research, Addison, Illinois, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Deerbrook Medical Associates, Vernon Hills, Illinois, United States|Physicians Research Group, Indianapolis, Indiana, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Clinilabs, Inc., New York, New York, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Pharmquest, Greensboro, North Carolina, United States|Crescent Medical Research, Salisbury, North Carolina, United States|Community Health Care, Inc., Canal Fulton, Ohio, United States|Holzer Clinic, Inc, Gallipolis, Ohio, United States|Wells Institute For Health Awareness, Kettering, Ohio, United States|Newark Physician Associates, Newark, Ohio, United States|Daniel G. Williams, Md, Perrysburg, Ohio, United States|Physician Research, Inc., Zanesville, Ohio, United States|Gilbert Medical Research, Llc, Bethany, Oklahoma, United States|Tulsa Clinical Research, Llc, Tulsa, Oklahoma, United States|Integris Family Care Yukon, Yukon, Oklahoma, United States|Williamette Valley Clinical Studies, Eugene, Oregon, United States|Dingmans Medical, Dingmans Ferry, Pennsylvania, United States|Integrated Medical Group Pc/Fleetwood Clinical Research, Fleetwood, Pennsylvania, United States|Wellmon Family Practice, Shippensburg, Pennsylvania, United States|Safe Harbor Clinical Research, E. Providence, Rhode Island, United States|Southeastern Research Associates, Inc., Greenville, South Carolina, United States|Holston Medical Group, Bristol, Tennessee, United States|Parkway Medical Group, Fayetteville, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Southwind Medical Specialists, Memphis, Tennessee, United States|Dallas Diabetes & Endocrine Center, Dallas, Texas, United States|Endocrine Associates, Houston, Texas, United States|Village Family Practice, Houston, Texas, United States|Juno Research, Llc., Houston, Texas, United States|Non-Invasive Cardiovascular, Pa, Houston, Texas, United States|Excel Clinical Research, Houston, Texas, United States|Texas Center For Drug Development, Houston, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|Covenant Clinical Research, Pa, San Antonio, Texas, United States|S.A.M. Clinical Research Center, San Antonio, Texas, United States|Avastra Clinical Trials, Midvale, Utah, United States|Seven Corners Medical Center, Falls Church, Virginia, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Northwest Clinical Research Center, Bellevue, Washington, United States|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Aminjikarai, Chennai, India|Local Institution, Haryana, Karnal, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Indore, Madhya Pradesh, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Nagpur, Maharashtra, India|Local Institution, Chennai, Tamilnadu, India|Local Institution, Ghaziabad, Uttar Pradesh, India|Local Institution, Jaipur, India|Local Institution, Bucheon, Gyeonggi-Do, Korea, Republic of|Local Institution, Goyang-Si, Gyeonggi-Do, Korea, Republic of|Local Institution, Guri-Si, Gyeonggi-Do, Korea, Republic of|Local Institution, Sungnam, Gyeonggi-Do, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Incheon, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michioacan, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Durango, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Fajardo, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Ekaterinaburg, Russian Federation|Local Institution, Kemerovo, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution, Moscov, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Samara, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Smolensk, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, Tyumen, Russian Federation|Local Institution, Vladimir, Russian Federation|Local Institution, Volgograd, Russian Federation|Local Institution, Voronezh, Russian Federation|Local Institution, Yaroslavl, Russian Federation|Local Institution, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00859898"
149,"NCT00857584","Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy",,"Completed","Has Results","Bipolar Disorder|Bipolar Depression","Drug: Extended release quetiapine (quetiapine XR)|Drug: Sertraline|Drug: adequate mood stabilizer","The Mean Change From Baseline to Week 2 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score|The Mean Change From Baseline to Week 1 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score|The Mean Change From Baseline to Week 4 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score|The Mean Change From Baseline to Week 8 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score|The Mean Change From Baseline to Week 1 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score|The Mean Change From Baseline to Week 2 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score|The Mean Change From Baseline to Week 4 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score|The Mean Change From Baseline to Week 8 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score|The Mean Change From Baseline to Week 4 in the Hamilton Anxiety Rating Scale (HARS) Total Score|The Mean Change From Baseline to Week 8 in the Hamilton Anxiety Rating Scale (HARS) Total Score|Number of Patients Response at Week 1|Number of Patients With Response at Week 2|Number of Patients With Response at Week 4.|Number of Patients With Response at Week 8.|Number of Patients With Remission at Week 1.|Number of Patients With Remission at Week 2.|Number of Patients With Remission at Week 4.|Number of Patients With Remission at Week 8.","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1443L00058","May 2009","February 2011","February 2011","March 6, 2009","April 10, 2012","April 18, 2012","Research Site, Santander, Cantabria, Spain|Research Site, Zamora, Castilla-León, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Vitoria, Pais Vasco, Spain",,"https://ClinicalTrials.gov/show/NCT00857584"
150,"NCT00855959","Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients",,"Completed","Has Results","Asthma","Drug: Budesonide|Drug: Pulmicort Turbuhaler","Morning Peak Expiratory Flow (mPEF)|Evening Peak Expiratory Flow (ePEF)|Asthma Symptom Score (Daytime); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)|Asthma Symptom Score (Night-time); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)|Asthma Symptom Score (Total); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)|Use of Rescue Medication (Daytime)|Use of Rescue Medication (Night-time)|Use of Rescue Medication (Total)|Night-time Awakenings Due to Asthma Symptoms|Forced Expiratory Volume in 1 Second (FEV 1.0)|Forced Vital Capacity (FVC)|Number of Participants With Adverse Events (AEs)","AstraZeneca","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","108","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5259C00001","February 2009","August 2009","August 2009","March 5, 2009","March 11, 2011","March 11, 2011","Research Site, Ichikawa, Chiba, Japan|Research Site, Yokosuka, Kanagawa, Japan|Research Site, Chiyoda, Tokyo, Japan|Research City, Hino, Tokyo, Japan|Research Site, Setagaya, Tokyo, Japan|Research Site, Tachikawa, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00855959"
151,"NCT00855166","Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Dapagliflozin|Drug: Metformin|Drug: Sitagliptin|Drug: Placebo","Adjusted Mean Change in Total Body Weight|Adjusted Mean Change in Waist Circumference|Adjusted Mean Change in Body Fat Mass|Proportion of Participants With Body Weight Decrease ≥5%","AstraZeneca|Bristol-Myers Squibb","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 3","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D1690C00012","February 2009","June 2010","December 2011","March 4, 2009","October 14, 2013","October 14, 2013","Research Site, Blagoevgrad, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Beroun, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Semily, Czech Republic|Research Site, Slany, Czech Republic|Research Site, Balatonfured, Hungary|Research Site, Budapest, Hungary|Research Site, Csongrad, Hungary|Research Site, Kecskemet, Hungary|Research Site, TAT, Hungary|Research Site, Elblag, Poland|Research Site, Krakow, Poland|Research Site, Torun, Poland|Research Site, Goteborg, Sweden|Research Site, Jarfalla, Sweden|Research Site, Lund, Sweden|Research Site, Malmo, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00855166"
152,"NCT00839800","Study to Investigate the Efficacy of Symbicort® SMART.","SAKURA","Completed","Has Results","Asthma","Drug: Symbicort Turbuhaler|Drug: Terbutaline Turbuhaler","The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study|Number of Asthma Exacerbations|Morning Peak Expiratory Flow (PEF)|Evening PEF|Forced Expiratory Volume in One Second (FEV1)|Use of As-needed Medication|Asthma Symptom Score|Nights With Awakening(s) Due to Asthma Symptoms|The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations|Symptom-free Days (no Symptoms and no Awakenings)|Percentage of As-needed-free Days|Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)|Asthma Control Questionnaire (ACQ)","AstraZeneca","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","2091","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D589LC00001","February 2009","February 2011","February 2011","February 10, 2009","November 30, 2012","November 30, 2012","Research Site, Capital Federal, Buenos Aires, Argentina|Research Site, Mar Del Plata, Buenos Aires, Argentina|Research Site, Monte Grande, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Santa Fe, Argentina|Research Site, Porto Alegre, Brasil, Brazil|Research Site, Belo Horizonte, MG, Brazil|Research Site, Juiz de Fora, MG, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Porto Alegre, RS, Brazil|Research Site, Florianopolis, Santa Catarina, Brazil|Research Site, Santo Andre, SP, Brazil|Research Site, Shenyang, Liaoning, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Chongqing, China|Research Site, Guang Zhou, China|Research Site, Nanjing, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Xi An, China|Research Site, Tres Rios, Cartago, Costa Rica|Research Site, Barrio San Bosco, San Jose, Costa Rica|Research Site, Budapest, Hungary|Research Site, Cegled, Hungary|Research Site, Debrecen, Hungary|Research Site, Deszk, Hungary|Research Site, Gyula, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szazhalombatta, Hungary|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Mysore, Karnataka, India|Research Site, Trivandrum, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Coimabatore, Tamilnadu, India|Research Site, Noida, India|Research Site, Komaki, Aichi, Japan|Research Site, Seto, Aichi, Japan|Research Site, Asahi, Chiba, Japan|Research Site, Matsuyama, Ehime, Japan|Research Site, Kitakyusyu, Fukuoka, Japan|Research Site, Yanagawa, Fukuoka, Japan|Research Site, Isesaki, Gunma, Japan|Research Site, ORA, Gunma, Japan|Research Site, Fukuyama, Hiroshima, Japan|Research Site, Hiroshima-shi, Hiroshima, Japan|Research Site, Asahikawa, Hokkaido, Japan|Research Site, Chitose, Hokkaido, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Tomakomai, Hokkaido, Japan|Research Site, AKO, Hyogo, Japan|Research Site, Himeji, Hyogo, Japan|Research Site, Kobe-city, Hyogo, Japan|Research Site, Hitachi, Ibaraki, Japan|Research Site, Naka-gun, Ibaraki, Japan|Research Site, Morioka, Iwate, Japan|Research Site, Sakaide, Kagawa, Japan|Research Site, Kawasaki-shi, Kanagawa, Japan|Research Site, Kawasaki, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Sendai, Miyagi, Japan|Research Site, Nagaoka, Niigata, Japan|Research Site, Beppu, Oita, Japan|Research Site, Kurashiki, Okayama, Japan|Research Site, Sakai, Osaka, Japan|Research Site, Matsue, Shimane, Japan|Research Site, Utsunomiya, Tochigi, Japan|Research Site, Chuo, Tokyo, Japan|Research Site, Itabashi, Tokyo, Japan|Research Site, Kodaira, Tokyo, Japan|Research Site, Kokubunji, Tokyo, Japan|Research Site, Machida, Tokyo, Japan|Research Site, Nakano-ku, Tokyo, Japan|Research Site, Toshima-ku, Tokyo, Japan|Research Site, Fukuoka, Japan|Research Site, Kagoshima, Japan|Research Site, Kochi, Japan|Research Site, Kyoto, Japan|Research Site, Niigata, Japan|Research Site, Oita, Japan|Research Site, Okayama, Japan|Research Site, Bucheon, Korea, Republic of|Research Site, Cheongju, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Kubang Kerian, Kelantan, Malaysia|Research Site, Kuantan, Pahang, Malaysia|Research Site, Batu Caves, Selangor, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Penang, Malaysia|Research Site, Surco, Lima, Peru|Research Site, Lima, Peru|Research Site, Lipa City, Batangas, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Bangkoknoi, Bangkok, Thailand|Research Site, Naimuang, Nakhonratchasima, Thailand|Research Site, Hat Yai, Songkla, Thailand|Research Site, Bangkok, Thailand|Research Site, Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT00839800"
153,"NCT00837967","Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients",,"Completed","Has Results","Asthma","Drug: Symbicort Turbuhaler|Drug: Terbutaline Turbuhaler","Adverse Events|Serum Potassium - Average Concentration From Trapezoidal Area Under the Curve (AUC)|Blood Glucose - Average Concentration From Trapezoidal Area Under the Curve (AUC)|Electrocardiogram (ECG)- Average Trapezoidal Area Under the Curve (AUC)|Vital Sign (Blood Pressure)- Average Trapezoidal Area Under the Curve (AUC)|Vital Sign (Pulse Rate)- Average Trapezoidal Area Under the Curve (AUC)","AstraZeneca","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 3","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D589LC00003","January 2009","July 2009","July 2009","February 6, 2009","August 29, 2012","August 29, 2012","Research Site, Ibaragi, Japan|Research Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00837967"
154,"NCT00812955","Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (""Bad Cholesterol"") and Triglycerides",,"Completed","Has Results","Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia","Drug: ABT-143|Drug: simvastatin","Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C), With ABT-143 Capsules 10/135 Milligrams Versus Simvastatin Capsules 40 Milligrams (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C), With ABT-143 Capsules 5/135 Milligrams Versus Simvastatin Capsules 40 Milligrams (Full Analysis Set)","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","474","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-667","November 2008","June 2009","June 2009","December 22, 2008","August 1, 2012","October 3, 2012","Site Reference ID/Investigator# 12654, Birmingham, Alabama, United States|Site Reference ID/Investigator# 12634, Columbiana, Alabama, United States|Site Reference ID/Investigator# 12559, Huntsville, Alabama, United States|Site Reference ID/Investigator# 12499, Ozark, Alabama, United States|Site Reference ID/Investigator# 12673, Chandler, Arizona, United States|Site Reference ID/Investigator# 17282, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 12657, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 12489, Anaheim, California, United States|Site Reference ID/Investigator# 12495, Carmichael, California, United States|Site Reference ID/Investigator# 12467, Chula Vista, California, United States|Site Reference ID/Investigator# 12498, Long Beach, California, United States|Site Reference ID/Investigator# 12602, Los Angeles, California, United States|Site Reference ID/Investigator# 12510, Norwalk, California, United States|Site Reference ID/Investigator# 12550, Palm Desert, California, United States|Site Reference ID/Investigator# 16503, Roseville, California, United States|Site Reference ID/Investigator# 12678, Sacramento, California, United States|Site Reference ID/Investigator# 14241, Sacramento, California, United States|Site Reference ID/Investigator# 12473, San Diego, California, United States|Site Reference ID/Investigator# 12497, Walnut Creek, California, United States|Site Reference ID/Investigator# 12680, West Hills, California, United States|Site Reference ID/Investigator# 12461, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 12600, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 12679, Waterbury, Connecticut, United States|Site Reference ID/Investigator# 12598, Clearwater, Florida, United States|Site Reference ID/Investigator# 15542, Coral Gables, Florida, United States|Site Reference ID/Investigator# 12477, Daytona Beach, Florida, United States|Site Reference ID/Investigator# 12668, Delray Beach, Florida, United States|Site Reference ID/Investigator# 15483, Fort Lauderdale, Florida, United States|Site Reference ID/Investigator# 12645, Fort Myers, Florida, United States|Site Reference ID/Investigator# 12672, Hollywood, Florida, United States|Site Reference ID/Investigator# 17504, Jacksonville, Florida, United States|Site Reference ID/Investigator# 12781, Jacksonville, Florida, United States|Site Reference ID/Investigator# 12665, Jupiter, Florida, United States|Site Reference ID/Investigator# 12682, Longwood, Florida, United States|Site Reference ID/Investigator# 15486, Melbourne, Florida, United States|Site Reference ID/Investigator# 12502, New Port Richey, Florida, United States|Site Reference ID/Investigator# 12647, Ocala, Florida, United States|Site Reference ID/Investigator# 12520, Orlando, Florida, United States|Site Reference ID/Investigator# 12687, Ormond Beach, Florida, United States|Site Reference ID/Investigator# 12583, Sarasota, Florida, United States|Site Reference ID/Investigator# 12652, Tampa, Florida, United States|Site Reference ID/Investigator# 12557, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 12621, Winter Haven, Florida, United States|Site Reference ID/Investigator# 16505, Winter Park, Florida, United States|Site Reference ID/Investigator# 12675, Augusta, Georgia, United States|Site Reference ID/Investigator# 12620, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 12653, Roswell, Georgia, United States|Site Reference ID/Investigator# 12555, Suwanee, Georgia, United States|Site Reference ID/Investigator# 12787, Woodstock, Georgia, United States|Site Reference ID/Investigator# 12514, Chicago, Illinois, United States|Site Reference ID/Investigator# 12487, Peoria, Illinois, United States|Site Reference ID/Investigator# 12627, Peoria, Illinois, United States|Site Reference ID/Investigator# 12529, Evansville, Indiana, United States|Site Reference ID/Investigator# 12688, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 15485, South Bend, Indiana, United States|Site Reference ID/Investigator# 12676, Arkansas City, Kansas, United States|Site Reference ID/Investigator# 12597, Wichita, Kansas, United States|Site Reference ID/Investigator# 12472, Louisville, Kentucky, United States|Site Reference ID/Investigator# 12658, Mount Sterling, Kentucky, United States|Site Reference ID/Investigator# 12586, Baltimore, Maryland, United States|Site Reference ID/Investigator# 12480, Bethesda, Maryland, United States|Site Reference ID/Investigator# 12638, Oxon Hill, Maryland, United States|Site Reference ID/Investigator# 12513, Springfield, Massachusetts, United States|Site Reference ID/Investigator# 12663, Kalamazoo, Michigan, United States|Site Reference ID/Investigator# 12609, Brooklyn Center, Minnesota, United States|Site Reference ID/Investigator# 16622, Edina, Minnesota, United States|Site Reference ID/Investigator# 12625, Jackson, Mississippi, United States|Site Reference ID/Investigator# 12560, Olive Branch, Mississippi, United States|Site Reference ID/Investigator# 12677, St. Louis, Missouri, United States|Site Reference ID/Investigator# 12534, St. Peters, Missouri, United States|Site Reference ID/Investigator# 12592, Billings, Montana, United States|Site Reference ID/Investigator# 12655, Omaha, Nebraska, United States|Site Reference ID/Investigator# 12587, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 12554, Berlin, New Jersey, United States|Site Reference ID/Investigator# 12637, Elizabeth, New Jersey, United States|Site Reference ID/Investigator# 12463, Hillsborough, New Jersey, United States|Site Reference ID/Investigator# 12660, Trenton, New Jersey, United States|Site Reference ID/Investigator# 12506, Albuquerque, New Mexico, United States|Site Reference ID/Investigator# 12539, Johnson City, New York, United States|Site Reference ID/Investigator# 12631, Syracuse, New York, United States|Site Reference ID/Investigator# 17503, Cary, North Carolina, United States|Site Reference ID/Investigator# 12650, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 12504, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 12558, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 12671, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 12527, Hickory, North Carolina, United States|Site Reference ID/Investigator# 12608, Morehead City, North Carolina, United States|Site Reference ID/Investigator# 12535, Salisbury, North Carolina, United States|Site Reference ID/Investigator# 12656, Statesville, North Carolina, United States|Site Reference ID/Investigator# 17641, Wilmington, North Carolina, United States|Site Reference ID/Investigator# 12606, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 12614, Akron, Ohio, United States|Site Reference ID/Investigator# 12662, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 12545, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 12640, Kettering, Ohio, United States|Site Reference ID/Investigator# 12786, Mason, Ohio, United States|Site Reference ID/Investigator# 12630, Warren, Ohio, United States|Site Reference ID/Investigator# 12551, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 12611, Tulsa, Oklahoma, United States|Site Reference ID/Investigator# 12585, Medford, Oregon, United States|Site Reference ID/Investigator# 12610, Beaver, Pennsylvania, United States|Site Reference ID/Investigator# 12589, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 12607, Harleysville, Pennsylvania, United States|Site Reference ID/Investigator# 12641, Jersey Shore, Pennsylvania, United States|Site Reference ID/Investigator# 12507, Melrose Park, Pennsylvania, United States|Site Reference ID/Investigator# 12624, Perkasie, Pennsylvania, United States|Site Reference ID/Investigator# 12669, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 12788, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 12525, Pittsburgh, Pennsylvania, United States|Site Reference ID/Investigator# 12601, Tipton, Pennsylvania, United States|Site Reference ID/Investigator# 12686, Warminster, Pennsylvania, United States|Site Reference ID/Investigator# 12623, Mount Pleasant, South Carolina, United States|Site Reference ID/Investigator# 12681, Mount Pleasant, South Carolina, United States|Site Reference ID/Investigator# 12485, Simpsonville, South Carolina, United States|Site Reference ID/Investigator# 12639, Summerville, South Carolina, United States|Site Reference ID/Investigator# 15642, Germantown, Tennessee, United States|Site Reference ID/Investigator# 12643, Jackson, Tennessee, United States|Site Reference ID/Investigator# 12470, Dallas, Texas, United States|Site Reference ID/Investigator# 16081, Dallas, Texas, United States|Site Reference ID/Investigator# 12492, Dallas, Texas, United States|Site Reference ID/Investigator# 12464, Fort Worth, Texas, United States|Site Reference ID/Investigator# 12646, San Antonio, Texas, United States|Site Reference ID/Investigator# 16601, San Antonio, Texas, United States|Site Reference ID/Investigator# 12540, San Antonio, Texas, United States|Site Reference ID/Investigator# 12466, San Antonio, Texas, United States|Site Reference ID/Investigator# 12622, San Antonio, Texas, United States|Site Reference ID/Investigator# 12538, Norfolk, Virginia, United States|Site Reference ID/Investigator# 12616, Richmond, Virginia, United States|Site Reference ID/Investigator# 12476, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00812955"
155,"NCT00811473","Pediatric Bipolar Depression",,"Completed","Has Results","Bipolar Depression","Drug: Quetiapine XR|Drug: Placebo","Change in the Children Depression Rating Scale, Revised (CDRS-R) Total Score From Baseline to Final Assessment (Day 57)|Number of Patients Reaching Remission Where Remission is Defined as CDRS-R Total Score ≤28 at Final Assessment (Day 57).|The Number of Patients With the Response, Where Response is Defined as ≥50% Reduction From Baseline to Final Assessment (Day 57) in CDRS-R Total Score|Change From Baseline to Final Assessment (Day 57) in the CGI-BP-S|CGI-BP-C Score at Final Assessment (Day 57)|The Proportion of Patients at Final Assessment (Day 57) With Improvement of Overall Bipolar Illness","AstraZeneca","All","10 Years to 17 Years   (Child)","Phase 3","193","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D144AC00001","January 2009","November 2010","November 2010","December 19, 2008","December 1, 2011","July 15, 2014","Research Site, Dothan, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Escondido, California, United States|Research Site, Bradenton, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Eagle, Idaho, United States|Research Site, Hoffman Estates, Illinois, United States|Research Site, Terre Haute, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Clinton Township, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Flowood, Mississippi, United States|Research Site, St. Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Rochester, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Mason, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Charleston, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Wharton, Texas, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Bothell, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Bogota D.c, Cundinamarca, Colombia|Research Site, Bello, Colombia|Research Site, Bogota, Colombia|Research Site, Medellin, Colombia|Research Site, Vijaywada, Andh Prad, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Varanasi, Uttar Prad, India|Research Site, Leon, Mexico|Research Site, Monterrey, Mexico|Research Site, Belgrade, Serbia|Research Site, Novi Sad, Serbia|Research Site, Pretoria, Gauteng, South Africa|Research Site, Cape Town, W Cape, South Africa|Research Site, Changhua, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00811473"
156,"NCT00789854","Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients","RUBY","Completed","Has Results","Major Depressive Disorder|Treatment Resistant Depression","Drug: Quetiapine XR|Drug: Lithium carbonate|Drug: SSRI/Venlafaxine","Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Per Protocol Analysis Set)|Change in Depressive Symptoms Between Randomisation and Week 6 Measured by Change in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Modified Intention to Treat Analysis Set)|Depression Remission; Montgomery-Asberg Depression Rating Scale MADRS ≤10, All Patients|Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With One Previous Treatment Failure|Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤10, Patients With Two Previous Treatment Failure|Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤8|Depression Remission; Montgomery-Asberg Depression Rating Scale (MADRS) ≤12|Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, All Patients|Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With One Previous Treatment Failure|Response Rate; Montgomery-Asberg Depression Rating Scale (MADRS) Score Reduced ≥ 50%, Patients With Two Previous Treatment Failure|Responder: Clinical Global Impression Improvement (CGI-I) Item 2, All Patients|Responder: Clinical Global Impression Improvement (CGI)-I Item 2, Patients With One Previous Treatment Failure|Responder: Clinical Global Impression Improvement (CGI-I) Item 2, Patients With Two Previous Treatment Failure|Change in Clinical Global Impression Scale (CGI-S), All Patients|Change in Clinical Global Impression Scale (CGI-S), Patients With One Previous Treatment Failure|Change in Clinical Global Impression Scale (CGI-S), Patients With Two Previous Treatment Failure|Change in Beck Depression Inventory (BDI)|Change in Pain, Measured by Visual Analog Scale (VAS)|Change in Anxiety Measured by Visual Analog Scale (VAS)|Change in Anxiety Measured by State-Trait Anxiety Inventory (STAI), State Anxiety Inventory|Change in Anxiety Measured by STAI, Trait Anxiety Inventory|Change in Sleep Quality Measured by Montgomery Asberg Depression Rating Scale (MADRS), Item 4|Change in Sleep Quality Measured by Pittsburgh Sleep Quality Index (PSQI)|Change in Quality of Life Measured by Short-form Health Survey (SF-36), Mental Component|Change in Quality of Life Measured by Short-form Health Survey (SF-36), Physical Component|Change in Quality of Life Measured by Health Questionnaire EQ-5D as Utility|Change in Work Productivity and Activity Impairment: General Health (WPAI:GH)|Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, All Patients|Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With One Previous Treatment Failure|Change in Clinical Global Impression (CGI) Item 4 Efficacy and Safety Combined, Patients With Two Previous Treatment Failures","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","688","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1443L00044","November 2008","August 2009","August 2009","November 13, 2008","May 23, 2012","May 23, 2012","Research Site, Garran, Australian Capital Territory, Australia|Research Site, Brisbane, Queensland, Australia|Research Site, Everton Park, Queensland, Australia|Research Site, Townsville, Queensland, Australia|Research Site, Gilberton, South Australia, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Prahran, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Graz, Austria|Research Site, Klagenfurt, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wiener NEUSTADT, Austria|Research Site, Wien, Austria|Research Site, Assebroek, Belgium|Research Site, Diest, Belgium|Research Site, Liege, Belgium|Research Site, Tielt, Belgium|Research Site, Cerova Koria Village, Veliko Tarnovo, Bulgaria|Research Site, Kardjali, Bulgaria|Research Site, Pazardjik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Esbjerg N, Denmark|Research Site, Frederiksberg, Denmark|Research Site, Odense, Denmark|Research Site, Aachen, Germany|Research Site, Achim, Germany|Research Site, Augsburg, Germany|Research Site, Bad Homburg, Germany|Research Site, Bad Honnef, Germany|Research Site, Bad Saarow, Germany|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Bochum, Germany|Research Site, Butzbach, Germany|Research Site, Chemnitz, Germany|Research Site, Dresden, Germany|Research Site, Duren, Germany|Research Site, Dusseldorf, Germany|Research Site, Ellwangen, Germany|Research Site, Erbach, Germany|Research Site, Gelsenkirchen, Germany|Research Site, Gutersloh, Germany|Research Site, Halle, Germany|Research Site, Hattingen, Germany|Research Site, Herborn, Germany|Research Site, Kassel, Germany|Research Site, Kothen, Germany|Research Site, Neu-isenburg, Germany|Research Site, Neubrandenburg, Germany|Research Site, Nurnberg, Germany|Research Site, Oldenburg, Germany|Research Site, Ostfildern, Germany|Research Site, Schwerin, Germany|Research Site, Stuttgart, Germany|Research Site, Westerstede, Germany|Research Site, Wurzburg, Germany|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Gyula, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Bressanone, BZ, Italy|Research Site, Brunico, BZ, Italy|Research Site, Cagliari, CA, Italy|Research Site, Pisa, PI, Italy|Research Site, Roma, RM, Italy|Research Site, Bolzano, Italy|Research Site, Catania, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Braga, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Santarem, Portugal|Research Site, Bucharest, Romania|Research Site, Craiova, Romania|Research Site, Galati, Romania|Research Site, Sibiu, Romania|Research Site, Bratislava, Slovakia|Research Site, Krupina, Slovakia|Research Site, Levice, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Michalovce Stranany, Slovakia|Research Site, Presov, Slovakia|Research Site, Roznava, Slovakia|Research Site, Zilina-bytcica, Slovakia|Research Site, Zlate Moravce, Slovakia|Research Site, Sama de Langreo, Asturias, Spain|Research Site, Salamanca, Castilla Leon, Spain|Research Site, Zamora, Castilla Leon, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Addlestone, Surrey, United Kingdom|Research Site, Winnick, Warrington, United Kingdom|Research Site, Horsham, West Sussex, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Harrow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Winsford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00789854"
157,"NCT00777153","Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","REGAL","Completed","Has Results","Recurrent Glioblastoma","Drug: Cediranib|Drug: Lomustine Chemotherapy|Drug: Placebo Cediranib","Progression Free Survival (PFS)|Overall Survival (OS)|Response Rate|Alive and Progression Free Rate at 6 Months (APF6)|Daily Steroid Dose|Steroid Free Days","AstraZeneca","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","423","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D8480C00055","October 2008","April 2010","September 2016","October 22, 2008","December 21, 2012","December 28, 2016","Research Site, Birmingham, Alabama, United States|Research Site, Pheonix, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Gainesville, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Evanston, Illinois, United States|Research Site, Kansas City, Kansas, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Amherst, New York, United States|Research Site, New York, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Camperdown, Australia|Research Site, Heidelberg, Australia|Research Site, Nedlands, Australia|Research Site, Parkville, Australia|Research Site, St Leonards, Australia|Research Site, Woodville, Australia|Research Site, Graz, Austria|Research Site, Brussels (Anderlecht), Belgium|Research Site, Brussels (Jette), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Leuven, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Liberec, Czech Republic|Research Site, Bobigny, France|Research Site, Marseille, France|Research Site, Paris cedex 13, France|Research Site, Rennes, France|Research Site, Saint Herblain, France|Research Site, Villejuif, France|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Dresden, Germany|Research Site, Düsseldorf, Germany|Research Site, Göttingen, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Nordhausen, Germany|Research Site, Regensburg, Germany|Research Site, Amsterdam, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Groningen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00777153"
158,"NCT00772447","China Registration Study in Patients With Skin Infections",,"Completed","Has Results","Skin Diseases|Infectious","Drug: Daptomycin|Drug: Vancomycin","Change of Erythrocyte Volume Fraction(Percentage of Erythrocyte Volume in Total Volume of Blood)|Change in Creatinine Clearance|Change in Serum Total Creatine Phosphokinase (CPK)|Change in Urine pH|Shift in ECG|Blinded Investigator's Assessement of Clinical Response at TOC(Test of Cure)|Blinded Investigator's Assessement of Clinical Response at EOT(End of Therapy)|Microbiological Response at TOC(Test of Cure)|Microbiological Response at EOT(End of Therapy)|Per-pathogen(Methicillin Resistant Staphylococcus Aureus) Clinical Response at TOC(Test of Cure)|Per-pathogen(Methicillin Sensitive Staphylococcus Aureus) Clinical Response at TOC|Per-pathogen(Staphylococcus Aureus) Microbiological Response at TOC","AstraZeneca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","265","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","D1790C00003","September 2008","September 2010","September 2010","October 15, 2008","March 9, 2015","March 9, 2015","Research Site, Beijing, Beijing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Shenyang, Liaoning, China|Research Site, Shanghai, Shanghai, China|Research Site, Chengdu, Sichuan, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Hangzhou, China|Research Site, Qingdao, China",,"https://ClinicalTrials.gov/show/NCT00772447"
159,"NCT00765817","Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus",,"Completed","Has Results","Type 2 Diabetes","Drug: placebo|Drug: exenatide","Change in Glycosylated Hemoglobin (HbA1c)|Percentage of Patients Achieving HbA1c <=7%|Percentage of Patients Achieving HbA1c <=6.5%|Change in Fasting Serum Glucose|Change in 7-point Self-monitored Blood Glucose (SMBG) Profile|Change in Total Cholesterol|Change in Low Density Lipoprotein (LDL) Cholesterol|Change in High Density Lipoprotein (HDL) Cholesterol|Change in Triglycerides|Change in Body Weight|Change in Waist Circumference|Change in Daily Insulin Dose|Change in Daily Insulin Dose (on a Per Body Weight Basis)|Change in Systolic Blood Pressure (SBP)|Change in Diastolic Blood Pressure (DBP)|Minor Hypoglycemia Rate Per Year|Percentage of Subjects Experiencing Minor Hypoglycemia","AstraZeneca|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","261","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H8O-US-GWCO","October 2008","January 2010","January 2010","October 3, 2008","January 26, 2011","October 24, 2016","Research Site, Peoria, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Buena Park, California, United States|Research Site, Concord, California, United States|Research Site, Fresno, California, United States|Research Site, Greenbrae, California, United States|Research Site, La Mesa, California, United States|Research Site, Lancaster, California, United States|Research Site, Northridge, California, United States|Research Site, Palm Springs, California, United States|Research Site, Salinas, California, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Des Moines, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Matairie, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Chesterfield, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Berkeley Heights, New Jersey, United States|Research SIte, Teaneck, New Jersey, United States|Research Site, Alburquerque, New Mexico, United States|Research SIte, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Bend, Oregon, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Georgetown, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Vancouver, Washington, United States|Research Site, Kenosha, Wisconsin, United States|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Holon, Israel|Research Site, Kfar Sava, Israel|Research Site, Tel Hashomer, Israel|Research Site, Coatzacoalcos, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Carolina, Puerto Rico|Research Site, Hato Rey, Puerto Rico|Research Site, Ponce, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, Birmingham, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Livingston, United Kingdom|Research Site, Middlesbrough, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00765817"
160,"NCT00757588","Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin, 5 mg + insulin|Drug: Placebo + insulin","Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF])|Change From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Meal Tolerance Test (MTT)|Change From Baseline in 120-minute PPG Values During an MTT|Change From Baseline in Fasting Plasma Glucose Values|Percentage of Participants Achieving a Therapeutic Glycemic Response|Change From Baseline in Mean Total Daily Dose of Insulin (MTDDI) (LOCF)","AstraZeneca","All","18 Years to 78 Years   (Adult, Older Adult)","Phase 3","455","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV181-057|Eudract-2008-001089-10","November 2008","April 2010","April 2010","September 23, 2008","December 13, 2011","June 1, 2015","Clinical Research Advantage, Inc, Tempe, Arizona, United States|Valley Research, Fresno, California, United States|Torrance-Lomita Medical Center, Lomita, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Ritchken & First M.D.'S, San Diego, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Central Florida Clinical Trials, Inc., Altamonte Springs, Florida, United States|Family Care Associates Of Nw Florida, Chipley, Florida, United States|Panhandle Family Care Assoc. & Coastal Palms Res. Grp Inc., Marianna, Florida, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Danny W. Jackson P.A., Rolling Fork, Mississippi, United States|Southgate Medical Group, West Seneca, New York, United States|Southeastern Research Associates, Inc., Taylors, South Carolina, United States|Texas Center For Drug Development, Houston, Texas, United States|Dgd Research, Inc., San Antonio, Texas, United States|Aurora Advanced Healthcare, Milwaukee, Wisconsin, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Bathurst, New Brunswick, Canada|Local Institution, London, Ontario, Canada|Local Institution, Charlottetown, Prince Edward Island, Canada|Local Institution, Gatineau, Quebec, Canada|Local Institution, Laval, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Regina, Saskatchewan, Canada|Local Institution, Besancon Cedex, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Nantes, France|Local Institution, Valenciennes, France|Local Institution, Balatonfured, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Szentes, Hungary|Local Institution, Zalaegerszeg-Pozva, Hungary|Local Institution, Indore, Madhya Pradesh, India|Local Institution, Hariyana, India|Local Institution, Mumbai, India|Local Institution, Pune, India|Local Institution, Pune, India|Local Institution, Pune, India|Local Institution, Vellore, India|Local Institution, Ciudad De Mexico, Distrito Federal, Mexico|Local Institution, Zapopan, Jal., Jalisco, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrrey, Nuevo Leon, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Mexico City, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Elblag, Poland|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Lublin, Poland|Local Institution, Sopot, Poland|Local Institution, Szczecin, Poland|Local Institution, Wroclaw, Poland|Local Institution, Zabrze, Poland|Local Institution, Kursk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Smolensk, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, Yaroslaval, Russian Federation|Local Institution, Parktown, Gauteng, South Africa|Local Institution, Durban, Kwa Zulu Natal, South Africa|Local Institution, Umhlanga Rocks, Kwa Zulu Natal, South Africa|Local Institution, Goodwood, Western Cape, South Africa|Local Institution, Tygerberg, Western Cape, South Africa|Local Institution, Middlesborough, Cleveland, United Kingdom|Local Institution, Salford, Greater Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom|Local Institution, Sheffield, Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00757588"
161,"NCT00753896","Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin",,"Completed","Has Results","Type 2 Diabetes","Drug: exenatide","Percentage of Patients Experiencing Adverse Events|Assessment of Event Rate of Treatment-Emergent Hypoglycemic Events|Change in HbA1c From Baseline to Week 52|Percentage of Patients Achieving HbA1c <=7% at Week 52|Percentage of Patients Achieving HbA1c <=6.5% at Week 52|Change in Fasting Serum Glucose From Baseline to Week 52|Change in Body Weight From Baseline to Week 52|Change in Total Cholesterol From Baseline to Week 52|Change in High-density Lipoprotein (HDL) From Baseline to Week 52|Change in Triglycerides From Baseline to Week 52|Change in Blood Pressure From Baseline to Week 52","AstraZeneca|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","134","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-MC-GWDC","October 2008","July 2009","November 2009","September 17, 2008","March 20, 2012","April 21, 2015","Research Site, Mesa, Arizona, United States|Research Site, Tempe, Arizona, United States|Research Site, Concord, California, United States|Research Site, Fresno, California, United States|Research Site, La Mesa, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Bowling Green, Kentucky, United States|Research Site, Corvallis, Oregon, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, New Westminister, British Columbia, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Chihuahua, Chiuahua, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Baia Mare, Romania|Research Site, Brasov, Romania|Research Site, Bucharesti, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Suceava, Romania|Research Site, Johannesburg, South Africa|Research Site, Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT00753896"
162,"NCT00736879","Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Dapagliflozin|Drug: Placebo","Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants|Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (LOCF) - Randomized Participants|Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24 (LOCF) - Randomized Participants|Adjusted Mean Change From Baseline in Effect on 2-hour Post Liquid Meal Glucose at Week 24 (LOCF) - Randomized Participants|Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response at Week 24 (LOCF) - Randomized Participants|Adjusted Mean Change From Baseline in Waist Circumference at Week 24 (LOCF) - Randomization Participants|Number of Participants With Deaths, Serious AEs (SAEs), Adverse Events (AEs), Discontinuation Due to AEs, During the 12 Week Double Blind Period, Including Data After Rescue - All Treated Participants|Number of Participants With Adverse Events of Special Interest During the 12 Week Double Blind Period - All Treated Participants|Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure at Week 24, Including Data After Rescue - Treated Participants|Mean Change From Baseline in Seated Heart Rate at Week 24 - Treated Participants|Number of Participants With Normal or Abnormal Electrocardiogram Summary Tracing at Week 24 (LOCF) - Treated Participants|Number of Participants With Marked Laboratory Abnormalities in 24 Week Double Blind Treatment Period - Treated Participants","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","497","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MB102-032","September 22, 2008","December 29, 2009","December 29, 2009","August 18, 2008","May 2, 2014","April 20, 2017","Dedicated Clinical Research, Litchfield Park, Arizona, United States|43rd Medical Associates, P.C., Phoenix, Arizona, United States|Clinical Research Advantage, Inc., Tempe, Arizona, United States|Valley Research, Fresno, California, United States|Marina Raikhel, Md, Faafp, Lomita, California, United States|Richard S. Cherlin, Md, Los Gatos, California, United States|Orange County Research Center, Tustin, California, United States|Family Physicians Of Greeley, Greeley, Colorado, United States|Coastal Connecticut Research, Llc, New London, Connecticut, United States|Central Florida Clinical Trials, Inc., Altamonte Springs, Florida, United States|Westside Center For Clinical Research, Jacksonville, Florida, United States|Panhandle Family Care Associates, Marianna, Florida, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Belzoni Clinical Research, Belzoni, Mississippi, United States|R-Research, Hamilton, New Jersey, United States|Internist Associates Of Central New York, Syracuse, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Down East Medical Associates, Pa, Morehead City, North Carolina, United States|James J. Brown, Md, Akron, Ohio, United States|Integris Family Care South, Oklahoma, Oklahoma, United States|Southeastern Research Associates, Inc., Taylors, South Carolina, United States|Abbott Clinical Research Group, Inc, San Antonio, Texas, United States|Avastra Clinical Trials, Midvale, Utah, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|Capital Clinical Research Center, Olympia, Washington, United States|Stephen G. Danley, Do, Spokane, Washington, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Coquitlam, British Columbia, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Bathurst, New Brunswick, Canada|Local Institution, Ajax, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Waterloo, Ontario, Canada|Local Institution, Drummondville, Quebec, Canada|Local Institution, L'Ancienne Lorette, Quebec, Canada|Local Institution, St-Leonard, Quebec, Canada|Local Institution, Ahmedabad, India|Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Jaipur, India|Local Institution, Jaipur, India|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Durango, Mexico|Local Institution, Mexico City, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Ponce, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Kursk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Smolensk, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, Benoni, Gauteng, South Africa|Local Institution, Soweto, Gauteng, South Africa|Local Institution, Paarl, Western Cape, South Africa|Local Institution, Tygerberg, Western Cape, South Africa",,"https://ClinicalTrials.gov/show/NCT00736879"
163,"NCT00698932","Evaluate Efficacy and Safety of Saxagliptin in Adult Patients With Type 2 Diabetes Inadequate Glycemic Control",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo","Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)|Absolute Change (mmol/L) From Baseline to Week 24 in Fasting Plasma Glucose (FPG)|Absolute Change (mg/dL) From Baseline to Week 24 in Fasting Plasma Glucose (FPG)|Absolute Change (mmol*Min/L) From Baseline to Week 24 in Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During Mixed Meal (Instant Noodles) Tolerance Tests (MMTT) in All MMTT Participants|Absolute Change (mg*Min/dL) From Baseline to Week 24 in Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During Mixed Meal (Instant Noodles) Tolerance Tests (MMTT) in All MMTT Participants|Proportion of Patients Achieving a Therapeutic Glycemic Response Defined as HbA1c <7.0% at Week 24","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","568","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680C00005","June 2008","October 2009","October 2009","June 17, 2008","September 21, 2011","September 21, 2011","Research Site, Hefei, Anhui, China|Research Site, Fuzhou, Fujian, China|Research Site, Guangzhou, Guangdong, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Dalian, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Shanghai, Shanghai, China|Research Site, Chengdu, Sichuan, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Tianjin, China|Research Site, Hyderabaad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Coimbatore, India|Research Site, Jeonju, Chonbuk, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Makati City, Philippines|Research Site, Manila, Philippines|Research Site, Marikina City, Philippines|Research Site, Quezon City, Philippines",,"https://ClinicalTrials.gov/show/NCT00698932"
164,"NCT00690612","Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)","HIP","Completed","Has Results","Hypertension","Drug: candesartan cilexetil","Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP).|Mean Change From Baseline to Final Visit in Diastolic Blood Pressure (DBP).","AstraZeneca","All","1 Year to 10 Years   (Child)","Phase 3","35","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D2451C00006","September 2007","September 2009","September 2009","June 4, 2008","June 29, 2011","July 12, 2011","Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Strasbourg Cedex, France|Research Site, Erlangen, Germany|Research Site, Heidelberg, Germany|Research Site, Marburg, Germany|Research Site, Rostock, Germany|Research Site, Genova, GE, Italy|Research Site, Padova, PD, Italy|Research Site, Gda�sk, Poland|Research Site, Krakow, Poland|Research Site, Crimea, Ukraine|Research Site, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT00690612"
165,"NCT00683657","Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo","Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4|Change From Baseline in 4-Hour Mean Weighted Postprandial Plasma Glucose at Week 4|Change From Baseline in 2-Hour Postprandial Plasma Glucose After the Evening Meal at Week 4|Change From Baseline in Mean Daily Glucose at Week 4|Change From Baseline in 2-Day Average Fasting Plasma Glucose (FPG) at Week 4","AstraZeneca","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","93","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV181-066|Eudract-2008-000976-26","July 2008","February 2009","February 2009","May 23, 2008","March 10, 2010","June 1, 2015","Dedicated Phase I, Inc., Phoenix, Arizona, United States|Amcr Institute, Inc, Escondido, California, United States|Irvine Center For Clinical Research, Inc., Irvine, California, United States|Pacific Sleep Medicine Services (Avastra Clinical Trials), Redlands, California, United States|Advantage Clinical Research, Santa Ana, California, United States|Orange County Research Center, Tustin, California, United States|River Birch Research Alliance, Llc, Blue Ridge, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Jasper Clinic, Inc., Kalamazoo, Michigan, United States|Clinilabs, Inc., New York, New York, United States|Covance Cru, Inc., Portland, Oregon, United States|Dgd Research, Inc., San Antonio, Texas, United States|Avastra Clinical Trials, Midvale, Utah, United States|Local Institution, Martinez, Buenos Aires, Argentina|Local Institution, Holon, Israel|Local Institution, Jerusalem, Israel|Local Institution, Kfar-Saba, Israel|Local Institution, Zerifin, Israel|Local Institution, Milano, Italy|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Cebu City, Philippines|Local Institution, Marikina City, Philippines|Local Institution, Ponce, Puerto Rico|Local Institution, Gothenburg, Sweden|Local Institution, Huddinge, Sweden|Local Institution, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT00683657"
166,"NCT00683618","Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia",,"Completed","Has Results","Hypercholesterolemia","Drug: Rosuvastatin|Drug: Atorvastatin","Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg|Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 10mg With Atorvastatin 10mg|Percentage Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C) at Week 6|Percentage Change From Baseline in Total Cholesterol (TC ) at Week 6|Percentage Change From Baseline in Triglycerides (TG) at Week 6|Percentage Change From Baseline in Non High Density Lipoprotein-Cholesterol (nonHDL-C) at Week 6|Percentage Change From Baseline in Apolipoprotein B (ApoB) at Week 6|Percentage Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 6|Percentage Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (TC/HDL-C) at Week 6|Percentage Change From Baseline in Low Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (LDL-C/HDL-C) at Week 6|Percentage Change From Baseline in Non High Density Lipoprotein Cholesterol/High Density Lipoprotein Cholesterol (nonHDL-C/HDL-C) at Week 6|Percentage Change From Baseline in Apolipoprotein B/Apolipoprotein A I (ApoB/ApoA-I) at Week 6|Percentage of Patients Achieved ATP III Guideline (2001) Low Density Lipoprotein Cholesterol (LDL-C) Goal at Week 6|6 weeksPercentage of Patients Achieved ATP III Guideline (2001) Non High Density Lipoprotein-Cholesterol (nonHDL-C) Goal at Week 6|Percentage of Patients Achieved National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III Guideline (2001) Low Density Lipoprotein-Cholesterol (LDL-C) Goal After Titration","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","934","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D356FC00007","May 2008","July 2009","July 2009","May 23, 2008","March 12, 2012","March 21, 2012","Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Shenyang, Liaoning, China|Research Site, Beijing, China|Research Site, Shanghai, China|Research Site, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT00683618"
167,"NCT00680745","Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients",,"Completed","Has Results","Type 2 Diabetes","Drug: dapagliflozin|Drug: Glimepiride|Drug: metformin hydrochloride|Drug: pioglitazone hydrochloride|Drug: Rosiglitazone","Adjusted Mean Change in HbA1c Levels|Adjusted Mean Change in Body Weight|Adjusted Mean Change in 2-h Post-challenge Plasma Glucose Rise|Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%|Adjusted Mean Change in Body Weight for Participants With Baseline Body Mass Index (BMI)≥27 kg/m2|Adjusted Mean Change in Fasting Plasma Glucose (FPG)","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","597","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00005","April 2008","November 2009","May 2010","May 20, 2008","October 14, 2013","October 14, 2013","Research Site, Blansko, Czech Republic|Research Site, Breclav, Czech Republic|Research Site, Bruntal, Czech Republic|Research Site, Hodonin, Czech Republic|Research Site, Ostrava - Belsky Les, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Praha 1, Czech Republic|Research Site, Pribram Viii, Czech Republic|Research Site, Rakovnik, Czech Republic|Research Site, Semily, Czech Republic|Research Site, Balatonfured, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Csongrad, Hungary|Research Site, Eger, Hungary|Research Site, Gyongyos, Hungary|Research Site, Kecskemet, Hungary|Research Site, Mako, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Siofok, Hungary|Research Site, Szentes, Hungary|Research Site, TAT, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Jeonju, Chonbuk, Korea, Republic of|Research Site, Wonju, Kangwon-do, Korea, Republic of|Research Site, Suwon, Kyunggi-do, Korea, Republic of|Research Site, Bucheon, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Uljeongbu, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Manila, Philippines|Research Site, Marikina City, Philippines|Research Site, Pasig City, Philippines|Research Site, Bielsko - Biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chojnice, Poland|Research Site, Chrzanow, Poland|Research Site, Ciechocinek, Poland|Research Site, Czechowice-Dziedzice, Poland|Research Site, Elblag, Poland|Research Site, Gdansk, Poland|Research Site, Gniewkowo, Poland|Research Site, Grudziadz, Poland|Research Site, Ilawa, Poland|Research Site, Krakow, Poland|Research Site, Mragowo, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Ruda Slaska, Poland|Research Site, Sopot, Poland|Research Site, Torun, Poland|Research Site, Wroclaw, Poland|Research Site, Zabrze, Poland|Research Site, Zielona Gora, Poland|Research Site, Zory, Poland|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Dnipropetrov'sk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporozhye, Ukraine",,"https://ClinicalTrials.gov/show/NCT00680745"
168,"NCT00680017","30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease",,"Completed","Has Results","Dyslipidemia|Kidney Disease","Drug: ABT-335 plus rosuvastatin|Drug: Rosuvastatin","Median Percent Change in Triglycerides From Baseline to Week 8.|Mean Percent Change in High-Density Lipoprotein Cholesterol From Baseline to Week 8.","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-313","June 2008","April 2011","April 2011","May 19, 2008","July 16, 2012","October 3, 2012","Site Reference ID/Investigator# 22521, Birmingham, Alabama, United States|Site Reference ID/Investigator# 22478, Huntsville, Alabama, United States|Site Reference ID/Investigator# 8365, Madison, Alabama, United States|Site Reference ID/Investigator# 8416, Montgomery, Alabama, United States|Site Reference ID/Investigator# 7869, Chula Vista, California, United States|Site Reference ID/Investigator# 8435, Fountain Valley, California, United States|Site Reference ID/Investigator# 22487, Lincoln, California, United States|Site Reference ID/Investigator# 22426, Long Beach, California, United States|Site Reference ID/Investigator# 8096, Los Angeles, California, United States|Site Reference ID/Investigator# 22962, Norwalk, California, United States|Site Reference ID/Investigator# 8311, Riverside, California, United States|Site Reference ID/Investigator# 22816, Sacramento, California, United States|Site Reference ID/Investigator# 8510, Simi Valley, California, United States|Site Reference ID/Investigator# 22821, West Hills, California, United States|Site Reference ID/Investigator# 7958, Arvada, Colorado, United States|Site Reference ID/Investigator# 15881, Denver, Colorado, United States|Site Reference ID/Investigator# 8399, Westminster, Colorado, United States|Site Reference ID/Investigator# 23224, Boynton Beach, Florida, United States|Site Reference ID/Investigator# 22474, Clearwater, Florida, United States|Site Reference ID/Investigator# 21803, Coral Springs, Florida, United States|Site Reference ID/Investigator# 22811, Daytona Beach, Florida, United States|Site Reference ID/Investigator# 27103, Hollywood, Florida, United States|Site Reference ID/Investigator# 8398, Hudson, Florida, United States|Site Reference ID/Investigator# 26723, Kissimmee, Florida, United States|Site Reference ID/Investigator# 37676, Kissimmee, Florida, United States|Site Reference ID/Investigator# 8231, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 22486, Longwood, Florida, United States|Site Reference ID/Investigator# 22520, New Port Richey, Florida, United States|Site Reference ID/Investigator# 8226, Orlando, Florida, United States|Site Reference ID/Investigator# 22477, Ormond Beach, Florida, United States|Site Reference ID/Investigator# 8386, Pembroke Pines, Florida, United States|Site Reference ID/Investigator# 22518, Plant City, Florida, United States|Site Reference ID/Investigator# 12882, Port Charlotte, Florida, United States|Site Reference ID/Investigator# 37675, St. Cloud, Florida, United States|Site Reference ID/Investigator# 8410, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 21802, Winter Haven, Florida, United States|Site Reference ID/Investigator# 8136, Atlanta, Georgia, United States|Site Reference ID/Investigator# 23503, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 7948, Macon, Georgia, United States|Site Reference ID/Investigator# 22819, Roswell, Georgia, United States|Site Reference ID/Investigator# 22813, Suwanee, Georgia, United States|Site Reference ID/Investigator# 27682, Chicago, Illinois, United States|Site Reference ID/Investigator# 8227, Peoria, Illinois, United States|Site Reference ID/Investigator# 13922, Mishawaka, Indiana, United States|Site Reference ID/Investigator# 8094, Council Bluffs, Iowa, United States|Site Reference ID/Investigator# 22430, Iowa City, Iowa, United States|Site Reference ID/Investigator# 8093, Paducah, Kentucky, United States|Site Reference ID/Investigator# 38405, Baton Rouge, Louisiana, United States|Site Reference ID/Investigator# 8903, Shreveport, Louisiana, United States|Site Reference ID/Investigator# 21805, Auburn, Maine, United States|Site Reference ID/Investigator# 8092, Rockville, Maryland, United States|Site Reference ID/Investigator# 8225, Fall River, Massachusetts, United States|Site Reference ID/Investigator# 8407, Springfield, Massachusetts, United States|Site Reference ID/Investigator# 8415, Royal Oak, Michigan, United States|Site Reference ID/Investigator# 22222, Brooklyn Center, Minnesota, United States|Site Reference ID/Investigator# 8408, Olive Branch, Mississippi, United States|Site Reference ID/Investigator# 22703, Berlin, New Jersey, United States|Site Reference ID/Investigator# 22707, Elizabeth, New Jersey, United States|Site Reference ID/Investigator# 22702, Hillsborough, New Jersey, United States|Site Reference ID/Investigator# 8387, Flushing, New York, United States|Site Reference ID/Investigator# 8177, Great Neck, New York, United States|Site Reference ID/Investigator# 8146, Lake Success, New York, United States|Site Reference ID/Investigator# 22427, Williamsville, New York, United States|Site Reference ID/Investigator# 22481, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 22708, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 8434, Morehead City, North Carolina, United States|Site Reference ID/Investigator# 8417, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 8147, Columbus, Ohio, United States|Site Reference ID/Investigator# 22488, Mason, Ohio, United States|Site Reference ID/Investigator# 22479, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 23225, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 22482, Tulsa, Oklahoma, United States|Site Reference ID/Investigator# 8345, Bend, Oregon, United States|Site Reference ID/Investigator# 22704, Medford, Oregon, United States|Site Reference ID/Investigator# 8400, Portland, Oregon, United States|Site Reference ID/Investigator# 8411, Bethlehem, Pennsylvania, United States|Site Reference ID/Investigator# 8405, Carlisle, Pennsylvania, United States|Site Reference ID/Investigator# 22387, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 22815, Jersey Shore, Pennsylvania, United States|Site Reference ID/Investigator# 12881, Johnstown, Pennsylvania, United States|Site Reference ID/Investigator# 22706, Perkasie, Pennsylvania, United States|Site Reference ID/Investigator# 8095, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 22705, Tipton, Pennsylvania, United States|Site Reference ID/Investigator# 22817, Warminster, Pennsylvania, United States|Site Reference ID/Investigator# 8098, Providence, Rhode Island, United States|Site Reference ID/Investigator# 22823, Charleston, South Carolina, United States|Site Reference ID/Investigator# 8364, Columbia, South Carolina, United States|Site Reference ID/Investigator# 22429, Greenville, South Carolina, United States|Site Reference ID/Investigator# 22428, Mount Pleasant, South Carolina, United States|Site Reference ID/Investigator# 25302, Summerville, South Carolina, United States|Site Reference ID/Investigator# 22812, Dallas, Texas, United States|Site Reference ID/Investigator# 8536, Edinburg, Texas, United States|Site Reference ID/Investigator# 22810, Fort Worth, Texas, United States|Site Reference ID/Investigator# 24742, Houston, Texas, United States|Site Reference ID/Investigator# 26722, Houston, Texas, United States|Site Reference ID/Investigator# 8406, Houston, Texas, United States|Site Reference ID/Investigator# 8232, Lubbock, Texas, United States|Site Reference ID/Investigator# 22480, San Antonio, Texas, United States|Site Reference ID/Investigator# 8397, San Antonio, Texas, United States|Site Reference ID/Investigator# 21804, Ogden, Utah, United States|Site Reference ID/Investigator# 22423, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 8413, Gig Harbor, Washington, United States|Site Reference ID/Investigator# 24402, Carolina, Puerto Rico|Site Reference ID/Investigator# 22545, Humacao, Puerto Rico|Site Reference ID/Investigator# 8301, Manati, Puerto Rico|Site Reference ID/Investigator# 8299, Ponce, Puerto Rico|Site Reference ID/Investigator# 8418, Ponce, Puerto Rico|Site Reference ID/Investigator# 8419, Ponce, Puerto Rico|Site Reference ID/Investigator# 8421, San Juan, Puerto Rico|Site Reference ID/Investigator# 8300, San Juan, Puerto Rico|Site Reference ID/Investigator# 8422, San Juan, Puerto Rico|Site Reference ID/Investigator# 8423, San Juan, Puerto Rico|Site Reference ID/Investigator# 8420, Toa Baja, Puerto Rico|Site Reference ID/Investigator# 8298, Yabucoa, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00680017"
169,"NCT00676338","Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide once weekly|Drug: metformin|Drug: sitagliptin|Drug: pioglitazone","Change in HbA1c From Baseline to Week 26|Percentage of Patients Achieving HbA1c <=7% at Week 26|Change in Fasting Serum Glucose (FSG) From Baseline to Week 26|Change in Body Weight From Baseline to Week 26|Change in Fasting Total Cholesterol (TC) From Baseline to Week 26|Change in Fasting High-Density Lipoprotein (HDL) From Baseline to Week 26|Ratio of Fasting Triglycerides at Week 26 to Baseline|Assessment on Event Rate of Treatment-emergent Major Hypoglycemic Events|Assessment on Event Rate of Treatment-Emergent Minor Hypoglycemic Events|Change in Systolic Blood Pressure From Baseline to Week 26.|Change in Diastolic Blood Pressure From Baseline to Week 26.","AstraZeneca|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","820","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H8O-MC-GWCH (DURATION - 4)","November 2008","July 2010","January 2011","May 13, 2008","November 26, 2012","April 9, 2015","Research Site, Buena Park, California, United States|Research Site, Los Angeles, California, United States|Research Site, Valencia, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Des Moines, Iowa, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Billings, Montana, United States|Research Site, Toms River, New Jersey, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Danville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Wilke Barre, Pennsylvania, United States|Research Site, Austin, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, New Branufels, Texas, United States|Research Site, Buenos Aires, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Leuven, Belgium|Research Site, Marchovelette, Belgium|Research Site, Tessenderlo, Belgium|Research Site, Brasilia, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Joinville, Brazil|Research SIte, Porto Alegre, Brazil|Research Site, Recife, Brazil|Research Site, Sao Paolo, Brazil|Research Site, Coquitlam, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Gatineu, Quebec, Canada|Research Site, Mississauga, Canada|Research Site, Petitcodiac, Canada|Research Site, Pointe-Claire, Canada|Research Site, Regina, Canada|Research Site, Saint John, Canada|Research Site, Chateaugiron, France|Research Site, Murs Erigne, France|Research Site, Nantes, France|Research Site, Vieux Conde, France|Research Site, Dresden, Germany|Research Site, Mainz, Germany|Research Site, Muenster, Germany|Research Site, Rodgau, Germany|Research Site, Budapest, Hungary|Research Site, Gyula, Hungary|Research Site, Hodmezovasarhely, Hungary|Research Site, Pecs, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Channai, India|Research Site, Cochin, India|Research Site, Mumbai, India|Research Site, New Dehli, India|Research SIte, Pune, India|Research Site, Holon, Israel|Research SIte, Tel-Hashomer, Israel|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Siena, Italy|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Jeonju, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Sungnam, Korea, Republic of|Research Site, Chihuahua, Mexico|Research Site, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research Site, Lublin, Poland|Research Site, Szczecin, Poland|Research Site, Wroclaw, Poland|Research Site, Manati, Puerto Rico|Research Site, Toa Baja, Puerto Rico|Research Site, Galati, Romania|Research Site, Oradea, Romania|Research Site, Targu Mures, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Stavropol, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Trebisov, Slovakia|Research Site, Johannesburg, South Africa|Research Site, Kempton Park, South Africa|Research Site, Midrand, South Africa|Research Site, Soweto, South Africa|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Sisli-Istanbul, Turkey|Research Site, Bath, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Frome, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00676338"
170,"NCT00673231","Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Placebo","Adjusted Mean Change in HbA1c Levels|Adjusted Mean Change in Body Weight|Adjusted Mean Change in Calculated Mean Daily Insulin Dose|Proportion of Participants With Calculated Mean Daily Insulin Dose Reduction|Adjusted Mean Change in Fasting Plasma Glucose (FPG)","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00006","April 2008","May 2009","January 2011","May 7, 2008","August 23, 2013","October 29, 2013","Research Site, Fresno, California, United States|Research Site, Greenbrae, California, United States|Research Site, Roswell, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Springfield, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Pleven, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Langley, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Etobicoke, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Thornhill, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Longueuil, Quebec, Canada|Research Site, Mirabel, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Jyvaskyla, Finland|Research Site, Kuopio, Finland|Research Site, Lahti, Finland|Research Site, Oulu, Finland|Research Site, Seinajoki, Finland|Research Site, Turku, Finland|Research Site, Bad Oeynhausen, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Magdeburg, Germany|Research Site, Münster, Germany|Research Site, Riesa, Germany|Research Site, Wolmirstedt, Germany|Research Site, Csongrad, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Komarom, Hungary|Research Site, Miskolc, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Veszprem, Hungary|Research Site, Amersfoort, Netherlands|Research Site, Den Helder, Netherlands|Research Site, Leiden, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tg Mures, Mures, Romania|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Saint- Petersburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.-petersburg, Russian Federation|Research Site, St.petersburg, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Dolny Kubin, Slovakia|Research Site, Kosice, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Presov, Slovakia|Research Site, Sevilla, Andalucia, Spain|Research Site, Sabadell (barcelona), Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Alicante, Comunidad Valenciana, Spain|Research Site, Reading, Berks, United Kingdom|Research Site, Aylesbury, Bucks, United Kingdom|Research Site, Ashford, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Reading, United Kingdom|Research Site, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00673231"
171,"NCT00667992","Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma",,"Completed","Has Results","Asthma","Drug: Budesonide HFA|Drug: Budesonide CFC","PC 20 Methacholine (Provocative Concentration of Methacholine Causing 20 % Fall in FEV1(Forced Expiratory Volume)|Peak Exploratory Flow (PEF)|FEV1 (Forced Expiratory Volume in 1 Second)|FEF 25-75 (Forced Expiratory Flow 25-75)|eNO (Exhaled Nitrogen Oxide)|Asthma Symptom Score Morning|Asthma Symptom Score Evening|Asthma Symptom Score Total|Rescue Medication Morning|Rescue Medication Evening|Rescue Medication Total|Peak Exploratory Flow (PEF) Morning","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5252C00008","April 2008","May 2009","May 2009","April 28, 2008","November 7, 2012","November 7, 2012","Research Site, King of Prussia, Pennsylvania, United States|Research Site, Dundee, Scotland, United Kingdom|Research Site, Perth, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00667992"
172,"NCT00666458","18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)",,"Completed","Has Results","Type 2 Diabetes","Drug: saxagliptin|Drug: sitagliptin","Hemoglobin A1c (HbA1c) Change From Baseline to Week 18|Proportion of Patients Achieving Therapeutic Glycaemic Response Defined as HbA1c <= 6.5% at Week 18|Fasting Plasma Glucose Change From Baseline to Week 18 (mg/dL)|Fasting Plasma Glucose Change From Baseline to Week 18 (mmol/L)","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","822","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680C00002|EudraCT number 2007-006095-11","April 2008","March 2009","March 2009","April 25, 2008","April 15, 2010","April 15, 2010","Research Site, Lanus, Buenos Aires, Argentina|Research Site, Mar Del Plata, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Rosario, Argentina|Research Site, Santa Fe, Argentina|Research Site, Aalst, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brugge, Belgium|Research Site, Genk, Belgium|Research Site, Gozee, Belgium|Research Site, Hasselt, Belgium|Research Site, Liege, Belgium|Research Site, Saint-medard, Belgium|Research Site, Sint-gillis-waas, Belgium|Research Site, Tessenderlo, Belgium|Research Site, Thuillies, Belgium|Research Site, Aalborg, Denmark|Research Site, Arhus, Denmark|Research Site, Christiansfeld, Denmark|Research Site, Farso, Denmark|Research Site, Gentofte, Denmark|Research Site, Hobro, Denmark|Research Site, Kolding, Denmark|Research Site, Rodovre, Denmark|Research Site, Viborg, Denmark|Research Site, Angers, France|Research Site, Chateau Gontier, France|Research Site, Corbeil Essonnes, France|Research Site, La Seyne Sur Mer, France|Research Site, Laval, France|Research Site, Le Lavandou, France|Research Site, Montrevault, France|Research Site, Saint Cyr, France|Research Site, Tierce, France|Research Site, Toulon, France|Research Site, Witry Les Reims, France|Research Site, Bergamo, BG, Italy|Research Site, Foggia, FG, Italy|Research Site, Chiavari, GE, Italy|Research Site, Genova, GE, Italy|Research Site, Rozzano, MI, Italy|Research Site, Olbia, OT, Italy|Research Site, Padova, PD, Italy|Research Site, Pordenone, PN, Italy|Research Site, Mercato San Severino, SA, Italy|Research Site, Siena, SI, Italy|Research Site, Mexico, D.f., Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Monterrey, Mexico|Research Site, Alesund, Norway|Research Site, Elverum, Norway|Research Site, Halden, Norway|Research Site, Hamar, Norway|Research Site, Lierskogen, Norway|Research Site, Lillehammer, Norway|Research Site, Oslo, Norway|Research Site, Sandvika, Norway|Research Site, Strommen, Norway|Research Site, Svelvik, Norway|Research Site, Benoni, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Cape Town, Western Cape, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kwa Zulu Natal, South Africa|Research Site, Pretoria, South Africa|Research Site, Boras, Sweden|Research Site, Degeberga, Sweden|Research Site, Finspang, Sweden|Research Site, Goteborg, Sweden|Research Site, Jonkoping, Sweden|Research Site, Odeshog, Sweden|Research Site, Orebro, Sweden|Research Site, Pitea, Sweden|Research Site, Rattvik, Sweden|Research Site, Skanor, Sweden|Research Site, Timra, Sweden|Research Site, Trollhattan, Sweden|Research Site, Uddevalla, Sweden|Research Site, Umea, Sweden",,"https://ClinicalTrials.gov/show/NCT00666458"
173,"NCT00661362","Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo|Drug: Metformin","Absolute Change From Baseline to Week 24 in Glycosylated Haemoglobin A1c (HbA1c)|Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) mmol/L|Absolute Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) mg/dL|Change From Baseline in the Area Under the Curve (AUC) From 0 to 180 Minutes for Postprandial Glucose (PPG) During a Mixed Meal Tolerance Test (MMTT) in a Subgroup|Proportion of Patients Achieving a Therapeutic Glycemic Response","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","570","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680C00006","June 2008","September 2009","September 2009","April 18, 2008","March 8, 2012","March 8, 2012","Research Site, Hefei, Anhui, China|Research Site, Guangzhou, Guangdong, China|Research Site, Shi Jiazhuang, Hebei, China|Research Site, Ha'er Bing, Hei Longjiang, China|Research Site, Wuhan, Hu Bei, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Dalian, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Shanghai, Shanghai, China|Research Site, Chengdu, Sichuan, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Tianjin, China|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Nagpur, Maharashtra, India|Research Site, Bangalore, India|Research Site, Seongnam, Gyeonggi-do, Korea, Republic of|Research Site, Bucheon, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Pusan, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Uijeongbu-si, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00661362"
174,"NCT00660907","Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients",,"Completed","Has Results","Type 2 Diabetes","Drug: dapagliflozin|Drug: glipizide|Drug: metformin hydrochloride","Adjusted Mean Change in HbA1c Levels|Adjusted Mean Change in Body Weight|Proportion of Participants With at Least One Episode of Hypoglycemia|Proportion of Participants With Body Weight Reduction of at Least 5%","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","1217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1690C00004","March 2008","December 2009","January 2013","April 17, 2008","August 23, 2013","March 30, 2015","Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Corrientes, Argentina|Research Site, Córdoba, Argentina|Research Site, La Plata, Argentina|Research Site, Rosario, Argentina|Research Site, Santa Fe, Argentina|Research Site, L'aigle, France|Research Site, Murs Erigne, France|Research Site, Nantes Cedex 1, France|Research Site, Nantes, France|Research Site, Paris, France|Research Site, Tours, France|Research Site, Vannes, France|Research Site, Bad Lauterberg, Germany|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Heilbronn, Germany|Research Site, Ludwigshafen, Germany|Research Site, Mainz, Germany|Research Site, Pirna, Germany|Research Site, Schmiedeberg, Germany|Research Site, Wangen, Germany|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Acapulco, Mexico|Research Site, Guadalajara, Mexico|Research Site, México, Mexico|Research Site, Veracruz, Mexico|Research Site, Den Haag, Netherlands|Research Site, Deurne, Netherlands|Research Site, Gorinchem, Netherlands|Research Site, Groningen, Netherlands|Research Site, Lichtenvoorde (gld), Netherlands|Research Site, Losser, Netherlands|Research Site, Poortvliet, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Wildervank, Netherlands|Research Site, Zutphen, Netherlands|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Parow, South Africa|Research Site, Pretoria, South Africa|Research Site, Umkomaas, South Africa|Research Site, Witbank, South Africa|Research Site, Alicante, Spain|Research Site, Alzira (Valencia), Spain|Research Site, Barcelona, Spain|Research Site, Cornellá de Llobregat (BCN), Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Göteborg, Sweden|Research Site, Järfälla, Sweden|Research Site, Lund, Sweden|Research Site, Malmö, Sweden|Research Site, Skene, Sweden|Research Site, Stockholm, Sweden|Research Site, Södertälje, Sweden|Research Site, Umeå, Sweden|Research Site, Addlestone, United Kingdom|Research Site, Aylesbury, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Bury St Edmonds, United Kingdom|Research Site, Cookstown, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Ecclesfield, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Mortimer Reading, United Kingdom|Research Site, Trowbridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00660907"
175,"NCT00658021","Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes","Drug: Placebo|Drug: Exenatide","Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28|Number of Participants With Post-Treatment Adverse Events of Special Interest (AESI) During Safety Follow-up Period|Percentage of Participants Achieving HbA1c Goals of < 7%, <= 6.5%, and < 6.5% Through Week 28|Adjusted Change From Baseline in Body Weight Through Week 28|Adjusted Change From Baseline in Fasting Serum Glucose (FSG) at Week 28|Adjusted Change From Baseline in Self-Monitored Blood Glucose (SMBG) at Week 28|Adjusted Change From Baseline in Fasting Serum Insulin at Week 28|Adjusted Change From Baseline in Homeostasis Model Assessments - Beta-Cell Function (HOMA-B) and Insulin Sensitivity (HOMA-S) at Week 28|Percentage of Participants Discontinuing the Study Due to Failure to Maintain Glycemic Control Through Week 28","AstraZeneca|Quintiles, Inc.","All","10 Years to 17 Years   (Child)","Phase 3","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5550C00002|H8O-MC-GWBQ","May 30, 2008","April 18, 2019","April 1, 2020","April 14, 2008","December 1, 2020","December 1, 2020","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Montclair, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Ana, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, Dalton, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Dearborn, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Reno, Nevada, United States|Research Site, Jamaica, New York, United States|Research Site, Greenville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Spokane, Washington, United States|Research Site, Fortaleza, Brazil|Research Site, Juiz de Fora, Brazil|Research Site, Santo André, Brazil|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Pune, India|Research Site, Seoul, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Culiacán, Mexico|Research Site, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research Site, San Juan del Rio, Mexico|Research Site, Tamaupilas, Mexico|Research Site, Tampico, Mexico|Research Site, Quezon City, Philippines|Research Site, Moscow, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Moloto, South Africa|Research Site, Paarl, South Africa|Research Site, Pretoria, South Africa|Research Site, Verulam, South Africa","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT00658021/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT00658021/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00658021"
176,"NCT00641056","Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: Exenatide Once Weekly|Drug: Insulin Glargine","Change in HbA1c From Baseline to Week 26|Percentage of Patients Achieving HbA1c <=7.0% at Week 26|Percentage of Patients Achieving HbA1c <=6.5% at Week 26|Change in Fasting Serum Glucose (FSG) From Baseline to Week 26|Change in Body Weight (BW) From Baseline to Week 26|Change in Total Cholesterol From Baseline to Week 26|Change in High-density Lipoprotein Cholesterol (HDL) From Baseline to Week 26|Ratio of Triglycerides at Week 26 to Baseline|Change in Blood Pressure From Baseline to Week 26|Assessment on Event Rate of Treatment-emergent Hypoglycemic Episodes","AstraZeneca|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","467","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-MC-GWBR (DURATION - 3)","April 2008","May 2009","November 2009","March 21, 2008","July 4, 2012","June 15, 2015","Research Site, Escondido, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Idaho Falls, Idaho, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Dayton, Ohio, United States|Research Site, Ada, Oklahoma, United States|Research Site, San Antonio, Texas, United States|Research Site, Spokane, Washington, United States|Research Site, Wollongong, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Keswick, South Australia, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Melnik, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Stodulky, Czech Republic|Research Site, Aalborg, Denmark|Research Site, Arhus C, Denmark|Research Site, Herlev, Denmark|Research Site, Koge, Denmark|Research Site, Angers, France|Research Site, Corbeil Essoness, France|Research Site, Nancy, France|Research Site, Nanterre, France|Research Site, Toulouse, France|Research Site, Bad Mergentheim, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Falkensee, Germany|Research Site, Fulda, Germany|Research Site, Hamburg-Othmarschen, Germany|Research Site, Munster, Germany|Research Site, Rothenburg an der fulda, Germany|Research Site, Speyer, Germany|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Eger, Hungary|Research Site, Gyula, Hungary|Research Site, Pecs, Hungary|Research Site, Gyeonggi-Do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Merida, Mexico|Research Site, Mexico City, Mexico|Research Site, Tampico, Mexico|Research Site, Tijuana, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Gouda, Netherlands|Research Site, Hoogeveen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Zwijndrecht, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Caguas, Puerto Rico|Research Site, Yabucoa, Puerto Rico|Research Site, Moscow, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Alicante, Spain|Research Site, Alzira-Valencia, Spain|Research Site, Barcelona, Spain|Research Site, Bilbao, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Teruel, Spain|Research Site, Chia-Yi, Taiwan|Research Site, Tainan County, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00641056"
177,"NCT00640601","Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia","SPECTRUM","Completed","Has Results","Schizophrenia","Drug: Quetiapine Fumarate Extended- Release","Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study|Change in Clinical Global Impression-Clinical Benefit (CGI-CB) Score|Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Total Score|Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Positive Scale Score|Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Negative Scale Score|Change in Global Assessment Scale (GAS)|Change in Clinical Global Impression-Severity (CGI-S) Scale|Change in Clinical Global Impression-Improvement (CGI-I) Scale|Change in Social and Occupational Functioning Assessment Scale (SOFAS)|Change in Safety Measure: Simpson-Angus Scale (SAS)|Change in Barnes Akathisia Rating Scale (BARS)","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","331","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1443L00025","March 2008","July 2010","July 2010","March 21, 2008","June 22, 2012","June 25, 2012","Research Site, Garran, Australian Capital Territory, Australia|Research Site, Newcastle, New South Wales, Australia|Research Site, Brisbane, Queensland, Australia|Research Site, Meadowbrook, Queensland, Australia|Research Site, Dandenong, Victoria, Australia|Research Site, Calgary, Alberta, Canada|Research Site, Claresholm, Alberta, Canada|Research Site, Red Deer, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Miramichi, New Brunswick, Canada|Research Site, St John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Belleville, Ontario, Canada|Research Site, Brantford, Ontario, Canada|Research Site, Chatham, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Markham, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Orleans, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Rouyn-noranda, Quebec, Canada|Research Site, Verdun, Quebec, Canada|Research Site, Prince Albert, Saskatchewan, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, HK, Hong Kong|Research Site, Seoul, Korea, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00640601"
178,"NCT00640562","Quetiapine Extended Release Depression Symptoms","ExAttitude","Completed","Has Results","Schizophrenia|Depression","Drug: Quetiapine Extended Release|Drug: Risperidone","Change From Baseline to Week 12 of Calgary Depression Scale for Schizophrenia (CDSS) Score.|Change From Baseline to Week 12 of HAM-D Score|Change From Baseline to Week 12 of PANSS Score|- Change From Baseline to Week 12 of Clinical Global Impression (CGI- Severity of Illness) Score|CGI- Global Improvement Mean Score at Week 12|Change From Baseline to Week 12 of Drug Attitude Inventory 10 Item Scale (DAI 10) Score|Change From Baseline in the Simpson Angus Scale (SAS) Total Score to Week 12 as an Indication of Neurological Side Effects Section|Concomitant Use of Antidepressive Drugs From Baseline to Week 12|Change From Screening Visit to Week 12 of Prolactin Live|Body Mass Index (BMI) at Week 12","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1443L00031","February 2008","February 2010","February 2010","March 21, 2008","June 19, 2012","June 19, 2012","Research Site, Fermo, AP, Italy|Research Site, Bergamo, BG, Italy|Research Site, Brindisi, BR, Italy|Research Site, Carbonia, CA, Italy|Research Site, Termoli, CB, Italy|Research Site, Aversa, CE, Italy|Research Site, Catania, CT, Italy|Research Site, Nicosia, EN, Italy|Research Site, Lido Di Camaiore, LU, Italy|Research Site, Messina, ME, Italy|Research Site, Milazzo, ME, Italy|Research Site, Monza, MI, Italy|Research Site, Nocera Inferiore, SA, Italy|Research Site, Vallo Della Lucania, SA, Italy|Research Site, La Spezia, SP, Italy|Research Site, Collegno, TO, Italy|Research Site, Frattaminore, Italy|Research Site, Lecco, Italy|Research Site, Palermo, Italy|Research Site, Partinico, Italy|Research Site, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT00640562"
179,"NCT00637273","A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide once weekly|Drug: sitagliptin|Drug: pioglitazone|Drug: placebo tablet|Drug: placebo once weekly","Change in HbA1c From Baseline to Week 26|Percentage of Subjects Achieving HbA1c Target of <7% at Week 26|Percentage of Subjects Achieving HbA1c Target of <=6.5% at Week 26|Percentage of Subjects Achieving HbA1c Target of <=6.0% at Week 26|Change in Body Weight From Baseline to Week 26|Change in Fasting Plasma Glucose From Baseline to Week 26|Change in Systolic Blood Pressure From Baseline to Week 26|Change in Diastolic Blood Pressure From Baseline to Week 26|Change in Fasting Total Cholesterol From Baseline to Week 26|Change in Fasting High-density Lipoprotein (HDL) From Baseline to Week 26|Ratio of Fasting Triglycerides at Week 26 to Baseline|Assessment on Event Rate of Treatment-emergent Hypoglycemic Events","AstraZeneca|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","514","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BCB106 (DURATION - 2)","January 2008","February 2009","July 2009","March 17, 2008","June 19, 2012","April 7, 2015","Research Site, Peoria, Arizona, United States|Research Site, Artesia, California, United States|Research Site, Concord, California, United States|Research Site, Encino, California, United States|Research Site, Greenbrae, California, United States|Research Site, La Mesa, California, United States|Research Site, Orange, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Whittier, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Coral Gables, Florida, United States|Research Site, Deland, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Decatur, Georgia, United States|Research Site, Avon, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Paducah, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Oxon Hill, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Chelsea, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, St. Louis Park, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Butte, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, New Hyde Park, New York, United States|Research Site, New Windsor, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Athens, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Olympia, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Bangalore, India|Research Site, Indore, India|Research Site, Karnal, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Monterrey, NuevoLeon, Mexico|Research Site, Toluca, Mexico",,"https://ClinicalTrials.gov/show/NCT00637273"
180,"NCT00634114","Reflux Esophagitis Phase III Study (Maintenance Treatment)",,"Completed","Has Results","Reflux Esophagitis","Drug: Esomeprazole|Drug: Omeprazole","Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period.|Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 4 Weeks After Treatment|Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification up to 12 Weeks After Treatment","AstraZeneca","All","20 Years and older   (Adult, Older Adult)","Phase 3","540","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D961HC00006","January 2008",,"May 2009","March 12, 2008","June 17, 2010","June 17, 2010","Research Site, Kashiwa, Chiba, Japan|Research Site, Kisarazu, Chiba, Japan|Research Site, Koriyama, Fukishima, Japan|Research Site, Nihonmatsu, Fukishima, Japan|Research Site, Nishishirakawa, Fukishima, Japan|Research Site, Fukuoika, Fukuoka, Japan|Research Site, Kurume, Fukuoka, Japan|Research Site, Nukaya, Fukuoka, Japan|Research Site, Fukuoka, Fukuolka, Japan|Research Site, Koriyama, Fukushima, Japan|Research Site, Shirakawa, Fukushima, Japan|Research Site, Sugawa, Fukushima, Japan|Research Site, Gifu-shi, Gifu, Japan|Research Site, Maebashi, Gunma, Japan|Research Site, Yasunaka, Gunma, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Hitachi, Ibaraki, Japan|Research Site, Mito, Ibaraki, Japan|Research Site, Tsukuba, Ibaraki, Japan|Research Site, Sakaide, Kagawa, Japan|Research Site, Takamatsu, Kagawa, Japan|Research Site, Fujisawa, Kanagawa, Japan|Research Site, Kawasaki, Kanagawa, Japan|Research Site, Sagamihara, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Shibata, Myagi, Japan|Research Site, Kiso, Nagano, Japan|Research Site, Matsumoto, Nagano, Japan|Research Site, Fujiidera, Osaka, Japan|Research Site, Toyonaka, Osaka, Japan|Research Site, Ohtawara, Tochigi, Japan|Research Site, Toshima-ku, Tokayo, Japan|Research Site, Adachi, Tokyo, Japan|Research Site, Hachioji, Tokyo, Japan|Research Site, Kiyose, Tokyo, Japan|Research Site, Setagaya, Tokyo, Japan|Research Site, Shinagawa, Tokyo, Japan|Research Site, Shimonoseki, Yamaguchi, Japan|Research Site, Akita, Japan|Research Site, Fukuoka, Japan|Research Site, Kyoto, Japan|Research Site, Oita, Japan|Research Site, Shizuoka, Japan|Research Site, Tottori, Japan",,"https://ClinicalTrials.gov/show/NCT00634114"
181,"NCT00633932","Reflux Esophagitis Phase III Study (Initial Treatment)",,"Completed","Has Results","Reflux Esophagitis","Drug: Esomeprazole|Drug: Omeprazole","Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded ""O"" at Week 8 Out of Patients Who Were Graded ""A, B, C or D"" at Baseline According to Los Angeles Classification"".|Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded ""O"" at Week 4 Out of Patients Who Were Graded ""A, B, C or D"" at Baseline According to Los Angeles Classification","AstraZeneca","All","20 Years and older   (Adult, Older Adult)","Phase 3","602","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D961HC00002","December 2007",,"December 2008","March 12, 2008","April 8, 2010","December 20, 2010","Research Site, Kashiwa, Chiba, Japan|Research Site, Kisarazu, Chiba, Japan|Research Site, Koriyama, Fukishima, Japan|Research Site, Nihonmatsu, Fukishima, Japan|Research Site, Nishishirakawa, Fukishima, Japan|Research Site, Kurume, Fukuoka, Japan|Research Site, Nukaya, Fukuoka, Japan|Research Site, Shirakawa, Fukushima, Japan|Research Site, Sugawa, Fukushima, Japan|Research Site, Gifu-shi, Gifu, Japan|Research Site, Maebashi, Gunma, Japan|Research Site, Yasunaka, Gunma, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Hitachi, Ibaraki, Japan|Research Site, Mito, Ibaraki, Japan|Research Site, Tsukuba, Ibaraki, Japan|Research Site, Sakaide, Kagawa, Japan|Research Site, Takamatsu, Kagawa, Japan|Research Site, Fujisawa, Kanagawa, Japan|Research Site, Kawasaki, Kanagawa, Japan|Research Site, Sagamihara, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Shibata, Myagi, Japan|Research Site, Kiso, Nagano, Japan|Research Site, Matsumoto, Nagano, Japan|Research Site, Fujiidera, Osaka, Japan|Research Site, Toyonaka, Osaka, Japan|Research Site, Ohtawara, Tochigi, Japan|Research Site, Toshima-ku, Tokayo, Japan|Research Site, Adachi, Tokyo, Japan|Research Site, Hachioji, Tokyo, Japan|Research Site, Kiyose, Tokyo, Japan|Research Site, Setagaya, Tokyo, Japan|Research Site, Shinagawa, Tokyo, Japan|Research Site, Shimonoseki, Yamaguchi, Japan|Research Site, Akita, Japan|Research Site, Fukuoka, Japan|Research Site, Kyoto, Japan|Research Site, Oita, Japan|Research Site, Shizuoka, Japan|Research Site, Tottori, Japan",,"https://ClinicalTrials.gov/show/NCT00633932"
182,"NCT00628862","Evaluation of Efficacy and Safety of Formoterol in Patients With COPD Compared With Placebo in Patients in Japan, EU","OCEAN","Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Formoterol Turbuhaler® 4.5mg|Drug: Formoterol Turbuhaler® 9 mg|Drug: Turbuhaler® placebo","Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose|Forced Vital Capacity (FVC) 60 Minutes Post-dose|FEV1 Pre-dose|FVC Pre-dose|FEV1 5 Minutes Post-dose|FVC 5 Minutes Post-dose|Change in Peak Expiratory Flow (PEF), Morning|Change in Peak Expiratory Flow (PEF), Evening|Change in Night-time Awakenings Due to Symptoms|Breathlessness|Cough|Use of Reliever Medication|St George's Respiratory Questionnaire (SGRQ)","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","613","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D5122C00001|EudraCT no 2007-003999-19","December 2007","April 2009","April 2009","March 5, 2008","October 25, 2012","October 25, 2012","Research Site, Gabrovo, Bulgaria|Research Site, Lovech, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Troyan, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Nagoya, Aichi, Japan|Research Site, Seto, Aichi, Japan|Research Site, Noda, Chiba, Japan|Research Site, Touon, Ehime, Japan|Research Site, Yanagawa, Fukuoka, Japan|Research Site, ORA, Gunma, Japan|Research Site, OTA, Gunma, Japan|Research Site, Asahikawa, Hokkaido, Japan|Research Site, Chitose, Hokkaido, Japan|Research Site, Obihiro, Hokkaido, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Tomakomai, Hokkaido, Japan|Research Site, Yabu, Hyogo, Japan|Research Site, Naka-gun, Ibaraki, Japan|Research Site, Morioka, Iwate, Japan|Research Site, Kawasaki, Kangawa, Japan|Research Site, Sendai, Miyagi, Japan|Research Site, Katano, Osaka, Japan|Research Site, Kishiwada, Osaka, Japan|Research Site, Takatsuiki, Osaka, Japan|Research Site, Chiyoda, Tokyo, Japan|Research Site, UBE, Yamaguchi, Japan|Research Site, Hiroshima, Japan|Research Site, Kagoshima, Japan|Research Site, Kochi, Japan|Research Site, Kyoto, Japan|Research Site, Osaka, Japan|Research Site, Wakayama, Japan|Research Site, Deva, Hunedoara, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Constanta, Romania|Research Site, Iasi, Romania|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT00628862"
183,"NCT00628758","A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma","PASSION","Completed","Has Results","Asthma","Drug: Symbicort TBH - Turbuhaler|Drug: beta-II-agonist, inhale steroid","Time to First Severe Asthma Exacerbation|Number of Severe Asthma Exacerbations|Change in Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) Score|Mean Use of As-needed Medication Per Day During Treatment Period","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","430","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5890L00016","December 2005","September 2008","September 2008","March 5, 2008","August 14, 2012","August 14, 2012","Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Bursa, Turkey|Research Site, Denizli, Turkey|Research Site, Diyarbakir, Turkey|Research Site, Edirne, Turkey|Research Site, Eski?ehir, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Malatya, Turkey|Research Site, Manisa, Turkey|Research Site, Mersin, Turkey|Research Site, Samsun, Turkey|Research Site, Zonguldak, Turkey",,"https://ClinicalTrials.gov/show/NCT00628758"
184,"NCT00620542","CRESTOR Athero Imaging Head to Head IVUS Study","SATURN","Completed","Has Results","Coronary Atherosclerosis","Drug: Rosuvastatin|Drug: Atorvastatin","Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)|Numbers of Patients Showing Regression in PAV|Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)|Numbers of Patients Showing Regression in TAV|Total Cholesterol Blood Level|LDL-C Blood Level|HDL-C Blood Level|Triglycerides Blood Level|Non-HDL-C Blood Level|LDL-C/HDL-C Blood Level|Total Cholesterol/HDL-C Blood Level|Non-HDL-C/HDL-C Blood Level|Apolipoprotein B Blood Level|Apolipoprotein A-1 Blood Level|Apoliprotein B/Apolipoprotein A-1 Blood Level|VLDL-C During the 104 Week Treatment Period","AstraZeneca|The Cleveland Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","2333","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D356IC00001|2007-004000-13","January 2008","June 2011","June 2011","February 21, 2008","June 25, 2012","July 16, 2012","Research Site, Huntsville, Alabama, United States|Research Site, Los Angeles, California, United States|Research Site, Mountain View, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Torrance, California, United States|Research Site, Boulder, Colorado, United States|Research Site, Greeley, Colorado, United States|Research Site, Loveland, Colorado, United States|Research Site, Farmington, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Clearwater, Florida, United States|Research Site, Ft Lauderdale, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Winter Haven, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Elkhart, Indiana, United States|Research Site, Hammond, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Merrillville, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Davenport, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Ashland, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Covington, Louisiana, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Takoma Park, Maryland, United States|Research Site, Bay City, Michigan, United States|Research Site, Grand Blanc, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Midland, Michigan, United States|Research Site, Muskegon, Michigan, United States|Research Site, Petoskey, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Rochester, Minnesota, United States|Research Site, St Cloud, Minnesota, United States|Research Site, St. Paul, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, Johnson City, New York, United States|Research Site, New York, New York, United States|Research Site, Roslyn, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Elyria, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Perrysburg, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Eugene, Oregon, United States|Research Site, Hillsboro, Oregon, United States|Research Site, Danville, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Wormleysburg, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Germantown, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Oak Ridge, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Cap. Fed., Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Buenos Aires, Argentina|Research Site, Rosario, Santa Fe-argentina, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Liverpool, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Aalst, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels, Belgium|Research Site, Charleroi, Belgium|Research Site, Genk, Belgium|Research Site, Leuven, Belgium|Research Site, Cariacica, ES, Brazil|Research Site, Vitoria, ES, Brazil|Research Site, Goiania, GO, Brazil|Research Site, Uberlandia, MG, Brazil|Research Site, Cuiaba, MT, Brazil|Research Site, Curitiba, PR, Brazil|Research Site, Ribeirao Preto, SP, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Besancon, France|Research Site, Bron, France|Research Site, Creteil, France|Research Site, Le Plessis-robinson, France|Research Site, Marseille, France|Research Site, Pessac, France|Research Site, Quincy Sous Senart, France|Research Site, Strasbourg, France|Research Site, Toulouse, France|Research Site, Budapest, Hungary|Research Site, Szged, Hungary|Research Site, Arezzo, AR, Italy|Research Site, Sesto San Giovanni, Milano, Italy|Research Site, Milano, MI, Italy|Research Site, Rozzano, MI, Italy|Research Site, Parma, PR, Italy|Research Site, Siena, SI, Italy|Research Site, Udine, UD, Italy|Research Site, Novara, Italy|Research Site, Roma, Italy|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Aguascalientes, Mexico|Research Site, D.F, Mexico|Research Site, Monterrey, Mexico|Research Site, Puebla, Mexico|Research Site, Queretaro, Mexico|Research Site, Tijuana, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Breda, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Enschede, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Bialystok, Poland|Research Site, Katowice, Poland|Research Site, Kedzierzyn Kozle, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Zabrze, Poland|Research Site, Krasnogorsk, Moscow Region, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tumen, Russian Federation|Research Site, Malaga, Andalucia, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Badalona, Cataluna, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Alicante, Comunidad Valenciana, Spain",,"https://ClinicalTrials.gov/show/NCT00620542"
185,"NCT00617669","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer","ENTHUSE M1C","Completed","Has Results","Prostate Cancer","Drug: Docetaxel|Drug: ZD4054|Drug: Placebo","Overall Survival|Progression Free Survival|Incidence of Skeletal Related Events|Time to Prostate-specific Antigen (PSA) Progression|Time to Pain Progression|Pain Response|Health Related Quality of Life|PSA Response","AstraZeneca","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1494","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D4320C00033","January 2008","May 2011","July 2011","February 18, 2008","May 31, 2012","September 10, 2012","Research Site, Greenbrae, California, United States|Research Site, San Diego, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, PORTUGALt St. Lucie, Florida, United States|Research Site, Rockville, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Santa Fe, Argentina|Research Site, Darlinghurst, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Redcliffe, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Wodonga, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Fortaleza, Ceara/ LA, Brazil|Research Site, Goiania, Goias/ LA, Brazil|Research Site, Goiania, Goias, Brazil|Research Site, Belo Horizonte, Minas GERMANYais, Brazil|Research Site, Curitiba, Parana/ Brazil, Brazil|Research Site, Londrina, PR, Brazil|Research Site, PORTUGALto Alegre, Rio Grande do Sul/ LA, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Ribeirao Preto, Sao Paulo/ LA, Brazil|Research Site, Santo Andre, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Winnipeg, Manitoba, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Brno, CZECHOSLOVAKIA Republic, Czech Republic|Research Site, Jablonec nad Nisou, Czech Republic|Research Site, Kromeriz, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Prague 2, Czech Republic|Research Site, Prague 6, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Seinajoki, Finland|Research Site, La Roche sur Yon, FRANCEnce, France|Research Site, Marseille, FRANCEnce, France|Research Site, Paris, FRANCEnce, France|Research Site, Reims, FRANCEnce, France|Research Site, Villejuif, FRANCEnce, France|Research Site, Paris, France|Research Site, Saint Herblain, France|Research Site, Hannover, GERMANYmany, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Dresden, Germany|Research Site, Emmendingen, Germany|Research Site, Kirchheim-Teck, Germany|Research Site, Leipzig, Germany|Research Site, Luebeck, Germany|Research Site, Muenster, Germany|Research Site, Tuebingen, Germany|Research Site, Wuppertal, Germany|Research Site, Budapest, HUNGARYary, Hungary|Research Site, Gyor, HUNGARYary, Hungary|Research Site, Miskolc, HUNGARYary, Hungary|Research Site, Ny Regyh Za, HUNGARYary, Hungary|Research Site, Szeged, HUNGARYary, Hungary|Research Site, Bangalore, Karnataka, India|Research Site, Trivandrum, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Pune, Maharashtra, India|Research Site, Bikaner, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Vellore, Tamil Nadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Kolkota, West Bengal, India|Research Site, Delhi, India|Research Site, New Delhi, India|Research Site, Genoa, Italy|Research Site, Lugo (RA), Italy|Research Site, Rome, Italy|Research Site, Cheongju, Chungbuk, Korea, Republic of|Research Site, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Nowon-gu, Seoul, Korea, Republic of|Research Site, Seodaemun-gu, Seoul, Korea, Republic of|Research Site, Songpa-gu, Seoul, Korea, Republic of|Research Site, Nijmegen, Netherlands|Research Site, Cercado de Arequipa, Arequipa, Peru|Research Site, Cercado, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Lublin, POLANDand, Poland|Research Site, Swidnica, POLANDand, Poland|Research Site, Warszaa, POLANDand, Poland|Research Site, Koscierzyna, Poland|Research Site, Wroclaw, Poland|Research Site, Coimbra, PORTUGALtugal, Portugal|Research Site, PORTUGALto, PORTUGALtugal, Portugal|Research Site, Bucharest, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Barnaul, RUSSIAsia, Russian Federation|Research Site, Izhevsk, RUSSIAsia, Russian Federation|Research Site, Kursk, RUSSIAsia, Russian Federation|Research Site, Sochi, RUSSIAsia, Russian Federation|Research Site, Voronezh, RUSSIAsia, Russian Federation|Research Site, Belgrade, SERBIAbia, Serbia|Research Site, Beograd, SERBIAbia, Serbia|Research Site, Nis, SERBIAbia, Serbia|Research Site, Panorama, Cape Town, South Africa|Research Site, TyGERberg, Cape Town, South Africa|Research Site, Overport, Durban, South Africa|Research Site, Bloemfontein, South Africa|Research Site, PORt Elizabeth, South Africa|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Aarau, Switzerland|Research Site, Locarno, Switzerland|Research Site, Sursee, Switzerland|Research Site, Kaohsiung, TAIWANwan, Taiwan|Research Site, TAIWANpei, TAIWANwan, Taiwan|Research Site, Reading, Berkshire, United Kingdom|Research Site, Westgate Road, Newcastle Upon Tyne, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00617669"
186,"NCT00614939","Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo","Absolute Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) Level to Week 12 Last Observation Carried Forward (LOCF)|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (LOCF)- Moderate Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (LOCF) - Severe Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (LOCF) - End-Stage Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 (LOCF) - Moderate Renal Impairment Subgroup|Absolute Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) Level to Week 52|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - Moderate Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - Severe Renal Impairment Subgroup|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) to Week 52 - End-Stage Renal Impairment Subgroup","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","572","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D1680C00007|EudraCT number 2007-004951-12","January 2008","June 2009","March 2010","February 13, 2008","July 7, 2010","May 19, 2011","Research Site, Concord, California, United States|Research Site, Sacramento, California, United States|Research Site, Denver, Colorado, United States|Research Site, Topeka, Kansas, United States|Research Site, Baltimore, Maryland, United States|Research Site, Great Falls, Montana, United States|Research Site, Greenville, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Charleston, West Virginia, United States|Research Site, Brest, Belarus|Research Site, Gomel, Belarus|Research Site, Minsk, Belarus|Research Site, Dimitrovgrad, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Karlovac, Croatia|Research Site, Osijek, Croatia|Research Site, Rijeka, Croatia|Research Site, Split, Croatia|Research Site, Zagreb, Croatia|Research Site, Moravsky Krumlov, Czech Republic|Research Site, Praha 10, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Usti Nad Labem, Czech Republic|Research Site, Znojmo, Czech Republic|Research Site, Tallinn, Estonia|Research Site, Dieburg, Germany|Research Site, Dusseldorf, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Mannheim, Germany|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kecskemet, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Klaipeda, Lithuania|Research Site, Panevezys, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Lodz, 90-153, Poland|Research Site, Bialystok, Poland|Research Site, Ciechanow, Poland|Research Site, Golub Dobrzyn, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Makow Mazowiecki, Poland|Research Site, Radom, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Zabrze, Poland|Research Site, Satu-mare, Satu Mare, Romania|Research Site, Bacau, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Sf Gheorghe, Romania|Research Site, Chelyabinsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, St.petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Mykolayiv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT00614939"
187,"NCT00605267","Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment",,"Completed","Has Results","Breast Cancer","Drug: Tamoxifen|Drug: Anastrazole (Arimidex)|Drug: Goserelin acetate (Zoladex)","Best Overall Response Rate (BORR) (Calliper)|Best Overall Response Rate (BORR) (US)|Best Overall Response Rate (BORR) (MRI/CT)|Bone Mineral Density (BMD) Lumbar Spine|Bone Mineral Density (BMD) Cervical Thighbone|Bone Turnover Marker (BAP) EIA Method|Bone Turnover Marker (BAP) CLEIA Method|Bone Turnover Marker (NTX)|Serum Oestrone (E1) Concentrations|Serum Oestradiol (E2) Concentrations|Oestrogen Receptor (ER) Status|Progesterone Receptor (PgR) Status|Human Epidermal Growth Factor Receptor 2 (HER2) Status|Histopathological Response Rate (HRR)|Functional Assessment of Cancer Therapy-Breast (FACT-B)|Endocrine Subscale (ES)|Anastrozole Plasma Concentrations (Cmin)","AstraZeneca","Female","20 Years and older   (Adult, Older Adult)","Phase 3","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D539BC00001","October 2007","November 2009","December 2010","January 31, 2008","September 6, 2012","September 6, 2012","Research Site, Hakata, Fukuoka, Japan|Research Site, Kumamoto, Japan|Research Site, Nagoya, Japan|Research Site, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT00605267"
188,"NCT00603239","Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide|Drug: placebo","Change in Glycosylated Hemoglobin (HbA1c)|Percentage of Patients Achieving HbA1c <= 7%|Percentage of Patients Achieving HbA1c <= 6.5%|Change in Fasting Serum Glucose (FSG)|Change in Body Weight|Change in Waist Circumference|Change in Beta-cell Function|Change in Insulin Sensitivity.|Number of Subjects Who Experienced an Episode of Minor Hypoglycemia|Change in Impact of Weight on Quality of Life (IWQOL)-Lite Score|Change in Euroqol - 5 Domain Quality of Life (EQ-5D) Score","AstraZeneca|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H8O-MC-GWCG","January 2008","July 2009","July 2009","January 29, 2008","September 2, 2010","April 7, 2015","Research Site, Birmingham, Alabama, United States|Research Site, Concord, California, United States|Research Site, Fresno, California, United States|Research Site, Denver, Colorado, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Mogadore, Ohio, United States|Research Site, Corvallis, Oregon, United States|Research Site, New Westminster, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Celaya, Guanajuato, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, Chihuahua, Mexico|Research Site, Mexico City, Mexico|Research Site, Baia Mare, Romania|Research Site, Brasov, Romania|Research Site, Bucuresti, Romania|Research Site, Dolj, Romania|Research Site, Iasi, Romania|Research Site, Suceava, Romania|Research Site, Johannesburg, South Africa|Research Site, Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT00603239"
189,"NCT00600756","Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone","RECOVER","Completed","Has Results","Schizophrenic Disorders","Drug: Quetiapine XR|Drug: Risperidone","Responder Rate at Month 6 in the Per Protocol Population Using the Subjective Well-being Under Neuroleptics Scale, Short Version (SWN-K) Total Score|Change From Baseline in Mean Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Total Score at Month 12 in the Per Protocol Population|Change From Baseline in Mean Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Total Score at Month 12 in the Intent-to-Treat (ITT) Population|Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Subscale Score: Physical Functioning at Month 12 in the ITT Population.|Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Subscale Score: Social Integration at Month 12 in the ITT Population.|Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Subscale Score: Mental Functioning at Month 12 in the ITT Population.|Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Subscale Score: Self-control at Month 12 in the ITT Population.|Change From Baseline in the Subjective Well-Being Under Neuroleptic Treatment Scale (SWN-K) Subscale Score: Emotional Regulation at Month 12 in the ITT Population.|The Remission Rate in Both the Quetiapine XR Group and the Risperidone Group at Month 12 in the ITT Population|The Effect of Quetiapine XR Versus Risperidone at Month 12 in the ITT Population on Core Schizophrenic and Depressive Symptoms by Evaluating the Change From Baseline in CGI-SCH Overall Severity Score (Improved).|The Effect of Quetiapine XR Versus Risperidone at Month 12 in the ITT Population on Core Schizophrenic and Depressive Symptoms by Evaluating the Change From Baseline in CGI-SCH Overall Severity Score|The Effect of Quetiapine XR Versus Risperidone at Month 12 in the ITT Population on Core Schizophrenic and Depressive Symptoms by Evaluating the Change From Baseline in the Calgary Depression Scale for Schizophrenia (CDSS) Total Score|The Effect of Quetiapine XR Versus Risperidone by Evaluating the Relapse Rate at Month 12 in the ITT Population|Evaluation of Effect of Quetiapine XR Versus Risperidone on the Health-related Quality of Life of Patients With Schizophrenia by Evaluating the Change From Baseline in EQ-5D(Euro Quality of Life-5 Dimension) Index Score at Month 12 in the ITT Population.|To Evaluate the Effect of Quetiapine XR Versus Risperidone at Month 12 in the ITT Population Regarding Health Economics Outcomes by Evaluating the Functional Improvement Rate of the Modified Vocational Status Index/ Location Code Index: Stable State|The Effect of Quetiapine XR Versus Risperidone Regarding Health Economics Outcomes by Evaluating the Mean Number of Lost School/Work Days at Month 12 in the ITT Population|The Effect of Quetiapine XR Versus Risperidone Regarding Health Economics Outcomes by Evaluating the Participants With at Least 1 Hospitalization Due to Psychiatric Disorders at Month 12 in the ITT Population|Number of Subjects Who Had an Unscheduled Visits Due to Worsening of Schizophrenia, Dose Change, or Adverse Event at Month 12 in the ITT Population|The Effect of Quetiapine XR Versus Risperidone Regarding Health Economics Outcomes by Evaluating the Time Between First Study Drug Intake and First Hospitalization for Patients With 1 Hospitalization in the ITT Population|Number of Participants Using Antidepressants at Month 12 in the ITT Population|The Effect of Quetiapine XR Versus Risperidone Regarding Health Economics Outcomes by Evaluating the Number of Participants Using Other Psychotropic Medications at Month 12 in the ITT Population|The Compliance of Patients Taking Quetiapine XR Versus Risperidone at Month 12 by Evaluating the Number of Participants Who Returned Study Drug at Month 12 in the ITT Population|The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants With a Treatment-emergent Adverse Event (TEAEs) at Month 12 in the Safety Population|The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Discontinued the Study Because of an TEAE at Month 12 in the Safety Population|The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Had at Least 1 Extra-pyramidal TEAE at Month 12 in the Safety Population|The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Extra-pyramidal Events at Month 12 in the Safety Population|The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants Who Had at Least 1 Cardiac TEAE at Month 12 in the Safety Population|The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Mean Change From Baseline to Month 12 in Prolactin Levels in the Safety Population|The Safety and Tolerability of Quetiapine XR vs Risperidone by Evaluating the Number of Participants at Month 12 in Safety Population With Individual Symptoms Assessed by the Modified Udvalg for Kliniske Undersogelser, Side Effect Rating Scale: Neurologic|The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants at Month 12 in the Safety Population With Individual Symptoms Assessed by the Modified UKU: Hyperprolactinaemia in Women|The Safety and Tolerability of Quetiapine XR Versus Risperidone by Evaluating the Number of Participants at Month 12 in the Safety Population With Individual Symptoms Assessed by the Modified UKU: Sexual Dysfunction in Men","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","798","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1443L00039","January 2008","October 2009","October 2009","January 25, 2008","September 12, 2012","October 5, 2012","Research Site, Assebroek, Belgium|Research Site, Hasselt, Belgium|Research Site, Liege, Belgium|Research Site, Montignies-sur-sambre, Belgium|Research Site, Roeselare, Belgium|Research Site, Sint-denijs-westrem, Belgium|Research Site, Tournai, Belgium|Research Site, Salvador, BA, Brazil|Research Site, Fortaleza, CE, Brazil|Research Site, Aparecida de Goiania, GO, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Recife, PE, Brazil|Research Site, Curitiba, PR, Brazil|Research Site, Porto Alegre, RS, Brazil|Research Site, Itapira, SP, Brazil|Research Site, Ribeirao Preto, SP, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Sorocaba, SP, Brazil|Research Site, Botucatu, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Cerova Koria Village, Veliko Tarnovo, Bulgaria|Research Site, Pazardjik, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Barrio Los Yoses, San Jose, Costa Rica|Research Site, Curridabat, San Jose, Costa Rica|Research Site, Guadalupe, San Jose, Costa Rica|Research Site, Helsinki, Finland|Research Site, Kitee, Finland|Research Site, Kuopio, Finland|Research Site, Lapua, Finland|Research Site, Pori, Finland|Research Site, Raahe, Finland|Research Site, Rovaniemi, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Bad Saarow, Germany|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Bochum, Germany|Research Site, Butzbach, Germany|Research Site, Darmstadt, Germany|Research Site, Duisburg, Germany|Research Site, Gelsenkirchen, Germany|Research Site, Grevenbroich, Germany|Research Site, Hamburg, Germany|Research Site, Hattingen, Germany|Research Site, Hildesheim, Germany|Research Site, Koln, Germany|Research Site, Konigsbruck, Germany|Research Site, Mittweida, Germany|Research Site, Munchen, Germany|Research Site, Oranienburg, Germany|Research Site, Siegen, Germany|Research Site, Stralsund, Germany|Research Site, Wismar, Germany|Research Site, Andria, BA, Italy|Research Site, Feltre, BL, Italy|Research Site, Maddaloni, CE, Italy|Research Site, Sora, FR, Italy|Research Site, Genova, GE, Italy|Research Site, Milano, MI, Italy|Research Site, Perugia, PG, Italy|Research Site, Fidenza, PR, Italy|Research Site, Parma, PR, Italy|Research Site, Palmi, RC, Italy|Research Site, Rimini, RN, Italy|Research Site, Salerno, SA, Italy|Research Site, Sassari, SS, Italy|Research Site, Chioggia, VE, Italy|Research Site, Ancona, Italy|Research Site, Pompei, Italy|Research Site, Mexico, D.f., Mexico|Research Site, Mexico, D.F, Mexico|Research Site, Guadalajara Jalisco, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, SLP, Mexico|Research Site, Yucatan, Mexico|Research Site, Abraveses, Portugal|Research Site, Braga, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Santarem, Portugal|Research Site, Pitesti, Arges, Romania|Research Site, Bucharest, Romania|Research Site, Craiova, Romania|Research Site, Galati, Romania|Research Site, Sibiu, Romania|Research Site, Moscow, Russia, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Jaen, Andalucia, Spain|Research Site, Malaga, Andalucia, Spain|Research Site, Sevilla, Andalucia, Spain|Research Site, Sama de Langreo, Asturias, Spain|Research Site, Salamanca, Castilla Leon, Spain|Research Site, Zamora, Castilla Leon, Spain|Research Site, Mataro (barcelona), Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Elche (alicante), Comunidad Valenciana, Spain|Research Site, San Juan de Alicante, Comunidad Valenciana, Spain|Research Site, Vigo, Galicia, Spain|Research Site, Zamudio (vizcaya), Pais Vasco, Spain|Research Site, Prilly, Waadt, Switzerland|Research Site, WIL, Switzerland|Research Site, Ankara, Turkey|Research Site, Elazig, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Manisa, Turkey",,"https://ClinicalTrials.gov/show/NCT00600756"
190,"NCT00595517","Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer",,"Completed","Has Results","Gastric Ulcer|Duodenal Ulcer|Rheumatoid Arthritis|Osteoarthritis|Lumbago","Drug: Esomeprazole 20 mg","Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period|Number of Participants Without Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment|Number of Participants Without Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment|Number of Participants Without Gastric and/or Duodenal Ulcer up to 24 Weeks After Treatment","AstraZeneca","All","20 Years and older   (Adult, Older Adult)","Phase 3","395","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","D961HC00005","October 2007","September 2009","September 2009","January 16, 2008","September 14, 2012","September 14, 2012","Research Site, Oita, Japan|Research Site, Saitama, Japan|Research Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00595517"
191,"NCT00577824","Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)",,"Completed","Has Results","Type 2 Diabetes","Drug: exenatide|Drug: placebo","Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24|Percentage of Patients Achieving HbA1c < 7.0%|Percentage of Patients Achieving HbA1c < 6.5%|Change in Fasting Blood Glucose|Change in Body Weight|Change in Total Cholesterol|Change in Low Density Lipoprotein Cholesterol (LDL-C)|Change in High Density Lipoprotein Cholesterol (HDL-C)|Change in Triglycerides|Change in Waist Size|Change in Waist-to-hip Ratio|7 Point Self-monitored Blood Glucose (SMBG) Profiles at Baseline and Week 24|Change in Homeostasis Model Assessment - Beta Cell Function (HOMA-B)|Change in Homeostasis Model Assessment - Insulin Resistance (HOMA-R)|Change in Serum Insulin|Change in C-peptide|Change in 1,5-anhydroglucitol","AstraZeneca|Eli Lilly and Company","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 3","181","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H8O-JE-GWBB","January 2008","November 2008","November 2008","December 20, 2007","December 31, 2009","April 9, 2015","Research Site, Chiba, Japan|Research Site, Fukuoka, Japan|Research Site, Fukushima, Japan|Research Site, Hyogo, Japan|Research Site, Ibaragi, Japan|Research Site, Kanagawa, Japan|Research Site, Kumamoto, Japan|Research Site, Kyoto, Japan|Research Site, Nagano, Japan|Research Site, Oita, Japan|Research Site, Osaka, Japan|Research Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00577824"
192,"NCT00575588","52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period",,"Completed","Has Results","Type 2 Diabetes","Drug: Metformin|Drug: Sulphonylurea|Drug: Saxagliptin","Hemoglobin A1c (HbA1c) Change From Baseline to Week 52|Proportion of Participants Reporting at Least One Episode of Any Hypoglycaemic Event Over 52 Weeks|Body Weight Change From Baseline to Week 52|Mean Slope of the Regressions of Change From Week 24 to Week 52 in HbA1c","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","891","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1680C00001|EudraCT number 2007-003998-55","December 2007","August 2009","August 2010","December 18, 2007","September 6, 2010","March 21, 2012","Research Site, Hanko, Finland|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Kuusankoski, Finland|Research Site, Mikkeli, Finland|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Aschaffenburg, Germany|Research Site, Berlin, Germany|Research Site, Dortmund, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, Mulheim, Germany|Research Site, Pirna, Germany|Research Site, Ratzeburg, Germany|Research Site, Reinfeld, Germany|Research Site, Rhaunen, Germany|Research Site, Schmiedeberg, Germany|Research Site, Tubingen, Germany|Research Site, Wahlstedt, Germany|Research Site, Weinheim, Germany|Research Site, Balatonfured, Hungary|Research Site, Bekescsaba, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyula, Hungary|Research Site, Kalocsa, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Bangalore, Karnataka, India|Research Site, Indore, Madhya Pradesh, India|Research Site, Mumbai, Mashatra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Guri, Gyeonggi-do, Korea, Republic of|Research Site, Seongnam, Gyeonggi-do, Korea, Republic of|Research Site, Wonju, Kangwon-do, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Uijeongbu-si, Korea, Republic of|Research Site, Beek En Donk, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Deurne, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Losser, Netherlands|Research Site, Nijverdal, Netherlands|Research Site, Rijswijk, Netherlands|Research Site, Roelofarendsveen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Volendam, Netherlands|Research Site, Bergen, Norway|Research Site, Elverum, Norway|Research Site, Flatasen, Norway|Research Site, Hamar, Norway|Research Site, Honefoss, Norway|Research Site, Inderoy, Norway|Research Site, Oslo, Norway|Research Site, Radal, Norway|Research Site, Skedsmokorset, Norway|Research Site, Sogndal, Norway|Research Site, Spikkestad, Norway|Research Site, Trollasen, Norway|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Dolny Kubin, Slovakia|Research Site, Kosice - Tahanovce, Slovakia|Research Site, Moldava Nad Bodvou, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Annan, Dumfries and Galloway, United Kingdom|Research Site, Whitstable, Kent, United Kingdom|Research Site, Hamilton, Lanarkshire, United Kingdom|Research Site, Salford, Manchester, United Kingdom|Research Site, Crawley, West Sussex, United Kingdom|Research Site, Bradford-on-avon, Wiltshire, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Coatbridge, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Motherwell, United Kingdom|Research Site, Newcastle, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT00575588"
193,"NCT00554229","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases","ENTHUSE M1","Completed","Has Results","Prostate Cancer","Drug: ZD4054|Drug: Placebo","Overall Survival|Progression Free Survival|Time to Use of Opiates|Incidence of Skeletal Related Events|Bone Metastases Formation|Health Related Quality of Life|Time to Prostate-specific Antigen (PSA) Progression|Time to Pain Progression|Time to Initiation of Chemotherapy|Pharmacokinetic Characteristics of ZD4054","AstraZeneca","Male","18 Years and older   (Adult, Older Adult)","Phase 3","896","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4320C00014|2007-003227-20","November 2007","July 2010","August 2011","November 6, 2007","May 31, 2012","February 8, 2016","Research Site, Tucson, Arizona, United States|Research Site, Greenbrae, California, United States|Research Site, Los Angeles, California, United States|Research Site, Palm Springs, California, United States|Research Site, San Mateo, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainsville, Florida, United States|Research Site, Port St.Lucie, Florida, United States|Research Site, Des Moines, Iowa, United States|Research Site, Canton, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Norfolk, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Wheeling, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Buenos Aires Province, Argentina|Research Site, Santa Fe, Santa Fe Province, Argentina|Research Site, Hornsby, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Redcliffe, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Graz, Austria|Research Site, Wels, Austria|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Fortaleza, Ceara, Brazil|Research Site, Goiania, Goias, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Curitiba, Parana, Brazil|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, Ribeirao Preto, Sao Paulo, Brazil|Research Site, Santo Andre, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Kentville, Nova Scotia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Granby, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Point-Claire, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Haidian District, Beijing, China|Research Site, Xi Cheng District, Beijing, China|Research Site, Xicheng District, Beijing, China|Research Site, Wuhan, Hubei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Pudong New Area, Shanghai, China|Research Site, Shanghai, Shanghai, China|Research Site, Xuhui District, Shanghai, China|Research Site, Xi'an, Shanxi, China|Research Site, Prague 4, Prague, Czech Republic|Research Site, Prague 6, Prague, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Aalborg, Denmark|Research Site, Aarhus, Denmark|Research Site, Herlev, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Joensuu, Finland|Research Site, Kajaanintie, Finland|Research Site, Tampere, Finland|Research Site, Montpellier, France|Research Site, Paris, France|Research Site, Poitiers Cedex, France|Research Site, Suresnes, France|Research Site, Toulouse, France|Research Site, Villejuif, France|Research Site, Planegg, Muenchen, Germany|Research Site, Kirchheim, Teck, Germany|Research Site, Augsburg, Germany|Research Site, Bad Gegeberg, Germany|Research Site, Berlin, Germany|Research Site, Emmendingen, Germany|Research Site, Leipzig, Germany|Research Site, Luebeck, Germany|Research Site, Mannheim, Germany|Research Site, Muenchen, Germany|Research Site, Reutlingen, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Tuen Mun, Hong Kong|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Rohini, Delhi, India|Research Site, Trivandrum, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Mumbai, Maharashtra, India|Research Site, Chandigarh, Punjab, India|Research Site, Ludhiana, Punjab, India|Research Site, Bikaner, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Kolkota, West Bengal, India|Research Site, Gujarat, India|Research Site, New Delhi, India|Research Site, Milan, Italy|Research Site, Rome, Italy|Research Site, Asahi-City, Chiba, Japan|Research Site, Chiba-City, Chiba, Japan|Research Site, Narashino-city, Chiba, Japan|Research Site, Matsuyama-City, Ehime, Japan|Research Site, Fukuoka-City, Fukuoka, Japan|Research Site, Maebashi-City, Gunma, Japan|Research Site, Otake-City, Hiroshima, Japan|Research Site, Sapporo-City, Hokkaido, Japan|Research Site, Kobe-City, Hyogo, Japan|Research Site, Tsukuba-City, Ibaraki, Japan|Research Site, Kita-gun, Kagawa, Japan|Research Site, Sagamihara-City, Kanagawa, Japan|Research Site, Kyoto-City, Kyoto, Japan|Research Site, Sendai-City, Miyagi, Japan|Research Site, Oita-City, Oita, Japan|Research Site, Osaka-City, Osaka, Japan|Research Site, Osaka-Sayama-City, Osaka, Japan|Research Site, Suita-City, Osaka, Japan|Research Site, Wako-City, Saitama, Japan|Research Site, Hamamatsu-city, Shizuoka, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Fuchu_city, Tokyo, Japan|Research Site, Itabashi-Ku, Tokyo, Japan|Research Site, Meguro-ku, Tokyo, Japan|Research Site, Mitaka-City, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Nagasaki, Japan|Research Site, Heungduk-gu Cheongju, Chungbuk, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seo-gu, Pusan, Korea, Republic of|Research Site, Gangnam-gu, Seoul, Korea, Republic of|Research Site, Songpa-gu, Seoul, Korea, Republic of|Research Site, Metepec, Estado de Mexico, Mexico|Research Site, Distrito Federal Ciudad, Mexico|Research Site, Mexico City, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Bialystok, Poland|Research Site, Koscierzyna, Poland|Research Site, Krakow, Poland|Research Site, Rzeszow, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Stary Oskol, Belgorodskaya region, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, St. Petersgurg, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, Singapore, Singapore|Research Site, Tygerberg, Cape Town, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Pietermaritzburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Goteborg, Sweden|Research Site, Gothenburg, Sweden|Research Site, Stockholm, Sweden|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Locarno, Switzerland|Research Site, Sursee, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Reading, Berkshire, United Kingdom|Research Site, Cambridge, Cambridgeshire, United Kingdom|Research Site, Maidstone, Kent, United Kingdom|Research Site, Huddersfield, Yorkshire, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00554229"
194,"NCT00542789","Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID",,"Completed","Has Results","Gastric Ulcer|Duodenal Ulcer|Rheumatoid Arthritis|Osteoarthritis|Lumbago","Drug: Esomeprazole|Drug: Placebo","Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period|Absence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment|Absence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment","AstraZeneca","All","20 Years and older   (Adult, Older Adult)","Phase 3","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D961HC00001","August 2007",,"February 2009","October 12, 2007","May 28, 2010","May 28, 2010","Research Site, Chiryu, Aichi, Japan|Research Site, Seto, Aichi, Japan|Research Site, Yotukaido, Chiba, Japan|Research Site, Mizumaki, Fukuoka, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Akashi, HYOGOi, Japan|Research Site, Itami, Hyogo, Japan|Research Site, Koto, Hyogo, Japan|Research Site, Nishinomiya, Hyogo, Japan|Research Site, Hitachi, Ibaragi, Japan|Research Site, Morioka, Iwate, Japan|Research Site, Sagamihara, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Nagaokakyo, Kyoto, Japan|Research Site, Chiisagata, Nagano, Japan|Research Site, Matsumoto, Nagano, Japan|Research Site, Sasebo, Nagasaki, Japan|Research Site, Beppu, Oita, Japan|Research Site, Ihara, Okayama, Japan|Research Site, Hirakata, Osaka, Japan|Research Site, Sakai, Osaka, Japan|Research Site, Suita, Osaka, Japan|Research Site, Takatsuki, Osaka, Japan|Research Site, Kawagoe, Saitama, Japan|Research Site, Fukuroi, Shizuoka, Japan|Research Site, Hamamatsu, Shizuoka, Japan|Research Site, Izunokuni, Shizuoka, Japan|Research Site, Maikinohara, Shizuoka, Japan|Research Site, Yaizu, Shizuoka, Japan|Research Site, Shimotsuke, Tochigi, Japan|Research Site, Chiyoda, Tokyo, Japan|Research Site, Koto, Tokyo, Japan|Research Site, Musashimurayama, Tokyo, Japan|Research Site, Kyoto, Japan|Research Site, Nagano, Japan|Research Site, Oita, Japan|Research Site, Osaka, Japan|Research Site, Saitama, Japan|Research Site, Shizuoka, Japan",,"https://ClinicalTrials.gov/show/NCT00542789"
195,"NCT00536913","Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma","Spacer","Completed","Has Results","Asthma","Drug: Budesonide/formoterol pMDI 40/2.25ug + spacer|Drug: Budesonide/formoterol pMDI 40/2.25 ug","Urinary Free Cortisol (UFC)|Forced Expiratory Volume in 1 Second (FEV1)|Morning Peak Expiratory Flow (mPEF)|Evening Peak Expiratory Flow (ePEF)|Asthma Symptoms at Night|Asthma Symptoms at Day|Percentage of Nights With Awakenings Due to Asthma|Use of Rescue Medication at Night|Use of Rescue Medication at Day","AstraZeneca","All","6 Years to 11 Years   (Child)","Phase 3","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5897C00004","September 2007","February 2008","February 2008","September 28, 2007","February 27, 2012","April 6, 2012","Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Kaposvar, Hungary|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bytom, Poland|Research Site, Karpacz, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Warszawa, Poland|Research Site, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00536913"
196,"NCT00536731","Symbicort Rapihaler Therapeutic Equivalence Study","ESTHER","Completed","Has Results","Bronchial Asthma","Drug: Symbicort Turbuhaler|Drug: Symbicort pMDI|Drug: Pulmicort Turbuhaler","Morning Peak Expiratory Flow (PEF)|Evening Peak Expiratory Flow (PEF)|Asthma Symptom Score, Night|Asthma Symptom Score, Day|Asthma Symptom Score, Total|Percentage of Nights With Awakenings Due to Asthma|Use of Rescue Medication, Night|Use of Rescue Medication, Day|Use of Rescue Medication, Total|Percentage of Symptom-free Days|Percentage of Asthma Control Days|Percentage of Rescue Free Days|Forced Expiratory Volume in 1 Second (FEV1)","AstraZeneca","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","742","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5897C00003","September 2007","April 2008","April 2008","September 28, 2007","August 15, 2012","August 15, 2012","Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Rousse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Benesov U Prahy, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Kladno, Czech Republic|Research Site, Kolin, Czech Republic|Research Site, Kutna Hora, Czech Republic|Research Site, Litomerice, Czech Republic|Research Site, Neratovice, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 8, Czech Republic|Research Site, Rokycany, Czech Republic|Research Site, Strakonice, Czech Republic|Research Site, Balassagyarmat, Hungary|Research Site, Budapest, Hungary|Research Site, Cegléd, Hungary|Research Site, Debrecen, Hungary|Research Site, Deszk, Hungary|Research Site, Gyor, Hungary|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szarvas, Hungary|Research Site, Szeged, Hungary|Research Site, Százhalombatta, Hungary|Research Site, Törökbálint, Hungary|Research Site, Bialystok, Poland|Research Site, Bielsko-biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Chodziez, Poland|Research Site, Chrzanow, Poland|Research Site, Karpacz, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lomza, Poland|Research Site, Lublin, Poland|Research Site, Ostrow Wielkopolski, Poland|Research Site, Poznan, Poland|Research Site, Skierniewice, Poland|Research Site, Szczecin, Poland|Research Site, Tarnow, Poland|Research Site, Turek, Poland|Research Site, Wodzislaw Slaski, Poland|Research Site, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT00536731"
197,"NCT00534599","Generalized Anxiety Disorder Adjunct Study",,"Completed","Has Results","Anxiety|Anxiety Disorders|Anxiety Neuroses|Anxiety States","Drug: Placebo|Drug: quetiapine fumarate XR","Least Square Mean Change From Randomization to Week 8 in Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Least Square Mean Change From Randomization to Week 8 in Clinical Global Impression-Severity of Illness (CGI-S) Score|Number of Patients With Clinical Global Impression-Global Improvement (CGI-I) Score of ""Much/Very Much Improved"" at Week 8|Least Square Mean Change From Randomization to Week 8 in HAM-A Psychic Anxiety Subscale Score|Least Square Mean Change From Randomization to Week 8 in HAM-A Somatic Anxiety Subscale Score|Number of Patients With HAM-A Response (≥50% Score Reduction From Randomization) at Week 8|Number of Patients With HAM-A Remission (Total Score ≤7) at Week 8|Least Square Mean Change From Randomization to Week 8 in Quality of Life Enjoyment and Satisfaction Questionaire (Q-LES-Q) Percent Maximum Total Score|Mean Change From Randomization to Week 8 in Q-LES-Q Item 15 (Satisfaction With Medication) Score|Mean Change From Randomization to Week 8 in Q-LES-Q Item 16 (Overall Quality of Life) Score|Least Square Mean Change From Randomization to Week 1 in HAM-A Total Score|Least Square Mean Change From Randomization to Week 1 in HAM-A Psychic Anxiety Subscale Score|Least Square Mean Change From Randomization to Week 1 in HAM-A Somatic Anxiety Subscale Score|Least Square Mean Change From Randomization to Week 1 in CGI-S Score|Number of Patients With HAM-A Response (≥50% Score Reduction From Randomization) at Week 1","AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","409","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1441L00016","August 2007","September 2008","September 2008","September 26, 2007","April 5, 2011","April 14, 2011","Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Beverly Hills, California, United States|Research Site, Encino, California, United States|Research Site, Fresno, California, United States|Research Site, La Mesa, California, United States|Research Site, Oceanside, California, United States|Research Site, Redlands, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Sherman Oaks, California, United States|Research Site, Bradenton, Florida, United States|Research Site, Dayton, Florida, United States|Research Site, Hialeah, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Maitland, Florida, United States|Research Site, Miami, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Lafayette, Indiana, United States|Research Site, Merrillville, Indiana, United States|Research Site, Terre Haute, Indiana, United States|Research Site, Prairie Village, Kansas, United States|Research Site, Owenboro, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Rockville, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Cherry Hill, New Jersey, United States|Research Site, Clementon, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Cedarhurst, New York, United States|Research Site, Fresh Meadows, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Salem, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Witchita Falls, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00534599"
198,"NCT00528879","A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Placebo|Drug: Metformin","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Total Body Weight at Week 24 (Last Observation Carried Forward [LOCF])|Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) in Participants With Baseline HbA1c ≥9.0% at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Total Body Weight at Week 24 in Participants With Baseline Body Mass Index (BMI) ≥27 kg/m^2 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) in Participants With Baseline Body Mass Index (BMI) ≥27 kg/m^2 at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Fasting Plasma Glucose at Week 1 (Last Observation Carried Forward [LOCF])|Adjusted Percentage of Participants Achieving Hemoglobin A1c (HbA1C) ≤6.5% at Week 24 (Last Observation Carried Forward [LOCF])","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","915","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MB102-014 LT|MB102-014","September 2007","November 2008","May 2010","September 12, 2007","May 2, 2014","October 20, 2015","Clinical Research Advantage / Desert Clinical Res, Llc, Tempe, Arizona, United States|Medical Group Of Encino, Encino, California, United States|Valley Research, Fresno, California, United States|Randall Shue, D.O., Los Angeles, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Ritchken & First M.D.'S, San Diego, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Raikhel, Marina, Torrance, California, United States|Express Care Clinical Res, Colorado Springs, Colorado, United States|Denver Internal Medicine, Denver, Colorado, United States|New West Physicians, Golden, Colorado, United States|Central Florida Clinical Trials, Inc., Altamonte Springs, Florida, United States|Family Care Associates Of Nw Florida, Chipley, Florida, United States|Health Partners Research Foundation, Minneapolis, Minnesota, United States|Woodlake Research, Chesterfield, Missouri, United States|Nevada Alliance Against Diabetes, Las Vegas, Nevada, United States|Diabetes & Endocrinology Consultants, Pc, Morehead City, North Carolina, United States|Newark Physician Associates, Newark, Ohio, United States|Integris Family Care S. Penn, Oklahoma City, Oklahoma, United States|Cumberland Valley Endocrinology Center, Llc, Carlisle, Pennsylvania, United States|Banksville Medical Pc, Pittsburgh, Pennsylvania, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Southeastern Research Assoc, Taylors, South Carolina, United States|Texas Center For Drug Development, P.A., Houston, Texas, United States|Diabetes & Glandular Disease Research Associates, Inc., San Antonio, Texas, United States|S.A.M. Clinical Research Center, San Antonio, Texas, United States|Optimum Clinical Research, Salt Lake City, Utah, United States|Office Of Dr. Gray, Spokane, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Auton., Buenos Aires, Argentina|Local Institution, Ciudad Auton, Buenos Aires, Argentina|Local Institution, Mar Del Plata, Buenos Aires, Argentina|Local Institution, Zarate, Buenos Aires, Argentina|Local Institution, Villa Carlos Paz, Cordoba, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Itajuba, Minas Gerais, Brazil|Local Institution, Belem, Para, Brazil|Local Institution, Caxias Do Sul, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Marilia, Sao Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Kelowna, British Columbia, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Bathurst, New Brunswick, Canada|Local Institution, Mount Pearl, Newfoundland and Labrador, Canada|Local Institution, St-John, Newfoundland and Labrador, Canada|Local Institution, Sarnia, Ontario, Canada|Local Institution, Thornhill, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Charlottetown, Prince Edward Island, Canada|Local Institution, Drummondville, Quebec, Canada|Local Institution, Granby, Quebec, Canada|Local Institution, L'Ancienne Lorette, Quebec, Canada|Local Institution, Mirabel, Quebec, Canada|Local Institution, St-Leonard, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Guadalajara, Distrito Federal, Mexico|Local Institution, Zapopan, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrrey, Nuevo Leon, Mexico|Local Institution, Tampico, Tamaulipas, Mexico|Local Institution, Durango, Mexico",,"https://ClinicalTrials.gov/show/NCT00528879"
199,"NCT00528372","A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Dapagliflozin placebo|Drug: Metformin","Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1C (HbA1c) (Last Observation Carried Forward [LOCF]): Group 1|Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (Last Observation Carried Forward [LOCF]): Group 2|Adjusted Mean Change From Baseline to Week 24 in Fasting Plasma Glucose Levels (Last Observation Carried Forward [LOCF]): Group 1|Adjusted Mean Change From Baseline to Week 24 in Fasting Plasma Glucose Levels (Last Observation Carried Forward [LOCF]): Group 2|Adjusted Mean Change in Total Body Weight at Week 24 (Last Observation Carried Forward [LOCF]): Group 1|Adjusted Mean Change in Total Body Weight at Week 24 (Last Observation Carried Forward [LOCF]): Group 2|Adjusted Mean Change From Baseline in Fasting Plasma Glucose Levels at Week 1 (Last Observation Carried Forward [LOCF]): Group 1|Adjusted Mean Change From Baseline in Fasting Plasma Glucose Levels at Week 1 (Last Observation Carried Forward [LOCF]): Group 2|Adjusted Percentage of Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1c] <7.0%) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) in Patients With Baseline HbA1c ≥9.0% (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) in Participants With Baseline Body Mass Index (BMI) ≥27 kg/m^2 (Last Observation Carried Forward [LOCF])|Adjusted Percentage of Participants Who Achieved Hemoglobin A1c [HbA1c] ≤6.5% (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline to Week 24 in Total Body Weight in Patients With Baseline Body Mass Index ≥27 kg/m^2 (Last Observation Carried Forward)|Number of Participants With Adverse Events (AE), Hypoglycemia, Related AEs, Death as Outcome, Related Serious AEs (SAEs), SAEs and AEs Leading to Discontinuation, and Hypoglycemia Leading to Discontinuation (Short-term + Long-term Periods)|Number of Participants With Laboratory Test Results Meeting the Criteria for Marked Laboratory Abnormality (Short-term and Long-term Periods)|Number of Participants With Elevated Levels of Liver Enzymes on Laboratory Test Results (Short-term and Long-term Periods)|Number of Participants With Changes From Baseline in Electrocardiogram (ECG) Findings (Last Observation Carried Forward {LOCF])","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","1067","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MB102-013 LT","September 2007","February 2009","July 2010","September 12, 2007","May 14, 2014","October 20, 2015","43rd Medical Associates, P.C., Phoenix, Arizona, United States|Clin Res Advantage, Inc/East Valley Family Physicians, Plc, Tempe, Arizona, United States|Clinical Research Advantage, Inc, Tempe, Arizona, United States|Valley Research, Fresno, California, United States|Cherlin, Richard, Los Gatos, California, United States|Ritchken & First M.D.'S, San Diego, California, United States|Torrance Clinical Research, Torrance, California, United States|Aurora Family Medicine Center, P.C., Aurora, Colorado, United States|Expresscare Clinical Research, Colorado Springs, Colorado, United States|Center For Internal Medicine, Denver, Colorado, United States|Denver Internal Medicine Group, Denver, Colorado, United States|Central Florida Clinical Trials, Altamonte Springs, Florida, United States|Family Care Associates, Chipley, Florida, United States|Westside Center For Clinical Research, Jacksonville, Florida, United States|Panhandle Family Care Associates, Marianna, Florida, United States|Louisiana Heart Center, Slidell, Louisiana, United States|Jackson, Danny W., Rolling Fork, Mississippi, United States|Woodlake Research, Chesterfield, Missouri, United States|Nevada Alliance Against Diabetes, Las Vegas, Nevada, United States|Slocum-Dickson Medical Group, Pllc, New Hartford, New York, United States|Internist Associates Of Central New York, P. C., Syracuse, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Providence Health Partners, Dayton, Ohio, United States|Newark Physician Associates, Newark, Ohio, United States|Physician Research, Inc., Zanesville, Ohio, United States|Gilbert Medical Research, Llc, Bethany, Oklahoma, United States|Integris Family Care Yukon, Yukon, Oklahoma, United States|Banksville Medical, Pc, Pittsburgh, Pennsylvania, United States|Southeastern Research Associates, Inc., Taylors, South Carolina, United States|Holston Medical Group, Kingsport, Tennessee, United States|Village Family Practice, Houston, Texas, United States|Abbott Clinical Research Group, Inc., San Antonio, Texas, United States|Sam Clinical Research Center, San Antonio, Texas, United States|Taylor/Wade Medical, Bountiful, Utah, United States|Optimum Clinical Research, Inc., Salt Lake City, Utah, United States|J. Lewis Research, Inc, Salt Lake City, Utah, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|William L. Gray, Md, Spokane, Washington, United States|Local Institution, Calgary, Alberta, Canada|Local Institution, Kelowna, British Columbia, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Bathurst, New Brunswick, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Mount Pearl, Newfoundland and Labrador, Canada|Local Institution, St-John, Newfoundland and Labrador, Canada|Local Institution, St. John'S, Newfoundland and Labrador, Canada|Local Institution, Oakville, Ontario, Canada|Local Institution, Sarnia, Ontario, Canada|Local Institution, Thornhill, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Charlottetown, Prince Edward Island, Canada|Local Institution, Drummondville, Quebec, Canada|Local Institution, Granby, Quebec, Canada|Local Institution, L'Ancienne Lorette, Quebec, Canada|Local Institution, Mirabel, Quebec, Canada|Local Institution, St-Leonard, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Tijuana, Baja California, Mexico|Local Institution, Guadalajara, Distrito Federal, Mexico|Local Institution, Mexico, D. F., Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michioacan, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrrey, Nuevo Leon, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Durango, Mexico|Local Institution, Kursk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Smolensk, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, Yaroslaval, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00528372"
200,"NCT00525824","12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe","GRAVITY","Completed","Has Results","Hypercholesterolemia|Coronary Heart Disease|Atherosclerosis","Drug: Rosuvastatin (Crestor)|Drug: Ezetimibe|Drug: Simvastatin","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment|Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment|Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment|Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment|Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment|Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment|Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment|Percent Change in TC/HDL-C After 6 Weeks Combination Treatment|Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment|Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment|Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment|Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment|Percent Change in LDL-C After 6 Weeks Monotherapy","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","1743","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D356FC00003","August 2007","September 2008","September 2008","September 6, 2007","October 7, 2009","May 13, 2011","Research Site, Brentwood, Tennessee, United States|Research Site, Buenos Aires, Argentina|Research Site, Sao Paulo, SP, Brazil|Research Site, Santiago, Chile|Research Site, Brentwood, Colombia|Research Site, Brentwood, Lithuania|Research Site, Zwinderen, Netherlands|Research Site, Lima, San Isidro Lima, Peru|Research Site, Brentwood, Venezuela",,"https://ClinicalTrials.gov/show/NCT00525824"
201,"NCT00516074","A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide|Drug: placebo","Change in Mean 24-hour Heart Rate From Baseline to Endpoint|Change in Daytime Heart Rate From Baseline to Endpoint|Change in Nighttime (2400-0600) Heart Rate From Baseline to Endpoint|Change in Mean 24 Hour Systolic Blood Pressure From Baseline to Endpoint|Change in Mean 24 Hour Diastolic Blood Pressure From Baseline to Endpoint|Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint","AstraZeneca|Eli Lilly and Company","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H8O-MC-GWCD","September 2007","April 2008","April 2008","August 14, 2007","June 12, 2009","April 7, 2015","Research Site, Halifax, Nova Scotia, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Etten-Leur, Netherlands|Research Site, Leiden, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00516074"
202,"NCT00516048","An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide","Treatment-emergent Antibody Status (Maximum Titer Level Experienced)|Incidence of Potentially Immune-related Treatment-emergent Adverse Events|Change in Hemoglobin A1c (HbA1c) From Baseline to Endpoint","AstraZeneca|Eli Lilly and Company","All","20 Years and older   (Adult, Older Adult)","Phase 3","58","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-MC-GWBO","August 2007","April 2008","April 2008","August 14, 2007","June 17, 2009","April 7, 2015","Research Site, Keswick, South Australia, Australia|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Budapest, Hungary|Research Site, Gyula, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Milan, Italy|Research Site, Perugia, Italy|Research Site, Rome, Italy|Research Site, Seonnam City, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon City, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00516048"
203,"NCT00509028","Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma",,"Completed","Has Results","Asthma","Drug: Budesonide|Drug: Conventional Asthma Therapy","Number of Patients With Adverse Events (AEs).|Number of Patients With Abnormal Clinical Laboratory Test Values.|Number of Patients With Abnormal Vital Sign Values for the Following Variables: Blood Pressure (Sitting) and Pulse Rate (Sitting), as Judged by the Investigator|Number of Patients With Abnormal Plasma Cortisol Values.|Height|Weight|Morning Peak Expiratory Flow (PEF) Percentage of Predicted Normal|Change From Baseline of Respiratory Condition at Asthma Attacks (Daytime)|Change From Baseline of Respiratory Condition at Asthma Attacks (Nighttime)|Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Daytime)|Change From Baseline of Use of Inhaled Short-acting B-2 Agonist (Night-time)|Change From Baseline in Disturbance of Daily Activities|Change From Baseline in Disturbance of Night-time Sleep|Forced Expiratory Volume in One Second (FEV1) Percentage of Predicted Normal Change From Baseline","AstraZeneca","All","5 Years to 15 Years   (Child)","Phase 3","241","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5254C00006","December 2006","October 2008","October 2008","July 31, 2007","August 27, 2012","August 27, 2012","Research Site, Takizawa, Iwate, Japan",,"https://ClinicalTrials.gov/show/NCT00509028"
204,"NCT00500318","A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","Has Results","Pulmonary Disease, Chronic Obstructive","Drug: Aclidinium Bromide|Drug: Placebo","Change From Baseline in Exercise Endurance Time (ET)|Trough Forced Expiratory Volume in 1 Second (FEV1)|Trough Inspiratory Capacity (IC)|Functional Residual Capacity (FRC)|Inspiratory Capacity (IC)/Total Lung Capacity (TLC) Ratio","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","181","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAS-MD-CL26","July 2007","December 2008","September 2010","July 12, 2007","December 17, 2012","January 6, 2017","Forest Investigative Site 2088, Jasper, Alabama, United States|Forest Investigative Site 0909, Phoenix, Arizona, United States|Forest Investigative Site 0957, Long Beach, California, United States|Forest Investigative Site 0973, Los Angeles,, California, United States|Forest Investigative Site 0887, Los Angeles, California, United States|Forest Investigative Site 0988, Sacramento, California, United States|Forest Investigative Site 0885, Torrance, California, United States|Forest Investigative Site 2663, Clearwater, Florida, United States|Forest Investigative Site 1030, Jacksonville, Florida, United States|Forest Investigative Site 0974, Pensacola, Florida, United States|Forest Investigative Site 0980, Atlanta, Georgia, United States|Forest Investigative Site 0991, Atlanta, Georgia, United States|Forest Investigative Site 0987, Austell, Georgia, United States|Forest Investigative Site 2008, Marietta, Georgia, United States|Forest Investigative Site 0984, Iowa City, Iowa, United States|Forest Investigative Site 1080, Topeka, Kansas, United States|Forest Investigative Site 0898, Baltimore, Maryland, United States|Forest Investigative Site 0886, Boston, Massachusetts, United States|Forest Investigative Site 1029, N. Dartmouth, Massachusetts, United States|Forest Investigative Site 0889, Livonia, Michigan, United States|Forest Investigative Site 2079, St. Charles, Missouri, United States|Forest Investigative Site 2071, Omaha, Nebraska, United States|Forest Investigative Site 0972, Brooklyn, New York, United States|Forest Investigative Site 0971, Great Neck, New York, United States|Forest Investigative Site 1114, New York, New York, United States|Forest Investigative Site 2665, New York, New York, United States|Forest Investigative Site 2081, Charlotte, North Carolina, United States|Forest Investigative Site 0688, Charlotte, North Carolina, United States|Forest Investigative Site 0981, Toledo, Ohio, United States|Forest Investigative Site 1057, Hershey, Pennsylvania, United States|Forest Investigative Site 0888, Philadelphia, Pennsylvania, United States|Forest Investigative Site 0983, Scranton, Pennsylvania, United States|Forest Investigative Site 2072, Charleston, South Carolina, United States|Forest Investigative Site 1107, Columbia, South Carolina, United States|Forest Investigative Site 0979, Columbia, South Carolina, United States|Forest Investigative Site 1078, Greenville, South Carolina, United States|Forest Investigative Site 0900, Spartanburg, South Carolina, United States|Forest Investigative Site 0962, Nashville, Tennessee, United States|Forest Investigative Site 1082, Dallas, Texas, United States|Forest Investigative Site 2058, Dallas, Texas, United States|Forest Investigative Site 0890, Houston, Texas, United States|Forest Investigative Site 0977, Midvale, Utah, United States|Forest Investigative Site 0968, Edmonton, Alberta, Canada|Forest Investigative Site 0960, Kelowna, British Columbia, Canada|Forest Investigative Site 0905, Vancouver, British Columbia, Canada|Forest Investigative Site 0976, Winnipeg, Manitoba, Canada|Forest Investigative Site 0891, Hamilton, Ontario, Canada|Forest Investigative Site 2204, Ottawa, Ontario, Canada|Forest Investigative Site 0969, Windsor, Ontario, Canada|Forest Investigative Site 2205, Montreal, Quebec, Canada|Forest Investigative Site 0893, Ste-Foy, Quebec, Canada|Forest Investigative Site 0943, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00500318"
205,"NCT00468559","Phase 3/Safety & Efficacy of Esomeprazole in Infants",,"Completed","Has Results","Gastroesophageal Reflux Disease (GERD)","Drug: Open Label Run In Esomeprazole|Drug: Double Blind Esomeprazole|Drug: Double Blind Placebo","Number of Participants Discontinuing Due to Symptom Worsening in the Randomized Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint)|Number of Participants Discontinuing Due to Any Reason, Including Symptom Worsening, in the Randomized Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint)|Treatment Successes at the End of the 4-week Double-blind Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint).|Physician's Global Assessment (PGA) of Gastroesophageal Reflux Disease (GERD) Symptoms (Treatment Withdrawal Phase Endpoint)|Severity of Vomiting/Regurgitation Symptoms as Reported by the Parent/Guardian (Treatment Withdrawal Phase Endpoint)|Severity of Irritability Crying/Fussing Symptoms as Reported by the Parent/Guardian (Treatment Withdrawal Phase Endpoint)|Severity of Supraesophageal/Respiratory Disturbances (Coughing/Wheezing,Labored Breathing) as Reported by Parent/Guardian (Treatment Withdrawal Phase Endpoint)|Severity of Feeding Difficulties Reported by Parent/Guardian (Treatment Withdrawal Phase Endpoint)|Improvement in Physician's Global Assessment (PGA) Following Open-label Esomeprazole (Open-label Phase Endpoint)|Severity of Vomiting/Regurgitation Symptoms as Reported by the Parent/Guardian (Open-label Phase)|Severity of Irritability Crying/Fussing Symptoms as Reported by the Parent/Guardian (Open-label Phase Endpoint)|Severity of Supraesophageal/Respiratory Disturbances (Coughing/Wheezing,Labored Breathing) as Reported by Parent/Guardian (Open-label Phase Endpoint)|Severity of Feeding Difficulties as Reported by Parent/Guardian (Open-label Phase Endpoint)","AstraZeneca","All","1 Month to 11 Months   (Child)","Phase 3","98","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D9614C00096","April 2007","June 2008","June 2008","May 2, 2007","June 2, 2014","June 2, 2014","Research Site, Phoenix, Arizona, United States|Research Site, Atlanta, Georgia, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Marrero, Louisiana, United States|Research Site, Newton, Massachusetts, United States|Research Site, Southfield, Michigan, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, Akron, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Roanoke, Virginia, United States|Research Site, Lille Cedex, France|Research Site, Paris, France|Research Site, Bochum, Germany|Research Site, Greifswald, Germany|Research Site, Nurberg, Germany|Research Site, Potsdam, Germany|Research Site, Wuppertal, Germany|Research Site, Bialystok, Poland|Research Site, Krakow, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT00468559"
206,"NCT00463606","A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia",,"Completed","Has Results","Hypercholesterolemia|Dyslipidemia","Drug: ABT-335 and rosuvastatin calcium|Drug: ABT-335|Drug: rosuvastatin calcium","Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Triglycerides (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), With ABT-335 135 mg in Combination With Rosuvastatin 5 mg Versus ABT-335 135 mg Monotherapy (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), With ABT-335 135 mg in Combination With Rosuvastatin 5 mg Versus Rosuvastatin 5 mg Monotherapy (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Very-low-density Lipoprotein Cholesterol (VLDL-C) (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Apolipoprotein B (ApoB) (Full Analysis Set)|Median Percent Change From Baseline to the Final Visit in High Sensitivity C-reactive Protein (hsCRP) (Full Analysis Set)|Mean Percent Change From Baseline to the Final Visit in Total Cholesterol (Full Analysis Set)","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","760","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M06-844","April 2007","February 2008","February 2008","April 20, 2007","August 1, 2012","October 3, 2012","Site Reference ID/Investigator# 5469, Birmingham, Alabama, United States|Site Reference ID/Investigator# 4428, Birmingham, Alabama, United States|Site Reference ID/Investigator# 4985, Birmingham, Alabama, United States|Site Reference ID/Investigator# 4493, Huntsville, Alabama, United States|Site Reference ID/Investigator# 4510, Huntsville, Alabama, United States|Site Reference ID/Investigator# 4431, Ozark, Alabama, United States|Site Reference ID/Investigator# 4519, Tuscaloosa, Alabama, United States|Site Reference ID/Investigator# 4395, Chandler, Arizona, United States|Site Reference ID/Investigator# 4483, Gilbert, Arizona, United States|Site Reference ID/Investigator# 4411, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 4417, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 4702, Anaheim, California, United States|Site Reference ID/Investigator# 5593, Chula Vista, California, United States|Site Reference ID/Investigator# 4503, Concord, California, United States|Site Reference ID/Investigator# 4530, Encinitas, California, United States|Site Reference ID/Investigator# 4458, Fair Oaks, California, United States|Site Reference ID/Investigator# 4542, Fresno, California, United States|Site Reference ID/Investigator# 4574, Fresno, California, United States|Site Reference ID/Investigator# 4441, Lincoln, California, United States|Site Reference ID/Investigator# 4432, Long Beach, California, United States|Site Reference ID/Investigator# 5579, Los Angeles, California, United States|Site Reference ID/Investigator# 4980, Norwalk, California, United States|Site Reference ID/Investigator# 4392, Sacramento, California, United States|Site Reference ID/Investigator# 4896, Sacramento, California, United States|Site Reference ID/Investigator# 5582, San Diego, California, United States|Site Reference ID/Investigator# 6236, West Hills, California, United States|Site Reference ID/Investigator# 4442, Aurora, Colorado, United States|Site Reference ID/Investigator# 4419, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 4391, Waterbury, Connecticut, United States|Site Reference ID/Investigator# 4401, Coral Gables, Florida, United States|Site Reference ID/Investigator# 4453, Fort Lauderdale, Florida, United States|Site Reference ID/Investigator# 4490, Holly Hill, Florida, United States|Site Reference ID/Investigator# 4420, Hollywood, Florida, United States|Site Reference ID/Investigator# 5011, Jacksonville, Florida, United States|Site Reference ID/Investigator# 4444, Jacksonville, Florida, United States|Site Reference ID/Investigator# 4399, Jupiter, Florida, United States|Site Reference ID/Investigator# 4433, Kissimmee, Florida, United States|Site Reference ID/Investigator# 4469, Largo, Florida, United States|Site Reference ID/Investigator# 4525, Melbourne, Florida, United States|Site Reference ID/Investigator# 4477, Miami, Florida, United States|Site Reference ID/Investigator# 4430, New Port Richey, Florida, United States|Site Reference ID/Investigator# 4409, New Smyrna Beach, Florida, United States|Site Reference ID/Investigator# 4416, Ocala, Florida, United States|Site Reference ID/Investigator# 4528, Ocala, Florida, United States|Site Reference ID/Investigator# 5103, Orlando, Florida, United States|Site Reference ID/Investigator# 4446, Ormond Beach, Florida, United States|Site Reference ID/Investigator# 4524, Pensacola, Florida, United States|Site Reference ID/Investigator# 4505, Sarasota, Florida, United States|Site Reference ID/Investigator# 5580, Sarasota, Florida, United States|Site Reference ID/Investigator# 4494, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 4407, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 4512, Winter Haven, Florida, United States|Site Reference ID/Investigator# 5478, Blue Ridge, Georgia, United States|Site Reference ID/Investigator# 4388, Decatur, Georgia, United States|Site Reference ID/Investigator# 4511, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 4981, Roswell, Georgia, United States|Site Reference ID/Investigator# 4448, Roswell, Georgia, United States|Site Reference ID/Investigator# 4497, Suwanee, Georgia, United States|Site Reference ID/Investigator# 4439, Woodstock, Georgia, United States|Site Reference ID/Investigator# 4472, Arlington Heights, Illinois, United States|Site Reference ID/Investigator# 5585, Chicago, Illinois, United States|Site Reference ID/Investigator# 4520, Peoria, Illinois, United States|Site Reference ID/Investigator# 4527, Avon, Indiana, United States|Site Reference ID/Investigator# 4485, Evansville, Indiana, United States|Site Reference ID/Investigator# 4445, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 4438, Lafayette, Indiana, United States|Site Reference ID/Investigator# 5010, Newburgh, Indiana, United States|Site Reference ID/Investigator# 4403, Iowa City, Iowa, United States|Site Reference ID/Investigator# 4393, Arkansas City, Kansas, United States|Site Reference ID/Investigator# 4526, Overland Park, Kansas, United States|Site Reference ID/Investigator# 4423, Wichita, Kansas, United States|Site Reference ID/Investigator# 4424, Wichita, Kansas, United States|Site Reference ID/Investigator# 5027, Lexington, Kentucky, United States|Site Reference ID/Investigator# 4471, Louisville, Kentucky, United States|Site Reference ID/Investigator# 4406, New Orleans, Louisiana, United States|Site Reference ID/Investigator# 4509, Slidell, Louisiana, United States|Site Reference ID/Investigator# 5635, Auburn, Maine, United States|Site Reference ID/Investigator# 4502, Scarborough, Maine, United States|Site Reference ID/Investigator# 5070, Baltimore, Maryland, United States|Site Reference ID/Investigator# 4412, Haverhill, Massachusetts, United States|Site Reference ID/Investigator# 4487, Springfield, Massachusetts, United States|Site Reference ID/Investigator# 5533, Ann Arbor, Michigan, United States|Site Reference ID/Investigator# 6237, Ann Arbor, Michigan, United States|Site Reference ID/Investigator# 5583, Portage, Michigan, United States|Site Reference ID/Investigator# 4480, Brooklyn Center, Minnesota, United States|Site Reference ID/Investigator# 4515, Jackson, Mississippi, United States|Site Reference ID/Investigator# 4492, Olive Branch, Mississippi, United States|Site Reference ID/Investigator# 5636, Tupelo, Mississippi, United States|Site Reference ID/Investigator# 4500, Kansas City, Missouri, United States|Site Reference ID/Investigator# 4499, St. Peters, Missouri, United States|Site Reference ID/Investigator# 4979, Billings, Montana, United States|Site Reference ID/Investigator# 4481, Missoula, Montana, United States|Site Reference ID/Investigator# 4460, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 4466, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 5484, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 5444, Concord, New Hampshire, United States|Site Reference ID/Investigator# 4908, Elizabeth, New Jersey, United States|Site Reference ID/Investigator# 4504, South Bound Brook, New Jersey, United States|Site Reference ID/Investigator# 4394, Toms River, New Jersey, United States|Site Reference ID/Investigator# 4402, Trenton, New Jersey, United States|Site Reference ID/Investigator# 4427, Albuquerque, New Mexico, United States|Site Reference ID/Investigator# 4463, Bronxville, New York, United States|Site Reference ID/Investigator# 4415, New York, New York, United States|Site Reference ID/Investigator# 4440, Rochester, New York, United States|Site Reference ID/Investigator# 4464, Syracuse, New York, United States|Site Reference ID/Investigator# 4425, Williamsville, New York, United States|Site Reference ID/Investigator# 4473, Asheville, North Carolina, United States|Site Reference ID/Investigator# 4531, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 4396, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 5494, Hickory, North Carolina, United States|Site Reference ID/Investigator# 4479, Morehead City, North Carolina, United States|Site Reference ID/Investigator# 4461, Raleigh, North Carolina, United States|Site Reference ID/Investigator# 4498, Salisbury, North Carolina, United States|Site Reference ID/Investigator# 4405, Statesville, North Carolina, United States|Site Reference ID/Investigator# 4476, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 4390, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 4400, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 4501, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 4517, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 5584, Columbus, Ohio, United States|Site Reference ID/Investigator# 4410, Mogadore, Ohio, United States|Site Reference ID/Investigator# 4443, Sandusky, Ohio, United States|Site Reference ID/Investigator# 4523, Warren, Ohio, United States|Site Reference ID/Investigator# 4488, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 4451, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 4422, Tulsa, Oklahoma, United States|Site Reference ID/Investigator# 4482, Tulsa, Oklahoma, United States|Site Reference ID/Investigator# 4467, Medford, Oregon, United States|Site Reference ID/Investigator# 4470, Carlisle, Pennsylvania, United States|Site Reference ID/Investigator# 5581, Downingtown, Pennsylvania, United States|Site Reference ID/Investigator# 4434, Feasterville, Pennsylvania, United States|Site Reference ID/Investigator# 4478, Harleysville, Pennsylvania, United States|Site Reference ID/Investigator# 4436, Jersey Shore, Pennsylvania, United States|Site Reference ID/Investigator# 4397, Lansdale, Pennsylvania, United States|Site Reference ID/Investigator# 4426, Melrose Park, Pennsylvania, United States|Site Reference ID/Investigator# 4894, Newtown, Pennsylvania, United States|Site Reference ID/Investigator# 4496, Penndel, Pennsylvania, United States|Site Reference ID/Investigator# 4404, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 4437, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 4387, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 4447, Warminster, Pennsylvania, United States|Site Reference ID/Investigator# 4506, Charleston, South Carolina, United States|Site Reference ID/Investigator# 5443, Greenville, South Carolina, United States|Site Reference ID/Investigator# 4484, Greer, South Carolina, United States|Site Reference ID/Investigator# 4455, Moncks Corner, South Carolina, United States|Site Reference ID/Investigator# 4513, Mount Pleasant, South Carolina, United States|Site Reference ID/Investigator# 4521, Simpsonville, South Carolina, United States|Site Reference ID/Investigator# 4982, Summerville, South Carolina, United States|Site Reference ID/Investigator# 5586, Sioux Falls, South Dakota, United States|Site Reference ID/Investigator# 4435, Jackson, Tennessee, United States|Site Reference ID/Investigator# 4454, Johnson City, Tennessee, United States|Site Reference ID/Investigator# 4529, Nashville, Tennessee, United States|Site Reference ID/Investigator# 5454, Arlington, Texas, United States|Site Reference ID/Investigator# 5578, Houston, Texas, United States|Site Reference ID/Investigator# 5669, Houston, Texas, United States|Site Reference ID/Investigator# 4893, San Antonio, Texas, United States|Site Reference ID/Investigator# 4429, San Antonio, Texas, United States|Site Reference ID/Investigator# 4457, San Antonio, Texas, United States|Site Reference ID/Investigator# 4465, San Antonio, Texas, United States|Site Reference ID/Investigator# 4508, San Antonio, Texas, United States|Site Reference ID/Investigator# 4892, San Antonio, Texas, United States|Site Reference ID/Investigator# 5948, San Antonio, Texas, United States|Site Reference ID/Investigator# 4413, Temple, Texas, United States|Site Reference ID/Investigator# 4456, Falls Church, Virginia, United States|Site Reference ID/Investigator# 4459, Richmond, Virginia, United States|Site Reference ID/Investigator# 4408, Richmond, Virginia, United States|Site Reference ID/Investigator# 4421, Lakewood, Washington, United States|Site Reference ID/Investigator# 4468, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00463606"
207,"NCT00441727","Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)","Oberon","Completed","Has Results","Gastric Ulcer|Duodenal Ulcer","Drug: Esomeprazole 40 mg|Drug: Esomeprazole 20 mg|Drug: Placebo","Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s).|Percentage of Participants Who Experienced the Occurence of Gastric Ulcer.|Percentage of Participants Who Experienced the Occurrence of Duodenal Ulcer.|Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Dyspepsia Dimension During the 26-week Visit or the Week Prior to the Last Visit.|Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Gastroesophageal Reflux Disease Dimension During the 26-week Visit or the Week Prior to the Last Visit.|Number of Participants With Gastric and/or Duodenal Erosions.","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","2426","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","D961FC00003|EudraCT No. 2006-005073-22","February 2007","August 2008","August 2008","March 1, 2007","February 13, 2012","July 16, 2012","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Anaheim, California, United States|Research Site, Lancaster, California, United States|Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, San Carlos, California, United States|Research Site, San Diego, California, United States|Research Site, Torrington, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Smyrna Beach, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Zephyrhills, Florida, United States|Research Site, Fulton, Illinois, United States|Research Site, Wichita, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Hollywood, Maryland, United States|Research Site, Prince Frederick, Maryland, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Jackson, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Egg Harbor Township, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Great Neck, New York, United States|Research Site, Fayetteville, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Jacksonville, North Carolina, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Centerville, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Guthrie, Oklahoma, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Harrisburg, Pennsylvania, United States|Research Site, Cranston, Rhode Island, United States|Research Site, Johnston, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Simpsonville, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Christiansburg, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Buenos Aires- Argentina, Argentina|Research Site, Capital Federal, Buenos Aires, Argentina|Research Site, Loma Hermosa, Buenos Aires, Argentina|Research Site, Lomas de Zamora, Buenos Aires, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Mendoza, Argentina|Research Site, Rosario, Argentina|Research Site, Caboolture, Queensland, Australia|Research Site, Carina Heights, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Ballarat, Victoria, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, NSW, Australia|Research Site, Chirpan, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Rousse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Bay Roberts, Newfoundland and Labrador, Canada|Research Site, Carbonear, Newfoundland and Labrador, Canada|Research Site, Mount Pearl, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Niagara Falls, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Tillsonburg, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Pointe-claire, Quebec, Canada|Research Site, Laval, Canada|Research Site, Longueuil, Canada|Research Site, Quebec, Canada|Research Site, Beroun, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Liberec, Czech Republic|Research Site, Litomerice, Czech Republic|Research Site, Ostrava - Trebovice, Czech Republic|Research Site, Podborany, Czech Republic|Research Site, Poobram, Czech Republic|Research Site, Praha 1, Czech Republic|Research Site, Praha 4 - Sporilov, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Praha 9, Czech Republic|Research Site, Tabor, Czech Republic|Research Site, Joensuu, Finland|Research Site, Mikkeli, Finland|Research Site, Pietarsaari, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Vantaa, Finland|Research Site, Bochum, Germany|Research Site, Dresden, Germany|Research Site, Ludwigshafen, Germany|Research Site, Luedenscheid, Germany|Research Site, Magdeburg, Germany|Research Site, Munchen, Germany|Research Site, Oelde, Germany|Research Site, Potsdam, Germany|Research Site, Rodgau-dudenhofen, Germany|Research Site, Siegen, Germany|Research Site, Wangen, Germany|Research Site, Wolmirstedt, Germany|Research Site, Jakarta, Indonesia|Research Site, Semarang, Indonesia|Research Site, Surabaya, Indonesia|Research Site, Yogyakarta, Indonesia|Research Site, Seongnam-si, Kyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Mexico, D.f., Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, D.F, Mexico|Research Site, Mexico City, Mexico|Research Site, Asker, Norway|Research Site, Bergen, Norway|Research Site, Elverum, Norway|Research Site, Gjovik, Norway|Research Site, Hamar, Norway|Research Site, Levanger, Norway|Research Site, Lysaker, Norway|Research Site, Olesund, Norway|Research Site, Oslo, Norway|Research Site, Osteros, Norway|Research Site, Paradis, Norway|Research Site, Stavanger, Norway|Research Site, Tromso, Norway|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Chojnice, Poland|Research Site, Chrzanow, Poland|Research Site, Czechowice-dziedzice, Poland|Research Site, Czestochowa, Poland|Research Site, Elblog, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Ilawa, Poland|Research Site, Koscierzyna, Poland|Research Site, Krakow, Poland|Research Site, Sopot, Poland|Research Site, Tczew, Poland|Research Site, Warszawa, Poland|Research Site, Angra Do Herosmo, Portugal|Research Site, Braga, Portugal|Research Site, Castelo Branco, Portugal|Research Site, Coimbra, Portugal|Research Site, Covilha, Portugal|Research Site, Lisboa, Portugal|Research Site, Setubal, Portugal|Research Site, Vila Real, Portugal|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Satu-mare, Romania|Research Site, Tg. Mures, Romania|Research Site, Moscow, Russian Federation|Research Site, Saint- Petersburg, Russian Federation|Research Site, Banovce Nad Bebravou, Slovakia|Research Site, Banska Bysterica, Slovakia|Research Site, Brastislava, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Mesto Nad Vahom, Slovakia|Research Site, Piestany, Slovakia|Research Site, Povazska Bystrica, Slovakia|Research Site, Trnava, Slovakia|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand",,"https://ClinicalTrials.gov/show/NCT00441727"
208,"NCT00434967","Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo",,"Completed","Has Results","Hypertension","Drug: Candesartan cilexetil|Drug: Hydrochlorothiazide|Drug: Candesartan/HCT 32/25 mg","Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks).|Change in Sitting Systolic Blood Pressure (SBP) From Baseline to the End of the Study (Baseline to 8 Weeks)|The Number of Patients With Controlled Sitting DBP and Sitting SBP in Each Treatment Group at the End of the Study|Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Hypertension Control Rate at the End of the Study (Patients With Controlled Sitting SBP and Sitting DBP).|To Describe Safety and Tolerability of the Study Treatments With Regard to Adverse Events Including Those That Lead to Treatment Discontinuation as Well as With Regard to Pulse Rate, Laboratory, Electrocardiographic and Physical Examination Findings.|To Compare Treatment With Candesartan/HCT 32/25 mg to Each of Its Components With Regard to Change From Baseline to Week 8 in Standing DBP and Standing SBP.|To Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Sitting DBP Control Rate at the End of the Study (Patients With Controlled Sitting DBP Are Defined as Having a Sitting DBP <90 mmHg at the End of the Study).|To Compare Candesartan/HCT 32/25 mg to Its Components and to Placebo With Regard to Sitting DBP Responder Rate (Decrease in Sitting DBP ≥10 mmHg From Baseline to the End of the Study or a Sitting DBP <90 mmHg at the End of the Study).","AstraZeneca","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 3","2207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D2456C00002|EudraCT No. 2006-003963-30","January 2007","January 2008","January 2008","February 14, 2007","June 17, 2009","December 16, 2010","Research Site, Dour, Belgium|Research Site, Gozée, Belgium|Research Site, Hasselt, Belgium|Research Site, Linkebeek, Belgium|Research Site, Marchovelette, Belgium|Research Site, Ronquières, Belgium|Research Site, Saint-Médard, Belgium|Research Site, Steenokkerzel, Belgium|Research Site, Daugavpils, Latvia|Research Site, Ogre, Latvia|Research Site, Riga, Latvia|Research Site, Gozo, Malta|Research Site, Gwardiamangia, Malta|Research Site, Arad, Romania|Research Site, Bucuresti, Romania|Research Site, Iasi, Romania|Research Site, Pitesti, Romania|Research Site, Ploiesti, Romania|Research Site, Targoviste, Romania|Research Site, Timisoara, Romania|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Levice, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Presov, Slovakia|Research Site, Sahy, Slovakia",,"https://ClinicalTrials.gov/show/NCT00434967"
209,"NCT00434954","Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide twice daily (BID)|Drug: premixed insulin aspart twice daily (BID)","Change in Glycosylated Hemoglobin (HbA1c)|Incidence of Hypoglycemia (Percentage of Participants With at Least One Hypoglycemic Episode)|Percentage of Subjects Achieving HbA1c Target of < 6.5%|Percentage of Subjects Achieving HbA1c Target of < 7.0%|Incidence of Hypoglycemic Episodes [Blood Glucose <= 3.0 mmol/L or Severe] (Percentage of Subjects Who Experienced at Least One Treatment-emergent Hypoglycemic Episode During the 26-week Treatment Period)|Incidence of Nocturnal Hypoglycemia (Percentage of Subjects Who Experienced at Least One Episode of Nocturnal Hypoglycemia During the 26 Week Treatment Period)|7 Point Self-monitored Blood Glucose (SMBG) Profiles|Blood Lipid Levels|Change in Body Weight|Change in Body Mass Index (BMI)|Patient Reported Outcomes: Diabetes Treatment Satisfaction Questionnaire (DTSQ)|Patient Reported Outcomes: Quality of Life (SF-12)","AstraZeneca|Eli Lilly and Company","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","494","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-SB-GWBN","February 2007","June 2009","June 2009","February 14, 2007","August 23, 2010","April 7, 2015","Research Site, Bad Mergentheim, Germany|Research Site, Berlin, Germany|Research Site, Bosenheim, Germany|Research Site, Burghausen, Germany|Research Site, Datteln, Germany|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Friedrichsthal, Germany|Research Site, Hildesheim, Germany|Research Site, Hirschhorn, Germany|Research Site, Hohenmolsen, Germany|Research Site, Jena, Germany|Research Site, Lehrte, Germany|Research Site, Leipzig, Germany|Research Site, Ludwigsburg, Germany|Research Site, Mannheim, Germany|Research Site, Marburg, Germany|Research Site, Marktheidenfeld, Germany|Research Site, Meissen, Germany|Research Site, Munchen, Germany|Research Site, Offenbach, Germany|Research Site, Oschatz, Germany|Research Site, Pohlheim, Germany|Research Site, Regensburg, Germany|Research Site, Riesa, Germany|Research Site, Rodgau, Germany|Research Site, Roding, Germany|Research Site, Rosenheim, Germany|Research Site, Schluchtern, Germany|Research Site, Schwedt/Oder, Germany|Research Site, Sinsheim, Germany|Research Site, Speyer, Germany|Research Site, Unterhaching, Germany|Research Site, Volklingen, Germany|Research Site, Wallerfing, Germany|Research Site, Wangen, Germany|Research Site, Warburg, Germany|Research Site, Wiesbaden, Germany|Research Site, Wolfsburg, Germany",,"https://ClinicalTrials.gov/show/NCT00434954"
210,"NCT00427635","Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients",,"Completed","Has Results","GERD","Drug: Esomeprazole","Change From Baseline in Normalized Number of GERD Events Observed From Video and Cardiorespiratory Monitoring|Change From Baseline in Normalized Number of GERD Events During Video and Cardiorespiratory Monitoring Associated With Acid Reflux|Change From Baseline in Number of Reflux Episodes (Acid or Non-acid)|Change From Baseline in Number of Acidic Reflux Episodes|Change From Baseline in Number of Weakly Acidic Reflux Episodes|Change From Baseline in Number of Non Acidic Reflux Episodes|Change From Baseline in Number of Liquid Acidic Reflux Episodes|Change From Baseline in Number of Mixed Gas/Liquid Acidic Reflux Episodes|Change From Baseline in Mean Bolus Clearance Time|Change From Baseline in Mean Acid Clearance Time|Change From Baseline in Percentage Time With pH<4.0|Change From Baseline in Percentage Time With pH Within 4.0-6.9","AstraZeneca","All","up to 1 Month   (Child)","Phase 3","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D9614C00004","October 2006",,"April 2009","January 29, 2007","May 19, 2010","December 20, 2010","Research Site, North Adelaide, Australia|Research Site, Aachen, Germany|Research Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00427635"
211,"NCT00424268","Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)","HELIOS","Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Roflumilast|Drug: Placebo","Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)|Post-bronchodilator FEV1|COPD Exacerbation Rate (Moderate or Severe)|Transition Dyspnea Index (TDI) Focal Score|Shortness of Breath Questionnaire (SOBQ) Total Score","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","743","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BY217/M2-128|2006-004508-37","January 2007","January 2008","July 2008","January 19, 2007","May 19, 2011","December 5, 2016","Altana Pharma/Nycomed Investigational Site, Feldbach, Austria|Altana Pharma/Nycomed Investigational Site, Gänserndorf, Austria|Altana Pharma/Nycomed Investigational Site, Hallein, Austria|Altana Pharma/Nycomed Investigational Site, Linz, Austria|Altana Pharma/Nycomed Investigational Site, Spittal an der Drau, Austria|Altana Pharma/Nycomed Investigational Site, Beuvry, France|Altana Pharma/Nycomed Investigational Site, Chauny Cedex, France|Altana Pharma/Nycomed Investigational Site, Grasse, France|Altana Pharma/Nycomed Investigational Site, Lyon, France|Altana Pharma/Nycomed Investigational Site, Martigues Cedex, France|Altana Pharma/Nycomed Investigational Site, Montigny-Les-Metz, France|Altana Pharma/Nycomed Investigational Site, Nantes, France|Altana Pharma/Nycomed Investigational Site, Nice, France|Altana Pharma/Nycomed Investigational Site, Nimes Cedex 9, France|Altana Pharma/Nycomed Investigational Site, Nimes, France|Altana Pharma/Nycomed Investigational Site, Ollioules, France|Altana Pharma/Nycomed Investigational Site, Perpignan Cedex, France|Altana Pharma/Nycomed Investigational Site, Saint Laurent Du Var, France|Altana Pharma/Nycomed Investigational Site, Saint-Quentin, France|Altana Pharma/Nycomed Investigational Site, Toulon, France|Altana Pharma/Nycomed Investigational Site, Bad Homburg, Germany|Altana Pharma/Nycomed Investigational Site, Dortmund, Germany|Altana Pharma/Nycomed Investigational Site, Geesthacht, Germany|Altana Pharma/Nycomed Investigational Site, Gelnhausen, Germany|Altana Pharma/Nycomed Investigational Site, Göppingen, Germany|Altana Pharma/Nycomed Investigational Site, Hannover, Germany|Altana Pharma/Nycomed Investigational Site, Koblenz, Germany|Altana Pharma/Nycomed Investigational Site, Landsberg/Lech, Germany|Altana Pharma/Nycomed Investigational Site, Leonberg, Germany|Altana Pharma/Nycomed Investigational Site, Marburg, Germany|Altana Pharma/Nycomed Investigational Site, Saarbrücken, Germany|Altana Pharma/Nycomed Investigational Site, Saarlouis, Germany|Altana Pharma/Nycomed Investigational Site, Schwetzingen, Germany|Altana Pharma/Nycomed Investigational Site, Sinsheim, Germany|Altana Pharma/Nycomed Investigational Site, Weyhe, Germany|Altana Pharma/Nycomed Investigational Site, Witten, Germany|Altana Pharma/Nycomed Investigational Site, Budapest, Hungary|Altana Pharma/Nycomed Investigational Site, Budapest, Hungary|Altana Pharma/Nycomed Investigational Site, Budapest, Hungary|Altana Pharma/Nycomed Investigational Site, Cegled, Hungary|Altana Pharma/Nycomed Investigational Site, Csorna, Hungary|Altana Pharma/Nycomed Investigational Site, Erd, Hungary|Altana Pharma/Nycomed Investigational Site, Györ, Hungary|Altana Pharma/Nycomed Investigational Site, Hódmezovásárhely, Hungary|Altana Pharma/Nycomed Investigational Site, Matrahaza, Hungary|Altana Pharma/Nycomed Investigational Site, Nyiregyháza, Hungary|Altana Pharma/Nycomed Investigational Site, Szentes, Hungary|Altana Pharma/Nycomed Investigational Site, Szolnok, Hungary|Altana Pharma/Nycomed Investigational Site, Bassano Del Grappa (VI), Italy|Altana Pharma/Nycomed Investigational Site, Cisanello (PI), Italy|Altana Pharma/Nycomed Investigational Site, Foggia, Italy|Altana Pharma/Nycomed Investigational Site, Genova, Italy|Altana Pharma/Nycomed Investigational Site, Milano, Italy|Altana Pharma/Nycomed Investigational Site, Modena, Italy|Altana Pharma/Nycomed Investigational Site, Pavullo nel Frignano (MO), Italy|Altana Pharma/Nycomed Investigational Site, Pordenone, Italy|Altana Pharma/Nycomed Investigational Site, Reggio Emilia, Italy|Altana Pharma/Nycomed Investigational Site, Verona, Italy|Altana Pharma/Nycomed Investigational Site, Alicante, Spain|Altana Pharma/Nycomed Investigational Site, Baracaldo (Vizcaya), Spain|Altana Pharma/Nycomed Investigational Site, Candia, Spain|Altana Pharma/Nycomed Investigational Site, Escaldes-Engordany, Spain|Altana Pharma/Nycomed Investigational Site, Galdakao, Spain|Altana Pharma/Nycomed Investigational Site, Guadalajara, Spain|Altana Pharma/Nycomed Investigational Site, Jerez de la Frontera, Spain|Altana Pharma/Nycomed Investigational Site, La Coruna, Spain|Altana Pharma/Nycomed Investigational Site, Lleida, Spain|Altana Pharma/Nycomed Investigational Site, Lugo, Spain|Altana Pharma/Nycomed Investigational Site, Madrid, Spain|Altana Pharma/Nycomed Investigational Site, Madrid, Spain|Altana Pharma/Nycomed Investigational Site, Madrid, Spain|Altana Pharma/Nycomed Investigational Site, Mostoles Madrid, Spain|Altana Pharma/Nycomed Investigational Site, Pozuelo de Alarcón, Spain|Altana Pharma/Nycomed Investigational Site, Requena, Spain|Altana Pharma/Nycomed Investigational Site, Sant Cugat del Valles, Spain|Altana Pharma/Nycomed Investigational Site, Santa Cruz de Tenerife, Spain|Altana Pharma/Nycomed Investigational Site, Sevilla, Spain|Altana Pharma/Nycomed Investigational Site, Valencia, Spain|Altana Pharma/Nycomed Investigational Site, Valencia, Spain|Altana Pharma/Nycomed Investigational Site, Valencia, Spain|Altana Pharma/Nycomed Investigational Site, Valencia, Spain|Altana Pharma/Nycomed Investigational Site, Ashford, United Kingdom|Altana Pharma/Nycomed Investigational Site, Atherstone, Warwick, United Kingdom|Altana Pharma/Nycomed Investigational Site, Barry, United Kingdom|Altana Pharma/Nycomed Investigational Site, Bexhill-on-Sea, East Sussex, United Kingdom|Altana Pharma/Nycomed Investigational Site, Bolton Lancs, United Kingdom|Altana Pharma/Nycomed Investigational Site, Bolton, United Kingdom|Altana Pharma/Nycomed Investigational Site, Chesterfield Derbyshire, United Kingdom|Altana Pharma/Nycomed Investigational Site, Chesterfield, United Kingdom|Altana Pharma/Nycomed Investigational Site, Chippenham, United Kingdom|Altana Pharma/Nycomed Investigational Site, Co. Antrim, United Kingdom|Altana Pharma/Nycomed Investigational Site, Darlington, Co. Durham, United Kingdom|Altana Pharma/Nycomed Investigational Site, East Sussex, United Kingdom|Altana Pharma/Nycomed Investigational Site, Glasgow, United Kingdom|Altana Pharma/Nycomed Investigational Site, Harrow, United Kingdom|Altana Pharma/Nycomed Investigational Site, Keresely End, Coventry, United Kingdom|Altana Pharma/Nycomed Investigational Site, Plymouth, United Kingdom|Altana Pharma/Nycomed Investigational Site, Sheffield, United Kingdom|Altana Pharma/Nycomed Investigational Site, Solihull, United Kingdom|Altana Pharma/Nycomed Investigational Site, Swindon, Wilts, United Kingdom|Altana Pharma/Nycomed Investigational Site, Trowbridge, United Kingdom|Altana Pharma/Nycomed Investigational Site, Watford, United Kingdom|Altana Pharma/Nycomed Investigational Site, Yaxley, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00424268"
212,"NCT00419952","A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.",,"Completed","Has Results","Asthma","Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Budesonide HFA pMDI","Total Number of Asthma Exacerbations|Asthma Exacerbations|QT Interval Corrected Using the Fridericia Formula Measured Via Electrocardiogram (ECG)|Number of Patients With Shift From Normal to High Rate of Total Ectopic Ventricular Beats as Measured by 24-hour Holter Monitor Assessment|Number of Patients With Shift From Normal to High Rate of Total Ectopic Supraventricular Beats as Measured by 24-hour Holter Monitor Assessment|Total Number of Ventricular Runs as Measured by 24-hour Holter Monitor Assessment|Diary Assessments - Rescue-free Day|Diary Assessments - Symptom-free Day|Diary Assessments - Asthma-control Day|Onset of Effect Questionnaire (OEQ)|Peak Expiratory Flow (PEF) in Morning|Forced Expiratory Volume in One Second (FEV1)|Asthma Treatment Satisfaction Measure (ATSM)","AstraZeneca","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","742","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5896C00022","February 2007","November 2009","November 2009","January 9, 2007","October 30, 2012","October 30, 2012","Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Montgomery, Alabama, United States|Research Site, Muscle Shoals, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Buena Park, California, United States|Research Site, Foothill Ranch, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Riverside, California, United States|Research Site, Rolling Hills Estates, California, United States|Research Site, San Diego, California, United States|Research Site, Stockton, California, United States|Research Site, Torrance, California, United States|Research Site, Winnetka, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Newark, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Destin, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Opa Locka, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Port Charlotte, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Albany, Georgia, United States|Research Site, Atlanta, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Gainesville, Georgia, United States|Research Site, Savannah, Georgia, United States|Research Site, Stone Mountain, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Peoria, Illinois, United States|Research Site, River Forest, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Merrillville, Indiana, United States|Research Site, South Bend, Indiana, United States|Research Site, Topeka, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Bogalusa, Louisiana, United States|Research Site, Marrero, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Monroe, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Sunset, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Mitchellville, Maryland, United States|Research Site, Montgomery Village, Maryland, United States|Research Site, Wheaton, Maryland, United States|Research Site, Dartmouth, Massachusetts, United States|Research Site, Bay City, Michigan, United States|Research Site, Paw Paw, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Prentiss, Mississippi, United States|Research Site, Vicksburg, Mississippi, United States|Research Site, Omaha, Nebraska, United States|Research Site, Blackwood, New Jersey, United States|Research Site, Cherry Hill, New Jersey, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Verona, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, Newburgh, New York, United States|Research Site, North Syracuse, New York, United States|Research Site, Rochester, New York, United States|Research Site, Tonawanda, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Highpoint, North Carolina, United States|Research Site, Mooresville, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Lyndhurst, Ohio, United States|Research Site, Parma, Ohio, United States|Research Site, Toledo, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Beaver, Pennsylvania, United States|Research Site, Collegeville, Pennsylvania, United States|Research Site, Harrisburg, Pennsylvania, United States|Research Site, Havertown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Upland, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Simpsonville, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Union, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Killeen, Texas, United States|Research Site, Missouri City, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Sugarland, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Hampton, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Springfield, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00419952"
213,"NCT00419757","An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma",,"Completed","Has Results","Asthma","Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Budesonide HFA pMDI","Morning Peak Expiratory Flow (AM PEF)|Percentage of Participants With Pre-defined Asthma Events|Percentage of Participants With ""Withdrawals Due to Pre-defined Asthma Events""|Changes Pre-dose Forced Expiratory Volume in 1 Second (FEV1)|Change From Baseline in a Evening Peak Expiratory Flow (PM PEF)|Change in Nighttime Asthma Symptom Score From Baseline Through 12 Weeks|Change in Daytime Asthma Symptom Score From Baseline Through 12 Weeks|Change in Asthma Related Awakenings Free Nights, From Baseline Through 12 Weeks|Change From Baseline in Rescue Medication Use Over 12 Weeks of Treatment|Change From Baseline in Rescue-free Days Over 12 Weeks of Treatment|Change From Baseline in Symptom-free Days Over 12 Weeks of Treatment|Subject Global Assessment|Physician Global Assessment|Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Control Relief Index|Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Overall Perception of Medication|Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Comparison With Other Medications","AstraZeneca","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","558","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5896C00021","January 2007","June 2008","June 2008","January 9, 2007","August 27, 2012","August 27, 2012","Research Site, Anaheim, California, United States|Research Site, Chula Vista, California, United States|Research Site, Fresno, California, United States|Research Site, Fullerton, California, United States|Research Site, Los Angeles, California, United States|Research Site, National City, California, United States|Research Site, Rancho Cordova, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Stockton, California, United States|Research Site, Torrance, California, United States|Research Site, Pueblo, Colorado, United States|Research Site, Largo, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Naranja, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Newburgh, New York, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Boerne, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Spring, Texas, United States|Research Site, Aguas Buenas, Puerto Rico|Research Site, Caquas, Puerto Rico|Research Site, Cidra, Puerto Rico|Research Site, Levittown, Puerto Rico|Research Site, Ponce, Puerto Rico|Research Site, SanJuan, Puerto Rico|Research Site, Trujillo Alto, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00419757"
214,"NCT00419744","A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease","Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Formoterol Turbuhaler","Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year|Rate of Exacerbations Per Subject-year|Pre-dose Forced Expiratory Volume in 1 Second (FEV1)|Morning Peak Expiratory Flow (PEF)|Evening PEF|Dyspnea Symptom Scores|Use of Rescue Medication|St. George's Respiratory Questionnaire (SGRQ) Score","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","1200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D589CC00003","January 2007","August 2009","August 2009","January 9, 2007","September 16, 2010","September 16, 2010","Research Site, Jasper, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Fort Smith, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Foothill Ranch, California, United States|Research Site, Fullerton, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Banos, California, United States|Research Site, Mission Viejo, California, United States|Research Site, Pismo Beach, California, United States|Research Site, Rancho Cordova, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, Riverside, California, United States|Research Site, Rolling Hills Estates, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Sepulveda, California, United States|Research Site, Torrance, California, United States|Research Site, Englewood, Colorado, United States|Research Site, Wheat Ridge, Colorado, United States|Research Site, Stanford, Connecticut, United States|Research Site, Deland, Florida, United States|Research Site, Opalocka, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Panama City, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St Cloud, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Blue Ridge, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Boise, Idaho, United States|Research Site, Coeur D'alene, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Witchita, Kansas, United States|Research Site, Marrero, Louisiana, United States|Research Site, Metairie, Louisiana, United States|Research Site, Sunset, Louisiana, United States|Research Site, Bangor, Maine, United States|Research Site, Pittsfield, Massachusetts, United States|Research Site, Waltham, Massachusetts, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Florissant, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Papillion, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Springfield, New Jersey, United States|Research Site, Bronxville, New York, United States|Research Site, Elmira, New York, United States|Research Site, Larchmont, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Elizabeth City, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Chardon, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Sylvania, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Beaver, Pennsylvania, United States|Research Site, Bensalem, Pennsylvania, United States|Research Site, Downingtown, Pennsylvania, United States|Research Site, Harrisburg, Pennsylvania, United States|Research Site, Landsdale, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Warminster, Pennsylvania, United States|Research Site, Yardley, Pennsylvania, United States|Research Site, East Providence, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Gaffney, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Prosperity, South Carolina, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Union, South Carolina, United States|Research Site, Fayetteville, Tennessee, United States|Research Site, Boerne, Texas, United States|Research Site, Houston, Texas, United States|Research Site, McKinney, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Abingdon, Virginia, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, 9 de Julio, Buenos Aires, Argentina|Research Site, Capital Federal, Buenos Aires, Argentina|Research Site, Mar Del Plata, Buenos Aires, Argentina|Research Site, Ramos Mejia, Buenos Aires, Argentina|Research Site, Vicente Lopez, Buenos Aires, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Mendoza, Argentina|Research Site, San Juan, Argentina|Research Site, Fortaleza, CE, Brazil|Research Site, Goiania, GO, Brazil|Research Site, Recife, Pernambuco, Brazil|Research Site, Curitiba, PR, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Porta Alegre, RS, Brazil|Research Site, Florian�polis, Santa Catarina, Brazil|Research Site, Santo Andre, SP, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Valparaiso, Quinta Region, Chile|Research Site, Santiago, RM, Chile|Research Site, Rancagua, Vi Region, Chile|Research Site, Medillin, Antioquia, Colombia|Research Site, Barranquilla, Atl�ntico, Colombia|Research Site, Bogota Dc, Cundianmarca, Colombia|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Jesus Maria, Lima, Peru|Research Site, San Borja, Lima, Peru|Research Site, Surco, Lima, Peru|Research Site, Lima, Peru|Research Site, Belvilee, Cape Town, South Africa|Research Site, Tygerberg, Cape Town, South Africa|Research Site, Port Elizabeth, E Cape, South Africa|Research Site, Korsten, Port Elizabeth, South Africa|Research Site, Groenkloof, Pretoria, South Africa|Research Site, Thaba Tswane, Pretoria, South Africa|Research Site, Amanzimtoti, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Boksburg, South Africa|Research Site, Cape Town, South Africa|Research Site, Centurion, South Africa|Research Site, Durban, South Africa|Research Site, Humansdorp, South Africa|Research Site, Pretoria West, South Africa|Research Site, Pretoria, South Africa|Research Site, Roodepoort, South Africa|Research Site, Distrito Capital, Caracas, Venezuela",,"https://ClinicalTrials.gov/show/NCT00419744"
215,"NCT00401752","Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer",,"Completed","Has Results","Gastric Ulcer","Drug: Esomeprazole|Drug: Ranitidine","The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily Non-steroidal Anti-inflammatory Drug (NSAID)Therapy.|The Percentage of Subjects Whose Gastric Ulcer(s) Was (Were) Healed at Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.|The Resolution of Heartburn Symptoms at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.|Percentage of Participants With the Occurance of Any Adverse Event.|The Percentage of Participants Whose Duodenal Ulcer(s) (DUs) Was (Were) Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy.|The Percentage of Participants Whose GU(s) and DU(s) in Combination Were Healed at Week 4 and Week 8 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients Receiving Daily NSAID Therapy","AstraZeneca","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","397","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D9617L00001","March 2006",,"November 2008","November 22, 2006","July 8, 2010","July 8, 2010","Research Site, Fuzhou, Fujian, China|Research Site, Guangzhou, Guangdong, China|Research Site, Wuhan, Hubei, China|Research Site, Suzhou, Jiangsu, China|Research Site, Shenyang, Liaoning, China|Research Site, Xi'an, Shanxi, China|Research Site, Beijing, China|Research Site, Shanghai, China|Research Site, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT00401752"
216,"NCT00399035","Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","HORIZON II","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Cediranib|Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|Drug: XELOX (Capecitabine and Oxaliplatin)|Drug: Cediranib Placebo","Progression-free Survival|Overall Survival|Overall Response Rate|Best Percentage Change in Tumour Size|Duration of Response|Rate of Resection of Liver Metastases|Time to Wound Healing Complications","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","1254","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D8480C00051|EUDRACT No 2006-001194-14|HORIZON II","November 2006","March 2010","August 2016","November 14, 2006","October 30, 2012","December 28, 2016","Research Site, Buenos Aires City, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Resistencia, Argentina|Research Site, Rosario, Argentina|Research Site, Santa Fe, Argentina|Research Site, Ashford, Australia|Research Site, Camperdown, Australia|Research Site, Heidelberg, Australia|Research Site, Hornsby, Australia|Research Site, Liverpool, Australia|Research Site, Waratah, Australia|Research Site, Wodonga, Australia|Research Site, Curitiba, Brazil|Research Site, Goiânia, Brazil|Research Site, Jaú, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Santo André, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, ChongQing, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Brno, Czech Republic|Research Site, Ceske Budejovice, Czech Republic|Research Site, Cheb, Czech Republic|Research Site, Jicin, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Pribram - Zdabor, Czech Republic|Research Site, Sumperk, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Znojmo, Czech Republic|Research Site, Essen, Germany|Research Site, Freiburg, Germany|Research Site, Goslar, Germany|Research Site, Hamburg, Germany|Research Site, Hildesheim, Germany|Research Site, Mannheim, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Györ, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szombathely, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Hyderabad, India|Research Site, Trivandrum, India|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Gdańsk, Poland|Research Site, Gliwice, Poland|Research Site, Kraków, Poland|Research Site, Olsztyn, Poland|Research Site, Toruń, Poland|Research Site, Wrocław, Poland|Research Site, Bellinzona, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Locarno, Switzerland|Research Site, Zürich, Switzerland|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Aberdeen, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00399035"
217,"NCT00392288","Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.",,"Completed","Has Results","Asthma","Drug: Ciclesonide|Drug: Placebo","Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12.|Change From Baseline in Total Daily Asthma Symptom Score at Week 12.|Change From Baseline in Use of Albuterol/Salbutamol at Week 12.","AstraZeneca","All","4 Years to 11 Years   (Child)","Phase 3","528","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC6695|XRP1526","September 2006","February 2008","February 2008","October 25, 2006","December 30, 2009","February 1, 2017","sanofi-aventis, US, Bridgewater, New Jersey, United States|Sanofi-Aventis Hungaria, Budapest, Hungary|Sanofi-Aventis, Mexico, Mexico|sanofi-aventis Poland, Warszawa, Poland|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|sanofi-aventis South Africa, Midrand, South Africa",,"https://ClinicalTrials.gov/show/NCT00392288"
218,"NCT00391872","A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome","PLATO","Completed","Has Results","Acute Coronary Syndrome","Drug: Ticagrelor|Drug: Clopidogrel","Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke|Participants With Any Major Bleeding Event|Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization|Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke|Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.|Participants With MI Event|Participants With Death From Vascular Causes|Participants With Stroke|Participants With Death From Any Cause|Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding|Participants With Major or Minor Bleeding|Participants With Non-procedural Major Bleeding|Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding|Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding|Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization|Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","18624","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D5130C05262|PLATO","October 2006","March 2009","March 2009","October 25, 2006","March 13, 2012","March 13, 2012","Research Site, Birmingham, Alabama, United States|Research Site, Huntsville, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Bakersfield, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Burbank, California, United States|Research Site, Healdsburg, California, United States|Research Site, Los Angeles, California, United States|Research Site, Roseville, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Torrance, California, United States|Research Site, Fort Collins, Colorado, United States|Research Site, Danbury, Connecticut, United States|Research Site, Hartford, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Washington, District of Columbia, United States|Research Site, Atlantis, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Ft. Lauderdale, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Jupiter, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Miami Beach, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Rock Island, Illinois, United States|Research Site, Rockford, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Valparaiso, Indiana, United States|Research Site, Iowa City, Iowa, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Olathe, Kansas, United States|Research Site, Ashland, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Auburn, Maine, United States|Research Site, Bangor, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Salisbury, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Lansing, Michigan, United States|Research Site, Laper, Michigan, United States|Research Site, Pontiac, Michigan, United States|Research Site, Royal Oak, Michigan, United States|Research Site, Saginaw, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, St Paul, Minnesota, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Joplin, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, St Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Papillion, Nebraska, United States|Research Site, Newark, New Jersey, United States|Research Site, Oakland, New Jersey, United States|Research Site, Paterson, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Johnson City, New York, United States|Research Site, Kingston, New York, United States|Research Site, New Hartford, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Williamsville, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Greensboro, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bend, Oregon, United States|Research Site, Camp Hill, Pennsylvania, United States|Research Site, Danville, Pennsylvania, United States|Research Site, Doylestown, Pennsylvania, United States|Research Site, Harrisburg, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sayre, Pennsylvania, United States|Research Site, Sellersville, Pennsylvania, United States|Research Site, Wormleysburg, Pennsylvania, United States|Research Site, York, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Wakefield, Rhode Island, United States|Research Site, Anderson, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Jackson, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Marcos, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Falls Church, Virginia, United States|Research Site, Fredericksburg, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Winchester, Virginia, United States|Research Site, Everett, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Adrogue, Buenos Aires, Argentina|Research Site, Capital Federal, Buenos Aires, Argentina|Research Site, Ciudad Autonoma de Bs. As., Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Moron, Pcia. de Buenos Aires, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Tucuman, Tucuman - Argentina, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Corrientes, Argentina|Research Site, Salta, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Santa Fe, Argentina|Research Site, Bruce, Australian Capital Territory, Australia|Research Site, Chermside, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Dandenong, Victoria, Australia|Research Site, Geelong, Victoria, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Feldkirch, Austria|Research Site, Freistadt, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Modling, Austria|Research Site, Villach, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Bouge, Belgium|Research Site, Brasschaat, Belgium|Research Site, Brussels (anderlecht), Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Hasselt, Belgium|Research Site, HUY, Belgium|Research Site, Liege, Belgium|Research Site, Mechelen, Belgium|Research Site, MOL, Belgium|Research Site, Wilrijk, Belgium|Research Site, Maceio, AL, Brazil|Research Site, Salvador, BA, Brazil|Research Site, Brasilia, DF, Brazil|Research Site, Goiania, GO, Brazil|Research Site, Belo Horizonte, MG, Brazil|Research Site, Uberlandia, MG, Brazil|Research Site, Campo Grande, MS, Brazil|Research Site, Recife, PE, Brazil|Research Site, Curitiba, PR, Brazil|Research Site, Maringa, PR, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Natal, RN, Brazil|Research Site, Porto Alegre, RS, Brazil|Research Site, Sao Jose, SC, Brazil|Research Site, Aracaju, SE, Brazil|Research Site, S.j.rio Preto, SP, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Campinas, Brazil|Research Site, Burgas, Bulgaria|Research Site, Dimitrovgrad, Bulgaria|Research Site, Gabrovo, Bulgaria|Research Site, Haskovo, Bulgaria|Research Site, Kazanlak, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Russe, Bulgaria|Research Site, Smolian, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Campbell River, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, New Westminster, British Columbia, Canada|Research Site, Penticton, British Columbia, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Brockville, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Cornwall, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-georges, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Thetford Mines, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Guangzhou, Guangdong, China|Research Site, Shenyang, Liaoning, China|Research Site, Chengdu, Sichuan, China|Research Site, Beijing, China|Research Site, Hang Zhou, China|Research Site, Shanghai, Pudong, China|Research Site, Brno, CZ, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Kladno, Czech Republic|Research Site, Liberec, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Ostrava-poruba, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Slany, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Usti Nad Labem, Czech Republic|Research Site, Usti Nad Orlici, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Znojmo, Czech Republic|Research Site, Esbjerg, Denmark|Research Site, Fredericia, Denmark|Research Site, Frederiksberg, Denmark|Research Site, Frederikssund, Denmark|Research Site, Glostrup, Denmark|Research Site, Hellerup, Denmark|Research Site, Herlev, Denmark|Research Site, Herning, Denmark|Research Site, Hillerod, Denmark|Research Site, Hjorring, Denmark|Research Site, Holbaek, Denmark|Research Site, Horsens, Denmark|Research Site, Hvidovre, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Koge, Denmark|Research Site, Kolding, Denmark|Research Site, Naestved, Denmark|Research Site, Odense C, Denmark|Research Site, Roskilde, Denmark|Research Site, Silkeborg, Denmark|Research Site, Slagelse, Denmark|Research Site, Viborg, Denmark|Research Site, Hus (helsinki), Finland|Research Site, Jyvaskyla, Finland|Research Site, Kokkola, Finland|Research Site, Kuopio, Finland|Research Site, Lahti, Finland|Research Site, Lappeenranta, Finland|Research Site, Pori, Finland|Research Site, Rovaniemi, Finland|Research Site, Turku, Finland|Research Site, Abbeville, France|Research Site, Allauch, France|Research Site, Arras, France|Research Site, Avignon, France|Research Site, Bayonne, France|Research Site, Besancon, France|Research Site, Brest, France|Research Site, Caen, France|Research Site, Cholet, France|Research Site, Creteil, France|Research Site, Croix, France|Research Site, Dijon, France|Research Site, Douai, France|Research Site, Falaise, France|Research Site, Frejus, France|Research Site, La Rochelle, France|Research Site, Lagny Sur Marne, France|Research Site, Lille, France|Research Site, Limoges, France|Research Site, Lomme, France|Research Site, Marseille, France|Research Site, Nimes, France|Research Site, Orleans, France|Research Site, Paris, France|Research Site, PAU, France|Research Site, Pessac, France|Research Site, Quincy Sous Senart, France|Research Site, Rennes, France|Research Site, Rouen, France|Research Site, Senlis, France|Research Site, Strasbourg, France|Research Site, Toulouse, France|Research Site, Tourcoing, France|Research Site, Valenciennes, France|Research Site, Tbilisi, Georgia|Research Site, Aschaffenburg, Germany|Research Site, Bad Mergentheim, Germany|Research Site, Bad Nauheim, Germany|Research Site, Bad Rothenfelde, Germany|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Bonn, Germany|Research Site, Cloppenburg, Germany|Research Site, Coburg, Germany|Research Site, Dortmund, Germany|Research Site, Dresden, Germany|Research Site, Duisburg, Germany|Research Site, Erfurt, Germany|Research Site, Essen, Germany|Research Site, Esslingen, Germany|Research Site, Frankfurt, Germany|Research Site, Gottingen, Germany|Research Site, Greifswald, Germany|Research Site, Halle, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Jena, Germany|Research Site, Kiel, Germany|Research Site, Krefeld, Germany|Research Site, Limburg, Germany|Research Site, Lubeck, Germany|Research Site, Mainz, Germany|Research Site, Merseburg, Germany|Research Site, Monchengladbach, Germany|Research Site, Muhlheim An Der Ruhr, Germany|Research Site, Munster, Germany|Research Site, Regensburg, Germany|Research Site, Rostock, Germany|Research Site, ULM, Germany|Research Site, Warendorf, Germany|Research Site, Witten, Germany|Research Site, Wuppertal, Germany|Research Site, Wurzburg, Germany|Research Site, Heraklion, Crete, Greece|Research Site, Athens, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Piraeus, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Budapest, Hungary|Research Site, Cegled, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyula, Hungary|Research Site, Hodmez-vasarhely, Hungary|Research Site, Kaposvar, Hungary|Research Site, Kecskemet, Hungary|Research Site, Mosonmagyarovar, Hungary|Research Site, Pecs, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Hyderabad, Andhrapradesh, India|Research Site, Vijayawada, Andhrapradesh, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Gandhinagar, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Thrissur, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Patiala, Punjab, India|Research Site, Bikaner, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Chennai, Tamilnadu, India|Research Site, Coimabatore, Tamilnadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Denpasar, Bali, Indonesia|Research Site, Bandung, Jawa Barat, Indonesia|Research Site, Surabaya, Jawa Timur, Indonesia|Research Site, Jakarta, Indonesia|Research Site, Makassar, Indonesia|Research Site, Semarang, Indonesia|Research Site, Afula, Israel|Research Site, Ashkelon, Israel|Research Site, Beer Sheva, Israel|Research Site, Hadera, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Poriya M.p. Lower Galilee, Israel|Research Site, Rehovot, Israel|Research Site, Tel Aviv, Israel|Research Site, Zerifin, Israel|Research Site, Ancona, AN, Italy|Research Site, Bari, BA, Italy|Research Site, Bergamo, BG, Italy|Research Site, Caserta, CE, Italy|Research Site, Catania, CT, Italy|Research Site, Ferrara, FE, Italy|Research Site, Foggia, FG, Italy|Research Site, San Giovanni Rotondo, FG, Italy|Research Site, Bagno A Ripoli, FI, Italy|Research Site, Firenze, FI, Italy|Research Site, Legnano, MI, Italy|Research Site, Milano, MI, Italy|Research Site, Monza, MI, Italy|Research Site, Rozzano, MI, Italy|Research Site, Mantova, MN, Italy|Research Site, Modena, MO, Italy|Research Site, Pescara, PE, Italy|Research Site, Parma, PR, Italy|Research Site, Pavia, PV, Italy|Research Site, Ostia Lido, Roma, Italy|Research Site, Sassari, SS, Italy|Research Site, Treviso, TV, Italy|Research Site, Varese, VA, Italy|Research Site, Mestre, VE, Italy|Research Site, Verona, VR, Italy|Research Site, Massa Carrara, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Roma, Italy|Research Site, Seongnam, Gyeonggido, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Wonju, Korea, Republic of|Research Site, Kuching, Sarawak, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Penang, Malaysia|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, Durango, Mexico|Research Site, Puebla, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Almelo, Netherlands|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Apeldoorn, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Assen, Netherlands|Research Site, Blaricum, Netherlands|Research Site, Breda, Netherlands|Research Site, Capelle Aan Den Ijssel, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Deventer, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Drachten, Netherlands|Research Site, EDE, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Goes, Netherlands|Research Site, Gorinchem, Netherlands|Research Site, Gouda, Netherlands|Research Site, Haarlem, Netherlands|Research Site, Hardenberg, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Heerlen, Netherlands|Research Site, Helmond, Netherlands|Research Site, Hilversum, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Spijkenisse, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Veldhoven, Netherlands|Research Site, Vlaardingen, Netherlands|Research Site, Arendal, Norway|Research Site, Bergen, Norway|Research Site, Bodo, Norway|Research Site, Drammen, Norway|Research Site, Flekkefjord, Norway|Research Site, Gjovik, Norway|Research Site, Hamar, Norway|Research Site, Kongsberg, Norway|Research Site, Kristiansand, Norway|Research Site, Lillehammer, Norway|Research Site, Nordbyhagen, Norway|Research Site, Notodden, Norway|Research Site, Oslo, Norway|Research Site, RUD, Norway|Research Site, Tromso, Norway|Research Site, Tynset, Norway|Research Site, Cebu, Philippines|Research Site, Davao City, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Quezon City, Philippines|Research Site, Bialystok, Poland|Research Site, Bielsko-biala, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bytom, Poland|Research Site, Czestochowa, Poland|Research Site, Elblag, Poland|Research Site, Gda?sk, Poland|Research Site, Gdynia, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Inowroclaw, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Olawa, Poland|Research Site, Olsztyn, Poland|Research Site, Opole, Poland|Research Site, Ostrowiec Swietokrzyski, Poland|Research Site, Plock, Poland|Research Site, Poznan, Poland|Research Site, Radom, Poland|Research Site, Szczecin, Poland|Research Site, Tarnow, Poland|Research Site, Torun, Poland|Research Site, Walbrzych, Poland|Research Site, Warszawa, Poland|Research Site, Wejherowo, Poland|Research Site, Wloclawek, Poland|Research Site, Wroclaw, Poland|Research Site, Zamosc, Poland|Research Site, Amadora, Portugal|Research Site, Aveiro, Portugal|Research Site, Braga, Portugal|Research Site, Coimbra, Portugal|Research Site, Leiria, Portugal|Research Site, Lisboa, Portugal|Research Site, Penafiel, Portugal|Research Site, Santa Maria Da Feira, Portugal|Research Site, Santarem, Portugal|Research Site, Setubal, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Vila Real, Portugal|Research Site, San Juan, Puerto Rico|Research Site, Pitesti, Arges, Romania|Research Site, Cluj Napoca, Cluj, Romania|Research Site, Braila, Romania|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Buzau, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Suceava, Romania|Research Site, Khanty-mansiysk, Khanty-mansiysk Autonomous Dis, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Irkutsk, Russian Federation|Research Site, Kaliningrad, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Rostov-na-donu, Russian Federation|Research Site, Samara, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Vladivostok, Russian Federation|Research Site, Singapore, Singapore|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Liptovsky Mikulas, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Nove Zamky, Slovakia|Research Site, Piestany, Slovakia|Research Site, Ruzomberok, Slovakia|Research Site, Trnava, Slovakia|Research Site, Zilina, Slovakia|Research Site, Somerset West, Cape Town, South Africa|Research Site, Bloemfontein, Free State, South Africa|Research Site, Cape Town, South Africa|Research Site, Pretoria, South Africa|Research Site, Malaga, Andalucia, Spain|Research Site, Sevilla, Andalucia, Spain|Research Site, Gijon, Asturias, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Lerida, Cataluna, Spain|Research Site, Terrassa, Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Caceres, Extremadura, Spain|Research Site, Vigo(pontevedra), Galicia, Spain|Research Site, Palma de Mallorca, Islas Baleares, Spain|Research Site, Boras, Sweden|Research Site, Eksjo, Sweden|Research Site, Eskilstuna, Sweden|Research Site, Falun, Sweden|Research Site, Halmstad, Sweden|Research Site, Jonkoping, Sweden|Research Site, Kalmar, Sweden|Research Site, Karlskrona, Sweden|Research Site, Lidkoping, Sweden|Research Site, Linkoping, Sweden|Research Site, Ljungby, Sweden|Research Site, Lund, Sweden|Research Site, Ostersund, Sweden|Research Site, Skovde, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, Uppsala, Sweden|Research Site, Vasteras, Sweden|Research Site, Mendrisio, Ticino, Switzerland|Research Site, Bellinzona, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneve, Switzerland|Research Site, Kreuzlingen, Switzerland|Research Site, Lugano, Switzerland|Research Site, Niao-song-shiang, Kaohsiung, Taiwan|Research Site, Kweishan Shiang, Taoyuan Hsien, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Istanbul, Kartal, Turkey|Research Site, Ankara, Sihhiye, Turkey|Research Site, Adana, Turkey|Research Site, Antalya, Turkey|Research Site, Mersin, Turkey|Research Site, Dnepropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kiev, Ukraine|Research Site, Makiyivka, Ukraine|Research Site, Airdrie, Lanarkshire, United Kingdom|Research Site, Belfast, Northern Ireland, United Kingdom|Research Site, Basingstoke, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Blackpool, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00391872"
219,"NCT00389064","Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder",,"Completed","Has Results","Anxiety Disorders","Drug: Quetiapine XR|Drug: Placebo","Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score|Change in Health-related Quality of Life as Measured by Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Percent Maximum Total Score|Change in the Clinical Global Impression - Severity of Illness (CGI-S) Score|Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score|Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score|Hamilton Rating Scale for Anxiety (HAM-A) Response.|Number of Patients Reaching Hamilton Rating Scale for Anxiety (HAM-A) Remission|Change in Montgomery-Asberg Depression Rating Scale (MADRS)|Change in the Visual Analogue Scale (VAS) Measuring Pain|Safety and Well Tolerated as Measured in Adverse Event|Safety and Well Tolerated as Measured by Extra Pyramidal Symptoms (EPS)","AstraZeneca","All","66 Years and older   (Older Adult)","Phase 3","450","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D1448C00015|EUDRACT No: 2006-001195-21","September 2006","April 2008","April 2008","October 18, 2006","June 23, 2009","April 4, 2012","Research Site, Ft Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Roswell, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Bronx, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Avon Lake, Ohio, United States|Research Site, Eugene, Oregon, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Viljandi, Estonia|Research Site, Bialystok, Poland|Research Site, Gorlice, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Leszno, Poland|Research Site, Skorzewo, Poland|Research Site, Torun, Poland|Research Site, Wroclaw, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St-petersburg, Russian Federation|Research Site, Stavropol, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Glevakha, Kiev Region, Ukraine|Research Site, Dnepropetrovsk, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Odessa, Ukraine|Research Site, Vinnitsa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00389064"
220,"NCT00388973","Efficacy and Safety Study of Seroquel SR in the Treatment of Major Depressive Disorder",,"Completed","Has Results","Major Depressive Disorder","Drug: Quetiapine","Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to Week 9.|Change From Baseline in Health-related Quality of Life, Enjoyment and Satisfaction (Q-LES-Q)|Change From Baseline for Satisfaction With Medication From Quality of Life, Enjoyment, Satisfaction Questionaire (Q-LES-Q)|Change From Baseline in Anxiety Symptoms Measured by Hamilton Anxiety 14 Item Scale (HAM-A)|Change From Baseline in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index|Change From Baseline in Suicidal Thoughts as Measured by Montgomery-Asberg Depression Rating Scale (MADRS) Item 10|Change From Baseline in Somatic Symptoms Cluster From the Hamilton Anxiety Scale (HAM-A)|Tolerability as Measured by Adverse Event Withdrawals During Treatment","AstraZeneca","All","66 Years and older   (Older Adult)","Phase 3","338","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","D1448C00014|EUDRACT No: 2006-001196-38","September 2006","December 2007","December 2007","October 17, 2006","April 1, 2010","April 1, 2010","Research Site, Birmingham, Alabama, United States|Research Site, San Diego, California, United States|Research Site, Ft Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, Roswell, Georgia, United States|Research Site, Boston, Massachusetts, United States|Research Site, Brooklyn, New York, United States|Research Site, Eugene, Oregon, United States|Research Site, Jenkintown, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, City Bell, Buenos Aires, Argentina|Research Site, La Plata, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Capital Federal, Argentina|Research Site, Cordoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Viljandi, Estonia|Research Site, Helsinki, Finland|Research Site, Jarvenpaa, Finland|Research Site, Kuopio, Finland|Research Site, Salo, Finland|Research Site, Seinajoki, Finland|Research Site, Tampere, Finland|Research Site, Arkhangelsk, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Perm, Russian Federation|Research Site, St.-petersburg, Russian Federation|Research Site, Stavropol, Russian Federation|Research Site, Glevakha, Kiev Region, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Odessa, Ukraine|Research Site, Vinnitsa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00388973"
221,"NCT00384189","A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma","RAINBOW","Completed","Has Results","Asthma","Drug: Ciclesonide|Drug: Placebo|Drug: Salbutamol","Change From Baseline in Morning Peak Expiratory Flow (PEF)|Time to First Event of Lack of Efficacy (LOE) by Week 12|Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication, Morning PEF and PEF Fluctuation|Change From Baseline in Lung Function Variable Forced Expiratory Volume in One Second (FEV1)|Change From Baseline in Lung Function Variable PEF by Spirometry|Change From Baseline in Morning PEF From Diary|Change From Baseline in Evening PEF From Diary|Change From Baseline in Diurnal PEF Fluctuations|Change in Asthma Symptom Total Score|Change in Use of Rescue Medications|Percentage of Days With Asthma Control Based on Symptoms, Use of Rescue Medication and Morning PEF|Change From Baseline in Pediatric Asthma Quality of Life Questionnaire Standard [PAQLQ(S)] Overall Score|Change From Baseline in Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ) Overall","AstraZeneca|Nycomed GmbH","All","6 Years to 11 Years   (Child)","Phase 3","1080","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BY9010/M1-209|U1111-1172-2297","September 2006","August 2007","August 2008","October 5, 2006","August 16, 2016","February 1, 2017","Altana Pharma/Nycomed, Plovdiv, Bulgaria|Altana Pharma/Nycomed, Plovdiv, Bulgaria|Altana Pharma/Nycomed, Rousse, Bulgaria|Altana Pharma/Nycomed, Sofia, Bulgaria|Altana Pharma/Nycomed, Vama, Bulgaria|Altana Pharma/Nycomed, Dresden, Germany|Altana Pharma/Nycomed, Freising, Germany|Altana Pharma/Nycomed, Fulda, Germany|Altana Pharma/Nycomed, Homburg, Germany|Altana Pharma/Nycomed, Kassel, Germany|Altana Pharma/Nycomed, Leipzig, Germany|Altana Pharma/Nycomed, Mannheim, Germany|Altana Pharma/Nycomed, Marburg, Germany|Altana Pharma/Nycomed, München, Germany|Altana Pharma/Nycomed, Rosenheim, Germany|Altana Pharma/Nycomed, Schwäbisch Hall, Germany|Altana Pharma/Nycomed, Welzheim, Germany|Altana Pharma/Nycomed, Wesel, Germany|Altana Pharma/Nycomed, Budapest, Hungary|Altana Pharma/Nycomed, Budapest, Hungary|Altana Pharma/Nycomed, Debrecen, Hungary|Altana Pharma/Nycomed, Jaszbereny, Hungary|Altana Pharma/Nycomed, Kiskunhalas, Hungary|Altana Pharma/Nycomed, Miskolc, Hungary|Altana Pharma/Nycomed, Mosdós, Hungary|Altana Pharma/Nycomed, Mosonmagyaróvár, Hungary|Altana Pharma/Nycomed, Pecs, Hungary|Altana Pharma/Nycomed, Szeged, Hungary|Altana Pharma/Nycomed, Inowroclaw, Poland|Altana Pharma/Nycomed, Lodz, Poland|Altana Pharma/Nycomed, Lodz, Poland|Altana Pharma/Nycomed, Lublin, Poland|Altana Pharma/Nycomed, Poznan, Poland|Altana Pharma/Nycomed, Torun, Poland|Altana Pharma/Nycomed, Warszawa, Poland|Altana Pharma/Nycomed, Warszawa, Poland|Altana Pharma/Nycomed, Zawadzkie, Poland|Altana Pharma/Nycomed, Brasov, Romania|Altana Pharma/Nycomed, Bucharest, Romania|Altana Pharma/Nycomed, Bucharest, Romania|Altana Pharma/Nycomed, Bucharest, Romania|Altana Pharma/Nycomed, Bucharest, Romania|Altana Pharma/Nycomed, Bucharest, Romania|Altana Pharma/Nycomed, Bucharest, Romania|Altana Pharma/Nycomed, Cluj-Napoca, Romania|Altana Pharma/Nycomed, Cluj-Napoca, Romania|Altana Pharma/Nycomed, Craiova, Romania|Altana Pharma/Nycomed, Galati, Romania|Altana Pharma/Nycomed, Iasi, Romania|Altana Pharma/Nycomed, Sibiu, Romania|Altana Pharma/Nycomed, Chelyabinsk, Russian Federation|Altana Pharma/Nycomed, Ivanovo, Russian Federation|Altana Pharma/Nycomed, Kislovodsk, Russian Federation|Altana Pharma/Nycomed, Moscow, Russian Federation|Altana Pharma/Nycomed, Moscow, Russian Federation|Altana Pharma/Nycomed, Moscow, Russian Federation|Altana Pharma/Nycomed, Moscow, Russian Federation|Altana Pharma/Nycomed, Moscow, Russian Federation|Altana Pharma/Nycomed, Moscow, Russian Federation|Altana Pharma/Nycomed, Moscow, Russian Federation|Altana Pharma/Nycomed, Moscow, Russian Federation|Altana Pharma/Nycomed, Moscow, Russian Federation|Altana Pharma/Nycomed, Moscow, Russian Federation|Altana Pharma/Nycomed, Murmansk, Russian Federation|Altana Pharma/Nycomed, Novosibirsk, Russian Federation|Altana Pharma/Nycomed, Rostov, Russian Federation|Altana Pharma/Nycomed, Samara, Russian Federation|Altana Pharma/Nycomed, Smolensk, Russian Federation|Altana Pharma/Nycomed, St. Petersburg, Russian Federation|Altana Pharma/Nycomed, St. Petersburg, Russian Federation|Altana Pharma/Nycomed, St. Petersburg, Russian Federation|Altana Pharma/Nycomed, St. Petersburg, Russian Federation|Altana Pharma/Nycomed, St. Petersburg, Russian Federation|Altana Pharma/Nycomed, St.Petersburg, Russian Federation|Altana Pharma/Nycomed, St.Petersburg, Russian Federation|Altana Pharma/Nycomed, St.Petersburg, Russian Federation|Altana Pharma/Nycomed, St.Petersburg, Russian Federation|Altana Pharma/Nycomed, St.Petersburg, Russian Federation|Altana Pharma/Nycomed, St.Petersburg, Russian Federation|Altana Pharma/Nycomed, St.Petersburg, Russian Federation|Altana Pharma/Nycomed, Tomsk, Russian Federation|Altana Pharma/Nycomed, Vladimir, Russian Federation|Altana Pharma/Nycomed, Voronezh, Russian Federation|Altana Pharma/Nycomed, Bellville - Cape Town -, South Africa|Altana Pharma/Nycomed, Bloemfontein, South Africa|Altana Pharma/Nycomed, Cape Town, South Africa|Altana Pharma/Nycomed, Centurion, South Africa|Altana Pharma/Nycomed, Durban, Amanzimtoti, South Africa|Altana Pharma/Nycomed, Durban, South Africa|Altana Pharma/Nycomed, Gezina, Pretoria, South Africa|Altana Pharma/Nycomed, Morningside, Sandton, South Africa|Altana Pharma/Nycomed, Mowbray, Cape Town, South Africa|Altana Pharma/Nycomed, New Redruth, Alberton, South Africa|Altana Pharma/Nycomed, Panorama / RSA-Cape Town, South Africa|Altana Pharma/Nycomed, Somerset West, South Africa|Altana Pharma/Nycomed, Westville, South Africa|Altana Pharma/Nycomed, Wynberg, South Africa|Altana Pharma/Nycomed, Barcelona, Spain|Altana Pharma/Nycomed, Barcelona, Spain|Altana Pharma/Nycomed, Barcelona, Spain|Altana Pharma/Nycomed, Esplugues de Llobregat, Spain|Altana Pharma/Nycomed, Leganés, Spain|Altana Pharma/Nycomed, Madrid, Spain|Altana Pharma/Nycomed, Madrid, Spain|Altana Pharma/Nycomed, Madrid, Spain|Altana Pharma/Nycomed, Madrid, Spain|Altana Pharma/Nycomed, Manresa, Spain|Altana Pharma/Nycomed, Sabadell (Barcelona), Spain|Altana Pharma/Nycomed, Tarrasa, Spain|Altana Pharma/Nycomed, Dnipropetrovsk, Ukraine|Altana Pharma/Nycomed, Donetsk, Ukraine|Altana Pharma/Nycomed, Donetsk, Ukraine|Altana Pharma/Nycomed, Kharkiv, Ukraine|Altana Pharma/Nycomed, Kiev, Ukraine|Altana Pharma/Nycomed, Kyiv, Ukraine|Altana Pharma/Nycomed, Kyiv, Ukraine|Altana Pharma/Nycomed, Kyiv, Ukraine|Altana Pharma/Nycomed, Lviv, Ukraine|Altana Pharma/Nycomed, Odesa, Ukraine|Altana Pharma/Nycomed, Poltava, Ukraine|Altana Pharma/Nycomed, Simferopol, Ukraine|Altana Pharma/Nycomed, Vinnytsia, Ukraine|Altana Pharma/Nycomed, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT00384189"
222,"NCT00375492","Effect on Weight Loss of Exenatide Versus Placebo",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide|Drug: placebo","Change From Baseline in Body Weight|Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24|Change From Baseline in 6-point Self Monitored Blood Glucose (SMBG) Profile at Week 24|Change From Baseline in Waist Circumference at Week 24|Ratio of Homeostatic Model Assessment-Beta Cell (HOMA-B) at Week 24 to HOMA-B at Baseline|Ratio of Homeostatic Model Assessment-Insulin Sensitivity (HOMA-S) at Week 24 to HOMA-S at Baseline|Change From Baseline in High Density Lipoprotein (HDL) Cholesterol at Week 24|Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol at Week 24|Change From Baseline in Total Cholesterol at Week 24|Ratio of Triglycerides at Week 24 to Triglycerides at Baseline|Number of Participants With Hypoglycemic Events During the Study|Rate of Hypoglycemic Events","AstraZeneca|Eli Lilly and Company","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","196","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","H8O-US-GWBM","September 2006","February 2008","February 2008","September 13, 2006","September 4, 2009","April 7, 2015","Research Site, Peoria, Arizona, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, St. Louis, Missouri, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, San Antonio, Texas, United States|Research Site, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00375492"
223,"NCT00374907","A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise",,"Completed","Has Results","Type 2 Diabetes","Drug: Saxagliptin|Drug: Placebo|Drug: Metformin (blinded)|Drug: Metformin (open-label)","Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12|Insulin Secretion Rate AUC During IV Hyperglycemic Clamp - Percent Change From Baseline at Week 12","AstraZeneca","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","156","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV181-041","September 2006","January 2008","December 2009","September 12, 2006","January 21, 2011","May 7, 2015","Va San Diego Healthcare System, San Diego, California, United States|Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States|Diabetes & Glandular Disease Research Assoc,, Inc., San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00374907"
224,"NCT00363896","A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Aclidinium bromide|Drug: Placebo","Trough FEV1 (L) at 28 Weeks on Treatment|Trough Forced Expiratory Volume in the First Second (FEV1) (L) at 12 Weeks on Treatment|Time to First Moderate or Severe COPD Exacerbation at 52 Weeks on Treatment|Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at 52 Weeks on Treatment","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","843","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M/34273/30|ACCLAIM I|CT000740","July 2006","May 2008","May 2008","August 15, 2006","November 1, 2012","January 6, 2017","Almirall Investigational Sites#947, Escaldes, Andorra|Almirall Investigational Sites#645, Graz, Austria|Almirall Investigational Sites#646, Innsbruck, Austria|Almirall Investigational Sites#644, Linz, Austria|Almirall Investigational Sites#647, Wien, Austria|Almirall Investigational Sites#649, Wien, Austria|Almirall Investigational Sites#110, Aalst, Belgium|Almirall Investigational Sites#394, Brussels, Belgium|Almirall Investigational Sites#651, Edegem, Belgium|Almirall Investigational Sites#393, Namur, Belgium|Almirall Investigational Sites#658, Burgas, Bulgaria|Almirall Investigational Sites#653, Pleven, Bulgaria|Almirall Investigational Sites#654, Plovdiv, Bulgaria|Almirall Investigational Sites#656, Russe, Bulgaria|Almirall Investigational Sites#652, Sofia, Bulgaria|Almirall Investigational Sites#657, Sofia, Bulgaria|Almirall Investigational Sites#972, Sofia, Bulgaria|Almirall Investigational Sites#971, Sofia, Bulgaria|Almirall Investigational Sites#655, Varna, Bulgaria|Almirall Investigational Sites#953, Veliko Tarnovo, Bulgaria|Almirall Investigational Sites#664, Lovosice, Czech Republic|Almirall Investigational Sites#660, Neratovice, Czech Republic|Almirall Investigational Sites#662, Plzen, Czech Republic|Almirall Investigational Sites#666, Prague, Czech Republic|Almirall Investigational Sites#661, Praha, Czech Republic|Almirall Investigational Sites#665, Tabor, Czech Republic|Almirall Investigational Sites#659, Tremosna, Czech Republic|Almirall Investigational Sites#954, Zatec, Czech Republic|Almirall Investigational Sites#398, Aalborg, Denmark|Almirall Investigational Sites#397, Odense C., Denmark|Almirall Investigational Sites#390, Århus C, Denmark|Almirall Investigational Sites#594, Beuvry, France|Almirall Investigational Sites#593, Brest Cedex, France|Almirall Investigational Sites#750, Grasse, France|Almirall Investigational Sites#669, Montpellier,cedex 5, France|Almirall Investigational Sites#672, Paris, France|Almirall Investigational Sites#948, Perpignan Cedex, France|Almirall Investigational Sites#549, Rouen , Cedex, France|Almirall Investigational Sites#671, Strasbourg Cedex, France|Almirall Investigational Sites#752, Vieux Conde, France|Almirall Investigational Sites#678, Bad Wörishofen, Germany|Almirall Investigational Sites#677, Berlin-Spandau, Germany|Almirall Investigational Sites#758, Berlin, Germany|Almirall Investigational Sites#765, Berlin, Germany|Almirall Investigational Sites#680, Berlin, Germany|Almirall Investigational Sites#681, Bonn, Germany|Almirall Investigational Sites#191, Grosshansdorf, Germany|Almirall Investigational Sites#766, Hamburg, Germany|Almirall Investigational Sites#757, Jena, Germany|Almirall Investigational Sites#675, Mainz, Germany|Almirall Investigational Sites#684, Budapest, Hungary|Almirall Investigational Sites#687, Debrecen, Hungary|Almirall Investigational Sites#683, Debrecen, Hungary|Almirall Investigational Sites#688, Nyiregyhaza, Hungary|Almirall Investigational Sites#686, Szekesfehervar, Hungary|Almirall Investigational Sites#689, Szombathely, Hungary|Almirall Investigational Sites#682, Tatabanya, Hungary|Almirall Investigational Sites#685, Torokbalint, Hungary|Almirall Investigational Sites#459, Genova, Italy|Almirall Investigational Sites#774, Milano, Italy|Almirall Investigational Sites#286, Modena, Italy|Almirall Investigational Sites#694, Napoli, Italy|Almirall Investigational Sites#635, Perugia, Italy|Almirall Investigational Sites#777, Pordenone, Italy|Almirall Investigational Sites#346, Breda, Netherlands|Almirall Investigational Sites#551, Eindhoven, Netherlands|Almirall Investigational Sites#348, Hengelo, Netherlands|Almirall Investigational Sites#695, Hoofddorp, Netherlands|Almirall Investigational Sites#700, Lodz, Poland|Almirall Investigational Sites#698, Lodz, Poland|Almirall Investigational Sites#697, Torun, Poland|Almirall Investigational Sites#699, Warszawa, Poland|Almirall Investigational Sites#696, Warszawa, Poland|Almirall Investigational Sites#702, Warszawa, Poland|Almirall Investigational Sites#706, Wroclaw, Poland|Almirall Investigational Sites#705, Zabrze, Poland|Almirall Investigational Sites#701, Zawadzkie, Poland|Almirall Investigational Sites#962, Brasov, Romania|Almirall Investigational Sites#714, Bucharest, Romania|Almirall Investigational Sites#970, Bucuresti, Romania|Almirall Investigational Sites#713, Cluj-Napoca, Romania|Almirall Investigational Sites#712, Iasi, Romania|Almirall Investigational Sites#961, Judetul Brasov, Romania|Almirall Investigational Sites#709, Palazu Mare, Romania|Almirall Investigational Sites#711, Targu Mures, Romania|Almirall Investigational Sites#715, Timisoara, Romania|Almirall Investigational Sites#717, Moscow region, Russian Federation|Almirall Investigational Sites#462, Moscow, Russian Federation|Almirall Investigational Sites#977, Moscow, Russian Federation|Almirall Investigational Sites#721, Moscow, Russian Federation|Almirall Investigational Sites#540, Moscow, Russian Federation|Almirall Investigational Sites#967, Moscow, Russian Federation|Almirall Investigational Sites#716, Moscow, Russian Federation|Almirall Investigational Sites#722, Moscow, Russian Federation|Almirall Investigational Sites#719, Moscow, Russian Federation|Almirall Investigational Sites#582, Moscow, Russian Federation|Almirall Investigational Sites#785, Moscow, Russian Federation|Almirall Investigational Sites#976, Moscow, Russian Federation|Almirall Investigational Sites#588, Saint Petersburg, Russian Federation|Almirall Investigational Sites#720, Saint Petersburg, Russian Federation|Almirall Investigational Sites#965, Saint Petersburg, Russian Federation|Almirall Investigational Sites#969, saint Petersburg, Russian Federation|Almirall Investigational Sites#543, Saint Petersburg, Russian Federation|Almirall Investigational Sites#787, Saint Petersburg, Russian Federation|Almirall Investigational Sites#975, Saint Petersburg, Russian Federation|Almirall Investigational Sites#465, Saint Petersburg, Russian Federation|Almirall Investigational Sites#966, Saint Petersburg, Russian Federation|Almirall Investigational Sites#972, Saint Petersburg, Russian Federation|Almirall Investigational Sites#786, Saint Petersburg, Russian Federation|Almirall Investigational Sites#963, Saint Petersburg, Russian Federation|Almirall Investigational Sites#718, Sochi, Russian Federation|Almirall Investigational Sites#16, Badalona, Spain|Almirall Investigational Sites#7, Barcelona, Spain|Almirall Investigational Sites#317, Barcelona, Spain|Almirall Investigational Sites#61, Madrid, Spain|Almirall Investigational Sites#938, Málaga, Spain|Almirall Investigational Sites#727, Palma de Mallorca, Spain|Almirall Investigational Sites#723, San Juan de Alicante, Spain|Almirall Investigational Sites#725, Terrassa, Spain|Almirall Investigational Sites#738, Bedford, United Kingdom|Almirall Investigational Sites#42, Bristol, United Kingdom|Almirall Investigational Sites#734, Cottingham, United Kingdom|Almirall Investigational Sites#735, Doncaster, United Kingdom|Almirall Investigational Sites#788, Exeter, United Kingdom|Almirall Investigational Sites#737, Hereford, United Kingdom|Almirall Investigational Sites#784, London, United Kingdom|Almirall Investigational Sites#37, London, United Kingdom|Almirall Investigational Sites#730, Newcastle upon Tyne, United Kingdom|Almirall Investigational Sites#731, Peterborough, United Kingdom|Almirall Investigational Sites#728, Solihull, United Kingdom|Almirall Investigational Sites#732, Suffolk, United Kingdom|Almirall Investigational Sites#736, Windsor, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00363896"
225,"NCT00360334","A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients",,"Completed","Has Results","Type 2 Diabetes","Drug: exenatide|Drug: insulin glargine","Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg)|Percent of Patients Who Achieved HbA1c ≤ 7.4% and Weight Gain ≤ 0.5kg|Change in Fasting Serum Glucose|Percent of Patients Achieving HbA1c ≤ 7.4%|Percent of Patients Achieving HbA1c < 7%|Percent of Patients Achieving HbA1c < 6.5%|Change in 7 Point Self Monitored Blood Glucose Profile|Change in Body Mass Index (BMI)|Change in Waist Circumference|Change in Waist-to-hip Ratio|Change in Body Weight|Percent Change in Body Weight|Percent of Patients Achieving 5% Weight Loss|Percent of Patients Achieving 10% Weight Loss|Change in Systolic Blood Pressure|Change in Diastolic Blood Pressure|Change in Fasting Serum Total Cholesterol (TC)|Change in High Density Lipoprotein (HDL) Cholesterol|Change in TC to HDL Cholesterol Ratio|Change in Fasting Serum Triglycerides|Change in Low Density Lipoprotein (LDL) Cholesterol|Change in Apolipoprotein-B|Incidence of Hypoglycemic Episodes|Incidence of Nocturnal Hypoglycemic Episodes|Incidence of Severe Hypoglycemic Episodes|Hypoglycemic Rate Per 30 Days|Nocturnal Hypoglycemic Rate Per 30 Days|Severe Hypoglycemic Rate Per 30 Days","AstraZeneca|Eli Lilly and Company","All","30 Years and older   (Adult, Older Adult)","Phase 3","235","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-BP-GWBG","June 2006","April 2008","April 2008","August 4, 2006","June 5, 2009","April 7, 2015","Research Site, Aberdeen, United Kingdom|Research Site, Bath, United Kingdom|Research Site, Blackburn, United Kingdom|Research Site, Bolton, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Chippenham, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Haywards Heath, United Kingdom|Research Site, High Wycombe, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Ipswich, United Kingdom|Research Site, Kent, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Livingstone, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Oldham, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Rochdale, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Wakefield, United Kingdom|Research Site, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00360334"
226,"NCT00359762","Exenatide Versus Glimepiride in Patients With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide|Drug: glimepiride","Number of Patients With Treatment Failure|Time to Treatment Failure|Homeostasis Model Assessment of Beta-cell Function (HOMA-B) at Year 3|Change in HOMA-B From Baseline to Endpoint|Fasting Proinsulin/Insulin Ratio at Year 3|Change in Fasting Proinsulin/Insulin Ratio From Baseline to Endpoint.|Ratio of the 30 Minute Increment in Plasma Insulin Concentration and the 30 Minute Increment in Plasma Glucose During the Oral Glucose Tolerance Test (DI30/DG30 Ratio) at Year 3|Change in DI30/DG30 Ratio From Baseline to Endpoint|Disposition Index at Year 3|Change in Disposition Index From Baseline to Endpoint|Change in HbA1c From Baseline to Year 3|Change in HbA1c From Baseline to Endpoint|Fasting Plasma Glucose at Year 3|Change in Fasting Plasma Glucose From Baseline to Endpoint|Postprandial (2 Hours) Plasma Glucose at Year 3|Change in Postprandial (2 Hours) Plasma Glucose From Baseline to Endpoint|Change in Body Weight From Baseline to Year 3|Systolic Blood Pressure at Year 3|Diastolic Blood Pressure at Year 3|Heart Rate at Year 3|Triglycerides at Year 3|Total Cholesterol at Year 3|High-density Lipoprotein (HDL) Cholesterol at Year 3|Hypoglycemia Rate Per Year|Change in HbA1c From Baseline to Year 2 for Patients Randomized at Entry in Period III|Change in HbA1c From Baseline to Year 2 for Patients Not Randomized at Entry in Period III|Hypoglycemia Rate Per Year in Period III","AstraZeneca|Eli Lilly and Company","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","1029","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-EW-GWBE","September 2006","March 2011","March 2011","August 2, 2006","March 14, 2013","September 15, 2015","Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Vienna, Austria|Research Site, Beroun, Czech Republic|Research Site, Ceske Budejovice, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Liberec, Czech Republic|Research Site, Pisek, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Trebic, Czech Republic|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Pori, Finland|Research Site, Vaasa, Finland|Research Site, Alencon, France|Research Site, Bois-Guillaume, France|Research Site, Bourg des Comptes, France|Research Site, Broglie, France|Research Site, Bron, France|Research Site, Fleville Devant Nancy, France|Research Site, Le Creusot, France|Research Site, Le Mans, France|Research Site, Loudun, France|Research Site, Montigny les Metz, France|Research Site, Nevers, France|Research Site, Strasbourg, France|Research Site, Thouars, France|Research Site, Tours, France|Research Site, Valreas, France|Research Site, Vihiers, France|Research Site, Vénissieux, France|Research Site, Aschaffenburg, Germany|Research Site, Dresden, Germany|Research Site, Eisenach, Germany|Research Site, Essen Schonnebeck, Germany|Research Site, Essen, Germany|Research Site, Falkensee, Germany|Research Site, Fulda, Germany|Research Site, Hamburg-Altona, Germany|Research Site, Hamburg-Ottmarschen, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Leipzig, Germany|Research Site, Munster, Germany|Research Site, Saarbrucken, Germany|Research Site, Schenklengsfeld, Germany|Research Site, Schkeuditz, Germany|Research Site, St. Ingbert, Germany|Research Site, Staffelstein, Germany|Research Site, Witten, Germany|Research Site, Budapest, Hungary|Research Site, Gyula, Hungary|Research Site, Kecskemet, Hungary|Research Site, Veszprem, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, County Galway, Ireland|Research Site, County Waterford, Ireland|Research Site, Dublin, Ireland|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Tel Hashomer, Israel|Research Site, Ancona, Italy|Research Site, Arenzano, Italy|Research Site, Atri, Italy|Research Site, Bergamo, Italy|Research Site, Catanzaro, Italy|Research Site, Firenze, Italy|Research Site, Foggia, Italy|Research Site, Forli, Italy|Research Site, Genova, Italy|Research Site, Grosseto, Italy|Research Site, Milano, Italy|Research Site, Monserrato (Cagliari), Italy|Research Site, Napoli, Italy|Research Site, Palermo, Italy|Research Site, Perugia, Italy|Research Site, Pescara, Italy|Research Site, Pisa, Italy|Research Site, Ravenna, Italy|Research Site, Roma, Italy|Research Site, San Benedetto del Tronto, Italy|Research Site, Siena, Italy|Research Site, Treviso, Italy|Research Site, Verona, Italy|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Celaya, Guanajuato, Mexico|Research Site, Pachuca, Hidalgo, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Lublin, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Fribourg, Switzerland|Research Site, Geneva, Switzerland|Research Site, Geneve, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Luzern, Switzerland|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Brandford on Avon, United Kingdom|Research Site, County Antrim, United Kingdom|Research Site, Downpatrick, United Kingdom|Research Site, Frome, United Kingdom|Research Site, Midsomer Norton, United Kingdom|Research Site, Omagh, United Kingdom|Research Site, Penzance, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Southdown, United Kingdom|Research Site, Wiltshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00359762"
227,"NCT00358436","Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Aclidinium bromide|Drug: Placebo","Trough FEV1 (L) at 28 Weeks on Treatment|Trough FEV1 (L) at 12 Weeks on Treatment|Time to First Moderate or Severe COPD Exacerbation at 52 Weeks on Treatment|Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at 52 Weeks on Treatment","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","804","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M/34273/31|ACCLAIM II|CT000742","August 2006","June 2008","June 2008","July 31, 2006","November 1, 2012","January 4, 2017","Almirall Investigational Sites#926, Jasper, Alabama, United States|Almirall Investigational Sites#858, Ozark, Alabama, United States|Almirall Investigational Sites#900, Phoenix, Arizona, United States|Almirall Investigational Sites#899, Tucson, Arizona, United States|Almirall Investigational Sites#855, Tucson, Arizona, United States|Almirall Investigational Sites#879, Little Rock, Arkansas, United States|Almirall Investigational Sites#932, Carmichael, California, United States|Almirall Investigational Sites#904, Encinitas, California, United States|Almirall Investigational Sites#903, Fullerton, California, United States|Almirall Investigational Sites#930, Los Angeles, California, United States|Almirall Investigational Sites#922, Los Angeles, California, United States|Almirall Investigational Sites#893, North Hills, California, United States|Almirall Investigational Sites#871, Rancho Mirage, California, United States|Almirall Investigational Sites#902, Riverside, California, United States|Almirall Investigational Sites#850, San Diego, California, United States|Almirall Investigational Sites#897, San Diego, California, United States|Almirall Investigational Sites#924, Torrance, California, United States|Almirall Investigational Sites#882, Walnut Creek, California, United States|Almirall Investigational Sites#895, Denver, Colorado, United States|Almirall Investigational Sites#880, Fort Collins, Colorado, United States|Almirall Investigational Sites#888, Wheat Ridge, Colorado, United States|Almirall Investigational Sites#952, Waterbury, Connecticut, United States|Almirall Investigational Sites#844, Bay Pines, Florida, United States|Almirall Investigational Sites#863, Clearwater, Florida, United States|Almirall Investigational Sites#152, Deland, Florida, United States|Almirall Investigational Sites#8533, Melbourne, Florida, United States|Almirall Investigational Sites#920, Tamarac, Florida, United States|Almirall Investigational Sites#894, Tampa, Florida, United States|Almirall Investigational Sites#889, Tampa, Florida, United States|Almirall Investigational Sites#890, Atlanta, Georgia, United States|Almirall Investigational Sites#907, Decatur, Georgia, United States|Almirall Investigational Sites#931, Gainesville, Georgia, United States|Almirall Investigational Sites#849, Marietta, Georgia, United States|Almirall Investigational Sites#933, Chicago, Illinois, United States|Almirall Investigational Sites#872, Hines, Illinois, United States|Almirall Investigational Sites#892, River Forest, Illinois, United States|Almirall Investigational Sites#864, Evansville, Indiana, United States|Almirall Investigational Sites#876, Bowling Green, Kentucky, United States|Almirall Investigational Sites#923, Florence, Kentucky, United States|Almirall Investigational Sites#866, Lafayette, Louisiana, United States|Almirall Investigational Sites#911, Shreveport, Louisiana, United States|Almirall Investigational Sites#883, Biddeford, Maine, United States|Almirall Investigational Sites#976, Lewiston, Maine, United States|Almirall Investigational Sites#843, Baltimore, Maryland, United States|Almirall Investigational Sites#868, Cadillac, Michigan, United States|Almirall Investigational Sites#884, Minneapolis, Minnesota, United States|Almirall Investigational Sites#916, Saint Charles, Missouri, United States|Almirall Investigational Sites#906, Butte, Montana, United States|Almirall Investigational Sites#909, Omaha, Nebraska, United States|Almirall Investigational Sites#846, Cherry Hill, New Jersey, United States|Almirall Investigational Sites#885, Newark, New Jersey, United States|Almirall Investigational Sites#921, Summit, New Jersey, United States|Almirall Investigational Sites#896, Albuquerque, New Mexico, United States|Almirall Investigational Sites#861, Chapel Hill, North Carolina, United States|Almirall Investigational Sites#919, Charlotte, North Carolina, United States|Almirall Investigational Sites#878, Elizabeth City, North Carolina, United States|Almirall Investigational Sites#842, Williamston, North Carolina, United States|Almirall Investigational Sites#915, Winston Salem, North Carolina, United States|Almirall Investigational Sites#848, Cincinatti, Ohio, United States|Almirall Investigational Sites#870, Cincinnati, Ohio, United States|Almirall Investigational Sites#847, Columbus, Ohio, United States|Almirall Investigational Sites#928, Sylvania, Ohio, United States|Almirall Investigational Sites#905, Eugene, Oregon, United States|Almirall Investigational Sites#860, Medford, Oregon, United States|Almirall Investigational Sites#886, Medford, Oregon, United States|Almirall Investigational Sites#910, Charleston, South Carolina, United States|Almirall Investigational Sites#918, Greer, South Carolina, United States|Almirall Investigational Sites#898, Dallas, Texas, United States|Almirall Investigational Sites#854, Fort Worth, Texas, United States|Almirall Investigational Sites#875, Houston, Texas, United States|Almirall Investigational Sites#881, San Antonio, Texas, United States|Almirall Investigational Sites#951, Richmond, Virginia, United States|Almirall Investigational Sites#856, Milwaukee, Wisconsin, United States|Almirall Investigational Sites#800, Buenos Aires, Argentina|Almirall Investigational Sites#744, Buenos Aires, Argentina|Almirall Investigational Sites#792, Buenos Aires, Argentina|Almirall Investigational Sites#793, Buenos Aires, Argentina|Almirall Investigational Sites#799, Buenos Aires, Argentina|Almirall Investigational Sites#795, Buenos Aires, Argentina|Almirall Investigational Sites#801, Buenos Aires, Argentina|Almirall Investigational Sites#791, Buenos Aires, Argentina|Almirall Investigational Sites#797, El Palomar, Argentina|Almirall Investigational Sites#740, La Plata, Argentina|Almirall Investigational Sites#801, Rosario, Argentina|Almirall Investigational Sites#796, San Miguel de Tucuman, Argentina|Almirall Investigational Sites#794, Vicente López, Argentina|Almirall Investigational Sites#807, Adelaide, Australia|Almirall Investigational Sites#834, Auchenflower, Australia|Almirall Investigational Sites#808, Bankstown, Australia|Almirall Investigational Sites#806, Boxhill, Australia|Almirall Investigational Sites#814, Cairns, Australia|Almirall Investigational Sites#813, Camperdown, Australia|Almirall Investigational Sites#811, Carina Heights, Australia|Almirall Investigational Sites#803, Clayton, Australia|Almirall Investigational Sites#809, Kippa Ring, Australia|Almirall Investigational Sites#8121, Nedlands, Australia|Almirall Investigational Sites#812, Nedlands, Australia|Almirall Investigational Sites#805, Toorak Gardens, Australia|Almirall Investigational Sites#815, Woodville, Australia|Almirall Investigational Sites#823, Edmonton, Canada|Almirall Investigational Sites#818, Kelowna, Canada|Almirall Investigational Sites#822, Montreal, Canada|Almirall Investigational Sites#817, Niagara Falls, Canada|Almirall Investigational Sites#821, Ottawa, Canada|Almirall Investigational Sites#935, Ottawa, Canada|Almirall Investigational Sites#820, Toronto, Ontario, Canada|Almirall Investigational Sites#827, Monterrey, Mexico|Almirall Investigational Sites#826, Zapopan, Mexico|Almirall Investigational Sites#936, Auckland, New Zealand|Almirall Investigational Sites#830, Grafton, New Zealand|Almirall Investigational Sites#832, Tauranga, New Zealand|Almirall Investigational Sites#833, Amanzimtoti, South Africa|Almirall Investigational Sites#836, Bloemfontain, South Africa|Almirall Investigational Sites#841, Bloemfontein, South Africa|Almirall Investigational Sites#839, Cape Town, South Africa|Almirall Investigational Sites#835, Cape Town, South Africa|Almirall Investigational Sites#837, Cape Town, South Africa|Almirall Investigational Sites#840, Cape Town, South Africa|Almirall Investigational Sites#834, Durban, South Africa|Almirall Investigational Sites#838, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT00358436"
228,"NCT00357734","Iressa Follow-up Trial",,"Completed","Has Results","Lung Cancer|Breast Cancer","Drug: Gefitinib","Number of Serious Adverse Events (SAEs)|Number of Serious Adverse Events (SAEs) Related to ZD1839|Number of Other Adverse Events (AEs)|Number of Other Adverse Events (AEs) Related to ZD1839|Progression-free Survival (PFS)|Overall Survival (OS)","AstraZeneca","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1839IL/0555|D7913L00008","January 2005","May 2015","May 2015","July 27, 2006","June 23, 2016","August 30, 2016","Research Site, Freiburg, Germany|Research Site, Gauting, Germany|Research Site, Großhansdorf, Germany|Research Site, Hemer, Germany|Research Site, Jena, Germany|Research Site, Minden, Germany|Research Site, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT00357734"
229,"NCT00355615","PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin",,"Completed","Has Results","Familial Hypercholesterolemia","Drug: Rosuvastatin|Drug: Placebo","Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase|Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)|Percent Control Rate Based on Achievement of LDL-C Target of <110 mg/dL During Double-blind Dose Treatment|Percent Change in HDL-C|Percent Change in Non-HDL-C at 12 Weeks|Percent Change in Triglycerides (TG)|Percent Change in Total Cholesterol (TC)|Percent Change in Apolipoprotein A-1 (ApoA-1)|Percent Change in Apolipoprotein B (ApoB)|Percent Change in ApoB/ApoA-1|Percent Change in LDL-C/HDL-C|Percent Change in TC/HDL-C|Percent Change in Non-HDL-C/HDL-C","AstraZeneca","All","10 Years to 17 Years   (Child)","Phase 3","173","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D3561C00087|PLUTO","July 2006","July 2008","July 2008","July 24, 2006","July 20, 2009","August 31, 2011","Research Site, Los Angeles, California, United States|Research Site, Hyde Park, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Wexford, Pennsylvania, United States|Research Site, Hamilton, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Sherbrook, Quebec, Canada|Research SIte, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Hoorn, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Utrecht, Netherlands|Research SIte, Waalwijk, Netherlands|Research Site, Oslo, Norway|Research Site, Cordoba, Spain|Research Site, Madrid, Spain|Research Site, Reus, Spain",,"https://ClinicalTrials.gov/show/NCT00355615"
230,"NCT00327015","A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise",,"Completed","Has Results","Diabetes","Drug: Saxagliptin|Drug: Metformin|Drug: Placebo|Drug: pioglitazone","Change From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy|Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy|Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy|Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy|Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy|Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy|Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy|Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy|Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy|Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy","AstraZeneca","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","1306","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV181-039","May 2006","November 2007","December 2008","May 17, 2006","September 25, 2009","April 29, 2015","East Bay Clinical Trial Center, Concord, California, United States|Encompass Clinical Research, Encinitas, California, United States|Community Clinical Trials, Orange, California, United States|Coastal Biomedical Research Inc, Santa Monica, California, United States|Encompass Clinical Research, Spring Valley, California, United States|St. Joseph'S Medical Associates, Stockton, California, United States|Clinical Therapeutics Corporation, Coral Gables, Florida, United States|Florida Research Network, Llc, Gainesville, Florida, United States|Fpa Clinical Research, Kissimmee, Florida, United States|Emerald Coast Research Group, Marianna, Florida, United States|Baptist Diabetes Associates, Miami, Florida, United States|Middle Georgia Drug Study Center, Llc, Perry, Georgia, United States|Cedar Crosse Research Center, Chicago, Illinois, United States|Adviso Medical Research, Llc, Chicago, Illinois, United States|Deerbrook Medical Associates, Vernon Hills, Illinois, United States|Physicians Research Group, Indianapolis, Indiana, United States|Professional Network Research Of Kansas, Wichita, Kansas, United States|Medical Arts Research Collaborative, Llc, Excelsior Springs, Missouri, United States|Nevada Alliance Against Diabetes, N. Las Vegas, Nevada, United States|Metrolina Medical Research, Charlotte, North Carolina, United States|Durham Internal Medicine Assoc., Durham, North Carolina, United States|Down East Medical Associates, Morehead City, North Carolina, United States|Midwest Regional Research, Inc., Bellbrook, Ohio, United States|Massillon Family Practice, Massillon, Ohio, United States|Your Diabetes Endocrine Nutrition Group, Mentor, Ohio, United States|Newark Physician Associates, Newark, Ohio, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Safe Harbor Clinical Research, E. Providence, Rhode Island, United States|Internal Medicine Of Greer, Greer, South Carolina, United States|Middle Tennessee Clinical Research, Fayetteville, Tennessee, United States|Frontier Clinical Research, Llc., Memphis, Tennessee, United States|Capital Medical Clinic, Llp, Austin, Texas, United States|Endocrine Associates, Houston, Texas, United States|Advances In Health,Inc, Houston, Texas, United States|Juno Research, Llc, Houston, Texas, United States|Non Invasive Cardiovascular Pa, Houston, Texas, United States|Tiena Health Research, Irving, Texas, United States|Diabetes Center Of The Southwest, Midland, Texas, United States|Hill Country Medical Associates, New Braunfels, Texas, United States|Pearland Primary Care Associates, Llp, Pearland, Texas, United States|Med-Cure Primary Care Physicians, Rosenberg, Texas, United States|Gsa Research, San Antonio, Texas, United States|Covenant Clinical Research, Pa, San Antonio, Texas, United States|S.A.M. Clinical Research Center, San Antonio, Texas, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|Salem Va Medical Ctr Research & Devlopment, Salem, Virginia, United States|Physicians Clinic Of Spokane, Spokane, Washington, United States|Local Institution, Belgrano, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Chacabuco, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Moron, Buenos Aires, Argentina|Local Institution, San Martin, Buenos Aires, Argentina|Local Institution, San Pedro, Buenos Aires, Argentina|Local Institution, Zarate, Buenos Aires, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Lanus Este, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Mendoza, Argentina|Local Institution, Salta, Argentina|Local Institution, Salta, Argentina|Local Institution, San Juan, Argentina|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Goiania, Goias, Brazil|Local Institution, Belem, Para, Brazil|Local Institution, Recife, Pe, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Campinas, Sao Paulo, Brazil|Local Institution, Marília, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Aschaffenburg, Germany|Local Institution, Bad, Germany|Local Institution, Dresden, Germany|Local Institution, Dresden, Germany|Local Institution, Duisburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kuenzing, Germany|Local Institution, Ludwigshafen, Germany|Local Institution, Magdeburg, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Saarbrücken, Germany|Local Institution, Vellmar, Germany|Local Institution, Wangen Im Allgau, Germany|Local Institution, Eger, Hungary|Local Institution, Gyula, Hungary|Local Institution, Szentes, Hungary|Local Institution, Szigetvár, Hungary|Local Institution, Érd, Hungary|Local Institution, Panjagutta, Hyderabad, Andhra Pradesh, India|Local Institution, Vasanth Nagar, Bangalore, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Pune, Maharashtra, India|Local Institution, Kandivili West, Mumbai, India|Local Institution, Sarita Vihar, New Delhi, India|Local Institution, Chennai, Tamil Nadu, India|Local Institution, Bangalore, India|Local Institution, Chennai, India|Local Institution, Haryana, India|Local Institution, Rajasthan, India|Local Institution, Rajasthan, India|Local Institution, Vellore, Tamilnadu, India|Local Institution, Catania, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, Garza Garcia, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Cebu City, Philippines|Local Institution, Iloilo City, Philippines|Local Institution, Manila City, Philippines|Local Institution, Marikina City, Philippines|Local Institution, Pasig City, Philippines|Local Institution, Quezon City, Philippines|Local Institution, Gniewkowo, Poland|Local Institution, Gorzow Wielkopolski, Poland|Local Institution, Izabelin, Poland|Local Institution, Krakow, Poland|Local Institution, Lublin, Poland|Local Institution, Michalow-Regionow, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Zabrze, Poland|Local Institution, Carolina, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Rio Pieoras, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Kemerovo, Russia, Russian Federation|Local Institution, Moscow, Russia, Russian Federation|Local Institution, Moscow, Russia, Russian Federation|Local Institution, Moscow, Russia, Russian Federation|Local Institution, Nizhniy Novgorod, Russia, Russian Federation|Local Institution, Izhevsk, Russian Federation|Local Institution, Kirov, Russian Federation|Local Institution, Krasnodar, Russian Federation|Local Institution, Krasnodar, Russian Federation|Local Institution, Kursk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, Perm, Russian Federation|Local Institution, Rostov-Na-Donu, Russian Federation|Local Institution, Rostov-Na-Donu, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Smolensk, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St-Petersburg, Russian Federation|Local Institution, St. Peterburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, Tuymen, Russian Federation|Local Institution, Vladimir, Russian Federation|Local Institution, Volgograd, Russian Federation|Local Institution, Volgograd, Russian Federation|Local Institution, Yaroslaval, Russian Federation|Local Institution, Yaroslavl, Russian Federation|Local Institution, Dniepropetrovsk, Ukraine|Local Institution, Kharkiv, Ukraine|Local Institution, Kharkiv, Ukraine|Local Institution, Kyiv, Ukraine|Local Institution, Kyiv, Ukraine|Local Institution, Lutsk, Ukraine|Local Institution, Lviv, Ukraine|Local Institution, Lviv, Ukraine|Local Institution, Odessa, Ukraine|Local Institution, Ternopil, Ukraine",,"https://ClinicalTrials.gov/show/NCT00327015"
231,"NCT00322452","First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia","IPASS","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Gefitinib|Drug: Carboplatin|Drug: Paclitaxel","Median Progression Free Survival (PFS) in Months|Median Overall Survival (OS) in Months at OS Data Cut Off (14th June 2010)|Objective Tumour Response Rate According to RECIST|Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Neutropenia|Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Thrombocytopenia|Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Leukopenia|Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Anaemia|Neurotoxicity|Rashes/Acnes|Diarrhoea|Nausea|Vomiting|Common Toxicity Criteria (CTC) Grade 3, 4, or 5 Liver Transaminases|Quality of Life (QoL) as Measured by the Total Score of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire|Quality of Life (QoL) as Measured by the Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) Questionnaire|Symptom Improvement as Measured by the Lung Cancer Subscale (LCS) of the FACT-L Questionnaire","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","1329","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D791AC00007|Iressa Pan Asian Study (IPASS)","March 2006","April 2008","June 2010","May 8, 2006","May 17, 2010","November 7, 2013","Research Site, Fuzhou, Fujian, China|Research Site, Guangzhou, Guangdong, China|Research Site, Wuhan, Hubei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Dalian, Liaoning, China|Research Site, Chongqing, Sichuan, China|Research Site, Beijing, China|Research Site, Chengdu, China|Research Site, Hangzhou, China|Research Site, Shanghai, China|Research Site, Hong Kong, Hong Kong|Research Site, Semarang, Central Java, Indonesia|Research Site, Malang, East Java, Indonesia|Research Site, Jakarta, Indonesia|Research Site, Solo, Indonesia|Research Site, Surabaya, Indonesia|Research Site, Yogyakarta, Indonesia|Research Site, Nagoya, Aichi, Japan|Research Site, Okazaki, Aichi, Japan|Research Site, Kashiwa, Chiba, Japan|Research Site, Matsuyama, Ehime, Japan|Research Site, Sapporo, Hokkaido, Japan|Research Site, Akashi, Hyogo, Japan|Research Site, Kobe, Hyogo, Japan|Research Site, Kanazawa, Ishikawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Omura, Nagasaki, Japan|Research Site, Izumisano, Osaka, Japan|Research Site, Osakasayama, Osaka, Japan|Research Site, Sakai, Osaka, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Koto-ku, Tokyo, Japan|Research Site, Shinjuku, Tokyo, Japan|Research Site, Ube, Yamaguchi, Japan|Research Site, Fukuoka, Japan|Research Site, Kumamoto, Japan|Research Site, Okayama, Japan|Research Site, Osaka, Japan|Research Site, Kota Kinabalu, Sabah, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Nilai, Malaysia|Research Site, Penang, Malaysia|Research Site, Petaling Jaya, Malaysia|Research Site, Cebu City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Singapore, Singapore|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Songkla, Thailand",,"https://ClinicalTrials.gov/show/NCT00322452"
232,"NCT00316082","Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise",,"Completed","Has Results","Diabetes","Drug: Saxagliptin|Drug: Placebo|Drug: metformin","Change From Baseline in Hemoglobin A1 (A1C) at Week 24|Change From Baseline in A1C at Week 24 - Saxagliptin 5 mg QPM|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Percentage of Participants Achieving A1C < 7% at Week 24|Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24","AstraZeneca","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","365","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV181-038","June 2006","November 2007","November 2008","April 20, 2006","September 25, 2009","April 29, 2015","Tomac, Inc., Columbiana, Alabama, United States|Winston Technology, Inc., Haleyville, Alabama, United States|Clinical Reseacrh Advantage/ Brown Family Medicine, Mesa, Arizona, United States|Strategos Medical Group, Bakersfield, California, United States|Providence Clinical Research, Burbank, California, United States|Rx For Life, Inc, Cudahy, California, United States|Medical Group Of Encino, Encino, California, United States|Southland Clinical Research Center, Inc., Fountain Valley, California, United States|Valley Research, Fresno, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|In Private Prictice Clinic, Pico Rivera, California, United States|San Jose Clinical Research, Inc., San Jose, California, United States|Central Florida Clinical Trials, Inc., Altamonte Springs, Florida, United States|Accelovance, Melbourne, Florida, United States|University Family Healthcare, Pa, Sarasota, Florida, United States|Premier Healthcare, St. Petersburg, Florida, United States|Pinnacle Medical Research, Overland Park, Kansas, United States|Kansas City University Of Medicine And Biosciences, Kansas City, Missouri, United States|Primary Care Physicians, Pc, Wentzville, Missouri, United States|Physicians Research Center, Toms River, New Jersey, United States|Hudson Valley Clinical Research Center, Kingston, New York, United States|Neem Research Group Of Charlotte, Charlotte, North Carolina, United States|Diabetes Center- East Carolina University, Greenville, North Carolina, United States|Crescent Medical Research, Salisbury, North Carolina, United States|Community Health Care, Inc., Barberton, Ohio, United States|Clinical Research Limited, Canton, Ohio, United States|Wells Institute For Health Awareness, Kettering, Ohio, United States|Clinical Research Source, Inc, Perrysburg, Ohio, United States|Accelovance, Oklahoma City, Oklahoma, United States|Integris Family Care South, Oklahoma City, Oklahoma, United States|The Office Of Patricia Buchanan, Eugene, Oregon, United States|Cumberland Valley Endocrinology Center, Llc, Carlisle, Pennsylvania, United States|Fleetwood Clinical Research, Fleetwood, Pennsylvania, United States|Banksville Medical, Pc, Pittsburgh, Pennsylvania, United States|Biomedical Research Associates, Llc, Shippensburg, Pennsylvania, United States|Middle Tyger Family Medicine, Duncan, South Carolina, United States|Southeastern Research Assoc, Taylors, South Carolina, United States|Versoza & Ungab Internal Medicine Associates, Bartlett, Tennessee, United States|Collierville Medical Specialist, Collierville, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Med-South Research, Memphis, Tennessee, United States|Southwind Medical Specialist, Memphis, Tennessee, United States|Precision Family Medicine, Carrollton, Texas, United States|Alpha Therapy Research Center, Corpus Christi, Texas, United States|Village Family Practice, Houston, Texas, United States|Texas Center For Drug Development, P.A., Houston, Texas, United States|Abbott Clinical Research Group, Inc, San Antonio, Texas, United States|Taylor/Wade Medical, Bountiful, Utah, United States|Optimum Clinical Research, Salt Lake City, Utah, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Spokane Internal Medicine, Spokane, Washington, United States|Local Institution, Manipal, Karnataka, India|Local Institution, Kochi, Kerala, India|Local Institution, Attavar, Mangalore, India|Local Institution, Sarita Vihar, New Delhi, India|Local Institution, Bangalore, India|Local Institution, Mumbai, India|Local Institution, Mumbai, India|Local Institution, Nagpur, India|Local Institution, Moscov, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, Smolensk, Russian Federation|Local Institution, St.Petersburg, Russian Federation|Local Institution, Volgograd, Russian Federation|Local Institution, Changhua, Taiwan|Local Institution, Kaohsiung County, Taiwan|Local Institution, Taichung City, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Tao-Yuan County, Taiwan",,"https://ClinicalTrials.gov/show/NCT00316082"
233,"NCT00313313","A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas",,"Completed","Has Results","Diabetes","Drug: Saxagliptin|Drug: Glyburide|Drug: Placebo|Drug: Metformin","Change From Baseline in Hemoglobin A1c (A1C) at Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Percentage of Participants Achieving A1C < 7% at Week 24|Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24","AstraZeneca","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","768","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV181-040","April 2006","September 2007","September 2008","April 12, 2006","September 25, 2009","May 4, 2015","Reserach Solutions, Llc, Jonesboro, Arkansas, United States|Searcy Medical Center, Searcy, Arkansas, United States|Stewart Medical Group, Alhambra, California, United States|Southland Clinical Research Center, Inc., Fountain Valley, California, United States|Valley Research, Fresno, California, United States|Randall Shue, D.O., Los Angeles, California, United States|Clinical Trials Research, Roseville, California, United States|New West Physicians, Golden, Colorado, United States|Phoenix Internal Medicine Associates, Llc, Waterbury, Connecticut, United States|Christiana Care Research Institute, Newark, Delaware, United States|Central Florida Clinical Trials, Altamonte Springs, Florida, United States|Family Care Assoc & Emerald Care Res Grp, Chipley, Florida, United States|Clinical Therapeutics Corporation, Coral Gables, Florida, United States|Fpa Clinical Research, Kissimmee, Florida, United States|Emerald Coast Research Group, Marianna, Florida, United States|University Of Miami Diabetes Research Inst., Miami, Florida, United States|Atlanta Pharmaceutical Research Center, Inc, Dunwoody, Georgia, United States|Cedar-Crosse Research Ctr, Chicago, Illinois, United States|Family Medical Center Of Hart Co., Munfordville, Kentucky, United States|Columbia Medical Practice, Columbia, Maryland, United States|Va Medical Center, Kansas City, Missouri, United States|St. Louis Center For Clinical Research, St. Louis, Missouri, United States|Nevada Alliance Against Diabetes, North Las Vegas, Nevada, United States|Physicians Research Center, Toms River, New Jersey, United States|Cny Family Care, East Syracuse, New York, United States|Metrolina Internal Medicine, Charlotte, North Carolina, United States|Med Res Assoc Charlotte, Charlotte, North Carolina, United States|Regional Physicians Research, High Point, North Carolina, United States|Diabetes & Endocrinology Consultants, Pc, Morehead City, North Carolina, United States|Mountain Top Clinical Research Center, Sparta, North Carolina, United States|Daystar Clinical Research, Inc., Akron, Ohio, United States|Community Health Care, Canal Fulton, Ohio, United States|Triphase Research, Ltd., Franklin, Ohio, United States|Albert J Weisbrot,Md&Assoc Inc, Mason, Ohio, United States|Dr Bahagwan Dass Md, Youngstown, Ohio, United States|Oklahoma Cardiovascular And Hypertension Center, Oklahoma City, Oklahoma, United States|Utica Park Clinic, Tulsa, Oklahoma, United States|Integris Family Care Yukon, Yukon, Oklahoma, United States|Coordinators Plus, Llc, Eugene, Oregon, United States|Oregon Clinical Research, Portland, Oregon, United States|Pearl Clinical Research, Norristown, Pennsylvania, United States|Banksville Medical Pc, Pittsburgh, Pennsylvania, United States|Guthrie Clinic, Ltd, Sayre, Pennsylvania, United States|Upstate Pharmaceutical Research, Simsonville, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|Southeastern Research Assoc, Taylors, South Carolina, United States|Capital Medical Clinic, Llp, Austin, Texas, United States|Texas Center For Drug Development, P.A., Houston, Texas, United States|Breath Of Life Research Institute, Katy, Texas, United States|Diabetes & Glandular Disease Research Assoc, Pa, San Antonio, Texas, United States|S.A.M. Clinical Research Center, San Antonio, Texas, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Office Of Dr. Gray, Spokane, Washington, United States|Advanced Healthcare S.C., Milwaukee, Wisconsin, United States|Local Institution, Mar Del Plata, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, B. Rodolfo Teofilo, Ceara, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Belem, Para, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Campinas, Sao Paulo, Brazil|Local Institution, Marília, Sao Paulo, Brazil|Local Institution, Sao Paulo - Sp, Sao Paulo, Brazil|Local Institution, Vila Mariana, Sao Paulo, Brazil|Local Institution, Hong Kong, Hong Kong|Local Institution, Kowloon, Hong Kong|Local Institution, Givatayim, Israel|Local Institution, Haifa, Israel|Local Institution, Holon, Israel|Local Institution, Jerusalem, Israel|Local Institution, Rishon Le-Zion, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Zefat, Israel|Local Institution, Zerifin, Israel|Local Institution, Kyunggi-Do, Korea, Republic of|Local Institution, Kyunggi-Do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Suwon, Korea, Republic of|Local Institution, Tijuana, B.C., Baja California, Mexico|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Durango, Mexico|Local Institution, San Isidro, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Cebu, Philippines|Local Institution, Manila, Philippines|Local Institution, Quezon, Philippines|Local Institution, Carolina, Puerto Rico|Local Institution, Guaynabo, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Singapore, Singapore|Local Institution, Umhlanga Rocks, Kwa Zulu Natal, South Africa|Local Institution, Kimberley, Northern Cape, South Africa|Local Institution, Tygerberg, Western Cape, South Africa|Local Institution, Cape Town, South Africa|Local Institution, Johannesburg, South Africa|Local Institution, Changhua, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00313313"
234,"NCT00313209","Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)","EOS","Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Roflumilast|Drug: Placebo","Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)|Post-bronchodilator FEV1|COPD Exacerbation Rate (Mild, Moderate or Severe)|Transition Dyspnea Index (TDI) Focal Score|Shortness of Breath Questionnaire (SOBQ) Total Score","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","933","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BY217/M2-127|2005-005080-28","April 2006","July 2007","February 2008","April 12, 2006","May 19, 2011","December 14, 2016","Altana Pharma/Nycomed Investigational Site, Linz, Austria|Altana Pharma/Nycomed Investigational Site, Neusiedl/See, Austria|Altana Pharma/Nycomed Investigational Site, Perg, Austria|Altana Pharma/Nycomed Investigational Site, Salzburg, Austria|Altana Pharma/Nycomed Investigational Site, St. Pölten, Austria|Altana Pharma/Nycomed Investigational Site, Steyr, Austria|Altana Pharma/Nycomed Investigational Site, Wiener Neustadt, Austria|Altana Pharma/Nycomed Investigational Site, Wien, Austria|Altana Pharma/Nycomed Investigational Site, Wien, Austria|Altana Pharma/Nycomed Investigational Site, Wien, Austria|Altana Pharma/Nycomed Investigational Site, Zwettl, Austria|Altana Pharma/Nycomed Investigational Site, Arlon, Belgium|Altana Pharma/Nycomed Investigational Site, Bruxelles, Belgium|Altana Pharma/Nycomed Investigational Site, Bruxelles, Belgium|Altana Pharma/Nycomed Investigational Site, Duffel, Belgium|Altana Pharma/Nycomed Investigational Site, Genk, Belgium|Altana Pharma/Nycomed Investigational Site, Gilly, Belgium|Altana Pharma/Nycomed Investigational Site, Halen, Belgium|Altana Pharma/Nycomed Investigational Site, Jette, Belgium|Altana Pharma/Nycomed Investigational Site, Leuven, Belgium|Altana Pharma/Nycomed Investigational Site, Liège, Belgium|Altana Pharma/Nycomed Investigational Site, Malmedy, Belgium|Altana Pharma/Nycomed Investigational Site, Montigny-Le-Tilleul, Belgium|Altana Pharma/Nycomed Investigational Site, Namur, Belgium|Altana Pharma/Nycomed Investigational Site, Veurne, Belgium|Altana Pharma/Nycomed Investigational Site, Ajax, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Halifax, N.S., Canada|Altana Pharma/Nycomed Investigational Site, Hamilton, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Hamilton, Canada|Altana Pharma/Nycomed Investigational Site, Laval, Canada|Altana Pharma/Nycomed Investigational Site, London, Canada|Altana Pharma/Nycomed Investigational Site, Mirabel, Canada|Altana Pharma/Nycomed Investigational Site, Montreal, PQ, Canada|Altana Pharma/Nycomed Investigational Site, Montreal, Canada|Altana Pharma/Nycomed Investigational Site, Montreal, Canada|Altana Pharma/Nycomed Investigational Site, New Market, ON, Canada|Altana Pharma/Nycomed Investigational Site, North Bay, Canada|Altana Pharma/Nycomed Investigational Site, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Ottawa, Canada|Altana Pharma/Nycomed Investigational Site, Quebec City, Canada|Altana Pharma/Nycomed Investigational Site, Regina, Saskatchewan, Canada|Altana Pharma/Nycomed Investigational Site, Saint John, Canada|Altana Pharma/Nycomed Investigational Site, Sainte-Foy, Quebec, Canada|Altana Pharma/Nycomed Investigational Site, Saskatoon SK, Canada|Altana Pharma/Nycomed Investigational Site, Sherbrooke, PQ, Canada|Altana Pharma/Nycomed Investigational Site, Toronto, ON, Canada|Altana Pharma/Nycomed Investigational Site, Toronto, ON, Canada|Altana Pharma/Nycomed Investigational Site, Vancouver, BC, Canada|Altana Pharma/Nycomed Investigational Site, Windsor, Canada|Altana Pharma/Nycomed Investigational Site, Winnipeg MB, Canada|Altana Pharma/Nycomed Investigational Site, Woodstock, Canada|Altana Pharma/Nycomed Investigational Site, Beausoleil, France|Altana Pharma/Nycomed Investigational Site, Beuvry, France|Altana Pharma/Nycomed Investigational Site, Chauny Cedex, France|Altana Pharma/Nycomed Investigational Site, Grasse, France|Altana Pharma/Nycomed Investigational Site, Grenoble, France|Altana Pharma/Nycomed Investigational Site, Lille Cedex, France|Altana Pharma/Nycomed Investigational Site, Lyon, France|Altana Pharma/Nycomed Investigational Site, Martigues Cedex, France|Altana Pharma/Nycomed Investigational Site, Montpellier Cedex, France|Altana Pharma/Nycomed Investigational Site, Nantes, France|Altana Pharma/Nycomed Investigational Site, Nice Cedex 1, France|Altana Pharma/Nycomed Investigational Site, Nice, France|Altana Pharma/Nycomed Investigational Site, Nimes, France|Altana Pharma/Nycomed Investigational Site, Saint Laurent Du Var, France|Altana Pharma/Nycomed Investigational Site, Saint-Quentin, France|Altana Pharma/Nycomed Investigational Site, Trelaze, France|Altana Pharma/Nycomed Investigational Site, Aschaffenburg, Germany|Altana Pharma/Nycomed Investigational Site, Bochum, Germany|Altana Pharma/Nycomed Investigational Site, Bonn, Germany|Altana Pharma/Nycomed Investigational Site, Geesthacht, Germany|Altana Pharma/Nycomed Investigational Site, Gelnhausen, Germany|Altana Pharma/Nycomed Investigational Site, Großhansdorf, Germany|Altana Pharma/Nycomed Investigational Site, Hannover, Germany|Altana Pharma/Nycomed Investigational Site, Koblenz, Germany|Altana Pharma/Nycomed Investigational Site, Köln, Germany|Altana Pharma/Nycomed Investigational Site, Marburg, Germany|Altana Pharma/Nycomed Investigational Site, Saarbruecken, Germany|Altana Pharma/Nycomed Investigational Site, Schwetzingen, Germany|Altana Pharma/Nycomed Investigational Site, Sinsheim, Germany|Altana Pharma/Nycomed Investigational Site, Surwold, Germany|Altana Pharma/Nycomed Investigational Site, Witten, Germany|Altana Pharma/Nycomed Investigational Site, Würzburg, Germany|Altana Pharma/Nycomed Investigational Site, Bari, Italy|Altana Pharma/Nycomed Investigational Site, Bologna, Italy|Altana Pharma/Nycomed Investigational Site, Catania, Italy|Altana Pharma/Nycomed Investigational Site, Cisanello (PI), Italy|Altana Pharma/Nycomed Investigational Site, Genova, Italy|Altana Pharma/Nycomed Investigational Site, Livorno, Italy|Altana Pharma/Nycomed Investigational Site, Milano, Italy|Altana Pharma/Nycomed Investigational Site, Pordenone, Italy|Altana Pharma/Nycomed Investigational Site, Roma, Italy|Altana Pharma/Nycomed Investigational Site, Saluzzo (CN), Italy|Altana Pharma/Nycomed Investigational Site, Torino, Italy|Altana Pharma/Nycomed Investigational Site, Tradate (VA), Italy|Altana Pharma/Nycomed Investigational Site, Verona, Italy|Altana Pharma/Nycomed Investigational Site, Vittorio Veneto (TV), Italy|Altana Pharma/Nycomed Investigational Site, Alkmaar, Netherlands|Altana Pharma/Nycomed Investigational Site, Almelo, Netherlands|Altana Pharma/Nycomed Investigational Site, Eindhoven, Netherlands|Altana Pharma/Nycomed Investigational Site, Helmond, Netherlands|Altana Pharma/Nycomed Investigational Site, Schiedam, Netherlands|Altana Pharma/Nycomed Investigational Site, Zwolle, Netherlands|Altana Pharma/Nycomed Investigational Sites, Kapstadt, South Africa|Altana Pharma/Nycomed Investigational Site, Alicante, Spain|Altana Pharma/Nycomed Investigational Site, Barcelona, Spain|Altana Pharma/Nycomed Investigational Site, Barcelona, Spain|Altana Pharma/Nycomed Investigational Site, Barcelona, Spain|Altana Pharma/Nycomed Investigational Site, Barcelona, Spain|Altana Pharma/Nycomed Investigational Site, Elche (Alicante), Spain|Altana Pharma/Nycomed Investigational Site, Fuentesnuevas, Ponferrada (León), Spain|Altana Pharma/Nycomed Investigational Site, Guadalajara, Spain|Altana Pharma/Nycomed Investigational Site, Laredo (Cantabria), Spain|Altana Pharma/Nycomed Investigational Site, Mataró, Barcelona, Spain|Altana Pharma/Nycomed Investigational Site, Petrer (Alicante), Spain|Altana Pharma/Nycomed Investigational Site, Sabadell, Spain|Altana Pharma/Nycomed Investigational Site, Tarrasa (Barcelona), Spain|Altana Pharma/Nycomed Investigational Site, Torrelavega (Cantabria), Spain|Altana Pharma/Nycomed Investigational Site, Belfast, United Kingdom|Altana Pharma/Nycomed Investigational Site, Belfast, United Kingdom|Altana Pharma/Nycomed Investigational Site, Belfast, United Kingdom|Altana Pharma/Nycomed Investigational Site, Bexhill-on-Sea, East Sussex, United Kingdom|Altana Pharma/Nycomed Investigational Site, Bradford on Avon, Wiltshire, United Kingdom|Altana Pharma/Nycomed Investigational Site, Bradford, United Kingdom|Altana Pharma/Nycomed Investigational Site, Chesterfield Derbyshire, United Kingdom|Altana Pharma/Nycomed Investigational Site, Coleraine, United Kingdom|Altana Pharma/Nycomed Investigational Site, Cookstown, United Kingdom|Altana Pharma/Nycomed Investigational Site, East Sussex, United Kingdom|Altana Pharma/Nycomed Investigational Site, Edinburg, United Kingdom|Altana Pharma/Nycomed Investigational Site, Glasgow, United Kingdom|Altana Pharma/Nycomed Investigational Site, Hastings, United Kingdom|Altana Pharma/Nycomed Investigational Site, Middlessex, United Kingdom|Altana Pharma/Nycomed Investigational Site, Sunbury on Thames, Middlessex, United Kingdom|Altana Pharma/Nycomed Investigational Site, Watford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00313209"
235,"NCT00308139","Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide, long acting release|Drug: exenatide","Change in HbA1c From Baseline to Week 30|Sub-study Relative Bioavailability of Exenatide When Administered Using the Exenatide Once Weekly Dual Chambered Pen and the Exenatide Once Weekly Single Dose Tray (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose)|Change in HbA1c From Baseline to Week 364|Percentage of Subjects Achieving HbA1c Target of <7%|Percentage of Subjects Achieving HbA1c Target of <=6.5%|Percentage of Subjects Achieving HbA1c Target of <=6.0%|Exenatide LAR Steady State Concentration From Week 29 to Week 30|Change in 2 Hours (2h) Postprandial Glucose From Baseline to Week 14|Sub-study Safety and Tolerability of Exenatide When Administered Using the Once Weekly Single Dose Tray and the Once Weekly Dual (Single Dose Tray-11 Weekly Doses Switch to Dual Chamber Pen-11 Weekly Dose)|Change in Body Weight From Baseline to Week 30|Change in Body Weight From Baseline to Week 364|Change in Fasting Plasma Glucose From Baseline to Week 30|Change in Fasting Plasma Glucose From Baseline to Week 364|Change in Blood Pressure From Baseline to Week 30|Change in Blood Pressure From Baseline to Week 364|Change in Total Cholesterol From Baseline to Week 30|Change in Total Cholesterol From Baseline to Week 364|Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 30|Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 364|Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 364|Ratio of Triglycerides at Week 30 to Baseline|Ratio of Triglycerides at Week 364 to Baseline|Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With SU Use at Screening|Assessment on Event Rate of Treatment-emergent Hypoglycemic Events With Non-SU Use at Screening","AstraZeneca","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","303","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2993LAR-105 (DURATION - 1)|MB001-010","April 2006","July 2008","August 2014","March 29, 2006","August 17, 2012","August 26, 2015","Research Site 182, Encino, California, United States|Research Site 171, La Jolla, California, United States|Research Site 518, San Diego, California, United States|Research Site 024, Walnut Creek, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site 057, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site 149, Indianapolis, Indiana, United States|Research Site 099, Lexington, Kentucky, United States|Research Site 017, Detroit, Michigan, United States|Research Site 224, Minneapolis, Minnesota, United States|Research Site 312, St. Louis, Missouri, United States|Research Site 023, Butte, Montana, United States|Research Site 053, Rochester, New York, United States|Research Site 002, Durham, North Carolina, United States|Research Site 123, Winston-Salem, North Carolina, United States|Research Site 405, Cincinnati, Ohio, United States|Research Site 557, Marion, Ohio, United States|Research Site 231, Portland, Oregon, United States|Research Site 152, Philadelphia, Pennsylvania, United States|Research Site 587, Greer, South Carolina, United States|Research Site 015, Dallas, Texas, United States|Research Site 009, San Antonio, Texas, United States|Research Site 108, Olympia, Washington, United States|Research Site, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00308139"
236,"NCT00306163","Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)",,"Completed","Has Results","Asthma","Drug: Ciclesonide|Drug: Fluticasone","PC20 AMP (Post-treatment Compared to Baseline)|Δ (FVC/SVC) at PC20 (AMP)|Safety and Tolerability","AstraZeneca","All","18 Years to 60 Years   (Adult)","Phase 3","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BY9010/NL-101","May 2006","August 2008","September 2008","March 23, 2006","April 26, 2010","February 1, 2017","Altana Pharma/Nycomed, RB Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT00306163"
237,"NCT00297115","Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Roflumilast|Drug: Placebo","Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)|COPD Exacerbation Rate (Moderate or Severe)|Post-bronchodilator FEV1 [L]|Time to Mortality Due to Any Reason|Natural Log-transformed C-reactive Protein (CRP)|Mean Transition Dyspnea Index (TDI) Focal Score During the Treatment Period","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","1568","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BY217/M2-125","March 2006","April 2008","August 2008","February 28, 2006","May 19, 2011","November 6, 2016","Altana Pharma/Nycomed Investigational Site, Bayou La Batre, Alabama, United States|Altana Pharma/Nycomed Investigational Site, Birmingham, Alabama, United States|Altana Pharma/Nycomed Investigational Site, Birmingham, Alabama, United States|Altana Pharma/Nycomed Investigational Site, Huntsville, Alabama, United States|Altana Pharma/Nycomed Investigational Site, Bullhead City, Arizona, United States|Altana Pharma/Nycomed Investigational Site, Phoenix, Arizona, United States|Altana Pharma/Nycomed Investigational Site, Phoenix, Arizona, United States|Altana Pharma/Nycomed Investigational Site, Fort Smith, Arkansas, United States|Altana Pharma/Nycomed Investigational Site, Little Rock, Arkansas, United States|Altana Pharma/Nycomed Investigational Site, Anaheim, California, United States|Altana Pharma/Nycomed Investigational Site, Burbank, California, United States|Altana Pharma/Nycomed Investigational Site, Carlsbad, California, United States|Altana Pharma/Nycomed Investigational Site, Fresno, California, United States|Altana Pharma/Nycomed Investigational Site, Lakewood, California, United States|Altana Pharma/Nycomed Investigational Site, Long Beach, California, United States|Altana Pharma/Nycomed Investigational Site, Los Alamitos, California, United States|Altana Pharma/Nycomed Investigational Site, Los Angeles, California, United States|Altana Pharma/Nycomed Investigational Site, Roseville, California, United States|Altana Pharma/Nycomed Investigational Site, Sacramento, California, United States|Altana Pharma/Nycomed Investigational Site, San Diego, California, United States|Altana Pharma/Nycomed Investigational Site, San Diego, California, United States|Altana Pharma/Nycomed Investigational Site, Sepulveda, California, United States|Altana Pharma/Nycomed Investigational Site, Stockton, California, United States|Altana Pharma/Nycomed Investigational Site, Denver, Colorado, United States|Altana Pharma/Nycomed Investigational Site, Waterbury, Connecticut, United States|Altana Pharma/Nycomed Investigational Site, Washington, District of Columbia, United States|Altana Pharma/Nycomed Investigational Site, Clearwater, Florida, United States|Altana Pharma/Nycomed Investigational Site, Deland, Florida, United States|Altana Pharma/Nycomed Investigational Site, Fort Lauderdale, Florida, United States|Altana Pharma/Nycomed Investigational Site, Jacksonville, Florida, United States|Altana Pharma/Nycomed Investigational Site, Miami Beach, Florida, United States|Altana Pharma/Nycomed Investigational Site, Miami, Florida, United States|Altana Pharma/Nycomed Investigational Site, Miami, Florida, United States|Altana Pharma/Nycomed Investigational Site, Ocala, Florida, United States|Altana Pharma/Nycomed Investigational Site, Ormand Beach, Florida, United States|Altana Pharma/Nycomed Investigational Site, Port Orange, Florida, United States|Altana Pharma/Nycomed Investigational Site, Tamarac, Florida, United States|Altana Pharma/Nycomed Investigational Site, Vero Beach, Florida, United States|Altana Pharma/Nycomed Investigational Site, Atlanta, Georgia, United States|Altana Pharma/Nycomed Investigational Site, Blue Ridge, Georgia, United States|Altana Pharma/Nycomed Investigational Site, Columbus, Georgia, United States|Altana Pharma/Nycomed Investigational Site, Decatur, Georgia, United States|Altana Pharma/Nycomed Investigational Site, Ft. Gordon, Georgia, United States|Altana Pharma/Nycomed Investigational Site, Marietta, Georgia, United States|Altana Pharma/Nycomed Investigational Site, Rincon, Georgia, United States|Altana Pharma/Nycomed Investigational Site, Savannah, Georgia, United States|Altana Pharma/Nycomed Investigational Site, Twin Falls, Idaho, United States|Altana Pharma/Nycomed Investigational Site, Champaign, Illinois, United States|Altana Pharma/Nycomed Investigational Site, Chicago, Illinois, United States|Altana Pharma/Nycomed Investigational Site, Elk Grove Village, Illinois, United States|Altana Pharma/Nycomed Investigational Site, North Chicago, Illinois, United States|Altana Pharma/Nycomed Investigational Site, Peoria, Illinois, United States|Altana Pharma/Nycomed Investigational Site, River Forest, Illinois, United States|Altana Pharma/Nycomed Investigational Site, Elkhart, Indiana, United States|Altana Pharma/Nycomed Investigational Site, Indianapolis, Indiana, United States|Altana Pharma/Nycomed Investigational Site, Indianapolis, Indiana, United States|Altana Pharma/Nycomed Investigational Site, New Albany, Indiana, United States|Altana Pharma/Nycomed Investigational Site, Dubuque, Iowa, United States|Altana Pharma/Nycomed Investigational Site, Fort Dodge, Iowa, United States|Altana Pharma/Nycomed Investigational Site, Iowa City, Iowa, United States|Altana Pharma/Nycomed Investigational Site, Waterloo, Iowa, United States|Altana Pharma/Nycomed Investigational Site, Olathe, Kansas, United States|Altana Pharma/Nycomed Investigational Site, Topeka, Kansas, United States|Altana Pharma/Nycomed Investigational Site, Campbellsville, Kentucky, United States|Altana Pharma/Nycomed Investigational Site, Hazard, Kentucky, United States|Altana Pharma/Nycomed Investigational Site, Louisville, Kentucky, United States|Altana Pharma/Nycomed Investigational Site, Metairie, Louisiana, United States|Altana Pharma/Nycomed Investigational Site, West Monroe, Louisiana, United States|Altana Pharma/Nycomed Investigational Site, Columbia, Maryland, United States|Altana Pharma/Nycomed Investigational Site, Boston, Massachusetts, United States|Altana Pharma/Nycomed Investigational Site, Brighton, Michigan, United States|Altana Pharma/Nycomed Investigational Site, Interlochen, Michigan, United States|Altana Pharma/Nycomed Investigational Site, Livonia, Michigan, United States|Altana Pharma/Nycomed Investigational Site, Portage, Michigan, United States|Altana Pharma/Nycomed Investigational Site, Saginaw, Michigan, United States|Altana Pharma/Nycomed Investigational Site, Duluth, Minnesota, United States|Altana Pharma/Nycomed Investigational Site, Edina, Minnesota, United States|Altana Pharma/Nycomed Investigational Site, Minneapolis, Minnesota, United States|Altana Pharma/Nycomed Investigational Site, Rochester, Minnesota, United States|Altana Pharma/Nycomed Investigational Site, Chesterfield, Missouri, United States|Altana Pharma/Nycomed Investigational Site, Jefferson City, Missouri, United States|Altana Pharma/Nycomed Investigational Site, Kansas City (-1453), Missouri, United States|Altana Pharma/Nycomed Investigational Site, Kansas City, Missouri, United States|Altana Pharma/Nycomed Investigational Site, St. Louis, Missouri, United States|Altana Pharma/Nycomed Investigational Site, St. Louis, Missouri, United States|Altana Pharma/Nycomed Investigational Site, Sunset, Missouri, United States|Altana Pharma/Nycomed Investigational Site, Bozeman, Montana, United States|Altana Pharma/Nycomed Investigational Site, Butte, Montana, United States|Altana Pharma/Nycomed Investigational Site, Omaha, Nebraska, United States|Altana Pharma/Nycomed Investigational Site, Las Vegas, Nevada, United States|Altana Pharma/Nycomed Investigational Site, Las Vegas, Nevada, United States|Altana Pharma/Nycomed Investigational Site, Absecon, New Jersey, United States|Altana Pharma/Nycomed Investigational Site, Hamilton, New Jersey, United States|Altana Pharma/Nycomed Investigational Site, South Bound Brook, New Jersey, United States|Altana Pharma/Nycomed Investigational Site, Camillus, New York, United States|Altana Pharma/Nycomed Investigational Site, Corning, New York, United States|Altana Pharma/Nycomed Investigational Site, Cortland, New York, United States|Altana Pharma/Nycomed Investigational Site, New Hyde Park, New York, United States|Altana Pharma/Nycomed Investigational Site, New Hyde Park, New York, United States|Altana Pharma/Nycomed Investigational Site, Syracuse, New York, United States|Altana Pharma/Nycomed Investigational Site, Charlotte, North Carolina, United States|Altana Pharma/Nycomed Investigational Site, Huntersville, North Carolina, United States|Altana Pharma/Nycomed Investigational Site, Winston Salem, North Carolina, United States|Altana Pharma/Nycomed Investigational Site, Canton, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Cincinnati, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Columbus, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Sylvania, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Toledo, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Toledo, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Toledo, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Oklahoma City, Oklahoma, United States|Altana Pharma/Nycomed Investigational Site, Medford, Oregon, United States|Altana Pharma/Nycomed Investigational Site, Portland, Oregon, United States|Altana Pharma/Nycomed Investigational Site, Erie, Pennsylvania, United States|Altana Pharma/Nycomed Investigational Site, Hershey, Pennsylvania, United States|Altana Pharma/Nycomed Investigational Site, Philadelphia, Pennsylvania, United States|Altana Pharma/Nycomed Investigational Site, Philadelphia, Pennsylvania, United States|Altana Pharma/Nycomed Investigational Site, Pittsburgh, Pennsylvania, United States|Altana Pharma/Nycomed Investigational Site, Stoneboro, Pennsylvania, United States|Altana Pharma/Nycomed Investigational Site, Swarthmore, Pennsylvania, United States|Altana Pharma/Nycomed Investigational Site, Johnston, Rhode Island, United States|Altana Pharma/Nycomed Investigational Site, Charleston, South Carolina, United States|Altana Pharma/Nycomed Investigational Site, Greenville, South Carolina, United States|Altana Pharma/Nycomed Investigational Site, Greenville, South Carolina, United States|Altana Pharma/Nycomed Investigational Site, Greer, South Carolina, United States|Altana Pharma/Nycomed Investigational Site, Union, South Carolina, United States|Altana Pharma/Nycomed Investigational Site, Williamston, South Carolina, United States|Altana Pharma/Nycomed Investigational Site, Johnson City, Tennessee, United States|Altana Pharma/Nycomed Investigational Site, Knoxville, Tennessee, United States|Altana Pharma/Nycomed Investigational Site, Memphis, Tennessee, United States|Altana Pharma/Nycomed Investigational Site, Nashville, Tennessee, United States|Altana Pharma/Nycomed Investigational Site, New Tazewell, Tennessee, United States|Altana Pharma/Nycomed Investigational Site, Boerne, Texas, United States|Altana Pharma/Nycomed Investigational Site, Corsicana, Texas, United States|Altana Pharma/Nycomed Investigational Site, Fort Worth, Texas, United States|Altana Pharma/Nycomed Investigational Site, Houston, Texas, United States|Altana Pharma/Nycomed Investigational Site, Houston, Texas, United States|Altana Pharma/Nycomed Investigational Site, Hurst, Texas, United States|Altana Pharma/Nycomed Investigational Site, McKinney, Texas, United States|Altana Pharma/Nycomed Investigational Site, San Antonio, Texas, United States|Altana Pharma/Nycomed Investigational Site, San Antonio, Texas, United States|Altana Pharma/Nycomed Investigational Site, Seguin, Texas, United States|Altana Pharma/Nycomed Investigational Site, Tyler, Texas, United States|Altana Pharma/Nycomed Investigational Site, Salt Lake City, Utah, United States|Altana Pharma/Nycomed Investigational Site, Salt Lake City, Utah, United States|Altana Pharma/Nycomed Investigational Site, Lynchburg, Virginia, United States|Altana Pharma/Nycomed Investigational Site, Seattle, Washington, United States|Altana Pharma/Nycomed Investigational Site, Spokane, Washington, United States|Altana Pharma/Nycomed Investigational Site, Charleston, West Virginia, United States|Altana Pharma/Nycomed Investigational Site, Glendale, Wisconsin, United States|Altana Pharma/Nycomed Investigational Site, Glendale, Wisconsin, United States|Altana Pharma/Nycomed Investigational Site, Calgary, Alberta, Canada|Altana Pharma/Nycomed Investigational Site, Calgary, Alberta, Canada|Altana Pharma/Nycomed Investigational Site, Edmonton, Alberta, Canada|Altana Pharma/Nycomed Investigational Site, Spruce Grove, Alberta, Canada|Altana Pharma/Nycomed Investigational Site, Burnaby, British Columbia, Canada|Altana Pharma/Nycomed Investigational Site, Penticton, British Columbia, Canada|Altana Pharma/Nycomed Investigational Site, Vancouver, British Columbia, Canada|Altana Pharma/Nycomed Investigational Site, Truro, Nova Scotia, Canada|Altana Pharma/Nycomed Investigational Site, Chatham, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Hamilton, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, London, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Mississauga, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Ottawa, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Sarnia, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Scarborough, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Toronto, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Montreal, Quebec, Canada|Altana Pharma/Nycomed Investigational Site, Montreal, Quebec, Canada|Altana Pharma/Nycomed Investigational Site, Sainte-Foy, Quebec, Canada|Altana Pharma/Nycomed Investigational Site, Sherbrooke, Quebec, Canada|Altana Pharma/Nycomed Investigational Site, St. Romuald, Quebec, Canada|Altana Pharma/Nycomed Investigational Site, Ste-Foy, Quebec, Canada|Altana Pharma/Nycomed Investigational Site, Antigonish, Canada|Altana Pharma/Nycomed Investigational Site, Bridgewater, Canada|Altana Pharma/Nycomed Investigational Site, Calgary, Canada|Altana Pharma/Nycomed Investigational Site, Corunna, Canada|Altana Pharma/Nycomed Investigational Site, Edmonton, Canada|Altana Pharma/Nycomed Investigational Site, Fort Erie, Canada|Altana Pharma/Nycomed Investigational Site, Grimsby, Canada|Altana Pharma/Nycomed Investigational Site, Hamilton, Canada|Altana Pharma/Nycomed Investigational Site, Longueuil, Canada|Altana Pharma/Nycomed Investigational Site, Montreal, Canada|Altana Pharma/Nycomed Investigational Site, Ontario, Canada|Altana Pharma/Nycomed Investigational Site, Richmond Hill, Canada|Altana Pharma/Nycomed Investigational Site, Saint John, Canada|Altana Pharma/Nycomed Investigational Site, Sherbrooke, Canada|Altana Pharma/Nycomed Investigational Site, St Jerome, Canada|Altana Pharma/Nycomed Investigational Site, St Leonard, Canada|Altana Pharma/Nycomed Investigational Site, Toronto, Canada|Altana Pharma/Nycomed Investigational Site, Winnipeg, Canada|Altana Pharma/Nycomed Investigational Site, Berlin, Germany|Altana Pharma/Nycomed Investigational Site, Berlin, Germany|Altana Pharma/Nycomed Investigational Site, Berlin, Germany|Altana Pharma/Nycomed Investigational Site, Berlin, Germany|Altana Pharma/Nycomed Investigational Site, Berlin, Germany|Altana Pharma/Nycomed Investigational Site, Berlin, Germany|Altana Pharma/Nycomed Investigational Site, Berlin, Germany|Altana Pharma/Nycomed Investigational Site, Berlin, Germany|Altana Pharma/Nycomed Investigational Site, Donaustauf, Germany|Altana Pharma/Nycomed Investigational Site, Großhansdorf, Germany|Altana Pharma/Nycomed Investigational Site, Halle, Germany|Altana Pharma/Nycomed Investigational Site, Hamburg, Germany|Altana Pharma/Nycomed Investigational Site, Landsberg/Lech, Germany|Altana Pharma/Nycomed Investigational Site, Neuruppin, Germany|Altana Pharma/Nycomed Investigational Site, Oschersleben, Germany|Altana Pharma/Nycomed Investigational Site, Potsdam, Germany|Altana Pharma/Nycomed Investigational Site, Potsdam, Germany|Altana Pharma/Nycomed Investigational Site, Regensburg, Germany|Altana Pharma/Nycomed Investigational Site, Rüdersdorf, Germany|Altana Pharma/Nycomed Investigational Site, Ulm, Germany|Altana Pharma/Nycomed Investigational Site, Bangalore, Karnataka, India|Altana Pharma/Nycomed Investigational Site, Bangalore, India|Altana Pharma/Nycomed Investigational Site, Bangalore, India|Altana Pharma/Nycomed Investigational Site, Chennai, India|Altana Pharma/Nycomed Investigational Site, Coimbatore, Tamilnadu, India|Altana Pharma/Nycomed Investigational Site, Coimbatore, India|Altana Pharma/Nycomed Investigational Site, Coimbatore, India|Altana Pharma/Nycomed Investigational Site, Goa, India|Altana Pharma/Nycomed Investigational Site, Hyderabad, India|Altana Pharma/Nycomed Investigational Site, Indore, South Tukuganj, India|Altana Pharma/Nycomed Investigational Site, Mangalore, India|Altana Pharma/Nycomed Investigational Site, Mangalore, India|Altana Pharma/Nycomed Investigational Site, Mumbai, Byculla, India|Altana Pharma/Nycomed Investigational Site, Mumbai, Dadar (E), India|Altana Pharma/Nycomed Investigational Site, Mumbai, India|Altana Pharma/Nycomed Investigational Site, Mysore, India|Altana Pharma/Nycomed Investigational Site, Nagpur, India|Altana Pharma/Nycomed Investigational Site, Nagpur, India|Altana Pharma/Nycomed Investigational Site, Nagpur, India|Altana Pharma/Nycomed Investigational Site, Pune, India|Altana Pharma/Nycomed Investigational Site, Pune, India|Altana Pharma/Nycomed Investigational Site, Shastri Nagar, Jaipur, India|Altana Pharma/Nycomed Investigational Site, Bergamo, Italy|Altana Pharma/Nycomed Investigational Site, Bologna, Italy|Altana Pharma/Nycomed Investigational Site, Cassano Murge, Italy|Altana Pharma/Nycomed Investigational Site, Firenze, Italy|Altana Pharma/Nycomed Investigational Site, Milano, Italy|Altana Pharma/Nycomed Investigational Site, Parma, Italy|Altana Pharma/Nycomed Investigational Site, Pavia, Italy|Altana Pharma/Nycomed Investigational Site, Roma, Italy|Altana Pharma/Nycomed Investigational Site, Trieste, Italy|Altana Pharma/Nycomed Investigational Site, Verona, Italy|Altana Pharma/Nycomed Investigational Site, Veruno, Italy|Altana Pharma/Nycomed Investigational Site, Chrzanów, Poland|Altana Pharma/Nycomed Investigational Site, Czestochowa, Poland|Altana Pharma/Nycomed Investigational Site, Dzialdowo, Poland|Altana Pharma/Nycomed Investigational Site, Katowice, Poland|Altana Pharma/Nycomed Investigational Site, Kraków, Poland|Altana Pharma/Nycomed Investigational Site, Kraków, Poland|Altana Pharma/Nycomed Investigational Site, Lublin, Poland|Altana Pharma/Nycomed Investigational Site, Poznan, Poland|Altana Pharma/Nycomed Investigational Site, Warsawa, Poland|Altana Pharma/Nycomed Investigational Site, Warszawa, Poland|Altana Pharma/Nycomed Investigational Site, Wodzislaw Slaski, Poland|Altana Pharma/Nycomed Investigational Site, Zgierz, Poland|Altana Pharma/Nycomed Investigational Site, Bellville, Cape Town, South Africa|Altana Pharma/Nycomed Investigational Site, Berea, Durban, South Africa|Altana Pharma/Nycomed Investigational Site, Bloemfontein, South Africa|Altana Pharma/Nycomed Investigational Site, C/O Netcare & Garsfontein Roads, South Africa|Altana Pharma/Nycomed Investigational Site, Cape Town, Tygerberg, South Africa|Altana Pharma/Nycomed Investigational Site, Cape Town, South Africa|Altana Pharma/Nycomed Investigational Site, Cape Town, South Africa|Altana Pharma/Nycomed Investigational Site, Durban, Amanzimtoti, South Africa|Altana Pharma/Nycomed Investigational Site, Durbanville / Cape Town, South Africa|Altana Pharma/Nycomed Investigational Site, Mowbray, Cape Town, South Africa|Altana Pharma/Nycomed Investigational Site, Paarl, Cape Town, South Africa|Altana Pharma/Nycomed Investigational Site, Pretoria, South Africa|Altana Pharma/Nycomed Investigational Site, Somerset West, South Africa|Altana Pharma/Nycomed Investigational Site, Badajoz, Spain|Altana Pharma/Nycomed Investigational Site, Calde (Lugo), Spain|Altana Pharma/Nycomed Investigational Site, Cartagena, Spain|Altana Pharma/Nycomed Investigational Site, Elda, Spain|Altana Pharma/Nycomed Investigational Site, Getafe, Spain|Altana Pharma/Nycomed Investigational Site, Guadalajara, Spain|Altana Pharma/Nycomed Investigational Site, Madrid, Spain|Altana Pharma/Nycomed Investigational Site, Madrid, Spain|Altana Pharma/Nycomed Investigational Site, Merida (Badajoz), Spain|Altana Pharma/Nycomed Investigational Site, Partida de Bacarot (Alicante), Spain|Altana Pharma/Nycomed Investigational Site, Pontevedra, Spain|Altana Pharma/Nycomed Investigational Site, Requena, Spain|Altana Pharma/Nycomed Investigational Site, Santiago de Compostela, Spain|Altana Pharma/Nycomed Investigational Site, Talavera de la Reina (Toledo), Spain|Altana Pharma/Nycomed Investigational Site, Tarrasa (Barcelona), Spain|Altana Pharma/Nycomed Investigational Site, Toldeo, Spain|Altana Pharma/Nycomed Investigational Site, Valencia, Spain|Altana Pharma/Nycomed Investigational Site, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT00297115"
238,"NCT00297102","Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)",,"Completed","Has Results","Chronic Obstructive Pulmonary Disease (COPD)","Drug: Roflumilast|Drug: Placebo","Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)|COPD Exacerbation Rate (Moderate or Severe)|Post-bronchodilator FEV1 [L]|Time to Mortality Due to Any Reason|Natural Log-transformed C-reactive Protein (CRP)|Mean Transition Dyspnea Index (TDI) Focal Score During the Treatment Period","AstraZeneca","All","40 Years and older   (Adult, Older Adult)","Phase 3","1523","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BY217/M2-124","February 2006","July 2008","September 2008","February 28, 2006","May 19, 2011","January 16, 2017","Altana Pharma/Nycomed Investigational Site, Fullerton, California, United States|Altana Pharma/Nycomed Investigational Site, Los Angeles, California, United States|Altana Pharma/Nycomed Investigational Site, Los Angeles, California, United States|Altana Pharma/Nycomed Investigational Site, Palmdale, California, United States|Altana Pharma/Nycomed Investigational Site, Rancho Mirage, California, United States|Altana Pharma/Nycomed Investigational Site, San Diego, California, United States|Altana Pharma/Nycomed Investigational Site, Bay Pines, Florida, United States|Altana Pharma/Nycomed Investigational Site, Miami, Florida, United States|Altana Pharma/Nycomed Investigational Site, Panama City, Florida, United States|Altana Pharma/Nycomed Investigational Site, Atlanta, Georgia, United States|Altana Pharma/Nycomed Investigational Site, Marietta, Georgia, United States|Altana Pharma/Nycomed Investigational Site, Hines, Illinois, United States|Altana Pharma/Nycomed Investigational Site, South Bend, Indiana, United States|Altana Pharma/Nycomed Investigational Site, Lebanon, Kentucky, United States|Altana Pharma/Nycomed Investigational Site, Metairie, Louisiana, United States|Altana Pharma/Nycomed Investigational Site, New Orleans, Louisiana, United States|Altana Pharma/Nycomed Investigational Site, Slidell, Louisiana, United States|Altana Pharma/Nycomed Investigational Site, Sunset, Louisiana, United States|Altana Pharma/Nycomed Investigational Site, Bangor, Maine, United States|Altana Pharma/Nycomed Investigational Site, Baltimore, Maryland, United States|Altana Pharma/Nycomed Investigational Site, North Dartmouth, Massachusetts, United States|Altana Pharma/Nycomed Investigational Site, Edina, Minnesota, United States|Altana Pharma/Nycomed Investigational Site, Minneapolis, Minnesota, United States|Altana Pharma/Nycomed Investigational Site, Chesterfield, Missouri, United States|Altana Pharma/Nycomed Investigational Site, St. Louis, Missouri, United States|Altana Pharma/Nycomed Investigational Site, Billings, Montana, United States|Altana Pharma/Nycomed Investigational Site, Missoula, Montana, United States|Altana Pharma/Nycomed Investigational Site, Lincoln, Nebraska, United States|Altana Pharma/Nycomed Investigational Site, Omaha, Nebraska, United States|Altana Pharma/Nycomed Investigational Site, Reno, Nevada, United States|Altana Pharma/Nycomed Investigational Site, Cherry Hill, New Jersey, United States|Altana Pharma/Nycomed Investigational Site, Springfield, New Jersey, United States|Altana Pharma/Nycomed Investigational Site, New York, New York, United States|Altana Pharma/Nycomed Investigational Site, Winston Salem, North Carolina, United States|Altana Pharma/Nycomed Investigational Site, Cincinnati, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Columbus, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Toledo, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Youngstown, Ohio, United States|Altana Pharma/Nycomed Investigational Site, Lake Oswego, Oregon, United States|Altana Pharma/Nycomed Investigational Site, Philadelphia, Pennsylvania, United States|Altana Pharma/Nycomed Investigational Site, Cranston, Rhode Island, United States|Altana Pharma/Nycomed Investigational Site, East Providence, Rhode Island, United States|Altana Pharma/Nycomed Investigational Site, Austin, Texas, United States|Altana Pharma/Nycomed Investigational Site, Dallas, Texas, United States|Altana Pharma/Nycomed Investigational Site, Charlottesville, VA, Virginia, United States|Altana Pharma/Nycomed Investigational Site, Bellingham, Washington, United States|Altana Pharma/Nycomed Investigational Site, Marietta, Wisconsin, United States|Altana Pharma/Nycomed Investigational Site, Adelaide South Australia, Australia|Altana Pharma/Nycomed Investigational Site, Box Hill, Australia|Altana Pharma/Nycomed Investigational Site, Camperdown, Australia|Altana Pharma/Nycomed Investigational Site, Clayton, Australia|Altana Pharma/Nycomed Investigational Site, Concord, Australia|Altana Pharma/Nycomed Investigational Site, Geelong, Australia|Altana Pharma/Nycomed Investigational Site, Kippa-ring, Australia|Altana Pharma/Nycomed Investigational Site, Nedlands, Australia|Altana Pharma/Nycomed Investigational Site, South Brisbane, Australia|Altana Pharma/Nycomed Investigational Site, Toorak Gardens, Australia|Altana Pharma/Nycomed Investigational Site, Wayville, Australia|Altana Pharma/Nycomed Investigational Site, Feldbach, Austria|Altana Pharma/Nycomed Investigational Site, Gänserndorf, Austria|Altana Pharma/Nycomed Investigational Site, Hallein, Austria|Altana Pharma/Nycomed Investigational Site, Innsbruck, Austria|Altana Pharma/Nycomed Investigational Site, Linz, Austria|Altana Pharma/Nycomed Investigational Site, Natters, Austria|Altana Pharma/Nycomed Investigational Site, Spittal an der Drau, Austria|Altana Pharma/Nycomed Investigational Site, Belo Horizonte - MG CEP, Brazil|Altana Pharma/Nycomed Investigational Site, Botucatu - SP CEP, Brazil|Altana Pharma/Nycomed Investigational Site, Curitiba-PR, Brazil|Altana Pharma/Nycomed Investigational Site, Florianópolis-SC, Brazil|Altana Pharma/Nycomed Investigational Site, Juiz de Fora-MG, Brazil|Altana Pharma/Nycomed Investigational Site, Porto Alegre-RS, Brazil|Altana Pharma/Nycomed Investigational Site, Porto Alegre-RS, Brazil|Altana Pharma/Nycomed Investigational Site, Porto Alegre, Brazil|Altana Pharma/Nycomed Investigational Site, Quadra 605 Brasilia - DF, Brazil|Altana Pharma/Nycomed Investigational Site, Recife - PE, Brazil|Altana Pharma/Nycomed Investigational Site, Rio de Janeiro-RJ, Brazil|Altana Pharma/Nycomed Investigational Site, Santo André-SP, Brazil|Altana Pharma/Nycomed Investigational Site, São Paulo-SP, Brazil|Altana Pharma/Nycomed Investigational Site, São Paulo-SP, Brazil|Altana Pharma/Nycomed Investigational Site, São Paulo-SP, Brazil|Altana Pharma/Nycomed Investigational Site, Beuvry, France|Altana Pharma/Nycomed Investigational Site, Chauny cedex, France|Altana Pharma/Nycomed Investigational Site, Clermont-Ferrand Cedex1, France|Altana Pharma/Nycomed Investigational Site, Ferolles-Attily, France|Altana Pharma/Nycomed Investigational Site, Grasse, France|Altana Pharma/Nycomed Investigational Site, La Teste de Buch, France|Altana Pharma/Nycomed Investigational Site, Lens, France|Altana Pharma/Nycomed Investigational Site, Libourne, France|Altana Pharma/Nycomed Investigational Site, Lille cedex, France|Altana Pharma/Nycomed Investigational Site, Lyon, France|Altana Pharma/Nycomed Investigational Site, Marcq en Baroeul, France|Altana Pharma/Nycomed Investigational Site, Martigues Cedex, France|Altana Pharma/Nycomed Investigational Site, Metz, France|Altana Pharma/Nycomed Investigational Site, Montigny - Les - Metz, France|Altana Pharma/Nycomed Investigational Site, Montpellier Cedex, France|Altana Pharma/Nycomed Investigational Site, Montpellier, France|Altana Pharma/Nycomed Investigational Site, Nice, France|Altana Pharma/Nycomed Investigational Site, Nimes, France|Altana Pharma/Nycomed Investigational Site, Ollioules, France|Altana Pharma/Nycomed Investigational Site, Paris Cedex 18, France|Altana Pharma/Nycomed Investigational Site, Perpignan Cedex, France|Altana Pharma/Nycomed Investigational Site, Saint Laurent Du Var, France|Altana Pharma/Nycomed Investigational Site, Saint-Etienne, France|Altana Pharma/Nycomed Investigational Site, Saint-Quentin, France|Altana Pharma/Nycomed Investigational Site, Toulon, France|Altana Pharma/Nycomed Investigational Site, Vieux Conde, France|Altana Pharma/Nycomed Investigational Site, Deggendorf, Germany|Altana Pharma/Nycomed Investigational Site, Fulda, Germany|Altana Pharma/Nycomed Investigational Site, Kassel, Germany|Altana Pharma/Nycomed Investigational Site, Lübeck, Germany|Altana Pharma/Nycomed Investigational Site, Marburg, Germany|Altana Pharma/Nycomed Investigational Site, Schwetzingen, Germany|Altana Pharma/Nycomed Investigational Site, Balassagyarmat, Hungary|Altana Pharma/Nycomed Investigational Site, Budapest, Hungary|Altana Pharma/Nycomed Investigational Site, Budapest, Hungary|Altana Pharma/Nycomed Investigational Site, Budapest, Hungary|Altana Pharma/Nycomed Investigational Site, Debrecen, Hungary|Altana Pharma/Nycomed Investigational Site, Gyula, Hungary|Altana Pharma/Nycomed Investigational Site, Komárom, Hungary|Altana Pharma/Nycomed Investigational Site, Mosdós, Hungary|Altana Pharma/Nycomed Investigational Site, Mosonmagyaróvár, Hungary|Altana Pharma/Nycomed Investigational Site, Nyiregyháza, Hungary|Altana Pharma/Nycomed Investigational Site, Pécs, Hungary|Altana Pharma/Nycomed Investigational Site, Szeged, Hungary|Altana Pharma/Nycomed Investigational Site, Tapolca, Hungary|Altana Pharma/Nycomed Investigational Site, Tauranga, New Zealand|Altana Pharma/Nycomed Investigational Site, Bucharest, Romania|Altana Pharma/Nycomed Investigational Site, Bucharest, Romania|Altana Pharma/Nycomed Investigational Site, Bucharest, Romania|Altana Pharma/Nycomed Investigational Site, Bucharest, Romania|Altana Pharma/Nycomed Investigational Site, Bucharest, Romania|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, Moscow, Russian Federation|Altana Pharma/Nycomed Investigational Site, St. Petersburg, Russian Federation|Altana Pharma/Nycomed Investigational Site, St. Petersburg, Russian Federation|Altana Pharma/Nycomed Investigational Site, St. Petersburg, Russian Federation|Altana Pharma/Nycomed Investigational Site, St. Petersburg, Russian Federation|Altana Pharma/Nycomed Investigational Site, St. Petersburg, Russian Federation|Altana Pharma/Nycomed Investigational Site, Baillieston, Glasgow, United Kingdom|Altana Pharma/Nycomed Investigational Site, Bangor, Northern Ireland, United Kingdom|Altana Pharma/Nycomed Investigational Site, Bath, Avon, United Kingdom|Altana Pharma/Nycomed Investigational Site, Bath, United Kingdom|Altana Pharma/Nycomed Investigational Site, Belfast, United Kingdom|Altana Pharma/Nycomed Investigational Site, Birmingham, United Kingdom|Altana Pharma/Nycomed Investigational Site, Chesterfield, United Kingdom|Altana Pharma/Nycomed Investigational Site, Co. Antrim, United Kingdom|Altana Pharma/Nycomed Investigational Site, Cottingham, E York, United Kingdom|Altana Pharma/Nycomed Investigational Site, County Antrim, United Kingdom|Altana Pharma/Nycomed Investigational Site, Downpatrick, Northern Ireland, United Kingdom|Altana Pharma/Nycomed Investigational Site, East Sussex, United Kingdom|Altana Pharma/Nycomed Investigational Site, East Sussex, United Kingdom|Altana Pharma/Nycomed Investigational Site, Fife, United Kingdom|Altana Pharma/Nycomed Investigational Site, Glasgow, United Kingdom|Altana Pharma/Nycomed Investigational Site, Glasgow, United Kingdom|Altana Pharma/Nycomed Investigational Site, Glengormley Newtownabbey, United Kingdom|Altana Pharma/Nycomed Investigational Site, Harrow, United Kingdom|Altana Pharma/Nycomed Investigational Site, Kent, United Kingdom|Altana Pharma/Nycomed Investigational Site, Leamington Spa, United Kingdom|Altana Pharma/Nycomed Investigational Site, Liverpool, United Kingdom|Altana Pharma/Nycomed Investigational Site, Nottingham, United Kingdom|Altana Pharma/Nycomed Investigational Site, Nottingham, United Kingdom|Altana Pharma/Nycomed Investigational Site, Randalstown, United Kingdom|Altana Pharma/Nycomed Investigational Site, Sheffield, United Kingdom|Altana Pharma/Nycomed Investigational Site, Solihull, United Kingdom|Altana Pharma/Nycomed Investigational Site, Southampton, United Kingdom|Altana Pharma/Nycomed Investigational Site, Southdown, Bath, United Kingdom|Altana Pharma/Nycomed Investigational Site, Sunbury on Thames, Middlesex, United Kingdom|Altana Pharma/Nycomed Investigational Site, Vale of Glamorgan, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00297102"
239,"NCT00295633","A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Saxagliptin|Drug: Placebo|Drug: pioglitazone|Drug: rosiglitazone|Drug: metformin","Change From Baseline in Hemoglobin A1c (A1C) at Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Percentage of Participants Achieving A1c <7% at Week 24|Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24","AstraZeneca","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","565","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV181-013","March 2006","October 2007","October 2008","February 24, 2006","September 25, 2009","April 7, 2015","Winston Technology, Inc., Haleyville, Alabama, United States|Sunbelt Research Group, Llc, Mobile, Alabama, United States|Iicr, Inc., Ozark, Alabama, United States|Clinical Research Advantage, Inc, Mesa, Arizona, United States|Nea Clinic, Jonesboro, Arkansas, United States|Little Rock Family Practice Clinic, Little Rock, Arkansas, United States|Impact Clinical Trials, Beverly Hills, California, United States|Lovelace Scientific Resources, Inc., Beverly Hills, California, United States|Medical Group Of Encino, Encino, California, United States|Marin Endocrine Care And Research, Inc., Greenbrae, California, United States|Del Rosario Medical Clinic, Inc., Huntington Park, California, United States|Loma Linda Va Healthcare Systems, Loma Linda, California, United States|Peak Health Medical Group, Los Angeles, California, United States|Richard Cherlin, Md, Los Gatos, California, United States|Mission Internal Medical Group, Mission Viejo, California, United States|Desert Medical Advances, Palm Desert, California, United States|Denver Internal Medicine Group, Denver, Colorado, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Phoenix Internal Medicine Associates, Llc, Waterbury, Connecticut, United States|Central Florida Clinical Trials, Inc., Altamonte Springs, Florida, United States|Southern Family Healthcare, Pa, Chipley, Florida, United States|Doctors Medical Center Of Walton County, Defuniak Springs, Florida, United States|Horizon Institute For Clinical Research, Hollywood, Florida, United States|Jacksonville Center For Clinical Research, Jacksonville, Florida, United States|Panhandle Family Care Associates, Marianna, Florida, United States|Nextphase Clinical Trials, Inc, Miami, Florida, United States|Baptist Diabetes Associates, Miami, Florida, United States|Heart & Vascular Center Research, Inc., Sarasota, Florida, United States|Alan B. Miller, Md, Dunwoody, Georgia, United States|Marietta Clinical Research, Inc., Marietta, Georgia, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|D. Thomas Rogers, Md, Facs, Kahului, Hawaii, United States|Southeast Idaho Family Practice, Idaho Falls, Idaho, United States|Cedar-Crosse Research Center, Chicago, Illinois, United States|Physicians Research Group, Indianapolis, Indiana, United States|Northwest Indiana Center For Clinical Research, Valparaiso, Indiana, United States|Lipid Research Clinic, Iowa City, Iowa, United States|Professional Research Network Of Kansas, Wichita, Kansas, United States|Mouhaffel, Assad H., West Monroe, Louisiana, United States|Promed Physicians Family Practice, Portage, Michigan, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Radiant Research Las Vegas, Las Vegas, Nevada, United States|Nevada Alliance Against Diabetes, North Las Vegas, Nevada, United States|Office Of Ammar Bazerbashi, Md, Holmdel, New Jersey, United States|Urgentmed, P.C., South Bound Brook, New Jersey, United States|Medical Research Associates Of Charlotte, Inc., Charlotte, North Carolina, United States|Carolina Pharmaceutical Research, Statesville, North Carolina, United States|Community Health Care, Canal Fulton, Ohio, United States|Clinical Research Limited, Canton, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Providence Health Partners - Center For Clinical Research, Dayton, Ohio, United States|Holzer Clinic, Gallipolis, Ohio, United States|Wells Institute For Health Awareness, Kettering, Ohio, United States|David Witkin, Md, Eugene, Oregon, United States|Harleysville Medical Associates, Harleysville, Pennsylvania, United States|Family Medical Associates, Levittown, Pennsylvania, United States|Banksville Medical Pc, Pittsburgh, Pennsylvania, United States|Three Rivers Medical Associates, Pa, Columbia, South Carolina, United States|Radiant Research, Greer, Greer, South Carolina, United States|Upstate Pharmaceutical Research, Simpsonville, South Carolina, United States|East Tennessee Medical Group, Alcoa, Tennessee, United States|Healthstar Physicians, Morristown, Tennessee, United States|Hayes Endocrine And Diabetes Center, Nashville, Tennessee, United States|Capital Medical Clinic, Llp, Austin, Texas, United States|Texas Diabetes And Endocrinology, P.A., Austin, Texas, United States|Radiant Research-Austin, Austin, Texas, United States|Priscilla Hollander, Md, Phd, Dallas, Texas, United States|The Medical Group Of Texas, Fort Worth, Texas, United States|Mobley Research Center, Houston, Texas, United States|Family Physician, Pa, Houston, Texas, United States|Mapleridge Medical Center, Houston, Texas, United States|Diabetes Center Of The Southwest, Midland, Texas, United States|Pearland Primary Care Associates, Llp, Pearland, Texas, United States|Med-Cure, Rosenberg, Texas, United States|Radiant Research San Antonio, San Antonio, Texas, United States|S.A.M. Clinical Research Center, San Antonio, Texas, United States|Collom And Carney Clinic, Texarkana, Texas, United States|National Clinical Research, Inc., Richmond, Virginia, United States|Tidewater Integrated Medical Research, Virginia Beach, Virginia, United States|Local Institution, Belgrano, Buenos Aires, Argentina|Local Institution, Chacabuco, Buenos Aires, Argentina|Local Institution, Ciudad Auton., Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Moron, Buenos Aires, Argentina|Local Institution, Ciudad De Mendoza, Mendoza, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Lanus Este, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, St. Johns, Newfoundland and Labrador, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Sarnia, Ontario, Canada|Local Institution, St Catharines, Ontario, Canada|Local Institution, St-Leonard, Quebec, Canada|Local Institution, Ste-Foy, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Chennai, India|Local Institution, Chennai, India|Local Institution, Chennai, India|Local Institution, Chennai, India|Local Institution, Hariyana, India|Local Institution, Hyderabad, India|Local Institution, Indore, India|Local Institution, Maharashtra, India|Local Institution, Mangalore, India|Local Institution, Mumbai, India|Local Institution, Mumbai, India|Local Institution, Pune, India|Local Institution, Vellore, India|Local Institution, Chichuahua, Chihuahua, Mexico|Local Institution, Angeles Del Pedregal, Distrito Federal, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Michoacan, Morelos, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Cercado De Lima, Lima, Peru|Local Institution, La Victoria, Lima, Peru|Local Institution, Miraflores, Lima, Peru|Local Institution, San Isidro, Lima, Peru|Local Institution, San Martin De Porres, Lima, Peru|Local Institution, Santiago De Surco, Lima, Peru|Local Institution, Cebu City, Philippines|Local Institution, Cebu City, Philippines|Local Institution, Iloilo City, Philippines|Local Institution, Las Pinas, Philippines|Local Institution, Pasig City, Philippines|Local Institution, Carolina, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Rio Piedras, Puerto Rico|Local Institution, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00295633"
240,"NCT00295620","Secondary Adjuvant Long Term Study With Arimidex","SALSA","Completed","Has Results","Breast Cancer","Drug: Anastrozole","Disease-free Survival After Prolonged Endocrine Treatment|Overall Survival After Prolonged Endocrine Treatment|Time to First Clinical Fracture|Time to Secondary Carcinoma|Time to Contralateral Breast Cancer","AstraZeneca","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","3484","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1033AU/0003|ABCSG 16|D5392L00016|SALSA","March 1, 2004","June 30, 2017","June 30, 2017","February 24, 2006","October 2, 2019","October 2, 2019","Research Site, Amstetten, Austria|Research Site, Bad Ischl, Austria|Research Site, Baden, Austria|Research Site, Bregenz, Austria|Research Site, Dornbirn, Austria|Research Site, Eisenstadt, Austria|Research Site, Feldbach, Austria|Research Site, Feldkirch, Austria|Research Site, Freistadt, Austria|Research Site, Fuerstenfeld, Austria|Research Site, Gmunden, Austria|Research Site, Graz, Austria|Research Site, Guessing, Austria|Research Site, Hainburg, Austria|Research Site, Hall in Tirol, Austria|Research Site, Innsbruck, Austria|Research Site, Kirchdorf, Austria|Research Site, Klagenfurt, Austria|Research Site, Klagenfurt, Austria|Research Site, Klagenfurt, Austria|Research Site, Krems, Austria|Research Site, Kufstein, Austria|Research Site, Leoben, Austria|Research Site, Lienz, Austria|Research Site, Linz, Austria|Research Site, Linz, Austria|Research Site, Mistelbach, Austria|Research Site, Moedling, Austria|Research Site, Neunkirchen, Austria|Research Site, Oberpullendorf, Austria|Research Site, Oberwart, Austria|Research Site, Ried im Innkreis, Austria|Research Site, Rottenmann, Austria|Research Site, Salzburg, Austria|Research Site, Scheibbs, Austria|Research Site, Schladming, Austria|Research Site, Schwarzach, Austria|Research Site, St. Poelten, Austria|Research Site, St. Veit an der Glan, Austria|Research Site, Steyr, Austria|Research Site, Vienna, Austria|Research Site, Vienna, Austria|Research Site, Vienna, Austria|Research Site, Vienna, Austria|Research Site, Vienna, Austria|Research Site, Vienna, Austria|Research Site, Villach, Austria|Research Site, Villach, Austria|Research Site, Voecklabruck, Austria|Research Site, Waidhofen an der Thaya, Austria|Research Site, Weiz, Austria|Research Site, Wels, Austria|Research Site, Wiener Neustadt, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Wolfsberg, Austria|Research Site, Zams, Austria","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT00295620/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT00295620/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00295620"
241,"NCT00256698","Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy","FACT","Completed","Has Results","Breast Cancer","Drug: Fulvestrant|Drug: Anastrozole","Time to Progression (TTP)|Percentage of Evaluable Participants With Objective Response Rate (ORR)|Percentage of Clinical Benefit Rate (CBR) Responders|Duration of Response (DoR)|Duration of Clinical Benefit (DoCB)|Time to Treatment Failure (TTF)|Overall Survival (OS)","AstraZeneca","Female","Child, Adult, Older Adult","Phase 3","514","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D6997L00002|9238SW/0001|FACT","January 2004","April 2009","February 2012","November 22, 2005","February 9, 2011","August 1, 2012","Research Site, Brampton, Canada|Research Site, Halifax, Canada|Research Site, Kingston, Canada|Research Site, Ontario, Canada|Research Site, Toronto, Canada|Research Site, San Jose, Costa Rica|Research Site, Hameenlinna, Finland|Research Site, Turku, Finland|Research Site, Avignon, France|Research Site, Caen, France|Research Site, Creteil, France|Research Site, Grenoble, France|Research Site, La Chaussee Saint Victor, France|Research Site, Perigueux, France|Research Site, Perpignan, France|Research Site, Saint Cyr Sur Louire, France|Research Site, Toulouse, France|Research Site, Augsburg, Germany|Research Site, Dusseldorf, Germany|Research Site, Erlangen, Germany|Research Site, Frankfurt, Germany|Research Site, Gifhorn, Germany|Research Site, Grosshadern, Germany|Research Site, Halle, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Ingolstadt, Germany|Research Site, Kassel, Germany|Research Site, Kiel, Germany|Research Site, Koln, Germany|Research Site, Leipzig, Germany|Research Site, Leverkusen, Germany|Research Site, Magdeburg, Germany|Research Site, Mannheim, Germany|Research Site, Marburg, Germany|Research Site, Munchen, Germany|Research Site, Rostock, Germany|Research Site, Trier, Germany|Research Site, Ulm, Germany|Research Site, Ziwicken, Germany|Research Site, Guatemala, Guatemala|Research Site, Reykjavik, Iceland|Research Site, Como, Italy|Research Site, Fabriano, Italy|Research Site, Ferrara, Italy|Research Site, Firenze, Italy|Research Site, Lugo, Italy|Research Site, Milano, Italy|Research Site, Taormina, Italy|Research Site, Treviglio, Italy|Research Site, Vicenza, Italy|Research Site, Drammen, Norway|Research Site, Ilesund, Norway|Research Site, Oslo, Norway|Research Site, Porsgrunn, Norway|Research Site, Stavanger, Norway|Research Site, Troms, Norway|Research Site, Trondheim, Norway|Research Site, Cascais, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Halmstad, Sweden|Research Site, Helsingborg, Sweden|Research Site, Kalmar, Sweden|Research Site, Karlskrona, Sweden|Research Site, Kristianstad, Sweden|Research Site, Link'ping, Sweden|Research Site, M'lndal, Sweden|Research Site, Malm, Sweden|Research Site, Norrk'ping, Sweden|Research Site, Skelleftea, Sweden|Research Site, Skovde, Sweden|Research Site, Stockholm, Sweden|Research Site, Sunderbyn, Sweden|Research Site, Sundsvall, Sweden|Research Site, Umea, Sweden|Research Site, V'rnamo, Sweden|Research Site, V'stervik, Sweden|Research Site, Varberg, Sweden|Research Site, Ankara, Turkey|Research Site, Edirne, Turkey|Research Site, Gaziantep, Turkey|Research Site, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00256698"
242,"NCT00252733","Diabetic Retinopathy Candesartan Trials","DIRECT","Completed","Has Results","Type 1 Diabetes","Drug: candesartan cilexetil","Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale.|Rate of Change in Urinary Albumin Excretion Rate (UAER).","AstraZeneca|Takeda","All","18 Years to 50 Years   (Adult)","Phase 3","5238","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D2453C00045|DIRECT|SH-AHM-0045","June 2001","April 2008","April 2008","November 15, 2005","April 13, 2012","May 14, 2014","Research Site, Herston, Australia|Research Site, Perth, Australia|Research Site, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT00252733"
243,"NCT00252720","DIabetic Retinopathy Candesartan Trials.","DIRECT","Completed","Has Results","Type 1 Diabetes","Drug: candesartan","Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale|Number of Participants With a Regression of Diabetic Retinopathy.|Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).|Rate of Change in Urinary Albumin Excretion Rate (UAER).","AstraZeneca|Takeda","All","18 Years to 55 Years   (Adult)","Phase 3","1850","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D2453C00046|DIRECT|SH-AHM-0046","August 2001","February 2008","April 2008","November 15, 2005","June 3, 2014","June 3, 2014",,,"https://ClinicalTrials.gov/show/NCT00252720"
244,"NCT00252694","DIabetic Retinopathy Candesartan Trials","DIRECT","Completed","Has Results","Type 2 Diabetes","Drug: candesartan","Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale|Number of Participants With at Least a 3 Step Improvement or a Persistent 2-step Improvement in the ETDRS Severity Scale.|Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).|Rate of Change in Urinary Albumin Excretion Rate (UAER).","AstraZeneca|Takeda","All","37 Years to 75 Years   (Adult, Older Adult)","Phase 3","4717","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D2453C00047|DIRECT|SH-AHM-0047","August 2001","February 2008","April 2008","November 15, 2005","June 6, 2014","June 6, 2014",,,"https://ClinicalTrials.gov/show/NCT00252694"
245,"NCT00251979","A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer",,"Completed","Has Results","Gastrointestinal Hemorrhage","Drug: Esomeprazole","Clinically Significant Rebleeding Within 72 Hours of Continous Infusion of Esomeprazole or Placebo|Clinically Significant Rebleeding Within 7 Days|Clinically Significant Rebleeding Within 30 Days|Death Within 72 Hours|Death Within 30 Days|Death Related to Rebleeding Within 30 Days as Judged by the EpC|Requirement for Surgery Within 72 Hours|Requirement for Surgery Within 30 Days|Requirement for Endoscopic Re-treatment Within 72 Hours|Requirement for Endoscopic Re-treatment Within 30 Days|Number of Blood Units Transfused Within 72 Hours|Number of Blood Units Transfused Within 30 Days|Number of Days Hospitalized Due to Rebleeding During the 30-day Treatment Period","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","1312","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","D961DC00001","October 2005","December 2007","December 2007","November 11, 2005","June 17, 2011","June 17, 2011","Research Site, Braunau/Inn, Austria|Research Site, Feldbach, Austria|Research Site, Graz, Austria|Research Site, Krems, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Aalborg, Denmark|Research Site, Amager, Denmark|Research Site, Glostrup, Denmark|Research Site, Holstebro, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Odense, Denmark|Research Site, Randers, Denmark|Research Site, Slagelse, Denmark|Research Site, Helsinki, Finland|Research Site, Kuopio, Finland|Research Site, Amiens, France|Research Site, Bordeaux, France|Research Site, Clermont-Ferrand CEDEX 1, France|Research Site, Lille, France|Research Site, Nice Cedex 3, France|Research Site, Paris Cedex 12, France|Research Site, Paris Cedex 13, France|Research Site, Rouen, France|Research Site, Berlin, Germany|Research Site, Bochum, Germany|Research Site, Celle, Germany|Research Site, Dresden, Germany|Research Site, Karlsruhe, Germany|Research Site, Leipzig, Germany|Research Site, Ludwigshafen, Germany|Research Site, Magdeburg, Germany|Research Site, Weimar, Germany|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Arnhem, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Hengelo, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Alesund, Norway|Research Site, Drammen, Norway|Research Site, Kristiansand, Norway|Research Site, Lorenskog, Norway|Research Site, Oslo, Norway|Research Site, Tonsberg, Norway|Research Site, Bucharest, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Tg. Mures, Romania|Research Site, Timisoara, Romania|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Pietermaritzburg, South Africa|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sabadell, Spain|Research Site, Santiago, Spain|Research Site, Goteborg, Sweden|Research Site, Karlstad, Sweden|Research Site, Kristianstad, Sweden|Research Site, Linköping, Sweden|Research Site, Norrkoping, Sweden|Research Site, Ostersund, Sweden|Research Site, Skövde, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, Trollhättan, Sweden|Research Site, Ankara, Turkey|Research Site, Bursa, Turkey|Research Site, Izmir, Turkey|Research Site, Izmit, Turkey|Research Site, Birmingham, United Kingdom|Research Site, Derby, United Kingdom|Research Site, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00251979"
246,"NCT00251927","Esomeprazole (NEXIUM) vs. Surgery","LOTUS","Completed","Has Results","Gastroesophageal Reflux","Drug: esomeprazole|Procedure: Laparoscopic fundoplication (surgery)","Number of Participants With Treatment Failure at 5 Years|Los Angeles (LA) Grade 'Normal' at 5 Year Visit|Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With no Heartburn|Total Score for Microscopic Reflux-related Changes in the Distal Esophagus 2 cm Above the Z-line, at 5 Year Visit|Percentage Time With pH<4 During 24-hour pH Metry at 5 Year Visit|Los Angeles (LA) Grade 'A' at 5 Year Visit|Los Angeles (LA) Grade 'B' at 5 Year Visit|Los Angeles (LA) Grade C at 5 Year Visit|Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With Mild Heartburn|Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With Moderate Heartburn|Investigator-assessed Heartburn Severity at 5 Year Visit, Participants With Severe Heartburn","AstraZeneca","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","626","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D9612C00003|SH-NEG-0003","October 2001","April 2009","April 2009","November 11, 2005","August 8, 2012","August 8, 2012","Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Zell am See, Austria|Research Site, Brussels (Anderlecht), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Haine-Saint-Paul, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Rimavska Sobota, Belgium|Research Site, Glostrup, Denmark|Research Site, Herning, Denmark|Research Site, Hillerød, Denmark|Research Site, Hvidovre, Denmark|Research Site, Kolding, Denmark|Research Site, Odense C, Denmark|Research Site, Viborg, Denmark|Research Site, Århus C, Denmark|Research Site, Kuopio, Finland|Research Site, Tampere, Finland|Research Site, Bordeaux, France|Research Site, Creteil, France|Research Site, GRENOBLE Cedex 09, France|Research Site, Nantes, France|Research Site, Nice, France|Research Site, NIMES Cedex 4, France|Research Site, Rouen, France|Research Site, Dresden, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Herne, Germany|Research Site, Köln, Germany|Research Site, München, Germany|Research Site, Tübingen, Germany|Research Site, Wiesbaden, Germany|Research Site, Würzburg, Germany|Research Site, Reykjavik, Iceland|Research Site, Brescia, Italy|Research Site, Firenze, Italy|Research Site, Modena, Italy|Research Site, Monfalcone, Italy|Research Site, Padova, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Rozzano, Italy|Research Site, San Donato Milanese, Italy|Research Site, Torino, Italy|Research Site, Utrecht, Netherlands|Research Site, Bergen, Norway|Research Site, Bodø, Norway|Research Site, Kristiansand S, Norway|Research Site, Oslo, Norway|Research Site, Tromsø, Norway|Research Site, Trondheim, Norway|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00251927"
247,"NCT00244621","Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age",,"Completed","Has Results","Hypertension","Drug: candesartan cilexetil (Atacand)","Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP)|Mean Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)|Change in Albumin/Creatinine (A/C) Ratio for Each Assigned Dose Level From Baseline to Day 28|Change in Protein/Creatinine (P/C) Ratio for Each Assigned Dose Level From Baseline to Day 28","AstraZeneca","All","1 Year to 6 Years   (Child)","Phase 3","95","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D2451C00002|328","November 2004","August 2008","August 2008","October 27, 2005","September 15, 2009","August 31, 2011","Research Site, Birmingham, Alabama, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Detroit, Michigan, United States|Research Site, Durham, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Malvern, Pennsylvania, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Beaumont, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Arhus, Denmark|Research Site, Strasbourg Cedex, France|Research Site, Berlin, Germany|Research Site, Erlangen, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Marburg, Germany|Research Site, Rostock, Germany|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Gdansk, Poland|Research Site, Kraków, Poland|Research Site, Warszawa, Poland|Research Site, San Juan, Puerto Rico|Research Site, Crimea, Ukraine|Research Site, Kyiv, Ukraine|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00244621"
248,"NCT00240331","AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)",,"Completed","Has Results","Renal Failure","Drug: 10mg Rosuvastatin|Drug: Placebo","Number of Randomised Participants With a Major Cardiovascular Event (Non-fatal Stroke, Non-fatal Myocardial Infarction or Cardiovascular Death)|Number of Randomised Participants That Died From Any Cause.|Number of Randomised Participants With a Major Cardiovascular Event or That Died From Any Known Cause|Number of Randomised Participants That Died From Cardiovascular Cause|Number of Randomised Participants That Died From Non Cardiovascular Cause|Number of Randomised Participants With an Atherosclerotic Cardiac Event (Non-fatal Myocardial Infarction or Coronary Heart Disease (CHD) Death)|Number of Randomised Participants That Experienced a Procedure as a Result of Stenosis or Thrombosis of the Vascular Access (Arteriovenous (AV) Fistulas and Grafts Only) for Haemodialysis.|Number of Randomised Participants That Experienced a Coronary or Peripheral Revascularisation (Including Above Ankle Limb Amputations).","AstraZeneca","All","50 Years to 80 Years   (Adult, Older Adult)","Phase 3","2776","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","4522IL/0096|D3562C00096","January 2003","October 2008","October 2008","October 18, 2005","November 4, 2009","May 19, 2011","Research Site, St Leonards, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Bregenz, Austria|Research Site, Feldkirch-Tisis, Austria|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, St. Poelten, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Aalst, Belgium|Research Site, Antwerpen, Belgium|Research Site, Brussels, Belgium|Research Site, La Louviere, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Curitiba, PR, Brazil|Research Site, Sao Paulo, SP, Brazil|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Lethbridge, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Trois-Rivieres, Quebec, Canada|Research Site, Kitchener, Canada|Research Site, Rosemount, Canada|Research Site, Hodonin, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Liberec, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Tabor, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Fredericia, Denmark|Research Site, Frederiksberg, Denmark|Research Site, Herlev, Denmark|Research Site, Holbaek, Denmark|Research Site, Horsens, Denmark|Research Site, København Ø, Denmark|Research Site, Roskilde, Denmark|Research Site, Rønne, Denmark|Research Site, Slagelse, Denmark|Research Site, Sønderborg, Denmark|Research Site, Viborg, Denmark|Research Site, Helsinki, Finland|Research Site, Hyvinkaa, Finland|Research Site, Joensuu, Finland|Research Site, Kotka, Finland|Research Site, Kuopio, Finland|Research Site, Lahti, Finland|Research Site, Oulu, Finland|Research Site, Pori, Finland|Research Site, Tammisaari, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Amiens, France|Research Site, Annonay Cedex, France|Research Site, Aubervilliers, France|Research Site, Beauvais, France|Research Site, Bethune Cedex, France|Research Site, Boulogne Sur Mer, France|Research Site, Chambery, France|Research Site, Champigny Sur Marne, France|Research Site, Colmar Cedex, France|Research Site, Creil Cedex 1, France|Research Site, Evreux Cedex, France|Research Site, Fleury Merogis, France|Research Site, Foix Cedex, France|Research Site, Le Kremlin-Bicetre, France|Research Site, Maubeuge, France|Research Site, Meaux, France|Research Site, Mont de Marsan Cedex, France|Research Site, Montbonnot Saint Martin, France|Research Site, Nimes, France|Research Site, Olivet, France|Research Site, Paris, France|Research Site, Quimper Cedex, France|Research Site, Saint Maurice, France|Research Site, Saint Michel, France|Research Site, Tournan En Brie, France|Research Site, Valenciennes Cedex, France|Research Site, Vandoeuvre Les Nancy, France|Research Site, Vichy, France|Research Site, Ansbach, Germany|Research Site, Aschaffenburg, Germany|Research Site, Bad Münder, Germany|Research Site, Berlin, Germany|Research Site, Bischofswerda, Germany|Research Site, Dresden, Germany|Research Site, Duisburg, Germany|Research Site, Düsseldorf, Germany|Research Site, Erlangen, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg, Germany|Research Site, Greifswald, Germany|Research Site, Hann Münden, Germany|Research Site, Ingolstadt, Germany|Research Site, Jena, Germany|Research Site, Kaufbeuren, Germany|Research Site, Luedenscheid, Germany|Research Site, Marktheidenfeld, Germany|Research Site, München, Germany|Research Site, Pfarrkirchen, Germany|Research Site, Pirmasens, Germany|Research Site, Regensburg, Germany|Research Site, Rostock, Germany|Research Site, Saarbrucken, Germany|Research Site, Tangermünde, Germany|Research Site, Waldshut, Germany|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Thessaloniki, Greece|Research Site, Veroia, Greece|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Veszprém, Hungary|Research Site, Reykjavik, Iceland|Research Site, Galway, Ireland|Research Site, Bergamo, BG, Italy|Research Site, Treviglio, BG, Italy|Research Site, Cremona, CR, Italy|Research Site, Genova, GE, Italy|Research Site, Lodi, LO, Italy|Research Site, Milano, Mi, Italy|Research Site, Rozzano, MI, Italy|Research Site, Reggio Calabria, RC, Italy|Research Site, Busto Arsizio, VA, Italy|Research Site, Seongnam-Si, Korea, Korea, Republic of|Research Site, Seoul, Korea, Korea, Republic of|Research Site, Mexico, D.f., Mexico|Research Site, Acapulco, Guerrero, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Monterrey, Nuevo Leon, Mexico|Research Site, Distrito Federal, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, Alkmaar, Netherlands|Research Site, Almelo, Netherlands|Research Site, Amersfoort, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Deventer, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Emmen, Netherlands|Research Site, Groningen, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sittard, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Bergen, Norway|Research Site, Drammen, Norway|Research Site, Fredrikstad, Norway|Research Site, Lillehammer, Norway|Research Site, Lorenskog, Norway|Research Site, Oslo, Norway|Research Site, Skien, Norway|Research Site, Stavanger, Norway|Research Site, Trondheim, Norway|Research Site, Tønsberg, Norway|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Opole, Poland|Research Site, Plock, Poland|Research Site, Rybnik, Poland|Research Site, Wloclawek, Poland|Research Site, Eksjö, Sweden|Research Site, Eskilstuna, Sweden|Research Site, Falun, Sweden|Research Site, Gävle, Sweden|Research Site, Göteborg, Sweden|Research Site, Jönköping, Sweden|Research Site, Karlstad, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Mölndal, Sweden|Research Site, Norrköping, Sweden|Research Site, Skövde, Sweden|Research Site, Stockholm, Sweden|Research Site, Trollhättan, Sweden|Research Site, Uppsala, Sweden|Research Site, Örebro, Sweden|Research Site, Aarau, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneve, Switzerland|Research Site, Lausanne, Switzerland|Research Site, St. Gallen, Switzerland|Research Site, Zürich, Switzerland|Research Site, Istanbul, Altunizade, Turkey|Research Site, Cebeci, Ankara, Turkey|Research Site, Kampus, Antalya, Turkey|Research Site, Antalya, Arapsuyu, Turkey|Research Site, Ankara, Besevler, Turkey|Research Site, Izmir, Bornova, Turkey|Research Site, Bursa, Gorukle, Turkey|Research Site, Istanbul, Haydarpasa, Turkey|Research Site, Antrim, Northern Ireland, United Kingdom|Research Site, Belfast, Northern Ireland, United Kingdom|Research Site, Newry, Northern Ireland, United Kingdom|Research Site, Omagh, Northern Ireland, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Dumfries, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Kilmarnock, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Middlesborough, United Kingdom|Research Site, Newcastle, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Rhyl, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00240331"
249,"NCT00227305","Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder","ANCHOR 150","Completed","Has Results","Schizophrenia|Bipolar I Disorder","Drug: quetiapine fumarate","Incidence and Nature of Adverse Events (AEs)|Number of Patients Withdrawn Due to AEs.|Changes in Laboratory Test Results (Prolactin)|Categorical Change From OL Baseline to Week 26 in Simpson-Angus Scale (SAS)Total Score|Categorical Change From Baseline in Barnes Akathisia Rating Scale (BARS) Global Score|Change From Baseline in Weight|Change From Baseline in Supine Pulse|Change From OL Baseline in Supine Systolic BP.|Change From OL Baseline in Supine Diastolic BP.|Changes in Tanner Stage|Change From Baseline in Children's Global Assessment Scale (CGAS) Score","AstraZeneca","All","10 Years to 17 Years   (Child)","Phase 3","381","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1441C00150","August 2004","December 2007","December 2007","September 28, 2005","October 5, 2012","January 8, 2013","Research Site, Dothan, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Cerritos, California, United States|Research Site, Riverside, California, United States|Research Site, Sacramento, California, United States|Research Site, San Diego, California, United States|Research Site, Denver, Colorado, United States|Research Site, Altamonte Springs, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Oak Brook, Illinois, United States|Research Site, Newton, Kansas, United States|Research Site, Overland Park, Kansas, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Rochester, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Lyndhurst, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Virginia Beach, Virginia, United States|Research Site, Bellevue, Washington, United States|Research Site, Kirkland, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Lucknow, India|Research Site, Kuala Lumpur, Malaysia|Research Site, Petaling Jaya, Malaysia|Research Site, Davao City, Philippines|Research Site, Mandaluyong City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Poznan, Poland|Research Site, Torun, Poland|Research Site, Moscow, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Novi Sad, Serbia|Research Site, Pretoria, South Africa|Research Site, Kharkov, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odessa, Ukraine",,"https://ClinicalTrials.gov/show/NCT00227305"
250,"NCT00163293","Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)","POPCICLE","Completed","Has Results","Asthma","Drug: Ciclesonide|Drug: Placebo","Time to First Asthma Exacerbation|Exacerbations (Post-hoc Analysis of Annual Rates)|Growth Velocity as Assessed by Stadiometric Height Measurement|Mean Rate of Asthma Exacerbations Per Year|Duration of Exacerbations|Number of Exacerbations Per Participant|Percentage of Participants Who Dropped-out Due to Asthma Exacerbation|Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Absolute Value)|Change From Baseline in Forced Expiratory Volume in One Second (FEV1) (Percent Predicted)|Morning and Evening Peak Expiratory Flow (PEF) Measurements by Diary Entries|Change From Baseline in PEF by Diary Entries|Change From Baseline in Diurnal PEF Fluctuation|Total Asthma Symptom Score by Diary Entries|Percentage of Nights With Nocturnal Awakenings Due to Asthma Symptoms|Rescue Medication Use Per Day|Percentage of Rescue Medication Free Days|Percentage of Asthma Symptom Free Days|Quality of Life Assessments as Per Paediatric Asthma Quality of Life Questionnaire, Standardized (PAQLQ[S])|Quality of Life Assessments as Per Paediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ)|Number of Participants With Clinically Significant Vital Signs Findings|Number of Participants With Clinically Significant Physical Examination Findings|Number of Participants With Clinically Significant Laboratory Values|Number of Participants With Adverse Events and Serious Adverse Events","AstraZeneca","All","4 Years to 11 Years   (Child)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BY9010/CA-101|2007-003736-34|U1111-1189-7814","January 1, 2005","June 1, 2009","April 1, 2010","September 14, 2005","December 22, 2010","April 26, 2017","Altana Pharma/Nycomed, Calgary, Canada|Altana Pharma/Nycomed, Fleurimont, Canada|Altana Pharma/Nycomed, London,ON, Canada|Altana Pharma/Nycomed, London, Canada|Altana Pharma/Nycomed, Winnipeg, Canada|Altana Pharma/Nycomed, Budapest, Hungary|Altana Pharma/Nycomed, Kapstadt, South Africa",,"https://ClinicalTrials.gov/show/NCT00163293"
251,"NCT00135330","An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: exenatide|Drug: rosiglitazone","Change in ASIiAUC During a Hyperglycemic Clamp Test.|Change in AUC for Glucose During a Meal Challenge Test (MCT).|Change in Insulin Sensitivity Index as Measured by M-value.|Change in Insulin AUC in the First Stage From Baseline to Endpoint.|Change in Insulin iAUC From Baseline to Endpoint.|Ratio (Value at Endpoint Divided by Value at Baseline) of AUC for Insulin During a Meal Challenge Test (MCT).|Change in AUC for C-peptide During a Meal Challenge Test (MCT).|Change in Incremental for Postprandial Glucose During a Meal Challenge Test (MCT).|Change in Incremental for Postprandial Insulin During Meal Challenge Test (MCT).|Change in Incremental for Postprandial C-peptide During Meal Challenge Test (MCT).|Change in HbA1c|Change in Fasting Serum Glucose Concentration.|Change in Fasting C-peptide|Change in Fasting Insulin|Change in Fasting Proinsulin|Change in Body Weight|Change in Fasting Total Cholesterol.|Change in Fasting HDL Cholesterol|Change in Fasting LDL Cholesterol|Change in Fasting Triglycerides|Change in Percent Body Fat During a Meal Challenge Test (MCT)|Change in Body Fat Mass During a Meal Challenge Test (MCT)|Change in Lean Body Mass During a Meal Challenge Test (MCT)|Change in Waist Circumference|Change in Hip Circumference|Change in Waist-to-hip Ratio|Incidence of Hypoglycemia Events|Hypoglycemia Rate Per 30 Days Per Patient|Pedal Edema Score","AstraZeneca|Eli Lilly and Company","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-US-GWAY","October 2005","July 2008","July 2008","August 26, 2005","August 28, 2009","April 7, 2015","Research Site, Phoenix, Arizona, United States|Research Site, San Francisco, California, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Pittsfield, Massachusetts, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Rochester, Minnesota, United States|Research Site, Bronx, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Cincinatti, Ohio, United States|Research Site, League City, Texas, United States|Research Site, New Braunfels, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Renton, Washington, United States|Research Site, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00135330"
252,"NCT00121667","Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Saxagliptin + Metformin|Drug: Placebo + Metformin|Drug: Pioglitazone","Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24|Baseline and Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Percentage of Participants Achieving Therapeutic Glycemic Response (A1C < 7.0%) at Week 24|Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC)","AstraZeneca","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","1462","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV181-014","August 2005","October 2006","February 2010","July 21, 2005","April 8, 2011","April 29, 2015","Local Institution, Anniston, Alabama, United States|Local Institution, Birmingham, Alabama, United States|Local Institution, Calera, Alabama, United States|Local Institution, Haleyville, Alabama, United States|Local Institution, Mesa, Arizona, United States|Local Institution, Phoenix, Arizona, United States|Local Institution, Jonesboro, Arkansas, United States|Local Institution, Little Rock, Arkansas, United States|Local Institution, Sherwood, Arkansas, United States|Local Institution, Encino, California, United States|Local Institution, Fountain Valley, California, United States|Local Institution, Fresno, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Mission Viejo, California, United States|Local Institution, Northridge, California, United States|Local Institution, Orange, California, United States|Local Institution, Roseville, California, United States|Local Institution, Sacramento, California, United States|Local Institution, Spring Valley, California, United States|Local Institution, Tustin, California, United States|Local Institution, Castle Rock, Colorado, United States|Local Institution, Colorado Springs, Colorado, United States|Local Institution, Denver, Colorado, United States|Local Institution, Golden, Colorado, United States|Local Institution, Loveland, Colorado, United States|Local Institution, Altamonte Springs, Florida, United States|Local Institution, Chipley, Florida, United States|Local Institution, Cocoa Beach, Florida, United States|Local Institution, Coral Gables, Florida, United States|Local Institution, Fort Lauderdale, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Kissimmee, Florida, United States|Local Institution, Marianna, Florida, United States|Local Institution, Miami, Florida, United States|Local Institution, New Port Richey, Florida, United States|Local Institution, Ocala, Florida, United States|Local Institution, Tallahassee, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Decatur, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Vernon Hills, Illinois, United States|Local Institution, Elkhart, Indiana, United States|Local Institution, Lafayette, Indiana, United States|Local Institution, Iowa City, Iowa, United States|Local Institution, Waterloo, Iowa, United States|Local Institution, Topeka, Kansas, United States|Local Institution, Lexington, Kentucky, United States|Local Institution, Munfordville, Kentucky, United States|Local Institution, New Orleans, Louisiana, United States|Local Institution, West Monroe, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Chester, Maryland, United States|Local Institution, Prince Frederick, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Kansas City, Missouri, United States|Local Institution, St. Louis, Missouri, United States|Local Institution, Kalispell, Montana, United States|Local Institution, Omaha, Nebraska, United States|Local Institution, Las Vegas, Nevada, United States|Local Institution, Toms River, New Jersey, United States|Local Institution, Albuquerque, New Mexico, United States|Local Institution, Charlotte, North Carolina, United States|Local Institution, Greensboro, North Carolina, United States|Local Institution, Morehead City, North Carolina, United States|Local Institution, Salisbury, North Carolina, United States|Local Institution, Sparta, North Carolina, United States|Local Institution, Wilmington, North Carolina, United States|Local Institution, Winston Salem, North Carolina, United States|Local Institution, Athens, Ohio, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Lyndhurst, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Tulsa, Oklahoma, United States|Local Institution, Eugene, Oregon, United States|Local Institution, Portland, Oregon, United States|Local Institution, Carlisle, Pennsylvania, United States|Local Institution, Langhorne, Pennsylvania, United States|Local Institution, Levittown, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Charleston, South Carolina, United States|Local Institution, Duncan, South Carolina, United States|Local Institution, Bristol, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Bryan, Texas, United States|Local Institution, Carrollton, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Temple, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Local Institution, Hampton, Virginia, United States|Local Institution, Virginia Beach, Virginia, United States|Local Institution, Olympia, Washington, United States|Local Institution, Spokane, Washington, United States|Local Institution, Mar Del Plata, Buenos Aires, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Sydney, New South Wales, Australia|Local Institution, Woollongong, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Kippa Ring, Queensland, Australia|Local Institution, Meadowbrook, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Woodville South, South Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belem, Para, Brazil|Local Institution, Porto alegre, Rio Grande Do Sul, Brazil|Local Institution, Campinas, Sao Paulo, Brazil|Local Institution, Marilia, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Coquitlam, British Columbia, Canada|Local Institution, Kelowna, British Columbia, Canada|Local Institution, Surrey, British Columbia, Canada|Local Institution, Brandon, Manitoba, Canada|Local Institution, Portage La Prairie, Manitoba, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Bathurst, New Brunswick, Canada|Local Institution, Mount Pearl, Newfoundland and Labrador, Canada|Local Institution, St. John's, Newfoundland and Labrador, Canada|Local Institution, St. Johns, Newfoundland and Labrador, Canada|Local Institution, Aylmer, Ontario, Canada|Local Institution, London, Ontario, Canada|Local Institution, Oakville, Ontario, Canada|Local Institution, Sarnia, Ontario, Canada|Local Institution, Thornhill, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Woodstock, Ontario, Canada|Local Institution, Charlottetown, Prince Edward Island, Canada|Local Institution, Drummondville, Quebec, Canada|Local Institution, Fleurimont, Quebec, Canada|Local Institution, Longueuil, Quebec, Canada|Local Institution, St. Leonard, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Santiago De Chile, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Celaya, Guanajuato, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michioacan, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Distrito Federal, Mexico|Local Institution, Durango, Mexico|Local Institution, Carolina, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Rio Pieoras, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Hualien, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00121667"
253,"NCT00121641","Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Saxagliptin|Drug: Placebo matching Saxagliptin|Drug: Metformin|Drug: Placebo matching Metformin","Hemoglobin A1c (A1C) Changes From Baseline at Week 24|A1C Changes From Baseline at Week 24 - Open Label Cohort|Baseline and Change From Baseline at Week 24 in Fasting Plasma Glucose (FPG)|Percentage of Participants Achieving Therapeutic Glycemic Response (A1C < 7.0%) at Week 24|Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC)|Baseline and Change From Baseline at Week 24 in Fasting Plasma Glucose (FPG) - Open Label Cohort|Percentage of Participants Achieving Therapeutic Glycemic Response (A1C < 7.0%) at Week 24 - Open Label Cohort|Baseline and Change From Baseline at Week 24 in Postprandial Glucose (PPG) Area Under the Curve (AUC) - Open Label Cohort","AstraZeneca","All","18 Years to 77 Years   (Adult, Older Adult)","Phase 3","1035","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CV181-011","July 2005","August 2006","February 2010","July 21, 2005","May 11, 2011","April 3, 2015","Local Institution, Anniston, Alabama, United States|Local Institution, Birmingham, Alabama, United States|Local Institution, Calera, Alabama, United States|Local Institution, Jonesboro, Arizona, United States|Local Institution, Mesa, Arizona, United States|Local Institution, Pheonix, Arizona, United States|Local Institution, Little Rock, Arkansas, United States|Local Institution, Anaheim, California, United States|Local Institution, Fountain Valley, California, United States|Local Institution, Fresno, California, United States|Local Institution, Long Beach, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Northridge, California, United States|Local Institution, Rolling Hills Estates, California, United States|Local Institution, Sacramento, California, United States|Local Institution, Santa Ana, California, United States|Local Institution, Spring Valley, California, United States|Local Institution, Tustin, California, United States|Local Institution, Castle Rock, Colorado, United States|Local Institution, Denver, Colorado, United States|Local Institution, Loveland, Colorado, United States|Local Institution, Altamonte Springs, Florida, United States|Local Institution, Chipley, Florida, United States|Local Institution, Cocoa Beach, Florida, United States|Local Institution, Coral Gables, Florida, United States|Local Institution, Fort Lauderdale, Florida, United States|Local Institution, Jupiter, Florida, United States|Local Institution, Kissimmee, Florida, United States|Local Institution, Marianna, Florida, United States|Local Institution, New Port Richey, Florida, United States|Local Institution, Ocala, Florida, United States|Local Institution, West Palm Beach, Florida, United States|Local Institution, Vernon Hills, Illinois, United States|Local Institution, Dubuque, Iowa, United States|Local Institution, Iowa City, Iowa, United States|Local Institution, Waterloo, Iowa, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Lexington, Kentucky, United States|Local Institution, Munfordville, Kentucky, United States|Local Institution, New Orleans, Louisiana, United States|Local Institution, West Monroe, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Chester, Maryland, United States|Local Institution, Prince Frederick, Maryland, United States|Local Institution, Ayer, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Rolling Fork, Mississippi, United States|Local Institution, Kansas City, Missouri, United States|Local Institution, Springfield, Missouri, United States|Local Institution, St. Louis, Missouri, United States|Local Institution, Kalispell, Montana, United States|Local Institution, Omaha, Nebraska, United States|Local Institution, Las Vegas, Nevada, United States|Local Institution, Middletown, New Jersey, United States|Local Institution, Toms River, New Jersey, United States|Local Institution, Cooperstown, New York, United States|Local Institution, Greensboro, North Carolina, United States|Local Institution, Huntersville, North Carolina, United States|Local Institution, Sparta, North Carolina, United States|Local Institution, Statesville, North Carolina, United States|Local Institution, Winston Salem, North Carolina, United States|Local Institution, Athens, Ohio, United States|Local Institution, Franklin, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Tulsa, Oklahoma, United States|Local Institution, Portland, Oregon, United States|Local Institution, Fleetwood, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Charleston, South Carolina, United States|Local Institution, Bristol, Tennessee, United States|Local Institution, Morristown, Tennessee, United States|Local Institution, Bryan, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, Fort Worth, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Temple, Texas, United States|Local Institution, Texarkana, Texas, United States|Local Institution, The Colony, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Local Institution, Virginia Beach, Virginia, United States|Local Institution, Olympia, Washington, United States|Local Institution, Sydney, New South Wales, Australia|Local Institution, Woollongong, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Kippa Ring, Queensland, Australia|Local Institution, Meadowbrook, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Woodville South, South Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Kelowna, British Columbia, Canada|Local Institution, Quesnel, British Columbia, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Portage La Prairie, Manitoba, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Bathurst, New Brunswick, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Manuels, Newfoundland and Labrador, Canada|Local Institution, Mount Pearl, Newfoundland and Labrador, Canada|Local Institution, St. John's, Newfoundland and Labrador, Canada|Local Institution, Newmarket, Ontario, Canada|Local Institution, Oakville, Ontario, Canada|Local Institution, Peterborough, Ontario, Canada|Local Institution, Sarnia, Ontario, Canada|Local Institution, Strathroy, Ontario, Canada|Local Institution, Thornhill, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Charlottetown, Prince Edward Island, Canada|Local Institution, Drummondville, Quebec, Canada|Local Institution, Fleurimont, Quebec, Canada|Local Institution, Gatineau, Quebec, Canada|Local Institution, Granby, Quebec, Canada|Local Institution, Longueuil, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, St. Leonard, Quebec, Canada|Local Institution, Ste-Foy, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico D.F., Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Hermosillo, Sonora, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Durango, Mexico|Local Institution, Carolina, Puerto Rico|Local Institution, Guaynabo, Puerto Rico|Local Institution, Ponce, Puerto Rico|Local Institution, Rio Piedras, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Hualien, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00121641"
254,"NCT00097500","Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes Mellitus","Drug: exenatide|Drug: Insulin glargine|Drug: Metformin","Beta-cell Function After 52 Weeks of Therapy|Beta-cell Function 4 Weeks After Cessation of Therapy|Change in First Phase C-peptide Release|Change in Second Phase C-peptide Release|Change in Glycosylated Hemoglobin (HbA1c)|Change in Fasting Plasma Glucose|Seven Point Self Monitored Blood Glucose (SMBG) Measurements|Change in Body Weight|M-value at Baseline, Week 52 and Week 56","AstraZeneca|Eli Lilly and Company","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 3","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2993-114","September 2004","December 2009","December 2009","November 25, 2004","January 10, 2011","April 7, 2015","Research Site, Helsinki, Finland|Research Site, Amsterdam, Netherlands|Research Site, Goteborg, Sweden",,"https://ClinicalTrials.gov/show/NCT00097500"
255,"NCT00082381","Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Exenatide (AC2993)|Drug: Insulin glargine","Change in Glycosylated Hemoglobin (HbA1c)|Percentage of Patients Achieving HbA1c <=7%|Change in Body Weight|Change in Fasting Serum Glucose|Change in 7-point Self-monitored Blood Glucose (SMBG) Profile|Percentage of Patients With Hypoglycemic Events|Change in Rate of Hypoglycemic Events","AstraZeneca|Eli Lilly and Company","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 3","551","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-MC-GWAA","June 2003","July 2008","July 2008","May 11, 2004","July 31, 2013","April 7, 2015","Radiant Research-San Diego, San Diego, California, United States|Dorothy L. and James E. Frank Diabetes Research Institute, San Mateo, California, United States|Internal Medicine Associates Department of Research, Fort Myers, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Baptist Diabetes Associates, Miami, Florida, United States|Metabolic Research Institute, Inc., West Palm Beach, Florida, United States|Springfield Diabetes & Endocrine Center, Springfield, Illinois, United States|Frederick Primary Care Associates, Frederick, Maryland, United States|Radiant Research, Inc., St. Louis, Missouri, United States|Lovelace Scientific Resources, Inc., Las Vegas, Nevada, United States|Diabetes, Endocrine & Nutrition, Hampton, New Hampshire, United States|Lovelace Scientific Resources, Albuquerque, New Mexico, United States|Great Lakes Medical Research, Westfield, New York, United States|DOCS, Beth Israel Medical Center, Yonkers, New York, United States|Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States|Jon Shapiro, MD, Philadelphia, Pennsylvania, United States|Endocrinology Consultants of East Tennessee, Knoxville, Tennessee, United States|Israel Hartman, MD, Arlington, Texas, United States|Diabetes & Glandular Research Associates, P.A., San Antonio, Texas, United States|Jack Wahlen, MD, Ogden, Utah, United States|Rainier Clinical Research Center, Inc., Renton, Washington, United States|Australian Clinical Research Centre, Miranda, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Clinical Trial and Research Unit, Wollongong, New South Wales, Australia|Royal Brisbane Hospital, Brisbane, Queensland, Australia|Royal Adelaid Hospital, Adelaid, South Australia, Australia|Repatriation General Hospital, Daw Park, South Australia, Australia|SA Endocrine Clinical Research, Keswick, South Australia, Australia|Eastern Health (Box Hill Hospital), Box Hill, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Freemantle Hospital, Freemantle, Western Australia, Australia|UZ Antwerpen, Endegem, Belgium|UZ Gent, Gent, Belgium|UZ Gasthuisberg, Leuven, Belgium|CHU Sart Tilman, Liege, Belgium|A.Z. Jan Palfijn, Merksem, Belgium|Sint Niklaasstraat, Sint Gillis Waas, Belgium|Hospital Nossa Senhora das Gracas, Curitiba, Brazil|Centro Integrado de Diabetes e Hipertensao, Fortaleza, Brazil|Centro de Pesquisas em Diabetes e Doencas Endocrino Metabolicas/HUWC/UFC, Fortaleza, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Eiran Sairaala c/o9 Clires, Helsinki, Finland|Torikeskuksen Laakariasema, Yliopistonkatu, Jyvaskyla, Finland|Oulu Deakoness Institution, Oulu, Finland|Diabetologische Schwerpunktpraxis, Aschaffenburg, Germany|Diabetologische Scherpunktpraxis, Bosenheim, Germany|Diabetologische Schwerpunktpraxis, Dortmund, Germany|Krankenhaus Bethanien, Hamburg, Germany|Universitatskliniken des Saarlandes, Homburg/Saar, Germany|IKFE GmbH, Mainz, Germany|Profil Institut fur Stoffwechselforschung GmbH, Neuss, Germany|Diabetologische Schwerpunktpraxis, Neuwied, Germany|Diabetes Centrum Bilthoven, Bilthoven, Netherlands|Atrium Medisch Centrum Brunssum, Brunssum, Netherlands|Sint Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Refaja ziekenhuis, Stadskanaal, Netherlands|Medisch Centrum, Westeinde, Netherlands|Markeveien Spesialistpraksis, Bergen, Norway|Spesiallegetjenesten AS, Jessheim, Norway|Betanien Spesialistsenter, Oslo, Norway|Sykehuset Asker of Baerum HF, Rud, Norway|Forskningsstiftelsen Hjertelaget, Stravanger, Norway|Bydgoskie Centrum Diabetologii i Endokrynologii, Bydgoszcz, Poland|Oddzial Chorob Wewnetrznych, Czestochowa, Poland|NZOZ ""Diab-Endo-Met"", Krakow, Poland|Poradnia Diabetologiczna, Lodz, Poland|Poradnia Diabetologiczna, Lublin, Poland|Oddzial Chorob Wewnetrznych, Mielec, Poland|Oddzial Chorob Wewnetrznych i Diabetologii, Warszawa, Poland|Wojewodzka Poradnia dla Chorych na Cukrzyce, Warszawa, Poland|Hospital Garcia de Orta-Servico de Endocrinologia, Almada, Portugal|Centro Hospitalar de Coimbra, Coimbra, Portugal|Associacao Protectora dos Diabeticos de Portugal, Lisboa, Portugal|Hospital Geral de Santo Antonio, Porto, Portugal|Universidad Central del Caribe, Bayamon, Puerto Rico|Hospital Alejandro Otero Lopez, Manati, Puerto Rico|Dr. Luis Ruiz, Ponce, Puerto Rico|RCMI-Clinical Research Center, Rio Piedras, Puerto Rico|San Juan Health Center, San Juan, Puerto Rico|Centro de Endocrinologia del Este, Yabucoa, Puerto Rico|Hospital Vega Baja, Alicante, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital Gral de Mostoles, Madrid, Spain|Hospital Virgen de Valme, Sevilla, Spain|Hospital la Ribera, Alzira, Valencia, Spain|Lundberglaboratoriet for diabetesforskning, Goteborg, Sweden|Medicinska kliniken, Helsingborg, Sweden|Kliniska Forskningsenheren, Lund, Sweden|Diabetesmottagningen, Intermedicinska kliniken, Stockholm, Sweden|CME, M71, Stockholm, Sweden|Enheten for metabol kontroll, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT00082381"
256,"NCT00082407","Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: exenatide|Drug: biphasic insulin aspart","Change in Glcosylated Hemoglobin (HbA1c)|Percentage of Patients Achieving HbA1c <=7%|Change in Body Weight|Change in Fasting Serum Glucose|Change in 7-point Self-monitored Blood Glucose (SMBG) Profile|Percentage of Patients With Hypoglycemic Events|Change in Rate of Hypoglycemic Events","AstraZeneca|Eli Lilly and Company","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 3","505","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H8O-MC-GWAD","November 2003","July 2008","July 2008","May 10, 2004","July 31, 2013","April 7, 2015","Clinical Hospital Osijek, Osijek, Croatia|Klinica bolnica Dubrava, Zagreb, Croatia|Klinicki bolnicki centar Zagreb-Rebro, Zagreb, Croatia|Opca bolnica ""Sveti Duh"", Zagreb, Croatia|Internistische Gemeinschaftspraxis, Augsburg, Germany|Dr. Karlheinz Hehemann, Beckum, Germany|Dr. Klaus Busch, Dortmund, Germany|Medical Clinic and Policlinic 3, Giessen, Germany|Diabetologische Schwerpunktpraxis, Hamburg, Germany|IKFE GmbH, Mainz, Germany|Institut for diabetic research, Munich, Germany|Profil, Institut fur Stoffwechselstorungen, Neuss, Germany|Dr. Thomas Behnke, Neuwied, Germany|Dr. Bernd Donaubauer, Oschatz, Germany|Marienhospital Osnabruck, Osnabruck, Germany|Dr. Joerg Steindorf, Schkeuditz, Germany|Dr. Jerzi Jasinski, Wiesbaden, Germany|""Polyclinic"" General Hospital of Athens, Athens, Greece|Department of Endocrinology, Athens, Greece|Diabetes Center, Athens, Greece|University Hospital of Patras, Patras, Greece|1st Internal Medicine Department ""Papagergiou"", Thessaloniki, Greece|Instituto di Endocrinologia, Catania, Italy|Dipartimento di fisiopatologia clinica, Florence, Italy|U.O. Medicina Generale, Milan, Italy|Ospedale Civile di Padova, Padova, Italy|Policlinico Univarsitario P. Giaccone, Palermo, Italy|U.O. Universita di Malattie del Metabolismo e Diabetologia, Torino, Italy|Gelre Ziekenhuizen, Apeldoorn, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Maxima Medisch Centrum Location Eindhoven, Eindhoven, Netherlands|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Hospital de Santo Andre, Leiria, Portugal|Associacao Protectora dos Diabeticos de Portugal, Lisboa, Portugal|Hospital Pedro Hispano, Matosinhos, Portugal|Spitalul Judetean Brasov, Brasov, Romania|Institutul de Diabet, Bucuresti, Romania|Spitalul Clinic nr. 1 Judetean, Judet Timis, Romania|National Endocrinology Research Center, Moscow, Russian Federation|Setchenov Moscow Medical Academy, Moscow, Russian Federation|Moscow State Medical Stomatological, Moscow, Russian Federation|Russian Medical Academy for Advanced Medical Studies, Ministry of Health, Moscow, Russian Federation|Hospital of St. Elizabeth's, St. Petersburg, Russian Federation|City Clinical Hospital #2, St. Petersburg, Russian Federation|Medical Military Academy, St. Petersburg, Russian Federation|Univerzitetni klinicni center Ljubljana, Ljubljana, Slovenia|Splosna bolnisnica Maribor, Maribor, Slovenia|Hospital Vega Baja, Alicante, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Endocrinology Service (Planta Baja), Palma de Mallorca, Spain|Hospital Virgen de Valme, Sevilla, Spain|Hospital General de Teruel, Teruel, Spain|Hospital la Ribera Alzira, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Tzu Chi General Hospital, Hualien, Taiwan|Veteran General Hospital-Taichung, Taichung, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Diabetes Research, Ward 34, Birmingham Heartlands Hospital, Birmingham, United Kingdom|Diabetes Unit, Blackburn Royal Infirmary, Blackburn, United Kingdom|Colchester General Hospital, Colchester, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Glasgow Royal Infirmary, Glasgow, United Kingdom|The Michael White Center for Diabetes and Endocrinology, Hull, United Kingdom|Clinical Sciences Centre, Liverpool, United Kingdom|Education Centre, James Cook University Hospital, Middlesbrough, United Kingdom|Wellcome Labs, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom|Queens Medical Centre, Nottingham, United Kingdom|Diabetes Trial Unit OCDEM, Churchill Hospital, Oxford, United Kingdom|Diabetes Unit, Gladsone Centre, Maelor Hospital, Wrexham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00082407"
257,"NCT02635386","EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)",,"Completed","Has Results","Polycystic Ovary Syndrome|Obesity","Drug: Exenatide once weekly (EQW )|Drug: Dapagliflozin (DAPA)|Drug: EQW plus DAPA|Drug: Dapagliflozin plus Glucophage (MET ER)|Drug: Phentermine /Topiramate (PHEN/ TPM) ER","Oral Disposition (Insulin Sensitivity-insulin Secretion) Index|Absolute Body Weight|Body Mass Index (BMI)|Change in Percent Body Weight|Central Adiposity (Waist Circumference)|Waist-to-Hip Ratio (WHR)|Waist-to-Height Ratio (WHtR)|Total Fat Mass (kg) Evaluated by DEXA|Total Body Fat (%) by DEXA|Android-Gynoid Ratio (AGR) as Determined by DEXA|Trunk/Leg Fat Ratio by DEXA|Fasting Blood Glucose|OGTT Mean Blood Glucose (MBG)|Fasting Insulin Sensitivity (HOMA-IR)|Matsuda Sensitivity Index Derived From the OGTT(SI OGTT)|Corrected First Phase Insulin Secretion (IGI/HOMA-IR)|Total Cholesterol Levels|Triglyceride (TRG) Levels|Total Testosterone Concentrations|Dehydroepiandrosterone Sulfate (DHEA-S) Levels|Free Androgen Index (FAI)|Systolic Blood Pressure (SBP)|Diastolic Blood Pressure (DBP)","Woman's|AstraZeneca","Female","18 Years to 45 Years   (Adult)","Phase 3","119","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","RP15-008|AZ ESR-14-10725","March 22, 2016","July 22, 2020","October 9, 2020","December 18, 2015","January 29, 2021","January 29, 2021","Woman's Hospital, Baton Rouge, Louisiana, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02635386/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02635386/Prot_SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02635386"
258,"NCT02338193","Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women","DAPA-GDM","Completed","Has Results","Diabetes Prevention in Women After GDM Who Are at High-risk","Drug: DAPA/MET XR|Drug: DAPA|Drug: MET XR","Change in Body Weight|Change in Percent Body Weight|Body Mass Index (BMI)|Waist Circumference (WC)|Waist- to -Hip Ratio (WHR; Measure of Central Adiposity)|Waist-to-height Ratio (WHtR)|Diastolic Blood Pressure (DBP)|Systolic Blood Pressure (SBP)|Liver Enzymes|Total Cholesterol Levels (CHOL)|Triglyceride (TRG) Levels|Fasting Blood Glucose (FBG)|Mean Blood Glucose (MBG) During an OGTT|Fasting Insulin Sensitivity (HOMA-IR)|Matsuda Sensitivity Index (SI OGTT)|First Phase Insulin Secretion (IGI/HOMA-IR)","Woman's|AstraZeneca","Female","18 Years to 45 Years   (Adult)","Phase 3","69","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","RP-14-012","September 22, 2015","February 13, 2019","March 13, 2019","January 14, 2015","April 30, 2019","June 11, 2019","Woman's Hospital, Baton Rouge, Louisiana, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02338193/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02338193/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02338193"
259,"NCT02022007","Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis","BMS-AZPCOS","Completed","Has Results","Polycystic Ovary Syndrome|Disorder of Glucose Regulation","Drug: Metformin XR|Drug: Saxagliptin|Drug: Saxagliptin-Metformin XR","Glucose Metabolism|Oral Disposition Index|Fasting Glucose|Mean Blood Glucose During the OGTT|Matsuda Index of Insulin-Sensitivity (SI OGTT)|Pancreatic ß-cell Compensatory Function|Body Mass Index at 16 Weeks|Waist Circumference at 16 Weeks|Menstrual Cycle Interval at 16 Weeks|Triglyceride (TRG) /HDL-cholesterol Ratio|Free Androgen Index (FAI)","Woman's|AstraZeneca","Female","18 Years to 42 Years   (Adult)","Phase 3","38","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","RP13-013|BMS CV181-354","March 2014","August 2016","October 2016","December 27, 2013","June 28, 2017","June 28, 2017","Woman's Hospital, Baton Rouge, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT02022007"
260,"NCT03127644","ZS Ph2/3 Dose-response Study in Japan",,"Completed","Has Results","Hyperkalemia","Drug: Sodium Zirconium Cyclosilicate (ZS) 5g|Drug: Sodium Zirconium Cyclosilicate (ZS) 10g|Drug: Placebo","Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment|Percentage of Patients Who Achieved Normokalaemia at 48 Hours|Exponential Rate of Change in S-K Values During the Initial 24 Hours of Study Drug Treatment|Percentage of Patients Who Achieved Normokalaemia at 24 Hours|Percentage of Patients Who Achieved Normokalaemia at Each Scheduled Potassium Assessment Time Point|Mean Change From Baseline in S-K Values at All Measured Time Intervals|Mean Percent Change From Baseline in S-K Values at All Measured Time Intervals|Time to Normalisation in S-K Values|Time to a Decrease in S-K Levels of 0.5 mmol/L","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D9482C00002","June 14, 2017","February 23, 2018","February 23, 2018","April 25, 2017","May 20, 2019","May 20, 2019","Research Site, Chiba-shi, Japan|Research Site, Chiba-shi, Japan|Research Site, Hanyu-shi, Japan|Research Site, Higashiibaraki-gun, Japan|Research Site, Hitachinaka-shi, Japan|Research Site, Ina-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kahoku-gun, Japan|Research Site, Kamakura-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kasugai-shi, Japan|Research Site, Kawachinagano-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Koga-shi, Japan|Research Site, Kusatsu-shi, Japan|Research Site, Matsudo-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Naka-shi, Japan|Research Site, Omura-shi, Japan|Research Site, Shimajiri-gun, Japan|Research Site, Shizuoka-shi, Japan|Research Site, Yao-shi, Japan|Research Site, Yotsukaido-shi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03127644/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03127644/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03127644"
261,"NCT02547935","A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD",,"Completed","Has Results","Type 2 Diabetes Mellitus, CKD and Albuminuria","Drug: Dapagliflozin 10 mg|Drug: Saxagliptin 2.5 mg|Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg","Adjusted Mean Change From Baseline in Glycosylated Haemoglobin (HbA1c): Comparison of Dapagliflozin 10 mg Plus Saxagliptin 2.5 mg and Placebo at Week 24|Adjusted Mean Percent Change From Baseline in Urine Albumin-to-Creatinine Ratio (UACR) at Week 24|Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24|Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24|Percentage of Patients Achieving at Least 30% Reduction in UACR at Week 24|Percentage of Patients Achieving a Reduction in HbA1c of Less Than 7.0% at Week 24|Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24|Adjusted Mean Change From Baseline in HbA1c: Comparison of Dapagliflozin 10 mg and Placebo at Week 24","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2|Phase 3","459","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D1690C00023","September 21, 2015","May 18, 2018","May 18, 2018","September 14, 2015","June 4, 2019","August 21, 2019","Research Site, Peoria, Arizona, United States|Research Site, Chula Vista, California, United States|Research Site, Concord, California, United States|Research Site, El Centro, California, United States|Research Site, La Mesa, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Gatos, California, United States|Research Site, North Hollywood, California, United States|Research Site, Riverside, California, United States|Research Site, San Diego, California, United States|Research Site, San Dimas, California, United States|Research Site, Hollywood, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Meridian, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Bangor, Maine, United States|Research Site, Kansas City, Missouri, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Bronx, New York, United States|Research Site, Springfield Gardens, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Morehead City, North Carolina, United States|Research Site, Rocky Mount, North Carolina, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Brownsville, Texas, United States|Research Site, Cypress, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burke, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Box Hill, Australia|Research Site, Campbelltown, Australia|Research Site, Geelong, Australia|Research Site, Herston, Australia|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Ajax, Ontario, Canada|Research Site, Cambridge, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Hachioji-shi, Japan|Research Site, Higashiosaka-shi, Japan|Research Site, Kisarazu-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Neyagawa-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Toyonaka-shi, Japan|Research Site, Ansan-si, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Wonju-si, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterey, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Queretaro, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Zapopan, Mexico|Research Site, Benoni, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Kuilsrivier, South Africa|Research Site, Mamelodi East, South Africa|Research Site, Muckleneuk, South Africa|Research Site, Paarl, South Africa|Research Site, Pretoria, South Africa|Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sabadell (Barcelona), Spain|Research Site, Santiago(A Coruña), Spain|Research Site, Valencia, Spain|Research Site, Changhua, Taiwan|Research Site, Kaohsiung Hsien, Taiwan|Research Site, New Taipei City, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Yong-Kang City, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02547935/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/35/NCT02547935/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02547935"
262,"NCT01242527","Epanova® for Lowering Very High Triglycerides","EVOLVE","Completed","Has Results","Severe Hypertriglyceridemia","Drug: placebo|Drug: omefas","Fasting Serum Triglycerides","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","399","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OM-EPA-003","January 2011","March 2012","April 2012","November 17, 2010","September 6, 2013","August 4, 2016","National City, California, United States|Sacramento, California, United States|Manchester, Connecticut, United States|Coral Gables, Florida, United States|Hialeah, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|St Petersburg, Florida, United States|Summerfield, Florida, United States|Atlanta, Georgia, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Olive Branch, Mississippi, United States|High Point, North Carolina, United States|Salisbury, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Bristol, Tennessee, United States|Johnson City, Tennessee, United States|Kingsport, Tennessee, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Olympia, Washington, United States|Copenhagen, Denmark|Gentofte, Denmark|Herlev, Denmark|Viborg, Denmark|Baja, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Debrecen, Hungary|Satoraljaujhely, Hungary|Szekesfehervar, Hungary|Szikszo, Hungary|Karnal, Haryana, India|Bangalore, Karnataka, India|Bangalore, Karnataka, India|Bangalore, Karnataka, India|Banswada, Karnataka, India|Indore, Madhya Pradesh, India|Pune, Maharashtra, India|Jaipur City, Rajasthan, India|Chennai, Tamil nadu, India|Surat, India|Amsterdam, Netherlands|Groningen, Netherlands|Rotterdam, Netherlands|Rotterdam, Netherlands|Utrecht, Netherlands|Moscow, Russian Federation|Novosibirsk, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Kharkiv, Ukraine|Kharkiv, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Kiev, Ukraine|Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01242527"
263,"NCT00952588","Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients","SPARK-AML1","Completed","Has Results","Acute Myeloid Leukemia","Drug: AZD1152|Drug: LDAC","Percentage of Patients With Overall Complete Response for Stage I|Duration of Response (DoR): Stage I and Transition Phase|Disease Free Survival (DFS)|Time To Complete Response (TTCR)|Overall Survival (OS)|Percent of Patients With Worsened Trial Outcome Index (TOI)|Percent of Patients With Worsened Functional Assessment of Cancer Therapy - Leukaemia (FACT-Leu) Score.","AstraZeneca","All","60 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D1531C00009","July 2009","June 2011","June 2011","August 6, 2009","March 31, 2014","February 24, 2020","Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, New York, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Greenville, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Westmead, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Melbourne, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Angers Cedex 01, France|Research Site, Clermont-ferrand, France|Research Site, Grenoble Cedex 09, France|Research Site, Lyon Cedex 03, France|Research Site, Marseille Cedex 09, France|Research Site, Nantes, France|Research Site, Duisburg, Germany|Research Site, Erlangen, Germany|Research Site, Frankfurt, Germany|Research Site, Munster, Germany|Research Site, Villingen-schwenningen, Germany|Research Site, Bologna, BO, Italy|Research Site, Genova, GE, Italy|Research Site, Orbassano, TO, Italy|Research Site, Udine, UD, Italy|Research Site, Roma, Italy|Research Site, Nagoya, Aichi, Japan|Research Site, Yoshida-gun, Fukui, Japan|Research Site, Maebashi, Gunma, Japan|Research Site, Isehara, Kanagawa, Japan|Research Site, Yokohama, Kanagawa, Japan|Research Site, Chuo, Tokyo, Japan|Research Site, Fukuoka, Japan|Research Site, Brasov, Romania|Research Site, TG Mures, Romania|Research Site, Oviedo, Asturias, Spain|Research Site, Badalona(barcelona), Cataluna, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Madrid, Comunidad DE Madrid, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, Brighton, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00952588"
264,"NCT00663260","Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment",,"Completed","Has Results","Diabetes Mellitus, Type 2","Drug: Dapagliflozin|Drug: Placebo","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]|Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 (Last Observation Carried Forward [LOCF])|Adjusted Mean Change From Baseline in Total Body Weight (kg) at Week 24 (Last Observation Carried Forward [LOCF])","AstraZeneca|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","631","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MB102-029","June 2008","December 2009","June 2011","April 22, 2008","February 10, 2017","February 10, 2017","Vista Medical Research, Inc., Mesa, Arizona, United States|Valley Research, Fresno, California, United States|Marin Endocrine Care & Research, Inc., Greenbrae, California, United States|Office Of Richard Cherlin, Md, Los Gatos, California, United States|Diabetes Medical Center Of California, Northridge, California, United States|Apex Research Of Riverside, Riverside, California, United States|La Biomed At Harbor Ucla Med Ctr., Torrance, California, United States|Endocrine Associates Of The Rockies, Denver, Colorado, United States|Panhandle Family Care Associates, Marianna, Florida, United States|Genesis Clinical Research, Tampa, Florida, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Twin Cities Clinical Research, Brooklyn Center, Minnesota, United States|Kcva Medical Center Research Svc (151), Kansas City, Missouri, United States|Va Nebraska-Western Iowa Health Care System (Nwihcs), Omaha, Nebraska, United States|University Of Medicine And Dentistry Of New Jersey, Voorhees, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|Slocum-Dickson Medical Group, Pllc, New Hartford, New York, United States|Community Health Care Of Manchester, Akron, Ohio, United States|Center For Thyroid Diseases And Endocrinology, Beachwood, Ohio, United States|Physician Research, Inc., Zanesville, Ohio, United States|Univ Of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States|Rogue Valley Clinical Research, Medford, Oregon, United States|Drexel University College Of Medicine, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Low Country Internal Medicine Of Sc, Pa, Charleston, South Carolina, United States|Carolina Health Specialists, Myrtle Beach, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Research Institute Of Dallas, Dallas, Texas, United States|Westbury Medical Clinic P.A., Houston, Texas, United States|The Strelitz Diabetes Center, Norfolk, Virginia, United States|Capital Clinical Research Center, Olympia, Washington, United States|Cedar Research Llc, Tacoma, Washington, United States|Aurora Advanced Healthcare, Milwaukee, Wisconsin, United States|Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Mar Del Plata, Buenos Aires, Argentina|Local Institution, Zarate, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Salta, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Woollongong, New South Wales, Australia|Local Institution, Launceston, Tasmania, Australia|Local Institution, Calgary, Alberta, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Barrie, Ontario, Canada|Local Institution, Thornhill, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Gatineau, Quebec, Canada|Local Institution, Laval, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Regina, Saskatchewan, Canada|Local Institution, Copenhagen Nv, Denmark|Local Institution, Gentofte, Denmark|Local Institution, Hvidovre, Denmark|Local Institution, Besancon Cedex, France|Local Institution, Brest Cedex, France|Local Institution, Paris Cedex 10, France|Local Institution, Paris, France|Local Institution, Poitiers Cedex, France|Local Institution, Indore, Madhya Pradesh, India|Local Institution, Pune, Maharashtra, India|Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Chennai, India|Local Institution, Pune, Maharashtra, India|Local Institution, Rajasthan, India|Local Institution, Chieri, Italy|Local Institution, Chieti Scalo, Italy|Local Institution, Modena, Italy|Local Institution, Padova, Italy|Local Institution, Perugia, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Celaya, Guanajuato, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Durango, Mexico|Local Institution, Cercado De Lima, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Caguas, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, San Sebastian De Los, Spain|Local Institution, Vizcaya, Spain",,"https://ClinicalTrials.gov/show/NCT00663260"
265,"NCT00384176","First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX","HORIZON III","Completed","Has Results","Colorectal Cancer","Drug: Cediranib|Drug: Bevacizumab|Drug: 5-fluorouracil ( in FOLFOX)|Drug: Leucovorin (in FOLFOX)|Drug: Oxaliplatin (in FOLFOX)","Progression Free Survival|Overall Survival|Objective Response Rate|Duration of Response|Percentage Change in Tumour Size|Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2|Phase 3","1814","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D8480C00013|Eudract Number 2005-003440-66","August 30, 2006","November 15, 2009","August 19, 2015","October 5, 2006","November 28, 2012","April 14, 2017","Research Site, Anniston, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Casa Grande, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Palm Springs, California, United States|Research Site, San Diego, California, United States|Research Site, Fairfield, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Bay Pines, Florida, United States|Research Site, Fort Meyers, Florida, United States|Research Site, Port St Lucie, Florida, United States|Research Site, Port St. Lucie, Florida, United States|Research Site, Galesburg, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Layfayette, Indiana, United States|Research Site, New Albany, Indiana, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Layfayette, Louisiana, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, St Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Summit, New Jersey, United States|Research Site, Fresh Meadows, New York, United States|Research Site, Northport, New York, United States|Research Site, Rochester, New York, United States|Research Site, Fayetteville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Coos Bay, Oregon, United States|Research Site, Hilton Head Island, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, White River Junction, Vermont, United States|Research Site, Abingdon, Virginia, United States|Research Site, Alexandria, Virginia, United States|Research Site, Armidale, New South Wales, Australia|Research Site, Coffs Harbour, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Hornsby, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Port Macquarie, New South Wales, Australia|Research Site, Randwick, New South Wales, Australia|Research Site, St. Leonards, New South Wales, Australia|Research Site, Tamworth, New South Wales, Australia|Research Site, Waratah, New South Wales, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Epping, Victoria, Australia|Research Site, Ashford, Australia|Research Site, Bedford Park, Australia|Research Site, Bendigo, Australia|Research Site, Box Hill, Australia|Research Site, Camperdown, Australia|Research Site, Coffs Harbour, Australia|Research Site, Darlinghurst, Australia|Research Site, East-Melbourne, Australia|Research Site, Epping, Australia|Research Site, Herston, Australia|Research Site, Hobart, Australia|Research Site, Hornsby, Australia|Research Site, Kogarah, Australia|Research Site, Lismore, Australia|Research Site, Malvern, Australia|Research Site, Nedlands, Australia|Research Site, Port Macquarie, Australia|Research Site, Randwick, Australia|Research Site, South Brisbane, Australia|Research Site, St. Leonards, Australia|Research Site, Tamworth, Australia|Research Site, Waratah, Australia|Research Site, Wodonga, Australia|Research Site, Woodville South, Australia|Research Site, Kundratstrasse 3, Vienna, Austria|Research Site, Innsbruck, Austria|Research Site, Kundratstrasse 3, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Zams, Austria|Research Site, Bonheiden, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels (woluwe-st-lambert), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Ghent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Roeselare, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, St Catharines, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czech Republic|Research Site, Chomutov, Czech Republic|Research Site, Kutna Hora, Czech Republic|Research Site, Nova Ves pod Plesi, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Tabor, Czech Republic|Research Site, Alexandria, Egypt|Research Site, Cairo, Egypt|Research Site, Helsinki, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Vaasa, Finland|Research Site, Boulogne Cedex, France|Research Site, La Roche S YON, France|Research Site, Marseille Cedex 08, France|Research Site, Nantes,, France|Research Site, Nantes, France|Research Site, Paris Cedex 15, France|Research Site, Paris, France|Research Site, Saint Gregoire, France|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Freiburg, Germany|Research Site, Halle, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Munchen, Germany|Research Site, München, Germany|Research Site, Neu-isenburg, Germany|Research Site, Tubingen, Germany|Research Site, Tübingen, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Pecs, Hungary|Research Site, Pécs, Hungary|Research Site, Szeged, Hungary|Research Site, Tatabanya, Hungary|Research Site, Tatabánya, Hungary|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Varanasi, Uttar Prad, India|Research Site, Kolkata, W Bengal, India|Research Site, Bangalore, India|Research Site, Bhopal, India|Research Site, Chennai, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Sheikhpura, India|Research Site, Holon, Israel|Research Site, Kfar-saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel-Hashomer, Israel|Research Site, Tiberias, Israel|Research Site, Tzrifin, Israel|Research Site, Genova, GE, Italy|Research Site, Rozzano, MI, Italy|Research Site, Ancona, Italy|Research Site, Genova, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Riga, Latvia|Research Site, Floriana, Malta|Research Site, Valletta, Malta|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Molo, Philippines|Research Site, Quezon City, Philippines|Research Site, Bytom, Poland|Research Site, Elblag, Poland|Research Site, Gdynia, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Poznań, Poland|Research Site, Rybnik, Poland|Research Site, Warszawa, Poland|Research Site, Barnaul, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tumen, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Cape Town, South Africa|Research Site, Lyttelton Manor, South Africa|Research Site, Polokwane, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, Cordoba, Andalucia, Spain|Research Site, Zaragoza, Aragon, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Granollers, Cataluna, Spain|Research Site, Hospitalet de Llobregat(barcel, Cataluna, Spain|Research Site, Terrassa(barcelona), Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruna, Galicia, Spain|Research Site, A Coruña, Spain|Research Site, Córdoba, Spain|Research Site, Granollers, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Manresa, Spain|Research Site, Oviedo, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-yuan, Taiwan|Research Site, Nakhonratchasima, Naimuang, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Rachathewi, Thailand|Research Site, Songkla, Thailand|Research Site, Istanbul, Goztepe, Turkey|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Cherkassy, Ukraine|Research Site, Chernigiv, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kherson, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Simferopol, Ukraine|Research Site, Sumy, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Ternopol, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Southampton, Hampshire, United Kingdom|Research Site, Maidstone, Kent, United Kingdom|Research Site, Northwood, Middlesex, United Kingdom|Research Site, Sutton, Surrey, United Kingdom|Research Site, Bebington, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Ipswich, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Newcastle-upon-tyne, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Stockport, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Hanoi city, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT00384176"
266,"NCT00357370","A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes",,"Completed","Has Results","Type 2 Diabetes","Drug: Dapagliflozin|Drug: Placebo","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2|Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2|Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <7.0% at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2|Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) <=6.5% at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2|Participants Achieving a Therapeutic Glycemic Response (Hemoglobin A1c [HbA1C]) Decrease From Baseline >= 0.5% at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2|Adjusted Mean Total Daily Dose of Insulin (TDDI) Change From Baseline at Week 12 (LOCF), Including Data After Up-titration of Insulin) - Cohort 2","AstraZeneca|Bristol-Myers Squibb","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","163","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MB102-009","October 2006","March 2008","March 2008","July 27, 2006","May 11, 2017","May 11, 2017","Nea Clinic, Jonesboro, Arkansas, United States|Valley Research, Fresno, California, United States|Bernstein, Richard, Greenbrae, California, United States|Jacksonville Center For Clinical Research, Jacksonville, Florida, United States|Endocrine Research Solutions, Inc., Roswell, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Model Clinical Research Llc, Baltimore, Maryland, United States|University Of Michigan, Ann Arbor, Michigan, United States|St. Louis Center For Clinical Research, St. Louis, Missouri, United States|Suny Upstate Medical University, Syracuse, New York, United States|Mountain Diabetes And Endocrine Center, Asheville, North Carolina, United States|Your Diabetes Endocrine Nutrition Group, Mentor, Ohio, United States|Research Institute Of Dallas, P.A., Dallas, Texas, United States|Diabetes And Glandular Disease Research Associates, P.A., San Antonio, Texas, United States|Rainier Clinical Research Center, Renton, Washington, United States|Advanced Healthcare S.C., Milwaukee, Wisconsin, United States|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Bathurst, New Brunswick, Canada|Local Institution, Gatineau, Quebec, Canada|Local Institution, Laval, Quebec, Canada|Local Institution, Longueuil, Quebec, Canada|Local Institution, Pointe-Claire, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00357370"
267,"NCT01992523","Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )",,"Completed","Has Results","Acute Coronary Syndrome|Adverse Reaction to Antiplatelet Agent","Drug: Ticagrelor mashed pills|Drug: Ticagrelor integral pills","Residual Platelet Reactivity|High Residual Platelet Reactivity|Bleeding Events|Dyspnoea and/or Symptomatic Bradycardia","David Antoniucci|AstraZeneca|A.R. CARD Onlus Foundation|Careggi Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","82","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MOJITO Study","November 2013","March 2014","April 2014","November 25, 2013","March 17, 2015","March 17, 2015","Department of Cardiology, Patras University Hospital, Patras, Greece|Careggi Hospital, Florence, Italy",,"https://ClinicalTrials.gov/show/NCT01992523"
268,"NCT00728481","The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis",,"Completed","Has Results","Eosinophilic Esophagitis|Gastroesophageal Reflux Disease|EE|GERD","Drug: Esomeprazole|Drug: Budesonide","Histological Response to Treatment|Symptomatic Response to Treatment|Change in Dysphagia Symptoms in Subjects With Histological Response to Treatment|Change in Dysphagia Symptoms in Subjects With Non-significant Histological Response to Treatment|Participants With Presence of Esophageal Rings/Furrows at Six Month Endoscopy|Participants With Presence of Erosive Esophagitis at Six Month Endoscopy","Mayo Clinic|AstraZeneca","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","51","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-006685","May 2008","December 2010","December 2010","August 5, 2008","December 6, 2012","January 14, 2016","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00728481"
269,"NCT00671853","Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)",,"Completed","Has Results","Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders","Drug: Quetiapine XR|Drug: Placebo for quetiapine XR","Change in the 17 Item Hamilton Rating Scale for Depression (HAM-D-17) Score|Response Rate (≥ 50% Improvement) on Hamilton Rating Scale for Depression (HAM-D-17)|Remission Rate (≤ 7) on Hamilton Rating Scale for Depression (HAM-D-17)|Change in Clinical Global Impressions of Improvement or Severity (CGI-I or S) Score|Change in the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score|Change in Hamilton Rating Scale for Anxiety (HAM-A)","University Hospitals Cleveland Medical Center|National Alliance for Research on Schizophrenia and Depression|AstraZeneca","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","10-06-19","April 2008","March 2011","March 2011","May 5, 2008","October 11, 2013","December 29, 2016","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00671853"
270,"NCT01196741","Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer","SaPPrOC","Completed","Has Results","Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer","Drug: Paclitaxel|Drug: Saracatinib|Drug: Matched placebo","6 Month Progression-free Survival Rate (PFS) (Based on Combined Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 +/- Gynecologic Cancer Intergroup (GCIG) CA125 Criteria)|Overall Survival|Objective Response Rate Based on Investigator Assessment Based on RECIST v1.1 +/- GCIG CA125 Criteria|Median Duration of Response|Quality of Life: Trial Outcome Index (TOI) Based on FACT-O|Median Time To Progression Based on RECIST v1.1 and GCIG CA125 Criteria|Median PFS","University College, London|AstraZeneca|Cancer Research UK","Female","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","107","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UCL/09/105|Funder reference (academic)|Funder reference (industry)|2009-017171-13","March 2011","November 2012","January 2014","September 8, 2010","May 5, 2015","May 5, 2015","Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|St Bartholomew's Hospital, London, Greater London, United Kingdom|University College London Hospital, London, Greater London, United Kingdom|Guy's Hospital, London, Greater London, United Kingdom|The Royal Mardsen Hospital, London, Greater London, United Kingdom|The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom|Mount Vernon Hospital, Rickmansworth, Middlesex, United Kingdom|The Churchill Hospital, Oxford, Oxfordshire, United Kingdom|Queen's Hospital, Burton upon Trent, Staffordshire, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|St James's University Hospital, Leeds, Yorkshire, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01196741"
271,"NCT01052428","Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)","P1A1","Completed","Has Results","Mitral Regurgitation","Drug: metoprolol succinate (Toprol XL)|Drug: Placebo","Left Ventricular End Diastolic Volume Indexed to Body Surface Area|Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume|Left Ventricular End-Diastolic Radius to Wall Thickness|Left Ventricular End Systolic Volume Indexed to Body Surface Area|Left Ventricular Ejection Fraction|Systolic Longitudinal Strain|Peak Early Filling Rate: Rate of Change Over Time","University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)|AstraZeneca","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","38","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","F040601008","August 2004","July 2010","July 2010","January 20, 2010","April 16, 2012","November 22, 2012","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01052428"
272,"NCT01052272","Impact of Diabetes on Left Ventricular Remodeling","P3","Completed","Has Results","Diabetes","Drug: Ramipril|Drug: Candesartan cilexetil|Drug: Allopurinol","Left Ventricular End Diastolic Volume Indexed to Body Surface Area (LVEDV/BSA)|Left Ventricular End-Diastolic Radius to Wall Thickness (LVED Radius/Wall Thickness)|Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume (LVED Mass/LVEDV)|Left Ventricular Ejection Fraction (LVEF)|Left Ventricular End Systolic Volume Indexed to Body Surface Area (LVESV/BSA)|LV End Systolic Maximum Shortening (LVES Max Shortening)|Peak Early Filling Rate Normalized to EDV","University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI)|AstraZeneca","All","21 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","72","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F040105007","July 2005","November 2010","November 2010","January 20, 2010","December 17, 2012","December 17, 2012","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT01052272"
273,"NCT00880919","Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)",,"Completed","Has Results","Borderline Personality Disorder","Drug: quetiapine extended-release|Drug: Placebo","Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD)|Montgomery-Åsberg Depression Rating Scale (MADRS)|Borderline Evaluation of Severity Over Time (BEST)|Overt Aggression Scale - Modified (OAS-M)|Global Assessment of Functioning Scale (GAF)|Barratt Impulsiveness Scale (BIS)|Symptom Checklist -90-Revised (SCL-90-R)|Young Mania Rating Scale (YMS)|Sheehan Disability Scale (SDS)","University of Minnesota|AstraZeneca|University of Iowa|Mclean Hospital","All","18 Years to 45 Years   (Adult)","Phase 3","95","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","0709M16844|IRUSQUET0454","June 2008","March 2013","March 2013","April 14, 2009","December 28, 2016","March 9, 2017","University of Iowa, Department of Psychiatry, Iowa City, Iowa, United States|McLean Hospital, Harvard Medical School, Department of Psychiatry, Belmont, Massachusetts, United States|University of Minnesota Medical Center, Fairview Riverside, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00880919"
274,"NCT01813435","GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation",,"Completed","Has Results","Coronary Artery Disease (CAD)","Drug: Ticagrelor|Drug: Acetylsalicylic Acid|Drug: Clopidogrel","Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI)|Number of Participants With All-cause Mortality|Number of Participants With Myocardial Infarction|Number of Participants With New Q-wave Myocardial Infarction|Number of Participants With a Composite of All-cause Mortality, Stroke, or New Q-wave Myocardial Infarction|Number of Participants With a Stroke|Number of Participants With a Myocardial Revascularisation|Number of Participants With a Definite Stent Thrombosis|Number of Participants With a Bleeding Academic Research Consortium (BARC) 3 or 5 Bleeding","ECRI bv|Biosensors International|AstraZeneca|The Medicines Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","15991","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECRI-12-001, 02EU11","July 1, 2013","November 9, 2015","April 26, 2018","March 19, 2013","July 5, 2019","August 1, 2019","Research centre Brisbane, 6101, Brisbane, Australia|Research centre Melbourne, 6104, Melbourne, Australia|Research centre Melbourne, 6105, Melbourne, Australia|Research centre Graz, 4305, Graz, Austria|Rsearch centre Innsbruck, 4303, Innsbruck, Austria|Research centre Linz, 4304, Linz, Austria|Research centre Vienna, 4301, Vienna, Austria|Research centre Vienna, 4302, Vienna, Austria|Research centre Aalst, 3201, Aalst, Belgium|Research centre Aalst, 3206, Aalst, Belgium|Research centre Bonheiden, 3204, Bonheiden, Belgium|Research centre Charleroi, 3202, Charleroi, Belgium|Research centre Genk, 3205, Genk, Belgium|Research centre Hasselt, 3203, Hasselt, Belgium|Research centre Rio de Janeiro, 5503, Rio de Janeiro, Brazil|Research centre Rio de Janeiro, 5504, Rio de Janeiro, Brazil|Research centre Sao Paulo, 5501, Sao Paulo, Brazil|Research centre Sao Paulo, 5502, Sao Paulo, Brazil|Research centre Uberlândia, 5505, Uberlândia, Brazil|Research centre Burgas, 9902, Burgas, Bulgaria|Research centre Plovdiv, 9905, Plovdiv, Bulgaria|Research centre Sofia, 9901, Sofia, Bulgaria|Research centre Sofia, 9903, Sofia, Bulgaria|Research centre Sofia, 9904, Sofia, Bulgaria|Research centre Sofia, 9907, Sofia, Bulgaria|Research centre Sofia, 9908, Sofia, Bulgaria|Research centre Varna, 9906, Varna, Bulgaria|Research centre Newmarket, 1003, Newmarket, Canada|Research centre Quebec, 1001, Quebec, Canada|Research centre Copenhagen, 4501, Copenhagen, Denmark|Research centre Roskilde, 4503, Roskilde, Denmark|Research centre Aix en Provence, 3311, Aix en Provence, France|Research centre Caen, 3308, Caen, France|Research centre Caen, 3309, Caen, France|Research centre Clermont-Ferrand, 3303, Clermont-Ferrand, France|Research centre Dijon, 3313, Dijon, France|Research centre Grenoble, 3312, Grenoble Cedex, France|Research centre Lyon, 3316, Lyon, France|Research centre Nancy, 3314, Nancy, France|Research centre Paris, 3301, Paris, France|Research centre Paris, 3305, Paris, France|Research centre Rouen, 3307, Rouen, France|Research centre Saint Etienne, 3310, Saint Etienne, France|Research centre Toulouse, 3302, Toulouse, France|Research centre Bad Krozingen, 4904, Bad Krozingen, Germany|Research centre Bad Nauheim, 4902, Bad Nauheim, Germany|Research centre Berlin, 4918, Berlin, Germany|Research centre Bonn, 4911, Bonn, Germany|Research centre Dresden, 4908, Dresden, Germany|Research centre Essen, 4903, Essen, Germany|Research centre Fulda, 4905, Fulda, Germany|Research centre Giessen 4901, Giessen, Germany|Research centre Göttingen, 4907, Göttingen, Germany|Research centre Landshut, 4909, Landshut, Germany|Research centre Lubeck, 4917, Lubeck, Germany|Research centre Mainz, 4910, Mainz, Germany|Research centre Mannheim, 4912, Mannheim, Germany|Research centre Mönchengladbach, 4915, Mönchengladbach, Germany|Research centre Neuss, 4916, Neuss, Germany|Research centre Tubingen, 4914, Tubingen, Germany|Research centre Villingen - Schwenningen, 4919, Villingen - Schwenningen, Germany|Research centre Balatonfüred, 3608, Balatonfüred, Hungary|Research centre Budapest, 3602, Budapest, Hungary|Research centre Budapest, 3603, Budapest, Hungary|Research centre Debrecen, 3607, Debrecen, Hungary|Research centre Gyula, 3606, Gyula, Hungary|Research centre Nyíregyháza, 3605, Nyíregyháza, Hungary|Research centre Pécs, 3604, Pécs, Hungary|Research centre szeged, 3601, Szeged, Hungary|Research centre Arezzo, 3902, Arezzo, Italy|Research centre Brescia, 3912, Brescia, Italy|Research centre Ferrara, 3905, Ferrara, Italy|Research centre Milano, 3901, Milano, Italy|Research centre Pavia, 3903, Pavia, Italy|Research centre Terni, 3909, Terni, Italy|Research centre Alkmaar, 3106, Alkmaar, Netherlands|OLVG Research centre Amsterdam, 3104, Amsterdam, Netherlands|UMCG Groningen, 3108, Groningen, Netherlands|Research centre Leeuwarden, 3102, Leeuwarden, Netherlands|Research centre Nieuwegein, 3107, Nieuwegein, Netherlands|Research centre Nijmegen, 3105, Nijmegen, Netherlands|EMC Rotterdam, 3101, Rotterdam, Netherlands|Maasstad Rotterdam, 3103, Rotterdam, Netherlands|Research centre Tilburg, 3109, Tilburg, Netherlands|Research centre Chrzanow, 4802, Chrzanow, Poland|Research centre Dabrowa Gornicza, 4801, Dabrowa Gornicza, Poland|Research centre Kedzierzyn-Kozle, 4805, Kedzierzyn-Kozle, Poland|Research centre Krakov, 4807, Krakov, Poland|Research centre Mielec, 4809, Mielec, Poland|Research centre Nysa, 4808, Nysa, Poland|Research centre Ustroń, 4803, Ustroń, Poland|Research centre Gaia, 3501, Gaia, Portugal|Research centre Lisbon, 3503, Lisbon, Portugal|Research centre Lisbon, 3504, Lisbon, Portugal|Research centre Lisbon, 3505, Lisbon, Portugal|Research centre Singapore, 6501, Singapore, Singapore|Research centre Singapore, 6502, Singapore, Singapore|Research centre Barcelona, 3401, Barcelona, Spain|Research centre Barcelona, 3403, Barcelona, Spain|Research centre Barcelona, 3405, Barcelona, Spain|Research centre Huelva, 3408, Huelva, Spain|Research centre Madrid 3410, Madrid, Spain|Research centre Madrid, 3402, Madrid, Spain|Research centre Madrid, 3407, Madrid, Spain|Research centre Madrid, 3409, Madrid, Spain|Research centre Vigo, 3404, Vigo, Spain|Research centre Bern, 4106, Bern, Switzerland|Research centre Bern, 4107, Bern, Switzerland|Research centre Geneva, 4101, Geneva, Switzerland|Research centre Lausanne, 4104, Lausanne, Switzerland|Research centre Liestal, 4108, Liestal, Switzerland|Research centre Lugano, 4105, Lugano, Switzerland|Research centre Belfast, 4420, Belfast, United Kingdom|Research Centre Belfast, 4423, Belfast, United Kingdom|Research centre Blackburn, 4404, Blackburn, United Kingdom|Research centre Blackpool, 4408, Blackpool, United Kingdom|Research centre Bournemouth, 4418, Bournemouth, United Kingdom|Research centre Brighton, 4405, Brighton, United Kingdom|Research centre Cambridge, 4417, Cambridge, United Kingdom|Research centre Cardiff, 4402, Cardiff, United Kingdom|Research centre Glasgow, 4407, Glasgow, United Kingdom|Research centre Leicester, 4421, Leicester, United Kingdom|Research centre Liverpool, 4001, Liverpool, United Kingdom|Research centre Manchester, 4403, Manchester, United Kingdom|Research centre Manchester, 4406, Manchester, United Kingdom|Research centre Newcastle, 4413, Newcastle, United Kingdom|Research centre Rhyl, 4414, Rhyl, United Kingdom|Research centre Southampton, 4415, Southampton, United Kingdom|Research centre Stevenage, 4412, Stevenage, United Kingdom|Research centre Wolverhampton, 4422, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01813435"
275,"NCT00588406","Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.",,"Completed","Has Results","Asthma","Drug: Budesonide|Drug: albuterol|Drug: Ipratropium bromide|Drug: Prednisone","FEV1 Percent Predicted|Hospitalization","Northwell Health|AstraZeneca|Jacobi Medical Center|Nassau University Medical Center","All","18 Years to 60 Years   (Adult)","Phase 3","95","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","07.02.019","September 2007","December 2009","December 2009","January 8, 2008","January 21, 2016","January 21, 2016","Jacobi Medical Center, Bronx, New York, United States|Nassau University Medical Center, East Meadow, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States",,"https://ClinicalTrials.gov/show/NCT00588406"
276,"NCT00193596","Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site",,"Completed","Has Results","Neoplasms, Unknown Primary","Drug: Etoposide|Drug: Gemcitabine|Drug: Irinotecan|Drug: Paclitaxel|Drug: Carboplatin","Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death|Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease","SCRI Development Innovations, LLC|AstraZeneca|Pharmacia and Upjohn|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","198","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRI UNKPRI 12","September 2003","September 2008","June 2009","September 19, 2005","May 3, 2013","May 3, 2013","Northeast Alabama Regional Medical Center, Anniston, Alabama, United States|Clearview Cancer Institute, Huntsville, Alabama, United States|Southern Cancer Center, Sacred Heart Heath System Medical Oncology Group, Mobile, Alabama, United States|Northeast Arkansas Clinic, Jonesboro, Arkansas, United States|Tower Oncology, Beverly Hills, California, United States|Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States|Mercy Hospital Miami, Miami, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Phoebe Cancer Center, Albany, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Wellstar Cancer Research, Marietta, Georgia, United States|Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|Terrebonne General Medical Center, Houma, Louisiana, United States|Mercy Hospital, Portland, Maine, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|St. Joseph Mercy Oakland Hospital, Cancer Center, Pontiac, Michigan, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|Montana Cancer Institute Foundation, Missoula, Montana, United States|Methodist Cancer Center, Omaha, Nebraska, United States|Aultman Hospital, Canton, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Consultants in Medical Oncology and Hematology, Drexel Hill, Pennsylvania, United States|Reading Hospital Regional Cancer Center, West Reading, Pennsylvania, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Kingsport Hematology-Oncology, Kingsport, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|South Texas Oncology and Hematology, San Antonio, Texas, United States|Cancer Outreach Associates, Abingdon, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00193596"
277,"NCT01248416","Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature","ThrasherAI","Completed","Has Results","Idiopathic Short Stature","Drug: Aromatase Inhibitor|Drug: Growth Hormone|Drug: Aromatase Inhibitor and Growth Hormone","Change in Height|Change in Predicted Height|Change in Bone Density z Score Adjusted for Height|Change in Lean Body Mass|Change in Body Mass Index|Change in IGF-I Concentrations|Change in Testosterone|Change in Estradiol|Change in Estrone","Nemours Children's Clinic|Thrasher Research Fund|Genentech, Inc.|Novartis|AstraZeneca|Pfizer","Male","12 Years to 18 Years   (Child, Adult)","Phase 3","76","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","180984","November 2010","September 2016","September 2016","November 25, 2010","June 7, 2018","August 7, 2018","Nemours Children's Clinic, Jacksonville, Florida, United States|Nemours Children's Clinic, Orlando, Florida, United States|Nemours Children's Clinic- Jefferson, Philadelphia, Pennsylvania, United States|Veronica Mericq, MD, Santiago, Chile",,"https://ClinicalTrials.gov/show/NCT01248416"
